<SEC-DOCUMENT>0001558370-24-015433.txt : 20241113
<SEC-HEADER>0001558370-24-015433.hdr.sgml : 20241113
<ACCEPTANCE-DATETIME>20241113073034
ACCESSION NUMBER:		0001558370-24-015433
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		83
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20241113
DATE AS OF CHANGE:		20241113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Liquidia Corp
		CENTRAL INDEX KEY:			0001819576
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				851710962
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39724
		FILM NUMBER:		241451183

	BUSINESS ADDRESS:	
		STREET 1:		419 DAVIS DRIVE, SUITE 100
		CITY:			MORRISVILLE
		STATE:			NC
		ZIP:			27560
		BUSINESS PHONE:		919.328.4400

	MAIL ADDRESS:	
		STREET 1:		419 DAVIS DRIVE, SUITE 100
		CITY:			MORRISVILLE
		STATE:			NC
		ZIP:			27560
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>lqda-20240930x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.8.0.95 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 11/13/2024 3:22:40 AM -->
<!-- iXBRL Library version: 1.0.9027.2259 -->
<!-- iXBRL Service Job ID: 535ca64d-3bf9-4419-b08c-c940bec8c878 -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:lqda="http://liquidia.com/20240930" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" xs:nil="true" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" name="us-gaap:CommitmentsAndContingencies" id="Hidden_DVKJjtpYYEaK1FOJGf_f5g"/><ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" xs:nil="true" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_G7RdtXnBf0WgJFsdqp6jvA"/><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:EntityCentralIndexKey" id="Tc_k-PF8Ae41U-NhZIAKUenZA_2_1">0001819576</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:CurrentFiscalYearEndDate" id="Tc_LowbsVg02k6QBlBfmWdhgg_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:DocumentFiscalYearFocus" id="Tc_Pu1hS3ILIEeXkVRjaod1Tw_4_1">2024</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:DocumentFiscalPeriodFocus" id="Tc_0e8bLGyIEEC2WQ_3un-YmQ_5_1">Q3</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:AmendmentFlag" id="Tc_V7IgufauZEqHCTa6f94FJg_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" xs:nil="true" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_WDRn4vkaQU-_GJyXGW7r-g" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Hidden_fljXNZJ780WhJZl0xfbOZw"/><ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" xs:nil="true" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_CfxUqp13dkiX5pxqnNfcWg" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Hidden_KgzYt7L2DEmD5XrMEpBoAQ"/><ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" xs:nil="true" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_3f2n43cTpEKLLf2BEff-rw" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Hidden_od59HwKFmkW8EjvwzxxZHg"/><ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" xs:nil="true" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_58oqF0uKeUmLTXXZbeZuOw" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Hidden__L855O1ENEa44A4aGasXbw"/></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="lqda-20240930.xsd"/></ix:references><ix:resources><xbrli:context id="Duration_1_1_2024_To_9_30_2024_srt_TitleOfIndividualAxis_lqda_BoardOfDirectorsMember_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_k0mS-FrErEGcCSQNS7upnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lqda:BoardOfDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lqda:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_12_2023_To_12_12_2023_srt_TitleOfIndividualAxis_lqda_LargestStockholderAndMemberOfBoardOfDirectorsMember_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_gnFwleLvT02Zo7EgTUlKNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lqda:LargestStockholderAndMemberOfBoardOfDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lqda:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-12</xbrli:startDate><xbrli:endDate>2023-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_4_2024_To_1_4_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_rWhTZuGpl06hF6C5gOgr0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-04</xbrli:startDate><xbrli:endDate>2024-01-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_12_2023_To_12_12_2023_srt_TitleOfIndividualAxis_lqda_Mr.PaulB.ManningMember_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_ET_kOfe7OUyGZnegoThYVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lqda:Mr.PaulB.ManningMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lqda:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-12</xbrli:startDate><xbrli:endDate>2023-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_12_2023_To_12_12_2023_srt_TitleOfIndividualAxis_lqda_CaliganPartnersLPMember_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_yy0o7xFcx0aREDaZ1VnfRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lqda:CaliganPartnersLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lqda:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-12</xbrli:startDate><xbrli:endDate>2023-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_glcrSVianU6a1o46EeXtNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TAyoFb0K3kegpTygRfEduw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TmKhLmYzCECUkE-NW019MQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ScrF8tr1w0-MxUBmw2dweg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5u8PMn6XnUeumeLh8ydfDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_FQbXKficgEeFRZOCIK6Svw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AFsBC1pdhU25u5j1c2Q6ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_UnpCcNxeWkirPc8V7uSOcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_bmSEVHYEX0GyBAzQZDTzxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zXAQdDuaAUShk1iCOS3LQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sg-6UkrcA0mC1Q9jWG_gTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_FtiVafAv4UWr8JRCklLjuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uAdhr2xcg06h66-QEsr0Rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fVis6Rc0lU24mViOdhLPQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0jwCrvtl9UmljYaJoSpv6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_caIrfeIWIUSr-5YM1URrGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2PLVLFxMP0GKVplKYm4eUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VaQV6KiTs0uXI_fEPfZBIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_D-bH4JsxuEqUTMaVgHIQIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_T0JQS0-8iUiQm5svY1pKoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_C8mVC4eTakmAXbazP4Sw7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7AEtKY-q0EKpSlxBuo5Tpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fCrJtKAilUWF6oakyV0Nxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7E3fQ6q_00GZ5N7nqYsJJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GIpJ2QgtfkiSIOYQwZQCIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HrYg36StAUevt9it2sHW4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vBNSpOjO0k-ci40DF_S6vQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aaTdBw1wLEmeLLnJDiO8qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_6YbY13rlnk2AxDHTatb6fA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_0Q4e0dBgsk2MRpxDh6fJYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lqda:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_4_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VFjgbZY-JEy1XAWMuIb9qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_12_2023_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_ZMC_KO-DIESEKNwQeHuFPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_12_2023_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_n5jOtXbc5063nwGCNNyeNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lqda:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MBzkjBjqCku_2H2dhAQG9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_lqda_The2020PlanMember_CEMyV83-zUCOMl6DTROCNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:The2020PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_c3RkhmYjMUymom-OGSSabQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_Y_FZ3m3A40qqKnWMJKMAEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_WDRn4vkaQU-_GJyXGW7r-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_3f2n43cTpEKLLf2BEff-rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lqda:EmployeePurchaseRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_CfxUqp13dkiX5pxqnNfcWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_58oqF0uKeUmLTXXZbeZuOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lqda:EmployeePurchaseRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_kteGXRriH0alvhRWw4-p7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_PerformanceBasedRestrictedStockUnitsMember_Yv0caJPQY0mJtH96769LWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lqda:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_PerformanceBasedRestrictedStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ObYqzytTmk-rYw5p78JFbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lqda:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_PerformanceBasedRestrictedStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_h6JlHh_6Hk2OCYyiU3MA8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lqda:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_m7APsiBNMkuX9fDgBs78Wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_27_2023_To_1_27_2023_us-gaap_DebtInstrumentAxis_lqda_ArSiliconValleyBankTermLoansMember_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_lBeKdvCPDUmyLAg_84HrDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lqda:ArSiliconValleyBankTermLoansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-27</xbrli:startDate><xbrli:endDate>2023-01-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_OtherCommitmentsAxis_lqda_AgreementWithLGMPharmaLLCMember_a_fkJlyRgkS7OKPppsJs0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">lqda:AgreementWithLGMPharmaLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_NBou6jkXCUKIl86emqBNpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_VYpHUurxNEuWKkqyAiGjGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_HhiaPNdxpU2kL50_8kQ28g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_iPwI9W-yukKJZYkZvhU5ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember__bkosJSnNUKdzQ6jMHMqOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_lqda_LabAndBuildToSuitEquipmentMember_vbQ7hgEZXU2QQ8szN1HAtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lqda:LabAndBuildToSuitEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_u0t7q0rYoUCrtJJgFwTvrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_vuK9MdKws0WBj-FZvfK_jA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_P6CllWvurEyyz948ZgWhnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_W1eYleOODEWnNYcNk76J4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_JDWBnuimj0OiMbqSGdD8Ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_lqda_LabAndBuildToSuitEquipmentMember_3By5Ws9wr0KTAbJFyx2jow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lqda:LabAndBuildToSuitEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_4_30_2021_dei_LegalEntityAxis_lqda_LiquidiaPAHAndSandozMember_srt_LitigationCaseAxis_lqda_UTCAndSmithsMedicalLitigationMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_HugoVmm5y0mmurW4-YSz7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lqda:LiquidiaPAHAndSandozMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lqda:UTCAndSmithsMedicalLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_RIO6XDdLvUCyictd22yGPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_8_2024_To_1_8_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_ud0mQkQYWkGjIgetbIuylw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-08</xbrli:startDate><xbrli:endDate>2024-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_12_2023_To_12_12_2023_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_CQWWEiOLTEaaVRh41M4MgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-12</xbrli:startDate><xbrli:endDate>2023-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_lZWG9RJZDEmZsvf2PUlu_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lqda:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2024_To_11_1_2024_dei_LegalEntityAxis_lqda_LiquidiaPAHAndSandozMember_srt_LitigationCaseAxis_lqda_BreachOfContractClaimMember_dVqpqeHTvEyS2ITxDkE5Vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lqda:LiquidiaPAHAndSandozMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lqda:BreachOfContractClaimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-01</xbrli:startDate><xbrli:endDate>2024-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_xRg1wcXNfk271ht3s4kIeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_7_1_2024_XRrRRtHXS0yYWbSCULb-5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_5_2024_To_1_5_2024_viljKiMR20eRuvibROMGtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-05</xbrli:startDate><xbrli:endDate>2024-01-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_cXF6Jhyv9Ums3sgX3ZsQgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_4sm_WwX1i06DJVradQbuAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_rJo_5hCZZ0eoAsQBkZvmzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_icDoJJYujESK_TgeFGGuBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_seQD86Gg-k-g0j-4Yfw1cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_uwLnN9HvMUyPs1gUVBzqIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1P_inS6zXkWNbG-ht9J6vg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_bNNJw9ET4UKPsBG0tkb61Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2wjFZ4y_OU6vooFOFqzXIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_srt_CounterpartyNameAxis_lqda_SandozMember_raO9GBmyIE-5ZvV1IBniiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lqda:SandozMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_PlanNameAxis_lqda_The2020PlanMember_q3rF1sbUKU-D4Hw_9Wjf4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:The2020PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_PlanNameAxis_lqda_InducementPlan2022Member_59X93Oj32UqU-HIAb8N6uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:InducementPlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_IvI4h9c3EUuyg5PQrrLhMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_25_2022_us-gaap_PlanNameAxis_lqda_InducementPlan2022Member_QcdutN2Mc0eer7i2vctGcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:InducementPlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_SvbWarrantTermBAndTermCTranchesMember_wOo46pKdiUGRSW3RPNRPxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lqda:SvbWarrantTermBAndTermCTranchesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_SvbWarrantInitialTrancheMember_vINmu1l2Ck24QYQ5Ny4zow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lqda:SvbWarrantInitialTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_OtherWarrantsMember_n4R8mkRr-0KRugEMPPOtqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lqda:OtherWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_ArSvbWarrantsInitialTrancheMember_ffU72mNG2UiEuncpq3Bk3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lqda:ArSvbWarrantsInitialTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_6z62s4VwhEOUHWT_u7NrVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_h-v_IaJxz0SgsF5X90JwfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_kMc1M1fUA0aLfEacYxGcNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_ANzvLLeodEu35lLZjmLNlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_RXXfSfHAKUOxB0bjch78SQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_hRZjTb3f50WuaHZvxqO0dQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_9fQbmG5QVECfc_dtjchxWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_bAuPCroLc0CrK6O9kr5tog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_TzBMkys33EuWe4DPMyM4ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_Qb1al7pN5Eum9jNVekDffw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_0ZcXs57SsESdiizR7P7_-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_U5I2QUtyeUKSw5V0JR-EtQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_Ccuko3guq0aS4kOvVeM9WQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_aep-yz_sAU6w4KnoDTuRXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_canxHtd-XkG4uVMvRpE1FQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_XlMlf1imU0CKFBvkuE1IEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_QGpDrn6it0u-SFLEKVzU7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_1muCQV59SEeHsD-Yav1p6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9ztv0G7UzkWrHinKet79MQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_5JpbAcp9g0S1jyEmoVFeoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_9Shl9FOqAEm1xT8OQEZiPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_MRV76XSit0KBbsAP3TiUpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_8RApRitnUUKh4kBFAXN1pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_sVbvNMFieEqahGNDqo00CQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_b9IfscRcGUihtJB5srkY2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_wV-uPH-HE0C8hSHXy_alBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_We2fnt_wf0y9QPYfo6rVXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ynF1uQCSmUyLHWdxX__Sxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_8_2024_To_1_8_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_u77gK6C1w06rKnCiKbNkfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-08</xbrli:startDate><xbrli:endDate>2024-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Xp3560lqZU2xfNzbsFaQdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6Z3BVNcjGUCp4hge4qevNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_9bh_UZq1Z06Lu_r7nFqRFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QZw6OTAtg0azS_m5VGB6bA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_f-rSQLlZh0qWc3XMDnx8Sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_athnGX3vVUWNi8j4p4X8yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oTd2Y4azxE6k0h-MkNkt7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_fj9qXeNqAUyr-FVp6nmzpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_wXfmt2J2LE2WLZnDVgzsJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a9uUf5liUEShuVXaMIN48A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_74IJvwrt6EmcH2m1d12TYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_i3PmmyVMRUO1q-dHTQOURQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4juqE32tLUykVWFmMMpgzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_z8Y4XLDSWUyq3w7U4D0TuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wgxF__1apky0OItCKW6-bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jVVuLhnI7EmDjNeG2Ga_NQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_stBhy-3vH0CN55lEF1pbPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ESYXfJPI-k-Cm-6QGRH6Sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_52Y2y5aCZ06_iOiL1avbmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fl_qDLX5AkK2MTZFNhq5Zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5GOcXOaV5U2T36M6_dQLCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Yh1HtfeM1U6dLWe0U9X_hQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_lTtrHrdNKk2SU5Ol2ar1-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_PlanNameAxis_lqda_The2020PlanMember_WZy6bkl5x06pEBTAbp6atA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:The2020PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_xFqmiRrTOkqulJr1LBWAnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_srt_CounterpartyNameAxis_lqda_HealthcareRoyaltyPartnersIvL.pMember_srt_StatementScenarioAxis_lqda_ForCalendarYearBeginningOnJanuary12024Member_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_jT09y22dlU-r4cO26SYVlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lqda:HealthcareRoyaltyPartnersIvL.pMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">lqda:ForCalendarYearBeginningOnJanuary12024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_srt_CounterpartyNameAxis_lqda_HealthcareRoyaltyPartnersIvL.pMember_srt_StatementScenarioAxis_lqda_AfterCalendarYearEndingOnDecember312024Member_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_Eu2lyuSqdUWRsk5xpT6IEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lqda:HealthcareRoyaltyPartnersIvL.pMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">lqda:AfterCalendarYearEndingOnDecember312024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_27_2023_To_1_27_2023_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_ewbpUOaI7UyQVn102NdAXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-27</xbrli:startDate><xbrli:endDate>2023-01-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_k-djEJags0G4_tYSdX2F1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_12_2024_To_9_12_2024_us-gaap_TypeOfArrangementAxis_lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember_90dvyAHXdUi7zLcPG7LSyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:FifthAmendmentToRevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-12</xbrli:startDate><xbrli:endDate>2024-09-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2024_To_9_30_2024_us-gaap_TypeOfArrangementAxis_lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember_L0sD_tmmekuf3ox2hlAg-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:FifthAmendmentToRevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_5_2024_To_1_5_2024_us-gaap_TypeOfArrangementAxis_lqda_FourthAmendmentToRevenueInterestFinancingAgreementMember_KQa5hA-xwU2M20pCIYuA9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:FourthAmendmentToRevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-05</xbrli:startDate><xbrli:endDate>2024-01-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_27_2023_To_7_27_2023_us-gaap_TypeOfArrangementAxis_lqda_SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember_JoeWZnLjZ0ynl9XNGamlHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-27</xbrli:startDate><xbrli:endDate>2023-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2024_To_9_30_2024_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_aLJKJ9CWC0enkGwFB_L9fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_9_2023_To_1_9_2023_srt_StatementScenarioAxis_lqda_OnSecondPortionOfFundedInvestmentAmountMember_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_vs2P5tJ_80ax80uJ--MG3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">lqda:OnSecondPortionOfFundedInvestmentAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-09</xbrli:startDate><xbrli:endDate>2023-01-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_9_2023_To_1_9_2023_srt_StatementScenarioAxis_lqda_OnFirstFundedPortionOfInvestmentAmountMember_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_aXDyEn_Gnkq9Wg0YnjtxyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">lqda:OnFirstFundedPortionOfInvestmentAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-09</xbrli:startDate><xbrli:endDate>2023-01-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_13_2024_To_9_30_2024_i691B_ItG0GtXHNs1Fzb9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-13</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_1_4_2024_lOhuZ940QEqjnjbxJodNUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_12_2024_CIE4XyPuXU-VCdM-JmlrRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_11_2024_Ev9Bn70vFE2agHiszGrR1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_5_2024_3NJ3uFG5A06JS2suMz0vng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-01-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_4_2024_bF-IBdhTwk-KlM3yC7Lrpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-01-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_30_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lqda_PBMMember_BakiyxxweE66bApftnb0xA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">lqda:PBMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_14_2023_us-gaap_OtherCommitmentsAxis_lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember_zRac0Pl5b0Geps4g1_aVUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">lqda:AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2018_To_8_31_2018_srt_CounterpartyNameAxis_lqda_SandozMember_bR-PCAVcsEa0W4IuOAk7hQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lqda:SandozMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-01</xbrli:startDate><xbrli:endDate>2018-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_12_2024_To_9_12_2024_aSxtNfNO5k-96RR4O_eJ5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-12</xbrli:startDate><xbrli:endDate>2024-09-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_12_2023_To_12_12_2023_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_-VeA1df9x0OIOsIgO9z0NA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lqda:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-12</xbrli:startDate><xbrli:endDate>2023-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_srt_CounterpartyNameAxis_lqda_SandozMember_rx6kg0vHT0uP6yMhTHZMqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lqda:SandozMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_srt_CounterpartyNameAxis_lqda_SandozMember_KdRq-SWRhUqv88cPuzMv1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lqda:SandozMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_6_2024_To_9_11_2024_EiDEZtBwZ0mjbahWfp4TWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-06</xbrli:startDate><xbrli:endDate>2024-09-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_srt_MajorCustomersAxis_lqda_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_VjK3Qv7B0EufQgTVe6t9Mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lqda:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_lqda_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_flP9Ohx3sEW9JMma2AxykA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lqda:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_9_2023_To_1_9_2023_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_fo6QHS2lUkOEV604PgAJ-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-09</xbrli:startDate><xbrli:endDate>2023-01-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2023_To_6_30_2023_srt_StatementGeographicalAxis_srt_NorthAmericaMember_us-gaap_OtherCommitmentsAxis_lqda_PharmosaLicenseAgreementMember_QWvVbOqoFUaZurD06Zgd0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">lqda:PharmosaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2023_To_6_30_2023_srt_StatementGeographicalAxis_lqda_OtherThenNorthAmericaMember_us-gaap_OtherCommitmentsAxis_lqda_PharmosaLicenseAgreementMember_PWs3djrXF0qDVpc8vjHEMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lqda:OtherThenNorthAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">lqda:PharmosaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2023_To_6_30_2023_us-gaap_OtherCommitmentsAxis_lqda_PharmosaLicenseAgreementMember_kTOrGdUxVkmmOH0NFjgVRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">lqda:PharmosaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_OtherCommitmentsAxis_lqda_ChasmTechnologiesAgreementMember_17fard0TZkuq54S0aOBFBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">lqda:ChasmTechnologiesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_14_2023_To_7_14_2023_us-gaap_OtherCommitmentsAxis_lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember_9-1NFSrmLU2h8Mehfb8Z0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">lqda:AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-14</xbrli:startDate><xbrli:endDate>2023-07-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_WarrantsToPurchaseCommonStockMember_nREMiBhLNEmIWUNmI18Y6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lqda:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_lqda_WarrantsToPurchaseCommonStockMember_W3GhsPkTi0ad1ra4mD2y0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lqda:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_OtherCommitmentsAxis_lqda_AgreementWithLGMPharmaLLCMember_HIEBrzKy8U2iausIsKFPnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">lqda:AgreementWithLGMPharmaLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_OtherCommitmentsAxis_lqda_PharmosaLicenseAgreementMember_74ZGg3byiEqvxeoe8yh5pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">lqda:PharmosaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_30_2024_hkahraS0RkyEbsZVtds9bQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_customer_rCtGSEdMk0iBBkxQf_23NA"><xbrli:measure>lqda:customer</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_tranche_wUAWxTjoVkeKHp1IAnkhew"><xbrli:measure>lqda:tranche</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment_5Yg_HHT1gEGJPlsg-11Qtw"><xbrli:measure>lqda:segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_361b8e75_0ae2_4fd2_8faa_5941173c7e67"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 7pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 7pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:DocumentType" id="Narr_eBlJJAILukefrQrJJEysSA"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 7pt 0pt;">(Mark One)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:DocumentQuarterlyReport" id="Narr_eos5EDgIEk2xeXyuK4Z9IQ"><span style="font-family:'Segoe UI Symbol';font-style:normal;">&#9746;</span></ix:nonNumeric><b style="font-style:normal;font-weight:bold;"> </b><b style="font-style:normal;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934 </b><span style="font-style:normal;">For the fiscal quarter ended </span><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:DocumentPeriodEndDate" id="Narr_h3hY9j1UjUmFa8-kqR-Cmw"><span style="font-style:normal;">September&#160;30,&#160;2024</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 7pt 0pt;">or</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:0.7pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:10.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:7pt;margin-top:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:DocumentTransitionReport" id="Narr_l-iXA6wKBk2zR0V2Mbuj-g"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:7pt;margin-top:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b> For the transition period from to</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 7pt 0pt;">Commission File Number: <ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:EntityFileNumber" id="Narr_U7406VX_UU-X3PGvS9WfbA">001-39724</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:EntityRegistrantName" id="Narr_hPgZ9BV1O02kSO2eyruK_w"><b style="font-weight:bold;">LIQUIDIA CORPORATION</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Exact Name of Registrant as Specified in Its Charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_10b3b943_d1c5_407b_a828_35111e38747f"></a><a id="Tc_EXiV1zkyt0i4KJWBiNOSIQ_2_0"></a><a id="Tc_C5ENyyS1Ik-MN69wLgjfbQ_2_2"></a><a id="Tc_1zh45xSBvU-WUXmN8gbvpw_4_0"></a><a id="Tc_Na2kQcyTW0Wk229W7K8IAg_5_0"></a><a id="Tc_8RKN0Qcd30KoM4Jhk1zzAQ_5_2"></a><a id="Tc_Vi56fDw88UCNT23u03BfyQ_6_0"></a><a id="Tc_gXNpS1AzX0CnuoKeBnBdRA_7_0"></a><a id="Tc_YONDQWopukSFs_F1oyW27g_8_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.7pt;"><td style="vertical-align:bottom;width:49.12%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:EntityIncorporationStateCountryCode" id="Tc_wevI8ers1E-pQ58UKWyBCA_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.96%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:48.91%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:EntityTaxIdentificationNumber" id="Tc_K5elnsxmzU2P39Ku3X4vog_1_2"><b style="font-weight:bold;">85-1710962</b></ix:nonNumeric></p></td></tr><tr style="height:11.2pt;"><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(State or Other Jurisdiction of Incorporation or Organization)</p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr><tr style="height:12.25pt;"><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:EntityAddressAddressLine1" id="Tc_XVL2tPPuGEKNKfT_DjL2ZQ_3_0"><b style="font-weight:bold;">419 Davis Drive, Suite&#160;100</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:12pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.7pt;"><td style="vertical-align:bottom;width:49.12%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:EntityAddressCityOrTown" id="Narr_u43_mxCeS0aqkDLmMf_Gqg"><b style="font-weight:bold;">Morrisville</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:EntityAddressStateOrProvince" id="Narr_diigUlvSlEuMyJ7YajJyDA"><b style="font-weight:bold;">North Carolina</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.96%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:48.91%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:EntityAddressPostalZipCode" id="Tc_Y_slWv76qkOu0l-5eJn7_Q_4_2"><b style="font-weight:bold;">27560</b></ix:nonNumeric></p></td></tr><tr style="height:11.2pt;"><td style="vertical-align:bottom;width:49.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Address of Principal Executive Offices)</p></td><td style="vertical-align:bottom;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr><tr style="height:9.55pt;"><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Registrant&#8217;s telephone number, including area code: <b style="font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:CityAreaCode" id="Narr_UzmBNXJFkkWR4qItUW7xdA"><b style="font-weight:bold;">919</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:LocalPhoneNumber" id="Narr_4o21ahoHT0C_PUUbwchBTw"><b style="font-weight:bold;">328-4400</b></ix:nonNumeric></p></td></tr><tr style="height:11pt;"><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">N/A</b></p></td></tr><tr style="height:11.5pt;"><td colspan="3" style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Former name, former address and former fiscal&#160;year, if changed since last report)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><a id="_583ccefe_96b8_4ee4_8a1a_8e8e7df15549"></a><a id="Tc_uh4MUMRLuEmg-xYXH_BcQA_1_0"></a><a id="Tc_ddDpmIs3nEioBW9cJ1XoPA_1_1"></a><a id="Tc_TPMBTmUxeUOYMsgnH7yBFA_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:20.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:44.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:10.65pt;"><td style="vertical-align:bottom;width:35.16%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;width:20.79%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:bottom;width:44.03%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr style="height:10.3pt;"><td style="vertical-align:bottom;width:35.16%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:Security12bTitle" id="Tc_x0hJxo3JPkWnuHTv63zbAw_2_0">Common stock, $0.001 par value per share</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:20.79%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:TradingSymbol" id="Tc_yyPN5iac8Eu45sRu8USvQw_2_1">LQDA</ix:nonNumeric></p></td><td style="vertical-align:bottom;width:44.03%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:SecurityExchangeName" id="Tc_sxgoY6Klsk2hqys6VDO-MQ_2_2">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:EntityCurrentReportingStatus" id="Narr_jKBvUX_KaE-eHSygXMWPJQ">Yes</ix:nonNumeric> <span style="font-family:'Segoe UI Symbol';">&#9746;</span> No <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:EntityInteractiveDataCurrent" id="Narr_DxyhJBemyEqvBqn030ZdmA">Yes</ix:nonNumeric> <span style="font-family:'Segoe UI Symbol';">&#9746;</span> No <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Large Accelerated Filer <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accelerated Filer <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:EntityFilerCategory" id="Narr_exTsc8kkq0O2yd_3d7V2Qg"><span style="font-size:8pt;">Non-accelerated Filer</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p></td><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Smaller Reporting Company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:EntitySmallBusiness" id="Narr_7ybVGWW5OEKRj8xR7mTYwA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Emerging Growth Company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:EntityEmergingGrowthCompany" id="Narr_iijZ8Umq9UWSoUdfu-Qhbg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 7pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 7pt 0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). Yes <ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="dei:EntityShellCompany" id="Narr_PLQwA2UdcUayWSVrc1Mspw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric> No <span style="font-family:'Segoe UI Symbol';">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of October 30, 2024, there were <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_10_30_2024_hkahraS0RkyEbsZVtds9bQ" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_AEPazt8UqkOAWz8kxfhCpQ">84,636,621</ix:nonFraction> shares of the registrant&#8217;s common stock outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt 0pt 7pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 7pt 0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_6dc1221a_72e7_4d9d_954c_d3849ad55577"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">LIQUIDIA CORPORATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:81.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:81.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:92.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Page</p></td></tr><tr style="height:12.7pt;"><td colspan="3" style="vertical-align:bottom;width:92.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTI"><span style="font-style:normal;font-weight:normal;">PART&#160;I. FINANCIAL INFORMATION</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item1CondensedFinancialStatements"><span style="font-style:normal;font-weight:normal;">Item 1.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1CondensedFinancialStatements"><span style="font-style:normal;font-weight:normal;">Condensed Financial Statements (unaudited)</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 39pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;"><a href="#ConsolidatedBalanceSheets_307918"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 39pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;"><a href="#ConsolidatedStatementsofOperationsandCom"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2024 and 2023</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 39pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:81.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ConsolidatedStatementsofStockholdersEqui"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Stockholders&#8217; Equity for the Three and Nine Months Ended September 30, 2024 and 2023</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">8</p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 39pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;"><a href="#ConsolidatedStatementsofCashFlowsUnaudit"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">9</p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 39pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:81.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NotestoConsolidatedFinancialStatementsUn"><span style="font-style:normal;font-weight:normal;">Notes to </span><span style="font-style:normal;font-weight:normal;">Condensed </span><span style="font-style:normal;font-weight:normal;">Consolidated Financial Statements</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10</p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 39pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#MDandA"><span style="font-style:normal;font-weight:normal;">Item 2.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#MDandA"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">32</p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:81.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Item 3.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">44</p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:81.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item4ControlsandProcedures_859066"><span style="font-style:normal;font-weight:normal;">Item 4.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_859066"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">44</p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:81.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:92.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTII_408667"><span style="font-style:normal;font-weight:normal;">PART II. OTHER INFORMATION</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:81.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item1LegalProceedings_577079"><span style="font-style:normal;font-weight:normal;">Item 1.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_577079"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">46</p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:81.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item1ARiskFactors"><span style="font-style:normal;font-weight:normal;">Item 1A.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">46</p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:81.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item5OtherInfo"><span style="font-style:normal;font-weight:normal;">Item 5.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInfo"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">89</p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#Item6Exhibits_907929"><span style="font-style:normal;font-weight:normal;">Item 6.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_907929"><span style="font-style:normal;font-weight:normal;">Exhibits</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">90</p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:81.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 39pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:81.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3pt 0pt 0pt;"><a href="#SIGNATURES_439630"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">91</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This Quarterly Report on Form&#160;10-Q, or this Quarterly Report, includes our trademarks, trade names and service marks, such as Liquidia, the Liquidia logo, YUTREPIA and PRINT, or <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">P</span>article <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">R</span>eplication <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">I</span>n <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">N</span>on-wetting <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">T</span>emplates, which are protected under applicable intellectual property laws and are the property of Liquidia Technologies, Inc. This Quarterly Report also contains trademarks, trade names and service marks of other companies, which are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this Quarterly Report may appear without the &#174;, &#8482; or <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties&#8217; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_231f6008_45d9_4891_9fbe_e475767338b8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Cautionary Note&#160;Regarding Forward-Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;">This Quarterly Report on Form&#160;10-Q contains forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report may be forward-looking statements. The forward-looking statements are contained principally in the sections entitled &#8220;Risk Factors,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; but are also contained elsewhere in this Quarterly Report. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;intends,&#8221; &#8220;targets,&#8221; &#8220;projects,&#8221; &#8220;contemplates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates, including the potential for, and timing regarding, final approval by the FDA (as defined below) of and our ability to commercially launch YUTREPIA, including the potential impact of regulatory review, approval, and exclusivity developments which may occur for competitors, and the scope of any such approvals and the indications for which we receive approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timeline or outcome related to our patent litigation with United Therapeutics that was filed in the U.S. District Court for the District of Delaware, our litigation with United Therapeutics that was filed in the Superior Court for Durham County, North Carolina, the lawsuit we filed against the FDA in the U.S. District Court for the District of Columbia, including the cross claims filed by United Therapeutics in that action, or any future litigation with United Therapeutics or any other third-party, including any related rehearings or appeals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and our business partners&#8217; ability to obtain and maintain regulatory clearance for the infusion pump that we are developing with Sandoz (as defined below) and Mainbridge (as defined below);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and our ability to obtain and maintain regulatory approval for L606, an investigational, liposomal formulation of treprostinil that we licensed from Pharmosa (as defined below);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to continue operations as a going concern without obtaining additional funding;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding the size of the patient populations, market acceptance, third-party payor coverage and opportunity for those drug products that we commercialize in collaboration with third parties, including Sandoz&#8217;s first-to-file fully substitutable generic treprostinil injection;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability and market acceptance of medical devices and components of medical devices used to administer our drug products and drug products that we commercialize with third parties, including ICU Medical&#8217;s CADD-MS 3 infusion pump, the RG 3ml Medication Cartridge that we developed in collaboration with Chengdu Shifeng Medical Technologies LTD. used for the subcutaneous administration of Sandoz&#8217;s generic treprostinil injection, ICU Medical&#8217;s CADD Legacy and CADD-Solis infusion pumps used for the intravenous administration of Sandoz&#8217;s generic treprostinil injection, the infusion pump that we are developing with Sandoz and Mainbridge for the subcutaneous administration of Sandoz&#8217;s generic treprostinil injection, Plastiape&#8217;s RS00 Model 8 dry powder inhaler, which we plan to use for the administration of YUTREPIA, and any devices used for the administration of L606;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to satisfy the covenants contained in the RIFA (as defined below);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to retain, attract and hire key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prevailing economic, market and business conditions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to predict, foresee, and effectively address or mitigate future developments resulting from health epidemics or other global shutdowns, which could include a negative impact on the availability of key personnel, the temporary closure of our facility or the facilities of our business partners, suppliers, third-party service providers or other vendors, or delays in payments or purchasing decisions, or the interruption of domestic and global supply chains, the economy and capital or financial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost and availability of capital and any restrictions imposed by lenders or creditors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the industry in which we operate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the failure to renew, or the revocation of, any license or other required permits;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unexpected charges or unexpected liabilities arising from a change in accounting policies, including any such changes by third parties with whom we collaborate and from whom we receive a portion of their net profits, or the effects of acquisition accounting varying from our expectations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that the credit ratings of our company or our subsidiaries may be different from what the companies expect, which may increase borrowing costs and/or make it more difficult for us to pay or refinance our debts and require us to borrow or divert cash flow from operations in order to service debt payments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fluctuations in interest rates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse outcomes of pending or threatened litigation or governmental investigations, including our ongoing litigation involving United Therapeutics and the FDA and any future litigation with United Therapeutics, the FDA or any other third party;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effects on our company or our subsidiaries of future changes in law, including regulatory developments or legislative actions, including changes in healthcare, environmental and other laws and regulations to which we are subject, or judicial decisions overturning or establishing new legal precedents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conduct of and changing circumstances related to third-party relationships on which we rely, including the level of credit worthiness of counterparties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the volatility and unpredictability of the stock market and credit market conditions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">conditions beyond our control, such as natural disasters, global pandemics, or acts of war or terrorism;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variations between the stated assumptions on which forward-looking statements are based and our actual experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other legislative, regulatory, economic, business, and/or competitive factors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our plans to develop and commercialize our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our planned clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of the availability of data from our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and related contents of our planned regulatory filings and/or applications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical utility of our product candidates and their potential advantages compared to other treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our commercialization, marketing and distribution capabilities and strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain arrangements for the manufacture of our product candidates and the ability and sufficiency of our current manufacturing facilities to produce development and commercial quantities of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain collaborations, including any third-party license agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our estimates regarding the market opportunities for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our intellectual property position and the duration of our patent rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fluctuations in the trading price of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our estimates regarding future expenses, capital requirements and needs for additional financing; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expected use of proceeds from prior public offerings and the period over which such proceeds, together with our available cash, will be sufficient to meet our operating needs.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 12pt 7.2pt;">You should refer to the &#8220;Risk Factors&#8221; section of this Quarterly Report on Form 10-Q for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions, and we may not actually achieve the plans, intentions or expectations included in our forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 12pt 7.2pt;">These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. While we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Quarterly Report on Form&#160;10-Q.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;"><i style="font-style:italic;">Unless the context otherwise requires, references in this Quarterly Report on Form 10-Q to </i>&#8220;<i style="font-style:italic;">we,</i>&#8221;<i style="font-style:italic;"> </i>&#8220;<i style="font-style:italic;">us</i>&#8221;<i style="font-style:italic;">, </i>&#8220;<i style="font-style:italic;">our</i>&#8221;<i style="font-style:italic;">, </i>&#8220;<i style="font-style:italic;">Liquidia</i>&#8221;<i style="font-style:italic;"> and the </i>&#8220;<i style="font-style:italic;">Company</i>&#8221;<i style="font-style:italic;"> refer to Liquidia Corporation, a Delaware corporation, and unless specified otherwise, include our wholly owned subsidiaries, Liquidia Technologies, Inc., a Delaware corporation, or Liquidia Technologies, and Liquidia PAH, LLC (formerly known as RareGen, LLC, or RareGen), a Delaware limited liability company, or Liquidia PAH.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;"><span style="font-style:italic;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><a id="PARTI"></a><a id="_PART_I._FINANCIAL"></a><a id="_0939c5b3_87d2_4904_9fea_8b9605c8e2fc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">PART I. FINANCIAL INFORMATION </p><a id="_Item_1._Condensed"></a><a id="Item1CondensedFinancialStatements"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1. Condensed Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liquidia Corporation</b></p><a id="ConsolidatedBalanceSheets_307918"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Condensed Consolidated Balance Sheets (unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_0de6e4c8_6cce_4e72_a7b5_6b64790c6bd6"></a><a id="Tc_G6oYc7E_L0KloQfKpMR3Bw_1_2"></a><a id="Tc_KyjJ1v9-U0ySzWNmQenFaw_1_5"></a><a id="Tc_dFDa86A7Mk-GqX_oSJKHag_2_2"></a><a id="Tc_c9bytsH8dki89SZSd4yLkA_2_5"></a><a id="Tc_6TK6iRRVkUO9cse5zrfANA_3_0"></a><a id="Tc_yXzHBaJsz0a9xlG4TCBFFA_4_0"></a><a id="Tc_nIsagyWZ8U2eIC4TsapMAA_5_0"></a><a id="Tc_-vmNTCBZ_0axH5x5KU-DIw_5_2"></a><a id="Tc_AEXIUf8Af0imXvyUDVVoQw_5_5"></a><a id="Tc_IWWZ3Z08j0ONm1Gyh-clMg_6_0"></a><a id="Tc_UYkMNn1eREGctyK8NnvfPw_7_0"></a><a id="Tc_SQ_fKSYG8UuBOd3CmtYjtQ_7_6"></a><a id="Tc_8hb_yTLW5UKVCsoVyFheyA_8_0"></a><a id="Tc_Iddsi0Gfc0KtLtxnp132Jg_9_0"></a><a id="Tc_zAwN7tAOH0KZm2Jc4UIhJA_10_0"></a><a id="Tc_avtEBT_2LUSxuUTBjin8KA_11_0"></a><a id="Tc_Q05eSHMTlkue30jfrO5q6A_12_0"></a><a id="Tc_-GMSN3tPEUuz1jhBcx8n8w_13_0"></a><a id="Tc_bnfJa_u1Wk-i4pmm8M-kAw_14_0"></a><a id="Tc_KG_0pwg1ZEWj7oivEP0WZQ_15_0"></a><a id="Tc_7ZBS1lkvqEWPofbUGweISQ_16_0"></a><a id="Tc_StLO8zi98Uitzj7T8ZFYhA_17_0"></a><a id="Tc_jE8xAWqpkU2WeTcnIovH_Q_17_2"></a><a id="Tc_WXjv_dHWqEmt0Yj9XzcZKw_17_5"></a><a id="Tc_u3TZdqfB2UKgzQhBgM75FA_18_0"></a><a id="Tc_OH7NxF8J-UK5LBOeUM_uag_19_0"></a><a id="Tc_oMkdMExeF0O-yGGVqpeJTQ_20_0"></a><a id="Tc_gm0Dsu-W0E-04NacGQuUYA_20_2"></a><a id="Tc_E8Nv9LcovkWy7pbbBZ9tJg_20_5"></a><a id="Tc_YM4IZVlvEkuPAniSoKsqiQ_21_0"></a><a id="Tc_gPax3vxDt0iP2OStfbvwXQ_22_0"></a><a id="Tc_sD4kulrwZkuA3DjjbW5uMA_23_0"></a><a id="Tc_JRYom4Z1uU-6kZxv-Cd9PQ_24_0"></a><a id="Tc_Lz6xr06DEU6oyKQFmhJiQA_25_0"></a><a id="Tc_mIRTDCMlMEiaHHPrKaip8Q_26_0"></a><a id="Tc_TxjE50cheUW76mxmKlwJhA_27_0"></a><a id="Tc_ezYF0DBG1ECA63hqZZNxOg_28_0"></a><a id="Tc_0tQag-g_10eIASWF4GqI3g_29_0"></a><a id="Tc_Glp66jhqm06y-YcxMyI9dw_30_0"></a><a id="Tc__Lz_IOAOck27p5fjbEOuoA_31_0"></a><a id="Tc_J6xWtLvDAkKPUJjpCpGWZA_32_0"></a><a id="Tc_idtqiHM0mkySmowiJWu4Wg_33_0"></a><a id="Tc_5hpH42E3fE6T8dI7ZcWZjA_34_0"></a><a id="Tc_S9qHDRam7kKCYzRSB3lRqA_35_0"></a><a id="Tc_k4WK6MbMdEGN68zZeQoROg_36_0"></a><a id="Tc_ZuR-qaUA-0Cq7NKH4jflQw_36_2"></a><a id="Tc_YiBItYoEY0OWzsBAYjbmfA_36_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc__k7ZwiqYWE283SpY0IhzKA_5_3">204,368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_434QywMtWE2_ePZ4lVFOrA_5_6">83,679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts receivable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_NlFzQKe92UydYcSVjqY4fw_6_3">4,202</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_KxNJXB4XkUWfbrpHYQdFVA_6_6">4,061</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_c8F9YFrK2UuQEgwgL0J-EQ_7_3">38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_QvTXJ_mhx0GFHRAwswYR_w_8_3">5,604</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_oyoBQAhsHk-lPcfjpSfTNA_8_6">2,159</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_U9Rw-zkITkKcqlofB7ZUAw_9_3">214,212</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_YDLnp5PCKEmRXMC8NULU8A_9_6">89,899</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, plant and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_qHKc1GvHS0OAq5J7-DglrQ_10_3">7,784</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_wB4nKdzuKEC2xwnp_0Ii0A_10_6">4,480</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease right-of-use assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_qsSQ2lyHekeMDjD4s_gX9g_11_3">1,371</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_wg2Spk-rdkqtimSb2VghVA_11_6">1,704</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Indemnification asset, related party</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:IndemnificationAssetRelatedParty" scale="3" id="Tc_ppCjovzm90O6apJRBXEWrA_12_3">7,206</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="lqda:IndemnificationAssetRelatedParty" scale="3" id="Tc_UtuilfXCk06I0xTh3WDcCg_12_6">6,707</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract acquisition costs, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:BusinessCombinationContractAcquisitionCostsNet" scale="3" id="Tc_320CGRAK4k-fDtjQjaUnbA_13_3">7,433</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="lqda:BusinessCombinationContractAcquisitionCostsNet" scale="3" id="Tc__Nm982K6YE24aQJsAJWEmg_13_6">7,922</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible asset, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_yRk5Q49TNE6ryF9NDNm9fA_14_3">3,219</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_x2Y44X29Rkyoesoo9Emf1Q_14_6">3,430</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="Tc_2PiVWdLFLEiAhLT8y6FTwQ_15_3">3,903</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="Tc_eftr8Mzk2U-RwqX00JuQYg_15_6">3,903</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_7EidA0en5kKswJTDY8jtWQ_16_3">7,758</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_RLRsK-wh90-H3TjtvIUkMw_16_6">287</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_y-ay9O-3xkeXCgjr7rchEg_17_3">252,886</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_xLArdtuSlUqTo6lZwMOWug_17_6">118,332</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and stockholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_MFiIwSq1fUie2O7DwX2mhw_20_3">2,298</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_hjxpbJglM0KVXfpBV9XmLQ_20_6">1,396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:AccruedExpensesAndOtherLiabilitiesCurrent" scale="3" id="Tc_x4nXw76SMU2qe4gd-EnTvw_21_3">17,039</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="lqda:AccruedExpensesAndOtherLiabilitiesCurrent" scale="3" id="Tc_qd4Bdezg5kmLb5n-zQGC7Q_21_6">13,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Revenue interest financing payable, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingPayableCurrent" scale="3" id="Tc_SSfIWzV9V0uAfLLzd6xiqA_22_3">13,252</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingPayableCurrent" scale="3" id="Tc_aCW2p3ZQdUOClahpz1YPtA_22_6">2,615</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating and finance lease liabilities, current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:OperatingAndFinanceLeaseLiabilityCurrent" scale="3" id="Tc_hLpfY10DnU2KE9u5YLRfaA_23_3">1,249</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="lqda:OperatingAndFinanceLeaseLiabilityCurrent" scale="3" id="Tc_p81uTLM24kGWpc9TeLzRCw_23_6">1,139</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_S1oRdiOcz0qGHhjWCncGlQ_24_3">33,838</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_aPg7akutLUWaQc_FdauxMg_24_6">18,550</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Litigation finance payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LitigationReserveNoncurrent" scale="3" id="Tc_Y1WpZfZVZkOJ8kpQaRdZDw_25_3">7,196</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LitigationReserveNoncurrent" scale="3" id="Tc_qclzraLzCke6O-ghadNqVg_25_6">6,707</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue interest financing payable, noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingPayableNoncurrent" scale="3" id="Tc_5mYf1qerAU6hYqe3cvA6WQ_26_3">99,892</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingPayableNoncurrent" scale="3" id="Tc_w_W-v_dnhUa1u9DJ7vFoLw_26_6">43,418</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating and finance lease liabilities, noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:OperatingAndFinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_smpgkaz2vUCbqcH70hWGpg_27_3">1,442</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="lqda:OperatingAndFinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_iFlHJAE-q0qt5ck3Q_CoFQ_27_6">2,364</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_Kq3mH77CwkWIaoOV67W_rQ_28_3">142,368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_y3_FGT4Tg0WyycBu13kErw_28_6">71,039</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commitments and contingencies (Note 13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Preferred stock &#8212; <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_F39jKySA5UKxJd6_-JNYZg"><ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_12s4QOrn7Ui2MGL2ynNoVA">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_LWuWzjfzh0insGgPhL5j1Q"><ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_n1fMzCwD6UChavKeJd61Bg">none</ix:nonFraction></ix:nonFraction> outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="Tc_PGL4ZB71rkWg2JjC9XZqFg_31_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="Tc_Pxh6Ug_Kg0uLe-0EPt3Log_31_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Common stock &#8212; $<ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_LpTJuno240-c8EVrhMDwcQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_owkuqdVu70W8S6mOFA2ldA">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_Ucqfcs0APE274bD7t4W-_g">115,000,000</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_gnwou4P7HESn3kr-4Nlh4g">100,000,000</ix:nonFraction> shares authorized as of September&#160;30,&#160;2024 and December&#160;31,&#160;2023, respectively, <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_BTk0JBctG0qUQLaKWtoA5A"><ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_mvSuteEi_UmcSn5OSGwkKQ">84,545,409</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_vXrcdJ_SG0ikaS4oayc8lA"><ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_6_XR6f-EhUeRK_F6FOQ-Fg">68,629,575</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September&#160;30,&#160;2024 and December&#160;31,&#160;2023, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_loCn1Im8a0qWjNoXN6rh3w_32_3">85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_R7Dm2aqHTE2A12vIjsN7Mw_32_6">69</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_8iUhOrH410SAGY0bx_B2Ew_33_3">631,556</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_3m2JjAuLoEqA9pNUAoXfaQ_33_6">476,322</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_vLLCTXeF-U-irntBP97anA_34_3">521,123</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_SMTfdSTGvUezDVO1Mc98ww_34_6">429,098</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_x1qOS4Fm3Eee_cRMgSVnIw_35_3">110,518</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_UbhyNNU6jUetDd1WGC3kuw_35_6">47,293</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_8XMyEULSy0KLodKCfzv7DQ_36_3">252,886</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_q3IYQmprVkOwMpUozmzzsQ_36_6">118,332</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p><a id="_00cc8133_a5c9_4722_a0f6_d28719d7d7d8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liquidia Corporation</b></p><a id="ConsolidatedStatementsofOperationsandCom"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_72d36845_7b46_48d2_8899_58e25065ce15"></a><a id="_27f9573b_4131_44de_8292_5f3d7fe9455e"></a><a id="Tc_PRYIS1scCk-7nKlBo16ryA_1_2"></a><a id="Tc_bp5sRbX5IEuC9_NeDz8Hug_1_8"></a><a id="Tc_36puzuOb-ke8aocg7EmBbw_2_2"></a><a id="Tc_L406ZmBBcEKLr64-BUdopQ_2_5"></a><a id="Tc_AOh6uzF6HUSffRZavpe-VQ_2_8"></a><a id="Tc_q_zw5SkI3UG7mUmy7ZUAug_2_11"></a><a id="Tc_ye3omDKX3EOp9mKnTQ9Ykw_3_0"></a><a id="Tc_D8obNi2-xkePB9D1aDwYDQ_3_2"></a><a id="Tc_MAO5BuJAcUCJB8Ps56_fuQ_3_5"></a><a id="Tc_BV9ysra1PEuNGtk7zsm5eQ_3_8"></a><a id="Tc_W7A7sz3Na0ayva7Iv0B2yw_3_11"></a><a id="Tc_NKNFrJOWKkyZco-zGOOj3A_4_0"></a><a id="Tc_u4EktJgNcEKkvpyAT6l65Q_5_0"></a><a id="Tc_30KlRZm7l023UtzXGqGBNQ_6_0"></a><a id="Tc_c8wTOvJxsUGOeh6i2xM2jg_7_0"></a><a id="Tc_XqadPMKPiU6C7UuHgi2COA_8_0"></a><a id="Tc_eSuICa1nrk2KW_aQDA5blQ_9_0"></a><a id="Tc_Hv-pUvYg-UadZ5LK12l5_g_10_0"></a><a id="Tc_UyaDhklrtEugI2-yg_nzng_11_0"></a><a id="Tc_IQc7iDwyRkCd6l9cIAyRIw_12_0"></a><a id="Tc_OeTLwjOr0Uenq88C4m3ViQ_13_0"></a><a id="Tc_vjwDtisYCUyyp5GJQcBH5A_13_6"></a><a id="Tc_xlSXfLFt_0GfVUx-QccwGQ_14_0"></a><a id="Tc_LEj6MPgOhkOICqs8NOoILg_15_0"></a><a id="Tc__mtQi4KwckGrHNw9TgjX5g_15_2"></a><a id="Tc_4b4OluzJuUqaGftnFK1qLw_15_5"></a><a id="Tc_DtUVb-4TrkW8l_Q5TimVEg_15_8"></a><a id="Tc_rNnWvBYXkEi6pDh15R0n_w_15_11"></a><a id="Tc_HsMKcbH-Akm7I-fXPEKgpA_16_0"></a><a id="Tc_2wyLAPzAekezeOz8LTTt2w_16_2"></a><a id="Tc_Qm9E1nEwyE-hbw57NzwtqQ_16_5"></a><a id="Tc_VJd2pQcn8UKSiALZs-X0kw_16_8"></a><a id="Tc_R9zt2ATu_EaIkCNJSExLNQ_16_11"></a><a id="Tc_j1168RnLJUOtwGa3oMf6eA_17_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:44.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:44.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:44.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_Vu1d2mLJJk6cbHSHVagG1w_3_3">4,448</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_oG9EuTySOk2ayTx_UqOP6g_3_6">3,678</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_RoAaS_VQwEuHelAeWiirvQ_3_9">11,079</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="Tc_aNgngLYKDkSq3YPhRMy1Mw_3_12">12,957</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Costs and expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:44.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_L0ZRCScwL0qpXzOhouxu1w_5_3">1,565</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_RQjnnwy_MkS9Rn8aJdytDQ_5_6">570</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_C5XFeB-f3E6PkXzt5VF23A_5_9">4,525</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="Tc_7KS5L2eaq0CZB_utBCw6bQ_5_12">1,895</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_GfKGINGn3kG5LLGGK6kpoQ_6_3">11,890</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_uQ5s5KGr70OGP7Iqwg0nHg_6_6">7,440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_3fC-9iTps06qrMYE_PtNZQ_6_9">31,367</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_T3P0ytPGg0aKnrCDhywr8g_6_12">30,413</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_DBGDKSEg3kiFw_e7080yJQ_7_3">20,182</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_ELVS3k4Qb0-GyGU-NSR19A_7_6">10,559</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_ldE_mNik6kqMoQYu1_z72A_7_9">60,374</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_L2koxWtYdkeTaZ63auoNUw_7_12">27,597</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total costs and expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_hoOG6eBxf06iuQQQWBSsAA_8_3">33,637</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_AqN3x6T1H0aJVOVYVgsTdw_8_6">18,569</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_XLRiEoxZ1UmybC2fG05Pfg_8_9">96,266</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="Tc_Et1jF9sJAEeN1GrLuVzmmw_8_12">59,905</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_y2Z5rm2ho0qCBanIhn7oyw_9_3">29,189</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_mTryNOVNpEi4BTp4M-rfNg_9_6">14,891</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_Pr9awI8sKEWN9Bm23tTbaw_9_9">85,187</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_0ZeXRbVFfEy-ipHvymbzxg_9_12">46,948</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:44.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:44.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_omGpBAT0qU2t8zWTXk-uCA_11_3">1,815</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_11nHhjFMWEyYL8-w6ryjTA_11_6">862</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_mj95ncP9ukyvMyRZh6evXw_11_9">5,550</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_MpPQM7NkU06fkr-Q6Xc5Kw_11_12">2,518</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:44.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_wna3WpuN20W0j_N4c52pHA_12_3">2,996</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_WiE0BKmqe0CXZrnMXUVXzQ_12_6">1,761</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_1R5PV8ZCq0e_1pgXJgDilg_12_9">8,120</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_yaWSRkslYke-MAyvSDCadA_12_12">4,311</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:44.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gain (loss) on extinguishment of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="Tc_X7UVgW2YBUGOsOb-Y_wjng_13_3">7,215</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_LBldoN7QL0yynNfBTMWfRA_13_9">4,268</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_CRUtrWDOtkew3g4OxnfmJQ_13_12">2,311</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:44.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_NFG6XNl2eUix5flSgRCTWg_14_3">6,034</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_NYrK4iQrXUmnlx3PTvZywg_14_6">899</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_2dw_g9KNRUehVr0ugFdQGg_14_9">6,838</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_ydZPtjgVkUSSmFjsCukyKg_14_12">4,104</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:44.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss and comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_iUAfF4_UYUOgQMwkoUx1eg_15_3">23,155</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_pIrSTG3b3Ee63bhiKqymHQ_15_6">15,790</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Z59PncgqMUaFQUSWdrVebA_15_9">92,025</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_M5TzcYMq306p4R76Y_Z83A_15_12">51,052</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:44.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per common share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_9DmcWEg4XUKJaGGzoG4D9g_16_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_9DmcWEg4XUKJaGGzoG4D9g_16_3_2">0.30</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_tXOtIRfl7kS22p8G6d0B1g_16_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_tXOtIRfl7kS22p8G6d0B1g_16_6_2">0.24</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_ApHc9bEkfkCtIBkuNj1U_g_16_9"><ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_ApHc9bEkfkCtIBkuNj1U_g_16_9_2">1.20</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_uXekJ52DYECMmrwnHJv2RQ_16_12"><ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_uXekJ52DYECMmrwnHJv2RQ_16_12_2">0.79</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:44.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_gb1Nyy-zV0mw2tD7YavBvg_17_3"><ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_gb1Nyy-zV0mw2tD7YavBvg_17_3_2">78,316,820</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_hhDlFayXzEWhE__06UxTSg_17_6"><ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_hhDlFayXzEWhE__06UxTSg_17_6_2">64,857,508</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_Yy3ZrCy1W0iCZlKhqsyqZw_17_9"><ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_Yy3ZrCy1W0iCZlKhqsyqZw_17_9_2">76,719,990</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_wy4IjjZ6xUiUenlmOL_oZA_17_12"><ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_wy4IjjZ6xUiUenlmOL_oZA_17_12_2">64,767,893</ix:nonFraction></ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_2fb5d0ce_5f88_45f1_ae6b_33fc3fcf29f6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liquidia Corporation</b></p><a id="ConsolidatedStatementsofStockholdersEqui"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Condensed Consolidated Statements of Stockholders&#8217; Equity (unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands, except shares amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_6acef719_c40d_414c_a19d_be46dad2b98a"></a><a id="Tc_CelIU3vHSU-HhO-Rsg-RSg_2_2"></a><a id="Tc_L9EaMw02C0W1bZ5PkpCbOg_2_4"></a><a id="Tc_pnYoCMVJTkmoYyreps2pAg_2_7"></a><a id="Tc_ZPVOko1duEiaBurtzrO9lg_2_13"></a><a id="Tc_HAEXKhA8TU2kzfW9fR1B2g_3_2"></a><a id="Tc_uDKjJMB0Z0Ob16RAFBkdTQ_3_4"></a><a id="Tc_viRX8ovr-E2FYZGpFDxEIQ_3_7"></a><a id="Tc_PuUk16ig6U2XbtEYVjcV3w_3_10"></a><a id="Tc_HQJcJEob60Oerb5Argjp4A_3_13"></a><a id="Tc_Soh9NMQyrUiPCH5WIf_JjA_4_2"></a><a id="Tc_MSSdmi8uh0mzhqPjWSw4pw_4_4"></a><a id="Tc_1uUahh_3jk2NV1TUIng8YQ_4_7"></a><a id="Tc_KRfaxIZjfUC4x8Qu2MDVlg_4_10"></a><a id="Tc_gNKwoTr-lUaQna_G9zHbxA_4_13"></a><a id="Tc_U5mOYueBrUil6lzbcQ6MIw_5_0"></a><a id="Tc_9-JL64Uoh0CdOe6FI68mGw_5_4"></a><a id="Tc_iehCXpChpkK9aJIsZ-Af9Q_5_7"></a><a id="Tc_xHrJyIirKUSLDGOo2f-UEQ_5_10"></a><a id="Tc_sTohQBN_6kmSQ-PQTjuWvQ_5_13"></a><a id="Tc_ThjvDu-XSUiP0wb3hXa-uw_6_0"></a><a id="Tc_JrUNx5XtIkOzWqPrtFNIdQ_6_5"></a><a id="Tc_mJvo9cOyzU6Gu2YWJ4VbMQ_7_0"></a><a id="Tc_bpN0jS3C9US1rXzhBvlfFg_7_5"></a><a id="Tc_-VKULnCMZUSzwPIQQh-tSg_7_8"></a><a id="Tc_idMXXWP3VUC5h-FfFiW93g_7_14"></a><a id="Tc_uWdVUwE25EWTTGdrEZKFWg_8_0"></a><a id="Tc_2FfEIVFh3kWNSUJFC0yjBg_8_5"></a><a id="Tc_6y1hJUsREEqK3uBdniyFOA_9_0"></a><a id="Tc__CLxG2Oe6EOeUKtJF6ndzg_9_5"></a><a id="Tc_MwUHGYREaU6XXpaPMcQgug_9_8"></a><a id="Tc_8QmyXTyN6ke_vQ2eZSYBiQ_9_14"></a><a id="Tc_P9t1mXfv8UWlFTg3OoutOQ_10_0"></a><a id="Tc_SVY7dJZ_FUC2RB1PUvYL-w_11_0"></a><a id="Tc_A1JHL30OSUW9KP84xfih2w_11_2"></a><a id="Tc_RQJSYmNlB0CQpn1IlSdF_g_11_5"></a><a id="Tc_eNIktNSQ_EeQPTF03lTSCw_12_0"></a><a id="Tc_QdyA8en3s0GWGqolWLfdcA_12_2"></a><a id="Tc_XhMmcMxa6UOGBtnfpjaWQA_12_5"></a><a id="Tc_iwXm9wnPb06C6m8vP6YewQ_12_8"></a><a id="Tc_2PCm_VL04UOI4Fo_bCoG8Q_13_0"></a><a id="Tc_vJHKVKHrRkqUlk6Nzchgcg_13_4"></a><a id="Tc_MJYWbsSQAkGM5y_hjiEZAA_13_7"></a><a id="Tc_icSAPqxZSEGprmP87200lg_13_10"></a><a id="Tc_mCawR12c7kWUWjCsDPGZgQ_13_13"></a><a id="Tc_1GLPRJ40NkCOaQaA29atQg_14_0"></a><a id="Tc_On1L2gT2TU2-facgYlMm1w_14_5"></a><a id="Tc_P9jLfviMZkaMIMQZc93ipw_15_0"></a><a id="Tc_tEgHX2rji0iFEmpgQgU40w_15_5"></a><a id="Tc_rBoyENLNMkC_CJ1um-JNrQ_15_8"></a><a id="Tc_nmWtr8yBIk68JtS_FbA4QA_15_14"></a><a id="Tc_xPodg0efgEatLjY3Das9CA_16_0"></a><a id="Tc_17vXSiuoMEaziqvv3Sby9w_16_2"></a><a id="Tc_kscp8RIGwkqp3v7rH2iGMQ_16_5"></a><a id="Tc_7HG-sOCL5k-UkOL6Eb5B0g_16_8"></a><a id="Tc_PgdSQlLBXkGWx4x0k_wx2g_16_14"></a><a id="Tc_4WM8yWACG0KtFyozX5kdiQ_17_0"></a><a id="Tc_dVgRi_wF_EWcfkV7LziKIA_17_2"></a><a id="Tc_V03Ykczle0-gZeCHuIvjmw_17_5"></a><a id="Tc_0crPowjo7EOX5kr0D_uDig_18_0"></a><a id="Tc_bUNzL-E5cEibrW2-D2RD9g_18_2"></a><a id="Tc_0u8ePNZUPkSZAO2rByBV5Q_18_5"></a><a id="Tc_Stm_DS5iZU-avwk5twQN9g_18_8"></a><a id="Tc_ba1VqlWkVk6IQVVXTd9uqg_19_0"></a><a id="Tc_91lVnUZClUWPxABzxp-YZQ_19_4"></a><a id="Tc_2Ka_yPpP5EWTtEExVjnikQ_19_7"></a><a id="Tc_ig0WaE6eik6pYCzOzLo_oQ_19_10"></a><a id="Tc_FBFTwaU6r0uXiuwbp6KV-Q_19_13"></a><a id="Tc_kbHOu9zFmE6oUEJdB-MkYA_20_0"></a><a id="Tc_16RS4ToRDE64a5fU4KF9Jw_21_0"></a><a id="Tc_UGs7OxiyekWk4UWGZlbUNQ_21_5"></a><a id="Tc_nmjcN0H780SyrePFVDZ-Gg_21_8"></a><a id="Tc_3aXyXh9sXkWWxyT8vuysRA_21_14"></a><a id="Tc_0En7g_SOHEO9TLPtBQVdAw_22_0"></a><a id="Tc_U5ic6pTMiEm91xQo7IMrEA_22_5"></a><a id="Tc_wq920BOKAEq9-KdwfhrrZg_23_0"></a><a id="Tc__IAt69n4C0iEc6LLHl1vgA_23_5"></a><a id="Tc_6GyIb8XSWEet7kfVX0wU6A_23_8"></a><a id="Tc_ba7k_BIj4Uu8ZMgCg9A7bQ_23_14"></a><a id="Tc_n2Quj4Hhc0OV_daGOdO1BQ_24_0"></a><a id="Tc_0SVasSlYZ0eX0QkiNZBjEA_25_0"></a><a id="Tc_sCRUaERI5UWSFKv7urb4AA_25_2"></a><a id="Tc_Cj_7f8P3NU2h-WqYUfXBXA_25_5"></a><a id="Tc_2_MZ2yuzQEqZC0Aq8vQQ5w_26_0"></a><a id="Tc_jYfVIwVRqEqu1dVe6mgDiQ_26_2"></a><a id="Tc_ffDKEnZJFUWK96YgdGMNtw_26_5"></a><a id="Tc_8S9_295GlEKzd1wOv93V6g_26_8"></a><a id="Tc_bHD7n6GCGUS98LV-IJ9KEA_27_0"></a><a id="Tc_nS129FaGnkSBoKgYvGEgDA_27_4"></a><a id="Tc_UZIk282uRUGnTHM2TRCelg_27_7"></a><a id="Tc_WIC2qbXl_UKHtF3LF0z_HQ_27_10"></a><a id="Tc_9LVwOBPoRU6Zz7ELaCEesw_27_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:top;width:44.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance as of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7E3fQ6q_00GZ5N7nqYsJJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_39K0hSGG3kCm65lU5ibmqg_5_2">68,629,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7E3fQ6q_00GZ5N7nqYsJJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_JrmGohtcH0mbYcprq456dg_5_5">69</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sg-6UkrcA0mC1Q9jWG_gTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_gVQzt1uU3UyAI3qv8G8Oyw_5_8">476,322</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zXAQdDuaAUShk1iCOS3LQA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_nMgglAXnfkaGAthiUfwWVg_5_11">429,098</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_xZg1P4maDUOAxM1Ngaf1YA_5_14">47,293</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Yh1HtfeM1U6dLWe0U9X_hQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_qX6RBD5YA0y14yGEUvYfwA_6_2">23,247</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QZw6OTAtg0azS_m5VGB6bA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_AA4UxUiAaEe7snzUF5asJQ_6_8">99</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jVVuLhnI7EmDjNeG2Ga_NQ" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc__MpQhHZo8UasC9nDj_siRQ_6_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_3_31_2024_f-rSQLlZh0qWc3XMDnx8Sw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_QchZqhX1zk2BP3z5zc4AoQ_6_14">99</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock upon vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Yh1HtfeM1U6dLWe0U9X_hQ" decimals="INF" format="ixt:numdotdecimal" name="lqda:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" scale="0" id="Tc_YVER94FSO0GqwMO7uWVlZw_7_2">383,133</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jVVuLhnI7EmDjNeG2Ga_NQ" decimals="-3" format="ixt:zerodash" name="lqda:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" scale="3" id="Tc_j9mEdRTatk-V73FtiGRdGA_7_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock under employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Yh1HtfeM1U6dLWe0U9X_hQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_twVIf7UYdkG4f38x7x6BNA_8_2">67,982</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QZw6OTAtg0azS_m5VGB6bA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_Z6vbt_QBuk61HjA88__o8g_8_8">404</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jVVuLhnI7EmDjNeG2Ga_NQ" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_420pbfQTFkKauR6jb5qm1g_8_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_3_31_2024_f-rSQLlZh0qWc3XMDnx8Sw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_iRNJg2k35kqs_-f_th55kg_8_14">404</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock upon exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Yh1HtfeM1U6dLWe0U9X_hQ" decimals="INF" format="ixt:numdotdecimal" name="lqda:StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" scale="0" id="Tc_pTqwbEQk8EKCuEkp7pdBOA_9_2">946</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jVVuLhnI7EmDjNeG2Ga_NQ" decimals="-3" format="ixt:zerodash" name="lqda:StockIssuedDuringPeriodValueCommonStockWarrantsExercised" scale="3" id="Tc_pGLZmfjI802bGHVwoEDMyg_9_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Sale of common stock, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Yh1HtfeM1U6dLWe0U9X_hQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_KsZVeCequk6tuejPIs7xQg_10_2">7,182,532</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Yh1HtfeM1U6dLWe0U9X_hQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_C3dtqOVMVku1w-Ed3F4Enw_10_5">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QZw6OTAtg0azS_m5VGB6bA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_HGDHWBiexES_sxcs58Kp6g_10_8">74,861</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jVVuLhnI7EmDjNeG2Ga_NQ" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_AwLL6mcAyUG9MMaA2mFbhg_10_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_3_31_2024_f-rSQLlZh0qWc3XMDnx8Sw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_t2Al9vmUXkyt--AIHcQUTQ_10_14">74,868</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QZw6OTAtg0azS_m5VGB6bA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_z1l9Z0g81UG_HuHpXrbzyQ_11_8">4,524</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jVVuLhnI7EmDjNeG2Ga_NQ" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_W8NaYdMuYUSNLW4iEF9EOA_11_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_3_31_2024_f-rSQLlZh0qWc3XMDnx8Sw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_ygk18Vtwx06ajeqGVEMDCg_11_14">4,524</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jVVuLhnI7EmDjNeG2Ga_NQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Hpg0nVQv50S3SIhs1merww_12_11">40,928</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_3_31_2024_f-rSQLlZh0qWc3XMDnx8Sw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_65kia26Gek-wzRdiME4gqw_12_14">40,928</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:44.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance as of March&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fCrJtKAilUWF6oakyV0Nxw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_OeeD-E64ykaXcnHcKwSfbw_13_2">76,287,415</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fCrJtKAilUWF6oakyV0Nxw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_2bB5tmpKLU65-HCoiC19tg_13_5">76</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_UnpCcNxeWkirPc8V7uSOcA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_wrgQT2R36EyIBP1Eps5iEg_13_8">556,210</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AFsBC1pdhU25u5j1c2Q6ug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_rH0Uoc2HpU-A4bwlbENjig_13_11">470,026</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_3_31_2024_bmSEVHYEX0GyBAzQZDTzxQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_emKqcyfaLUOQJwBKriat5Q_13_14">86,260</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_stBhy-3vH0CN55lEF1pbPw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_8vHNb4jxHUKA1zJCV5pRrw_14_2">10,686</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6Z3BVNcjGUCp4hge4qevNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_a1BwgIcMyk2Gl8surrpRQg_14_8">32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a9uUf5liUEShuVXaMIN48A" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_ExXRqiy_DUGEJWeQRBwX3g_14_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_4_1_2024_To_6_30_2024_9bh_UZq1Z06Lu_r7nFqRFg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_Xos9PzXHq0u2D_HoRfccdw_14_14">32</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock upon vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_stBhy-3vH0CN55lEF1pbPw" decimals="INF" format="ixt:numdotdecimal" name="lqda:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" scale="0" id="Tc_qDPjqyL_dEmJrdOrgWdK7w_15_2">116,447</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a9uUf5liUEShuVXaMIN48A" decimals="-3" format="ixt:zerodash" name="lqda:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" scale="3" id="Tc_efFsCSmeK0Gr1ExBAiQljQ_15_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Sale of common stock, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a9uUf5liUEShuVXaMIN48A" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_zOaP7ghYyk-snys7c8X98Q_16_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:44.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6Z3BVNcjGUCp4hge4qevNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Rl6jaaImWEyuST0rRNfDzg_17_8">4,372</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a9uUf5liUEShuVXaMIN48A" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_m-J4IzI7tU2oP3fad6JZpA_17_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_4_1_2024_To_6_30_2024_9bh_UZq1Z06Lu_r7nFqRFg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_I1GVEurwaUKaefwESv5qXg_17_14">4,372</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a9uUf5liUEShuVXaMIN48A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_9unPyEbh30W7dl1KuB7ynA_18_11">27,942</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_4_1_2024_To_6_30_2024_9bh_UZq1Z06Lu_r7nFqRFg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_f9V2yDz5rUWLdhjAE7W06g_18_14">27,942</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:44.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance as of June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7AEtKY-q0EKpSlxBuo5Tpw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_Vl_HFBOoN0yQpO80VRNQeA_19_2">76,414,548</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7AEtKY-q0EKpSlxBuo5Tpw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc__oq1i5zYEUKz8wVEorQmaA_19_5">76</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5u8PMn6XnUeumeLh8ydfDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_VX-6EEExAUeaPESzGVej9g_19_8">560,614</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ScrF8tr1w0-MxUBmw2dweg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_5GDni-xw-kygQ5sjG-Jf5w_19_11">497,968</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_6_30_2024_FQbXKficgEeFRZOCIK6Svw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_aObeNc3T1EGCiKIBGfS5lA_19_14">62,722</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5GOcXOaV5U2T36M6_dQLCw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_5N4LHVLpo0-0C9yitdGUWQ_20_2">317,720</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5GOcXOaV5U2T36M6_dQLCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_rJ1Q-cT22km2RKv-wRWVBQ_20_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Xp3560lqZU2xfNzbsFaQdQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_XotWO4dvxUOXo71HdxEg-Q_20_8">1,548</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wgxF__1apky0OItCKW6-bw" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_v3tB44oEAEKckbhO74zhXw_20_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_l5Qz6E_wH0yq3vUmr78TLA_20_14">1,549</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock upon vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5GOcXOaV5U2T36M6_dQLCw" decimals="INF" format="ixt:numdotdecimal" name="lqda:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" scale="0" id="Tc_R_wL4j9dZ0ywahk3Qag_2A_21_2">116,247</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wgxF__1apky0OItCKW6-bw" decimals="-3" format="ixt:zerodash" name="lqda:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" scale="3" id="Tc_KePFAz6aLU-ZQKW3uIghNg_21_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock under employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5GOcXOaV5U2T36M6_dQLCw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_dAxjCxg_wk-ArJeNSS4ndA_22_2">104,413</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Xp3560lqZU2xfNzbsFaQdQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_txbJhY2lnEiCsjQC26CvzA_22_8">844</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wgxF__1apky0OItCKW6-bw" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_gXbTrFpIPkWIShX4L6vIog_22_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_ezXTgmkLoUuj5Huj5GMxbg_22_14">844</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock upon exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5GOcXOaV5U2T36M6_dQLCw" decimals="INF" format="ixt:numdotdecimal" name="lqda:StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" scale="0" id="Tc_aINV6XBaH0ayVMFWVDZtWA_23_2">8,212</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wgxF__1apky0OItCKW6-bw" decimals="-3" format="ixt:zerodash" name="lqda:StockIssuedDuringPeriodValueCommonStockWarrantsExercised" scale="3" id="Tc_7rTVN-e9_UCMG0-N8AUXvQ_23_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Sale of common stock, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5GOcXOaV5U2T36M6_dQLCw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_-60eXiixpE2_YvW5m-vGFA_24_2">7,584,269</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5GOcXOaV5U2T36M6_dQLCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_RwVlTrbgIU-fH5EYappIBQ_24_5">8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Xp3560lqZU2xfNzbsFaQdQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_raSxSfYoHE2uz7dKnhd1cg_24_8">63,669</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wgxF__1apky0OItCKW6-bw" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_PtjeREtwW0aSKgCyACKI-A_24_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_SmJiDZYETEWlUPMZJNssIg_24_14">63,677</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Xp3560lqZU2xfNzbsFaQdQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_TN8T4XZjNE-SHBEHSFg1FA_25_8">4,881</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wgxF__1apky0OItCKW6-bw" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_7oxKHODldEuVio563dVkXA_25_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_3e9M6_V_wkSK_vGkoHYUjw_25_14">4,881</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wgxF__1apky0OItCKW6-bw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_TQzmcgJl5kWgw_YIU131tw_26_11">23,155</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_QuQM5dPrz066TNhBlpeZ8Q_26_14">23,155</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:44.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance as of September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MBzkjBjqCku_2H2dhAQG9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_fW37x64EGEGomDmBuTIqJg_27_2">84,545,409</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MBzkjBjqCku_2H2dhAQG9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_spvpaziYfk2NRSN_mFoEBA_27_5">85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TmKhLmYzCECUkE-NW019MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_KrmHZDPeuEmlDqQMSU1L6Q_27_8">631,556</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TAyoFb0K3kegpTygRfEduw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_wxNLK9c_hkK-TfvgFeJEsw_27_11">521,123</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_RvZkv8KbqUSThAFUMs9sxg_27_14">110,518</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e749ef42_715e_452f_89a2_93607b90dc4b"></a><a id="Tc_qdCgJGJIj0OT8lzUvdcExw_2_2"></a><a id="Tc_KDLEO_VhK0SgKu50CazFKQ_2_4"></a><a id="Tc__CRImfuAvUOhCHIaNgwy-w_2_7"></a><a id="Tc_9nJQmdJ6hUC4g-AS-A4Msg_2_13"></a><a id="Tc_DIPOuee0fkO3_dNd4opwaQ_3_2"></a><a id="Tc_fxMIjMMrHk2wQNDxHFKMfQ_3_4"></a><a id="Tc_dOaoGJSWLUuDHG55DTDqjg_3_7"></a><a id="Tc_Fvwz51zwq0OG6OKOkQ4H2g_3_10"></a><a id="Tc_5OFsvhwvgUKb9S9QWuqgwA_3_13"></a><a id="Tc_8MrGj6pxEki9KScFHebODQ_4_2"></a><a id="Tc_uSEtU5HnK0SKK_2UdeP35A_4_4"></a><a id="Tc_z_3-AP9el0GqrqEtxhqpNA_4_7"></a><a id="Tc_B14tj8z7lUiitkwKKsMhKQ_4_10"></a><a id="Tc_zlfkb65LZU29T7DFTSZHaQ_4_13"></a><a id="Tc_pR9ub0eMnkiJtZVl18CD8g_5_0"></a><a id="Tc_Eh2aA80TfUezcWbFvIuj8Q_5_4"></a><a id="Tc_pha_hpuEXkOLZGiQ6dXDpw_5_7"></a><a id="Tc_3yCTOT2hekyfaLH6oAG0oA_5_10"></a><a id="Tc_07KQEhs1Z0m24f0MnEAX8Q_5_13"></a><a id="Tc_lsuRkZ75nEu_BFM914wmJA_6_0"></a><a id="Tc_G71fZyPFHESKxLQwZmzcpw_6_5"></a><a id="Tc_heRUOS0dRUehhIp-NoEd8Q_7_0"></a><a id="Tc__J23yeUPEkiDNuCEI4RGqA_7_14"></a><a id="Tc_eSaOlPM2W0GYJCFZJGRdPg_8_0"></a><a id="Tc_anydkhkis0aTMXvPwAjFQQ_8_5"></a><a id="Tc_7E_IEGpwJEGF5zwpxZyceA_9_0"></a><a id="Tc_HW22l1q-gUulZ0Dlc33vUQ_9_2"></a><a id="Tc_b2vJYB4vdEG1XIbB-qooMQ_9_5"></a><a id="Tc_NefmeCQ1UEe1hbLTdZjcLA_10_0"></a><a id="Tc_JckGROvfuEGsyM5szsN9WQ_10_2"></a><a id="Tc_DS3R3yCiH0SbmXbij5FiSg_10_5"></a><a id="Tc_7XGi4r4IEU6e6SssjFDviA_10_8"></a><a id="Tc_P5qEKCdU-kGRpAMgqCLYOg_11_0"></a><a id="Tc_KIHHn_zKn0mSm0lgV-8W4A_11_4"></a><a id="Tc_b8DDhBHCw02A4kqPamN5oQ_11_7"></a><a id="Tc_NuznmOoDMkCjh_i9SvPOjA_11_10"></a><a id="Tc_3qlQbRUzVEKzPtlQpiUfdw_11_13"></a><a id="Tc_TqXxwcJFqUqOFg6vekuzaw_12_0"></a><a id="Tc_lvzUhYPlK0m0beCYqOwBfw_12_5"></a><a id="Tc_XNVshCEP7Umz5w0zddi9AQ_13_0"></a><a id="Tc_fW606O5C9UaxFalwx13SXQ_13_5"></a><a id="Tc_g7ofOh5FeUComCUUB-ehcw_13_8"></a><a id="Tc_RMzjTTbjR0-u13nHNvIR-A_13_14"></a><a id="Tc_RA5SuImIx0epRFmNiUka6A_14_0"></a><a id="Tc_KT1hgi708UWuO9JkNG2n5w_14_2"></a><a id="Tc_3opmpUF7gUmTepZPLFDobg_14_5"></a><a id="Tc_UVkXyfYhVEeTYWINYZO_jA_15_0"></a><a id="Tc_ZwRquLGqDk6jWve0mCYOOg_15_2"></a><a id="Tc_4tk4gehz9EaSAyURLlEw5w_15_5"></a><a id="Tc_llbULGowqU251gHJq5FplQ_15_8"></a><a id="Tc_oyLjtI7QYkSVOcpwAJIokw_16_0"></a><a id="Tc_XquchcnMlEiXUsUCky0eYg_16_4"></a><a id="Tc_4KzdIKohSkCu2FBr5vVZ_A_16_7"></a><a id="Tc_GXfVOUDBwU2M15NKx2GZHg_16_10"></a><a id="Tc_j3tRcNUjT0KTCIBJsbmgjA_16_13"></a><a id="Tc_NR-cTFz5LU2rRObmZ0N5IA_17_0"></a><a id="Tc_BDnQt0TD9kikvsRW43ETpA_17_5"></a><a id="Tc_ZrAdoQcFVkGABsN44heDkg_18_0"></a><a id="Tc_XLQC5sTvNUOaA3aKLW8DXQ_18_5"></a><a id="Tc_atfQSkiSTUGY9KMffP9uKA_18_8"></a><a id="Tc_FFpKp2q5V0agSXMReyuODg_18_14"></a><a id="Tc_fNzvRTFYQ0yuOi4khWoh2A_19_0"></a><a id="Tc_y9jqm2Cn6kyTpjl95Dy9WA_19_5"></a><a id="Tc_oMOC6_JzCU6xj-6-uyymHA_20_0"></a><a id="Tc_iPiDjyWfmEmfcm-npeG5Zw_20_2"></a><a id="Tc_Nf1jmGqKREy6sdbdwg22CA_20_5"></a><a id="Tc_zCF1GfffcEiXIYc5ne4CeQ_21_0"></a><a id="Tc_rl0_S7cBp0aPjxD10-bg1w_21_2"></a><a id="Tc_jIweAoc390eDY4SeQa_dsg_21_5"></a><a id="Tc_Tc-Wsx990EerkHL2j0mlcg_21_8"></a><a id="Tc_flit0Tq9p0iEu6CCrigTHw_22_0"></a><a id="Tc_8JkUbBuNLUGdXNEidXw2OA_22_4"></a><a id="Tc_4-hh_Kd5nUeU8a6ps4I8aQ_22_7"></a><a id="Tc_5PknmZ_OBECTKI5QnIWuzg_22_10"></a><a id="Tc_2DHHsUyVSEOTFozQF4WG3g_22_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:44.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:44.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:44.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:top;width:44.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:top;width:44.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:top;width:44.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance as of December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aaTdBw1wLEmeLLnJDiO8qg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_DI08rqII0UmOLeU07OmLNA_5_2">64,517,912</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aaTdBw1wLEmeLLnJDiO8qg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_NWPqDrDj1Eu_EgY558fMOA_5_5">64</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_C8mVC4eTakmAXbazP4Sw7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_jbZAn1t08U6DCaDGq-GiHA_5_8">440,954</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_T0JQS0-8iUiQm5svY1pKoQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_z4oZbp79c0637mjRWznoiQ_5_11">350,596</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2022_h-v_IaJxz0SgsF5X90JwfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_BempzZDddUCUvNwi3q_Prg_5_14">90,422</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fl_qDLX5AkK2MTZFNhq5Zw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_aoehAMjQWUWnvmP9q-31Hw_6_2">21,447</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_z8Y4XLDSWUyq3w7U4D0TuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_dReJ7psbUUyKGNlbuIV_0Q_6_8">79</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4juqE32tLUykVWFmMMpgzA" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_ROz0OBmrGUSeWOS-8KrKRw_6_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_3_31_2023_wXfmt2J2LE2WLZnDVgzsJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_ZrWNWI1ypkKI9dqwvd5iRw_6_14">79</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock upon vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fl_qDLX5AkK2MTZFNhq5Zw" decimals="INF" format="ixt:numdotdecimal" name="lqda:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" scale="0" id="Tc_-bwreN59iUOEgDAeth-FnQ_7_2">89,804</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fl_qDLX5AkK2MTZFNhq5Zw" decimals="-3" format="ixt:numdotdecimal" name="lqda:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" scale="3" id="Tc_U_ymZs9SuU2NcGwfyaxf8A_7_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_z8Y4XLDSWUyq3w7U4D0TuQ" decimals="-3" format="ixt:numdotdecimal" name="lqda:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" sign="-" scale="3" id="Tc_So4IIOAP_U6lLnVitQMyFA_7_8">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4juqE32tLUykVWFmMMpgzA" decimals="-3" format="ixt:zerodash" name="lqda:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" scale="3" id="Tc_HfStrjMLM06ouEMV00LHEg_7_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:44.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock under employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fl_qDLX5AkK2MTZFNhq5Zw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_sHdjcETg9UWReSiWTlvHwg_8_2">81,281</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_z8Y4XLDSWUyq3w7U4D0TuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_W5pCz5NupEqA017Plw2oDA_8_8">335</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4juqE32tLUykVWFmMMpgzA" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_Qa9u49JM6kKRIrJT0zXCgQ_8_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_3_31_2023_wXfmt2J2LE2WLZnDVgzsJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_fPDyljRO7EaszykbhkS4pQ_8_14">335</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_z8Y4XLDSWUyq3w7U4D0TuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_xyEMqATEa0WaVHBViMo3bA_9_8">2,552</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4juqE32tLUykVWFmMMpgzA" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc__yaO64TKXEetbXMd6wgXXg_9_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_3_31_2023_wXfmt2J2LE2WLZnDVgzsJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_AS6uSN5kiEa-2CjGTsm3-A_9_14">2,552</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4juqE32tLUykVWFmMMpgzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_8yn6is_NxEqR-syVvvP_fg_10_11">11,745</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_3_31_2023_wXfmt2J2LE2WLZnDVgzsJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_P9Qzp2WcJk6fAuCDtoOLsg_10_14">11,745</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:44.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance as of March&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vBNSpOjO0k-ci40DF_S6vQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_WiI8F1z2pk21xnof6CGOzQ_11_2">64,710,444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vBNSpOjO0k-ci40DF_S6vQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_0vPKYxxUVUeSiM8zuP0lCg_11_5">65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VaQV6KiTs0uXI_fEPfZBIA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_q_FA8rrDnEmsDMmz_oA1zQ_11_8">443,919</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2PLVLFxMP0GKVplKYm4eUw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_mEzrcXbgakqpcoCI3E2IRw_11_11">362,341</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_3_31_2023_D-bH4JsxuEqUTMaVgHIQIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Caw4skxtq0mPiBHo1qO8EQ_11_14">81,643</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_52Y2y5aCZ06_iOiL1avbmQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_yM8Y3CAQiUuHZdtJ-uacMQ_12_2">10,173</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oTd2Y4azxE6k0h-MkNkt7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_-MCByWQcP0aED6hak4TWrA_12_8">32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_i3PmmyVMRUO1q-dHTQOURQ" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_ncoNmHjl0EGFaup9MldCNw_12_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_4_1_2023_To_6_30_2023_fj9qXeNqAUyr-FVp6nmzpA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_MMFzcvlxyE61j0zXp-q19Q_12_14">32</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock upon vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_52Y2y5aCZ06_iOiL1avbmQ" decimals="INF" format="ixt:numdotdecimal" name="lqda:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" scale="0" id="Tc_RCHstbUp_UeD5cH6ItM_MQ_13_2">19,765</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_i3PmmyVMRUO1q-dHTQOURQ" decimals="-3" format="ixt:zerodash" name="lqda:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" scale="3" id="Tc_PtLSbSJV6kGtwBQhHa21rg_13_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:44.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oTd2Y4azxE6k0h-MkNkt7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_EKha_BUaHkqt-Pe7JZVHrA_14_8">2,499</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_i3PmmyVMRUO1q-dHTQOURQ" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_cCICtx75HkelT7meIL3kHg_14_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_4_1_2023_To_6_30_2023_fj9qXeNqAUyr-FVp6nmzpA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_X1tJQrVdzky4CFb9wXAX9w_14_14">2,499</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_i3PmmyVMRUO1q-dHTQOURQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_FA1wVp94QkC_BAzwT_q9rg_15_11">23,517</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_4_1_2023_To_6_30_2023_fj9qXeNqAUyr-FVp6nmzpA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ia6LiMJjYUyi5HtesItgYA_15_14">23,517</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:44.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance as of June&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HrYg36StAUevt9it2sHW4Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_WWTz3DVNeUyzjOQs6zNULQ_16_2">64,740,382</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HrYg36StAUevt9it2sHW4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_VBaGWFbiUkiUUBD1QGlKaQ_16_5">65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0jwCrvtl9UmljYaJoSpv6Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_QmR91FgMA0OYGVNW6tYqRw_16_8">446,450</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fVis6Rc0lU24mViOdhLPQw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_iKHcbnnQik-cvT_5khfm1A_16_11">385,858</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_6_30_2023_caIrfeIWIUSr-5YM1URrGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_59QIv5ONXkusDrU9Dwz-jA_16_14">60,657</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock upon exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ESYXfJPI-k-Cm-6QGRH6Sw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_X4xR3dFeaEOqtSUR48UooQ_17_2">79,506</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_athnGX3vVUWNi8j4p4X8yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_FYhmghzasEWT1AltzBBZzg_17_8">304</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_74IJvwrt6EmcH2m1d12TYQ" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_XMWJmYLCTkGpAul3j76NqA_17_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_dnOwhnrvn0q5amTn0MFe1g_17_14">304</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock upon vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ESYXfJPI-k-Cm-6QGRH6Sw" decimals="INF" format="ixt:numdotdecimal" name="lqda:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" scale="0" id="Tc_9xNbYjEzS0e300_fnfJzOw_18_2">19,766</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_74IJvwrt6EmcH2m1d12TYQ" decimals="-3" format="ixt:zerodash" name="lqda:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" scale="3" id="Tc_6iH_QJgOf0ms-LPeGz7xXQ_18_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:44.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Issuance of common stock under employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ESYXfJPI-k-Cm-6QGRH6Sw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_WxtpDjBlk06RPh3I6claMQ_19_2">59,641</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_athnGX3vVUWNi8j4p4X8yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_eO1CEsKH40WP0XVGbREr2A_19_8">348</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_74IJvwrt6EmcH2m1d12TYQ" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_69kCY1tqBkmxpJY7-FucGw_19_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_-nWaBCKd60-KLJEtKRLPSw_19_14">348</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_athnGX3vVUWNi8j4p4X8yg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_t0TkCOePGUCk8fcdKxnJ4w_20_8">2,487</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_74IJvwrt6EmcH2m1d12TYQ" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_02_xQ6JK0UG2wW8Md8B3hw_20_11">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_yKn8K3PtNEasmxSXFJR0lQ_20_14">2,487</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:44.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_74IJvwrt6EmcH2m1d12TYQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_J-GT2cVF50myueNItWoWLQ_21_11">15,790</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_YlQPZmDWIU259YUVfJCwgA_21_14">15,790</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:44.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Balance as of September&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GIpJ2QgtfkiSIOYQwZQCIw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_VLWXYVjptkSGm2iqA7rLiw_22_2">64,899,295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GIpJ2QgtfkiSIOYQwZQCIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_4o-4SDSYkUe4AenURRrUuQ_22_5">65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uAdhr2xcg06h66-QEsr0Rw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_pURN6t89906ffjurehJawg_22_8">449,589</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_FtiVafAv4UWr8JRCklLjuA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_63k6hQPG8UiFHFvs-3Fdlw_22_11">401,648</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2023_6z62s4VwhEOUHWT_u7NrVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_NuU3TP4GT0Sfs4FhkLJBkA_22_14">48,006</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_b7a5618a_359c_46d0_b06b_41508028f03f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liquidia Corporation</b></p><a id="ConsolidatedStatementsofCashFlowsUnaudit"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Condensed Consolidated Statements of Cash Flows (unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d33198b9_54f7_4754_b7c9_2794476db4d7"></a><a id="Tc_xxN4e3xaFUSB1nQxWVU1hg_1_2"></a><a id="Tc__nN3vPWkb02d2btyWIMa6w_2_2"></a><a id="Tc_B0s2e6zg8kGLZ6O-IM4fVA_2_5"></a><a id="Tc_ZVlvgwsSRUmLubqk3KzPag_3_0"></a><a id="Tc_GOMKwvdWqUyh4W1crQiTAg_4_0"></a><a id="Tc_kFWCEfEzqE6Gz9AYZzq44A_4_2"></a><a id="Tc_DKPOTgxFckSDzMJ3vcNf3g_4_5"></a><a id="Tc_LpGtOV9gj0yh85_NJYk8XA_5_0"></a><a id="Tc_cdjW1QMBYkuAyja9C5CqrA_6_0"></a><a id="Tc_OAA0Vf_hL0-IH3luumiVWQ_6_3"></a><a id="Tc_BXFsujxzmEKZHMib18vUaA_7_0"></a><a id="Tc_zrOWQaVSD0CRSdy_4VegnQ_8_0"></a><a id="Tc_4jb6GnSQDEOjXEOPhY38IQ_9_0"></a><a id="Tc_wBRV1svUqUyhcJbYwLyd-A_10_0"></a><a id="Tc_Jshq0bhND0y2OYjtZb4ZBw_11_0"></a><a id="Tc_WobbgEtTWUmlGPDvUqLRaQ_12_0"></a><a id="Tc_gsjKf491cEimxLxgoTYwFw_13_0"></a><a id="Tc_i_5aAHnj6kyMDHPF2PQAAA_14_0"></a><a id="Tc_d8WdCoLmqUGv5HykmRjFZQ_15_0"></a><a id="Tc_ajNbipXh0EC0vSHw6F9aEA_15_6"></a><a id="Tc_lzw2te2BGkKIBqqm3ATSuQ_16_0"></a><a id="Tc_DQ17G-qwLkCwV-ktg4tHSw_17_0"></a><a id="Tc_iUfrHPq_90eMi_mJrbPwbw_18_0"></a><a id="Tc_YWXgVoBFQkW-v61H1U1hwg_19_0"></a><a id="Tc_Hnuy7EcGsUqHvBXDZcTgeg_20_0"></a><a id="Tc_be86XHUImk2xzqlHM7c1Ag_21_0"></a><a id="Tc_UsWPJ0_jv0-PWrWztQ_SZQ_22_0"></a><a id="Tc_sbdIrWfiUE23TyhIKhpSyQ_23_0"></a><a id="Tc_EwfESIpuLkekIFq9jaAjYg_23_3"></a><a id="Tc__gZn4n6pG0e5APnXFqjS5g_24_0"></a><a id="Tc_lXRVwLLkj0-VMbZBUkFT0w_25_0"></a><a id="Tc_VTzU9DhDr0Ccn-TquKCBZw_26_0"></a><a id="Tc_s7BRtCW3tEuRz94KHLvj5A_27_0"></a><a id="Tc_8P3A8UJhtk607O_BUSmVWw_28_0"></a><a id="Tc_7x796FqW60CU-lYTUa7IiA_29_0"></a><a id="Tc_taHjWthI9EG3DU7s8RhtmA_29_3"></a><a id="Tc_06AM3tjIKEqahJWdYCSWfg_30_0"></a><a id="Tc_lXJHEeBZoUeNc67Y0fC0hQ_30_3"></a><a id="Tc_P1JHj45dyUSgA4hgNx677Q_31_0"></a><a id="Tc_8jlQYCEbTEWzYOUUQlVvxw_32_0"></a><a id="Tc_CYtVgwFUqUmrP9trH-D60Q_33_0"></a><a id="Tc_yrtUk9030kK14K11saCgQQ_34_0"></a><a id="Tc_Iiagd0bt4kiO1UNud2QoDw_34_6"></a><a id="Tc_J2SlBlaUoUioGLCu5D4LJA_35_0"></a><a id="Tc_KxyHOnhjBESU5H6OyjNVcQ_36_0"></a><a id="Tc_FoGr9vdk40CdBRQAVj9EuQ_37_0"></a><a id="Tc_eU7-E3HpWkSVMKvq80pxIw_38_0"></a><a id="Tc_jj9FRccuaUeSEx_sFU6iVQ_39_0"></a><a id="Tc_PbF73Kw8s0iB7mnatJJ7Zg_39_2"></a><a id="Tc_T7_6HoL4L0OX-uKTNL1ZNA_39_5"></a><a id="Tc_uMiGwjl_40uLYmH2qkTNkg_40_0"></a><a id="Tc_XcU3H8oTpUGvZYHyfG57Xg_41_0"></a><a id="Tc_fAmiXPt90U-JwHF9tGreRA_41_2"></a><a id="Tc_IwnqzKCiV0mrkT1xNdNoUg_41_5"></a><a id="Tc_l57GLD6KCECEyJjMHTeiSA_42_0"></a><a id="Tc_HR6ETDrjOEeCQjL1N0olLQ_42_2"></a><a id="Tc_dwocJs37tEqAOTEjDk20aw_42_5"></a><a id="Tc_pzRdqa6eyU-awXfTz4sLHw_43_0"></a><a id="Tc_ojIzt_Urn0O6EuYn0rVuhw_43_2"></a><a id="Tc_Q7Th8_QpSkKQih2ebl6bww_43_5"></a><a id="Tc_Ti_Y_LinYUuc9SlnmZJB1Q_43_6"></a><a id="Tc_VPNkItBHXkOndj_RcQ97Jw_44_0"></a><a id="Tc_dd4h1bg7f0iZY6Uz9LISXQ_44_2"></a><a id="Tc_qJ3QO0wuDUSIqgP-2Xz4CA_44_5"></a><a id="Tc_cD7N78JFak6ojgps_L-iBg_44_6"></a><a id="Tc_XE87-h3xoUmXKWCPuso6Zw_45_0"></a><a id="Tc_T1svt2RJGkmy5PcLKE1o5A_45_2"></a><a id="Tc_f-k0FvEDeEqvcnNuD2ZVMg_45_5"></a><a id="Tc_CtuUQDal7kmawfcXgkcVDw_45_6"></a><a id="Tc_UMpnLRRE5021XCPuPm09KQ_46_0"></a><a id="Tc_hRxnU-eNgkypmkC1vZ_NbQ_46_2"></a><a id="Tc_pNFLTkk3TEyaVONq1UAGqw_46_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_2neTY6LGJEG1rzKpv6lBkw_4_3">92,025</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_xyIhqKKLY0iNxNX3uY070Q_4_6">51,052</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Acquired in-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="lqda:AcquiredInProcessResearchAndDevelopment" scale="3" id="Tc_Hu-npCF5MUi-ab8Hz2_aDQ_6_6">10,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_tbFQ2V5sL0KNc2dyH7V5xw_7_3">13,777</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_t6JyHYzs2UivFKZjdOHxxw_7_6">7,538</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_wvErZuL-eUS9BQQft4BYAg_8_3">1,679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_eiFdsScpV0GGPPUusXjXyw_8_6">1,672</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Non-cash lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="lqda:NoncashPortionOfLeaseExpense" scale="3" id="Tc_TS-76k4DmEaHC6KBjSpAEw_9_3">361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="lqda:NoncashPortionOfLeaseExpense" scale="3" id="Tc_r7TKJoHRe0qQa4LkF2T6Hw_9_6">289</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss (gain) on disposal of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets" sign="-" scale="3" id="Tc_6Tap0rB9e0yAFsFSnG8OaQ_10_3">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="Tc_ARwyMnT2QkWT94tyw6BFVQ_10_6">2</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss on extinguishment of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_x9yHt2aBS0uqTKCTF68XwA_11_3">4,268</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_Jp7WXEONc0-DEhKfhDRNJA_11_6">2,311</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accretion and non-cash interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="lqda:AccretionAndNonCashInterestExpense" scale="3" id="Tc_9Wn1-Dlf5kqyCm_iQiacyA_12_3">8,114</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="lqda:AccretionAndNonCashInterestExpense" scale="3" id="Tc_MShoYESliUiNnwQRz6pMQw_12_6">4,133</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts receivable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInReceivables" scale="3" id="Tc_vSTOX6X660Gexlxhz5GkQg_14_3">141</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInReceivables" sign="-" scale="3" id="Tc_Zfep32r040yiF8xD7ctrZQ_14_6">1,679</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_sa0_dCMNzUej_5gEuztEBQ_15_3">38</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_Ks5YJf1TPU2eOezVaQqp5g_16_3">3,445</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_nItcVe9yoEOqjFth113rlw_16_6">2,056</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other noncurrent assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="Tc_5hDb6Ilz1EufAn-qB5kqHA_17_3">7,471</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" sign="-" scale="3" id="Tc_p-EMmwzmRke7b5VUw3WskQ_17_6">20</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_SzpJjOxdsEuMrWXZZmxOgw_18_3">222</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_r4903ElHDUKGjdAyr9azRA_18_6">556</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="Tc_E2t_u8cz1EaqYThtO5U7Dw_19_3">3,291</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="Tc_GdWMG_dWZkqjcRY2r33nMA_19_6">1,102</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="lqda:IncreaseDecreaseInOperatingLeaseLiabilities" sign="-" scale="3" id="Tc_oxefXs3cdE-RouBUrO0fAA_20_3">760</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="lqda:IncreaseDecreaseInOperatingLeaseLiabilities" sign="-" scale="3" id="Tc_-MxGKSaSLEKuzvxA3L9saQ_20_6">660</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_HikaoKa0P0-d_B9s6_--Kw_21_3">72,609</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_PfQggOUWTkWm9ayjQGlrUg_21_6">25,582</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchase of in-process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="3" id="Tc_qefaLz_pLEGZbGhEdnN4eA_23_6">10,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchases of property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_eVjola2RHU-RFYQX10_gkg_24_3">3,661</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_5umKFPA5vUaoLQxYMS0f0Q_24_6">1,084</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from the sale of property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_7lo-J-MtjUu_p5tp1-sR2w_25_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_Sr2Va-_wL0GXDjZh6a_0_A_25_6">2</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_SQ1Q8Q393EurLthj7ilDOA_26_3">3,661</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_p_hfIuvP5kKdkDLb7S16hw_26_6">11,082</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from revenue interest financing, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="lqda:ProceedsFromRevenueInterestFinancingNet" scale="3" id="Tc_PM5KEOHY2UCn6Cf6pEoi1A_28_3">57,460</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="lqda:ProceedsFromRevenueInterestFinancingNet" scale="3" id="Tc_Ofy0qegt2UOUj7jKjNfWQA_28_6">41,744</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal payments on long-term debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="Tc_uO0kOjFnC06sahzceL_HsQ_29_6">20,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payments for debt prepayment and extinguishment costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="3" id="Tc_gvrIZ026D0KfHHO0Bd7c2Q_30_6">2,190</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payments on revenue interest financing liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="lqda:PaymentsOnRevenueInterestFinancingLiability" scale="3" id="Tc_iz2fBEvynE67Rmh1ouIonw_31_3">2,731</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="lqda:PaymentsOnRevenueInterestFinancingLiability" scale="3" id="Tc_8y4RLk8snUyxkWm5hKP2Cg_31_6">1,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal payments on finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_WAyJsVeLHEO8ZEcZz-sV4A_32_3">80</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_2GkbReQh1Eak4dMx6XraSQ_32_6">155</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Receipts from litigation financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LossContingencyReceivableProceeds" scale="3" id="Tc_UX8nop6xMk28dU-4cqZ6pQ_33_3">489</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LossContingencyReceivableProceeds" scale="3" id="Tc_mhZ9UMpGpUSRA9Fw4zdohA_33_6">109</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from sale of common stock, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="Tc_dtEEaaloCkaIAGjuccC5YA_34_3">138,893</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from issuance of common stock under stock incentive plans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="Tc_y1TroB4zQEGV7mJFMitYHA_35_3">2,928</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="Tc_eAL4U5SOPUC5f3-xRU939w_35_6">1,098</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_ztmpe-2je0-jNH4lFKQFwA_36_3">196,959</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_UgU3HP87kkiP6QgcBlweWQ_36_6">19,606</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net increase (decrease) in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_zQegfg_YO0mxxh77ZGbZAQ_37_3">120,689</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_WvqCAorgWkyrh3Dk0_Tr1g_37_6">17,058</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents, beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc_lnohH7ztNEu7BNYc_eipRQ_38_3">83,679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2022_h-v_IaJxz0SgsF5X90JwfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc_mLSEJhpujUmrpVeTy_NJeg_38_6">93,283</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents, end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc_qU54A9b3_E6vreMPg99dkg_39_3">204,368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2023_6z62s4VwhEOUHWT_u7NrVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" id="Tc_vWYBhZrRIkalsP6hif7QmQ_39_6">76,225</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Supplemental disclosure of cash flow information</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:zerodash" name="us-gaap:InterestPaidNet" scale="3" id="Tc_1ZLI4CUJn0us-DlDMpMYJg_41_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_vm_yfubXs0Cd02w8mQcMUw_41_6">360</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="lqda:OperatingLeaseLiabilitiesCashPaid" scale="3" id="Tc_jilicfKrrUq4vZWaZGuiRA_42_3">985</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="lqda:OperatingLeaseLiabilitiesCashPaid" scale="3" id="Tc_AmSY-0XnQ0qRMu4vhZpybw_42_6">956</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Offering costs incurred, but not paid included in accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="lqda:OfferingCostsIncurredIncludedInAccruedExpenses" scale="3" id="Tc_TK3V4_XlIkS4I-6bBazmyQ_43_3">348</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right of use assets obtained through lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="lqda:RightOfUseAssetObtainedInExchangeForLeaseLiability" scale="3" id="Tc_JE5NwvLA2UCZSaI6WGanhA_44_3">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-cash increase in property, plant and equipment through accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_a5taUGk53kaAk-c_AzEWgQ_45_3">625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-cash increase in indemnification asset through accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="lqda:IncreaseInIndemnificationAssetThroughAccountsPayable" scale="3" id="Tc_3ajaJPsCIEGeNW33sLcvXw_46_3">499</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="lqda:IncreaseInIndemnificationAssetThroughAccountsPayable" scale="3" id="Tc_qqwWGPPG3kGWCumFTkaJcQ_46_6">111</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these condensed consolidated financial statements.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e0f05977_14a9_4ca5_abe0_2dc1132b4d13"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Liquidia Corporation</b></p><a id="NotestoConsolidatedFinancialStatementsUn"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Notes&#160;to Condensed Consolidated Financial Statements (unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(tabular dollars in thousands)</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:NatureOfOperations" id="Tb_WPCAlNncJU2QO3_ky6OPDw" continuedAt="Tb_WPCAlNncJU2QO3_ky6OPDw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Description of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are a biopharmaceutical company focused on the development, manufacture, and commercialization of products that address unmet patient needs, with current focus directed towards rare cardiopulmonary diseases such as pulmonary arterial hypertension (&#8220;PAH&#8221;) and pulmonary hypertension associated with interstitial lung disease (&#8220;PH-ILD&#8221;). We operate through our wholly owned operating subsidiaries, Liquidia Technologies, Inc. (&#8220;Liquidia Technologies&#8221;) and Liquidia PAH, LLC (&#8220;Liquidia PAH&#8221;), formerly known as RareGen, LLC (&#8220;RareGen&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We currently generate revenue pursuant to a promotion agreement between Liquidia PAH and Sandoz Inc. (&#8220;Sandoz&#8221;), dated as of August&#160;1, 2018, as amended (the &#8220;Promotion Agreement&#8221;), sharing profit derived from the sale of Sandoz&#8217;s substitutable generic treprostinil injection (&#8220;Treprostinil Injection&#8221;) in the United States. Liquidia PAH has the exclusive rights to conduct commercial activities to encourage the appropriate use of Treprostinil Injection. We employ a targeted sales force calling on physicians and hospital pharmacies involved in the treatment of PAH and PH-ILD in the United States, as well as key stakeholders involved in the distribution and reimbursement of medicines to treat these patients. We established our commercial presence in the field to support Treprostinil Injection and have since expanded our presence to support the potential launch of YUTREPIA (treprostinil) inhalation powder (&#8220;YUTREPIA&#8221;), further validating our reputation as a company committed to supporting PAH and PH-ILD patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">We conduct research, development and manufacturing of novel products by applying our subject matter expertise in cardiopulmonary diseases and our proprietary PRINT</span><span style="font-size:7.5pt;letter-spacing:0.15pt;">&#174;</span><span style="font-size:10pt;">&#160;technology, a particle engineering platform, to enable precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Through development of our own products and research with third parties, we have experience applying PRINT across multiple routes of administration and drug payloads including inhaled therapies, vaccines, biologics, nucleic acids and ophthalmic implants, among others.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, low effort dry-powder inhaler (&#8220;DPI&#8221;) and by achieving higher dose levels than the labeled doses of current inhaled therapies. On August&#160;16, 2024, the United States Food and Drug Administration (the &#8220;FDA&#8221;) (i)&#160;granted tentative approval for our New Drug Application (&#8220;NDA&#8221;) for YUTREPIA for the treatment of PAH and PH-ILD and (ii)&#160;simultaneously determined that Tyvaso DPI, approved on May&#160;23, 2022, qualifies for a three-year New Clinical Investigation exclusivity for the chronic use of dry powder formulations of treprostinil for the approved indications. As a result, final approval of YUTREPIA for PAH and PH-ILD is currently delayed until after expiry of the three-year regulatory exclusivity for Tyvaso DPI on May&#160;23, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are also developing L606, an investigational, liposomal formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer, which we licensed from Pharmosa Biopharm Inc. (&#8220;Pharmosa&#8221;). L606 is currently being evaluated in an open-label study in the United States for treatment of PAH and PH-ILD with a planned pivotal study for the treatment of PH-ILD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We are subject to risks and uncertainties common to companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on third parties and key personnel, protection of proprietary technology, compliance with government regulations, and the ability to secure additional capital to fund operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_WPCAlNncJU2QO3_ky6OPDw_cont1" continuedAt="Tb_WPCAlNncJU2QO3_ky6OPDw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The current global macro-economic environment is volatile, which may result in supply chain constraints and elevated rates of inflation. In addition, we operate in a dynamic and highly competitive industry and believe that changes in any of the following areas could have a material adverse effect on our future financial position, results of operations, or cash flows: the ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval, market acceptance and third-party payor coverage for our products; development of sales channels; certain strategic relationships; litigation or claims against us, including claims related to intellectual property, product, regulatory, or other matters; and our ability to attract and retain employees necessary to support our growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Product candidates we develop require approval from the FDA and/or other international regulatory agencies prior to commercial sales. There can be no assurance that our product candidates will receive the necessary approvals or, if we do, the indications for which our products will be approved. If we are denied approval, approval is delayed, approval is for less than all of the indications we are seeking, or we are unable to maintain approval, it could have a material adverse impact on our business, financial position and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We rely on single source manufacturers and suppliers for the supply of our product candidates, adding to the manufacturing risks we face. In the event of any failure by a supplier, we could be left without backup facilities. Any disruption from these manufacturers or suppliers could have a negative impact on our business, financial position and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We have financed our growth and operations through a combination of funds generated from revenues, the issuance of convertible preferred stock and common stock, bank borrowings, bank borrowings with warrants, the issuance of convertible notes and warrants, and revenue interest financing. Since inception, we have incurred recurring losses, including a net loss of $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr_UVq8c0NGMUScGifRd-w-tw">92.0</ix:nonFraction> million for the nine months ended September&#160;30,&#160;2024. As of September&#160;30,&#160;2024, we had an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_2N6-j_hJn063e1Z5udEEYQ">521.1</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We expect to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates through clinical trials, seek regulatory approval of such product candidates and pursue commercialization of any approved product candidates. These efforts require significant amounts of capital, adequate personnel and infrastructure, and extensive compliance-reporting capabilities. Even if our development efforts are successful, it is uncertain when, if ever, we will realize significant revenue from product sales. Additionally, the Revenue Interest Financing Agreement with HealthCare Royalty Partners IV, L.P. (&#8220;HCR&#8221;) dated January 9, 2023, as amended (the &#8220;RIFA&#8221;) contains fixed quarterly payments and minimum cash covenants that require us to maintain cash and cash equivalents in an amount at least equal to $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_srt_CounterpartyNameAxis_lqda_HealthcareRoyaltyPartnersIvL.pMember_srt_StatementScenarioAxis_lqda_ForCalendarYearBeginningOnJanuary12024Member_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_jT09y22dlU-r4cO26SYVlQ" decimals="-5" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained" scale="6" id="Narr_HDrj2J1xYEyin6eEB7yM0A">7.5</ix:nonFraction> million during the calendar year beginning on January 1, 2024 and at least equal to $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_srt_CounterpartyNameAxis_lqda_HealthcareRoyaltyPartnersIvL.pMember_srt_StatementScenarioAxis_lqda_AfterCalendarYearEndingOnDecember312024Member_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_Eu2lyuSqdUWRsk5xpT6IEw" decimals="-5" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained" scale="6" id="Narr_jNgwEI0pxU6rdwnruBTk0Q">15.0</ix:nonFraction> million for the remainder of the payment term after the calendar year ended December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In September 2024, we entered into the Fifth Amendment to the RIFA pursuant to which HCR funded an additional $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_TypeOfArrangementAxis_lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember_L0sD_tmmekuf3ox2hlAg-g" decimals="-5" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche" scale="6" id="Narr_N5YyghIM5EyPnfCgNlgF-A">32.5</ix:nonFraction> million on September 12, 2024, for total funding of $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_aLJKJ9CWC0enkGwFB_L9fw" decimals="-6" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementAmountFunded" scale="6" id="Narr_oLmT7THw3UyMaYL6FteqDA">100</ix:nonFraction> million. Additionally, payments due under the RIFA were amended such that the one-time fixed payment previously due in July 2025 is now due in equal payments in January and July 2026. See Note 12&#160;for further information.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On September 12, 2024, we sold shares of our common stock in an underwritten registered public offering for net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_9_12_2024_To_9_12_2024_aSxtNfNO5k-96RR4O_eJ5w" decimals="-5" format="ixt:numdotdecimal" name="lqda:ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts" scale="6" id="Narr_RV2q-HygO0yiTRnVE2zJnA">53.7</ix:nonFraction> million and sold shares of our common stock for net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_9_12_2024_To_9_12_2024_aSxtNfNO5k-96RR4O_eJ5w" decimals="-5" format="ixt:numdotdecimal" name="lqda:ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts" scale="6" id="Narr_PLKuk93CwEKmLnew0_gsTQ">10.0</ix:nonFraction> million in a private offering. See Note 8 for further information.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our future funding requirements will be heavily determined by the timing of the potential commercialization of YUTREPIA and the resources needed to support development of our product candidates. Based on our current plans, we expect that we will require additional capital to fund operations as well as to pursue in-licenses or acquisitions of other product candidates. If we are unable to obtain additional funding, we could be required to delay, reduce, or eliminate research and development programs, product portfolio expansion, or future commercialization efforts, which could adversely affect our business prospects, or we may be unable to continue operations.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_WPCAlNncJU2QO3_ky6OPDw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Although we expect to continue to generate operating losses for the foreseeable future, we believe that as a result of the recent Fifth Amendment to the RIFA and net proceeds from the sale of common stock described above, excluding any future YUTREPIA product revenue, our cash and cash equivalents will be sufficient to fund operations, capital expenditures, and RIFA payments and allow us to remain in compliance with our minimum cash covenants pursuant to the RIFA for at least twelve months from the issuance date of these condensed consolidated financial statements. If we have not received full FDA approval and generated sufficient cash from product sales of YUTREPIA or are unable to access additional capital by the date of issuance of our fiscal year 2024 consolidated financial statements, we expect there would be substantial doubt about our ability to continue as a going concern as of that date. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect, which would have a material impact on our operations.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_W8KMD8D_nkK4bZ62ch8JYA" continuedAt="Tb_W8KMD8D_nkK4bZ62ch8JYA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Basis of Presentation, Significant Accounting Policies and Fair Value Measurements</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_x2MrxE0KR0G4IwrXC1Ve5A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The unaudited interim condensed consolidated financial statements as of September&#160;30,&#160;2024 and for the three and nine months ended September&#160;30,&#160;2024 and 2023 have been prepared pursuant to the rules&#160;and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for interim financial reporting. These condensed consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal recurring adjustments and accruals) necessary for a fair statement of the results for the periods presented in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The year-end condensed consolidated balance sheet data was derived from our audited consolidated financial statements but does not include all disclosures required by GAAP. Operating results for the three and nine months ended September&#160;30,&#160;2024 are not necessarily indicative of the results that may be expected for the fiscal&#160;year ending December&#160;31,&#160;2024. Certain information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with GAAP have been omitted in accordance with the SEC&#8217;s rules&#160;and regulations for interim reporting. <span style="background:#ffffff;">Certain amounts have been reclassified from the prior year presentation to conform to current presentation, specifically in relation to the balance sheet presentation of finance and operating leases. </span>Our financial position, results of operations and cash flows are presented in U.S. Dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with our audited consolidated financial statements for the&#160;year ended December&#160;31,&#160;2023, which are included in our 2023 Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31,&#160;2023 (the &#8220;2023 Annual Report on Form 10-K&#8221;).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:UseOfEstimates" id="Tb_PsFx8PFXE02qI2ZptcBg3Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the period. These estimates are based on historical experience and various other assumptions believed to be reasonable under the circumstances. We evaluate our estimates on an ongoing basis, including those related to the valuation of stock-based awards, certain accruals, the revenue interest financing payable, and intangible and contract acquisition cost amortization, and make changes to the estimates and related disclosures as our experience develops or new information becomes known. Actual results will most likely differ from those estimates.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_xpFeg02o5EWh_JTWZaEBIQ" continuedAt="Tb_xpFeg02o5EWh_JTWZaEBIQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">GAAP requires segmentation based on an entity&#8217;s internal organization and reporting of revenue and operating income based upon internal accounting methods commonly referred to as the &#8220;management approach.&#8221; Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources and in assessing performance. Our CODM is our Chief Executive Officer. We have determined that we have <ix:nonFraction unitRef="Unit_Standard_segment_5Yg_HHT1gEGJPlsg-11Qtw" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_peLBo4XhxEOhwgHsWsY-Fw">one</ix:nonFraction>&#160;operating and reporting segment.</p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_W8KMD8D_nkK4bZ62ch8JYA_cont1" continuedAt="Tb_W8KMD8D_nkK4bZ62ch8JYA_cont2"><ix:continuation id="Tb_xpFeg02o5EWh_JTWZaEBIQ_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our significant accounting policies are disclosed in Note&#160;2 of the consolidated financial statements for the&#160;years ended December&#160;31, 2023 and 2022, which are included in our 2023 Annual Report on Form 10-K. There have been no material changes to our significant accounting policies during the nine months ended September&#160;30,&#160;2024.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_GCI5zNlh9kqRYt8bHrKC1Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board under its accounting standards codifications (ASC) or other standard setting bodies and are adopted by us as of the specified effective date. For the nine months ended September&#160;30,&#160;2024, there were no newly adopted accounting pronouncements that had a material impact on our condensed consolidated financial statements. As of September&#160;30,&#160;2024, there are no recently issued but not yet adopted accounting pronouncements that are expected to materially impact our condensed consolidated financial statements.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="lqda:CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock" id="Tb_Xf-Dee1Rh0-9Hv7OOB6eZg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash, Cash Equivalents, and Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We consider all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject us to concentrations of credit risk consist of cash and cash equivalents. We are exposed to credit risk, subject to federal deposit insurance, in the event of default by the financial institutions holding our cash and cash equivalents to the extent of amounts recorded on the condensed consolidated balance sheet. Our cash and cash equivalents are held at multiple accredited financial institutions. We have not experienced any losses on such accounts and do not believe that we are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Such deposits have exceeded and will continue to exceed federally insured limits.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="Tb_ARjFJufJskKaccmncov61Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accounts Receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accounts receivable are stated at net realizable value and net of an allowance for credit losses as of each balance sheet date, if applicable. <ix:nonFraction unitRef="Unit_Standard_customer_rCtGSEdMk0iBBkxQf_23NA" contextRef="Duration_1_1_2024_To_9_30_2024_srt_MajorCustomersAxis_lqda_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_VjK3Qv7B0EufQgTVe6t9Mg" decimals="INF" format="ixt-sec:numwordsen" name="lqda:NumberOfCustomers" scale="0" id="Narr_URHTgK7TiEK8T9lZQI8Y_g"><ix:nonFraction unitRef="Unit_Standard_customer_rCtGSEdMk0iBBkxQf_23NA" contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_lqda_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_flP9Ohx3sEW9JMma2AxykA" decimals="INF" format="ixt-sec:numwordsen" name="lqda:NumberOfCustomers" scale="0" id="Narr_ODS74bG4LUyLH71C9KbjHw">One</ix:nonFraction></ix:nonFraction> customer accounted for <ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_1_2024_To_9_30_2024_srt_MajorCustomersAxis_lqda_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_VjK3Qv7B0EufQgTVe6t9Mg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_2W17woSGgkCa0YQ4wH7Kkw">96</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_lqda_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_flP9Ohx3sEW9JMma2AxykA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_b8yUKml0HES0CXt6ft04Xw">99</ix:nonFraction>% of our accounts receivable, net at September&#160;30,&#160;2024 and December&#160;31,&#160;2023, respectively. As of September&#160;30,&#160;2024 and December&#160;31,&#160;2023, we have not recorded an allowance for credit losses.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:InventoryPolicyTextBlock" id="Tb_FdOnlj_C30umMltJSz2VvQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Prelaunch Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We capitalize prelaunch inventory prior to receiving regulatory approval if regulatory approval and subsequent commercialization of a product is probable and we also expect future economic benefit from the sales of the product to be realized. Prior to this conclusion, we expense prelaunch inventory as research and development expense in the period incurred. For prelaunch inventory that is capitalized, we consider a number of specific facts and circumstances, including the product&#8217;s shelf life, the product's current status in the development and regulatory approval process, results from related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential obstacles to the approval process, viability of commercialization and market trends. In late 2023, based on our assessment of the legal and regulatory process related to YUTREPIA, we concluded that we met the criteria to capitalize expenditures for prelaunch inventory. We capitalized $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-5" format="ixt:numdotdecimal" name="lqda:InventoryCapitalizedCost" scale="6" id="Narr_dIeBQMd8SEKYRRYQNokwag">7.4</ix:nonFraction> million of prelaunch inventory as of September&#160;30,&#160;2024 and <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-5" format="ixt-sec:numwordsen" name="lqda:InventoryCapitalizedCost" scale="6" id="Narr_uWh-nM-bvE6E9WUwBnCqNA">none</ix:nonFraction> as of December&#160;31,&#160;2023. If either regulatory approval or market acceptance post-approval of YUTREPIA do not occur at all or on a timely basis prior to the inventory shelf-life expiration,&#160;we may be required to write-off some or all prelaunch inventory, which could affect our financial condition and financial results.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_HVj4Q5EogEyS_iWu1HokSA" continuedAt="Tb_HVj4Q5EogEyS_iWu1HokSA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;">We review long-lived assets, including definite-life intangible assets, for realizability on an ongoing basis. Changes in depreciation and amortization, generally accelerated depreciation and variable amortization, are determined and recorded when estimates of the remaining useful lives or residual values of long-term assets change. We also review </p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_W8KMD8D_nkK4bZ62ch8JYA_cont2" continuedAt="Tb_W8KMD8D_nkK4bZ62ch8JYA_cont3"><ix:continuation id="Tb_HVj4Q5EogEyS_iWu1HokSA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 12pt 0pt;">for impairment when conditions exist that indicate the carrying amount of the assets may not be fully recoverable. In those circumstances, we perform undiscounted operating cash flow analyses to determine if an impairment exists. When testing for asset impairment, we group assets and liabilities at the lowest level for which cash flows are separately identifiable. Any impairment loss is calculated as the excess of the asset&#8217;s carrying value over its estimated fair value. Fair value is estimated based on the discounted cash flows for the asset group over the remaining useful life or based on the expected cash proceeds for the asset less costs of disposal. Any impairment losses would be recorded in the consolidated statements of operations. To date, <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="Narr_xg4rAWrH_EuGtU1PXBOUtA">no</ix:nonFraction> such impairments have occurred.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="Tb_5FOMDqHlNUy-jNouIKvrEw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Goodwill</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 12pt 0pt;">We assess goodwill for impairment at least annually as of July 1 or whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. For example, significant and unanticipated changes or our inability to obtain or maintain regulatory approvals for our product candidates, including the NDA for YUTREPIA, could trigger testing of our goodwill for impairment at an interim date. We have <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportingUnits" scale="0" id="Narr_S2gH_qahTUqqmLj3NBP8ZA">one</ix:nonFraction> reporting unit. We have the option to first assess qualitative factors to determine whether events or circumstances indicate it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, in which case a quantitative impairment test is not required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Per ASC 350, <i style="font-style:italic;">Intangibles Goodwill and Other, </i>the quantitative goodwill impairment test is performed by comparing the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not impaired. An impairment loss is recognized for any excess of the carrying amount of the reporting unit&#8217;s goodwill over the fair value up to the amount of goodwill allocated to the reporting unit. Income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit are considered when measuring the goodwill impairment loss, if applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30,&#160;2024, we concluded there were no events or changes in circumstances which indicated that the carrying amount of goodwill was not recoverable. We completed our annual impairment test as of July 1, 2024 and concluded that <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_7_1_2024_XRrRRtHXS0yYWbSCULb-5g" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="Narr_u-GPmecjyEaaSWi1p90-8Q">no</ix:nonFraction> impairments had occurred.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="lqda:RevenueInterestFinancingPayablePolicyPolicyTextBlock" id="Tb_vPmyLVX-PUaNUiOKuqSnEQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Interest Financing Payable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recognized a liability related to amounts received in January 2023, July 2023, and January 2024 pursuant to the RIFA under ASC 470-10, <i style="font-style:italic;">Debt</i> and ASC 835-30, <i style="font-style:italic;">Interest - Imputation of Interest</i>. The liability will be accreted under the effective interest method based upon the estimated amount of future payments to be made pursuant to the RIFA. If the timing or amounts of any estimated future payments change, we will prospectively adjust the effective interest and the related amortization of the liability and related issuance costs. A significant increase or decrease in these estimates could materially impact the liability balance and related interest expense.<b style="font-weight:bold;"> </b>Amendments are assessed under ASC 470 to determine appropriate treatment as troubled debt restructurings, extinguishments or modifications.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_QfkdVlS8UkahqO3PjOpAoQ" continuedAt="Tb_QfkdVlS8UkahqO3PjOpAoQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recognize revenue in accordance with ASC 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;). The core principle of ASC 606 is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:16.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Step 1: Identify the contract with the customer</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:16.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Step 2: Identify the performance obligations in the contract</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:16.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Step 3: Determine the transaction price</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:16.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Step 4: Allocate the transaction price to the performance obligations in the contract</span></td></tr></table></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_W8KMD8D_nkK4bZ62ch8JYA_cont3" continuedAt="Tb_W8KMD8D_nkK4bZ62ch8JYA_cont4"><ix:continuation id="Tb_QfkdVlS8UkahqO3PjOpAoQ_cont1"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:16.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Step 5: Recognize revenue when the company satisfies a performance obligation</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In order to identify the performance obligations in a contract with a customer, we assess the promised goods or services in the contract and identify each promised good or service that is distinct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If a good or service is not distinct, the good or service is combined with other promised goods or services until a bundle of goods or services is identified that is distinct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. We evaluate any non-cash consideration, consideration payable to the customer, potential returns and refunds, and whether consideration contains a significant financing element in determining the transaction price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Revenue is measured based on consideration specified in a contract with a customer. We recognize revenue when it satisfies a performance obligation by transferring control over a service to a customer. The amount of revenue recognized reflects estimates for refunds and returns, which are presented as a reduction of accounts receivable where the right of setoff exists.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_6WU5M8WeD0yUMfoYvZkdiA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred in accordance with ASC 730,&#160;<i style="font-style:italic;">Research and Development</i> and include facility-related costs related to research and development activities, direct costs from third parties, such as contract research organizations (&#8220;CROs&#8221;), contract manufacturing organizations (CMOs&#8221;), and consultants, as well as employee-related expenses, including salaries, benefits, and stock-based compensation. Research and development expenses also include costs of acquired product licenses and related technology rights where there is no alternative future use.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="lqda:AccruedResearchAndDevelopmentExpensePolicyTextBlock" id="Tb_7ZhQivB3gkutf7bRasF-KQ" continuedAt="Tb_7ZhQivB3gkutf7bRasF-KQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accrued Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As part of the process of preparing the condensed consolidated financial statements, we are required to estimate accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our condensed consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of these estimates with the service providers and make adjustments if necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The significant estimates in our accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities. The financial terms of our agreements with CROs and CMOs are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from such estimate, we adjust the accrual or prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_Ti1QlV_GqU6AHh1vrTGaSw_1_2"></a><a id="Tc_n6FKkhCmcEG3d0ha5iYYFg_1_6"></a><a id="Tc_NWdYdxncJ0GtgXM8HvxoMQ_2_2"></a><a id="Tc_VRGi_WPFhkmXiiK3JKvAxw_2_6"></a><a id="Tc_Tu4OvNtowkG3VLz3FBcYxg_3_2"></a><a id="Tc_Q04f46bqI0SccfmqT5aPPA_3_4"></a><a id="Tc_Miqyl-xqqEKX48aZXohuwQ_3_6"></a><a id="Tc_2IUG6FPgF0mmYP4qhimZvw_3_8"></a><a id="Tc_tu60oZ6sgEyvOuhTQziJqA_4_0"></a><a id="Tc_T1OLWOkPk0yiIiYZ4uPQ2g_5_0"></a><a id="Tc_j07ZD9uqvUmBeFcF5SNMVw_6_0"></a><a id="Tc_CB4qo8BSFUSMkoDYN1plvg_7_0"></a><ix:continuation id="Tb_W8KMD8D_nkK4bZ62ch8JYA_cont4" continuedAt="Tb_W8KMD8D_nkK4bZ62ch8JYA_cont5"><ix:continuation id="Tb_7ZhQivB3gkutf7bRasF-KQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_zdocnOuykkiRYhjwMcdJrw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We estimate the grant date fair value of stock-based awards and amortize this fair value to compensation expense over the requisite service period or the vesting period of the respective award. In arriving at stock-based compensation expense, we estimate the number of stock-based awards that will be forfeited due to employee turnover. The forfeiture assumption is based primarily on turn-over historical experience. If the actual forfeiture rate is higher than the estimated forfeiture rate, then an adjustment will be made to increase the estimated forfeiture rate, which will result in a decrease to the expense recognized in our financial statements. If the actual forfeiture rate is lower than the&#160;estimated forfeiture rate, then an adjustment will be made to lower the&#160;estimated forfeiture rate, which will result in an increase to expense recognized in our financial statements. The expense we recognize in future periods will be affected by changes in the&#160;estimated forfeiture rate and may differ from amounts recognized in the current period. See Note 9.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_gdQRyQS9t0m-TYJvphm_Ig" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. Due to their anti-dilutive effect, the calculation of diluted net loss per share excludes the following common stock equivalent shares:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_7BU58C82hE24vu0aX8dNOQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_TzBMkys33EuWe4DPMyM4ng" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_8cFJ-iVoX0esC2-9Tn8ogg_4_2">9,113,427</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_canxHtd-XkG4uVMvRpE1FQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_dkemJZsGpkGUpqERPxtzlA_4_4">9,573,680</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_U5I2QUtyeUKSw5V0JR-EtQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_L76sTJpenEm4kzyw0i-Kzw_4_6">9,372,790</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_1muCQV59SEeHsD-Yav1p6Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_YnSGC5JY3EKJInCxcBVBFw_4_8">9,494,833</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted Stock Units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_bAuPCroLc0CrK6O9kr5tog" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_cD9Ve1TGl02wXY_wV4t-Xw_5_2">3,131,834</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_aep-yz_sAU6w4KnoDTuRXQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_0eg72cDZ5EG0bp8aY0RzpQ_5_4">1,704,353</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_0ZcXs57SsESdiizR7P7_-A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_0wouIoFEZ0G4YbBnp22QLw_5_6">3,062,498</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_QGpDrn6it0u-SFLEKVzU7A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_0IV6XVRuHUqicAyDKpdSow_5_8">1,689,998</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_9fQbmG5QVECfc_dtjchxWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_uStQDrOrvUW7w5Rxxn_U7g_6_2">450,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_Ccuko3guq0aS4kOvVeM9WQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_TAU8f3G-tkeK4C_dARWxXQ_6_4">450,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_Qb1al7pN5Eum9jNVekDffw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_XtMHW35iF02zTX1LRBxNcw_6_6">450,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_XlMlf1imU0CKFBvkuE1IEA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_wLh3UepWlE6jhWMtut4LaA_6_8">450,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_2FWG8fCjoEm_xeupn9iDUA_7_2">12,695,261</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_aXiXaW_DHk2oW5bjQIFNGg_7_4">11,728,033</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Zs-1E_28IECXSTf62kzUTA_7_6">12,885,288</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_widjw2pz4Uif9yT8pKX5Og_7_8">11,634,831</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Certain common stock warrants are included in the calculation of basic and diluted net loss per share since their exercise price is de minimis.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_xdt9pqwdBUuth1bFxeRLiQ" continuedAt="Tb_xdt9pqwdBUuth1bFxeRLiQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ASC 825,<span style="font-family:'Calibri','Helvetica','sans-serif';"> </span><i style="font-style:italic;">Financial Instruments</i> defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants (an exit price). As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. ASC 825 establishes a three-tiered approach for valuation of financial instruments, which requires that fair value measurements be classified and disclosed in one of three tiers, whether or not recognized on our condensed consolidated balance sheets at fair value. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Level 1&#160;&#8212; Quoted prices in active markets for identical assets or liabilities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Level 2&#160;&#8212; Inputs other than quoted prices included in active markets that are observable for the asset or liability, either directly or indirectly; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Level 3&#160;&#8212; Unobservable inputs for the asset and liability used to measure fair value, to the extent that observable inputs are not available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following table presents the placement in the fair value hierarchy of financial assets and liabilities measured at fair value as of September&#160;30,&#160;2024 and December&#160;31,&#160;2023:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="Tb_qG6-5zLigEul5ujiKjwVRQ" continuedAt="Tb_qG6-5zLigEul5ujiKjwVRQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_78c85d3c_65b1_417d_bb55_e7b6a60c68e7"></a><a id="Tc_vo4Q2cKhuES-6XqVTPK1uw_1_2"></a><a id="Tc_2JXtrm2q8EKc-h5_yt-neA_1_5"></a><a id="Tc_zrs3IrB1ikyonVzpwFwkbw_2_2"></a><a id="Tc_C9WnofzqVU-KHupuugZcGw_2_5"></a><a id="Tc_vZkLkDlhukaWLVdt0l-N0w_2_8"></a><a id="Tc_iE-ShLxLqEWWsRlQ6xGnvQ_3_2"></a><a id="Tc_UAsD2MpKvkmy0In4tJPEUw_3_5"></a><a id="Tc_vbgKpY7yr0y1CFy9UeeJgQ_3_8"></a><a id="Tc_pw_kcAe03U22DCjpz07Xaw_4_2"></a><a id="Tc_hvScxD8ACEqW6MvsCmWl_Q_4_5"></a><a id="Tc_TdLHZ-sOekqf0PI3D6y8NQ_4_8"></a><a id="Tc_eXkFToc1J0qgXqQR5qRVLQ_4_11"></a><a id="Tc_YzMn41ZVZEK4pyCrzvSqcg_5_0"></a><a id="Tc_SkHKqRgPEUWHqBFxCcVJ-w_5_2"></a><a id="Tc_Xzg4kp0G4kOnwK60Q-B1ow_5_5"></a><a id="Tc_nPk01VbGuEKy3Ed5QlIVQw_5_8"></a><a id="Tc_9pKmSWAaAU-qVA0zl83p7A_5_11"></a><a id="Tc_Vx9zl0zQp0aeJZLFGTU61w_6_0"></a><a id="Tc_JfKxB2JRfku3c-UgJuwBbQ_6_2"></a><a id="Tc_Z5YA5xMUzEyifK4rfNv0YA_6_5"></a><a id="Tc_gpqMVV2ddkKAfOhE86JIKw_6_6"></a><a id="Tc_6ZPPK4MnvUmAYM2XjpdNBQ_6_8"></a><a id="Tc_8jLGtX6_hUS7pt2J88Mb7g_6_9"></a><a id="Tc_fqgot2yNvUSEq-Nm5YX8jg_6_11"></a><a id="_5aa2fcd6_8fd3_44ae_b418_59bd76f11f91"></a><a id="Tc_WKi44mDC7UG5elqKgWj0KQ_1_2"></a><a id="Tc_jFuSub0fLE6msd1VKwneVQ_1_5"></a><a id="Tc_Q2EkTZyOMEakKsTtqY4Ccw_2_2"></a><a id="Tc_f5uGaZ0DwEaanLCTRZNJTw_2_5"></a><a id="Tc_svWkuccbE0CKETu4KpmC-A_2_8"></a><a id="Tc_ZUCyR_3IZECx91T_385MIQ_3_2"></a><a id="Tc_9mCK1BoIoU632IGa0d8Lng_3_5"></a><a id="Tc_L0aMlscL9ky5pvKdHvVTcg_3_8"></a><a id="Tc_IblUporvU0W7iL_jT1xVCQ_4_2"></a><a id="Tc_VlYAq9hxlUeXGWP_Xhl1Uw_4_5"></a><a id="Tc_jVBf0U6-HkutFSE1Q78z7Q_4_8"></a><a id="Tc_JIj-vleFiEyHQi2nACaVEg_4_11"></a><a id="Tc_oFEVf_l7E0GO5IAXFWm-Rg_5_0"></a><a id="Tc_GM0CMzELskONabBzT7SImQ_5_2"></a><a id="Tc_GKxZi81WYUC29I3acCHLXw_5_5"></a><a id="Tc_98cIS9YeHkef8Gvm5My_Mg_5_8"></a><a id="Tc_9waDbjOWgUSZYyokgGZlKQ_5_11"></a><a id="Tc_mkIohz92K0as5U24H4z5Tg_6_0"></a><a id="Tc_AOjm2UEGNki6hMQijojiTA_6_2"></a><a id="Tc_3ZrdBajFmUOvoyAxWXM51Q_6_5"></a><a id="Tc_oEWMCoeuaUOXmw2SamcHHA_6_6"></a><a id="Tc_1AvEy-ad20qUmYvCfceKZQ_6_8"></a><a id="Tc__QRKlq4W4Ei7jnEP095-UA_6_9"></a><a id="Tc_i7Kqf2G-50-pTFCYk3E_pQ_6_11"></a><ix:continuation id="Tb_W8KMD8D_nkK4bZ62ch8JYA_cont5"><ix:continuation id="Tb_xdt9pqwdBUuth1bFxeRLiQ_cont1"><ix:continuation id="Tb_qG6-5zLigEul5ujiKjwVRQ_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Money market funds (cash equivalents)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_kMc1M1fUA0aLfEacYxGcNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_ApnDAPzuqUmANr9LQImxDA_6_3">198,565</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_ANzvLLeodEu35lLZjmLNlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_q69b531HskefCLJwv7ya3A_6_12">198,565</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds (cash equivalents)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_RXXfSfHAKUOxB0bjch78SQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_YJuIkA_0K0aaIwohMXLE1w_6_3">79,912</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_hRZjTb3f50WuaHZvxqO0dQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_XOERFB4cr0KzJBJ28vJJLg_6_12">79,912</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Money market funds are included in cash and cash equivalents on our condensed consolidated balance sheet and are classified within Level 1 of the fair value hierarchy since they are valued using quoted market prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts reflected in our condensed consolidated balance sheets for cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their short-term nature. The carrying value of the revenue interest financing payable approximate fair value as the respective interest rates are reflective of current market rates on debt with similar terms and conditions. In addition, the revenue interest financing payable is <span style="background:#ffffff;">updated with the expected amount to be paid back each reporting period based on the contractual terms and current projections.</span></p></ix:continuation></ix:continuation><a id="Tc_tuM25HbXb0imIdMQox6g5A_1_2"></a><a id="Tc_NiQFdVCk3EmE8larZXoxRg_1_5"></a><a id="Tc_7D99_UiH5kuDHbZpujtIew_2_2"></a><a id="Tc_Bcq2AqxwvkyZwZpWRXDIZw_2_5"></a><a id="Tc_Kv6tWLLO90uwaLcCiO9WDA_3_0"></a><a id="Tc_cIe0VQNuz02V5duSfVv_Lw_3_2"></a><a id="Tc_TiRTdVhDnESJZxQxpsLkcA_3_5"></a><a id="Tc_MEWvxxRY50-NgfjjiP5Zxw_3_6"></a><a id="Tc_J5V2JZzyqkiK518b1mjCAA_4_0"></a><a id="Tc_tA9VgxQC50a9MvxwZW0WjQ_4_6"></a><a id="Tc_dvDFqEFBo06HEIJ_0a1bzw_5_0"></a><a id="Tc_yQdRM_BElkq5ZpZKAxYLlQ_5_2"></a><a id="Tc_6m9e3GQPN0-0WqZz9HqmaA_5_5"></a><a id="Tc_mK5i7kgqOkiOFQgWOZHsZA_5_6"></a><a id="Tc_Que0ZJMqIU2MQ-oVQ9deRQ_7_0"></a><a id="Tc_t5r3fm3c506NvXaAGnQnAg_8_0"></a><a id="Tc_SQJEp1xEoEKUSCh-nhZ7nQ_8_2"></a><a id="Tc_8vmMmQokpESUf43L44k7Fw_8_5"></a><a id="Tc_JZbe9LQKxEC20MyVPYa4fw_8_6"></a><a id="Tc_mOGzQKgVZ0ipU-8fhUF6lA_9_0"></a><a id="Tc_7einGtTtkkil7O_M3xlzjA_9_6"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_WRzgrSwS_UC2H2vRM6Tazw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">3. Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">Inventories are stated at the lower of average cost or net realizable value and consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_0yQtZYzkt0mbE4WTtTNVoA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="Tc_7AT0cp726UCRZUl40TKHTw_3_3">2,607</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="Tc_NUjb69YFnkqQf6S4X1KWIw_4_3">4,835</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:InventoryCurrentAndNonCurrent" scale="3" id="Tc_ypXjr4uD6kOOknVN2GVQEw_5_3">7,442</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Recognized as:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_HDXRN6-jdUmifnZ2j3X-qA_8_3">38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_xRg1wcXNfk271ht3s4kIeQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNoncurrent" scale="3" id="Tc_TWoY9MWDpUWQxK5E3lE-qA_9_3">7,404</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Prelaunch Inventory</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the nine months ended September&#160;30,&#160;2024, we capitalized costs of $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-5" format="ixt:numdotdecimal" name="lqda:CapitalizedCostsOfInventory" scale="6" id="Narr_uqBwRbAmFU-Ztj8nAadmbQ">7.4</ix:nonFraction> million associated with the production of YUTREPIA as a result of our determination that regulatory approval and subsequent commercialization is probable, and we also expect future economic benefit from the sales of YUTREPIA to be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Amounts recognized as <i style="font-style:italic;">Other Assets</i> are comprised entirely of raw materials and work in process inventories not expected to be sold within one year of the balance sheet date<span style="white-space:pre-wrap;">.  </span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_892VfmorlE6htx4L4VMZHQ" continuedAt="Tb_892VfmorlE6htx4L4VMZHQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_YbdvsRxZika8Kb9BOXGhxA_1_2"></a><a id="Tc_R9YmAieJ5ky49Q6LMg44QQ_1_5"></a><a id="Tc_90isLYWnZU6Azp2wpfW_Iw_2_2"></a><a id="Tc_JriU_oOZ1UumtNRHBS9Pew_2_5"></a><a id="Tc_IPsn5T04IE6-I2lgcJn3dg_3_0"></a><a id="Tc_snCGgEcf2EiYYn0wiWFkUQ_3_2"></a><a id="Tc_GDxTa-CUVkeY6af48KWn0w_3_5"></a><a id="Tc_64mgnoKyRUqBQbSFuyjBpg_4_0"></a><a id="Tc_-j4Rcq88FUuIi1E8h8gEbw_5_0"></a><a id="Tc_DBkH-6tQnEqKY1MqQwh8cA_6_0"></a><a id="Tc_iRexFu5PD06qB6vj0Hbnag_7_0"></a><a id="Tc_SPLa5InE1kOq0JcbiISCVw_8_0"></a><a id="Tc_6EuuXAd6gEy-EqNfIt4a1w_9_0"></a><a id="Tc_PZ7sbFr35Ump68N0VveZfQ_10_0"></a><a id="Tc_XDGyB2eA7Eux3gU0x9WaeA_11_0"></a><a id="Tc_71gKRUislku23RQbfi4wlg_11_2"></a><a id="Tc_GSEh-jDA3kOmSn3K24PHAQ_11_5"></a><ix:continuation id="Tb_892VfmorlE6htx4L4VMZHQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Property, Plant, and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property, plant and equipment consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_k5MedFYHukyJslH8n7hNQA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lab and build-to-suit equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_lqda_LabAndBuildToSuitEquipmentMember_vbQ7hgEZXU2QQ8szN1HAtw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Vj5OGMhW7U22bfwl4p7uHQ_3_3">6,953</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_lqda_LabAndBuildToSuitEquipmentMember_3By5Ws9wr0KTAbJFyx2jow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_3BRyKjLCBkC1rMhcHHTwTQ_3_6">6,834</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_NBou6jkXCUKIl86emqBNpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_JPTOnmD14kGIa65gOZoYcQ_4_3">19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_u0t7q0rYoUCrtJJgFwTvrA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_I8V614YOq02IechrWt4Cag_4_6">19</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_HhiaPNdxpU2kL50_8kQ28g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_HcO1V8QkFk2JekeS3UGfEQ_5_3">241</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_P6CllWvurEyyz948ZgWhnQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_HowwOd3a_06a_lTWDc1EtA_5_6">241</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer and other equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember__bkosJSnNUKdzQ6jMHMqOA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_ZGm9Ye62Mk-Zb0RRlN4k6g_6_3">740</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_JDWBnuimj0OiMbqSGdD8Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_aXlCoEnox0WVaul9SBCBLg_6_6">487</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_VYpHUurxNEuWKkqyAiGjGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_51HlJkSZIUmPPsLNIPe9gg_7_3">11,450</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_vuK9MdKws0WBj-FZvfK_jA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_n2-t3dPthEq7kAvUorE6Mg_7_6">11,409</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Construction-in-progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_iPwI9W-yukKJZYkZvhU5ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_KNJu-ZiqE0OdV5XwoN3u-w_8_3">4,315</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_W1eYleOODEWnNYcNk76J4A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_4yKvuIzF3kiVOux6CAxuhg_8_6">804</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Uq-86EmlcUieJjd8uOiyFw_9_3">23,718</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Q3-ioz8YVEaQjr2Lh67grg_9_6">19,794</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_52CbhYEhskueSg-NxSamLg_10_3">15,934</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_AXnhqhWL-0K_2Zjx6G_frw_10_6">15,314</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, plant and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_sMj_uNlJ9kG47Tmrbb6CBg_11_3">7,784</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_BolTiNiurkS_-qz1W-KW5A_11_6">4,480</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recorded depreciation and amortization expense related to property, plant and equipment of $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="6" id="Narr__vYxDF096Ua5628I2_RdLA">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="6" id="Narr_NOcVcGq01k-QHOGTrV-zWA">0.3</ix:nonFraction> million for the three months ended September&#160;30,&#160;2024 and 2023, respectively, and of $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="6" id="Narr_IXQuVGIGhEejSHfAHYtaag">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="6" id="Narr_8P8KfVltG06rKdqk9Ru0fg">0.9</ix:nonFraction> million for the nine months ended September&#160;30,&#160;2024 and 2023, respectively.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_4adCLPNDsUeMHHPu-LcR5w_1_2"></a><a id="Tc_29HwbsvNNUOdTrp86iLTmA_1_11"></a><a id="Tc_kfSfXEg7eESNeQ1k1uNYrw_2_2"></a><a id="Tc_IHt0KhDP3E28_d_7_lFiRg_2_5"></a><a id="Tc_qn6ax6U5ZUe-_1R0hWoY7w_2_8"></a><a id="Tc_fRcaGDcg20O2RUMAszaXmQ_2_11"></a><a id="Tc_a5kVV3madEuGQOFI3LDLOA_2_14"></a><a id="Tc__oh3PBHrIU257Bfc5IJZPg_2_17"></a><a id="Tc_J9Fr7jf4H0av-GgC_3sFLQ_3_0"></a><a id="Tc_SqujZq55WkG9t-9h1UtNPA_3_2"></a><a id="Tc_8Ik_0xMGqEqLlLv6sb15cA_3_5"></a><a id="Tc_OZKZdYghV0avlBrG3iHkAg_3_8"></a><a id="Tc_WAvVKFyGUUiFwq0r5-W3Lw_3_11"></a><a id="Tc_Alr3vD_ZA0ijkzeOIe5OKA_3_14"></a><a id="Tc__2EnI2GPqUm7zSDfsK6XHA_3_17"></a><a id="Tc_i1f748gEkUKP_oBX9lFzmg_4_0"></a><a id="Tc_iQrxvaasa0apIQRTsrH02A_4_2"></a><a id="Tc_gv92o-sSf02njJkgH7I7ew_4_5"></a><a id="Tc_p4dH5G0t9EK7xafLlbZPBw_4_8"></a><a id="Tc_CrkqLfyChUKlvIspa64lrA_4_11"></a><a id="Tc_3o6ogaCa90WvKq9PWMOKzQ_4_14"></a><a id="Tc_m6utCfgvOkOkpKOfgRYiFQ_4_17"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="lqda:ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock" id="Tb_2gqCcyKgZ0SzZ7pQ3ZejTA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Contract Acquisition Costs and Intangible Asset</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Contract acquisition costs and intangible asset are summarized as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="lqda:ScheduleOfContractAcquisitionCostsAndIntangibleAssetsTableTextBlock" id="Tb_fKMiROLTqEuKk37HiaAiXw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:25.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:25.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross Carrying Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net Carrying Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross Carrying Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net Carrying Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract acquisition costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostGross" scale="3" id="Tc_8X83zWpna0Gihkm5C6eVhg_3_3">12,980</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostAccumulatedAmortization" scale="3" id="Tc_ub36mTBmlk2-gCqg3OlH_A_3_6">5,547</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostNet" scale="3" id="Tc_PCbYkCddZkyTze0l1raAxg_3_9">7,433</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostGross" scale="3" id="Tc_xMoDs-DOnUug7S1eY05TpA_3_12">12,980</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostAccumulatedAmortization" scale="3" id="Tc_C_0yipGVUkWupzkSHoGPYg_3_15">5,058</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostNet" scale="3" id="Tc_URlPW1hJk0SGpl_63IhVRw_3_18">7,922</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" id="Tc_dc0cvBlzZ0WJNDNhaHvw_A_4_3">5,620</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_EBi7_58v9U6g20N0HPX4xw_4_6">2,401</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_k_J4ss33bUS082uUpSXeWw_4_9">3,219</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" id="Tc_ufpQ_rY5jUGi_pqLXXcTXQ_4_12">5,620</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_KbEnDdGHhUK8x4Sd0czV8A_4_15">2,190</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_bkZMfshBDUWophdMaoNDKA_4_18">3,430</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are amortizing the value of the contract acquisition costs and intangible asset on a pro-rata basis based on the estimated total revenue or net profits to be recognized over the period from November 18, 2020 through December 2032, the termination date of the Promotion Agreement (see Note 2-Revenue Recognition for our accounting policies). Amortization of contract acquisition costs is recorded as a reduction of revenue, and amortization of the intangible asset is recorded as cost of revenue. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recorded amortization related to the contract acquisition costs of $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="Narr_almsw7uGR02UC0CP0TsW8A">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="Narr__auwScfK9kCO5Dclcts9Og">0.1</ix:nonFraction> million for the three months ended September&#160;30,&#160;2024 and 2023, respectively, and of $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="Narr_-etGSQWGqkmCUWV-Ibjhbg">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="Narr_KhFcm0Bho0iXn1ETXqiivQ">0.5</ix:nonFraction> million for the nine months ended September&#160;30,&#160;2024 and 2023, respectively. We recorded amortization related to the intangible asset of $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="Narr_Qo-ceyKNmUCcjMljBOJNJg">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="Narr_-95rpxy48E-wb3ZGXWAAEA">0.1</ix:nonFraction> million for the three months ended September&#160;30,&#160;2024 and 2023, respectively, and of $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="Narr_nvP1DnF4uUidZLr1nbuDkA">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="Narr_IbA9maiIGUS0X3-ePe6PsQ">0.2</ix:nonFraction> million for the nine months ended September&#160;30,&#160;2024 and 2023, respectively. Annual amortization over the next five years is expected to immaterially fluctuate from the 2024 amounts, consistent with changes to net profits to be recognized pursuant to the Promotion Agreement over the period.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="lqda:IndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDisclosureTextBlock" id="Tb_AuReBcxWuEeqPIgQ3Pgg2g" continuedAt="Tb_AuReBcxWuEeqPIgQ3Pgg2g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Indemnification Asset with Related Party and Litigation Finance Payable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On June 3, 2020, Liquidia PAH entered into a litigation financing arrangement (the &#8220;Financing Agreement&#8221;) with Henderson SPV, LLC (&#8220;Henderson&#8221;). Liquidia PAH, along with Sandoz (collectively the &#8220;Plaintiffs&#8221;), are pursuing litigation against United Therapeutics Corporation (&#8220;United Therapeutics&#8221;) (the &#8220;RareGen Litigation&#8221;). Under the Financing Agreement, Henderson will fund Liquidia PAH&#8217;s legal and litigation expenses (referred to as &#8220;Deployments&#8221;) in exchange for a share of certain litigation or settlement proceeds. Deployments received from Henderson are recorded as a Litigation finance payable.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_AuReBcxWuEeqPIgQ3Pgg2g_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Litigation proceeds will be split equally between Liquidia PAH and Sandoz. Unless there is an event of default by Henderson, litigation proceeds received by Liquidia PAH must be applied first to repayment of total Deployments received. Litigation proceeds in excess of Deployments received are split between Liquidia PAH and Henderson according to a formula. Unless there is an event of default by PBM (as defined below), all proceeds received by Liquidia PAH are due to PBM as described further below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On November 17, 2020, Liquidia PAH entered into a Litigation Funding and Indemnification Agreement (&#8220;Indemnification Agreement&#8221;) with PBM RG Holdings, LLC (&#8220;PBM&#8221;). PBM is considered to be a related party as it is controlled by a major stockholder (which beneficially owns approximately <ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="As_Of_10_30_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lqda_PBMMember_BakiyxxweE66bApftnb0xA" decimals="3" format="ixt:numdotdecimal" name="lqda:RelatedPartyTransactionMajorStockholderOwnershipPercentageInCompany" scale="-2" id="Narr_IyJNFsB-okSFPbpZo0-_3g">7.9</ix:nonFraction>% of Liquidia Corporation common stock as of October 30, 2024), who is also a member of our Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Indemnification Agreement, PBM now controls the litigation, with Liquidia PAH&#8217;s primary responsibility being to cooperate to support the litigation proceedings as needed. The Indemnification Agreement provides that Liquidia PAH and its affiliates will not be entitled to any proceeds resulting from, or bear any financial or other liability for, the RareGen Litigation unless there is an event of default by PBM. Any Liquidia PAH litigation expenses not reimbursed by Henderson under the Financing Agreement will be reimbursed by PBM. Any proceeds received which Henderson is not entitled to under the Financing Agreement will be due to PBM.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Indemnification Asset is increased as we record third party legal and litigation expenses related to the RareGen litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30,&#160;2024 and December&#160;31,&#160;2023, the Indemnification Asset and Litigation Finance Payable were classified as long-term assets and liabilities, respectively, as it is considered unlikely that the RareGen Litigation would conclude prior to September&#160;30, 2025.</p></ix:continuation><a id="Tc_4Vkm_vnjJkC4ZnE1K9Eowg_1_2"></a><a id="Tc_0RKdDQ-f5kusfSVix6pFug_1_5"></a><a id="Tc_HTdr1BBQ-0WOkCyk3w0WDQ_2_2"></a><a id="Tc_HdytknVXsk20A8s7ERVf-Q_2_5"></a><a id="Tc_M7FBAQBOYUyrD34txN93bA_3_0"></a><a id="Tc_yOdOUj2ofEeleFOEIRNAqg_3_2"></a><a id="Tc_Er5XV3ZvSkK_5YH8Mn0mfg_3_5"></a><a id="Tc_FC4KK3HOFEG35WN3F4E7_w_4_0"></a><a id="Tc_OefuLI_BI02AbPHev9WZ5w_5_0"></a><a id="Tc_vsLovJJYxkuVXjUUMJug4g_5_6"></a><a id="Tc_84nXFvvvGEy1AiFVllyCaA_6_0"></a><a id="Tc_C15ehlwRVUuAdV9mgFoN3Q_7_0"></a><a id="Tc_ZS42BM7koEWxHUJox1MPMg_7_2"></a><a id="Tc_ziCG5Ew1Hk66osSTbFt0bA_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="lqda:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" id="Tb_Uqj98I7AN0qqZjFBTNSRJw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. Accrued Expenses and Other Current Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses and other current liabilities consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="lqda:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" id="Tb_Vee674mjZE-6XuXMw9rtmg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_NtDy_Ys9nEG1zEBOBwMXaw_3_3">8,488</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_Gg9ljY-850mMKHboigFg7Q_3_6">8,544</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:AccruedResearchAndDevelopmentExpenses" scale="3" id="Tc_Y7lAl9JnqEGpkMXXK2vDAw_4_3">2,381</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="lqda:AccruedResearchAndDevelopmentExpenses" scale="3" id="Tc_en8SUMayc0OHlkI8wxnBxg_4_6">2,902</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued inventory costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:AccruedInventoryCosts" scale="3" id="Tc_UnygWAXcTUytsDF_9FgRHQ_5_3">1,916</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_ZOiTPzK2b0CmpTMeo2OLaA_6_3">4,254</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="Tc_eiZpwf2zCUinh-UkcSddMg_6_6">1,954</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:AccruedExpensesAndOtherLiabilitiesCurrent" scale="3" id="Tc_ZLrjrQ0hVE2THbreoL9yCg_7_3">17,039</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="lqda:AccruedExpensesAndOtherLiabilitiesCurrent" scale="3" id="Tc_09L1Tu9xg0qkx6RwxPTkVg_7_6">13,400</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_YZVDt8za40qxelrf47TQ6w" continuedAt="Tb_YZVDt8za40qxelrf47TQ6w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Issuance of Common Stock on September 11, 2024 from an Underwritten Public Offering and Private Placement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In September 2024, we sold <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_lZWG9RJZDEmZsvf2PUlu_g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_tM2czsjY9EK9DOjaqmKn6A">6,460,674</ix:nonFraction> shares of our common stock in an underwritten registered public offering at an offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_0Q4e0dBgsk2MRpxDh6fJYA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_uPiXdXvtCkOwQdL_SFRWNA">8.90</ix:nonFraction> per share (the &#8220;2024 Offering&#8221;) for gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_lZWG9RJZDEmZsvf2PUlu_g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_TRJ4Ipix2EqsqFhZKeNJ5Q">57.5</ix:nonFraction> million, before deducting offering costs of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_lZWG9RJZDEmZsvf2PUlu_g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_YjpCte6C7E6zurmRxPWY4Q">3.8</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A fund affiliated with Paul B. Manning, a member of our Board of Directors, participated in the 2024 Offering and purchased shares of common stock in an aggregate amount of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_srt_TitleOfIndividualAxis_lqda_BoardOfDirectorsMember_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_k0mS-FrErEGcCSQNS7upnA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_i2svsZs1Mk6WVEU7mvlumg">3.0</ix:nonFraction> million at the public offering price per share and on the same terms as the other purchasers in the 2024 Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Concurrently with the 2024 Offering referenced above, we entered into a common stock purchase agreement with funds managed by Caligan Partners LP (&#8220;Caligan&#8221;), our largest stockholder, for the sale by us in a private placement of an </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_svHmJVQD00yIkA7UxrsrmQ_1_0"></a><a id="Tc_epK_OYJwu0-zMWjcDQLecg_2_0"></a><a id="Tc_ZqFb9x2chEinXpRQsyIu8A_2_2"></a><a id="Tc_BaW7Cm9TJUaOByNrWpEEtA_2_5"></a><a id="Tc_9ZDV1o3xS02skdwC2Zg5mw_3_2"></a><a id="Tc_SXpOJO2xM0OZ6ZBV2IrrkQ_3_5"></a><a id="Tc_W5-l9LQpeES-z6p7jf9ezw_4_2"></a><a id="Tc_2IbvaZ59CEyojSE634sJ3w_4_5"></a><a id="Tc_tVhQVVazmU6XZP2fbSaYMQ_5_2"></a><a id="Tc_SbKXlHz-6kWpTZDv46phyg_5_3"></a><a id="Tc_bLY1_92UoEulweeu0I9OYQ_5_5"></a><a id="Tc_to-NkW2jkES8SrEOiUcJHw_6_2"></a><a id="Tc_HXhARWQslkKHLZsJ_AxGJA_6_5"></a><ix:continuation id="Tb_YZVDt8za40qxelrf47TQ6w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_RIO6XDdLvUCyictd22yGPQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_1ieEU6zGLkudC5NNe2jJ_g">1,123,595</ix:nonFraction> shares of our common stock at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_6YbY13rlnk2AxDHTatb6fA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_g2DFgJb2mUWcTv0rmG_lPw">8.90</ix:nonFraction> per share for gross and net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_RIO6XDdLvUCyictd22yGPQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="Narr_3vDgoiRobkOadxzX4P5odA">10.0</ix:nonFraction> million (the &#8220;Caligan 2024 Private Placement&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Issuance of Common Stock on January 4, 2024 from a Private Placement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On January 4, 2024, we entered into a common stock purchase agreement with Legend Aggregator, LP for the sale by us in a private placement (the &#8220;2024 Private Placement&#8221;) of an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_4_2024_To_1_4_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_rWhTZuGpl06hF6C5gOgr0g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_6YCtTf-VZk2Zts0FFcX6Kw">7,182,532</ix:nonFraction> shares of our common stock at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="As_Of_1_4_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VFjgbZY-JEy1XAWMuIb9qw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_ck_SXDt6Fki1zfwAihRcjQ">10.442</ix:nonFraction> per share. The 2024 Private Placement closed on January 8, 2024, and we received gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_8_2024_To_1_8_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_ud0mQkQYWkGjIgetbIuylw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="Narr_yeZsCglw20mdmvM_e3glPg">75.0</ix:nonFraction> million, before deducting offering costs of less than $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_8_2024_To_1_8_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_u77gK6C1w06rKnCiKbNkfA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="Narr_AKcDZKPkCEG-D_6F44BjYA">0.1</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Issuance of Common Stock on December 12, 2023 from an Underwritten Public Offering and Private Placement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In December 2023, we sold <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_12_12_2023_To_12_12_2023_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_-VeA1df9x0OIOsIgO9z0NA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_5EcK9Op5uUaM3VbXNnyU7w">3,491,620</ix:nonFraction> shares of our common stock in an underwritten registered public offering at an offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="As_Of_12_12_2023_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_n5jOtXbc5063nwGCNNyeNg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_byJvaltkvE-FuM_G0__Cjw">7.16</ix:nonFraction> per share (the &#8220;2023 Offering&#8221;) for net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_12_12_2023_To_12_12_2023_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_-VeA1df9x0OIOsIgO9z0NA" decimals="-5" format="ixt:numdotdecimal" name="lqda:ProceedsFromIssuanceOfCommonStockNet" scale="6" id="Narr_Ua1bJCfYdEqM8DD8Yc5ciA">25.0</ix:nonFraction> million, before deducting offering costs of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_12_12_2023_To_12_12_2023_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_-VeA1df9x0OIOsIgO9z0NA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_rFWcDIT8DkaDP5G7WQFpcA">1.9</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Caligan and Paul B. Manning, participated in the 2023 Offering and purchased shares of common stock in an aggregate amount of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_12_12_2023_To_12_12_2023_srt_TitleOfIndividualAxis_lqda_LargestStockholderAndMemberOfBoardOfDirectorsMember_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_gnFwleLvT02Zo7EgTUlKNQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_FPQhW80_LkazNn-HWTYB8Q">10.0</ix:nonFraction><span style="white-space:pre-wrap;"> million at the public offering price per share and on the same terms as the other purchasers in the 2023 Offering.  Caligan purchased </span><ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_12_12_2023_To_12_12_2023_srt_TitleOfIndividualAxis_lqda_CaliganPartnersLPMember_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_yy0o7xFcx0aREDaZ1VnfRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_apQT07os8UWocReXRn7ZvQ">1,117,318</ix:nonFraction> shares of common stock in the 2023 Offering for an aggregate purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_12_12_2023_To_12_12_2023_srt_TitleOfIndividualAxis_lqda_CaliganPartnersLPMember_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_yy0o7xFcx0aREDaZ1VnfRw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_1HoLApgzLkGZfkWIIeou8g">8.0</ix:nonFraction> million and Paul B. Manning purchased <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_12_12_2023_To_12_12_2023_srt_TitleOfIndividualAxis_lqda_Mr.PaulB.ManningMember_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_ET_kOfe7OUyGZnegoThYVg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_-64_99jivEGfneanN24vIw">279,330</ix:nonFraction> shares of common stock in the 2023 Offering for an aggregate purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_12_12_2023_To_12_12_2023_srt_TitleOfIndividualAxis_lqda_Mr.PaulB.ManningMember_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_ET_kOfe7OUyGZnegoThYVg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_l7n5fUKB2kG6bIUOhx1fEg">2.0</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Concurrently with the 2023 Offering referenced above, we entered into a common stock purchase agreement with Roger Jeffs, our Chief Executive Officer, for the sale by us in a private placement of an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_12_12_2023_To_12_12_2023_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_CQWWEiOLTEaaVRh41M4MgQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_wrwqYo7GJk6PpOcY3AW2bQ">139,665</ix:nonFraction> shares of our common stock at a purchase price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="As_Of_12_12_2023_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_ZMC_KO-DIESEKNwQeHuFPA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_3fVDUUMiYEygzBRtkeKvEg">7.16</ix:nonFraction> per share for gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_12_12_2023_To_12_12_2023_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_CQWWEiOLTEaaVRh41M4MgQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="6" id="Narr_Q-jcSS8X5Ee8FS5i2S8p9Q">1.0</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the nine months ended September&#160;30,&#160;2024 and 2023, <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_WarrantsToPurchaseCommonStockMember_nREMiBhLNEmIWUNmI18Y6Q" decimals="INF" format="ixt:numdotdecimal" name="lqda:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" id="Narr_v9RpxNoUMU2n9DT9T2F0sQ">9,175</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_lqda_WarrantsToPurchaseCommonStockMember_W3GhsPkTi0ad1ra4mD2y0Q" decimals="INF" format="ixt-sec:numwordsen" name="lqda:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" id="Narr_JBKn90Slt0SYKCT-8jR7Aw">no</ix:nonFraction> warrants to purchase shares of common stock were exercised, respectively. Outstanding warrants consisted of the following as of September&#160;30,&#160;2024:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_Kdy2Z_rO6Ea-c-kIIvc4jg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:35.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:30.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration Date</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_ArSvbWarrantsInitialTrancheMember_ffU72mNG2UiEuncpq3Bk3g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_J-AH6hskgEK0ciYE7bzoyg_3_0">250,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_ArSvbWarrantsInitialTrancheMember_ffU72mNG2UiEuncpq3Bk3g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_pFY2sUz7x0G6qvR8miLjCQ_3_3">5.14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">January 6, 2032</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_SvbWarrantInitialTrancheMember_vINmu1l2Ck24QYQ5Ny4zow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_Rd59S1WHLUOwZ2U_l3Facg_4_0">100,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_SvbWarrantInitialTrancheMember_vINmu1l2Ck24QYQ5Ny4zow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_6p_Yt7gM4UWLlO3xIWQGLA_4_3">3.05</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">February 26, 2031</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_SvbWarrantTermBAndTermCTranchesMember_wOo46pKdiUGRSW3RPNRPxg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_TOHrp3N3_U2MSRU3ANLFqQ_5_0">100,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">n/a<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">February 26, 2031</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_OtherWarrantsMember_n4R8mkRr-0KRugEMPPOtqw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_1NEh1nUJjkCzQVQn3bRrJQ_6_0">56,397</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_OtherWarrantsMember_n4R8mkRr-0KRugEMPPOtqw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_GXuG8hols06ibDtbrG5mEg_6_3">0.02</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">December 31, 2026</p></td></tr></table></ix:nonNumeric><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">These warrants were issued on February 26, 2021, in connection with our previously outstanding debt with Silicon Valley Bank. These warrants only became exercisable if there was additional funding under the loan agreement, and the exercise price of these warrants was to be set upon such potential additional funding. The additional funding never occurred, and the loan agreement has since been repaid and terminated. While these warrants technically remain outstanding, they are not, and will never be, exercisable.</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_CK75B9u6zEGg0rJGZrLOKw" continuedAt="Tb_CK75B9u6zEGg0rJGZrLOKw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2020 Long-Term Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;">Our 2020 Long-Term Incentive Plan (the &#8220;2020 Plan&#8221;) provides for the granting of stock appreciation rights, stock awards, stock units, and other stock-based awards and for accelerated vesting under certain change of control transactions. The number of shares of our common stock available for issuance under the 2020 plan will automatically increase on January 1 of each year through 2030, by an amount equal to the smaller of (a) <ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_PlanNameAxis_lqda_The2020PlanMember_WZy6bkl5x06pEBTAbp6atA" decimals="2" format="ixt:numdotdecimal" name="lqda:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentAnnualIncreaseInCapitalShareReservedForFutureIssuance" scale="-2" id="Narr_8tY_PJ-qhkCzFp6w7djTyA">4</ix:nonFraction>% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by the Board of Directors (the &#8220;Evergreen Provision&#8221;). On January 1, 2024, the number of shares of common stock </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_CK75B9u6zEGg0rJGZrLOKw_cont1" continuedAt="Tb_CK75B9u6zEGg0rJGZrLOKw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 12pt 0pt;">available for issuance under the 2020 Plan automatically increased by <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_lqda_The2020PlanMember_CEMyV83-zUCOMl6DTROCNQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="Narr_WqVV8CF9kUaLjaMCo1mz2g">2,745,183</ix:nonFraction> shares pursuant to the Evergreen Provision. As of September&#160;30,&#160;2024, there were <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_9_30_2024_us-gaap_PlanNameAxis_lqda_The2020PlanMember_q3rF1sbUKU-D4Hw_9Wjf4Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_pzvXN1AS60-GwRw1q45pxA">900,518</ix:nonFraction> shares available for future grants under the 2020 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The 2020 Plan replaced all prior equity award plans and such plans have been discontinued. However, the awards outstanding under the prior equity award plans will continue to remain in effect in accordance with their terms. Awards that are forfeited under these prior plans upon cancellation, termination or expiration will not be available for grant under the 2020 Plan. As of September&#160;30,&#160;2024, a total of <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_9_30_2024_us-gaap_PlanNameAxis_lqda_The2020PlanMember_q3rF1sbUKU-D4Hw_9Wjf4Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_1wU13X2ePkOfNnbacmgB2g">473,076</ix:nonFraction> shares of common stock were reserved for issuance related to the remaining outstanding equity awards granted under the prior plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2022 Inducement Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On January 25, 2022, the Board of Directors approved the adoption of our 2022 Inducement Plan (the &#8220;2022 Inducement Plan&#8221;). The 2022 Inducement Plan was recommended for approval by the Compensation Committee of the Board (the &#8220;Compensation Committee&#8221;), and subsequently approved and adopted by the Board of Directors without stockholder approval pursuant to Rule 5635(c)(4) of the rules and regulations of The Nasdaq Stock Market, LLC (the &#8220;Nasdaq Listing Rules&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_1_25_2022_us-gaap_PlanNameAxis_lqda_InducementPlan2022Member_QcdutN2Mc0eer7i2vctGcQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_dBY1mceNoEOf1SNlOmndcQ">310,000</ix:nonFraction> shares of our common stock were reserved for issuance pursuant to equity awards that may be granted under the 2022 Inducement Plan, and the 2022 Inducement Plan will be administered by the Compensation Committee. In accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules, equity awards under the 2022 Inducement Plan may only be made to an employee who has not previously been an employee or member of the Board of Directors, or following a bona fide period of non-employment by us, if he or she is granted such equity awards in connection with his or her commencement of employment with us and such grant is an inducement material to his or her entering into employment with us. As of September&#160;30,&#160;2024, a total of <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_9_30_2024_us-gaap_PlanNameAxis_lqda_InducementPlan2022Member_59X93Oj32UqU-HIAb8N6uw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_DQs2eLjH-0-0lE0Oc6eUpQ">27,608</ix:nonFraction> shares were available for issuance under the 2022 Inducement Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employee Stock Purchase Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In November 2020, stockholders approved the Liquidia Corporation 2020 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The number of shares of our common stock available for issuance under the ESPP will automatically increase on January 1 of each year through 2030, by the lesser of (a) <ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_11_1_2020_To_11_30_2020_lTtrHrdNKk2SU5Ol2ar1-w" decimals="3" format="ixt:numdotdecimal" name="lqda:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding" scale="-2" id="Narr_Q-zzYhXES02pgiYO9NWEmA">1.0</ix:nonFraction>% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, (b) <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_11_1_2020_To_11_30_2020_lTtrHrdNKk2SU5Ol2ar1-w" decimals="INF" format="ixt:numdotdecimal" name="lqda:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuance" scale="0" id="Narr_7gcgSpfjVkawqM8TW7_UPA">150,000</ix:nonFraction> shares, or (c) an amount determined by the Board of Directors. On January 1, 2024, the number of shares of common stock available for issuance under the ESPP increased by <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_xFqmiRrTOkqulJr1LBWAnw" decimals="INF" format="ixt:numdotdecimal" name="lqda:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAvailableForIssuance" scale="0" id="Narr_pTFjHEdH802_c0k6g4eovg">150,000</ix:nonFraction> shares. As of September&#160;30,&#160;2024, a total of <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_9_30_2024_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_IvI4h9c3EUuyg5PQrrLhMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_HTX6cRWZakKSoxXMRcdBsQ">534,742</ix:nonFraction> shares of common stock are reserved for issuance under the ESPP. The ESPP allows eligible employees to purchase shares of our common stock at a discount through payroll deductions, subject to plan limitations. Unless otherwise determined by the administrator, the common stock will be purchased for the accounts of employees participating in the ESPP at a price per share that is <ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_m7APsiBNMkuX9fDgBs78Wg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="Narr_iK0BOEb10kSXAM15KPVShg">85</ix:nonFraction>% of the lesser of the fair market value of our common stock on the first and last trading day of the offering period. During the nine months ended September&#160;30,&#160;2024 and 2023, <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_m7APsiBNMkuX9fDgBs78Wg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Narr_M98HARLOHECjGi3nHT87ZA">172,395</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_glcrSVianU6a1o46EeXtNg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Narr_fX6JtAfea0Kv4kXGMXM0Iw">140,922</ix:nonFraction> shares were issued under the ESPP, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation Valuation and Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We account for employee stock-based compensation plans using the fair value method. The fair value method requires us to estimate the grant-date fair value of stock-based awards and amortize this fair value to compensation expense over the requisite service period or vesting term. The fair value of each option grant is estimated using a Black-Scholes option-pricing model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For restricted stock units (&#8220;RSUs&#8221;), the grant-date fair value is based upon the market price of our common stock on the date of the grant. This fair value is then amortized to compensation expense over the requisite service period or vesting term.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_389515f9_c075_423a_9357_ab78802f8f31"></a><a id="Tc_WYTAM7IQgUyAWh4pUFRIDQ_1_2"></a><a id="Tc_ienHmcpZX0i6iEzReDn1EQ_1_8"></a><a id="Tc_HXJSNUTZREC7JjXHbuWlgg_2_2"></a><a id="Tc__eSrABe-tEK2-UCfQu47yA_2_8"></a><a id="Tc_69OASZ-SdUC9isvo4KGGsA_3_0"></a><a id="Tc_6wEnhMuk0kKNVjE2SMRMPg_3_2"></a><a id="Tc_2BB5Y9TzS0iMGGFuWl-Ftg_3_5"></a><a id="Tc_xZGmUetkUkGTRRaPGMWCHA_3_8"></a><a id="Tc_Dq0Sg3cZu0uNsasX23FPyQ_3_11"></a><a id="Tc_CXwTPyB2p0eH2qCZ9-mYzA_4_0"></a><a id="Tc_7nK6oypZ9ky2Ci7RpuUqLg_4_2"></a><a id="Tc_wn6JzLyjbkqynxQPn12WbA_4_5"></a><a id="Tc_sYxV0eREcEiGizNjYM-o-Q_4_6"></a><a id="Tc_m-mA5fQRU061QiyhUYbTzg_4_8"></a><a id="Tc_sHiqxBO5lkOetVuiiyXqjg_4_11"></a><a id="Tc__lBeRI0G80SoOQjHNvcaOg_4_12"></a><a id="Tc_wlbrfuLFrkSFnpIzkIj6JA_5_0"></a><a id="Tc_sTgaze7EukiKDrcTHyPfow_6_0"></a><a id="Tc_aR3utiekJk6JSqPx0pXwoA_7_0"></a><a id="Tc_3JWP94JmEUa4Ytv6pymUPA_7_2"></a><a id="Tc_BfuPT6ql6kmlXjMhW_uXsg_7_5"></a><a id="Tc_hZJjxfnnLkW6vvMg46walg_7_8"></a><a id="Tc_nVY_4i5o70yjB5IShrGWig_7_11"></a><a id="Tc_DbYHInlAN0G4X7JPR7ZUyw_1_2"></a><a id="Tc_qD1jBe6LTEueNgWpJeEINw_2_5"></a><a id="Tc_pzFetVFPq0mQXVzxAYShRg_3_5"></a><a id="Tc_Q3IHwz9FUkKZ96XZlIc6pg_4_5"></a><a id="Tc_D3ABpFNHiUu13GPZSHnJyA_5_5"></a><a id="Tc_aXanmk_950GS4odEWQCinA_6_2"></a><a id="Tc_LTDTOnrS60Cbv1BwgkciEA_6_5"></a><a id="Tc_Wam-9PpZBECtiN6U9vYVmg_7_2"></a><a id="Tc_vwuta9M2hkOD3EuFGGBekg_7_5"></a><a id="Tc_dLL_0BPZpEe0KL7wej4Lyg_8_0"></a><a id="Tc_setAIltGwUCgyeV5IhciEg_8_2"></a><a id="Tc_OCC1zhoYQk6HwpgGzUuy8A_9_0"></a><a id="Tc_DMJLboBYUE6TUujEuKgWYg_9_2"></a><a id="Tc_rYoniraqUUq7TsUAMPAfzw_1_2"></a><a id="Tc_l_8XJ4pVy0OG64bB2FjBAg_2_2"></a><a id="Tc_2lO_0Yi8SU-IjGCPa9PV8Q_3_2"></a><a id="Tc_dGfrv_mCIkuM0XsWJpFwrg_3_4"></a><a id="Tc_VtP9MwYQGEeUEsW151iK3A_4_0"></a><a id="Tc_EXVNHH89Zkibj5kPuMFw2Q_5_0"></a><a id="Tc_hpgPdTsP6EW-RFdB2H5S7g_5_4"></a><a id="Tc_uyCWxJ3lTkCJAAiZoNexRw_6_0"></a><a id="Tc_fLPpehkY-Uqf-PXazi-0Fg_6_4"></a><a id="Tc_-KGFrwCCW06V2Fmip0ppdg_7_0"></a><a id="Tc_UX0NrjqVUE2f50ITTH1EFw_7_4"></a><a id="Tc_gmJuQp1SAkOoJ0zqI9JTvA_1_2"></a><a id="Tc_xWDS4tU3sU6yA6QNqGsWHQ_2_2"></a><a id="Tc_msI2X6WKokGMp9KmME5CLA_3_2"></a><a id="Tc_Gf2vCaraKk-Coq_Ph6mgwA_3_4"></a><a id="Tc_5xkR20bGqU2xIhWJ7xKPyg_4_0"></a><a id="Tc_EGEYrK8MzUqbzxpxSRaIkw_5_0"></a><a id="Tc_jrNZc81vSkGoNy2kt-bltg_5_2"></a><a id="Tc_oJTIAZnQLEuBMiOviF4WZA_5_4"></a><a id="Tc_9rFOAmVsSEuM5y8f0pPXNQ_6_0"></a><a id="Tc_rPdoX2Wtq02hoZkC9016mA_6_2"></a><a id="Tc_1odzHfHlHE6qfkXML-55tQ_6_4"></a><a id="Tc_hadFBF196E2rWujHgF_DaA_7_0"></a><ix:continuation id="Tb_CK75B9u6zEGg0rJGZrLOKw_cont2" continuedAt="Tb_CK75B9u6zEGg0rJGZrLOKw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Total stock-based compensation expense recognized for employees and non-employees was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_E_KqVzlC306iBE1s7ntlaw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">By Expense Category:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_9Shl9FOqAEm1xT8OQEZiPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_4v1TWC-C0EK98biYS5WFcQ_4_3">45</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_sVbvNMFieEqahGNDqo00CQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc__lAwcNpcjU6SIj1xA6Sovg_4_9">166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9ztv0G7UzkWrHinKet79MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_F49rLTc-hkW9hOWJNuHzGQ_5_3">839</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_b9IfscRcGUihtJB5srkY2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_89SV2kj6mEOImh87HJlAiw_5_6">555</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_MRV76XSit0KBbsAP3TiUpA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_2yrFcqNqBkeM45Eo2UGpmg_5_9">2,676</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_We2fnt_wf0y9QPYfo6rVXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_hqBohChqe0q71ggc2MwMug_5_12">1,714</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_5JpbAcp9g0S1jyEmoVFeoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_kmVF-i1RwECGIZQmhalSbA_6_3">3,997</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_wV-uPH-HE0C8hSHXy_alBg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_GEr0mGSUSEuUbb0xOX9ifw_6_6">1,932</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_8RApRitnUUKh4kBFAXN1pg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_dDQ7zc-Lj02wFJ0suOznHA_6_9">10,935</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ynF1uQCSmUyLHWdxX__Sxg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_1D0D14I5U02I7p7aXp6HeQ_6_12">5,824</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_RPQyLdTDYEOzbCN2mnqrdw_7_3">4,881</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_ZtiAp9jyUESOCLBI4mC1tw_7_6">2,487</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_e8rfByWwsUSTcKvPcehzFg_7_9">13,777</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_yvtyTod21UywPMvC23GXeA_7_12">7,538</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table summarizes the unamortized compensation expense and the remaining&#160;years over which such expense would be expected to be recognized, on a weighted average basis, by type of award:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" id="Tb_XqRJIqZH00KjMlhmsvuZdg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;September&#160;30,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Recognition</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unamortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Period</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2wjFZ4y_OU6vooFOFqzXIQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="Tc_C2L2FK6rD0-WJkmxezCd3g_8_3">9,789</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1P_inS6zXkWNbG-ht9J6vg" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Tc_zjUWdM0NJ0uePBYQJ1AgGQ_8_5"> 1.6</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted and performance stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_bNNJw9ET4UKPsBG0tkb61Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="Tc_rS4uGZDNDE2aNN0e_4DtOA_9_3">26,124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_uwLnN9HvMUyPs1gUVBzqIQ" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Tc_lzjX2DB3BE-KQl2hZ9Lk9A_9_5"> 2.5</ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fair Value of <i><img src="lqda-20240930x10q002.jpg" alt="Graphic" style="display:inline-block;height:0.65pt;width:0.65pt;"/></i>Stock Options Granted and Purchase Rights Issued under the ESPP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We use the Black-Scholes option-pricing model to determine the fair value of stock options granted and purchase rights issued under the ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the assumptions used for estimating the fair value of stock options granted under the Black-Scholes option-pricing model:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_loqmcF4cM0SKTZJn6ZTBKg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_fljXNZJ780WhJZl0xfbOZw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_KgzYt7L2DEmD5XrMEpBoAQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_WDRn4vkaQU-_GJyXGW7r-g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc__dofQTGLPUmWCRLReACMrQ_5_2">3.98</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_CfxUqp13dkiX5pxqnNfcWg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_CJSyBYQGLUm2dhGXyH43kQ">3.46</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_CfxUqp13dkiX5pxqnNfcWg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_iy3MYW6N-USKBOIiFPNORw">4.62</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_WDRn4vkaQU-_GJyXGW7r-g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_86EPTWZSlkaFN4rYYgbpMA_6_2">90</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_CfxUqp13dkiX5pxqnNfcWg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_JibL2aT5GkaHL2ZiHMswUw">91</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_CfxUqp13dkiX5pxqnNfcWg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_MtQegOs_MkWqMy_xguBbAw">95</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_WDRn4vkaQU-_GJyXGW7r-g" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_jFc28VpfOkWl_nYSmioQow_7_2">6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_c3RkhmYjMUymom-OGSSabQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_cci_KIDKC0GIFgsG9jAPsg">5.8</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_Y_FZ3m3A40qqKnWMJKMAEw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_WhCLlDVQ1UKn-UWhXphfhA">6.1</ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The weighted average fair value for options granted during the nine months ended September&#160;30,&#160;2024 and 2023 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_SRoC1Px3X02cg-EM7SrKKw">9.84</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_S6GVimtOYUCfm7W_IYOVJg">5.09</ix:nonFraction> per share, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the assumptions used for estimating the fair value of purchase rights granted to employees under the ESPP under the Black-Scholes option-pricing model:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_m7APsiBNMkuX9fDgBs78Wg" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_M4Kus1T5IUKNbbbnsMkBeQ" continuedAt="Tb_M4Kus1T5IUKNbbbnsMkBeQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_od59HwKFmkW8EjvwzxxZHg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden__L855O1ENEa44A4aGasXbw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_3f2n43cTpEKLLf2BEff-rw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_fqwbHYzGhE6VF6UZ7oVI-w">4.80</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_3f2n43cTpEKLLf2BEff-rw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_IgStDFZzPU-Pi1wczztnSw">5.27</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_58oqF0uKeUmLTXXZbeZuOw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_9geuoq8G7E-Xs0XO4H4HtA">5.20</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_58oqF0uKeUmLTXXZbeZuOw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_hWjhDJ-MvUWZtTSRtbLb1Q">5.47</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_3f2n43cTpEKLLf2BEff-rw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_cdiLsOIl2UGKei5xdu8GpQ">62</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_3f2n43cTpEKLLf2BEff-rw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_1YZ4azIWvUOPsMjwfOe7Ig">72</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_58oqF0uKeUmLTXXZbeZuOw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_UX9CNDfyJEuzWkVslaPTmw">60</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_58oqF0uKeUmLTXXZbeZuOw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_jhMeePNv1UKMxTuYf3GLwg">64</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_3f2n43cTpEKLLf2BEff-rw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_KnWa5GktpEe0vmPvwpTm9w_7_2">0.50</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_58oqF0uKeUmLTXXZbeZuOw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_pDKwi7HuVEqDBvJuCaHE_g_7_4">0.50</ix:nonNumeric></p></td></tr></table></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_Kt7WGT5Nr0arZOoJ9m3aOw_1_7"></a><a id="Tc_6q18c1B3nEyGP4q2HmND9Q_2_4"></a><a id="Tc_acb8ATlj7UaWPQtnZCI6nQ_2_7"></a><a id="Tc__wtG5FLh-E6L8yJNiVgvaw_3_4"></a><a id="Tc_nI8oTrsgjEKiAM5NCms8hg_3_7"></a><a id="Tc_3DbHNQ78nUy_a8dYleytFg_3_9"></a><a id="Tc_XFSCAq9grkujIKPhXGC16A_4_2"></a><a id="Tc_IvwfC9vtKE67hXMOp1zVDA_4_4"></a><a id="Tc_EDKA4GvT9Uq2BrN6Ggwklg_4_7"></a><a id="Tc_xAOMa1yVEUmBd7v_ElT9wA_4_9"></a><a id="Tc_0Rekzs5Qr0CzTdDgTX-REg_5_2"></a><a id="Tc_zdZJW7pUuEu79j_HSoPsxA_5_4"></a><a id="Tc_VaT_jV_2bUiRTF2OfcKQrw_5_7"></a><a id="Tc_8n22DoN9U0qZWpBF6asOfQ_5_9"></a><a id="Tc_KfVhxUzIMkWVrjI8ZDPoog_6_0"></a><a id="Tc_Dg8w4IVET06g-ZR2TCHBwA_6_4"></a><a id="Tc_jupScHcrbUiI1jdhoRFmqg_7_0"></a><a id="Tc_fVktBTYT40CVdFuLv5aetg_8_0"></a><a id="Tc_N_liKMbM7UGO5cNPkGHwuQ_9_0"></a><a id="Tc_wwOiucIKykqrvpQw8VTisA_10_0"></a><a id="Tc_UZc-6Orsk0a9SMWUJIya1Q_10_4"></a><a id="Tc_W4a0-ZX71EOGHUCySD8Hhg_10_9"></a><a id="Tc_i8Ve9_Dlhkm311Avjqf98Q_11_0"></a><a id="Tc_7RqxzUVwFEGtjiPOWl6okA_11_4"></a><a id="Tc_mLFeYe2TU0ezeOAZ9B9nfg_11_9"></a><a id="Tc_nczbBSXPNkmMY_bza8EQ5g_12_0"></a><a id="Tc_ifSHDpOxFUOWV48plaP3IA_12_4"></a><a id="Tc_xxbWET0ozUaT64pjhFHb7A_12_9"></a><a id="Tc_-J0VTgezF0WNEOQLsax7Qg_1_4"></a><a id="Tc_qDGet8VRS0mLRn4KO1laow_2_4"></a><a id="Tc_gB-n3lIWEE6lfJYmtao0oA_3_4"></a><a id="Tc_pcPBjxZT4EK4KdxTX8n_Xw_4_2"></a><a id="Tc_EGNjaKE6kUWqPJ9KHQX3_w_4_4"></a><a id="Tc_fmvYZpvswU2hQB5CypottA_5_2"></a><a id="Tc_lr4kp4KbZUSB68k1dTOq7g_5_4"></a><a id="Tc_Y32h2_IAu0eObtM69rEqwQ_6_0"></a><a id="Tc_yWebvOvHRkSXlKtiB4zSIg_6_4"></a><a id="Tc_cdrgrH_bfkWItd_VBpGgoQ_7_0"></a><a id="Tc_z8RRHqxLxEWZOTLtfUpyYw_8_0"></a><a id="Tc_3LDtu_82lkeYZwSbRKq9Kw_9_0"></a><a id="Tc_X7U_pSLK1UeMMp1I_xSqAg_10_0"></a><a id="Tc_ZvH8y-5LhE-vng-OLmRIlw_10_4"></a><ix:continuation id="Tb_CK75B9u6zEGg0rJGZrLOKw_cont3" continuedAt="Tb_CK75B9u6zEGg0rJGZrLOKw_cont4"><ix:continuation id="Tb_M4Kus1T5IUKNbbbnsMkBeQ_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Option Activity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options generally vest over a <ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_U5I2QUtyeUKSw5V0JR-EtQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_kcIOvfWfwkGGXzIUUnG0og">four-year</ix:nonNumeric> period in multiple tranches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table summarizes stock option activity during the nine months ended September&#160;30,&#160;2024:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_zNyc9zhijkCmT4gYW_sygg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding as of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_rvwEn3N7ykyRbnEiURLB9A_6_2">9,573,937</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_8HznTlOAw0qdqGqbuyuMjQ_6_5">4.80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_mXz-szDl10-NzJ-gFNBlYA_7_2">7,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_vmQNiEjq_0KtO6JtgLXSiQ_7_5">12.86</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_u7z8hIgVH0u_sxYasf8qlA_8_2">351,653</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_kOLxWb20VEmroq8CrKvSxg_8_5">4.78</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="Tc_QiI-ImPylUO-febsWZimYA_9_2">179,926</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_9PeqxWUUIUyXMT3bgj-7EA_9_5">7.24</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding as of September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_GSTx1KDlM0CplSffwnfXXA_10_2">9,049,858</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_9fU-G1ZNTUeFJNHXO2eDww_10_5">4.76</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_BydD2C85N0aY4KRKKhRm7Q_10_7"> 7.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_Yv7mG3PIMUGmtO6wmNooVA_10_10">47,835</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_qOmfZcUCOkmVVXloi_d_OQ_11_2">6,649,860</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_7bHAoN8RckqNn-zSuxIJJw_11_5">4.48</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_vfxzUV6bWkKtky8fJjOLhg_11_7"> 6.8</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_MpgOWgutoUq8B8gGH3yT7w_11_10">37,106</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and expected to vest as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_3PqKqUrI-kK74zTVX-pztQ_12_2">8,772,869</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_0rvC3a01aUiUCMKIEVn2kQ_12_5">4.73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_hKnNDgHXs0eMfzFFB0TS_Q_12_7"> 7.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="Tc_JYUQ7PtlYUCI6sOjPc6V4A_12_10">46,661</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of stock options in the table above represents the difference between the $<ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MBzkjBjqCku_2H2dhAQG9A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_bxTCZHMCAEWcKyJ6EkWjrA">10.00</ix:nonFraction> closing price of our common stock as of September&#160;30,&#160;2024 and the exercise price of outstanding, exercisable, and vested and expected to vest in-the-money stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Stock Units</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Restricted stock units (&#8220;RSUs&#8221;) represent the right to receive shares of our common stock at the end of a specified time period and/or upon the achievement of a specific milestone. RSUs can only be settled in shares of our common stock. RSUs generally vest over a <ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_uwLnN9HvMUyPs1gUVBzqIQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_pqwR1BCYEkSYZnQAppb8Ew">four-year</ix:nonNumeric> period similar to stock options granted to employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The tax withholding method used for most RSUs is the sell-to-cover method, in which shares with a market value equivalent to the tax withholding obligation are sold on behalf of the holder of the RSUs upon vesting and settlement to cover the tax withholding liability and the cash proceeds from such sales are remitted to taxing authorities by us. In circumstances where the sell-to-cover method is not used, the holder of the RSUs is required to remit cash to us to cover the tax withholding liability and the cash is then remitted to taxing authorities by us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A summary of unvested RSU awards outstanding as of September&#160;30,&#160;2024 and changes during the nine months ended September&#160;30,&#160;2024 are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="Tb_CEtcHBgOLESJuzqVFS9DxQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant-Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(per&#160;RSU)</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_kteGXRriH0alvhRWw4-p7w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_OpZN4Mh2o02jgbMZTFqA_A_6_2">1,657,978</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_kteGXRriH0alvhRWw4-p7w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_--2LyKu420y3kpQinGzGOg_6_5">6.41</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_uwLnN9HvMUyPs1gUVBzqIQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_eP8bfedF3UedCiB8Tf-eJQ_7_2">2,146,517</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_uwLnN9HvMUyPs1gUVBzqIQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_D2gLEfK2qk6SQJVdfj-ZBA_7_5">12.57</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_uwLnN9HvMUyPs1gUVBzqIQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_dqUfutJ6W0i4ccpUWND44Q_8_2">615,827</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_uwLnN9HvMUyPs1gUVBzqIQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_v_riC5zMAEO8JHyUCuQIkA_8_5">6.48</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_uwLnN9HvMUyPs1gUVBzqIQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_fDmc8PKg5Uqf7ZET4paLxQ_9_2">94,047</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_uwLnN9HvMUyPs1gUVBzqIQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_roqY5dCam0iY00uXUqyZMw_9_5">7.52</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_bNNJw9ET4UKPsBG0tkb61Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_3fVnukpV2kmCIvajez4M4A_10_2">3,094,621</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw" contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_bNNJw9ET4UKPsBG0tkb61Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_0DJD9wNLgkq_KVALFCpQnw_10_5">10.64</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;"><span style="font-size:1pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">RSUs granted during the nine months ended September&#160;30,&#160;2024, included <ix:nonFraction unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_PerformanceBasedRestrictedStockUnitsMember_Yv0caJPQY0mJtH96769LWA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_eJ_lEuuq4ECCc-awdbCoLA">520,526</ix:nonFraction> performance-based RSUs granted to our executive officers. These performance-based RSUs vest upon the later of (a) time-based vesting conditions and (b) the first commercial sale of YUTREPIA in the United States and are considered probable of vesting. The time-based vesting condition means <ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_PerformanceBasedRestrictedStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_h6JlHh_6Hk2OCYyiU3MA8w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_ikFc1SNRvk-LL6vuxHDLMw">25</ix:nonFraction>% of the performance-based RSUs vest <ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_PerformanceBasedRestrictedStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_h6JlHh_6Hk2OCYyiU3MA8w" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_xpk6XSs2SEyHKsseV9h8OA">one year</ix:nonNumeric> after grant date and quarterly thereafter for <ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_PerformanceBasedRestrictedStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ObYqzytTmk-rYw5p78JFbQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_d2HrKZhSqkaUThWakbJisw">three years</ix:nonNumeric>, subject to the executive&#8217;s continued service.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_CK75B9u6zEGg0rJGZrLOKw_cont4"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="Tb_fAVHubpRHky-NFOQlwKYuw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Revenue From Contracts With Customers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In August 2018, we entered into a Promotion Agreement with Sandoz under which we have the exclusive rights to conduct commercial activities to encourage the appropriate use of Treprostinil Injection for the treatment of patients with PAH in the United States. We paid Sandoz $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_8_1_2018_To_8_31_2018_srt_CounterpartyNameAxis_lqda_SandozMember_bR-PCAVcsEa0W4IuOAk7hQ" decimals="-6" format="ixt:numdotdecimal" name="lqda:PromotionAgreementPayment" scale="6" id="Narr_0WN58_frxkOrWOI5UQw-_w">20</ix:nonFraction> million at the inception of the Promotion Agreement in consideration for these rights. In exchange for conducting these commercial activities, we are entitled to receive a share of Net Profits (as defined within the Promotion Agreement) based on specified profit levels. The share of Net Profits received is subject to adjustments from Sandoz for certain items, such as distributor chargebacks, rebates, inventory returns, inventory write-offs and other adjustments. We expect to refund certain amounts to Sandoz through a reduction of the cash received from future Net Profits generated under the Promotion Agreement. As of September&#160;30,&#160;2024, a $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_srt_CounterpartyNameAxis_lqda_SandozMember_raO9GBmyIE-5ZvV1IBniiQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerRefundLiability" scale="6" id="Narr_0itVf1Ysu02eQ4f09ZN3Xw">0.5</ix:nonFraction> million refund liability is offset against accounts receivable from Sandoz related to expected refund amounts. Approximately <ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_7_1_2024_To_9_30_2024_srt_CounterpartyNameAxis_lqda_SandozMember_rx6kg0vHT0uP6yMhTHZMqQ" decimals="2" format="ixt:numdotdecimal" name="lqda:PercentageOfRevenueFromPromotionAgreement" scale="-2" id="Narr_5WwLI1liQESUbODqRpAh6w">98</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_1_2024_To_9_30_2024_srt_CounterpartyNameAxis_lqda_SandozMember_KdRq-SWRhUqv88cPuzMv1w" decimals="2" format="ixt:numdotdecimal" name="lqda:PercentageOfRevenueFromPromotionAgreement" scale="-2" id="Narr_K5cusGlI8UWTIiCR3igmCQ">98</ix:nonFraction>% of revenue during the three and nine months ended September&#160;30,&#160;2024, respectively, was generated from the Promotion Agreement.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="lqda:LeaseDisclosureTextBlock" id="Tb_UuB-YX7siE6jpY8d1N0kAA" continuedAt="Tb_UuB-YX7siE6jpY8d1N0kAA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">We are party to a non-cancelable operating lease for our laboratory and office space in Morrisville, North Carolina. The lease expires on October 31, 2026 with an option to </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" format="ixt:booleantrue" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Narr__Twsqc-XDkm49K0J3hvWIw"><span style="background:#ffffff;">extend</span></ix:nonNumeric><span style="background:#ffffff;"> for an additional period of </span><ix:nonNumeric contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_EUsLfkmiXkCFjt5Tyn-4dA"><span style="background:#ffffff;">five years</span></ix:nonNumeric><span style="background:#ffffff;"> with appropriate notice. We have not included the optional extension period in the measurement of lease liabilities because it is not reasonably certain that we will exercise the option to extend. The payments under this lease are subject to escalation clauses. Operating lease cost is allocated between research and development and general and administrative expenses based on the usage of the leased facilities. The related right-of-use assets are amortized on a straight-line basis over the lesser of the lease term or the estimated useful life of the asset.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Finance Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">We lease specialized laboratory equipment under finance leases. We do not have access to certain inputs used by our lessors to calculate the rate implicit in our finance leases and, as such, use our estimated incremental borrowing rate at the time of lease inception for the discount rate applied to our finance leases. The incremental borrowing rate used on finance leases was </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:LesseeFinanceLeaseDiscountRate" scale="-2" id="Narr_KlRekcbbcU-0oVPeI0I-iQ">6.5</ix:nonFraction>%</span><span style="background:#ffffff;">. Certain finance leases also include options to purchase the leased property. We recognize all such purchase options as part of our right-of-use assets and lease liabilities if we are reasonably certain that such purchase options will be exercised.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_4I_ZVotEzUeGgz-5_gI5BA_1_4"></a><a id="Tc_k9OBU-iHEEmcobaz7AhDRg_1_10"></a><a id="Tc_rI5h9aEliUW_DV8bWYrCVA_2_2"></a><a id="Tc_rf1UAAVqWUSMdsnIzIYJbg_2_4"></a><a id="Tc_nPV9OkRFHEa7Sk8fua5Ntg_2_7"></a><a id="Tc_HzDR0wvOu0GCsZfnuwhlHQ_2_10"></a><a id="Tc_Jm4rGglaVkGRS2AVgaNdNg_2_13"></a><a id="Tc_6M9IJ482SUifNR-se3iGSg_3_0"></a><a id="Tc_z8kOtyNWtk69qpz5VSAB0w_4_0"></a><a id="Tc_LwGGzyLTikiPA9DnBvNVfg_4_2"></a><a id="Tc_S-sKIDIEtEGLaaIiGle82Q_4_4"></a><a id="Tc_5j1vrEXF7EqG6NvsUEdqnw_4_7"></a><a id="Tc_DyLj8B8Qrkup9i7LKIXlrQ_4_10"></a><a id="Tc_DVRn7Vcsek-DEbEUWwfiOA_4_13"></a><a id="Tc_cAW_LO9L50mj8A66XE4KmQ_5_0"></a><a id="Tc_QOW-lLGlHUqYRSdgaVsbHA_5_2"></a><a id="Tc_hZQy9fKizkCjRj9nbxVQIg_6_0"></a><a id="Tc_Do7VoaOuk0qpw6kI4N14gQ_7_0"></a><a id="Tc__HIZ7Uet-EaSYQaKYNJfZg_7_2"></a><a id="Tc_zZbdC7UTukKiBxNd6dZ9nw_8_0"></a><a id="Tc_v0Nt2K0UGE-GqZzRHJo9DQ_8_2"></a><a id="Tc_UwhFCk04CkCcAifC1IVX_w_9_0"></a><a id="Tc_0PgAdEYE5Ea2EC4S8Sts-g_9_4"></a><a id="Tc_heha3uniIUOY-6t-Pbiqcw_9_7"></a><a id="Tc_brsMBLgmTUSEr-Jeh0VPuQ_9_10"></a><a id="Tc_n9eJt5PyykymNT9MVs0amw_9_13"></a><a id="_db00c278_b891_48d3_80ff_abf4b6e088ee"></a><a id="Tc_pu8kGS2-nkuoMiaf3M65dg_1_0"></a><a id="Tc_rhihUf5vfUewCgOu4q1n0g_2_0"></a><a id="Tc_6Zk0tYXDQEW856GK7dYFkA_3_0"></a><a id="Tc_E9GvKhf42E-D6to32xXxvg_4_0"></a><a id="Tc_9yDsKd38JEqAWSP_5MMREw_5_0"></a><a id="Tc_gLK5YZ2gO0-s804K2FvOiA_5_3"></a><a id="Tc_RYnzTgPEE0eNia2s_nNBaw_6_0"></a><a id="Tc_LC4dx0aVNEGpfiy6yBHSdQ_6_3"></a><a id="_ffe61682_d577_4f48_90d4_fb79be36cfb5"></a><a id="Tc_gJBsnO02Mkuwk-fNfXqviA_1_2"></a><a id="Tc_GEHEoeUGSE6xvbttJUNVCQ_1_5"></a><a id="Tc_cIro0ZmcoEO2umQoazihKw_2_0"></a><a id="Tc_9a_E7H-e4US7dGLAfOlbdA_2_2"></a><a id="Tc_f3myILs890qSV76zWQ8x1g_2_5"></a><a id="Tc_3GE9WwfONUO0HIA8z8hFaw_2_8"></a><a id="Tc_e7AMdSMuKka534fKaOyvSA_3_0"></a><a id="Tc_3xfmhYekg0uKjMk4e1LgAQ_3_2"></a><a id="Tc_bu1_JNvsGkKZl14r7ne3Og_3_5"></a><a id="Tc_wRqSPBqP402adAU-1V4cnA_3_8"></a><a id="Tc_PNVRUGjPkk62YpXQC88Qwg_4_0"></a><a id="Tc_jr2UyTXWu0CI2jo06jtU2w_5_0"></a><a id="Tc__5XAA2rZVEyhPunKMDMOHw_6_0"></a><a id="Tc_MwteG90AjE2T5ke-rqp-lw_7_0"></a><a id="Tc_shcI_YUIMECLdzwR2YJGlA_8_0"></a><a id="Tc__khTcRVarUSMdC1IEYt_Dg_8_2"></a><a id="Tc_Gu5kCDsdPEKSLoEllMSJwQ_8_5"></a><a id="Tc_YMtzu-gyjU2mDGe5ynDokQ_8_8"></a><ix:continuation id="Tb_UuB-YX7siE6jpY8d1N0kAA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Lease Balances, Costs, and Future Minimum Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Leases with an initial term of 12 months or less are not recorded on the balance sheet. As of September&#160;30,&#160;2024, we have not entered into any short-term leases. For lease agreements entered into or reassessed after the adoption of ASC 842</span><i style="font-style:italic;background:#ffffff;"> Leases</i><span style="background:#ffffff;">, we combine lease and non-lease components, if any. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">Our lease cost is reflected in the accompanying condensed statements of operations and comprehensive loss as follows</span>:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:LeaseCostTableTextBlock" id="Group_yZJL-feD7k6M46MuatvPmw" continuedAt="Group_yZJL-feD7k6M46MuatvPmw_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:23.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Fixed lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9ztv0G7UzkWrHinKet79MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_pQP0avvJjU21jgg-uh3Kxg_4_5">177</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_b9IfscRcGUihtJB5srkY2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_2o_corZlbkiM8-ILmjpHQQ_4_8">175</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_MRV76XSit0KBbsAP3TiUpA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_Zcfn56thd0K-a-sFA_YOlw_4_11">527</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_We2fnt_wf0y9QPYfo6rVXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_f92s9QkkrkOLNaJIFgC7rg_4_14">527</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:23.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Fixed lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_5JpbAcp9g0S1jyEmoVFeoA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_iWfAD1Xv0k-tH-Zi6ZCitA_5_5">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_wV-uPH-HE0C8hSHXy_alBg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_54vscnmEE0eLDiJFQtIyVg_5_8">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_8RApRitnUUKh4kBFAXN1pg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_yeceGuj0F02zsvb2EDs-Iw_5_11">59</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ynF1uQCSmUyLHWdxX__Sxg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_h78yrnAu_kKFhpxT7E8cpw_5_14">59</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9ztv0G7UzkWrHinKet79MQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_Ey3V2cvfJEy0oaxT5qcIoQ_7_5">22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_b9IfscRcGUihtJB5srkY2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_d_LXI8Jm3UuIlLfMDfNLHw_7_8">22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_MRV76XSit0KBbsAP3TiUpA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_mO93Omoi4EeH88mhefsLAA_7_11">67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_We2fnt_wf0y9QPYfo6rVXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_swqGn6i4Zkq8-omAAC2Qbw_7_14">74</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_4sm_WwX1i06DJVradQbuAA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="Tc_pvxh0VWlEkGTW6E9JZNqxw_8_5">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_icDoJJYujESK_TgeFGGuBw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="Tc_ZCPqJsqTc02E0pkdp27nSA_8_8">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_rJo_5hCZZ0eoAsQBkZvmzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="Tc_2IJQHjE7MUGn0JH4Mu8MLA_8_11">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_seQD86Gg-k-g0j-4Yfw1cw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="Tc_OGjW6gpfKU-P-qakWhYJDg_8_14">13</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:23.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total Lease Cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_WDA_V7oFQUCZCpi9hmAzcw_9_5">221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_sF2PoEtwmEybAR9z7dmd4A_9_8">220</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_HHUL9ACHM0ey-CBb2ncsWQ_9_11">659</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_BMrHOinzM0W1amCLoqVBDw_9_14">673</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:continuation id="Group_yZJL-feD7k6M46MuatvPmw_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The weighted average remaining lease term and discount rates as of September&#160;30,&#160;2024 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:88.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:88.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining lease term (years):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_tIUvhqsEY0-YQdrY_w-M3g_2_2"> 2.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_1I7I5pZE502A66OtQMqF1A_3_2"> 0.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average discount rate:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_KWdGhheOsUiiI8dabPxUvw_5_2">10.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:88.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_fKt1BD7gw0qmIEv7FvSyUw_6_2">6.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The discount rate for leases was estimated based upon market rates of collateralized loan obligations of comparable companies on comparable terms at the time of lease inception.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="lqda:LeaseLiabilityMaturityTableTextBlock" id="Tb_6_wtufemIUyH_jarQaaSIA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The future minimum lease payments as of September&#160;30,&#160;2024 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Year ending December&#160;31:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024 (three months remaining)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="Tc_RzvCUWXjd0udel8sPBj0rg_3_3">338</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="Tc_9ms5HYfBpESLTNvdfA2E2Q_3_6">29</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:LeaseLiabilityPaymentsDueRemainderOfFiscalYear" scale="3" id="Tc_uqLAV3BBn0qYFA1lVugCvg_3_9">367</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_8UAOSFJk-U2l1_sXgHCt7g_4_3">1,370</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_3UHb8kA_yEaANVCAirHQYA_4_6">64</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:LeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_FB_4pYsnrkyEENxGsevDDA_4_9">1,434</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_N72tQgOEBUmVKSAWHtSu6g_5_3">1,169</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:zerodash" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_U1TvuzPru0ifJpZGfoy-Vg_5_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:LeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_RMxvZwTEb0q-1M5uXKnOkA_5_9">1,169</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_ShI70Piei0aUNgZpdRc8VA_6_3">2,877</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="Tc_hbZB3sI6IUiWfNG9pUr2dw_6_6">93</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:LeaseLiabilityPaymentsDueTotal" scale="3" id="Tc_40wIU1-cK0i1Tppw79UGbw_6_9">2,970</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_8YGUmKXbaU-wJmUalB3Oqg_7_3">278</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_KdpazCZXxEGC0xipbQeqdg_7_6">2</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:LeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_-zgMj-DfMUaO4bzs0zlH5g_7_9">280</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_qTyLxedRgkWWVXqoZAvI7Q_8_3">2,599</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiability" scale="3" id="Tc_0O_JWBRjXUGIKN2KCYtSiA_8_6">91</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:LeaseLiability" scale="3" id="Tc_s3HBsnkXz0-llm1q913yhw_8_9">2,690</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="lqda:RevenueInterestFinancingPayableTextBlock" id="Tb_ZPdP6SoXY0WXbAD57O9epw" continuedAt="Tb_ZPdP6SoXY0WXbAD57O9epw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_ZPdP6SoXY0WXbAD57O9epw_cont1" continuedAt="Tb_ZPdP6SoXY0WXbAD57O9epw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Revenue Interest Financing Payable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On January 9, 2023, we entered into the RIFA with HCR and HealthCare Royalty Management, LLC, pursuant to which and subject to the terms and conditions contained therein, HCR agreed to pay us an aggregate investment amount of up to </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_9_2023_To_1_9_2023_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_fo6QHS2lUkOEV604PgAJ-g" decimals="-5" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementMaximumInvestmentAmount" scale="6" id="Narr_3nzq_BDSrEKNwAltYTAGLQ">100.0</ix:nonFraction></span><span style="background:#ffffff;"> million (the &#8220;Investment Amount&#8221;) in </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_tranche_wUAWxTjoVkeKHp1IAnkhew" contextRef="Duration_1_9_2023_To_1_9_2023_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_fo6QHS2lUkOEV604PgAJ-g" decimals="INF" format="ixt-sec:numwordsen" name="lqda:RevenueInterestFinancingAgreementNumberOfTranches" scale="0" id="Narr_WqQzh72abkuZHKITg5dFlw">four</ix:nonFraction></span><span style="background:#ffffff;"> tranches.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On January 27, 2023, </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_27_2023_To_1_27_2023_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_ewbpUOaI7UyQVn102NdAXw" decimals="-5" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementInitialInvestmentAmount" scale="6" id="Narr_9csRUhvIakanf03CS7hpsg">32.5</ix:nonFraction></span><span style="background:#ffffff;"> million of the Investment Amount was funded from the first tranche, </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_27_2023_To_1_27_2023_us-gaap_DebtInstrumentAxis_lqda_ArSiliconValleyBankTermLoansMember_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_lBeKdvCPDUmyLAg_84HrDg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="Narr_RcpflsnSsU6CcQJ4b79C7A">22.2</ix:nonFraction></span><span style="background:#ffffff;"> million of which was used to satisfy existing obligations due to Silicon Valley Bank. This repayment resulted in a loss on extinguishment during the year ended December&#160;31,&#160;2023 of&#160;</span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2023_To_12_31_2023_cXF6Jhyv9Ums3sgX3ZsQgg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="6" id="Narr_FIwZvSp2UkeIy9OnqcMvuQ">2.3</ix:nonFraction></span><span style="background:#ffffff;">&#160;million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On June 28, 2023 and July 27, 2023, we entered into the Second Amendment to the RIFA and Third Amendment to the RIFA, respectively, pursuant to which HCR funded $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_27_2023_To_7_27_2023_us-gaap_TypeOfArrangementAxis_lqda_SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember_JoeWZnLjZ0ynl9XNGamlHA" decimals="-5" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche" scale="6" id="Narr_iemgDQGrzESO4F9fApT-Pg">10.0</ix:nonFraction> million from the second tranche on July 27, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On January 3, 2024, we entered into the Fourth Amendment to the RIFA pursuant to which HCR funded an additional $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_5_2024_To_1_5_2024_us-gaap_TypeOfArrangementAxis_lqda_FourthAmendmentToRevenueInterestFinancingAgreementMember_KQa5hA-xwU2M20pCIYuA9w" decimals="-5" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche" scale="6" id="Narr_kGudNAnRQE-8OUX_VctlMw">25.0</ix:nonFraction> million from the second tranche on January 5, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On September 11, 2024 we entered into the Fifth Amendment to the RIFA pursuant to which HCR funded an additional $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_9_12_2024_To_9_12_2024_us-gaap_TypeOfArrangementAxis_lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember_90dvyAHXdUi7zLcPG7LSyw" decimals="-5" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche" scale="6" id="Narr_SbniifkQcEGN6-qG_eRBBQ">32.5</ix:nonFraction> million from the second tranche on September 12, 2024 and eliminated the third and fourth tranches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As consideration for the Investment Amount and pursuant to the RIFA, we have agreed to pay HCR according to a fixed quarterly payment schedule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">As of  September&#160;30,&#160;2024, we were required to pay </span>$<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-5" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingPayableCurrent" scale="6" id="Narr_1iLNcp4Qs0C-BGoFOfuK5Q">13.3</ix:nonFraction> million within one year of the balance sheet date, which is classified as current in our condensed consolidated balance sheet.<span style="background:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Aggregate payments to HCR are capped at <ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_9_2023_To_1_9_2023_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_fo6QHS2lUkOEV604PgAJ-g" decimals="0" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementHardCapPercentage" scale="0" id="Narr_GVtbqULJIUuaeFN0VSJ4ng">175</ix:nonFraction>% of funded portion of the Investment Amount (the &#8220;Hard Cap&#8221;), plus an amount, if any, that HCR would need to receive to yield an internal rate of return of (i) <ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_9_2023_To_1_9_2023_srt_StatementScenarioAxis_lqda_OnFirstFundedPortionOfInvestmentAmountMember_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_aXDyEn_Gnkq9Wg0YnjtxyQ" decimals="2" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementInternalRateOfReturn" scale="-2" id="Narr_XdFFDY998UWPKo2jXAR28Q">18</ix:nonFraction>% on the first $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_9_2023_To_1_9_2023_srt_StatementScenarioAxis_lqda_OnFirstFundedPortionOfInvestmentAmountMember_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_aXDyEn_Gnkq9Wg0YnjtxyQ" decimals="-5" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementAmountFunded" scale="6" id="Narr_6yQg7dffT0-SSUmR4VbAaw">67.5</ix:nonFraction> million funded and (ii) <ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_9_2023_To_1_9_2023_srt_StatementScenarioAxis_lqda_OnSecondPortionOfFundedInvestmentAmountMember_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_vs2P5tJ_80ax80uJ--MG3g" decimals="2" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementInternalRateOfReturn" scale="-2" id="Narr_1YZ7rcbZZkqwUFmUxYPFrQ">16</ix:nonFraction>% on the last $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_9_2023_To_1_9_2023_srt_StatementScenarioAxis_lqda_OnSecondPortionOfFundedInvestmentAmountMember_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_vs2P5tJ_80ax80uJ--MG3g" decimals="-5" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementAmountFunded" scale="6" id="Narr_t_mh048vD0GWmfaPC67jBQ">32.5</ix:nonFraction> million funded (the &#8220;IRR True-Up Payment&#8221;), unless the RIFA is earlier terminated. If a change of control occurs or upon the occurrence of an event of default, HCR may accelerate payments due under the RIFA up to the Hard Cap, plus the IRR True-Up Payment, plus any other obligations payable under the RIFA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The RIFA contains customary affirmative and negative covenants and customary events of default and other events that would cause acceleration, including, among other things, the occurrence of certain material adverse events or the material breach of certain representations and warranties and specified covenants, in which event HCR may elect to terminate the RIFA and require us to make payments to HCR equal to the lesser of (a) the Hard Cap, plus any other obligations payable under the RIFA, or (b) the funded portion of the Investment Amount, minus payments received by HCR in respect of the Revenue Interests, plus the IRR True-Up Payment. If the FDA grants final approval to an inhaled treprostinil product therapeutically equivalent to YUTREPIA and HCR has not received <ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_9_2023_To_1_9_2023_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_fo6QHS2lUkOEV604PgAJ-g" decimals="0" format="ixt:numdotdecimal" name="lqda:PercentageOfInvestmentAmountToBeRepaidOnFinalApproval" scale="0" id="Narr_6SLDBXUSo0uqjYvpTjG2gQ">100</ix:nonFraction>% of the amount funded by HCR to date, then we will be required to make payments to HCR equal to <ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_9_2023_To_1_9_2023_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_fo6QHS2lUkOEV604PgAJ-g" decimals="0" format="ixt:numdotdecimal" name="lqda:PercentageOfInvestmentAmountToBePaid" scale="0" id="Narr_kAvBI3cAikqB1x6WCZanpg">100</ix:nonFraction>% of the amount funded by HCR to date, minus payments received by HCR in respect of the Revenue Interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The RIFA contains certain restrictions on our ability, among other things, to incur additional debt, grant or permit additional liens, make investments and acquisitions, dispose of assets, pay dividends and distributions, subject to certain exceptions.&#160;<span style="background:#ffffff;">In addition, the RIFA contains a financial covenant that requires us to maintain cash and cash equivalents in an </span>amount at least equal to $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_9_2023_To_1_9_2023_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_fo6QHS2lUkOEV604PgAJ-g" decimals="-5" format="ixt:numdotdecimal" name="lqda:MinimumCashAndCashEquivalentsRequiredToBeMaintainedDuringYearTwo" scale="6" id="Narr_os8NXhrJY0S3j3Ijn11dxg">7.5</ix:nonFraction> million during the calendar year beginning on January 1, 2024 and at least equal to $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_9_2023_To_1_9_2023_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_fo6QHS2lUkOEV604PgAJ-g" decimals="-5" format="ixt:numdotdecimal" name="lqda:MinimumCashAndCashEquivalentsRequiredToBeMaintainedAfterYearTwo" scale="6" id="Narr_63nPVeqgyUiX6_14dTp-Jg">15.0</ix:nonFraction> million for the remainder of the payment term after the calendar year ended December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of the filing date of these condensed consolidated financial statements, we are not aware of any breach of covenants, or the occurrence of any material adverse event, nor have we received any notice of event of default from HCR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_xqHZaFZnmE6stLxTUl8hQw_1_0"></a><a id="Tc_KBP2T2jyFUCDe5TG8NZcKQ_1_2"></a><a id="Tc_NdYrzL_jU0Gqel4zXPwuPg_2_0"></a><a id="Tc_PqH2gz9RIUq8rzPVj0PVsA_3_0"></a><a id="Tc_8JRgIBmKoEWlGrf9srYdJg_4_0"></a><a id="Tc_NuxQyAmS-0WgCUNIW6uFgQ_5_0"></a><a id="Tc_PQoaRxydtkGAbfuD_EpW9w_5_2"></a><a id="Tc_PlQyFfHiP0Opj685XL8t5Q_6_0"></a><a id="Tc_HRer0YvuQUaCs1uS8XgQVg_7_0"></a><a id="Tc_DpsaDB6OvE21b8uPZGEYZw_7_2"></a><a id="Tc_Ua55z65-DkiO9h_6DDbWeQ_8_0"></a><a id="Tc_5R2M3lqH002OOyQ-r0zPcg_9_0"></a><a id="Tc_B_RHGJ5uZUGzvvoJYwSyxQ_10_0"></a><a id="Tc_YsmqCCFuPUGR2-_Rk7tRLw_11_0"></a><a id="Tc_t0g2UnIs0k6BvHLzxxciMg_11_2"></a><a id="Tc_iMTmp2zjqkOVe9yKIFXEeQ_12_0"></a><a id="Tc__Ty-7kroP06brXIEkdMi-w_13_0"></a><a id="Tc_TqEI9kn4pEmQG15Fant0Cw_13_2"></a><a id="Tc_E5SyJ-WfGUO681eXdD_66g_14_0"></a><a id="Tc_MLt3DmzV1UetheRfUNw27g_15_0"></a><a id="Tc_vqR3lqtUJkirhkd3y74n6A_15_2"></a><a id="Tc_IUh1HMt_h0GZLmW4BGqG-g_16_0"></a><a id="Tc_crfAV44ahkCIpvKXqGyTIw_17_0"></a><a id="Tc_exWCfcBmQUWUuMMOAiGPsg_17_2"></a><a id="_769d11f6_a4c2_4fb6_8745_4d31a8998a76"></a><a id="Tc_KpkcErJr0ka55fxg8QTLgQ_1_0"></a><a id="Tc_ENXYQgbgzkiiuY3LM7KujA_2_0"></a><a id="Tc_FcXBLHcQG0qmmg2ruqAVoA_2_2"></a><a id="Tc_kKDOjV2Bw0WP57cb0DlHQw_3_0"></a><a id="Tc_nnpan3OnMkGGgsI5fRm8Gg_4_0"></a><a id="Tc_FC8H4YkS4U6jINcLSnBV5A_5_0"></a><a id="Tc_Kl3NZ4WEj0yDebPHWT-KpQ_6_0"></a><a id="Tc_nLUj_M83REaWKYrP7VgtBw_7_0"></a><a id="Tc_lLR8dknXgUyVY5P61dEfCg_8_0"></a><a id="Tc_K-OcoA2LxEKHrmOCstEgUA_8_2"></a><ix:continuation id="Tb_ZPdP6SoXY0WXbAD57O9epw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Fourth Amendment to the RIFA qualifies as a debt extinguishment and issuance of a new debt instrument in accordance with ASC 405-20, Extinguishments of Liabilities. We recorded a loss on extinguishment during the quarter ended March 31, 2024 of $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_3_31_2024_f-rSQLlZh0qWc3XMDnx8Sw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="6" id="Narr_dGAuIfpzE0KZSHaU-9F-mQ">11.5</ix:nonFraction> million, equal to the fair value of the amended RIFA less the carrying value of the existing RIFA on January 5, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Fifth Amendment to the RIFA qualifies as a debt extinguishment and issuance of a new debt instrument in accordance with ASC 405-20, Extinguishments of Liabilities. We recorded a gain on extinguishment during the quarter ended September 30, 2024 of $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="Narr_NNOt3_SnQUmFi03Wk6EgcA">7.2</ix:nonFraction> million, equal to the fair value of the amended RIFA less the carrying value of the existing RIFA on September 12, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recorded the total funds received from HCR under the terms of the RIFA as a liability. The issuance costs, consisting primarily of legal fees, totaled $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_k-djEJags0G4_tYSdX2F1w" decimals="-5" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementIssuanceCosts" scale="6" id="Narr_MpgazgQsr0SV1HlZ0nFWXA">0.9</ix:nonFraction> million and were recorded as a deduction of the carrying amount of the liability and are being amortized under the effective interest method over the estimated period the liability will be repaid. We estimated the total amount of payments over the life of the RIFA to determine the interest expense to record to accrete the liability to the amount ultimately due. For the three and nine months ended September&#160;30,&#160;2024, we estimated an&#160;effective annual interest rate of approximately&#160;<ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_k-djEJags0G4_tYSdX2F1w" decimals="3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementEffectiveAnnualInterestRate" scale="-2" id="Narr_wXQh8Xulp0ioO_2_ZafFdg">15.2</ix:nonFraction>%. Over the course of the RIFA, the effective annual interest rate may be affected by potential changes in forecasted payments. On a quarterly&#160;basis, we will reassess the expected amount and timing of payments, recalculate the amortization and effective interest&#160;rate and adjust the accounting prospectively as needed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table presents the changes in the RIFA payable during the nine months ended September&#160;30,&#160;2024:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="lqda:ScheduleOfActivityOfRevenueInterestFinancingAgreementTableTextBlock" id="Tb_bC-Qfk6s5Ueb0wMLrO3KXA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw" decimals="-3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreement" scale="3" id="Tc_aywVA8ItHUu5EHBlaxniUA_1_3">46,033</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_1_4_2024_lOhuZ940QEqjnjbxJodNUA" decimals="-3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementAccretion" scale="3" id="Tc_Q7vTjLZZ4U68U5Oa5Lpgeg_2_3">107</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_1_4_2024_lOhuZ940QEqjnjbxJodNUA" decimals="-3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementAmortizationOfDebtDiscount" scale="3" id="Tc_XGI1j3hpu0eA6pmLQIHIUw_3_3">2</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Second tranche funding, net of fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_1_4_2024_lOhuZ940QEqjnjbxJodNUA" decimals="-3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche" scale="3" id="Tc_bH1cI86xS0KwXcfFU8YRCQ_4_3">24,975</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of January 5, 2024, prior to extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_1_4_2024_bF-IBdhTwk-KlM3yC7Lrpw" decimals="-3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreement" scale="3" id="Tc_htYG3lppPk29xN9jzGavfQ_5_3">71,117</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss on extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_5_2024_To_1_5_2024_viljKiMR20eRuvibROMGtg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="Tc_IJL1H0ghUkaTTlUjPc35wA_6_3">11,483</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of January 5, 2024, after extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_1_5_2024_3NJ3uFG5A06JS2suMz0vng" decimals="-3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreement" scale="3" id="Tc_CnRS1BDQ30GOdGal-LUzUQ_7_3">82,600</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_6_2024_To_9_11_2024_EiDEZtBwZ0mjbahWfp4TWA" decimals="-3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementAccretion" scale="3" id="Tc_N68OEm84A0mjMHF9rSd8aw_8_3">7,161</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_6_2024_To_9_11_2024_EiDEZtBwZ0mjbahWfp4TWA" decimals="-3" format="ixt:numdotdecimal" name="lqda:PaymentsOnRevenueInterestFinancingLiability" scale="3" id="Tc_Cztv6TsFH02qt9LR0Hq9MQ_9_3">2,731</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Second tranche funding, net of fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_6_2024_To_9_11_2024_EiDEZtBwZ0mjbahWfp4TWA" decimals="-3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche" scale="3" id="Tc_yeYp5ULWGU2p1oAiUNdkIQ_10_3">32,485</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of September 12, 2024, prior to extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_11_2024_Ev9Bn70vFE2agHiszGrR1Q" decimals="-3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreement" scale="3" id="Tc_hGeXhvOHSEKVPmHHQiI2-g_11_3">119,515</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Gain) on extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_9_12_2024_To_9_12_2024_aSxtNfNO5k-96RR4O_eJ5w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" sign="-" scale="3" id="Tc_aSyojTFRykitJRQnk2ZL2A_12_3">7,215</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of September 12, 2024, after extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_12_2024_CIE4XyPuXU-VCdM-JmlrRQ" decimals="-3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreement" scale="3" id="Tc_KT4CycEer0Ox5KgN7odapw_13_3">112,300</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_9_13_2024_To_9_30_2024_i691B_ItG0GtXHNs1Fzb9g" decimals="-3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementAccretion" scale="3" id="Tc_bXB4sERtrk2S9Jw61Kx98Q_14_3">844</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreement" scale="3" id="Tc_xrj0MJm2kk2uqjcF04oJzQ_15_3">113,144</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: current portion of revenue interest financing payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingPayableCurrent" scale="3" id="Tc_OuYd37zgfkG_7Vm47LAWaQ_16_3">13,252</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term portion of revenue interest financing payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingPayableNoncurrent" scale="3" id="Tc_v4jshyj2zU2EnMEACmiBCw_17_3">99,892</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="lqda:ScheduleOfExpectedAnnualPaymentsOnRevenueInterestFinancingAgreement" id="Tb_wqXJUw7QjkS3Ff5SxTvkuw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The expected annual payments on the revenue interest financing payable as of September&#160;30,&#160;2024 are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Year ending December&#160;31:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024 (three months remaining)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear" scale="3" id="Tc_wC8uRElG3k-1yfbv6f78Iw_2_3">2,122</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementExpectedPaymentsYearOne" scale="3" id="Tc_9nqg7IzMG0qZxki-zvxCqg_3_3">18,017</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementExpectedPaymentsYearTwo" scale="3" id="Tc_l4LeE9E9vUqkpDoSuw82FA_4_3">52,724</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementExpectedPaymentsYearThree" scale="3" id="Tc__HV2NlvRMUelmebqISXBew_5_3">32,962</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementExpectedPaymentsYearFour" scale="3" id="Tc_9nOYvVI1W0eLD0wM0iJOuA_6_3">32,962</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementExpectedPaymentsYearFiveAndThereafter" scale="3" id="Tc_RAC2xh1EZEu9DhPtRY-0Lw_7_3">31,828</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-3" format="ixt:numdotdecimal" name="lqda:RevenueInterestFinancingAgreementExpectedPaymentsTotal" scale="3" id="Tc_Ujhu7Ryp_EqC1TIIsnGkbg_8_3">170,615</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_cI2Dsun-rEmLml9wDtgsdA" continuedAt="Tb_cI2Dsun-rEmLml9wDtgsdA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. Commitments and Contingencies </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Pharmosa License Agreement and Device License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June 2023, we entered into a License Agreement with Pharmosa Biopharm Inc. (&#8220;Pharmosa&#8221;) pursuant to which we were granted an exclusive license in North America to develop and commercialize L606, an inhaled, sustained-release formulation of treprostinil currently being evaluated in a clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), and a non-exclusive license for the manufacture, development and use (but not commercialization) of such licensed product in most countries outside North America (the &#8220;Pharmosa License Agreement&#8221;). On October 2, 2024, we and Pharmosa entered into a First Amendment to the Pharmosa License Agreement (the &#8220;First Amendment&#8221;) which, among other things, expands our licensed territory beyond North America to include key markets in Europe, Japan and elsewhere.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;">Concurrently with the execution of the First Amendment, we and Pharmosa also entered into a Device License Agreement (the &#8220;Device License Agreement&#8221;). Pursuant to the terms of the Device License Agreement, Pharmosa will provide (i) an exclusive license to Liquidia Technologies for the right to develop, manufacture, use and commercialize Pharmosa&#8217;s next-generation smart-technology nebulizers (the &#8220;Device&#8221;) for use with L606 in most countries (subject to certain exceptions) (the &#8220;Territory&#8221;) and (ii) a non-exclusive license to Liquidia Technologies for the right to develop, manufacture and use (but not commercialize) the Device outside of the Territory.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Pharmosa License Agreement, as amended, we will be responsible for development, regulatory and commercial activities of L606 in the Territory. Pharmosa will manufacture clinical and commercial supplies of the liposomal formulation through its global supply chain and support us in establishing a redundant global supply chain. In consideration for these exclusive rights, we paid Pharmosa an upfront license fee of $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_6_1_2023_To_6_30_2023_us-gaap_OtherCommitmentsAxis_lqda_PharmosaLicenseAgreementMember_kTOrGdUxVkmmOH0NFjgVRg" decimals="-6" format="ixt:numdotdecimal" name="lqda:PaymentForUpfrontLicenseFee" scale="6" id="Narr_7d7Fec2vVESW-K03LHZt8w">10</ix:nonFraction> million and paid an additional $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_6_30_2023_us-gaap_OtherCommitmentsAxis_lqda_PharmosaLicenseAgreementMember_74ZGg3byiEqvxeoe8yh5pw" decimals="-5" format="ixt:numdotdecimal" name="lqda:AccruedAdditionalUpfrontLicenseFee" scale="6" id="Narr_0glbketqXE6yP4YuWlVeHQ">3.5</ix:nonFraction> million upfront license fee in October 2024 in <span style="color:#212529;">connection with the rights granted in the First Amendment and the Device License Agreement. In addition to the upfront fees, we </span>will pay Pharmosa potential development milestone payments tied to clinical development and approvals in PAH and/or PH-ILD of up to $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_6_1_2023_To_6_30_2023_us-gaap_OtherCommitmentsAxis_lqda_PharmosaLicenseAgreementMember_kTOrGdUxVkmmOH0NFjgVRg" decimals="-4" format="ixt:numdotdecimal" name="lqda:MaximumPotentialDevelopmentMilestonePayments" scale="6" id="Narr_KgbPITkxNkOovuJRfsdLag">37.75</ix:nonFraction> million, potential sales milestones of up to $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_6_1_2023_To_6_30_2023_srt_StatementGeographicalAxis_srt_NorthAmericaMember_us-gaap_OtherCommitmentsAxis_lqda_PharmosaLicenseAgreementMember_QWvVbOqoFUaZurD06Zgd0w" decimals="-6" format="ixt:numdotdecimal" name="lqda:MaximumPotentialSalesMilestones" scale="6" id="Narr_rjXumX2dDUGSUan4YhPhbg">185</ix:nonFraction> million in North America and $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_6_1_2023_To_6_30_2023_srt_StatementGeographicalAxis_lqda_OtherThenNorthAmericaMember_us-gaap_OtherCommitmentsAxis_lqda_PharmosaLicenseAgreementMember_PWs3djrXF0qDVpc8vjHEMw" decimals="-6" format="ixt:numdotdecimal" name="lqda:MaximumPotentialSalesMilestones" scale="6" id="Narr_tR4bd6q28Ua-u8aBq75evg">150</ix:nonFraction> million outside North American and two tiers of low, double-digit royalties on all net sales of L606. Pharmosa will also receive a $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_6_30_2023_us-gaap_OtherCommitmentsAxis_lqda_PharmosaLicenseAgreementMember_74ZGg3byiEqvxeoe8yh5pw" decimals="-6" format="ixt:numdotdecimal" name="lqda:MilestonePaymentsPayable" scale="6" id="Narr_o3q69ZRMPUCzp7L392V5UA">10</ix:nonFraction> million milestone payment for each additional indication approved after PAH and PH-ILD and each additional product approved under the license. We also retain the first right to negotiate for development and commercialization of L606 in Europe and other territories should Pharmosa seek a partner, subject to satisfaction of certain conditions as set forth in the Pharmosa License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Mainbridge Health Care Device Development and Supply Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2022, we entered into a Device Development and Supply Agreement (the &#8220;Pump Development Agreement&#8221;) with Mainbridge Health Partners, LLC (&#8220;Mainbridge&#8221;) and Sandoz Inc. (&#8220;Sandoz&#8221;). The Pump Development Agreement provides for the cooperation between us, Sandoz and Mainbridge to develop a new pump that is suitable for the subcutaneous administration of Treprostinil Injection. Mainbridge will perform all development, validation and testing activities required for the pump and related consumables in anticipation of submitting a 510(k)&#160;clearance application for the pump to the FDA. In connection with the Pump Development Agreement, we and Sandoz have agreed to pay Mainbridge certain future contingent milestone payments in accordance with the terms and conditions set forth therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">UNC License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We perform research under a license agreement with The University of North Carolina at Chapel Hill (&#8220;UNC&#8221;) as amended to date (the &#8220;UNC License Agreement&#8221;). As part of the UNC License Agreement, we hold an exclusive license to certain research and development technologies and processes in various stages of patent pursuit, for use in our research and development and commercial activities, with a term until the expiration date of the last to expire patent subject to the UNC License Agreement, subject to industry standard contractual compliance. Under the UNC License Agreement, we are obligated to pay UNC royalties equal to a low single digit&#160;percentage of all net sales of drug products whose manufacture, use or sale includes any use of the technology or patent rights covered by the UNC License </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_cI2Dsun-rEmLml9wDtgsdA_cont1" continuedAt="Tb_cI2Dsun-rEmLml9wDtgsdA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Agreement, including YUTREPIA. We may grant sublicenses of UNC licensed intellectual property in return for specified payments based on a&#160;percentage of any fee, royalty or other consideration received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Chasm Technologies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In March 2012, we entered into an agreement, as amended, with Chasm Technologies, Inc. for manufacturing consulting services related to our manufacturing capabilities during the term of the agreement. We agreed to pay future contingent milestones and royalties on net sales totaling no more than $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_OtherCommitmentsAxis_lqda_ChasmTechnologiesAgreementMember_17fard0TZkuq54S0aOBFBQ" decimals="-5" format="ixt:numdotdecimal" name="lqda:MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties" scale="6" id="Narr_ZSkuGOijfEyw5TT3APkirQ">1.5</ix:nonFraction> million, $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_OtherCommitmentsAxis_lqda_ChasmTechnologiesAgreementMember_17fard0TZkuq54S0aOBFBQ" decimals="-5" format="ixt:numdotdecimal" name="lqda:NetSalesEarnedRelatingToPaymentOfFutureContingentRoyalties" scale="6" id="Narr_k_UUH-_YA0GQY5ZhuGcEtQ">0.2</ix:nonFraction> million of which has been accrued as of September&#160;30,&#160;2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employment Agreements and Executive Severance and Change in Control Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have agreements with certain employees and an Executive Severance and Change in Control Plan which covers certain other employees which require payments if certain events, such as a change in control or termination without cause, occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Purchase Obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We enter into contracts in the normal course of business with contract service providers to assist in the performance of research and development and manufacturing activities. Subject to required notice periods and obligations under binding purchase orders, we can elect to discontinue the work under these agreements at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On July 14, 2023, we entered into an Amended and Restated Commercial Manufacturing Services and Supply Agreement with Lonza Tampa LLC (&#8220;Lonza&#8221;) (the &#8220;CSA&#8221;). Lonza is our sole supplier for encapsulation and packaging services for YUTREPIA. <span style="background:#ffffff;">Pursuant to the terms of the CSA, we deliver bulk treprostinil powder, manufactured using our proprietary PRINT</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;background:#ffffff;">&#174;</sup><span style="background:#ffffff;">&#160;technology, and Lonza encapsulates and packages it. </span>The CSA was effective upon signing and will be in effect for an initial term of <ix:nonNumeric contextRef="Duration_7_14_2023_To_7_14_2023_us-gaap_OtherCommitmentsAxis_lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember_9-1NFSrmLU2h8Mehfb8Z0Q" format="ixt-sec:durwordsen" name="lqda:CommercialManufacturingServicesAndSupplyAgreementInitialTerm" id="Narr_RIhpbNHbKE6xHzvgVFrNDw">5 years</ix:nonNumeric> from receipt of regulatory approval of YUTREPIA by the FDA (&#8220;Regulatory Approval&#8221;) absent termination by either party in accordance with the terms of the CSA.<span style="background:#ffffff;"> We may terminate the CSA upon </span><ix:nonNumeric contextRef="Duration_7_14_2023_To_7_14_2023_us-gaap_OtherCommitmentsAxis_lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember_9-1NFSrmLU2h8Mehfb8Z0Q" format="ixt-sec:durwordsen" name="lqda:CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection" id="Narr_I4rgWGg7VUeW1KTdaMUCdQ"><span style="background:#ffffff;">60 days</span></ix:nonNumeric><span style="background:#ffffff;">&#8217; written notice to Lonza in the event that the application for regulatory approval is rejected by the FDA and such FDA decision is not caused by the fault of the Company (the &#8220;Termination for FDA Rejection&#8221;). Lonza may terminate the CSA upon </span><ix:nonNumeric contextRef="Duration_7_14_2023_To_7_14_2023_us-gaap_OtherCommitmentsAxis_lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember_9-1NFSrmLU2h8Mehfb8Z0Q" format="ixt-sec:durwordsen" name="lqda:CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay" id="Narr_V5oTno9bE0SJcrqGtDL-_A"><span style="background:#ffffff;">120 days</span></ix:nonNumeric><span style="background:#ffffff;"> written notice if we do not receive regulatory approval by December&#160;31, 2024 (the &#8220;Termination for FDA Delay&#8221;). </span>Upon any Termination for FDA Rejection or Termination for FDA Delay, we would reimburse Lonza for <ix:nonFraction unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw" contextRef="Duration_7_14_2023_To_7_14_2023_us-gaap_OtherCommitmentsAxis_lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember_9-1NFSrmLU2h8Mehfb8Z0Q" decimals="2" format="ixt:numdotdecimal" name="lqda:PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures" scale="-2" id="Narr_OOJpai2Fm0exbiNTeobcLQ">50</ix:nonFraction>% of its documented out-of-pocket expenditures for any capital equipment that is purchased by Lonza after the effective date of the Agreement to perform the services for us, not to exceed $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_7_14_2023_us-gaap_OtherCommitmentsAxis_lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember_zRac0Pl5b0Geps4g1_aVUg" decimals="-5" format="ixt:numdotdecimal" name="lqda:ReimbursementOfCapitalExpenditureIncurredBySupplier" scale="6" id="Narr_b4wr11ZmmEOj748_uOP14A">2.5</ix:nonFraction> million in the aggregate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">We are required to provide Lonza with quarterly forecasts of our expected production requirements for the following </span><ix:nonNumeric contextRef="Duration_7_14_2023_To_7_14_2023_us-gaap_OtherCommitmentsAxis_lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember_9-1NFSrmLU2h8Mehfb8Z0Q" format="ixt-sec:durwordsen" name="lqda:TermOfSubmissionOfQuarterlyForecastOfExpectedProduction" id="Narr_A_qBWJGebEyhXnUuwiTkyg"><span style="background:#ffffff;">24-month</span></ix:nonNumeric><span style="background:#ffffff;"> period, the first </span><ix:nonNumeric contextRef="Duration_7_14_2023_To_7_14_2023_us-gaap_OtherCommitmentsAxis_lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember_9-1NFSrmLU2h8Mehfb8Z0Q" format="ixt-sec:durwordsen" name="lqda:InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder" id="Narr_1JMUJg5BPk65DmAyW0Gb-g"><span style="background:#ffffff;">twelve months</span></ix:nonNumeric><span style="background:#ffffff;"> of which is considered a binding, firm order. We are required to purchase certain minimum annual order quantities, which may be adjusted by us after the thirteenth month after receipt of regulatory approval (as defined in the CSA). The CSA provides for tiered pricing depending upon the batch size ordered. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, we are party to a multi-year supply agreement with LGM Pharma, LLC (LGM) to supply active pharmaceutical ingredients for YUTREPIA. Under the supply agreement with LGM, we are required to provide rolling forecasts, a portion of which will be considered a binding, firm order, subject to an annual minimum purchase commitment of $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_us-gaap_OtherCommitmentsAxis_lqda_AgreementWithLGMPharmaLLCMember_a_fkJlyRgkS7OKPppsJs0Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="6" id="Narr_x7MVsAvPwkuYwgSi5FqMGA">2.7</ix:nonFraction> million for the term of the agreement. The agreement expires <ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_OtherCommitmentsAxis_lqda_AgreementWithLGMPharmaLLCMember_HIEBrzKy8U2iausIsKFPnA" format="ixt-sec:durwordsen" name="lqda:AgreementExpirationTerm" id="Narr_BIWnsWGT2UyBJEqQhzZsrw">five&#160;years</ix:nonNumeric> from the first marketing authorization approval of YUTREPIA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30,&#160;2024, we have non-cancelable commitments for product manufacturing and supply costs of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg" decimals="-5" format="ixt:numdotdecimal" name="lqda:NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts" scale="6" id="Narr_0Ot18xxtgEO17uIqI8-ipw">14.7</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Contingencies and Commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">From time-to-time we are subject to claims and litigation in the normal course of business, none of which do we believe represent a risk of material loss or exposure. See Note&#160;14 for further discussion of pending legal proceedings.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_cI2Dsun-rEmLml9wDtgsdA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition to the commitments described above, we are party to other commitments, including non-cancelable leases and long-term debt, which are described elsewhere in these notes to the condensed consolidated financial statements.</p></ix:continuation><a id="Item2MDA"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="Tb_8gI4yQSmU0ubFkumn_Xy2g" continuedAt="Tb_8gI4yQSmU0ubFkumn_Xy2g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14. Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">YUTREPIA-Related Litigation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In 2020, United Therapeutics filed a complaint for patent infringement against the Company in the U.S. District Court for the District of Delaware (the &#8220;Original Hatch-Waxman Litigation&#8221;), asserting infringement by the Company of U.S. Patent Nos. 9,604,901, entitled &#8220;Process to Prepare Treprostinil, the Active Ingredient in Remodulin&#174;&#8221; (the &#8220;&#8216;901 Patent&#8221;), 9,593,066, entitled &#8220;Process to Prepare Treprostinil, the Active Ingredient in Remodulin&#174;&#8221; (the &#8220;&#8216;066 Patent&#8221;), and 10,716,793, entitled &#8220;Treprostinil Administration by Inhalation&#8221; (the &#8220;&#8216;793 Patent&#8221;) relating to United Therapeutics&#8217; Tyvaso&#174;, a nebulized treprostinil solution for the treatment of PAH. United Therapeutics&#8217; complaint was in response to the Company&#8217;s NDA for YUTREPIA, filed with the FDA, requesting approval to market YUTREPIA, a dry powder formulation of treprostinil for the treatment of PAH. The YUTREPIA NDA was filed under the 505(b)(2) regulatory pathway with Tyvaso&#174; as the reference listed drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In December 2021, United Therapeutics filed a stipulation of partial judgment with respect to the &#8216;901 Patent under which United Therapeutics agreed to the entry of judgment of the Company&#8217;s non-infringement of the &#8217;901 Patent.  In August 2022, Judge Andrews, who was presiding over the Original Hatch-Waxman Litigation, issued an opinion that claims 1, 2, 3, 6 and 9 of the &#8216;066 Patent were invalid, that the remaining asserted claims of the &#8216;066 Patent were not infringed by the Company.  In January 2021, the Company filed a petition for </span><i style="font-style:italic;">inter partes</i><span style="white-space:pre-wrap;"> review with the Patent Trial and Appeal Board (the &#8220;PTAB&#8221;) relating to the &#8216;793 Patent, seeking a determination that the claims in the &#8216;793 Patent are invalid. In July 2022, the PTAB ruled in the Company&#8217;s favor, concluding that based on the preponderance of the evidence, all the claims of the &#8217;793 Patent have been shown to be unpatentable. These decisions related to the &#8216;901 Patent, the &#8216;066 Patent and the &#8216;793 Patent have all been affirmed on appeal and are not subject to further appeal.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In connection with an amendment to the Company&#8217;s NDA filed in July 2023 to add PH-ILD as an indication for YUTREPIA, the Company provided a new notice of the paragraph IV certification to United Therapeutics as the owner of the patents that are the subject of the certification to which the NDA for YUTREPIA refers. As a result, in September 2023, United Therapeutics filed a second complaint for patent infringement against the Company in the U.S. District Court for the District of Delaware (Case No. 1:23-cv-00975-RGA) (the &#8220;New Hatch-Waxman Litigation&#8221;), again asserting infringement by the Company of the &#8216;793 Patent.  In November 2023, the U.S. Patent and Trademark Office (the &#8220;USPTO&#8221;) issued U.S. Patent No. 11,826,327, or the &#8216;327 Patent, entitled &#8220;Treatment for Interstitial Lung Disease&#8221;, to United Therapeutics. On November 30, 2023, United Therapeutics filed an amended complaint in the New Hatch-Waxman Litigation asserting infringement of the &#8216;327 Patent by the practice of YUTREPIA based on the amended NDA.  In January 2024, the Company filed an answer, counterclaims and a partial motion to dismiss the claims related to the &#8216;793 Patent as a result of the decision by the United States Court of Appeals for the Federal Circuit to affirm the PTAB&#8217;s finding that the &#8217;793 patent is unpatentable.  In February 2024, United Therapeutics stipulated to the dismissal of the claims in the New Hatch-Waxman Litigation related to the &#8216;793 Patent.  In February 2024, United Therapeutics also filed a motion seeking a preliminary injunction to prevent the Company from manufacturing, marketing, storing, importing, distributing, offering for sale, and/or selling YUTREPIA for the treatment of PH-ILD.  Judge Andrews denied the motion for a preliminary injunction in May 2024. Discovery in the case remains ongoing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FDA Litigation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In February 2024, United Therapeutics filed a complaint against the FDA in the U.S. District Court for the District of Columbia (the &#8220;D.C. District Court&#8221;), challenging the FDA&#8217;s acceptance of the Company&#8217;s amended NDA for review (the &#8220;Original FDA Litigation&#8221;).  The Company intervened and became a party to the lawsuit in March 2024.  </span><span style="letter-spacing:0.2pt;">In March&#160;2024, United Therapeutics filed a motion for a temporary restraining order and preliminary injunction in the FDA Litigation, seeking to enjoin the FDA from approving the Company&#8217;s NDA for YUTREPIA with respect to the indication to treat PH-ILD. United Therapeutics&#8217; motion was denied in March&#160;2024. On August&#160;20, 2024, United Therapeutics voluntarily dismissed its complaint, without prejudice.</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_8gI4yQSmU0ubFkumn_Xy2g_cont1" continuedAt="Tb_8gI4yQSmU0ubFkumn_Xy2g_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On August 21, 2024, the Company filed a lawsuit in the D.C. District Court to challenge the decision by the FDA to grant three-year regulatory exclusivity to Tyvaso DPI (the &#8220;New FDA Litigation&#8221;). The D.C. District Court has granted the parties&#8217; motion for an expedited summary judgment briefing schedule, with briefing to be completed on or before November 15, 2024 and a summary judgment hearing scheduled for December 5, 2024.  On September 16, 2024, United Therapeutics filed a cross claim in the New FDA Litigation, re-asserting its challenge to FDA&#8217;s acceptance of the Company&#8217;s amended NDA for review.  The Company intervened and became a party with respect to the cross claim on November 5, 2024.  United Therapeutics has filed a motion for an expedited summary judgment briefing schedule for its cross claim.  That motion remains pending.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Trade Secret Litigation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In December 2021, United Therapeutics filed a complaint in the Superior Court in Durham County, North Carolina, alleging that the Company and Robert Roscigno (&#8220;Dr. Roscigno&#8221;) a former United Therapeutics employee, who later joined the Company as an employee many years after terminating his employment with United Therapeutics, conspired to misappropriate certain trade secrets of United Therapeutics and engaged in unfair or deceptive trade practices. In January 2024, Dr. Roscigno filed a motion for summary judgment with respect to all claims, but the motion was denied in July 2024.  In addition, in July 2024, the Company filed a motion for summary judgment with respect to all claims.  A hearing on the Company&#8217;s motion for summary judgment has been scheduled for December 19, 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">In May 2024, United Therapeutics filed a second complaint in the Superior Court in Durham County, North Carolina, against Dr. Roscigno, alleging that he breached prior employment agreements with United Therapeutics by failing to assign to United Therapeutics his interest in patents obtained by the Company that relied upon or benefitted from certain inventions, discoveries, materials, authorship, derivatives and results developed by Dr. Roscigno while he was employed by United Therapeutics. The Company was also named as a defendant in this new lawsuit. As part of the lawsuit, United Therapeutics alleges that Dr. Roscigno misappropriated certain intellectual property of United Therapeutics which led to the development of YUTREPIA. The complaint also seeks declaratory judgement such that all right, title and interest in and to any patentable or unpatentable inventions, discoveries, and ideas made or conceived by Dr. Roscigno while employed by the Company should be assigned and transferred to United Therapeutics because they involved the use of United Therapeutics&#8217; confidential information. On July 30, 2024, the Company filed a motion to dismiss all claims.  A hearing on the Company&#8217;s motion to dismiss has been scheduled for December 19, 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RareGen Litigation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In April 2019, Sandoz and Liquidia PAH (then known as RareGen) filed a complaint against United Therapeutics and Smiths Medical (now ICU Medical) in the District Court of New Jersey (Case No. No. 3:19 cv 10170), (the &#8220;RareGen Litigation&#8221;), alleging that United Therapeutics and Smiths Medical violated the Sherman Antitrust Act of 1890, state law antitrust statutes and unfair competition statutes by engaging in anticompetitive acts regarding the drug treprostinil for the treatment of PAH. In March 2020, Sandoz and Liquidia PAH filed a first amended complaint adding a claim that United Therapeutics breached a settlement agreement that was entered into in 2015, in which United Therapeutics agreed to not interfere with Sandoz&#8217;s efforts to launch its generic treprostinil, by taking calculated steps to restrict and interfere with the launch of Sandoz&#8217;s competing generic product. United Therapeutics developed treprostinil under the brand name Remodulin&#174; and Smiths Medical manufactured a pump and cartridges that are used to inject treprostinil into patients continuously throughout the day. Sandoz and Liquidia PAH allege that United Therapeutics and Smiths Medical entered into anticompetitive agreements (i) whereby Smiths Medical placed restrictions on the cartridges such that they can only be used with United Therapeutics&#8217; branded Remodulin&#174; product and (ii) requiring Smiths Medical to enter into agreements with specialty pharmacies to sell the cartridges only for use with Remodulin&#174;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In November 2020, Sandoz and Liquidia PAH entered into a binding term sheet (the &#8220;Term Sheet&#8221;) with Smiths Medical in order to resolve the outstanding RareGen Litigation solely with respect to disputes between Smiths Medical, Liquidia PAH and Sandoz. In April 2021, Liquidia PAH and Sandoz entered into a Long Form Settlement Agreement (the &#8220;Settlement Agreement&#8221;) with Smiths Medical to further detail the terms of the settlement among such parties as reflected in the Term Sheet. Pursuant to the Term Sheet and the Settlement Agreement, the former RareGen members and Sandoz received a payment of $<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_4_1_2021_To_4_30_2021_dei_LegalEntityAxis_lqda_LiquidiaPAHAndSandozMember_srt_LitigationCaseAxis_lqda_UTCAndSmithsMedicalLitigationMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_HugoVmm5y0mmurW4-YSz7g" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLegalSettlements" scale="6" id="Narr_Z_xwQ_g4oU-CmYkPKClmhA">4.25</ix:nonFraction> million that was evenly split between the parties. In addition, pursuant to the Term Sheet and Settlement Agreement, Smiths Medical disclosed and made available to Sandoz and Liquidia PAH </p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_8gI4yQSmU0ubFkumn_Xy2g_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">certain specifications and other information related to the cartridge that Smiths Medical developed and manufactures for use with the CADD-MS 3 infusion pump (the &#8220;CADD-MS 3 Cartridge&#8221;). Pursuant to the Settlement Agreement, Smiths Medical also granted Liquidia PAH and Sandoz a non-exclusive, royalty-free license in the United States to Smiths Medical&#8217;s patents and copyrights associated with the CADD-MS 3 Cartridge and certain other information for use of the CADD-MS 3 pump and the CADD-MS 3 Cartridges. Smiths also agreed in the Settlement Agreement to provide information and assistance in support of Liquidia PAH&#8217;s efforts to receive FDA clearance for the RG 3ml Medication Cartridge (the &#8220;RG Cartridge&#8221;) and to continue to service certain CADD-MS 3 pumps that are available for use with the Treprostinil Injection through January 1, 2025. Liquidia PAH and Sandoz agreed, among other things, to indemnify Smiths from certain liabilities related to the RG Cartridge.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">In September 2021, United Therapeutics filed a motion for summary judgment with respect to all of the claims brought by Sandoz and Liquidia PAH against United Therapeutics. At the same time, Sandoz filed a motion for summary judgment with respect to the breach of contract claim. In March 2022, the Court issued an order granting partial summary judgment to United Therapeutics with respect to the antitrust and unfair competition claims, denying summary judgment to United Therapeutics with respect to the breach of contract claim, and granting partial summary judgment to Sandoz with respect to the breach of contract claim. A trial to determine the amount of damages due from United Therapeutics to Sandoz with respect to the breach of contract claim was held from late April to early May 2024, and closing arguments were held in June 2024.  On November 1, 2024, the Court entered a judgment in the amount of </span>$<ix:nonFraction unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ" contextRef="Duration_11_1_2024_To_11_1_2024_dei_LegalEntityAxis_lqda_LiquidiaPAHAndSandozMember_srt_LitigationCaseAxis_lqda_BreachOfContractClaimMember_dVqpqeHTvEyS2ITxDkE5Vw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" scale="6" id="Narr_s1stYe0rj0WdCDs-nj_EiA">70.6</ix:nonFraction><span style="white-space:pre-wrap;"> million.  United Therapeutics has filed a notice of its intent to appeal the decision.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Under the Promotion Agreement, all proceeds from the litigation will be divided evenly between Sandoz and Liquidia PAH. Under the litigation finance agreements that Liquidia PAH has entered into with Henderson and PBM, any net proceeds received by Liquidia PAH with respect to the RareGen Litigation will be divided between Henderson and PBM.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg" name="us-gaap:SubsequentEventsTextBlock" id="Tb_cFLX_2-RBEiQ7juBqKwHMQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15. Subsequent Event</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On October 2, 2024, we and Pharmosa entered into a First Amendment to the Pharmosa License Agreement (the &#8220;First Amendment&#8221;) and concurrently entered into a <span style="color:#212529;">Device License Agreement with Pharmosa. See Note 13 for additional information.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e95c5ddc_c7b2_4983_b9e7_5ca98b4c264c"></a><a id="MDandA"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and related notes appearing in this Quarterly Report on Form&#160;10-Q. This discussion and other parts of this Quarterly Report contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. As a result of many factors, including those factors set forth in the &#8220;Risk Factors&#8221; section of this Quarterly Report, our actual results could differ materially from the results described in, or implied by, the forward-looking statements contained in the following discussion and analysis.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Objective</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is intended to provide information necessary to understand our condensed consolidated financial statements and highlight certain other information which, in the opinion of management, will enhance a reader&#8217;s understanding of our financial condition, changes in financial condition and results of operations. In particular, the discussion is intended to provide an analysis of significant trends and material changes in our financial position and the operating results of our business during the three and nine months ended September&#160;30,&#160;2024 as compared to the three and nine months ended September&#160;30,&#160;2023. Also refer to our Annual Report on Form 10-K for the fiscal year ended December&#160;31,&#160;2023, which includes detailed discussions of various items impacting our business, results of operations and financial condition.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are a biopharmaceutical company focused on the development, manufacture, and commercialization of products that address unmet patient needs, with current focus directed towards rare cardiopulmonary diseases such as pulmonary arterial hypertension (&#8220;PAH&#8221;) and pulmonary hypertension associated with interstitial lung disease (&#8220;PH-ILD&#8221;). We operate through our wholly owned operating subsidiaries, Liquidia Technologies, Inc. (&#8220;Liquidia Technologies&#8221;) and Liquidia PAH, LLC (&#8220;Liquidia PAH&#8221;), formerly known as RareGen, LLC (&#8220;RareGen&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We currently generate revenue pursuant to a promotion agreement between Liquidia PAH and Sandoz Inc. (&#8220;Sandoz&#8221;), dated as of August 1, 2018, as amended (the &#8220;Promotion Agreement&#8221;), sharing profit derived from the sale of Sandoz&#8217;s substitutable generic treprostinil injection (&#8220;Treprostinil Injection&#8221;) in the United States. Liquidia PAH has the exclusive rights to conduct commercial activities to encourage the appropriate use of Treprostinil Injection. We employ a targeted sales force calling on physicians and hospital pharmacies involved in the treatment of PAH and PH-ILD in the United States, as well as key stakeholders involved in the distribution and reimbursement of medicines to treat these patients. We established our commercial presence in the field to support Treprostinil Injection and have since expanded our presence to support the potential launch of YUTREPIA (treprostinil) inhalation powder (&#8220;YUTREPIA&#8221;), further validating our reputation as a company committed to supporting PAH and PH-ILD patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We conduct research, development and manufacturing of novel products by applying our subject matter expertise in cardiopulmonary diseases and our proprietary PRINT&#174; technology, a particle engineering platform, to enable precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Through development of our own products and research with third parties, we have experience applying PRINT across multiple routes of administration and drug payloads including inhaled therapies, vaccines, biologics, nucleic acids and ophthalmic implants, among others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, low effort dry-powder inhaler (&#8220;DPI&#8221;) and by achieving higher dose levels than the labeled doses of current inhaled therapies. On August 16, 2024, the United States Food and Drug Administration (&#8220;FDA&#8221;) (i) granted tentative approval for our New Drug Application (&#8220;NDA&#8221;) for YUTREPIA for the treatment of PAH and PH-ILD and (ii) simultaneously determined that Tyvaso DPI, approved on May&#160;23, 2022, qualifies for a three-year New Clinical Investigation exclusivity for the chronic use of dry powder formulations of treprostinil for the approved indications. As a result, final approval of YUTREPIA for PAH and PH-ILD is currently delayed until after expiry of the three-year regulatory exclusivity for Tyvaso DPI on May&#160;23, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are also developing L606, an investigational, liposomal formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer, which we licensed from Pharmosa Biopharm Inc. (&#8220;Pharmosa&#8221;). L606 is currently being evaluated in an open-label study in the United States for treatment of PAH and PH-ILD with a planned pivotal study for the treatment of PH-ILD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In September 2024, we entered into the Fifth Amendment to the RIFA pursuant to which HCR funded an additional $32.5 million on September 12, 2024, for total funding of $100 million. Additionally, payments due under the RIFA were amended such that the one-time fixed payment previously due in July 2025 is now due in equal payments in January and July 2026. See Note 12&#160;for further information.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On September 12, 2024, we sold shares of our common stock in an underwritten registered public offering for net proceeds of approximately $53.7 million and sold shares of our common stock for net proceeds of approximately $10.0 million in a private offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On October 2, 2024, we and Pharmosa entered into a First Amendment to the Pharmosa License Agreement (the &#8220;First Amendment&#8221;) which, among other things, expands our licensed territory beyond North America to include key markets in Europe, Japan and elsewhere.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;">Concurrently with the execution of the First Amendment we and Pharmosa also entered into a Device License Agreement (the &#8220;Device License Agreement&#8221;). Pursuant to the terms of the Device License Agreement, Pharmosa will provide (i) an exclusive license to Liquidia Technologies for the right to develop, manufacture, use and commercialize Pharmosa&#8217;s next-generation smart-technology nebulizers (the &#8220;Device&#8221;) for use with L606 in most countries (subject to certain exceptions) (the &#8220;Territory&#8221;) and (ii) a non-exclusive license to Liquidia Technologies for the right to develop, manufacture and use (but not commercialize) the Device outside of the Territory.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Since inception, we have incurred significant operating losses. Our net loss was $92.0 million for the nine months ended September&#160;30,&#160;2024 and $78.5 million and $41.0 million for the&#160;years ended December&#160;31,&#160;2023 and 2022, respectively. As of September&#160;30,&#160;2024, we had an accumulated deficit of $521.1&#160;million. We expect to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates through clinical trials, seek regulatory approval of such product candidates and pursue commercialization of any approved product candidates. These efforts require significant amounts of capital, adequate personnel and infrastructure, and extensive compliance-reporting capabilities. Even if our development efforts are successful, it is uncertain when, if ever, we will realize significant revenue from product sales. Additionally, the Revenue Interest Financing Agreement with HealthCare Royalty Partners IV, L.P. (&#8220;HCR&#8221;) dated January 9, 2023, as amended (the &#8220;RIFA&#8221;) contains fixed quarterly payments and minimum cash covenants that require us to maintain cash and cash equivalents in an amount at least equal to $7.5 million during the calendar year beginning on January 1, 2024 and at least equal to $15.0 million for the remainder of the payment term after the calendar year ended December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our future funding requirements will be heavily determined by the timing of the potential commercialization of YUTREPIA and the resources needed to support the development of our product candidates. We expect that we will require additional capital to fund operations as well as to pursue in-licenses or acquisitions of other product candidates. If we are unable to obtain additional funding, we could be required to delay, reduce, or eliminate research and development programs, product portfolio expansion, or future commercialization efforts, which could adversely affect our business prospects, or we may be unable to continue operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Although we expect to continue to generate operating losses for the foreseeable future, we believe that as a result of the recent RIFA funding and net proceeds from the sale of common stock described above, excluding any future YUTREPIA product revenue, our cash and cash equivalents will be sufficient to fund operations, capital expenditures, and RIFA payments and allow us to remain in compliance with our minimum cash covenants pursuant to the RIFA for at least twelve months from the issuance date of these condensed consolidated financial statements. If we have not received full FDA approval and generated sufficient cash from product sales of YUTREPIA or are unable to access additional capital by the date of issuance of our fiscal year 2024 consolidated financial statements, we expect there would be substantial doubt about our ability to continue as a going concern as of that date. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect, which would have a material impact on our operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Components of Consolidated Statements of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-bottom:12pt;margin:0pt;">Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">We primarily generate revenue pursuant to the Promotion Agreement, under which we receive a 50% share in the profit derived from the sale of Treprostinil Injection in the United States. Liquidia PAH has the exclusive rights to conduct commercial activities to encourage the appropriate use of Treprostinil Injection. In May 2021, Liquidia PAH&#8217;s manufacturing partner, Chengdu Shifeng Medical Technologies LTD (&#8220;Chengdu&#8221;) began selling the RG Cartridge, which may be used to supply medications to PAH patients with the CADD-MS 3 pump manufactured by ICU Medical. We are aware of shortages of critical components of the CADD-MS 3 pump that have caused the number of CADD-MS 3 infusion pumps available for the subcutaneous administration of Treprostinil Injection to be limited. Due to this limitation in the availability of pumps, specialty pharmacies are not currently placing new patients on to subcutaneous Treprostinil Injection therapy in order to preserve the available pumps for those patients already receiving subcutaneous </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">administration of Treprostinil Injection. Revenue will continue to be impacted or at risk until new components or alternative pumps are available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-bottom:12pt;margin:0pt;">Cost of Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Cost of revenue consists of (i) an allocation of the cost of our sales force associated with calling on physicians and hospital pharmacies involved in the treatment of PAH with Treprostinil Injection, as well as key stakeholders involved in the distribution and reimbursement of Treprostinil Injection and (ii) amortization of the intangible asset associated with the Promotion Agreement. We amortize the intangible asset associated with the Promotion Agreement in a manner consistent with our recognition of the related revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist of expenses incurred in connection with the development of our product candidates. We expense research and development costs as incurred. These expenses include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred under agreements with contract research organizations as well as investigative sites and consultants that conduct our clinical trials and preclinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing process development and scale-up expenses and the cost of acquiring and manufacturing preclinical and clinical trial materials and commercial materials unless objective and persuasive evidence exists that regulatory approval and subsequent commercialization of a product candidate is probable and where we also expect the future economic benefit from the sales of the product candidate to be realized;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outsourced professional scientific development services;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">employee-related expenses, which include salaries, benefits and stock-based compensation for personnel in research and development functions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses relating to regulatory activities, including filing fees paid to regulatory agencies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">laboratory materials and supplies used to support our research activities; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of acquired product licenses and related technology rights where there is no alternative future use; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allocated facility-related costs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. In the near term we expect that our research and development expenses to increase as we complete manufacturing activities, conduct existing clinical trials, and initiate potential clinical trials. However, levels of research and development spending are highly dependent upon the selection and progression of product candidates. The successful development of our product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the remainder of the development of, or when, if ever, material net cash inflows may commence from any of our product candidates. This uncertainty is due to the numerous risks and uncertainties associated with the duration and cost of clinical trials, which vary significantly over the life of a project as a result of many factors, including:</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of clinical sites included in the trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the length of time required to enroll suitable patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients that ultimately participate in the trials;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of doses patients receive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration of patient follow-up; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of our clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;"><span style="background:#ffffff;">Our expenditures are subject to additional uncertainties, including the terms and timing of regulatory approvals. We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others. A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials, or our ability to manufacture and supply product, we could be required to expend significant additional financial resources and time on the completion of clinical development. Drug commercialization can take several years and millions of dollars in development costs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-bottom:11pt;margin:0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist principally of salaries and related costs for personnel in executive, administrative, finance and legal functions, including stock-based compensation. Other general and administrative expenses include facility-related costs, patent filing and prosecution costs and professional fees for marketing, legal, auditing and tax services and insurance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 11pt 0pt;">Other Income (Expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">Other income (expense) is comprised of interest income and expense and loss on extinguishment of debt. Interest income consists of interest earned on our cash equivalents. Interest expense consists of interest charges on the revenue interest financing payable, finance leases and long-term debt. These charges include monthly recurring interest on such obligations in addition to interest accretion and amortization of debt discounts and issuance costs to interest expense.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 11pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 11pt 0pt;">Three and Nine Months Ended September&#160;30,&#160;2024 compared with the Three and Nine Months Ended September&#160;30,&#160;2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">The following table summarizes the results of our operations for the three and nine months ended September&#160;30,&#160;2024 and 2023, together with the changes in those items in dollars and as a&#160;percentage (in thousands, except for&#160;percentages):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:21.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:21.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:21.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:18.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">%</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:21.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:21.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,448</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,678</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 770</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,079</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,957</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,878)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (14)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:21.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Costs and expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:21.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,565</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 570</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 995</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 175</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,525</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,895</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,630</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 139</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:21.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11,890</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,440</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,450</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 60</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 31,367</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 30,413</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 954</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:21.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,182</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,559</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 9,623</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 91</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 60,374</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,597</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 32,777</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 119</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:21.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total costs and expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 33,637</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,569</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,068</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 81</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 96,266</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 59,905</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 36,361</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 61</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:21.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (29,189)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (14,891)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (14,298)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 96</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (85,187)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (46,948)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (38,239)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 81</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:21.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:21.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,815</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 862</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 953</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 111</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,550</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,518</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,032</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 120</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:21.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,996)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,761)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,235)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 70</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (8,120)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,311)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,809)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 88</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:21.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gain (loss) on extinguishment of debt</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,215</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,215</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,268)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,311)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,957)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 85</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:21.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,034</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (899)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,933</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6,838)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (4,104)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,734)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 67</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:21.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss and comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (23,155)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (15,790)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (7,365)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 47</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (92,025)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (51,052)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (40,973)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 80</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">_______________</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">* Not meaningful</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Revenue was $4.4 million for the three months ended September&#160;30,&#160;2024, compared to $3.7 million for the three months ended September&#160;30,&#160;2023. Revenue related primarily to the Promotion Agreement. The increase of $0.7 million was primarily due to <span style="background:#ffffff;">the impact of higher sales quantities in the current period as compared to the same period in the prior year.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Revenue was $11.1 million for the nine months ended September&#160;30,&#160;2024, compared to $13.0 million for the nine months ended September&#160;30,&#160;2023. Revenue related primarily to <span style="background:#ffffff;">the Promotion Agreement. The decrease of $1.9 million was primarily due to the impact of unfavorable gross-to-net returns adjustments recorded in the current year.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cost of Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cost of revenue was $1.6 million for the three months ended September&#160;30,&#160;2024, compared to $0.6 million for the three months ended September&#160;30,&#160;2023. Cost of revenue related to the Promotion Agreement as noted above. The increase from the prior year was primarily due to our sales force expansion during the fourth quarter of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Cost of revenue was $4.5 million for the nine months ended September&#160;30,&#160;2024, compared to $1.9 million for the nine months ended September&#160;30,&#160;2023. Cost of revenue related to the Promotion Agreement as noted above. The increase from the prior year was primarily due to our sales force expansion during the fourth quarter of 2023.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses were $11.9 million for the three months ended September&#160;30,&#160;2024, compared to $7.4 million for the three months ended September&#160;30,&#160;2023. The increase of $4.5 million or 60% was primarily due to a $2.1 million increase in personnel expenses (including stock-based compensation) related to increased headcount, a $1.3 million increase in clinical expenses related to our L606 program, and a $2.5 million increase in expenses related to YUTREPIA research and development activities, including the ASCENT trial, offset by $1.5 million lower commercial manufacturing expenses reflecting the impact of expensing YUTREPIA inventory costs in the prior year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses were $31.4 million for the nine months ended September&#160;30,&#160;2024, compared to $30.4 million for the nine months ended September&#160;30,&#160;2023. The increase of $1.0 million or 3% was primarily due to a $5.4 million increase in personnel expenses (including stock-based compensation) related to increased headcount, a $4.6 million increase in clinical expenses related to our L606 program, and a $5.2 million increase in expenses related to YUTREPIA research and development activities, including the ASCENT trial, offset by (i) $4.3 million lower commercial manufacturing expenses reflecting the impact of expensing YUTREPIA inventory costs in the prior year and (ii) a $10.0 million upfront license fee due to Pharmosa for the exclusive license in North America to develop and commercialize L606 recorded during the three months ended June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses were $20.2 million for the three months ended September&#160;30,&#160;2024, compared to $10.6 million for the three months ended September&#160;30,&#160;2023. The increase of $9.6 million or 91% was primarily due to <span style="background:#ffffff;">a $6.7 million increase in personnel expenses (including stock-based compensation) driven by higher headcount and expansion of our sales force in the fourth quarter of 2023, </span>a $1.5 million increase in legal fees related to our <span style="background:#ffffff;">ongoing YUTREPIA-related litigation and a $0.5 million increase in commercial expenses in preparation for the potential commercialization of YUTREPIA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses were $60.4 million for the nine months ended September&#160;30,&#160;2024, compared to $27.6 million for the nine months ended September&#160;30,&#160;2023. The increase of $32.8 million or 119% was primarily due to <span style="background:#ffffff;">a $18.9 million increase in personnel expenses (including stock-based compensation) driven by higher headcount and expansion of our sales force in the fourth quarter of 2023, </span>a $5.5 million increase in legal fees related to our <span style="background:#ffffff;">ongoing YUTREPIA-related litigation, and a $6.0 million increase in commercial expenses in preparation for the potential commercialization of YUTREPIA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;background:#ffffff;">Other Income (Expense)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Total other income, net was $6.0 million for the three months ended September&#160;30,&#160;2024, compared with total other expense, net of $0.9 million for the three months ended September&#160;30,&#160;<span style="white-space:pre-wrap;">2023. The variance of $6.9 million was primarily driven by a $7.2 million  gain on extinguishment of debt resulting from the Fifth Amendment to the RIFA, which was executed in September 2024. Additionally, there was a $1.2 million increase in interest expense attributable to the higher borrowings under the RIFA as compared to the prior year and a $1.0 million increase in interest income attributable to higher money market balances.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Total other expense, net was $6.8 million for the nine months ended September&#160;30,&#160;2024, compared with $4.1 million for the nine months ended September&#160;30,&#160;2023. The increase of $2.7 million was primarily driven by a $2.0 million increase in the net loss on extinguishment of debt resulting from the Fourth and Fifth Amendments to the RIFA, which were executed in January 2024 and September 2024, respectively. Additionally, there was a $3.8 million increase in interest expense attributable to the higher borrowings under the RIFA compared to the prior year and a $3.0 million increase in interest income attributable to higher money market balances.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-bottom:12pt;margin:0pt;">Sources of Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We have financed our growth and operations through a combination of funds generated from revenues, the issuance of convertible preferred stock and common stock, bank borrowings, the issuance of convertible notes, and revenue interest financing. Our principal uses of cash have been for working capital requirements and capital expenditures. As of September&#160;30,&#160;2024&#160;and December&#160;31,&#160;2023, we had cash and cash equivalents of&#160;$204.4 million&#160;and $83.7 million, respectively. As of September&#160;30,&#160;2024, we had stockholders&#8217; equity of $110.5 million and an accumulated deficit of $521.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In September 2024, we sold 6,460,674 shares of our common stock in an underwritten registered public offering at an offering price of $8.90 per share (the &#8220;2024 Offering&#8221;) for gross proceeds of approximately $57.5 million, before deducting offering costs of approximately $3.8 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A fund affiliated with Paul B. Manning, a member of our Board of Directors, participated in the 2024 Offering and purchased shares of common stock in an aggregate amount of approximately $3.0 million at the public offering price per share and on the same terms as the other purchasers in the 2024 Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;">Concurrently with the 2024 Offering referenced above, we entered into a common stock purchase agreement with funds managed by Caligan Partners LP (&#8220;Caligan&#8221;), our largest stockholder, for the sale by us in a private placement of an aggregate of 1,123,595 shares of our common stock at a purchase price of $8.90 per share for gross and net proceeds of approximately $10.0 million (the &#8220;Caligan 2024 Private Placement&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">In January 2024, we sold 7,182,532 shares of our common stock in a private placement (the &#8220;2024 Private Placement&#8221;) at a purchase price of $10.442 per share for gross proceeds of approximately $75.0 million, before deducting offering expenses of less than $0.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">In December 2023, we sold 3,491,620 shares of our common stock in an underwritten registered public offering at an offering price of $7.16 per share for gross proceeds of approximately $25.0 million, before deducting offering costs of approximately $1.9 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">In December 2023, we also entered into a common stock purchase agreement with Roger Jeffs, our Chief Executive Officer, for the sale by us in a private placement of an aggregate of 139,665 shares of our common stock at a purchase price of $7.16 per share for gross proceeds of approximately $1.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">In January 2023, we entered into a Revenue Interest Financing Agreement with HealthCare Royalty Partners IV, L.P. (&#8220;HCR&#8221;), as amended (the &#8220;RIFA&#8221;), pursuant to which HCR has agreed to pay us an aggregate investment amount of up to $100.0 million (the &#8220;Investment Amount&#8221;). $32.5 million of the Investment Amount was funded on January 27, 2023, $22.2 million of which was used to satisfy in full and retire our previously outstanding debt with Silicon Valley Bank, with the excess proceeds funded to the Company. An additional $10.0 million of the Investment Amount was funded on July 27, 2023 (the &#8220;Second Tranche Amount&#8221;), which was used to fund payment of the $10.0 million upfront license fee due under the Pharmosa License Agreement. On January 5, 2024, an additional $25.0 million of the Investment Amount was funded. On September 12, 2024, an additional $32.5 million of the Investment Amount was funded. See Note&#160;12 to the condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q for information regarding repayment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-bottom:12pt;margin:0pt;">Future Funding Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">Prior to the potential FDA approval of YUTREPIA and until such time as we can generate significant revenues from its sale, if ever, we anticipate we will incur net losses and negative cash flows. We plan to focus in the near-term on preparations for the potential commercial launch of YUTREPIA, continuing promotion of Treprostinil Injection, investing in research and development efforts for our YUTREPIA and L606 programs, and expanding our corporate infrastructure. We may not be able to complete the development and initiate commercialization of these programs if, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">among other things, our clinical trials are not successful or if the FDA does not approve our product candidates when we expect, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">Our primary uses of capital are, and we expect will continue to be, compensation and related personnel expenses, clinical costs, manufacturing process development costs, external research and development services, laboratory and related supplies, regulatory expenses, legal costs, administrative and overhead costs and repayments under the RIFA. We also expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution as we prepare to potentially receive regulatory approval for YUTREPIA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">Our future funding requirements will be heavily determined by the timing of the potential commercialization of YUTREPIA, the indications, if any, for which YUTREPIA is approved and the resources needed to support the development of our product candidates. Based on our current plans, we expect that we will require additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We expect that, excluding any future YUTREPIA product revenue, our cash and cash equivalents will be sufficient to fund operations, capital expenditures, and RIFA payments and allow us to remain in compliance with our minimum cash covenants pursuant to the RIFA for at least twelve months from the issuance date of these condensed consolidated financial statements. If we have not received full FDA approval and generated sufficient cash from product sales of YUTREPIA or are unable to access additional capital by the date of issuance of our fiscal year 2024 consolidated financial statements, we expect there would be substantial doubt about our ability to continue as a going concern as of that date. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect, which would have a material impact on our operations. See Note 1 to the condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q for information regarding our ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may raise additional capital through licensing activities, other business arrangements or the sale of equity or convertible debt securities. In such an event, the ownership of our existing shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights associated with holdings of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceuticals, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and characteristics of the product candidates we pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of manufacturing our product candidates and any product we successfully commercialize;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs and the outcome of such litigation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, receipt and amount of sales of, or milestone payments related to or royalties on, our current or future product candidates, if any.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">See &#8220;Risk Factors&#8221; for additional risks associated with our substantial capital requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our sources and uses of cash and cash equivalents:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash provided by (used in):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (72,609)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (25,582)</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,661)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (11,082)</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 196,959</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19,606</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net increase (decrease) in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 120,689</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (17,058)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities increased $47.0 million to $72.6 million for the nine months ended September&#160;30,&#160;2024 compared to $25.6 million for the nine months ended September&#160;30,&#160;2023. The increase was primarily due to $38.7 million higher net loss adjusted for non-cash items and unfavorable working capital changes of $8.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities was $3.7 million for the nine months ended September&#160;30,&#160;2024 compared to $11.1 million for the nine months ended September&#160;30,&#160;2023. During the nine months ended September&#160;30,&#160;2024, net cash used in investing activities related to property, plant and equipment purchases. During the nine months ended September&#160;30,&#160;2023, we made a $10.0 million upfront license fee payment to Pharmosa for the exclusive license in North America to develop and commercialize L606 and paid $1.1 million for property, plant and equipment purchases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financing activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities was $197.0 million during the nine months ended September&#160;30,&#160;2024, compared to $19.6 million during the nine months ended September&#160;30,&#160;2023. During the nine months ended September&#160;30,&#160;2024, we received $138.9 million net proceeds from the sale of common stock primarily relating to the 2024 Offering and 2024 Private Placement, $57.5 million net proceeds from the RIFA, and $2.9 million from the issuance of common stock under stock incentive plans. These inflows were offset by $2.7 million in payments under the RIFA. During the nine months ended September&#160;30,&#160;2023, we received $41.7 million net proceeds from the RIFA of which $22.2 million was used to repay our indebtedness to Silicon Valley Bank.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Contractual Obligations and Commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><i style="font-style:italic;">Milestone and Royalty Obligations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">Under the UNC License Agreement, the Company is obligated to pay UNC royalties equal to a low single digit percentage of all net sales of drug products whose manufacture, use or sale includes any use of the technology or patent rights covered by the UNC License Agreement, including YUTREPIA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2012, we entered into an agreement, as amended, with Chasm Technologies,&#160;Inc. for manufacturing consulting services related to our manufacturing capabilities during the term of the agreement. We agreed to pay future contingent milestones and royalties, totaling no more than $1.5 million, $0.2 million of which was accrued as of September&#160;30,&#160;2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In December 2022, we entered into a Device Development and Supply Agreement (the &#8220;Pump Development Agreement&#8221;) with Mainbridge Health Partners, LLC (&#8220;Mainbridge&#8221;) and Sandoz Inc. (&#8220;Sandoz&#8221;). The Pump Development Agreement provides for the cooperation between us, Sandoz and Mainbridge to develop a new pump that </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">is suitable for the subcutaneous administration of Treprostinil Injection. Mainbridge will perform all development, validation and testing activities required for the pump and related consumables in anticipation of submitting a 510(k) clearance application for the pump to the FDA. In connection with the Pump Development Agreement, we and Sandoz have agreed to pay Mainbridge certain future contingent milestone payments in accordance with the terms and conditions set forth therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June 2023, we entered into a License Agreement with Pharmosa Biopharm Inc. (&#8220;Pharmosa&#8221;) pursuant to which we were granted an exclusive license in North America to develop and commercialize L606, an inhaled, sustained-release formulation of treprostinil currently being evaluated in a clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), and a non-exclusive license for the manufacture, development and use (but not commercialization) of such licensed product in most countries outside North America. In consideration for these exclusive rights, we will pay Pharmosa potential development milestone payments tied to PAH and PH-ILD indications of up to $30 million, potential sales milestones of up to $185 million and two tiers of low, double-digit royalties on net sales of L606. Pharmosa will also receive a $10 million milestone payment for each additional indication approved after PAH and PH-ILD and each additional product approved under the license. Concurrently with the execution of the Pharmosa License Agreement, we also entered into an Asset Transfer Agreement with Pharmosa pursuant to which Pharmosa will transfer its inventory of physical materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><i style="font-style:italic;">Purchase Obligations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">We enter into contracts in the normal course of business with contract service providers to assist in the performance of our research and development and manufacturing activities. Subject to required notice periods and our obligations under binding purchase orders, we can elect to discontinue the work under these agreements at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">On July 14, 2023, the Company entered into an Amended and Restated Commercial Manufacturing Services and Supply Agreement with Lonza Tampa LLC. Pursuant to the terms of the Agreement, Lonza provides us with manufacturing and storage services for YUTREPIA inhalation powder. We will deliver bulk treprostinil powder, manufactured using our proprietary PRINT&#174; technology, and Lonza will encapsulate and package the Product. Under the terms of the Agreement, we have agreed that upon any Termination for FDA Rejection or Termination for FDA Delay, we would reimburse Lonza for 50% of its documented out-of-pocket expenditures for any capital equipment that is purchased by Lonza after the effective date of the Agreement to perform the services for us, not to exceed $2.5 million in the aggregate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">In addition, we have entered into a multi-year supply agreement with LGM Pharma, LLC (&#8220;LGM&#8221;) to supply active pharmaceutical ingredients for YUTREPIA. Under our supply agreement with LGM, we are required to provide rolling forecasts, a portion of which will be considered a binding, firm order, subject to an annual minimum purchase commitment of $2.7 million for the term of the agreement. The agreement expires five&#160;years from the first marketing authorization approval of YUTREPIA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30,&#160;2024, we have non-cancelable commitments for product supply and manufacturing costs of approximately $14.7 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><i style="font-style:italic;">Lease Obligations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We have operating lease obligations including rental amounts due on leases of certain laboratory, manufacturing and office space and equipment under the terms of non-cancelable operating leases. These leases expire at various times through October&#160;2026. Minimum operating lease payments are $0.3 million in the remaining three months of 2024, $1.4 million in 2025, and $1.2 million in 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;margin:0pt;"><i style="font-style:italic;">Other Obligations and Contingencies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We from time-to-time are subject to claims and litigation in the normal course of business,&#160;none&#160;of which we believe represent a risk of material loss or exposure.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have agreements with certain employees and an Executive Severance and Change in Control Plan which covers certain other employees which require payments if certain events, such as a change in control or termination without cause, occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:11pt;margin:0pt;">Critical Accounting Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">We prepare our consolidated financial statements in conformity with U.S. GAAP. The preparation of these financial statements requires the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the periods presented. Actual results could differ from those estimates and assumptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">While we describe our significant accounting policies in Note&#160;2 to the condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q, we have identified the following critical accounting estimates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;padding-bottom:12pt;margin:0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;background:#ffffff;margin:0pt;">As part of the process of preparing our condensed consolidated financial statements, we are required to estimate our incurred expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our condensed consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">We base our expenses related to CROs and CMOs on our estimates of the services received and efforts expended pursuant to quotations and contracts with such vendors that conduct research and development and manufacturing activities on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented within this Quarterly Report on Form 10-Q.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Interest Financing Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We recognized a liability related to amounts received in January 2023, July 2023, January 2024, and September 2024 pursuant to the RIFA with HCR under ASC 470-10, <i style="font-style:italic;">Debt</i> and ASC 835-30, <i style="font-style:italic;">Interest - Imputation of Interest</i>. The liability will be accreted under the effective interest method based upon the estimated amount of future payments to be made pursuant to the RIFA. If the timing or amounts of any estimated future payments change, we will prospectively adjust the effective interest and the related amortization of the liability. A significant increase or decrease in these estimates could materially impact the liability balance and related interest expense. See Note 12 to the condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q for additional information.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Prelaunch Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We capitalize prelaunch inventory prior to receiving regulatory approval if regulatory approval and subsequent commercialization of a product is probable and we also expect future economic benefit from the sales of the product to be realized. Prior to this conclusion, we expense prelaunch inventory as research and development expense in the period incurred. For prelaunch inventory that is capitalized, we consider a number of specific facts and circumstances, including the product&#8217;s historical shelf life, the product's current status in the development and regulatory approval process, results from related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential obstacles to the approval process, viability of commercialization and market trends. In late 2023, based on our assessment of the legal and regulatory process related to YUTREPIA, we concluded that we met the criteria to capitalize expenditures for prelaunch inventory. We capitalized $7.4 million of prelaunch inventory as of September&#160;30,&#160;2024 and none as of December&#160;31,&#160;2023. We do not have an allowance for inventory obsolescence as of September&#160;30,&#160;2024. If either regulatory approval or market acceptance post-approval of YUTREPIA do not occur at all or on a timely basis prior to the inventory shelf-life expiration,&#160;we may be required to write-off some or all prelaunch inventory, which could affect our financial condition and financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Smaller Reporting Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As a &#8220;smaller reporting company,&#8221; as defined under Rule&#160;12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, in addition to providing reduced disclosure about our executive compensation arrangements and business developments, among other reduced disclosure requirements available to smaller reporting companies, we present only two&#160;years of audited financial statements in addition to any required unaudited interim financial statements with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We will be able to take advantage of these scaled disclosures for so long as (i) our common stock held by non-affiliates is less than $250 million measured on the last business day of our second fiscal quarter, or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and our common stock held by non-affiliates is less than $700 million measured on the last business day of our second fiscal quarter. To the extent we take advantage of any reduced disclosure obligations, it may make it harder for investors to analyze the Company&#8217;s results of operations and financial prospectus in comparison with other public companies. Until we cease to be a smaller reporting company, the scaled-back disclosure in our SEC filings will result in less information about our company being available than for other public companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Off-Balance Sheet Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules&#160;and regulations of the SEC.</p><a id="_bb442595_f01d_4e81_9000_233101ae9bce"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_c7c67afd_4310_42ad_8251_c22d80c620be"></a><a id="Item4ControlsandProcedures_859066"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4. Controls and Procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Evaluation of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">As of September&#160;30,&#160;2024, management, with the participation of the Chief Executive Officer and Chief Financial Officer, performed an evaluation of the effectiveness of the design and operation of the Company's disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on this evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures were effective&#160;at the reasonable assurance level <span style="color:#212529;">as of September&#160;30,&#160;2024.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">There were no changes in our internal control over financial reporting during the quarter ended September&#160;30,&#160;2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_78c2eda9_2f1a_4d37_8916_edb92f8fa5b3"></a><a id="PARTII_408667"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">PART&#160;II. OTHER INFORMATION.</p><a id="Item1LegalProceedings_577079"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1. Legal Proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For information on our legal proceedings, see Note 14 &#8220;Legal Proceedings&#8221; to the condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q. </p><a id="_9e2a3191_06d4_4045_9b6e_2129b9998ba4"></a><a id="Item1ARiskFactors"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1A. Risk Factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.8pt 12pt 0pt;"><i style="font-style:italic;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Quarterly Report on Form 10-Q, including our financial statements and the related notes thereto, </i>&#8220;<i style="font-style:italic;">Management</i>&#8217;<i style="font-style:italic;">s Discussion and Analysis of Financial Condition and Results of Operations,</i>&#8221;<i style="font-style:italic;"> and the information contained under the heading </i>&#8220;<i style="font-style:italic;">Cautionary Note Regarding Forward-Looking Statements</i>&#8221;<i style="font-style:italic;"> before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. We may update these risk factors in our periodic and other filings with the SEC.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of the principal risk factors described in this section:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We expect to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates through clinical trials, seek regulatory approval and pursue commercialization of any approved product candidates. The future viability of our company will depend on our ability to fund future operations and capital requirements with potential sales of any approved product candidates and/or with additional capital from external financing.</span></td><td style="width:3.8pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have a history of losses and our future profitability remains uncertain.</span></td><td style="width:3.8pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are primarily dependent on the success of our product candidates, YUTREPIA and L606, and these product candidates may fail to receive final marketing approval (in a timely manner or at all) for some or all of the indications for which we are seeking approval or may not be commercialized successfully.</span></td><td style="width:3.8pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">United Therapeutics has initiated multiple lawsuits against us in which it has claimed that YUTREPIA is infringing its patents, a separate lawsuit against us that we and a former United Therapeutics employee, who later joined us as an employee, conspired to misappropriate certain trade secrets of United Therapeutics and engaged in unfair or deceptive trade practices, and a separate lawsuit against the FDA asserting that the FDA improperly accepted for review an amendment to our NDA for YUTREPIA. These lawsuits, and other lawsuits that United Therapeutics may file in the future, may result in our company being further delayed in its efforts to commercialize YUTREPIA or result in substantial damage claims against us if we launch YUTREPIA and we are later found to infringe.</span></td><td style="width:3.8pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Liquidia PAH does not hold the FDA regulatory approval for Treprostinil Injection, the RG Cartridge or pumps used to administer Treprostinil Injection and is dependent on Sandoz, Chengdu and the pump manufacturers to manufacture and supply Treprostinil Injection, the RG Cartridge and pumps used to administer Treprostinil Injection, respectively, in compliance with FDA requirements, and is more broadly dependent on their FDA and healthcare compliance relative to Treprostinil Injection, the RG Cartridge and the pumps used to administer Treprostinil Injection, respectively.</span></td><td style="width:3.8pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Treprostinil Injection is presently administered subcutaneously via ICU Medical&#8217;s CADD-MS 3 infusion pump. ICU Medical no longer manufactures the CADD-MS 3 infusion pump and has indicated its intention to discontinue service and maintenance of CADD-MS 3 infusion pumps </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">after January&#160;1, 2025. Should components of the CADD-MS 3 pump become unavailable, ICU Medical&#8217;s ability to service and maintain such pumps may terminate earlier than anticipated. For instance, during 2022 we became aware of a potential shortage of a critical component of the CADD-MS 3 infusion pump that may cause the number of CADD-MS 3 infusion pumps available for the administration of Treprostinil Injection to </span></td><td style="width:3.8pt;"/></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">be depleted prior to January&#160;1, 2025. In the event the specialty pharmacies are unable to access sufficient quantities of operable pumps or in the event we are unable to identify or develop a new pump prior to the current pumps becoming unavailable, the commercial success of Treprostinil Injection may be adversely affected.</span></td><td style="width:3.8pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Sales of Treprostinil Injection are dependent on market acceptance of generic treprostinil for parenteral administration and the medical devices used for administration of Treprostinil Injection, including the ICU Medical infusion pumps, any future pumps that we develop, and the RG Cartridge, by patients, health care providers and by third-party payors, while interactions with these persons and entities are subject to compliance requirements. The commercial success of Treprostinil Injection may also be impacted by increasing generic competition which may result in declining prices for Treprostinil Injection.</span></td><td style="width:3.8pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We expect that we will need further financing for our existing business and future growth, which may not be available on acceptable terms, if at all. Failure to obtain funding on acceptable terms and on a timely basis may require us to curtail, delay or discontinue our product development efforts or other operations. The failure to obtain further financing may also prevent us from capitalizing on other potential product candidates or indications which may be more profitable than YUTREPIA and/or L606 or for which there may be a greater likelihood of success.</span></td><td style="width:3.8pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We face significant competition from large pharmaceutical companies, among others, in developing our products and in gaining regulatory approval to bring them to market in time to achieve commercial success, and our operating results will suffer if we are unable to compete effectively, including if one or more such products have a superior product profile to YUTREPIA and/or L606.</span></td><td style="width:3.8pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our financing facility with HCR contains operating and financial covenants that restrict our business and financing activities, and is subject to acceleration in specified circumstances, which may result in HCR taking possession and disposing of any collateral.</span></td><td style="width:3.8pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our products may not achieve market acceptance or third-party payor coverage.</span></td><td style="width:3.8pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our product candidates are based on proprietary, novel technology, which have not been used to manufacture any products that have been previously approved by the FDA, making it difficult to predict the time and cost of development and of subsequently obtaining final regulatory approval. In addition, we may experience unexpected challenges as we ramp up our manufacturing capacity to meet demand or during commercial manufacturing, which may result in our inability to supply sufficient quantities of product to meet demand.</span></td><td style="width:3.8pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our business and operations </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may be adversely affected by the effects of health epidemics.</span></td><td style="width:3.8pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not be able to build or maintain a commercial operation, including establishing and maintaining marketing and sales capabilities or entering into agreements with third parties to market and sell our drug products.</span></td><td style="width:3.8pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We depend on third parties for clinical and commercial supplies, including single suppliers for the active ingredient, the device, encapsulation and packaging of YUTREPIA and single suppliers for the drug product and device for L606. In the event of any disruption in these supplies, our ability to develop and commercialize, and the timeline for commercialization of, YUTREPIA and/or L606 may be adversely affected.</span></td><td style="width:3.8pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely on third parties to conduct our preclinical studies and clinical trials.</span></td><td style="width:3.8pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may become involved in litigation to protect our intellectual property, to enforce our intellectual property rights or to defend against claims of intellectual property infringement by third parties, which could be expensive, time-consuming and may not be successful.</span></td><td style="width:3.8pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We depend on skilled labor, and our business and prospects may be adversely affected if we lose the services of our skilled personnel, including those in senior management, or are unable to attract new skilled personnel. </span></td><td style="width:3.8pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We expect that the market price of our common stock may be volatile, and you may lose all or part of your investment.</span></td><td style="width:3.8pt;"/></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">As a public company, we are obligated to develop and maintain proper and effective internal control over financial reporting and any failure to do so may adversely affect investor confidence in us and, as a result, the trading price of our shares.</span></td><td style="width:3.8pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to our Financial Position and Need for Additional Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We expect to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates through clinical trials, seek regulatory approval and pursue commercialization of any approved product candidates. The future viability of our company will depend on our ability to fund future operations and capital requirements with potential sales of any approved product candidates and/or with additional capital from external financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.8pt 0pt 0pt;">We are subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, and the ability to secure additional capital to fund operations. We expect to incur significant expenses and may incur significant operating losses for the foreseeable future as we advance product candidates through clinical trials, seek regulatory approval and pursue commercialization of any approved product candidates. We do not expect to generate significant revenue unless and until we are able to obtain marketing approval for and successfully commercialize one or more of our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we would incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. These efforts require significant amounts of capital, adequate personnel and infrastructure, and extensive compliance-reporting capabilities. <span style="color:#212529;background:#ffffff;">If we have not received full FDA approval and generated sufficient cash from product sales of YUTREPIA or are unable to access additional capital by the date of issuance of our fiscal year 2024 consolidated financial statements, we expect there would be substantial doubt about our ability to continue as a going concern as of that date.&#160;</span>We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect, which would have a material impact on our operations. Even if our development efforts are successful, it is uncertain when, if ever, we will realize significant revenue from product sales. The future viability of our company will depend on our ability to fund future operations and capital requirements with potential sales of any approved product candidates and/or with additional capital from external financing. We may seek additional funding through public or private financings, debt financing or collaboration. Our inability to obtain funding, when needed, would have a negative impact on our financial condition and ability to pursue our business strategies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.8pt 0pt 7.2pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have a history of losses and our future profitability remains uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.8pt 0pt 0pt;">We have incurred net losses of $92.0 million during the nine months ended September&#160;30,&#160;2024, and $78.5 million and $41.0&#160;million during the years ended December&#160;31, 2023 and&#160;2022, respectively. We also had negative operating cash flows for each of these periods. As of September&#160;30,&#160;2024, we had an accumulated deficit of $521.1&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.8pt 0pt 0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.8pt 0pt 0pt;">Since our incorporation, we have invested heavily in the development of our product candidates and technologies, as well as in recruiting management and scientific personnel. To date, we have not commenced the commercialization of our product candidates and all of our revenue has been derived from up-front fees and milestone payments made to us in connection with licensing and collaboration arrangements we have entered into and the Promotion Agreement, under which we share in the profit derived from the sale of Treprostinil Injection in the United States. These up-front fees and milestone payments have been, and combined with revenue generated from Treprostinil Injection may continue to be, insufficient to match our operating expenses. We expect to continue to devote substantial financial and other resources to the clinical development of our product candidates and, as a result, must generate significant revenue to achieve and maintain profitability or we will need to raise additional capital to continue funding clinical development. We may continue to incur losses and negative cash flow and may never transition to profitability or positive cash flow.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.8pt 0pt 0pt;">&#160;</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We expect that we will need further financing for our existing business and future growth, which may not be available on acceptable terms, if at all. Failure to obtain funding on acceptable terms and on a timely basis may require us to curtail, delay or discontinue our product development efforts or other operations. The failure to obtain further financing may also prevent us from capitalizing on other potential product candidates or indications which may be more profitable than YUTREPIA and/or L606 or for which there may be a greater likelihood of success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.8pt 0pt 0pt;"><span style="white-space:pre-wrap;">We expect that we will need to raise additional funds to meet our future funding requirements for the continued research, development and commercialization of our product candidates and technology. Our future funding requirements will be heavily determined by the timing of the potential commercialization of YUTREPIA and the resources needed to support development of our product candidates.  In the event that funds generated from our operations are insufficient to fund our future growth, we may raise additional funds through the issuance of equity or debt securities or by borrowing from banks or other financial institutions. We cannot assure you that we will be able to obtain such additional financing on terms that are acceptable to us, or at all. Global and local economic conditions could negatively affect our ability to raise funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of such securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Such financing, even if obtained, may be accompanied by restrictive covenants that may, among others, limit our ability to pay dividends or require us to seek consent for payment of dividends, or restrict our freedom to operate our business by requiring consent for certain actions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.8pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.8pt 0pt 0pt;">If we fail to obtain financing on terms that are favorable to us, we will not be able to implement our growth plans, and we may be required to significantly curtail, delay or discontinue one or more of our research, development or manufacturing programs or the commercialization of any approved product. Furthermore, if we fail to obtain additional financing on terms that are acceptable to us, we may forgo or delay the pursuit of opportunities presented by other potential product candidates or indications that may later prove to have greater commercial potential than the product candidates and indications that we have chosen to pursue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.8pt 0pt 0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our financing facility with HCR contains operating and financial covenants that restrict our business and financing activities, and is subject to acceleration in specified circumstances, which may result in HCR taking possession and disposing of any collateral.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the RIFA, we may not, among other actions, without the prior written consent of HCR, (a) pay any dividends or make any other distribution or payment or redeem, retire or purchase any capital stock, except in certain prescribed circumstances, (b) create, incur, assume, or be liable with respect to any indebtedness except certain permitted indebtedness, or make or permit any payment on any indebtedness, except under certain limited circumstances, or (c) make any sale, transfer, out-license, lease or other disposition of any property or any economic interest, other than certain limited exceptions. Additionally, we are required (i) during the period from January 1, 2024 through December 31, 2024, to maintain at all times a minimum cash balance of $7.5 million, and (ii) during all periods after December 31, 2024, to maintain at all times a minimum cash balance of $15.0 million. Our obligations under the RIFA are collateralized by all of our assets and property, subject to limited exceptions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we breach certain of our covenants in the RIFA and are unable to cure such breach within the prescribed period or are not granted waivers in relation to such breach, it may constitute an event of default under the RIFA, giving HCR the right to require us to repay the then outstanding obligations immediately, and HCR could, among other things, foreclose on the collateral granted to them to collateralize such indebtedness, which includes our intellectual property, if we are unable to pay the outstanding debt immediately.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our management has broad discretion in using the net proceeds from our financing facility with HCR and prior equity offerings and may not use them effectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are using the net proceeds of our financing facility with HCR, our September 2024 public equity offering, the September 2024 Private Placement, the January 2024 Private Placement, our December 2023 public equity offering, the December 2023 Private Placement and prior public and private equity offerings to support the development and commercialization of YUTREPIA, including the potential commercial launch of YUTREPIA in the event of final FDA </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">approval, the commercialization of Treprostinil Injection, the development and servicing of pumps for the administration of Treprostinil Injection, the development of L606, and for general corporate purposes. Our management has broad discretion in the application of such proceeds and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our equity. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, diminish cash flows available to service our obligations to HCR, cause the value of our equity to decline and delay the development of our product candidates. Pending their use, we may invest such proceeds in short-term, investment-grade, interest-bearing securities, which may not yield favorable returns.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our ability to use our net operating loss carry forwards and certain other tax attributes may be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.8pt 0pt 0pt;">Under Section 382 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), if a corporation undergoes an &#8220;ownership change&#8221;, generally defined as a greater than 50.0% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research tax credits, to offset its post-change income may be limited. With our September 2024 public equity offering, the September 2024 Private Placement, the January 2024 Private Placement, our December 2023 public equity offering, the December 2023 Private Placement, our April 2022 public equity offering, our 2021 private placement, the closing of the RareGen acquisition in November 2020, our July 2020 public equity offering, our December 2019 private placement, issuances under our prior at-the-market facility, our March 2019 follow-on equity offering and our July 2018 initial public offering, as well as other past transactions, we may have already triggered an &#8220;ownership change&#8221; limitation. We have not completed a formal study to determine if any &#8220;ownership changes&#8221; within the meaning of IRC Section 382 have occurred. If &#8220;ownership changes&#8221; within the meaning of Section 382 of the Code have occurred, and if we earn net taxable income, our ability to use our net operating loss carryforwards and research and development tax credits generated since inception to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us and could require us to pay U.S. federal income taxes earlier than would be required if such limitations were not in effect. Similar rules and limitations may apply for state income tax purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 3.8pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes to existing tax laws, or challenges to our tax positions could adversely affect our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The tax regimes to which we are subject or under which we operate are unsettled and may be subject to significant change. The issuance of additional guidance related to existing or future tax laws, or changes to tax laws or regulations proposed or implemented by the current or a future U.S. presidential administration, Congress, or taxing authorities in other jurisdictions could materially affect our tax obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For example, beginning in 2022, the Tax Cuts and Jobs Act of 2017 eliminated the option to deduct research and development expenditures in the year incurred and instead requires taxpayers to capitalize and subsequently amortize such expenditures over five years for research activities conducted in the United States and over 15 years for research activities conducted outside the United States. In January 2024, the U.S. House of Representatives passed the Tax Relief for American Families and Workers Act, which would retroactively repeal for 2022 and 2023, and defer until 2026, the requirement to capitalize research and development expenditures for research activities conducted in the United States. Uncertainty exists as to whether the bill will be enacted into law. As another example, in August 2022, the Inflation Reduction Act of 2022 was enacted, and, among other things, included a new 15% alternative minimum tax on the adjusted financial statement income of certain large corporations for tax years beginning after December 31, 2022. To the extent that such changes have a negative impact on us, including as a result of related uncertainty, these changes could adversely impact our business, results of operations and financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition, U.S. federal, state and local tax laws are extremely complex and subject to various interpretations. Although we believe that our tax estimates and positions are reasonable, there can be no assurance that our tax positions will not be challenged by relevant tax authorities. If the relevant tax authorities assess additional taxes on us, this could result in adjustments to, or impact the timing or amount of, taxable income, deductions or other tax allocations, which may adversely affect our results of operations and financial position.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are a late-stage clinical biopharmaceutical company with no approved products and no historical revenue from the sale of our own products, which may make it difficult for you to evaluate our business, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;">We are a late-stage clinical biopharmaceutical company with no history of commercial operations upon which you can evaluate our prospects other than the activities we have undertaken with respect to the Promotion Agreement with Sandoz. Drug product development involves a substantial degree of uncertainty. Our operations to date have been limited to engaging in promotional and nonpromotional activities under the Promotion Agreement with Sandoz, developing our PRINT technology, undertaking preclinical studies and clinical trials for our product candidates and collaborating with pharmaceutical companies, including GSK, to expand the applications for our PRINT technology through licensing as well as joint product development arrangements. We have not obtained final marketing approval for any of our product candidates and, accordingly, have not demonstrated an ability to generate revenue from our own pharmaceutical products or successfully overcome the risks and uncertainties frequently encountered by companies undertaking drug product development. Consequently, your ability to assess our business, financial condition and prospects may be significantly limited. Further, the net losses that we incur may fluctuate significantly from quarter-to-quarter and year-to-year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. Other unanticipated costs may also arise in connection with the development of our product candidates and commercialization of any approved products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidia PAH does not hold the FDA regulatory approval for Treprostinil Injection and is dependent on Sandoz to manufacture and supply Treprostinil Injection in compliance with FDA requirements, and is more broadly dependent on Sandoz&#8217;s FDA and healthcare compliance relative to Treprostinil Injection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;">Sandoz holds the FDA approval, or the ANDA, for and controls Treprostinil Injection and is responsible among other things for the compliant manufacture, distribution, labeling, and advertising of Treprostinil Injection. As a result, we are dependent on Sandoz to manufacture and supply Treprostinil Injection, and are dependent on Sandoz for the continued FDA compliance of Treprostinil Injection. We do not have control over Sandoz&#8217;s compliance with laws and regulations applicable to drug manufacturers and ANDA holders (for example, applicable current good manufacturing practices, or cGMPs; FDA labeling, promotional labeling, and advertising requirements; pharmacovigilance and adverse event reporting; and other ongoing FDA reporting and submission requirements), nor over its compliance with healthcare compliance and fraud, waste, and abuse laws, or similar regulatory requirements and other laws and regulations, such as those related to environmental health and safety matters. In addition, we have no control over the ability of Sandoz to maintain adequate quality control, quality assurance and qualified personnel, or other personnel with roles related to the regulatory compliance of Treprostinil Injection and its labeling, promotion, and advertising or of Sandoz&#8217;s activities in relation to government healthcare programs. If the FDA or a comparable foreign regulatory authority finds deficiencies with the manufacture or quality assurance of Treprostinil Injection or identifies safety or efficacy concerns related to Treprostinil Injection, or if Sandoz otherwise is unable to comply with applicable laws, regulations and standards, Sandoz&#8217;s ability to manufacture, sell and supply Treprostinil Injection could be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;">Sandoz&#8217;s ability to consistently manufacture and supply Treprostinil Injection in a timely manner may also be interrupted by production shortages or other supply interruptions. Our share of net profits under the Promotion Agreement is reduced by certain manufacturing costs and other write-offs related to Sandoz&#8217;s inability to sell Treprostinil Injection, including in the event that Treprostinil Injection expires prior to sale. Currently, Treprostinil Injection expires 24 months after the date of manufacture.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sales of Treprostinil Injection are dependent on market acceptance of generic treprostinil for parenteral administration by patients, health care providers and by third-party payors, while interactions with these persons and entities are subject to compliance requirements. The commercial success of Treprostinil Injection may also be impacted by increasing generic competition which may result in declining prices for Treprostinil Injection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;">Our ability to sell Treprostinil Injection is dependent on market acceptance of generic treprostinil for parenteral administration by patients, health care providers and by third-party payors. If Treprostinil Injection does not achieve an adequate level of acceptance, we may not generate sufficient revenue to offset our cost of revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;">At the same time, arrangements with healthcare providers, physicians, third-party payors and customers, and our sales, marketing and educational activities, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain our business or financial arrangements and relationships.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;">The degree of market acceptance of Treprostinil Injection will depend on a number of factors, including:&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy, safety and potential advantages compared to alternative treatments;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to offer Treprostinil Injection for sale at competitive prices (generic drug prices, after initial generic entry, have been observed to decline with the entrance of additional generic competition);</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the convenience and ease of administration compared to alternative treatments;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product labeling or product insert requirements of the FDA or foreign regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling, including any black box warning;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new treatments, including the generic version of a brand, and of physicians to prescribe such treatments;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to hire and retain sales and marketing personnel and their ability to support Sandoz under the Promotion Agreement;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of Sandoz&#8217;s manufacturing and distribution support;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the requirement by third-party payors to use generic treprostinil for parenteral administration in place of Remodulin;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain availability of medical devices used to administer Treprostinil Injection and preferences of the target patient population and health care providers regarding the medical devices used to administer Treprostinil Injection versus medical devices used to administer Remodulin;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of third-party coverage and adequate reimbursement for Treprostinil Injection;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any restrictions on the use of Treprostinil Injection together with other medications; </span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our and Sandoz&#8217;s ability to maintain relationships with the specialty pharmacies; and</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the services provided by specialty pharmacies related to use of Treprostinil Injection.</span></td><td style="width:7.2pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our business may also be impacted by the need to maintain compliant operations (including oversight and monitoring of personnel and our activities) in relation to interactions with the persons and parties noted above, relative to FDA and healthcare law requirements, and with consideration of government and industry compliance best practices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Medical devices, which we do not control, are necessary for the administration of Treprostinil Injection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In order for Treprostinil Injection to be administered to patients, patients must use certain other medical equipment, including pumps, cartridges and infusion sets. We do not manufacture or control such medical equipment, which is manufactured by third parties and owned and dispensed by specialty pharmacies, hospitals or other third parties. Our ability to serve patients is dependent upon the ability of specialty pharmacies to maintain sufficient inventory of such medical equipment to provide to patients. If manufacturers cease to manufacture or support medical equipment or if specialty pharmacies are unable to obtain or maintain sufficient inventories of such medical equipment, our sales may be adversely impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have worked with Chengdu to develop the RG Cartridge, which received FDA 510(k) clearance in March 2021. The ability of patients to administer Treprostinil Injection through subcutaneous injection is dependent on the continued availability of the RG Cartridge. If the RG Cartridge experiences any quality problems, recalls or other adverse events, our ability to provide Treprostinil Injection to patients who receive treprostinil through subcutaneous injection will be limited.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, to administer Treprostinil Injection through subcutaneous injection, patients currently must use the CADD-MS 3 infusion pump manufactured by ICU Medical. ICU Medical no longer manufactures the CADD-MS 3 infusion pump and has indicated that they will no longer support the CADD-MS 3 infusion pump. Although we believe that the number of available CADD-MS 3 infusion pumps will be sufficient to serve patients through 2025, it is possible that the availability of CADD-MS 3 infusion pumps could end earlier. Due to this limitation in the availability of pumps, specialty pharmacies will limit the number of patients that they place on subcutaneous Treprostinil Injection therapy in order to ensure that patients placed on subcutaneous administration of Treprostinil Injection will not have to discontinue such treatment due to the unavailability of pumps. Until we are able to obtain a pump to replace the CADD-MS 3, the number of patients that can receive subcutaneous administration of Treprostinil Injection will continue to be constrained, which would continue to adversely affect sales of Treprostinil Injection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We are seeking to work with third parties to develop or procure other pumps that can be used to administer Treprostinil Injection in the future. For example, we have entered into an agreement with Sandoz and Mainbridge to develop a new pump that can be used to administer Treprostinil Injection in the future. Such pumps will require FDA 510(k) clearance before they can be sold. There is no guarantee that we or our partners will receive FDA 510(k) clearance for any such pumps or, even if they do receive FDA 510(k) clearance for any such pumps, that they will do so in a timely manner. For example, we have still not submitted a 510(k) clearance application and are currently uncertain when, if ever, such a 510(k) clearance application will be submitted.  If we are unable to identify, develop and obtain any required FDA clearance for new pumps for the subcutaneous administration of Treprostinil Injection prior to the unavailability of the CADD-MS 3, we may no longer be able to serve patients with Treprostinil Injection through the subcutaneous route of administration.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Failure by us or third parties to successfully develop or supply the medical equipment or to obtain or maintain regulatory approval or clearance of such medical equipment could negatively impact the market acceptance of and sales of Treprostinil Injection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We maintain our cash at financial institutions, often in balances that exceed federally insured limits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our cash is held in non-interest-bearing and interest-bearing accounts at multiple banking institutions that may exceed the Federal Deposit Insurance Corporation, or the FDIC insurance limits. If such banking institutions were to fail, we could lose all or a portion of those amounts held in excess of such insurance limitations. For example, the FDIC took control of Silicon Valley Bank, where we previously held all of our cash and cash equivalents, on March 10, 2023. The Federal Reserve subsequently announced that account holders would be made whole, and we were able to move substantially all of our cash and cash equivalents to another financial institution. However, the FDIC may not make all account holders whole in the event of future bank failures. In addition, even if account holders are ultimately made whole with respect to a future bank failure, account holders&#8217; access to their accounts and assets held in their accounts may be substantially delayed. Any material loss that we may experience in the future or inability for a material time period to access our cash and cash equivalents could have an adverse effect on our ability to pay our operational expenses or make other payments, which could adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to the Commercialization of our Product Candidates and Generic Treprostinil Injection</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">United Therapeutics has initiated lawsuits against us in which it claims that YUTREPIA is infringing its patents and that we have misappropriated its trade secrets and confidential information and has initiated a lawsuit against the FDA challenging the FDA&#8217;s acceptance of our amended NDA for YUTREPIA for review, which may result in our company being further delayed in its efforts to commercialize YUTREPIA and may limit the indications for which YUTREPIA is approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are developing YUTREPIA under the 505(b)(2) regulatory pathway with Tyvaso as the reference listed drug. Accordingly, under the Hatch-Waxman Amendments to the Food, Drug and Cosmetic Act, we were required to, in the NDA for YUTREPIA, certify that patents listed in the Orange Book for Tyvaso are invalid, unenforceable or will not be infringed by the manufacture, use or sale of YUTREPIA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In connection with an amendment to our NDA filed in July 2023 to add PH-ILD as an indication for YUTREPIA, we provided a new notice of the paragraph IV certification to United Therapeutics as the owner of the patents that are the subject of the certification to which the NDA for YUTREPIA refers. As a result, in September 2023, United Therapeutics filed a complaint for patent infringement against us in the U.S. District Court for the District of Delaware (Case No. 1:23-cv-00975-RGA) (the &#8220;New Hatch-Waxman Litigation&#8221;).  In the New Hatch-Waxman Litigation, United Therapeutics is asserting that the Company infringes U.S. Patent No. 11,826,327, or the &#8216;327 Patent, entitled &#8220;Treatment for Interstitial Lung Disease.&#8221;  In February 2024, United Therapeutics filed a motion seeking a preliminary injunction to prevent us from manufacturing, marketing, storing, importing, distributing, offering for sale, and/or selling YUTREPIA for the treatment of PH-ILD. Judge Andrews denied the motion for a preliminary injunction in May 2024. Discovery in the case remains ongoing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Although we do not believe United Therapeutics is entitled to a new 30-month stay or a preliminary injunction in connection with the New Hatch-Waxman Litigation, it is possible that the Court could rule that a new mandatory 30- month delay has been triggered with respect to the approval of the 505(b)(2) NDA application or that a preliminary injunction is warranted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In February 2024, United Therapeutics also filed a lawsuit against the FDA, challenging the FDA&#8217;s acceptance of our amended NDA for review (the &#8220;Original FDA Litigation&#8221;). In March 2024, United Therapeutics filed a motion for a temporary restraining order in the Original FDA Litigation, seeking to enjoin the FDA from approving our NDA for YUTREPIA with respect to the indication to treat PH-ILD. United Therapeutics&#8217; motion was denied in March 2024. In May 2024, both we and the FDA filed motions to dismiss United Therapeutics&#8217; complaint. Prior to the Court&#8217;s ruling on the motions to dismiss, United Therapeutics voluntarily dismissed its complaint in the Original FDA Litigation without prejudice.  In September 2024, United Therapeutics re-asserted its challenge to FDA&#8217;s acceptance of our amended NDA for review as a cross claim in the lawsuit we instituted against the FDA in August 2024 (the &#8220;New FDA Litigation&#8221;).  Although we do not believe the arguments of United Therapeutics have merit, it is possible that the Court could rule that the FDA must reject the amendment to the YUTREPIA NDA to add PH-ILD to the label, in which case we may be required to later file a supplement to our NDA to add PH-ILD to the label. If we are required to file a supplement to add PH-ILD to the label for YUTREPIA, although we do not believe United Therapeutics would be entitled to a new 30-month stay, it is possible that the FDA or a Court could rule that a new mandatory 30-month delay has been triggered with respect to the supplement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, United Therapeutics may seek to assert newly issued patents against us, including U.S. Patent Number 11,723,887, and may seek to enjoin the FDA from granting final approval to YUTREPIA or enjoin us from launching YUTREPIA through one or more additional legal proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">As a result of this litigation instituted to date and potential litigation that may be instituted in the future, we may be subject to significant delay and incur substantial additional costs in litigation before we are able to commercialize YUTREPIA, if at all. In addition, if United Therapeutics is successful in any of its claims that it has brought to date or any claims it may bring in the future, we may be unable to commercialize YUTREPIA for the treatment of one or more indications or at all until the expiration of the applicable United Therapeutics patents, which could materially harm our business. For example, in the event United Therapeutics prevails with respect to its claims regarding the &#8216;327 Patent, it is possible that an injunction could be issued, preventing the FDA from granting final approval for YUTREPIA for PH-ILD or forcing the FDA to revoke any prior approval for YUTREPIA for PH-ILD.  Also, although United Therapeutics&#8217; initial requests for injunctive relief have been denied, if United Therapeutics is successful in obtaining a preliminary injunction or temporary restraining order in the New Hatch-Waxman Litigation or the New FDA Litigation, we could be limited to commercializing YUTREPIA only for the PAH indication for an extended time period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In December 2021, United Therapeutics filed a complaint in the Superior Court in Durham County, North Carolina, alleging that we and Robert Roscigno (&#8220;Dr. Roscigno&#8221;), a former United Therapeutics employee, who later joined us as an employee many years after terminating his employment with United Therapeutics, conspired to misappropriate certain trade secrets of United Therapeutics and engaged in unfair or deceptive trade practices. In January 2024, Dr. Roscigno filed a motion for summary judgment on all claims, but the motion was denied in July 2024.  In addition, in July 2024, the Company filed a motion for summary judgment with respect to all claims.  Briefing on the Company&#8217;s motion is complete and a hearing has been scheduled for December 19, 2024.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In May 2024, United Therapeutics filed a second complaint in the Superior Court in Durham County, North Carolina, against Dr. Roscigno, alleging that he breached prior employment agreements with United Therapeutics by failing to assign to United Therapeutics his interest in patents obtained by the Company that relied upon or benefitted from certain inventions, discoveries, materials, authorship, derivatives and results developed by Dr. Roscigno while he was employed by United Therapeutics. The Company was also named as a defendant in this new lawsuit. As part of the lawsuit, United Therapeutics alleges that Dr. Roscigno misappropriated certain intellectual property of United Therapeutics which led to the development of YUTREPIA. The complaint also seeks declaratory judgement such that all right, title and interest in and to any patentable or unpatentable inventions, discoveries, and ideas made or conceived by Dr. Roscigno while employed by the Company should be assigned and transferred to United Therapeutics because they involved the use of United Therapeutics&#8217; confidential information.  On July 30, 2024, the Company filed a motion to dismiss all claims.  Briefing on the motion is complete and a hearing has been scheduled for December 19, 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Success in a lawsuit, including in any such lawsuit with respect to some patents or some claims in a given patent, does not mean that we will be similarly successful upon appeal of those decisions. In addition, success in one proceeding, including with respect to a given patent, patent claim or trade secret in one proceeding, does not mean we will be similarly successful with respect to that same or a similar patent, patent claim or trade secret in another proceeding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we are found to infringe, misappropriate or otherwise violate any United Therapeutics&#8217; intellectual property rights, we could be required to obtain a license from United Therapeutics to continue developing and marketing YUTREPIA. However, we may not be able to obtain any required license on commercially reasonable terms or at all. We could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent or to have misappropriated a trade secret of United Therapeutics. In addition, we may be forced to redesign YUTREPIA to avoid infringement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We face significant competition from large pharmaceutical companies, among others, in developing our products and in gaining regulatory approval to bring them to market in time to achieve commercial success, and our operating results will suffer if we are unable to compete effectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We face significant competition from industry players worldwide, including large multi-national pharmaceutical companies, other emerging or smaller pharmaceutical companies, as well as universities and other research institutions. Many of our competitors have substantially greater financial, technical and other resources, such as a larger research and development staff and more experience in manufacturing and marketing, than we do. As a result, these companies may obtain marketing approval for their product candidates more quickly than we are able to and/or be more successful in commercializing their products, including generic treprostinil products, than us. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaboration arrangements with large, established companies. We may also face competition as a result of advances in the commercial applicability of new technologies and greater availability of capital for investment in such technologies. Our competitors may also invest heavily in the discovery and development of novel drug products that could make our product candidates less competitive or may file FDA citizen petitions or other correspondence with the FDA, as United Therapeutics has recently done, which may delay the approval process for our product candidates. Furthermore, our competitors may succeed in developing, acquiring or licensing, on an exclusive basis, pharmaceutical products that are easier to develop, more effective or less costly than any product candidates that we are currently developing or that we may develop. Our competitors may also succeed in asserting existing patents or developing new patents, including patents that may issue from patent applications that are currently being pursued by United Therapeutics, to which we do not have a license, in an attempt to prevent us from marketing our products. These competitors may also compete with us in recruiting and retaining qualified sales personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any new drug product that competes with a prior approved drug product must demonstrate advantages in safety, efficacy, tolerability or convenience in order to overcome price competition and to be commercially successful. Our products, if and when approved, are expected to face competition from drug products that are already on the market, as well as those in our competitors&#8217; development pipelines. We expect that our lead program, YUTREPIA, an inhaled treprostinil therapy for the treatment of PAH and PH-ILD, and L606, a nebulized, liposomal formulation of treprostinil for treatment of PAH and PH-ILD, will face competition from the following inhaled prostacyclin analog therapies that are either currently marketed or in clinical development:</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:90pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:1pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9726;</td><td style="padding:0pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Tyvaso (treprostinil), marketed by United Therapeutics, has been approved for the treatment of PAH in the United States since 2009 and for PH-ILD since 2021. Tyvaso is the reference listed drug in our NDA for YUTREPIA. Following patent litigation, United Therapeutics and Watson Pharmaceuticals reached a settlement whereby Watson Pharmaceuticals will be permitted to enter the market with a generic version of Tyvaso beginning on January 1, 2026.</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Tyvaso DPI (treprostinil), licensed from MannKind by United Therapeutics, is a dry-powder formulation of treprostinil that was approved for the treatment of PAH and PH-ILD in the United States in May 2022.</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Treprostinil Palmitil Inhalation Powder (TPIP), is a dry-powder formulation of a treprostinil prodrug being developed by Insmed. Insmed announced the completion of an initial Phase 1 study in February 2021 which demonstrated that TPIP was generally safe and well tolerated, with a pharmacokinetic profile that supports once-daily dosing. Insmed initiated Phase 2 trials studying patients diagnosed with PAH and PH-ILD in May 2021 and December 2022, respectively. In May 2024, Insmed reported positive topline safety and tolerability data as well as certain exploratory efficacy endpoints from the Phase 2 PH-ILD. Based on these Phase 2 results, Insmed is pursuing discussions with global regulatory authorities on the design of a Phase 3 study in PH-ILD to initiate in 2025. If the TPIP clinical program is successful in demonstrating less frequent dosing with similar efficacy and safety to YUTREPIA and Tyvaso DPI, then TPIP has the potential to be viewed as a more attractive option and may take market share rapidly.</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Ventavis&#174; (iloprost), marketed by Actelion, a division of Johnson &amp; Johnson, has been approved for the treatment of PAH in the United States since 2004.</span></td><td style="width:7.2pt;"/></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition to these other inhaled treprostinil therapies, we expect that YUTREPIA and L606 will also face competition from other treprostinil-based drugs, including Orenitram, which is administered orally, and Remodulin, which is administered parenterally, both of which are marketed by United Therapeutics. Branded pharmaceutical companies such as United Therapeutics continue to defend their products vigorously through, among other actions, life cycle management, marketing agreements with third-party payors, pharmacy benefits managers and generic manufacturers. These actions add increased competition in the generic pharmaceutical industry, including competition for Treprostinil Injection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally, even though Sandoz launched the first-to-file fully substitutable generic treprostinil for parenteral administration in March 2019 that is sold primarily through the specialty pharmacies, Teva Pharmaceutical Industries Ltd. launched a generic treprostinil for parenteral administration in October 2019 that is sold primarily through a specialty pharmacy and to hospitals, Par Pharmaceutical, Inc. launched a generic treprostinil for parenteral administration after receiving approval in September 2019 that is sold primarily to hospitals, Dr. Reddy&#8217;s Laboratories Inc. launched a generic treprostinil for parenteral administration in April 2023, and Alembic received approval in February 2021 for generic treprostinil for parenteral administration. Such increased competition may result in a smaller than expected commercial opportunity for us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Generic drug prices may, and often do, decline, sometimes dramatically, especially as additional generic pharmaceutical companies (including low-cost generic producers outside of the United States) receive approvals and enter the market for a given product. The goals established under the Generic Drug User Fee Act, and increased funding of the FDA&#8217;s Office of Generic Drugs, have led to more and faster generic approvals, and consequently increased competition for generic products. The FDA has stated that it has established new steps to enhance competition, promote access and lower drug prices and is approving record-breaking numbers of generic applications. The FDA&#8217;s changes may benefit our competitors. Our ability to sell Treprostinil Injection and earn revenue is affected by the number of companies selling competitive products, including new market entrants, and the timing of their approvals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition to treprostinil-based therapies, other classes of therapeutic agents for the treatment of PAH include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.7pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span><span style="display:inline-block;width:18pt;"></span><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">IP-agonists</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, such as selexipag, marketed by Actelion, and ralinepeg, licensed from Arena Pharmaceuticals, Inc. by United Therapeutics, which is currently in clinical development.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Endothelin receptor antagonists</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, such as bosentan and macitentan, both marketed by Actelion, and ambrisentan, marketed by Gilead. Generic versions of bosentan and ambrisentan are currently available.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">PDE-5 inhibitors</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, such as tadalafil, marketed by United Therapeutics, and sildenafil, marketed by Pfizer Inc. Generic versions of both tadalafil and sildenafil are currently available.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Soluble guanylate cyclase (sGC) stimulator,</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">such as oral riociguat marketed by Bayer for PAH, and inhaled mosliciguat being developed by Pulmovant for PH-ILD.  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Activin signaling inhibitor, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">such as sotatercept marketed by Merck &amp; Co, and KER-012 being developed by Keros Therapeutics</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Merck &amp; Co&#8217;s injectable sotatercept, with a brand name of Winrevair, was approved by the FDA in March 2024 and is a potential first-in-class molecule that targets the proliferation of cells in the pulmonary arterial wall. Its clinical use is developing, and it is possible that it may be used prior to prostacyclin therapies, which may have an adverse effect on the market potential for YUTREPIA and/or L606.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are also aware of several other agents in clinical development that are exploring mechanisms of action which, if approved, could impact the standard of care for treating PAH and/or PH-ILD in the United States, including programs from Merck &amp; Co. Inc., and Gossamer Bio, Inc., among others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">There are a number of competitors seeking marketing approval and/or regulatory exclusivity with respect to products that are or would be competitive to our product candidate. Thus, we face the risk that one of our competitors will be granted marketing approval and/or regulatory exclusivity before we are able to obtain FDA approval for our product candidate. In that case, as stated above, there is the possibility that such a competitor would be able to prevent us from obtaining approval of and marketing our product candidate until the expiration of the competitor&#8217;s term of FDA regulatory exclusivity, which could be a term of three years for so-called New Clinical Investigation exclusivity, or could conceivably be for longer periods of time if the competitor is successful in being granted other forms of FDA regulatory exclusivity which might include, for example, Orphan Disease Designation exclusivity (seven years), New Chemical Entity exclusivity (five years), or Pediatric exclusivity (six months beyond other existing exclusivities or patent terms). For example, United Therapeutics was recently awarded New Clinical Investigation exclusivity for Tyvaso DPI, which will expire in May 2025.  As a result, unless we are successful in having such exclusivity overturned, the FDA will be unable to approve YUTREPIA until after the exclusivity expires in May 2025.  In the event United Therapeutics sought and was able to obtain one or more other regulatory exclusivities with respect to Tyvaso DPI, it could further significantly delay our ability to obtain final approval for YUTREPIA. Even if the FDA does not recognize any new regulatory exclusivity for United Therapeutics, United Therapeutics could challenge the FDA&#8217;s decision and seek an injunction to prevent approval of YUTREPIA in one or more indications until such challenge has been decided.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, if one of our competitors is granted marketing approval before we are able to obtain FDA approval for our product candidates, as was the case with respect to the approval of United Therapeutics&#8217; Tyvaso DPI product, such competitors will be able to promote and market their products before we are able to do so, which may place us at a competitive disadvantage in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">One or more products that are competitive with YUTREPIA could also obtain approval for additional indications or broader conditions of use. These additional indications and broader conditions of use could be protected by one or more patents or regulatory exclusivities, preventing YUTREPIA from obtaining approval for the same indications or conditions of use. For instance, if Liquidia is prevented from launching or selling YUTREPIA for the treatment of PH-ILD in connection with the patent litigation related to the &#8216;327 patent or the lawsuit that United Therapeutics filed </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">against the FDA, Tyvaso and Tyvaso DPI would have broader labels than YUTREPIA. In addition, United Therapeutics is currently studying Tyvaso for the treatment of idiopathic pulmonary fibrosis, an indication for which it has received an orphan drug designation. Thus, even if YUTREPIA is approved, such competitive products could have a broader label than the initial label for YUTREPIA. If YUTREPIA has a narrower label than other competitive products, it may affect our ability to compete with such products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The ability of competitors to utilize other regulatory incentive programs could also expedite their FDA review and approval timeline, which could result in their products reaching the market before our product candidate, and which could create further potential implications on exclusivity as noted above. For example, when a Priority Review Voucher is redeemed in connection with an NDA, the FDA&#8217;s goal review period would generally be expedited to six months, although this timeframe is not guaranteed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If we are unable to maintain our competitive position, our business and prospects will be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our products may not achieve market acceptance or adequate third-party payor coverage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are currently focused on developing drug products that can be approved under abbreviated regulatory pathways in the United States, such as the 505(b)(2) regulatory pathway, which allows us to rely on existing knowledge of the safety and efficacy of the relevant reference listed drugs to support our applications for approval in the United States. While we believe that it will be less difficult for us to convince physicians, patients and other members of the medical community to accept and use our drug products as compared to entirely new drugs, our drug products may nonetheless fail to gain sufficient market acceptance by physicians, patients, other healthcare providers and third-party payors. If any of our drug products fail to achieve sufficient market acceptance or third-party payor coverage, we may not be able to generate sufficient revenue to become profitable. The degree of market acceptance and third-party payor coverage of our drug products, if and when they are approved for commercial sale, will depend on a number of factors, including but not limited to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of our receipt of marketing approvals, the terms of such approvals and the countries in which such approvals are obtained;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the safety, efficacy, reliability and ease of administration of our drug products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of undesirable side effects and adverse events;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent of the limitations or warnings required by the FDA or comparable regulatory authorities in other countries to be contained in the labeling of our drug products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical indications for which our drug products are approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability and perceived advantages of alternative therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any publicity related to our drug products or those of our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the quality and price of competing drug products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain third-party payor coverage and sufficient reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of patients to pay out of pocket in the absence of third-party payor coverage; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the selling efforts and commitment of our commercialization collaborators.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If our drug products, if and when approved, fail to receive a sufficient level of market acceptance or sufficient third-party payor coverage, our ability to generate revenue from sales of our drug products will be limited, and our business and results of operations may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be able to build a commercial operation, including establishing and maintaining marketing and sales capabilities or entering into agreements with third parties to market and sell our drug products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In order to market and sell any of our drug products, if and when approved, we will be required to build our marketing and sales capabilities with respect to such products. With the acquisition of Liquidia PAH, we acquired a sales force to market generic treprostinil in accordance with the Promotion Agreement. In addition, during 2023, we significantly increased the size of our sales force in anticipation of a potential launch of YUTREPIA. However, if we experience </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">continued delays in the approval of YUTREPIA, we may be unable to retain our sales force.  Moreover, we cannot assure you that we will be successful in further building or effectively managing our marketing and sales capabilities or be able to do so in a cost-effective manner. In addition, we may enter into collaboration arrangements with third parties to market our drug products. We may face significant competition for collaborators. In addition, collaboration arrangements may be time-consuming to negotiate and document. We cannot assure you that we will be able to negotiate collaborations for the marketing and sales of our drug products on acceptable terms, or at all. Even if we do enter into such collaborations, we cannot assure you that our collaborators will be successful in commercializing our products. If we or our collaborators are unable to successfully commercialize our drug products, whether in the United States or elsewhere, our business and results of operations may be materially and adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As we seek to establish a commercial operation with respect to YUTREPIA in anticipation of potential approval from the FDA, we also continue to evaluate and develop additional drug candidates, including L606. There can be no assurance that we will be able to successfully manage the balance of our research and development operations with our commercial activities. Potential investors should be aware of the problems, delays, expenses and difficulties frequently encountered by companies balancing development of product candidates, which can include problems such as unanticipated issues relating to clinical trials and receipt of approvals from the FDA and foreign regulatory bodies, with commercialization efforts, which include problems relating to managing manufacturing and supply, reimbursement, marketing problems, and other additional costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There are risks involved with building and expanding our sales, marketing, and other commercialization capabilities. For example, recruiting and training a sales force is expensive and time-consuming. If the commercial launch of a drug candidate for which we recruit or have recruited a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Factors that may impact our efforts to commercialize our drug candidates on our own and generate product revenues include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to recruit and retain adequate numbers of effective sales and marketing personnel over a large geographic area;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and time associated with the initial and ongoing training of sales and marketing personnel on legal and regulatory compliance matters and monitoring their actions;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">understanding and training relevant personnel on the limitations on, and the transparency and reporting requirements applicable to, remuneration provided to actual and potential referral sources;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical indications for which the products are approved and the claims that we may make for the products;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations or warnings, including distribution or use restrictions, contained in the products&#8217; approved labeling;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability of sales personnel to obtain access to physicians or to effectively promote any future drugs;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the lack of complementary drugs to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any distribution and use restrictions imposed by the FDA or to which we agree;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liability for sales and marketing personnel who fail to comply with the applicable legal and regulatory requirements;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain a healthcare compliance program including effective mechanisms for compliance monitoring; and</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.2pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen costs and expenses associated with creating a sales and marketing organization.</span></td><td style="width:7.2pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In the future, we may choose to participate in sales activities with collaborators for some of our drug candidates. However, there are also risks with entering into these types of arrangements with third parties to perform sales, marketing and distribution services. For example, we may not be able to enter into such arrangements on terms that are favorable to us. Our drug revenues or the profitability of these drug revenues to us are likely to be lower than if we were to market and sell any drug candidates that we develop ourselves. In addition, we likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our drug </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">candidates effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our drug candidates. Further, our business, results of operations, financial condition and prospects will be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be exposed to claims and may not be able to obtain or maintain adequate product liability insurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our business is exposed to the risk of product liability and other liability risks that are inherent in the development, manufacture, clinical testing, commercialization and marketing of pharmaceutical products. These risks exist even if a product is approved for commercial sale by the FDA or comparable regulatory authorities in other countries and manufactured in licensed facilities. Our current product candidates, YUTREPIA and L606, and Treprostinil Injection are designed to affect important bodily functions and processes. Any side effects, manufacturing defects, misuse or abuse associated with our products could result in injury to a patient or even death.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Claims that are successfully brought against us could have a material and adverse effect on our financial condition and results of operations. Further, even if we are successful in defending claims brought against us, our reputation could suffer. Regardless of merit or eventual outcome, product liability claims may also result in, among others:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decreased demand for our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a withdrawal or recall of our products from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a withdrawal of participants from our ongoing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the distraction of our management&#8217;s attention from our core business activities to defend such claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional costs to us; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a loss of revenue.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our insurance may not provide adequate coverage against our potential liabilities. Furthermore, we, our collaborators or our licensees may not be able to obtain or maintain insurance on acceptable terms, or at all. Our inability to obtain sufficient product liability insurance at an acceptable cost and/or scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with our collaborators. The market for insurance coverage is increasingly expensive, and the costs of insurance coverage will increase as our clinical programs and commercialization efforts increase in size. In addition, our collaborators or licensees may not be willing to indemnify us against these types of liabilities and may not themselves be sufficiently insured or have sufficient assets to satisfy any product liability claims. To the extent that they are uninsured or uninsurable, claims or losses that may be suffered by us, our collaborators or our licensees may have a material and adverse effect on our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any claims against us, regardless of their merit, could severely harm our financial condition, strain our management and other resources, adversely affect or eliminate the prospects for commercialization or sales of a product that is the subject of any such claim, and could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to the Development and Regulatory Approval of our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are primarily dependent on the success of our product candidate, YUTREPIA, for which we received tentative approval from the FDA, and this product candidate may fail to receive final marketing approval (in a timely manner or at all), may fail to receive approval for one or more indications for which we have sought approval or may not be commercialized successfully.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We do not have any products approved for marketing in any jurisdiction and we have never generated any revenue from sales of our own products. Our ability to generate revenue from sales of our own products and achieve profitability depends on our ability, alone or with strategic collaboration partners, to successfully complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize, one or more of our product candidates. We expect that a substantial portion of our efforts and expenditure over the next few years will be devoted to our product candidate, YUTREPIA, a proprietary inhaled dry powder formulation of treprostinil for the treatment of PAH and PH-ILD, and L606, a nebulized, liposomal formulation of treprostinil for treatment of PAH and PH-ILD.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We received tentative approval of our NDA for YUTREPIA for the treatment of PAH and PH-ILD in August 2024. However, our receipt of tentative approval does not mean that we will receive final approval of our NDA for YUTREPIA in a timely manner or at all or that we will receive final approval for both indications. United Therapeutics has invested considerable time and resources in an effort to block final approval of YUTREPIA, and expectations related to final FDA approval and projected product launch timelines are impacted by ongoing litigation following lawsuits filed by United Therapeutics. For instance, in connection with an amendment to our NDA filed on July 24, 2023 to add PH-ILD as an indication for YUTREPIA, we provided a new notice of the paragraph IV certification to United Therapeutics as the owner of the patents that are the subject of the certification to which the NDA for YUTREPIA refers. As a result, in September 2023, United Therapeutics filed the New Hatch-Waxman Litigation, again asserting infringement by the Company of the &#8216;793 Patent, which lawsuit was amended on November 30, 2023, to add claims asserting infringement of the &#8216;327 Patent. Although the claims related to the &#8216;793 Patent were subsequently withdrawn, in February 2024, United Therapeutics also filed a motion seeking a preliminary injunction to prevent us from manufacturing, marketing, storing, importing, distributing, offering for sale, and/or selling YUTREPIA for the treatment of PH-ILD. That motion for preliminary injunction was denied, but United Therapeutics may still seek injunctive relief in the future. In September 2024, United Therapeutics also filed a cross claim in the New FDA Litigation, seeking to enjoin the FDA from approving our NDA for YUTREPIA with respect to the indication to treat PH-ILD. Although we do not believe United Therapeutics is entitled to any injunction or temporary restraining order in the New Hatch-Waxman Litigation or the New FDA Litigation, it is possible that the Court could rule that the FDA must reject the amendment to the YUTREPIA NDA to add PH-ILD to the label or that, even if YUTREPIA has launched for both PAH and PH-ILD, the Company must remove PH-ILD from the label for YUTREPIA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, a drug product that is granted tentative approval, like YUTREPIA, may be subject to additional review before final approval, particularly if tentative approval was granted more than three years before the earliest lawful approval date. The FDA&#8217;s tentative approval of YUTREPIA for the treatment of PAH and PH-ILD was based on information available to FDA at the time of the tentative approval letter (i.e., information in the application and the status of current good manufacturing practices of the facilities used in the manufacturing and testing of the drug product) and is therefore subject to change on the basis of new information that may come to FDA&#8217;s attention. A new drug product may not be marketed until the date of final approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Expectations for YUTREPIA and/or L606 also may be impacted by competing products, including Tyvaso&#174; DPI. <i style="font-style:italic;">See Item 1A. Risk Factors&#8212;We face significant competition from large pharmaceutical companies, among others, in developing our products and in gaining regulatory approval to bring them to market in time to achieve commercial success, and our operating results will suffer if we are unable to compete effectively.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">We cannot assure you that we will receive final marketing approval for YUTREPIA or L606 or, even if we do receive final marketing approval, the indications for which they will be approved. The FDA or comparable regulatory authorities in other countries may delay, limit or deny final approval of our product candidate for various reasons. For example, such authorities may disagree with the design, scope or implementation of our clinical trials, or with our interpretation of data from our preclinical studies or clinical trials. Further, there are numerous FDA personnel assigned to review different aspects of an NDA, and uncertainties can be presented by their ability to exercise judgment and discretion during the review process. During the course of review prior to final approval, the FDA may request or require additional preclinical, clinical, chemistry, manufacturing, and control (CMC) or other data and information or conduct additional inspections. If any additional issues were identified in such information requests or inspections or if FDA determines that we failed to include required CMC information in the NDA for our products, including YUTREPIA, we may be delayed in obtaining final approval or may be unable to obtain final approval. Furthermore, responses to FDA&#8217;s requests may be time-consuming and expensive. Status as a combination product, as is the case for YUTREPIA and L606, may complicate or delay the FDA review process. Product candidates that the FDA deems to be combination products, such as YUTREPIA and L606, or that otherwise rely on innovative drug delivery systems, may face additional challenges, risks and delays in the product development and regulatory approval process. Additionally, the FDA could delay approval of YUTREPIA and/or L606 even if approvable after completing its review. For example, Tyvaso DPI was granted regulatory exclusivity that will delay final approval of YUTREPIA until after the exclusivity expires in May 2025.  If a competing product comprised of an inhaled dry-powder formulation of treprostinil, such as Tyvaso DPI, is granted additional regulatory exclusivity, that could delay the final approval of YUTREPIA until said exclusivity expires. Moreover, the applicable requirements for approval may differ from country to country.  It is also possible that </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">recent decisions by the United States Supreme Court, eliminating court deference to decisions by administrative agencies, may delay any final decisions from the FDA as it considers how to implement this new ruling into its decision-making process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we successfully obtain marketing approvals for YUTREPIA and/or L606, we cannot assure you that they will be commercialized in a timely manner or successfully, or at all. For example, even if such products are approved by the FDA, they may not achieve a sufficient level of market acceptance or third-party payor coverage, or we may not be able to effectively build our marketing and sales capabilities or scale our manufacturing operations to meet commercial demand. The successful commercialization of YUTREPIA and L606 will also, in part, depend on factors that are beyond our control. Therefore, we may not generate significant revenue from the sale of such products, even if approved. Any delay or setback we face in the commercialization of YUTREPIA and/or L606 may have a material and adverse effect on our business and prospects, which will adversely affect your investment in our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our preclinical studies and clinical trials may not be successful and delays in such preclinical studies or clinical trials may cause our costs to increase and significantly impair our ability to commercialize our product candidates. Results of previous clinical trials or interim results of ongoing clinical trials may not be predictive of future results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Before we are able to commercialize our drug products, we are required to undertake extensive preclinical studies and clinical trials to demonstrate that our drug products are safe and effective for their intended uses. However, we cannot assure you that our drug products will, in preclinical studies and clinical trials, demonstrate safety and efficacy as necessary to obtain marketing approval. Due to the nature of drug product development, many product candidates, especially those in early stages of development, may be terminated during development. Although we believe we have completed clinical development for YUTREPIA, we have not yet obtained final approval for or commercialized any of our own product candidates and as a result do not have a track record of successfully bringing our own product candidates to market. Furthermore, YUTREPIA and L606 have, to date, been tested only in relatively small study</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">populations and, accordingly, the results from our earlier clinical trials may be less reliable than results achieved in larger clinical trials, if required. Additionally, the outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and preliminary and interim results of a clinical trial do not necessarily predict final results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Preclinical studies and clinical trials may fail due to factors such as flaws in trial design, dose selection and patient enrollment criteria. The results of preclinical studies and early clinical trials may not be indicative of the results of subsequent clinical trials. Product candidates may, in later stages of clinical testing, fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and earlier clinical trials. Moreover, there may be significant variability in safety or efficacy results between different trials of the same product candidate due to factors including, but not limited to, changes in trial protocols, differences in the composition of the patient population, adherence to the dosing regimen and other trial protocols and amendments to protocols and the rate of drop-out among patients in a clinical trial. If our preclinical studies or clinical trials are not successful and we are unable to bring our product candidates to market as a result, our business and prospects may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furthermore, conducting preclinical studies and clinical trials is a costly and time-consuming process. The length of time required to conduct the required studies and trials may vary substantially according to the type, complexity, novelty and intended use of the product candidate. A single clinical trial may take up to several years to complete. Moreover, our preclinical studies and clinical trials may be delayed or halted due to various factors, including, among others:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in raising the funding necessary to initiate or continue a clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in manufacturing sufficient quantities of product candidates for clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in reaching agreement on acceptable terms with prospective contract research organizations (CROs) and clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in obtaining institutional review board approval at clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in recruiting suitable patients to participate in a clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in patients&#8217;&#160;completion of clinical trials or their post-treatment follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities&#8217;&#160;interpretation of our preclinical and clinical data; and</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen safety issues, including a high and unacceptable severity, or prevalence, of undesirable side effects or adverse events caused by our product candidates or similar drug products or product candidates.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If our preclinical studies or clinical trials are delayed, the commercialization of our product candidates will be delayed and, as a result, we may incur substantial additional costs or not be able to recoup our investment in the development of our product candidates, which would have a material and adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Clinical trials and data analysis can be expensive, time-consuming and difficult to design and implement. If we are unsuccessful in obtaining regulatory approval for our products, or any required clinical studies of our products do not provide positive results, we may be required to delay or abandon development of such products, which would have a material adverse impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Continuing product development requires additional and extensive clinical testing. Human clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. The clinical trial process is also time-consuming. We cannot provide any assurance or certainty regarding when we might receive regulatory approval for our products, including YUTREPIA and L606. Furthermore, failure can occur at any stage of the process, and we could encounter problems that cause us to abandon an NDA filed with the FDA or repeat clinical trials. The commencement and completion of clinical trials for any current or future development product candidate may be delayed by several factors, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen safety issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determination of dosing issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of effectiveness during clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">slower than expected rates of patient recruitment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to monitor patients adequately during or after treatment; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability or unwillingness of medical investigators to follow our clinical protocols or amendments to our protocols.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, the FDA or an independent IRB may suspend our clinical trials at any time if it appears that we are exposing participants to unacceptable health risks or if the FDA finds deficiencies in our IND submissions or the conduct of these trials. Therefore, we cannot provide any assurance or predict with certainty the schedule for future clinical trials. Although clinical data is an essential part of NDA filings, NDAs must also contain a range of additional data including CMC data to meet FDA standards for approval. In the event we do not ultimately receive final regulatory approval for YUTREPIA and/or L606, we may be required to terminate development of these product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The marketing approval processes of the FDA and comparable regulatory authorities in other countries are unpredictable and our product candidates may be subject to multiple rounds of review or may not receive marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pursuing marketing approval for a pharmaceutical product candidate (for example, through the NDA process) is an extensive, lengthy, expensive and inherently uncertain process. We cannot assure you that any of our product candidates will receive marketing approval. Regulatory authorities may delay, limit or deny approval of our product candidates for many reasons, including, but not limited to, the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable regulatory authorities may, for a variety of reasons, take the view that the data collected from our preclinical and clinical trials and human factors testing, or data that we otherwise submit or reference to support an application, are not sufficient to support approval of a product candidate;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.7pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable regulatory authorities in other countries may ultimately conclude that our manufacturing processes or facilities or those of our third-party manufacturers do not sufficiently demonstrate compliance with cGMP to support approval of a product candidate, that the drug CMC data or device biocompatibility data for our product candidates otherwise do not support approval or that additional CMC data or information for our product candidates must be submitted for review;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.7pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate to the satisfaction of the FDA or comparable regulatory authorities in other countries that our product candidate is safe and effective for its proposed indication, or that its clinical and other benefits outweigh its safety risks;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.7pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval policies of the FDA or comparable regulatory authorities in other countries may change in a manner that renders our data insufficient for approval.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.7pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Even if we obtain marketing approval, the FDA or comparable regulatory authorities in other countries may approve our product candidates for fewer or more limited indications than those for which we requested approval or may include safety warnings or other restrictions that may negatively impact the commercial viability of our product candidates. Likewise, regulatory authorities may grant approval contingent on the performance of costly post-marketing clinical trials or other studies or the conduct of an expensive risk evaluation and mitigation strategies, or REMS, which could significantly reduce the potential for commercial success or viability of our product candidates. We also may not be able to find acceptable collaborators to manufacture our drug products, if and when approved, in commercial quantities and at acceptable prices, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may encounter difficulties in enrolling patients in our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We may not be able to commence or complete clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patient enrollment may be affected by a variety of factors, including, among others:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the severity of the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the design of the clinical trial protocol and amendments to a protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and nature of the patient population;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eligibility criteria for the clinical trial in question;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the perceived risks and benefits of the product candidate under clinical testing, including a high and unacceptable severity, or prevalence, of undesirable side effects or adverse events caused by our product candidates or similar products or product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the existing body of safety and efficacy data in respect of the product candidate under clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the proximity of patients to clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and nature of competing therapies and clinical trials; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;min-height:12.5pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other environmental factors such as pandemics or other natural or unforeseen disasters.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Any negative results we may report in clinical trials of our product candidates may also make it difficult or impossible to recruit and retain patients in other clinical trials of that same product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We expect that if we initiate, as we are currently contemplating, a clinical trial of YUTREPIA in pediatric patients, we may encounter difficulties enrolling patients in such a trial because of the limited number of pediatric patients with this disease. Furthermore, we are aware of a number of therapies for PAH that are being developed or that are already available on the market, and we expect to face competition from these investigational drugs or approved drugs for potential subjects in our clinical trials, including planned clinical trials for YUTREPIA and L606, which may delay enrollment in our planned clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delays or failures in planned patient enrollment or retention may result in increased costs, program delays, or both. We may, as a result of such delays or failures, be unable to carry out our clinical trials as planned or within the timeframe that we expect or at all, and our business and prospects may be materially and adversely affected as a result.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Product candidates that the FDA deems to be combination products, such as YUTREPIA and L606, or that otherwise rely on innovative drug delivery systems, may face additional challenges, risks and delays in the product development and regulatory approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA has indicated that it considers YUTREPIA, which is delivered by a DPI, and L606, which is delivered by a next generation nebulizer, to be drug-device combination products. Accordingly, the medical devices used to administer the products were, or in the case of L606 will be, evaluated as part of our NDA filing. When evaluating products that utilize a specific drug delivery system or device, the FDA will evaluate the characteristics of that delivery system and its functionality, as well as the potential for undesirable interactions between the drug and the delivery system, including the potential to negatively impact the safety or effectiveness of the drug. The FDA review process can be more complicated for combination products, and may result in delays, particularly if novel delivery systems are involved. We rely on third parties for the design and manufacture of the delivery systems for our products, including the DPI for YUTREPIA and the nebulizer for L606, and in some cases for the right to refer to their data on file with the FDA or other regulators. Quality or design concerns with the delivery system, or commercial disputes with these third parties, could delay or prevent regulatory approval and commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are pursuing the FDA 505(b)(2) pathway for our current product candidates. If we are unable to rely on the 505(b)(2) regulatory pathway to apply for marketing approval of our product candidates in the United States, seeking approval of these product candidates through the 505(b)(1) NDA pathway would require full reports of investigations of safety and effectiveness, and the process of obtaining marketing approval for our product candidates would likely be significantly longer and more costly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are currently focused on developing drug products that can be approved under abbreviated regulatory pathways in the United States, such as the 505(b)(2) regulatory pathway, which permits the filing of an NDA where at least some of the information required for approval comes from studies that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Section 505(b)(2), if applicable to us for a particular product candidate, would allow an NDA we submit to the FDA to rely in part on data in the public domain or the FDA&#8217;s prior conclusions regarding the safety and effectiveness of approved compounds, which could expedite the development program for a product candidate by potentially decreasing the amount of clinical data that we would need to generate in order to obtain FDA approval. We have pursued this pathway for our current product candidate, YUTREPIA,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">and are pursuing this pathway for L606. Even if the FDA allows us to rely on the 505(b)(2) regulatory pathway for a given product candidate, we cannot assure you that marketing approval will be obtained in a timely manner, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">The FDA may require us to perform additional clinical trials to support any change from the reference listed drug, which could be time-consuming and substantially delay our receipt of marketing approval. Also, as has been the experience of others in our industry, our competitors may file citizen petitions or other correspondence with the FDA or lawsuits against the FDA to contest approval of our NDA, which may delay or even prevent the FDA from approving any NDA that we submit under the 505(b)(2) regulatory pathway. For instance, United Therapeutics has a lawsuit against the FDA and recently filed a citizen petition in an attempt to prevent or delay the approval of YUTREPIA. If an FDA decision or action relative to our product candidate, or the FDA&#8217;s interpretation of Section 505(b)(2) more generally, is successfully challenged, it could result in delays or even prevent the FDA from approving a 505(b)(2) application for our product candidates or for certain indications for our product candidates. Even if we are able to utilize the 505(b)(2) regulatory pathway, the approval of a drug developed under the 505(b)(2) regulatory pathway may be delayed by one or more regulatory exclusivities.  For example, Tyvaso DPI was recently granted New Clinical Investigation exclusivity, which has delayed final approval of YUTREPIA until after the exclusivity expires in May 2025.  Also, a drug approved via this pathway may be subject to the same post-approval limitations, conditions and requirements as any other drug.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, we may face Hatch-Waxman litigation in relation to our NDAs submitted under the 505(b)(2) regulatory pathway, which may further delay or prevent the approval of our product candidates. The pharmaceutical industry is highly competitive, and 505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of sponsors of previously approved drugs that are referenced in a 505(b)(2) NDA. If the previously approved drugs referenced in an applicant&#8217;s 505(b)(2) NDA are protected by patent(s) listed in the Orange Book, the 505(b)(2) applicant is required to make a claim after filing its NDA or certain types of amendments to its NDA that each such patent is invalid, unenforceable or will not be infringed. The patent holder may thereafter bring suit for patent infringement, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">which will trigger a mandatory 30-month delay (or the shorter of dismissal of the lawsuit or expiration of the patent(s)) in approval of the 505(b)(2) NDA application. In addition, in the event the court in any such lawsuit finds that any claims of any of the asserted patents are both valid and infringed, the court would likely issue an injunction prohibiting approval of the product at issue until the expiration of the patent(s) found to have been infringed. For example, the YUTREPIA NDA was filed under the 505(b)(2) regulatory pathway with Tyvaso as the reference listed drug. Under the Hatch-Waxman Act, as a result of the litigation commenced by United Therapeutics in June 2020, the FDA was automatically precluded from approving the YUTREPIA NDA for up to 30 months. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Also, in connection with an amendment to our NDA filed in July 2023 to add PH-ILD as an indication for YUTREPIA, we provided a new notice of the paragraph IV certification to United Therapeutics as the owner of the patents that are the subject of the certification to which the NDA for YUTREPIA refers. As a result, in September 2023, United Therapeutics filed the New Hatch-Waxman Litigation, again asserting infringement by the Company of the &#8216;793 Patent, which lawsuit was amended on November 30, 2023, to add claims asserting infringement of the &#8216;327 Patent. In February 2024, United Therapeutics filed a motion seeking a preliminary injunction to prevent us from manufacturing, marketing, storing, importing, distributing, offering for sale, and/or selling YUTREPIA for the treatment of PH-ILD. Although the motion for preliminary injunction was denied, United Therapeutics may still seek injunctive relief and other remedies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, United Therapeutics may seek to assert newly issued patents against us, including U.S. Patent Number 11,723,887, and may seek to enjoin the FDA from granting final approval to YUTREPIA or enjoin us from launching YUTREPIA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">It is also not uncommon for a manufacturer of an approved product, such as United Therapeutics, to file a citizen petition or other correspondence with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing products or to take other actions, such as engaging in litigation with the FDA to enjoin approval of a competing product. If successful, such petitions, correspondence or litigation can significantly delay, or even prevent, the approval of the new product. For example, United Therapeutics is currently pursuing litigation under the Administrative Procedures Act, seeking to require the FDA to reject our amendment to the YUTREPIA NDA to add PH-ILD to the label. Even if the FDA ultimately prevails in such litigation, the FDA may substantially delay approval while it considers and responds to the petition or correspondence and is engaged in litigation or the FDA may be temporarily enjoined by a court from granting approval until the court has ruled on United Therapeutics&#8217; request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If the FDA determines that any of our product candidates do not qualify for the 505(b)(2) regulatory pathway, we would need to reconsider our plans and might not be able to commercialize our product candidates in a cost-efficient manner, or at all. If we were to pursue approval under the 505(b)(1) NDA pathway, we would be subject to more extensive requirements and risks such as conducting additional clinical trials, providing additional data and information or meeting additional standards for marketing approval. As a result, the time and financial resources required to obtain marketing approval for our product candidates would likely increase substantially and further complications and risks associated with our product candidates may arise. Also, new competing products may reach the market faster than ours, which may materially and adversely affect our competitive position, business and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be unable to continually develop a pipeline of product candidates, which could affect our business and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A key element of our long-term strategy is to continually develop a pipeline of product candidates by developing products for the treatment of pulmonary hypertension and proprietary innovations to FDA-approved drug products using our PRINT technology. If we are unable to identify suitable product candidates for the treatment of pulmonary hypertension or off-patent drug products for which we can develop proprietary innovations using our PRINT technology or are otherwise unable to expand our product candidate pipeline, whether through licensed or co-development opportunities, and obtain marketing approval for such product candidates within the timeframes that we anticipate, or at all, our business and prospects may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have conducted, and may in the future conduct, clinical trials for our product candidates outside the United States and the FDA may not accept data from such trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Although the FDA may accept data from clinical trials conducted outside the United States in support of safety and efficacy claims for our product candidates, if not conducted under an IND, this is subject to certain conditions set out in 21 C.F.R. &#167; 312.120. For example, in order for the FDA to accept data from such a foreign clinical trial, the study must have been conducted in accordance with Good Clinical Practice (GCP) including review and approval by an independent ethics committee and obtaining the informed consent from subjects of the clinical trials. The FDA must also be able to validate the data from the study through an onsite inspection if the agency deems it necessary. In addition, foreign clinical data submitted to support FDA applications should be applicable to the U.S. population and U.S. medical practice. Other factors that may affect the acceptance of foreign clinical data include differences in clinical conditions, study populations or regulatory requirements between the United States and the foreign country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Dependence on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We depend on third parties for clinical and commercial supplies, including single suppliers for the active ingredient, the device, encapsulation and packaging of YUTREPIA and single suppliers for the active ingredient, bulk product manufacturing and packaging of L606.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;">We depend on third-party suppliers for clinical and commercial supplies for the supply of materials and components necessary for clinical and commercial production of YUTREPIA and L606, including the active pharmaceutical ingredients which are used in our product candidates. These supplies may not always be available to us at the standards we require or on terms acceptable to us, or at all, and we may not be able to locate alternative suppliers in a timely manner, or at all. If we are unable to obtain necessary clinical or commercial supplies, our manufacturing operations and clinical trials and the clinical trials of our collaborators may be delayed or disrupted and our business and prospects may be materially and adversely affected as a result.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;">For example, we currently rely on a sole supplier for treprostinil, the active pharmaceutical ingredient of YUTREPIA, which sources treprostinil from a manufacturer in South Korea, with whom we have a long-term supply agreement. If our supplier is unable to supply treprostinil to us in the quantities we require, or at all, or otherwise defaults on its supply obligations to us, or if it ceases its relationship with us, we may not be able to obtain alternative supplies of treprostinil from other suppliers on acceptable terms, in a timely manner, or at all. We also rely on a sole supplier located in Tampa, Florida for encapsulation and packaging services, with whom we have a long-term contract. Furthermore, YUTREPIA is administered using the RS00 Model 8 DPI, which is manufactured by Plastiape, which is located in Italy. In the event of any prolonged disruption to our supply of treprostinil, the encapsulation and packaging services, or the manufacture and supply of RS00 Model 8 DPI, our ability to develop and commercialize, and the timeline for commercialization of, YUTREPIA may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;">We also rely upon Chengdu for the manufacture and supply of RG Cartridges for the subcutaneous administration of Treprostinil Injection and upon ICU Medical for ongoing servicing and support of the CADD-MS 3, CADD Legacy and CADD-Solis infusion pumps. In the event of any disruption to our supply of RG Cartridges or any disruption in the availability of parts or servicing for the CADD-MS 3, CADD Legacy and CADD-Solis infusion pumps, sales of Treprostinil Injection may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;">In addition, ICU Medical has indicated that they will no longer support the CADD MS-3. Although we believe that the number of available CADD-MS 3 infusion pumps will be sufficient to continue serving patients through the end of 2025, we are relying upon Mainbridge for the development of new pumps for the subcutaneous administration of Treprostinil Injection to replace the CADD MS-3. In addition, we have still not submitted a 510(k) clearance application and are currently uncertain when, if ever, such a 510(k) clearance application will be submitted. If we are unable to identify options to maintain the availability of the existing CADD MS-3 pumps until the new pumps are cleared by the FDA, sales of Treprostinil Injection may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;">For L606, we rely upon single sources of supply for the active pharmaceutical ingredient, manufacture of bulk drug product and packaging. Some of these suppliers are located in Taiwan. Although we are working to establish a </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;">secondary supply chain outside of Taiwan, if hostilities were to break out between Taiwan and China, we may be unable to secure a supply of L606. Also, we are currently evaluating devices to use for the administration of L606. If we are unable to identify a device to use for our L606 program, establish an agreement with the manufacturer of that device for the supply of such devices or obtain adequate quantities of that device in a timely manner or at all, we may be unable to successfully develop L606 or to do so in a timely manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;">If any of our sole source suppliers are adversely affected by geopolitical events, natural disasters or other events that disrupt or adversely affect their operations or their ability to supply us, our business may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to establish or maintain licensing and collaboration arrangements with other pharmaceutical companies on acceptable terms, or at all, we may not be able to develop and commercialize additional product candidates using our PRINT technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have collaborated, and may consider collaborating, with, among others, pharmaceutical companies to expand the applications for our PRINT technology through licensing as well as joint product development arrangements. In addition, if we are able to obtain marketing approval for our product candidates from regulatory authorities, we may enter into strategic relationships with collaborators for the commercialization of such products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Collaboration and licensing arrangements are complex and time-consuming to negotiate, document, implement and maintain. We may not be successful in our efforts to establish collaboration or other alternative arrangements should we so choose to enter into such arrangements. In addition, the terms of any collaboration or other arrangements that we may enter into may not be favorable to us or may restrict our ability to enter into further collaboration or other arrangements with third parties. For example, collaboration agreements may contain exclusivity arrangements which limit our ability to work with other pharmaceutical companies to expand the applications for our PRINT technology, as is the case in our collaboration agreement with GSK which restricts our ability to use PRINT for inhaled applications with respect to certain identified compounds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If we are unable to establish licensing and collaboration arrangements or the terms of such agreements we enter into are unfavorable to us or restrict our ability to work with other pharmaceutical companies, we may not be able to expand the applications for our PRINT technology or commercialize our products, if and when approved, and our business and prospects may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our collaboration and licensing arrangements may not be successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our collaboration and licensing arrangements, as well as any future collaboration and licensing arrangements that we may enter into, may not be successful. The success of our collaboration and licensing arrangements will depend heavily on the efforts and activities of our collaborators, which are not within our control. We may, in the course of our collaboration and licensing arrangements, be subject to numerous risks, including, but not limited to, the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our collaborators may have significant discretion in determining the efforts and resources that they will contribute;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial, abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing. For example, in July 2018, GSK notified us of its decision to discontinue development of the inhaled antiviral for viral exacerbations in COPD after completion of its related Phase 1 clinical trial and we do not believe that GSK is currently advancing any program under our collaboration;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our collaborators may independently, or in conjunction with others, develop products that compete directly or indirectly with our product candidates;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may grant exclusive rights to our collaborators that would restrict us from collaborating with others. For example, we are currently subject to certain restrictions with regard to our ability to enter into collaboration arrangements to use PRINT for the development of inhaled therapeutics using certain identified compounds pursuant to our collaboration with GSK;</span></td><td style="width:7.2pt;"/></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes may arise between us and our collaborators, which may cause a delay in or the termination of our research, development or commercialization activities;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our collaboration and licensing arrangements may be terminated, and if terminated, may result in our need for additional capital to pursue further drug product development or commercialization. For example, our development and licensing agreement with G&amp;W Laboratories, Inc., was mutually terminated in April 2018;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our collaborators may own or co-own certain intellectual property arising from our collaboration and licensing arrangements with them, which may restrict our ability to develop or commercialize such intellectual property; and</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our collaborators may alter the strategic direction of their business or may undergo a change of control or management, which may affect the success of our collaboration arrangements with them.</span></td><td style="width:7.2pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;"><span style="font-weight:bold;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to our Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be subject to claims from third parties that our products infringe their intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The pharmaceutical industry has experienced rapid technological change and obsolescence in the past, and our competitors have strong incentives to stop or delay any introduction of new drug products or related technologies by, among others, establishing intellectual property rights over their drug products or technologies and aggressively enforcing these rights against potential new entrants into the market. We expect that we and other industry participants will be increasingly subject to infringement claims as the number of competitors and drug products grows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our commercial success depends in large part upon our ability to develop, manufacture, market and sell our drug products or product candidates without infringing on the patents or other proprietary rights of third parties. It is not always clear to industry participants, including us, what the scope of a patent covers. Due to the large number of patents in issue and patent applications filed in our industry, there is a risk that third parties will claim that our products or technologies infringe their intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Claims for infringement of intellectual property which are brought against us, whether with or without merit, and which are generally uninsurable, could result in time-consuming and costly litigation, diverting our management&#8217;s attention from our core business and reducing the resources available for our drug product development, manufacturing and marketing activities, and consequently have a material and adverse effect on our business and prospects, regardless of the outcome. Moreover, such proceedings could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not being issued. We also may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Uncertainties resulting from the initiation and continuation of litigation or other proceedings could also have a material and adverse effect on our ability to compete in the market. Third parties making claims against us could obtain injunctive or other equitable relief against us, which could prevent us from further developing or commercializing our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In particular, under the Hatch-Waxman Act, the owner of patents listed on the Orange Book and referenced by an NDA applicant may bring patent infringement suit against the NDA applicant after receipt of the NDA applicant&#8217;s notice of paragraph IV certification. For example, in connection with an amendment to our NDA filed in July 2023 to add PH-ILD as an indication for YUTREPIA, a new notice of the paragraph IV certification was provided to United Therapeutics as the owner of the patents that are the subject of the certification to which the NDA for YUTREPIA refers. As a result, United Therapeutics filed the New Hatch-Waxman Litigation, in which it sought a preliminary injunction. While the motion for a preliminary injunction was denied, United Therapeutics may still seek injunctive relief in the New Hatch-Waxman Litigation. Although we do not believe United Therapeutics is entitled to a preliminary injunction in connection with the New Hatch-Waxman Litigation, it is possible that the Court could enjoin us from commercializing YUTREPIA for the treatment of PH-ILD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, United Therapeutics may seek to assert newly issued patents against us, including U.S. Patent Number 11,723,887, and may seek to enjoin the FDA from granting final approval to YUTREPIA or enjoin us from launching YUTREPIA, including through temporary restraining orders or injunctions that they may seek in the New FDA Litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In the event of a successful infringement claim against us, including an infringement claim filed in response to a paragraph IV certification, we may be required to pay damages, cease the development or commercialization of our drug products or product candidates, limit the label of our products to fewer indications than intended, re-engineer or redevelop our drug products or product candidates or enter into royalty or licensing agreements, any of which could have a material and adverse impact on our business, financial condition and results of operations. Any effort to re-engineer or redevelop our products would require additional monies and time to be expended and may not ultimately be successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Infringement claims may be brought against us in the future, and we cannot assure you that we will prevail in any ensuing litigation given the complex technical issues and inherent uncertainties involved in intellectual property litigation. Our competitors may have substantially greater resources than we do and may be able to sustain the costs of such litigation more effectively than we can.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our commercial success depends largely on our ability to protect our intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our commercial success depends, in large part, on our ability to obtain and maintain patent protection and trade secret protection in the United States and elsewhere in respect of our product candidates and PRINT technology. If we fail to adequately protect our intellectual property rights, our competitors may be able to erode, negate or preempt any competitive advantage we may have. To protect our competitive position, we have filed and will continue to file for patents in the United States and elsewhere in respect of our product candidates and PRINT technology. The process of identifying patentable subject matter and filing a patent application is expensive and time-consuming. We cannot assure you that we will be able to file the necessary or desirable patent applications at a reasonable cost, in a timely manner, or at all. Further, since certain patent applications are confidential until patents are issued, third parties may have filed patent applications for subject matter covered by our pending patent applications without us being aware of</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">such applications, and our patent applications may not have priority over patent applications of others. In addition, we cannot assure you that our pending patent applications will result in patents being obtained. Once published, all patent applications and publications throughout the world, including our own, become prior art to our new patent applications and may prevent patents from being obtained or interfere with the scope of patent protection that might be obtained. The standards that patent offices in different jurisdictions use to grant patents are not always applied predictably or uniformly and may change from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Even if we have been or are able to obtain patent protection for our product candidates or PRINT technology, if the scope of such patent protection is not sufficiently broad, we may not be able to rely on such patent protection to prevent third parties from developing or commercializing product candidates or technology that may copy our product candidates or technology. The enforceability of patents in the pharmaceutical industry involves complex legal and scientific questions and can be uncertain. Accordingly, we cannot assure you that third parties will not successfully challenge the validity, enforceability or scope of our patents. A successful challenge to our patents may lead to generic versions of our drug products being launched before the expiry of our patents or otherwise limit our ability to stop others from using or commercializing similar or identical products and technology. A successful challenge to our patents may also reduce the duration of the patent protection of our drug products or technology. In addition, we cannot assure you that we will be able to detect unauthorized use or take appropriate, adequate and timely actions to enforce our intellectual property rights. If we are unable to adequately protect our intellectual property, our business, competitive position and prospects may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Even if our patents or patent applications are unchallenged, they may not adequately protect our intellectual property or prevent third parties from designing around our patents or other intellectual property rights. If the patent applications we file or may file do not lead to patents being granted or if the scope of any of our patent applications is challenged, we may face difficulties in developing our product candidates, companies may be dissuaded from collaborating with us, and our ability to commercialize our product candidates may be materially and adversely affected. We are unable to predict which of our patent applications will lead to patents or assure you that any of our patents will not be found invalid or </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">unenforceable or challenged by third parties. The patents of others may prevent the commercialization of product candidates incorporating our technology. In addition, given the amount of time required for the development, clinical testing and regulatory review of new product candidates, any patents protecting our product candidates may expire before or shortly after such product candidates might become approved for commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Moreover, the issuance of a patent is not conclusive as to the inventorship of the patented subject matter, or its scope, validity or enforceability. We cannot assure you that all of the potentially relevant prior art, that is, any evidence that an invention is already known, relating to our patents and patent applications, has been found. If such prior art exists, it may be used to invalidate a patent or may prevent a patent from being issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Questions may also arise as to the ownership of our patents. For instance, in May 2024, United Therapeutics filed a complaint in the Superior Court in Durham County, North Carolina, in which it is seeking declaratory judgement such that all right, title and interest in and to any patentable or unpatentable inventions, discoveries, and ideas made or conceived by Dr. Roscigno while employed by the Company should be assigned and transferred to United Therapeutics because they involved the use of United Therapeutics&#8217; confidential information. If successful, United Therapeutics could obtain an ownership interest in our patents, which may either limit our ability to prevent United Therapeutics from using out patented inventions or even allow United Therapeutics to prevent us from using our own patented inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, we, our collaborators or our licensees may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. As a result, we may miss potential opportunities to seek patent protection or strengthen our patent position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to protect our trade secrets, the value of our PRINT technology and product candidates may be negatively impacted, which would have a material and adverse effect on our competitive position and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition to patent protection, we rely on trade secret protection to protect certain aspects of our intellectual property. We also license trade secrets from Pharmosa with respect to L606. While we require parties who have access to any portion of our trade secrets, such as our employees, consultants, advisers, CROs, CMOs, collaborators and other third parties, to enter into non-disclosure and confidentiality agreements with us, we cannot assure you that these parties will not disclose our proprietary information, including our trade secrets, in breach of their contractual obligations. Enforcing a claim that a party has illegally disclosed or misappropriated a trade secret is difficult, costly and time-consuming, and we may not be successful in doing so. If the steps we have taken to protect our trade secrets are deemed by the adjudicating court to be inadequate, we may not be able to obtain adequate recourse against a party for misappropriating our trade secrets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade secrets can be difficult to protect as they may, over time, be independently discovered by our competitors or otherwise become known despite our trade secret protection. If any of our trade secrets were to be lawfully obtained or independently developed by our competitors, we would have no right to prevent such competitors, or those to whom they communicate such technology or information, from using that technology or information to compete with us. Such competitors could attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If our trade secrets were to be disclosed to or independently developed by our competitors, our competitors may be able to exploit our PRINT technology to develop competing product candidates, and the value of our PRINT technology and our product candidates may be negatively impacted. This would have a material and adverse effect on our competitive position and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We rely on licenses to intellectual property that are owned by third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have entered and may, in the future, enter into license agreements with third parties to license the rights to use their technologies in our research, development and commercialization activities. License agreements generally impose various diligence, milestone payment, royalty, insurance and other obligations on us, and if we fail to comply with these obligations, our licensors may have the right to terminate these license agreements. Termination of these license </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">agreements or the reduction or elimination of our licensed rights or the exclusivity of our licensed rights may have an adverse impact on, among others, our ability to develop and commercialize our product candidates. We cannot assure you that we will be able to negotiate new or reinstated licenses on commercially acceptable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, we license certain patent rights for our PRINT technology from UNC under the UNC License. Under the UNC License, UNC has the right to terminate our license if we materially breach the agreement and fail to cure such breach within the stipulated time. In the event that UNC terminates our license and we have a product that relies on that license, including YUTREPIA, it may bring a claim against us, and if they are successful, we may be required to compensate UNC for the unauthorized use of their patent rights through the payment of royalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Similarly, under our license agreement with Pharmosa, Pharmosa has the right to terminate our license if we materially breach the agreement and fail to cure such breach within the stipulated time. In the event that Pharmosa terminates our license and we have a product that relies on that license, including L606, it may bring a claim against us, and if they are successful, we may be required to compensate Pharmosa for the unauthorized use of their patent rights through the payment of royalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Also, the agreements under which we license patent rights may not give us control over patent prosecution or maintenance, so that we may not be able to control which claims or arguments are presented and may not be able to secure, maintain or successfully enforce necessary or desirable patent protection from those patent rights. We do not have primary control over patent prosecution and maintenance for certain of the patents we license, and therefore cannot assure you that these patents and applications will be prosecuted or maintained in a manner consistent with the best interests of our business. We also cannot assure you that patent prosecution and maintenance activities by our licensors, if any, will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pursuant to the terms of some of our license agreements with third parties, some of our third-party licensors have the right, but not the obligation, in certain circumstances, to control the enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents. Even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors, and we cannot assure you that we will receive such cooperation on commercially acceptable terms, or at all. We also cannot assure you that our licensors will allocate sufficient resources or prioritize their or our enforcement of these patents or defense of these claims to protect our interests in the licensed patents. If we cannot obtain patent protection, or enforce existing or future patents against third parties, our competitive position, business and prospects may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Further, licenses to intellectual property may not always be available to us on commercially acceptable terms, or at all. In the event that the licenses we rely on are not available to us on commercially acceptable terms, or at all, our ability to commercialize our PRINT technology or product candidates, and our business and prospects, may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be able to enforce our intellectual property rights throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Filing, prosecuting, enforcing and defending patents on our PRINT technology and our product candidates throughout the world may be prohibitively expensive and may not be financially or commercially feasible. In countries where we have not obtained patent protection, our competitors may be able to use our proprietary technologies to develop competing product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Also, the legal systems of non-U.S. jurisdictions may not protect intellectual property rights to the same extent or in the same manner as the laws of the United States, and we may face significant difficulty in enforcing our intellectual property rights in these jurisdictions. The legal systems of certain developing countries may not favor the enforcement of patents and other intellectual property rights. We may therefore face difficulty in stopping the infringement or misappropriation of our patents or other intellectual property rights in those countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We need to protect our trademark, trade name and service mark rights to prevent competitors from taking advantage of our name recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We believe that the protection of our trademark, trade name and service mark rights, such as Liquidia, the Liquidia logo, PRINT, and YUTREPIA, is an important factor in product recognition, protecting our brand, maintaining goodwill and maintaining or increasing market share. We may expend substantial cost and effort in an attempt to register new trademarks, trade names and service marks and maintain and enforce our trademark, trade name and service mark rights. If we do not adequately protect our rights in our trademarks, trade names and service marks from infringement, any name recognition that we have developed in those trademarks could be lost or impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third parties may claim that the sale or promotion of our products, when and if approved, may infringe on the trademark, trade name and service mark rights of others. Trademark, trade name and service mark infringement problems occur frequently in connection with the sale and marketing of pharmaceutical products. If we become involved in any dispute regarding our trademark, trade name and service mark rights, regardless of whether we prevail, we could be required to engage in costly, distracting and time-consuming litigation that could harm our business. If the trademarks, trade names and service marks we use are found to infringe upon the trademarks, trade names or service marks of another company, we could be liable for damages and be forced to stop using those trademarks, trade names or service marks, and as a result, we could lose all the name recognition that has been developed in those trademarks, trade names or service marks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to the Manufacturing of our Product Candidates&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our product candidates are based on our proprietary, novel technology, which has not been used to manufacture any products that have been previously approved by the FDA, making it difficult to predict the time and cost of development and of subsequently obtaining final regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our future success depends on the successful development of our novel PRINT technology and products based on it, including YUTREPIA, and the development of L606 using Pharmosa&#8217;s proprietary liposomal technology. To our knowledge, no regulatory authority has granted final approval to market or commercialize drugs made using our PRINT technology or Pharmosa&#8217;s liposomal technology. We may never receive final approval to market and commercialize any product candidate that uses our PRINT technology or Pharmosa&#8217;s liposomal technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Even if we receive final approval to market YUTREPIA and/or L606, we will need to scale up our manufacturing capabilities to effectively commercialize the products. We have never completed a scale up of our PRINT manufacturing process or the manufacturing process for L606, and, if we are unable to do so in an effective and timely manner, our ability to commercialize these products, even if they receive final FDA approval, will be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may experience unexpected challenges as we ramp up our manufacturing capacity to meet demand or during commercial manufacturing, which may result in our inability to supply sufficient quantities of product to meet demand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The manufacturing process for our products is complex, due in part to strict regulatory requirements. A failure of our quality control systems in our facilities or those of our CMOs could cause problems to arise in connection with facility operations for a variety of reasons, including equipment malfunction, viral contamination, failure to follow specific manufacturing instructions, protocols and standard operating procedures, problems with raw materials or environmental factors. Such problems could affect production of a single batch or a series of batches, requiring the destruction of products, or could halt manufacturing operations altogether. For instance, as we scale up the manufacture of YUTREPIA, we are adjusting the speed and temperature at which our blister packs are sealed to reduce the risk of the product being exposed to moisture. Our failure to meet required quality standards may result in our failure to timely deliver products to our customers in sufficient quantities to meet demand, which in turn could damage our reputation for quality and service. Any such incident could, among other things, lead to increased costs, lost revenue, damage to our reputation and relationships with patients, health care providers and third-party payors, time and expense spent investigating the cause and, depending on the cause, similar losses with respect to other batches. With respect to our commercial manufacturing, if problems are not discovered before the product is released to the market, we may be </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">subject to regulatory actions, including product recalls, product seizures, injunctions to halt manufacture and distribution, restrictions on our operations, civil sanctions, including monetary sanctions, and criminal actions. In addition, such issues could subject us to litigation, the cost of which could be significant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our operations are concentrated in Morrisville, North Carolina and interruptions affecting us or our suppliers due to natural disasters or other unforeseen events could materially and adversely affect our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Most of our current operations are concentrated in Morrisville, North Carolina. In addition, our inventory is warehoused in a limited number of locations. A fire, flood, hurricane, earthquake or other disaster or unforeseen event resulting in significant damage to our facilities or to inventory held by us could significantly disrupt or curtail or require us to cease our operations. It would be difficult, costly and time- consuming to transfer resources from one facility to another, to repair or replace our facility or to replace inventory in the event that it is significantly damaged. In addition, our insurance may not be sufficient to cover all of our losses and may not continue to be available to us on acceptable terms, or at all. In addition, if one of our suppliers experiences a similar disaster or unforeseen event, we could face significant loss of our inventory and significant delays in obtaining our supplies or be required to source supplies from an alternative supplier and may incur substantial costs as a result. Any significant uninsured loss, prolonged or repeated disruption to operations or inability to operate, experienced by us or by our suppliers, could materially and adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, for L606, we rely upon single sources of supply for the active pharmaceutical ingredient and manufacture of bulk drug that are located in Taiwan. Although we are working to establish a secondary supply chain outside of Taiwan, if hostilities were to break out between Taiwan and China, we may be unable to secure a supply of L606, which could limit our ability to continue development of L606 and materially and adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to our Employees&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We depend on skilled labor, and our business and prospects may be adversely affected if we lose the services of our skilled personnel, including those in senior management, or are unable to attract new skilled personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our ability to continue our operations and manage our potential future growth depends on our ability to hire and retain suitably skilled and qualified employees, including those in senior management, in the long-term. Due to the specialized nature of our work, there is a limited supply of suitable candidates. We compete with other biotechnology and pharmaceutical companies, educational and research institutions and government entities, among others, for research, technical, clinical and sales and marketing personnel. In addition, in order to manage our potential future growth effectively, we will need to improve our financial controls and systems and, as necessary, recruit sales, marketing, managerial and finance personnel. The loss of the services of members of our sales team could seriously harm our ability to successfully implement our business strategy. If we are unable to attract and retain skilled personnel, including in particular Roger Jeffs, our Chief Executive Officer, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, our business and prospects may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Future sales of our Common Stock or securities convertible into our Common Stock in the public market could cause our stock price to fall.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our stock price could decline as a result of sales of a large number of shares of our Common Stock or the perception that these sales could occur. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of October 30, 2024, 84,636,621 shares of our Common Stock were outstanding, of which 76,405,243 shares of Common Stock, or 90.3% of our outstanding shares as of October 30, 2024, are freely tradable without restriction or further registration under the Securities Act, provided however, some of these shares are held by persons deemed to be </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8220;affiliates&#8221; under the Securities Act, including our officers and directors, as well as our principal stockholders, and may not be sold except: (i) in compliance with Rule 144 under the Securities Act or (ii) pursuant to any other applicable exemption under the Securities Act. The remaining 8,231,378 shares held by our stockholders as of October 30, 2024 have not been registered under the Securities Act and may be only be sold (i) pursuant to an effective registration statement under the Securities Act covering the sale of those shares, (ii) in compliance with Rule 144 under the Securities Act or (iii) pursuant to any other applicable exemption under the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Shares issued upon purchase under the employee stock purchase plan or upon the exercise of stock options or vesting of restricted stock units outstanding under our equity incentive plans or pursuant to future awards granted under those plans will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules, any applicable market standoff and lock-up agreements, and Rule 144 and Rule 701 under the Securities Act. We have registered the offer and sale of all shares of Common Stock that we may issue under our equity compensation plans, including the employee stock purchase plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We expect that the market price of our Common Stock may be volatile, and you may lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The trading prices of the securities of pharmaceutical and biotechnology companies have been highly volatile. As such, the trading price of our Common Stock may be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. The market price for our Common Stock may be influenced by many factors, including:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of any clinical trials of any product candidate we may develop, including L606, or those of our competitors;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of Sandoz&#8217;s Treprostinil Injection to which we have commercial rights pursuant to the Promotion Agreement;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the market acceptance of the RG Cartridge for the subcutaneous administration of Treprostinil Injection;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether Mainbridge is able to complete the development of a new pump for the subcutaneous administration of Treprostinil Injection and obtain FDA clearance on a timely basis or at all;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our cash resources;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approvals or success of competitive products or technologies;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential approvals of any product candidate we may develop, including YUTREPIA and L606, for marketing by the FDA or equivalent foreign regulatory authorities (and, if approved, the scope of the indications for which such product candidates are approved) or any failure to obtain such approvals;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our involvement in significant lawsuits, such as stockholder litigation, litigation involving the FDA, including the New FDA Litigation, or litigation related to intellectual property, including </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">inter partes</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> review proceedings and Hatch-Waxman litigation with originator companies or others which may hold patents, including the ongoing litigation in connection with the patents, trade secrets and confidential information that United Therapeutics has asserted against us;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory or legal developments in the United States and other countries;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of our efforts to commercialize any product candidate we may develop, including YUTREPIA and L606, in the event we receive final approval from the FDA;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments or disputes concerning patents or other proprietary rights;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the recruitment or departure of key personnel;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the level of expenses related to any of our product candidates or clinical development programs;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of our efforts to discover, develop, acquire or in-license additional product candidates or products;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variations in our financial results or those of companies that are perceived to be similar to us;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the structure of healthcare payment systems;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market conditions in the pharmaceutical and biotechnology sectors and issuance of new or changed securities analysts&#8217; reports or recommendations;</span></td><td style="width:7.2pt;"/></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic, industry and market conditions; and</span></td><td style="width:7.2pt;"/></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the other factors described in this &#8220;Risk Factors&#8221; section.</span></td><td style="width:7.2pt;"/></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The stock market in general, and market prices for the securities of pharmaceutical companies like ours in particular, have from time to time experienced volatility that often has been unrelated to the operating performance of the underlying companies. These broad market and industry fluctuations may adversely affect the market price of our Common Stock, regardless of our operating performance. Stock prices of many pharmaceutical companies have fluctuated in a manner unrelated or disproportionate to the operating performance of those companies. In several recent situations when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our stockholders were to bring a lawsuit against us, the defense and disposition of the lawsuit could be costly and divert the time and attention of our management and harm our operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our principal stockholders and management own a significant percentage of our stock and will be able to exercise significant influence over matters subject to stockholder approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our executive officers, directors and principal stockholders, together with their respective affiliates, beneficially owned 39.0% of our capital stock as of October 30, 2024. Accordingly, our executive officers, directors and principal stockholders have significant influence in determining the composition of our board of directors (the &#8220;Board&#8221;), and voting on all matters requiring stockholder approval, including mergers and other business combinations, and continue to have significant influence over our operations. This concentration of ownership could have the effect of delaying or preventing a change in our control or otherwise discouraging a potential acquirer from attempting to obtain control of us that you may believe are in your best interests as one of our stockholders. This in turn could have a material adverse effect on our stock price and may prevent attempts by our stockholders to replace or remove the Board or management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">As a public company, we are obligated to develop and maintain proper and effective internal controls over financial reporting and any failure to do so may adversely affect investor confidence in us and, as a result, the trading price of our shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our Common Stock. In addition, any future testing by us conducted in connection with Section 404 of the Sarbanes-Oxley Act of 2002, as amended (the &#8220;Sarbanes-Oxley Act&#8221;) or the subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our consolidated financial statements or identify other areas for further attention or improvement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As required by the Sarbanes Oxley Act and commencing with the fiscal year ended December 31, 2019, we were required to furnish a report by management on, among other things, the effectiveness of our internal controls over financial reporting. See Item 4. Controls and Procedures for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Because we are a &#8220;smaller reporting company,&#8221; we may take advantage of certain scaled disclosures available to us, resulting in holders of our securities receiving less Company information than they would receive from a public company that is not a smaller reporting company. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are a &#8220;smaller reporting company&#8221; as defined under Rule 12b-2 of the Exchange Act. As of December 31, 2023, we are no longer an &#8220;emerging growth company,&#8221; as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012. As a smaller reporting company, we may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as (i) our Common Stock held by non-affiliates is less than $250 million measured on the last business day of our second fiscal quarter, or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and our Common Stock held by non-affiliates is less than $700 million measured on the last business day of our second fiscal quarter. Based on the closing price of our common stock on June 30, 2024 we will remain a smaller </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">reporting company through at least the end of 2025.  To the extent we take advantage of any reduced disclosure obligations, it may make it harder for investors to analyze the Company&#8217;s results of operations and financial prospectus in comparison with other public companies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As a smaller reporting company, we are permitted to comply with scaled-back disclosure obligations in our SEC filings compared to other issuers, including with respect to disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We have elected to adopt the accommodations available to smaller reporting companies. Until we cease to be a smaller reporting company, the scaled-back disclosure in our SEC filings will result in less information about our company being available than for other public companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If investors consider our Common Stock less attractive as a result of our election to use the scaled-back disclosure permitted for smaller reporting companies, there may be a less active trading market for our Common Stock and our share price may be more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us difficult, limit attempts by our stockholders to replace or remove our current management and adversely affect our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provisions of our certificate of incorporation and bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our stock. Among other things, the certificate of incorporation and bylaws:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">permit the Board to issue up to 10 million shares of preferred stock, with any rights, preferences and privileges as they may designate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that the authorized number of directors may be changed only by resolution of our Board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and may not be taken by written consent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">create a staggered board of directors such that all members of our Board are not elected at one time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allow for the issuance of authorized but unissued shares of our capital stock without any further vote or action by our stockholders; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish advance notice requirements for nominations for election to the Board or for proposing matters that can be acted upon at stockholders&#8217;&#160;meetings.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law (&#8220;DGCL&#8221;) which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any stockholder owning in excess of 15% of our outstanding stock for a period of three years following the date on which the stockholder obtained such 15% equity interest in us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The terms of our authorized preferred stock selected by our Board at any point could decrease the amount of earnings and assets available for distribution to holders of our Common Stock or adversely affect the rights and powers, including voting rights, of holders of our Common Stock without any further vote or action by the stockholders. As a result, the rights of holders of our Common Stock will be subject to, and may be adversely affected by, the rights of the holders of any preferred stock that may be issued by us in the future, which could have the effect of decreasing the market price of our Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Any provision of our certificate of incorporation or bylaws or Delaware corporate law that has the effect of delaying or deterring a change in control could limit opportunities for our stockholders to receive a premium for their shares of Common Stock, and could also affect the price that investors are willing to pay for our Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our certificate of incorporation designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our certificate of incorporation provides that, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for: (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors or officers to us or our stockholders; (iii) any action asserting a claim against us arising pursuant to any provision of the DGCL, our certificate of incorporation or our bylaws; or (iv) any action asserting a claim against us governed by the internal affairs doctrine; provided, that, this provision would not apply to suits brought to enforce a duty or liability created by the Securities Act or Exchange Act. Furthermore, our bylaws designate the federal district courts of the United States as the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Any person</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have received notice of and consented to the foregoing provisions. This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds more favorable for disputes with us or our directors or officers, which may discourage such lawsuits against us and our directors or officers. Alternatively, if a court were to find this choice of forum provision inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business, financial condition, prospects or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Because we do not anticipate paying any cash dividends on our Common Stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have never declared or paid cash dividends on our equity securities. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of our existing RIFA with HCR preclude us, and the terms of any future debt or financing agreement may preclude us, from paying dividends. As a result, capital appreciation, if any, of our equity securities will likely be your sole source of gain for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">An impairment of our long-lived contract acquisition costs and intangible assets, including goodwill, could have a material non-cash adverse impact on our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In connection with the accounting for our RareGen acquisition, we have recorded significant amounts of contract acquisition costs, intangible assets, and goodwill. Under GAAP, we must assess, at least annually and potentially more frequently, whether the value of goodwill has been impaired. Contract acquisition costs and amortizing intangible assets will be assessed for impairment in the event of an impairment indicator. The valuation of goodwill depends on a variety of factors, the success of our business, including our ability to obtain regulatory approval for YUTREPIA, global market and economic conditions, earnings growth and expected cash flows. Impairments may be caused by factors outside our control, such as actions by the FDA, increasing competitive pricing pressures, and various other factors. Significant and unanticipated changes or our inability to obtain or maintain regulatory approvals for our product candidates, including the NDA for YUTREPIA, could require a non-cash charge for impairment in a future period, which may significantly affect our results of operations in the period of such charge.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General Risks Related to the Commercialization of our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our business and operations may be adversely affected by the effects of health epidemics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our business and operations could be adversely affected by health epidemics in regions where we have offices, manufacturing facilities, concentrations of clinical trial sites or other business operations, and could cause significant disruption in the operations of clinical trial sites, contract manufacturers or suppliers and contract research organizations upon whom we rely.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The extent to which health epidemics impact our business and operations, including our clinical development and regulatory efforts, will depend on future developments that are highly uncertain and cannot be predicted with confidence at the time of this Quarterly Report on Form 10-Q, such as the severity and duration of future outbreaks, the duration and effect of business disruptions and the short-term effects, the administration, availability and efficacy of vaccination programs and the ultimate effectiveness of travel restrictions, quarantines, social distancing requirements and business closures in the United States and other countries to contain and treat any such health epidemic. These impacts could adversely affect our business, financial condition, results of operations and growth prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, to the extent any health epidemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described in this &#8220;Risk Factors&#8221; section and the &#8220;Risk Factors&#8221; sections of the documents incorporated by reference herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability. Changes and instability in global economic conditions and geopolitical matters could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. and global markets are experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between Russia and Ukraine. In February 2022, a full-scale military invasion of Ukraine by Russian troops began. Although the length and impact of the ongoing military conflict is highly unpredictable, the conflict in Ukraine has led to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions, which has contributed to periods of high inflation globally. We are continuing to monitor inflation, the situation in Ukraine and global capital markets and assessing its potential impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The global economy has been, and may continue to be, negatively impacted by Russia&#8217;s invasion of Ukraine. As a result of Russia&#8217;s invasion of Ukraine, the U.S., the European Union, the United Kingdom, and other G7 countries, among other countries, have imposed substantial financial and economic sanctions on certain industry sectors and parties in Russia. Broad restrictions on exports to Russia have also been imposed. These measures include: (i) comprehensive financial sanctions against major Russian banks; (ii) additional designations of Russian individuals with significant business interests and government connections; (iii) designations of individuals and entities involved in Russian military activities; and (iv) enhanced export controls and trade sanctions limiting Russia&#8217;s ability to import various goods. Russian military actions and the resulting sanctions could continue to adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets, potentially making it more difficult for us to obtain additional funds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, on October 7, 2023, Hamas militants and members of other terrorist organizations infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of terror attacks on civilian and military targets. Thereafter, Hamas launched extensive rocket attacks on Israeli population and industrial centers located along the Israeli border with the Gaza Strip. Shortly following the attack, Israel&#8217;s security cabinet declared war against Hamas and launched an aerial bombardment of various targets within the Gaza Strip. The Israeli government subsequently called for the evacuation of over one million residents of the northern part of the Gaza Strip and initiated ground operations in the Gaza Strip. It is possible that other terrorist and/or regional organizations will join the hostilities as well, including Hezbollah in Lebanon, and Palestinian military organizations in the West Bank, resulting in a widening of the conflict. The intensity and duration of Israel&#8217;s current war against Hamas is difficult to predict as are such war&#8217;s economic implications on the global economy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, since the commencement of these events, there have been continued hostilities along Israel&#8217;s northern border with Lebanon (with the Hezbollah terror organization) and southern border (with the Houthi movement in Yemen). It is possible that hostilities with Hezbollah in Lebanon will escalate, and that other terrorist organizations, including Palestinian military organizations in the West Bank as well as other hostile countries will join the hostilities. Such clashes may escalate in the future into a greater regional conflict.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Furthermore, because of current geopolitical tensions, the Biden administration has recently signed multiple executive orders regarding China. One particular executive order titled Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy, signed on September 12, 2022, will likely impact the pharmaceutical industry to encourage U.S. domestic manufacturing of pharmaceutical products. Moreover, there have been Congressional legislative proposals, such as the recent bill titled the BIOSECURE Act, to discourage contracting with Chinese companies on the development or manufacturing of pharmaceutical products. The BIOSECURE Act passed the U.S. House of Representatives on September 9, 2024. The version of the BIOSECURE Act that passed the U.S. House of Representatives included a grandfather clause that would allow contracts entered into with the Chinese companies named therein prior to the effective date of such legislation until January 1, 2032. The BIOSECURE Act must also pass the U.S. Senate before going to President Biden for either his veto or signature, and it is uncertain whether the bill will be brought to the floor for a vote by the U.S. Senate before the current legislative session expires on January 3, 2025.  Any additional executive orders or legislative action regarding or potential sanctions on China could materially impact our current manufacturing partners.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Although our business has not been materially impacted by these geopolitical tensions to date, such matters may affect our business and it is impossible to predict the extent to which our operations, or those of our suppliers and manufacturers, will be impacted in the short and long term, or the ways in which such matters may impact our business. The extent and duration of the military action, sanctions, actual or perceived political instability and resulting market disruptions are impossible to predict but could be substantial. Any such disruptions may also magnify the impact of other risks described herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The U.S. political and economic environment could materially impact our business operations and financial performance,</span>&#160;<span style="font-style:italic;font-weight:bold;">and uncertainty surrounding the potential legal, regulatory and policy changes by a new U.S. presidential administration may directly affect us and the global economy.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The political and economic environment in the U.S. and elsewhere has resulted in and will continue to result in some uncertainty. Changing regulatory policies because of the changing political environment could impact our regulatory and compliance costs and future revenues, all of which could materially and adversely affect our business, financial condition and operating results. Failure to adapt to or comply with evolving regulatory requirements or investor or stakeholder expectations and standards could negatively impact our reputation, ability to do business with certain partners, access to capital and our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Further, the recent presidential election and congressional seat turnover may result in increased regulatory and economic uncertainty. Changes in federal policy by the executive branch and regulatory agencies may occur over time through the new presidential administration&#8217;s and/or Congress&#8217;s policy and personnel changes, which could lead to changes involving the level of oversight and focus on the pharmaceutical industry; however, the nature, timing and economic and political effects of such potential changes remain highly uncertain. Any future changes in federal and state laws and regulations, as well as the interpretation and implementation of such laws and regulations, could affect us in substantial and unpredictable ways. At this time, it is unclear what laws, regulations and policies may change and whether future changes or uncertainty surrounding future changes will adversely affect our operating environment and therefore our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If the FDA or comparable regulatory authorities in other countries approve generic versions of our product candidates, or do not grant our product candidates a sufficient period of market exclusivity before approving their generic versions, our ability to generate revenue may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Once an NDA is approved, the drug product covered will be listed as a reference listed drug in the FDA&#8217;s Orange Book. In the United States, manufacturers of drug products may seek approval of generic versions of reference listed drugs through the submission of abbreviated new drug applications, or ANDAs. In support of an ANDA, a generic manufacturer is generally required to show that its product has the same active pharmaceutical ingredient(s), dosage form, strength, route of administration and conditions of use or labeling as the reference listed drug and that the generic version is bioequivalent to the reference listed drug. Generic drug products may be significantly less expensive to bring to market than the reference listed drug, and companies that produce generic drug products are generally able to offer </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">them at lower prices. Thus, following the introduction of a generic drug product, a significant percentage of the sales of any reference listed drug may be lost to the generic drug product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA will not approve an ANDA for a generic drug product until the applicable period of market exclusivity for the reference listed drug has expired. The applicable period of market exclusivity varies depending on the type of exclusivity granted. A grant of market exclusivity is separate from the existence of patent protection and manufacturers may seek to launch generic versions of our drug products following the expiry of their respective marketing exclusivity periods, even if our drug products are still under patent protection at the relevant time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any competition that our product candidates may face, if and when such product candidates are approved for marketing and commercialized, from generic versions could substantially limit our ability to realize a return on our investment in the development of our product candidates and have a material and adverse effect on our business and prospects.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are subject to risks related to information technology systems, including cyber-security risks; successful cyber-attacks or technological malfunctions can result in, among other things, financial losses, the inability to process transactions, the unauthorized release of confidential information and reputational risk, all of which would negatively impact our business, financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our use of technology is critical to our continued operations. We are susceptible to operational, financial and information security risks resulting from cyber-attacks or technological malfunctions. Successful cyber-attacks or technological malfunctions affecting us, our CMOS or our business partners can result in, among other things, financial losses, the inability to process transactions, the unauthorized release of confidential or proprietary information and reputational risk. As cybersecurity threats continue to evolve, we may be required to use additional resources to continue to modify or enhance protective measures or to investigate security vulnerabilities, which could have a material adverse effect on our business, financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General Risks Related to the Development and Regulatory Approval of our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if we obtain marketing approval for our product candidates in the United States, we or our collaborators may not obtain marketing approval for the same product candidates elsewhere.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may enter into strategic collaboration arrangements with third parties to commercialize our product candidates outside of the United States. In order to market any product candidate outside of the United States, we or our collaborators will be required to comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be recognized or accepted by regulatory authorities in other countries, and obtaining marketing approval in one country does not mean that marketing approval will be obtained in any other country. Approval processes vary among countries and additional product testing and validation, or additional administrative review periods, may be required from one country to the next.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Seeking marketing approval in countries other than the United States could be costly and time-consuming, especially if additional preclinical studies or clinical trials are required to be conducted. We currently do not have any product candidates approved for sale in any jurisdiction, including non-U.S. markets, and we do not have experience in obtaining marketing approval in non-U.S. markets. We currently also have not identified any collaborators to market our products outside of the United States and cannot assure you that such collaborators, even if identified, will be able to successfully obtain marketing approval for our product candidates outside of the United States. If we or our collaborators fail to obtain marketing approval in non-U.S. markets, or if such approval is delayed, our target market may be reduced, and our ability to realize the full market potential of our products will be adversely affected.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General Risks Related to Healthcare Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The pharmaceutical industry is subject to a range of laws and regulations in areas including healthcare program requirements and fraud, waste, and abuse; healthcare and related marketing compliance and transparency; and privacy and data security. Our failure to comply with these laws and regulations as they are, or in the future become, applicable to us may have an adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;">Healthcare providers, physicians and third-party payors often play a primary role in the recommendation and prescription of any drug products for which we may obtain marketing approval, or for which we may provide contracted promotional services to third parties. Our current and future arrangements with healthcare providers, physicians, third-party payors and customers, and our sales, marketing and educational activities, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations (at the federal and state level) that may constrain our business or financial arrangements and relationships through which we market, sell, or distribute drug products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;">In addition, we may be subject to transparency laws and patient privacy regulation by both the federal government and the states in which we conduct our business. We also plan to conduct clinical trials and may in the future conduct business in jurisdictions outside of the United States, which may cause us to become subject to transparency law and privacy regulations in those jurisdictions as well.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;">The laws that may affect our ability to operate include, but are not limited to, the following examples:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.9pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The federal Anti-Kickback Statute, or AKS, prohibits, among other things, persons and entities including pharmaceutical manufacturers from, among other things, knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for or the purchase, lease, or order of, or the arranging for an item or service for which payment may be made, in whole or in part, under federal healthcare programs such as the Medicare and Medicaid programs.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The federal civil and criminal false claims laws and civil monetary penalty laws impose a range of prohibitions and compliance considerations. For example, the False Claims Act, or the FCA, prohibits individuals or entities from, among other things, knowingly presenting, or causing to be presented, claims for payment to, or approval by, the federal government that are false, fictitious or fraudulent or knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. Claims resulting from a violation of the federal AKS constitute a false or fraudulent claim for purposes of the FCA. Promotion that is deemed to be &#8220;off label&#8221; can be the basis of FCA exposure.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.7pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Federal law includes provisions (established under the Health Insurance Portability and Accountability Act of 1996) addressing healthcare fraud and false statements relating to healthcare matters. The healthcare fraud statute prohibits knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private payors. The false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Violations of these statutes is a felony and may result in fines, imprisonment or exclusion from governmental programs.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.7pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Privacy and data security laws may apply to our business. Under Section 5(a) of the Federal Trade Commission Act, the Federal Trade Commission expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Medical data is considered sensitive data that merits stronger safeguards. States may also impose requirements, for example the California Consumer Privacy Act created data privacy obligations for covered companies and providing privacy rights to California residents, including the right to opt out of certain </span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disclosures of their information. In addition, if we engage in business activities outside of the United States, including clinical trials that we plan to conduct outside of the United States, we may become subject to privacy and data security laws in those additional jurisdictions in which we operate or conduct clinical trials.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.7pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The federal physician payment transparency requirements, sometimes referred to as the &#8220;Physician Payments Sunshine Act,&#8221; requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under government healthcare programs to annually report to the Centers for Medicare and Medicaid Services, or the CMS, information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Payments and transfers of value made to certain other providers such as nurse practitioners and physician assistants will also need to be reported under the Sunshine Act.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.7pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">For both investigational and commercialized products, interactions with or communications directed to healthcare professionals, patients or patient- or disease-advocates or advocacy groups, and payors, are subject to heightened scrutiny by the FDA. Relative to nonpromotional communications, for example, there are specific and limited FDA accommodations for nonpromotional, truthful and non-misleading sharing of information regarding products in development and off-label uses including dissemination of peer-reviewed reprints, support of independent continuing medical education, and healthcare economic discussions with payors. In a competitive environment, a company&#8217;s communications about products in development may also be subject to heightened scrutiny.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.7pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply to items or services reimbursed by any third-party payor, including commercial insurers, and in some cases may apply regardless of payor (i.e., even for self-pay scenarios). Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report pricing and marketing information, including, among other things, information related to payments to physicians and other healthcare providers or marketing expenditures, state and local laws that require the registration of pharmaceutical sales representatives. Many of these state laws differ from each other in significant ways and may not have the same effect, and may apply more broadly or be stricter than their federal counterparts, thus complicating compliance efforts; and</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.7pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Price reporting laws require the calculation and reporting of complex pricing metrics to government programs, where such reported prices may be used in the calculation of reimbursements or discounts on our drug products. Participation in such programs and compliance with their requirements may subject us to increased infrastructure costs and potentially limit our ability to price our drug products.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Ensuring that our business and business arrangements with third parties comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert management&#8217;s attention from the business, even if the government ultimately finds that no violation has occurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If our operations are found to be in violation of any of the laws or regulations described above or any other laws or government regulations that apply to us, we may be subject to penalties and potentially, the curtailment or restructuring of our operations as well as additional governmental reporting obligations and oversight, any of which could adversely affect our ability to operate our business and our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Recently enacted and future legislation and other legal developments may increase the difficulty and cost for us to obtain marketing approval of and commercialize our products and product candidates and affect the prices we may obtain.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In the United States, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the ACA, is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose taxes and fees on the health industry and impose additional health policy reforms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Among the provisions of the ACA of importance to our product candidates are the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:27.75pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.9pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment of a new pathway for approval of lower-cost biosimilars to compete with biologic products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.9pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an annual, nondeductible fee payable by any entity that manufactures or imports specified branded prescription drugs and biologic agents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.9pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.9pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer point-of-sale discounts off negotiated prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.9pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">extension of manufacturers&#8217; Medicaid rebate liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.9pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion of eligibility criteria for Medicaid programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.9pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.9pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.9pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order initiating a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of 2011, enacted in August 2011, required sequestration that included aggregate reductions of Medicare payments to providers, which went into effect on April 1, 2013 and, due to subsequent legislative amendments, will remain in effect through 2032, unless additional Congressional action is taken. Under current legislation, the actual reduction in Medicare payments will increase in future years of the sequester. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and an increase in the statute of limitations period for the government to recover overpayments to providers from three to five years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Further, in March 2021, the American Rescue Plan Act of 2021 was signed into law, which, among other things, eliminated the statutory cap on drug manufacturers&#8217; Medicaid Drug Rebate Program rebate liability, effective January 1, 2024. Under current law enacted as part of the ACA, drug manufacturers&#8217; Medicaid Drug Rebate Program rebate liability is capped at 100% of the average manufacturer price for a covered outpatient drug. In addition, on September 20, 2024, the Centers for Medicare &amp; Medicaid Services issued a final rule titled &#8220;Medicaid Program; Misclassification of Drugs, Program Integrity Updates Under the Medicaid Drug Rebate Program&#8221; which may impact our reimbursement and rebate strategy.  We expect that other healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">being able to price our products at what we consider to be a fair or competitive price, generate revenue, attain profitability, or commercialize our product candidates, if approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products. Individual states in the United States have become increasingly active in implementing regulations designed to contain pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. Most significantly, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or the IRA, into law. This statute marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation; and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services, or HHS, to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. Further, the Biden administration released an additional executive order on October 14, 2022, directing HHS to submit a report within 90 days on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. In response to the executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our ability to price our products appropriately, which could negatively impact our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates, if approved, or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA or foreign regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There is also a great degree of uncertainty regarding how the recent U.S. Supreme Court decisions, including Loper Bright Enterprises v. Raimondo and Corner Post, Inc. v. Board of Governors of the Federal Reserve System, will impact FDA&#8217;s enforcement and decision-making authority. Loper Bright explicitly overturned Chevron deference, which previously gave judicial deference to administrative action by agencies in the executive branch. Further, the Supreme Court&#8217;s decision in Corner Post may result in challenges to FDA decisions by new litigants long into the future, resulting in greater uncertainty about our continued operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General Risks Related to Our Dependence on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We rely on third parties to conduct our preclinical studies and clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We currently rely on, and plan to continue to rely on, third-party contract research organizations, or CROs, to monitor and manage data for our preclinical studies and clinical trials. However, we are responsible for ensuring that each of our trials is conducted in accordance with the applicable regulatory standards and our reliance on CROs does not relieve us of our regulatory responsibilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The CROs on which we rely are required to comply with FDA regulations (and the regulations of comparable regulatory authorities in other countries) regarding GCP. Regulatory authorities enforce GCP standards through periodic </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">inspections. If any of the CROs on which we rely fail to comply with the applicable GCP standards, the clinical data generated in our clinical trials may be deemed unreliable. While we have contractual agreements with these CROs, we have limited influence over their actual performance and cannot control whether or not they devote sufficient time and resources to our preclinical studies and clinical trials. A failure to comply with the applicable regulations in the conduct of the preclinical studies and clinical trials for our product candidates may require us to repeat such studies or trials, which would delay the process of obtaining marketing approval for our product candidates and have a material and adverse effect on our business and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Some of our CROs have the ability to terminate their respective agreements with us if, among others, it can be reasonably demonstrated that the safety of the patients participating in our clinical trials warrants such termination. If any of our agreements with our CROs is terminated, and if we are not able to enter into agreements with alternative CROs on acceptable terms or in a timely manner, or at all, the clinical development of our product candidates may be delayed and our development expenses could be increased.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General Risks Related to Legal Compliance Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if we obtain regulatory approval for a product candidate, our products and business will remain subject to ongoing regulatory obligations and review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, drug supply chain security surveillance and tracking, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and comparable requirements outside of the United States. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. Any regulatory approvals that we may receive for our product candidates may also be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS as a condition of approval of our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. We will also be required to report certain adverse reactions and production problems, if any, to the FDA or other regulatory agencies and to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. As such, we may not promote our products for indications or uses for which they do not have FDA or other regulatory agency approval. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process. We could also be asked to conduct post-marketing clinical studies to verify the safety and efficacy of our product candidates in general or in specific patient subsets. An unsuccessful post-marketing study or failure to complete such a clinical study could result in the withdrawal of marketing approval. Furthermore, any new legislation addressing drug safety issues could result in delays in product development or commercialization or increased costs to assure compliance. Foreign regulatory authorities impose similar requirements. If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issue warning letters asserting that we are in violation of the law;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek an injunction or impose civil or criminal penalties or monetary fines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend or withdraw regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspend any of our ongoing clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refuse to approve pending applications or supplements to approved applications submitted by us or our strategic partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrict the marketing or manufacturing of our products;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seize or detain products, or require a product recall;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refuse to permit the import or export of our product candidates; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:25.7pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refuse to allow us to enter into government contracts.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our product candidates. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Environmental, social and governance matters may impact our business and reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Governmental authorities, non-governmental organizations, customers, investors, external stakeholders and employees are increasingly sensitive to environmental, social and governance, or ESG, concerns, such as diversity and inclusion, climate change, water use, recyclability or recoverability of packaging, and plastic waste. This focus on ESG concerns may lead to new requirements that could result in increased costs associated with developing, manufacturing and distributing our products. Our ability to compete could also be affected by changing customer preferences and requirements, such as growing demand for more environmentally friendly products, packaging or supplier practices, or by failure to meet such customer expectations or demand. While we strive to improve our ESG performance, we risk negative stockholder reaction, including from proxy advisory services, as well as damage to our brand and reputation, if we do not act responsibly, or if we are perceived to not be acting responsibly in key ESG areas, including equitable access to medicines and vaccines, product quality and safety, diversity and inclusion, environmental stewardship, support for local communities, corporate governance and transparency, and addressing human capital factors in our operations. If we do not meet the ESG expectations of our investors, customers and other stakeholders, we could experience reduced demand for our products, loss of customers, and other negative impacts on our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Climate change or legal, regulatory or market measures to address climate change may negatively affect our business, results of operations, cash flows and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We believe that climate change has the potential to negatively affect our business and results of operations, cash flows and prospects. We are exposed to physical risks (such as extreme weather conditions or rising sea levels), risks in transitioning to a low-carbon economy (such as additional legal or regulatory requirements, changes in technology, market risk and reputational risk) and social and human effects (such as population dislocations and harm to health and well-being) associated with climate change. These risks can be either acute (short-term) or chronic (long-term).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The adverse impacts of climate change include increased frequency and severity of natural disasters and extreme weather events such as hurricanes, tornados, wildfires (exacerbated by drought), flooding, and extreme heat. Extreme weather and sea-level rise pose physical risks to our facilities as well as those of our suppliers. Such risks include losses incurred as a result of physical damage to facilities, loss or spoilage of inventory, and business interruption caused by such natural disasters and extreme weather events. Other potential physical impacts due to climate change include reduced access to high-quality water in certain regions and the loss of biodiversity, which could impact future product development. These risks could disrupt our operations and its supply chain, which may result in increased costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">New legal or regulatory requirements may be enacted to prevent, mitigate, or adapt to the implications of a changing climate and its effects on the environment. These regulations, which may differ across jurisdictions, could result in us being subject to new or expanded carbon pricing or taxes, increased compliance costs, restrictions on greenhouse gas emissions, investment in new technologies, increased carbon disclosure and transparency, upgrade of facilities to meet </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">new building codes, and the redesign of utility systems, which could increase our operating costs, including the cost of electricity and energy used by us. Our supply chain would likely be subject to these same transitional risks and would likely pass along any increased costs to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General Risks Related to our Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may become involved in litigation to protect our intellectual property or enforce our intellectual property rights, which could be expensive, time-consuming and may not be successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Competitors may infringe our patents or misappropriate or otherwise violate our intellectual property rights. To counter infringement or unauthorized use, we may engage in litigation to, among others, enforce or defend our intellectual property rights, determine the validity or scope of our intellectual property rights and those of third parties, and protect our trade secrets. Such actions may be time-consuming and costly and may divert our management&#8217;s attention from our core business and reduce the resources available for our clinical development, manufacturing and marketing activities, and consequently have a material and adverse effect on our business and prospects, regardless of the outcome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, in an infringement proceeding, a court may decide that a patent owned by, or licensed to, us is invalid or unenforceable, or may refuse to stop the other party from using the technology in question on the ground that our patents do not cover such technology. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that our confidential information may be compromised by disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. While various extensions may be available, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We intend to seek extensions of patent terms in the United States and, if available, in other countries where we prosecute patents. In the United States, the Hatch-Waxman Act permits patent owners to request a patent term extension, based on the regulatory review period for a product, of up to five years beyond the normal expiration of the patent, which is limited to one patent claiming the approved drug product or use in an indication (or any additional indications approved during the period of extension). However, the applicable authorities, including the FDA and the USPTO, in the United States, and comparable regulatory authorities in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or grant more limited extensions than we had requested. In such event, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our preclinical and clinical data in their marketing approval applications with the FDA to launch their drug product earlier than might otherwise be the case.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General Risks Related to the Manufacturing of our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our facilities are subject to extensive and ongoing regulatory requirements and failure to comply with these regulations may result in significant liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our company and our facilities are subject to payment of fees, registration and listing requirements, ongoing review and periodic inspections by the FDA and other regulatory authorities for compliance with quality system regulations, including the FDA&#8217;s cGMP requirements. These regulations cover all aspects of the manufacturing, testing, quality control and record-keeping of our drug products. Furthermore, the facilities where our product candidates are manufactured may be subject to additional inspections by the FDA before we can obtain final marketing approval and remain subject to periodic inspection even after our product candidates have received marketing approval. Suppliers of </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">components and materials, such as active pharmaceutical ingredients, used to manufacture our drug products are also required to comply with the applicable regulatory standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The manufacture of pharmaceutical products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. We and any contract manufacturers that we may engage in the future must comply with cGMP requirements. Manufacturers of pharmaceutical products often encounter difficulties in production, particularly in scaling up and validating initial production and contamination controls. These problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Compliance with these regulatory standards often requires significant expense and effort. If we or our suppliers are unable to comply with the applicable regulatory standards or take satisfactory corrective steps in response to adverse results of an inspection, this could result in enforcement action, including, among others, the issue of a public warning letter, a shutdown of or restrictions on our or our suppliers&#8217; manufacturing operations, delays in approving our drug products and refusal to permit the import or export of our drug products. Any adverse regulatory action taken against us could subject us to significant liability and harm our business and prospects.</p><a id="Item5OtherInfo"></a><a id="_9577001a_402e_4380_a255_abf1fe98b205"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 5. Other Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Rule 10b5-1 Trading Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the three months ended September&#160;30,&#160;2024, <ix:nonNumeric contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" format="ixt:booleanfalse" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_WzzRIkTEfUed9YNtjhERlw">n</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" format="ixt:booleanfalse" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_lFK9bxdFeEatLYFbsE5Iww">o</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" format="ixt:booleanfalse" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_TDiqbrorgkm8lkOBS9xfWg">n</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q" format="ixt:booleanfalse" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_-wtq7w8rr0iV-LNdvX9Dew">e</ix:nonNumeric> of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act)&#160;adopted&#160;or&#160;terminated&#160;any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any &#8220;non-Rule 10b5-1 trading arrangement&#8221; as defined in Item 408(c) of Regulation S-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the three months ended September&#160;30,&#160;2024, the Company did not adopt or terminate a Rule 10b5-1 trading arrangement (as defined in Item 408(a)(1)(i) of Regulation S-K).</p><a id="_9ecb9ee0_8b66_4625_a636_5e42d833cd1d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-weight:normal;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:11.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Item6Exhibits_907929"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;6. Exhibits</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The exhibits listed on the Exhibit&#160;Index hereto are filed or furnished (as stated therein) as part of this Quarterly Report on Form&#160;10-Q.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit No.</b></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Document</b></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">10.1</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1819576/000110465924099305/tm2423869d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Common Stock Purchase Agreement by and among Liquidia Corporation and the Purchasers, dated September 10, 2024 (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K, filed with the SEC on September 12, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">10.2</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1819576/000110465924099305/tm2423869d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement by and among Liquidia Corporation and the Purchasers, dated September 10, 2024 (incorporated by reference to Exhibit 10.2 of the Company&#8217;s Current Report on Form 8-K, filed with the SEC on September 12, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">10.3</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1819576/000110465924099305/tm2423869d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fifth Amendment to Revenue Interest Financing Agreement, dated as of September 11, 2024, by and between Liquidia Technologies, Inc. and Healthcare Royalty Partners IV, L.P. (incorporated by reference to Exhibit 10.3 of the Company&#8217;s Current Report on Form 8-K, filed with the SEC on September 12, 2024).</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">10.4*++</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="lqda-20240930xex10d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Device License Agreement, dated as of October 2, 2024, by and between Liquidia Technologies, Inc. and Pharmosa Biopharm Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">10.5*++</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="lqda-20240930xex10d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to the License Agreement, dated as of October 2, 2024, by and between Liquidia Technologies, Inc. and Pharmosa Biopharm Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">31.1*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="lqda-20240930xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes- Oxley Act.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">31.2*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="lqda-20240930xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes- Oxley Act.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">32.1**</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="lqda-20240930xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes- Oxley Act.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">32.2**</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="lqda-20240930xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes- Oxley Act.</span></a></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">101.INS*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">Inline XBRL Instance Document</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">101.SCH*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">Inline XBRL Taxonomy Extension Schema Document</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">101.CAL*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">101.DEF*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">101.LAB*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">104*</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:87.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;">Cover Page&#160;Interactive Data File (formatted in Inline XBRL and contained in Exhibit&#160;101).</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">*</span></span>Filed herewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">**</span></span>Furnished herewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">++</span></span>Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(b)(10). The omitted</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span></span>information is not material and would likely cause competitive harm to the Company if publicly disclosed.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_6882667f_0365_415c_825a_b0768b1c21da"></a><a id="SIGNATURES_439630"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DATE: November 13, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:47.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:11pt;"><td style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">LIQUIDIA CORPORATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.5pt;"><td style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:47.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Roger A. Jeffs, Ph.D.</p></td></tr><tr style="height:9.75pt;"><td style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Roger A. Jeffs, Ph.D.</p></td></tr><tr style="height:12.25pt;"><td style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DATE: November 13, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:47.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:11pt;"><td style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">LIQUIDIA CORPORATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:11.5pt;"><td style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:47.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Michael Kaseta</p></td></tr><tr style="height:9.75pt;"><td style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael Kaseta</p></td></tr><tr style="height:12.25pt;"><td style="vertical-align:top;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Operating Officer and Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>2
<FILENAME>lqda-20240930xex10d4.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 11/13/2024 03:22:37 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><a name="_9kP1qJ9mv4AD"></a><a name="_Hlk170912958"></a><font style="font-style:italic;font-weight:bold;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:2.38;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:2.38;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:2.38;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:2.38;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:2.38;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:2.38;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:2.38;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:2.38;text-align:right;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:2.38;text-align:center;margin:0pt;"><b style="font-weight:bold;">DEVICE LICENSE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-variant:small-caps;">dated as of October 2, 2024</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-variant:small-caps;">by and between</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-variant:small-caps;">Pharmosa Biopharm Inc.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-variant:small-caps;">and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:2.38;text-align:center;margin:0pt;"><font style="font-variant:small-caps;">Liquidia Technologies, Inc</font><a name="_Hlk170912959"></a><font style="font-variant:small-caps;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:2.38;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:2.38;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:2.38;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:2.38;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:2.38;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:2.38;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:2.38;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:2.38;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:2.38;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;font-size:11pt;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">ARTICLE 1 DEFINTIONS&#8230;..&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;...</b><font style="font-weight:bold;">1</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:6pt;margin-left:0pt;margin-top:6pt;overflow:hidden;position:relative;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-transform:uppercase;">ARTICLE 2</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;text-transform:uppercase;"><font style="white-space:pre-wrap;"> </font>L</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-transform:uppercase;">icenses AND OTHER RIGHTS</b></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:2.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-transform:uppercase;">8</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">2.1</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Grant of License to Company</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">8</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">2.2</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Grant of Sublicense by Company</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">8</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">2.3</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Licensor Technology Transfer</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">8</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">2.4</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Manufacturing Technology Transfer</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">8</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">2.5</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Procedures for Licensor Technology Transfer</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">9</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">2.6</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Second Device Option</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">9</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">2.7</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Company Technology Transfer</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">9</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:6pt;margin-left:0pt;margin-top:6pt;overflow:hidden;position:relative;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-transform:uppercase;">ARTICLE 3 DEVELOPMENT, COMMERCIALIZATION and Manufacture OF DEVICES</b></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:2.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-transform:uppercase;">10</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">3.1</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Development</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">.</font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">10</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">3.2</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Commercialization</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">12</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">3.3</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Manufacturing</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">.</font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">12</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">3.4</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Right to Subcontract of Company</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">13</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">3.5</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Trademarks</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">.</font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">13</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:6pt;margin-left:0pt;margin-top:6pt;overflow:hidden;position:relative;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-transform:uppercase;">ARTICLE 4 REGULATORY MATTERS</b></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:2.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-transform:uppercase;">13</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">4.1</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Regulatory Filings</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">13</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">4.2</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Communications with Authorities</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">13</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">4.3</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Licensor Support in Regulatory Matters</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  .</font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">13</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">4.4</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Adverse Event Reporting</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">14</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin:0pt 0pt 0pt 11pt;"><font style="display:inline-block;text-indent:0pt;width:33pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">4.5</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;">Safety Data Exchange Agreement</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;white-space:pre-wrap;">.  </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin:0pt 0pt 0pt 11pt;"><font style="display:inline-block;text-indent:0pt;width:33pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;">14</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:6pt;margin-left:0pt;margin-top:6pt;overflow:hidden;position:relative;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-transform:uppercase;">ARTICLE 5 CONSIDERATION</b></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:2.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-transform:uppercase;">15</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">5.1</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Consideration</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">15</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">5.2</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">No Double-Counting</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">15</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:6pt;margin-left:0pt;margin-top:6pt;overflow:hidden;position:relative;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-transform:uppercase;">ARTICLE 6 INTELLECTUAL PROPERTY MATTERS</b></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:2.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-transform:uppercase;">15</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">6.1</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Certification Under Drug Price Competition and Patent Restoration Act</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">15</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">6.2</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Listing of Patents</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">15</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">6.3</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Further Assurances</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">15</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">6.4</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Patent Prosecution and Maintenance</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">.</font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">15</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">6.5</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Enforcement</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">.</font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">17</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">6.6</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Third Party Actions Claiming Infringement</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">.</font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">18</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:6pt;margin-left:0pt;margin-top:6pt;overflow:hidden;position:relative;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-transform:uppercase;">ARTICLE 7 CONFIDENTIALITY</b></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:2.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-transform:uppercase;">19</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">7.1</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Confidentiality Obligations</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">19</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">7.2</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Use</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">19</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">7.3</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Required Disclosure</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">20</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">7.4</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Publications</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">20</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">7.5</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Press Releases and Disclosure</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">.</font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">20</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:6pt;margin-left:0pt;margin-top:6pt;overflow:hidden;position:relative;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-transform:uppercase;">ARTICLE 8 REPRESENTATIONS, WARRANTIES AND COVENANTS</b></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:2.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-transform:uppercase;">21</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">8.1</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Representations and Warranties</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">21</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">8.2</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Additional Representations and Warranties of Licensor</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">21</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">8.3</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Licensor Covenants</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">24</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:6pt;margin-left:0pt;margin-top:6pt;overflow:hidden;position:relative;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-transform:uppercase;">ARTICLE 9 INDEMNIFICATION AND INSURANCE</b></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:2.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-transform:uppercase;">24</font></font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">9.1</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Indemnification by Company</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">. </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">24</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">9.2</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Indemnification by Licensor</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  .</font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">24</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">9.3</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">No Consequential Damages</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">25</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">9.4</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Notification of Claims; Conditions to Indemnification Obligations</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">25</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">9.5</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Insurance</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">25</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:6pt;margin-left:0pt;margin-top:6pt;overflow:hidden;position:relative;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-transform:uppercase;">ARTICLE 10 TERM AND TERMINATION</b></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:2.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-transform:uppercase;">25</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">10.1</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Term and Expiration</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">25</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">10.2</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Termination upon Material Breach</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">.</font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">26</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">10.3</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Bankruptcy Event Termination</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">26</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">10.4</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Mutual Termination</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">26</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">10.5</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Effects of Termination</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">.</font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">26</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">10.6</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Additional Effects of Termination for a Licensor Bankruptcy Event</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">.</font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">28</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">10.7</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Other Remedies</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">29</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:6pt;margin-left:0pt;margin-top:6pt;overflow:hidden;position:relative;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-transform:uppercase;">ARTICLE 11 DISPUTE RESOLUTION</b></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:2.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-transform:uppercase;">29</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">11.1</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">General</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">29</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">11.2</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Escalation to Executive Officers</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">29</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">11.3</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Arbitration</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">.</font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">29</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">11.4</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Injunctive Relief</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">. </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">31</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:6pt;margin-left:0pt;margin-top:6pt;overflow:hidden;position:relative;text-transform:uppercase;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-transform:uppercase;">ARTICLE 12 MISCELLANEOUS PROVISIONS</b></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:2.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-transform:uppercase;">31</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">12.1</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Relationship of the Parties</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">31</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">12.2</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Assignment</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">.</font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">31</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">12.3</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Performance and Exercise by Affiliates</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">31</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">12.4</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Further Actions</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">32</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">12.5</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Accounting Procedures</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">32</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">12.6</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Force Majeure</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">32</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">12.7</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">No Trademark Rights</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">32</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">12.8</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Entire Agreement of the Parties; Amendments</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">32</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:9.63%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">12.9</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Captions</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">32</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:12.04%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">12.10</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Governing Law</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">32</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:12.04%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">12.11</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Notices and Deliveries</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">32</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:12.04%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">12.12</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Language. </b></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">33</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:12.04%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">12.13</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Waiver</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">.</font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">33</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:12.04%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">12.14</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Severability</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">. </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">33</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:12.04%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">12.15</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">No Implied License</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">. </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">34</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:12.04%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">12.16</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Interpretation</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">34</font></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-variant:small-caps;margin-bottom:0pt;margin-left:11pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;min-width:12.04%;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">12.17</font></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:bold;">Counterparts</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;white-space:pre-wrap;">.  </font></font><font style="bottom:2.8793945pt;display:block;height:1em;left:0pt;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-variant:small-caps;font-weight:normal;">36</font></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedules:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Schedule 1.21 - Licensor&#8217;s Knowledge Individuals</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Schedule 1.28 &#8211; Licensor Know-How</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Schedule 1.29 - Licensor&#8217;s Knowledge Individuals</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Schedule 1.30 &#8211; Licensor Patents</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Schedule 1.37 - PN1[***] Device Specification</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Schedule 1.38 - PN2[***] Device Specification</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Schedule 2.3 - Licensor Technology Transfer Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Schedule 7.5.1 - Initial Press Release</p><p style="display:none;font-size:11pt;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">DEVICE LICENSE AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Device License Agreement (this &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;) is dated as of October 2, 2024 (the &#8220;<b style="font-weight:bold;">Effective Date</b>&#8221;) by and between <a name="_Hlk133941304"></a>Pharmosa Biopharm Inc., a corporation incorporated under the laws of Taiwan having a place of business at 11F, No. 508, Section 7, Zhongxiao East Road, Nangang District, Taipei City 115, Taiwan (&#8220;<b style="font-weight:bold;">Licensor</b>&#8221;), and <a name="_Hlk133941338"></a>Liquidia Technologies, Inc., a corporation incorporated under the laws of the State of Delaware, USA having a place of business at 419 Davis Drive, Suite 100, Morrisville, NC 27560, USA (&#8220;<b style="font-weight:bold;">Company</b>&#8221;). &#160;Licensor and Company may be referred to herein as a &#8220;<b style="font-weight:bold;">Party</b>&#8221; or, collectively, as the &#8220;<b style="font-weight:bold;">Parties</b>&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">RECITALS:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Whereas</b><font style="font-variant:small-caps;">,</font> the Parties entered into that certain License Agreement, dated as of June 28, 2023 (the &#8220;<b style="font-weight:bold;">Original Product Agreement</b>&#8221;), pursuant to which, <i style="font-style:italic;">inter alia</i>, Licensor granted to Company an exclusive license under certain intellectual property rights controlled by Licensor to develop, have developed, manufacture, have manufactured, use and commercialize Products, as more fully set forth therein;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Whereas</b>, concurrently with the execution of this Agreement, the Parties are entering to that certain First Amendment to the License Agreement, dated as of the Effective Date (the &#8220;<b style="font-weight:bold;">First Amendment</b>&#8221; and, together with the Original Product Agreement, the &#8220;<b style="font-weight:bold;">Product Agreement</b>&#8221;) to amend certain terms of the Original Product Agreement, as more fully set forth therein;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">WHEREAS</b><font style="text-transform:uppercase;">, </font>Licensor is engaged in the development of the Licensor Technology and the development of Devices; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Whereas</b>, Company desires to license from Licensor, and Licensor wishes to license to Company, on an exclusive basis, the right to Develop, manufacture, use and Commercialize Devices in the Field in the Territory on the terms and conditions herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Now, Therefore</b>, in consideration of the various promises and undertakings set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE 1</font><a name="_Toc138665345"></a><a name="_Ref103657529"></a><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc178261121"></a>Definitions</div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise specifically provided herein, the following terms shall have the following meanings:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338872949"></a><a name="_Toc178260952"></a><a name="_Toc178261122"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Adverse Event</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means any serious untoward medical occurrence in a patient or subject resulting from the use of a Device on such patient or subject, but only if and to the extent that such serious untoward medical occurrence is required under Laws to be reported to applicable Regulatory Authorities.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref338868769"></a><a name="_Toc338872950"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref_ContractCompanion_9kb9Ur1AH"></a><a name="_Toc178260953"></a><a name="_Toc178261123"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Affiliate</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means a Person that controls, is controlled by or is under common control with a Party, but only for so long as such control exists. &#160;For the purposes of this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">1.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, the word &#8220;control&#8221; (including, with correlative meaning, the terms &#8220;controlled by&#8221; or &#8220;under the common control with&#8221;) means the actual power, either directly or indirectly through one or more intermediaries, to direct the management and policies of such Person or entity, whether by the ownership of more than fifty percent (50%) of the voting stock of such entity, or by contract or otherwise.</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc178260954"></a><a name="_Toc178261124"></a><a name="_Toc338872952"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Bankruptcy Event</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means: (a) voluntary or involuntary proceedings by or against a Party are instituted in bankruptcy under any insolvency Law, which proceedings, if involuntary, shall not have been dismissed within [***] days after the date of filing; (b) a receiver or custodian is appointed for a Party; (c) proceedings are instituted by or against a Party for corporate reorganization, dissolution, liquidation or winding-up of such Party, which proceedings, if involuntary, shall not have been dismissed within [***] days after the date of filing; or (d) substantially all of the assets of a Party are seized or attached and not released within [***] days thereafter.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc178260955"></a><a name="_Toc178261125"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Business Days</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means the days when the banks in Taiwan and the United States remain open.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.5</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc178260956"></a><a name="_Toc178261126"></a><a name="_Toc338872955"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Change of Control</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to a Person: (a) a transaction or series of related transactions that results in the sale or other disposition of all or substantially all of such Person&#8217;s assets; or (b) a merger or consolidation in which such Person is not the surviving corporation or in which, if such Person is the surviving corporation, the shareholders of such Person immediately prior to the consummation of such merger or consolidation do not, immediately after consummation of such merger or consolidation, possess, directly or indirectly through one or more intermediaries, a majority of the voting power of all of the surviving entity&#8217;s outstanding stock and other securities and the power to elect a majority of the members of such Person&#8217;s board of directors; or (c) a transaction or series of related transactions (which may include a tender offer for such Person&#8217;s stock or the issuance, sale or exchange of stock of such Person) if the shareholders of such Person immediately prior to the initial such transaction do not, immediately after consummation of such transaction or any of such related transactions, own, directly or indirectly through one or more intermediaries, stock or other securities of the entity that possess a majority of the voting power of all or such Person&#8217;s outstanding stock and other securities and the power to elect a majority of the members of such Person&#8217;s board of directors.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.6</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc178260957"></a><a name="_Toc178261127"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Clinical Trial</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means a clinical trial in human subjects that has been approved by a Regulatory Authority and Institutional Review Board or Ethics Committee, and is designed to measure the safety and/or efficacy of a Product (including a Product utilizing a Device) or Device Product.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.7</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338872956"></a><a name="_Toc178260958"></a><a name="_Toc178261128"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Combination Product</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means a Device that is combined with one (1) or more products (including a Product under the Product Agreement), processes, devices, pieces of equipment or components, either co-formulated or packaged together and sold as a single unit for a single price.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.8</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338872957"></a><a name="_Toc178260959"></a><a name="_Toc178261129"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Commercialization</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Commercialize</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means any and all activities undertaken before and after Regulatory Approval of a MAA for the Device or Device Product and that relate to the marketing, promoting, distributing, importing or exporting for sale, offering for sale, and selling of the Device or Device Product, and interacting with Regulatory Authorities regarding the foregoing.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.9</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338872958"></a><a name="_Toc178260960"></a><a name="_Toc178261130"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Commercially Reasonable Efforts</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to the efforts to be expended by a Party with respect to any objective, such reasonable, diligent, and good faith efforts as such Party would normally use to accomplish a similar objective under similar circumstances. &#160;For clarity, Commercially Reasonable Efforts will not mean that a Party guarantees that it will actually accomplish the applicable task or objective.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338872959"></a></font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.10</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338872961"></a><a name="_Toc178260961"></a><a name="_Toc178261131"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Compulsory License</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means a compulsory license under Licensor Technology obtained by a Third Party through the order, decree, or grant of a competent Governmental Body or court, authorizing such Third Party to develop, make, have made, use, sell, offer to sell or import a Device or Device Product in the Field in any country in the Territory.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;For clarity, the failure of a court to enjoin infringement as a remedy in a patent infringement proceeding shall not be deemed to be a </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Compulsory License. &#160;A Compulsory License shall not be deemed to be a sublicense under </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.11</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338872962"></a><a name="_Toc178260962"></a><a name="_Toc178261132"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Compulsory License Compensation</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; shall mean, for a given Device or Device Product and a given country or region in the Territory, the compensation received from a licensee of the Compulsory License by Company or Licensor or any of their Affiliates or Sublicensees under a Compulsory License.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.12</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Confidential Information</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; of a Party, means information relating to the business, operations or products of a Party or any of its Affiliates, including any Know-How, that such Party discloses to the other Party under this Agreement, or otherwise becomes known to the other Party by virtue of this Agreement.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.13</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338872963"></a><a name="_Toc178260963"></a><a name="_Toc178261133"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Controlled</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="A_Toc389645239"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> means, with respect to (a) Patent Rights, (b) Know-How or (c) biological, chemical or physical material, that a Party or one of its Affiliates owns or has a license or sublicense to such Patent Rights, Know-How or material (or in the case of material, has the right to physical possession of such material) and has the ability to grant a license or sublicense to, or assign its right, title and interest in and to, such Patent Rights, Know-How or material as provided for in this Agreement without violating the terms of any agreement or other arrangement with any Third Party, or misappropriating the proprietary or trade secret information of a Third Party.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.14</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338872964"></a><a name="_Toc178260964"></a><a name="_Toc178261134"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Cover</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;, &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Covering</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Covered</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to a Device or Device Product, that the using, selling, or offering for sale of such Device or Device Product would, but for a license granted in this Agreement under the Licensor Patents, infringe a Valid Claim of the Licensor Patents in the country in which the activity occurs.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.15</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc178260965"></a><a name="_Toc178261135"></a><a name="_Toc338872965"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">[***]</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.16</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc178260966"></a><a name="_Toc178261136"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Development</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Develop</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to a Device or Device Product, the performance of all pre-clinical and clinical research and development (including toxicology, pharmacology, test method development and stability testing, process development, formulation development, quality control development, statistical analysis), Clinical Trials (excluding Clinical Trials conducted after Regulatory Approval of an MAA), manufacturing and regulatory activities that are required to obtain Regulatory Approval of such Device or Device Product in the Territory.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.17</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc178260967"></a><a name="_Toc178261137"></a><a name="_Toc338872970"></a><a name="_DV_C19"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Device</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means (a) the PN2[***] Device or (b) upon exercise of the Second Device Option, the PN1[***] Device.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.18</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc178260968"></a><a name="_Toc178261138"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Device Product</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means a Combination Product containing a Product.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.19</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc178260969"></a><a name="_Toc178261139"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Executive Officers</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means, together, the Chief Executive Officer of Company and the General Manager of Licensor or their respective designees.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.20</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc178260970"></a><a name="_Toc178261140"></a><a name="_Ref132555972"></a><a name="_Ref133937896"></a><a name="_Ref338866430"></a><a name="_Toc338872971"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Existing Product</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in the Product Agreement.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.21</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref168433168"></a><a name="_Toc178260971"></a><a name="_Toc178261141"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Existing Third Party Agreements</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means the agreements set forth on </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> 1.21</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.22</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338872972"></a><a name="_Toc178260972"></a><a name="_Toc178261142"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">FDA</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means the United States Food and Drug Administration or a successor federal agency thereto.</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.23</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338872973"></a><a name="_Toc178260973"></a><a name="_Toc178261143"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Field</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means all uses in humans, including, without limitation, the diagnosis, treatment, management or prevention of any and all diseases.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.24</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc178260974"></a><a name="_Toc178261144"></a><a name="_Toc338872975"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">GAAP</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means US generally accepted accounting principles, as such principles may be amended from time to time.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.25</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc178260975"></a><a name="_Toc178261145"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Governmental Body</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means any: (a) nation, principality, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or quasi-governmental authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, board, instrumentality, officer, official, representative, organization, unit, body or entity and any court or other tribunal); (d) multi-national or supranational organization or body; or (e) individual, entity, or body exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.26</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338872979"></a><a name="_Toc178260976"></a><a name="_Toc178261146"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Know-How</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means any: (a) scientific or technical information, results and data of any type whatsoever, in any tangible or intangible form whatsoever, that is not in the public domain or otherwise publicly known, including discoveries, inventions, trade secrets, devices, databases, practices, protocols, regulatory filings, methods, processes (including manufacturing processes, specification and techniques), techniques, concepts, ideas, specifications, formulations, formulae, data (including pharmacological, biological, chemical, toxicological, clinical and analytical information, quality control, trial and stability data), case reports forms, medical records, data analyses, reports, studies and procedures, designs for experiments and tests and results of experimentation and testing (including results of research or development), summaries and information contained in submissions to and information from ethical committees, or Regulatory Authorities, and manufacturing process and development information, results and data, whether or not patentable, all to the extent not claimed or disclosed in a patent or patent application; and (b) compositions of matter, assays, animal models and physical, biological or chemical material, including drug substance samples, intermediates of drug substance samples, drug product samples and intermediates of drug product samples. &#160;The fact that an item is known to the public shall not be taken to exclude the possibility that a compilation including the item, and/or a development relating to the item, is (and remains) not known to the public. &#160;&#8220;Know-How&#8221; includes any rights including copyright, database or design rights protecting such Know-How. &#160;&#8220;Know-How&#8221; excludes Patent Rights.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.27</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338872981"></a><a name="_Toc178260977"></a><a name="_Toc178261147"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Law</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Laws</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means all applicable laws, statutes, rules, regulations, ordinances and other pronouncements having the binding effect of law of any Governmental Body.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.28</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref132648858"></a><a name="_Toc178260978"></a><a name="_Toc178261148"></a><a name="_Ref338866449"></a><a name="_Toc338872983"></a><a name="_Ref131775216"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Licensor Know-How</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means all Know-How that is Controlled by Licensor or any of its Affiliates as of the Effective Date, including what is set forth on </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">1.28</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, or at any time thereafter during the Term that is necessary or useful in the Development, manufacture, use, or Commercialization of Devices or Device Products in the Field.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.29</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref136802412"></a><a name="_Toc178260979"></a><a name="_Toc178261149"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Licensor&#8217;s Knowledge</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means, with respect to a matter that is the subject of a given representation or warranty of Licensor, the actual knowledge of the executive officers of Licensor, and the vice presidents and senior directors of Licensor&#8217;s research and development department, including the individuals set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">1.29</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, after making reasonable inquiry into the relevant subject matter.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.30</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref338866503"></a><a name="_Toc338872985"></a><a name="_Ref131775293"></a><a name="_Toc178260980"></a><a name="_Toc178261150"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Licensor Patents</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means all Patent Rights that are Controlled by Licensor or any of its Affiliates as of the Effective Date or at any time thereafter during the Term that are necessary or useful for the research, Development, manufacture, use, or Commercialization of Devices or Device Products in the Field. &#160;Listed on </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">1.30</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> are all Licensor Patents existing as of the Effective Date; provided, that Licensor shall update </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">1.30</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> from time-to-time to include any new Patent Rights that come to be Controlled by Licensor or any of its Affiliates at any time during the Term on or following the Effective Date that are necessary or useful for the Development, manufacture, use, or Commercialization of a Device or Device Product.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.31</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc178260981"></a><a name="_Toc178261151"></a><a name="_Toc338872986"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Licensor Technology</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means the Licensor Patents and the Licensor Know-How.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.32</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338872987"></a><a name="_Toc178260982"></a><a name="_Toc178261152"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">MAA</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means a Marketing Authorization Application submitted pursuant to the requirements of the FDA, as more fully defined in 21 U.S. C.F.R.&#167;&#160;314.3 et seq, a Biologics License Application submitted pursuant to the requirements of the FDA, as more fully defined in 21 U.S. C.F.R. &#167;&#160;601, and any equivalent application submitted in any country in the Territory, including all additions, deletions or supplements thereto, and as any and all such requirements may be amended, or supplanted, at any time.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.33</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc178260983"></a><a name="_Toc178261153"></a><a name="_Ref338866831"></a><a name="_Ref338872680"></a><a name="_Toc338872991"></a><a name="_Hlk132350496"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Manufacturing Cost</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means the actual and verifiable costs and expenses paid by Licensor to one (1) or more manufacturers or suppliers (including Device Manufacturers) for the manufacture and supply of Devices or other consumables related thereto, including but not limited to, Licensor&#8217;s external, Out-of-Pocket Expenses for materials, production, factory overhead, quality control, quality assurance, bulk and finished packaging, transportation and insurance.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.34</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338872992"></a><a name="_Toc178260984"></a><a name="_Toc178261154"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Out-of-Pocket Expenses</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means expenses actually paid by a Party or its Affiliate to any Third Party.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338872993"></a></font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.35</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc178260985"></a><a name="_Toc178261155"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Patent Rights</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means: (a) an issued or granted patent, including any extension, supplemental protection certificate, registration, confirmation, reissue, reexamination or renewal thereof; (b) a pending patent application, including any continuation, divisional, continuation-in-part, substitute or provisional application thereof; and (c) all counterparts or foreign equivalents of any of the foregoing issued by or filed in any country or other jurisdiction.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.36</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338872994"></a><a name="_Toc178260986"></a><a name="_Toc178261156"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Person</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means any natural person, corporation, firm, business trust, joint venture, association, organization, company, partnership or other business entity, or any government or agency or political subdivision thereof.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.37</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref167962793"></a><a name="_Toc178260987"></a><a name="_Toc178261157"></a><a name="_Toc338872995"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">PN1[***] Device</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means the [***] nebulizer currently under development by Licensor under the [***], including any improvements, enhancements or modifications thereto or derivatives thereof (including any future generation device thereof). &#160;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">1.37</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">sets forth a description of the PN1[***] Device as it exists as of the Effective Date. &#160;The [***] Device will include such further development and changes as are made in accordance with </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.1.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.38</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref167962830"></a><a name="_Toc178260988"></a><a name="_Toc178261158"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">PN2[***] Device</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means the [***] nebulizer currently under development by Licensor under the [***], including any improvements, enhancements or modifications thereto or derivatives thereof (including any future generation device thereof).</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">1.38</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> sets forth a description of the PN2[***] Device as it exists as of the Effective Date. The [***] Device will include such further development and changes as are made in accordance with </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.1.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160; </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.39</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc178260989"></a><a name="_Toc178261159"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Price Approvals</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means, in those countries in the Territory where Regulatory Authorities may approve or determine pricing and/or pricing reimbursement for pharmaceutical or biotechnology products, such pricing and/or pricing reimbursement approval or determination.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.40</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338872996"></a><a name="_Toc178260990"></a><a name="_Toc178261160"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Product</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in the Product Agreement.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.41</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338872998"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">[***]</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.42</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc178260992"></a><a name="_Toc178261162"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Regulatory Approval</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means any and all approvals, licenses, registrations, or authorizations of the relevant Regulatory Authority, including Price Approvals, necessary for the Development, manufacture, use, storage, import, transport or Commercialization of a Device or Device Product in a particular country or jurisdiction. &#160;For the avoidance of doubt, Regulatory Approval to Commercialize a Device or Device Product shall include Price Approval, if required in a particular country or jurisdiction.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.43</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338872997"></a><a name="_Toc178260993"></a><a name="_Toc178261163"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Regulatory Authority</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means: (a) in the US, the FDA; or (b) in any other jurisdiction anywhere in the world, any regulatory body with similar regulatory authority over pharmaceutical or biotechnology products.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.44</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338872999"></a><a name="_Toc178260994"></a><a name="_Toc178261164"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Royalty Term</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; has the meaning set forth in the Product Agreement.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.45</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338873001"></a><a name="_Toc178260995"></a><a name="_Toc178261165"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Sublicensee</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means a Person other than an Affiliate of Company to which Company (or its Affiliate) has, pursuant to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, granted sublicense rights under any of the Licensed Rights; provided, that &#8220;Sublicensee&#8221; shall exclude distributors and Subcontractors.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;For clarity, the licensee of a Compulsory License shall not be deemed to be a Sublicensee.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.46</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338873003"></a><a name="_Toc178260996"></a><a name="_Toc178261166"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Tax</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Taxes</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means any federal, state, local or foreign income, gross receipts, license, payroll, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">employment</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, excise, severance, stamp, occupation, premium, windfall profits, environmental, customs duties, capital stock, franchise, profits, withholding, social security, unemployment, disability, real property, personal property, sales, use, transfer, registration, value added, alternative or add-on minimum, estimated, or other tax of any kind whatsoever, including any interest, penalty, or addition thereto, whether disputed or not.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.47</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338873004"></a><a name="_Toc178260997"></a><a name="_Toc178261167"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Territory</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means all of the countries, jurisdictions and territories in the world, except China (including Hong Kong and Macao), North Korea, the Republic of Korea, Taiwan, Kingdom of Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Oman, Bahrain, Iraq, Egypt, Lebanon, Jordan, Morocco, Algeria, Iran, Tunisia, Sudan, Yemen, Libya, Syria, Turkey, Malaysia, Indonesia, Thailand, Philippines, Singapore, Brunei, Vietnam, Lao, Cambodia and Myanmar.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.48</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338873005"></a><a name="_Toc178260998"></a><a name="_Toc178261168"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Third Party</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means any Person other than Licensor, Company or any of their respective Affiliates.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.49</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338873006"></a><a name="_Toc178260999"></a><a name="_Toc178261169"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Third Party Action</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means any Action made by a Third Party against either Party that claims that a Device or Device Product, or its use, Development, manufacture or Commercialization infringes or misappropriates such Third Party&#8217;s intellectual property rights.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.50</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338873007"></a><a name="_Toc178261000"></a><a name="_Toc178261170"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Third Party License Agreement</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means any agreement entered into by a Party or its Affiliate with a Third Party, or any amendment or supplement thereto, in each case following the Effective Date, whereby royalties, fees or other payments are to be made by a Party or its Affiliate to such Third Party in connection with the grant of rights under intellectual property rights Controlled by </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">such Third Party, which rights are necessary or useful to Develop, manufacture, have made, import, export, use or Commercialize a Device under the Licensed Rights.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.51</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338873008"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc178261001"></a><a name="_Toc178261171"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">United States</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">US</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means the United States of America, its territories and possessions.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.52</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338873009"></a><a name="_Toc178261002"></a><a name="_Toc178261172"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">USD</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; or &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">$</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means the lawful currency of the United States.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.53</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc178261003"></a><a name="_Toc178261173"></a><a name="_Toc338873010"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Valid Claim</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221; means (a) a claim of an issued and unexpired patent which has not lapsed or been revoked, abandoned or held unenforceable or invalid by a final decision of a court or governmental or supra-governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, reexamination or disclaimer or otherwise, or (b) a pending claim of a patent application which patent application has not been pending for more than five (5) years from the date of filing such application and which claim has not lapsed or been cancelled, withdrawn, abandoned or rejected.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">1.54</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc338873011"></a><a name="_Toc178261004"></a><a name="_Toc178261174"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Other Terms</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;The definition of each of the following terms is set forth in the section of this Agreement indicated below:</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><div style="margin-top:12pt;"></div><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:78.5%;" align="center"><tr><td style="vertical-align:top;width:75.09%;background:#aeaaaa;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><a name="_Hlk167688306"></a><b style="font-weight:bold;">Defined Term</b></p></td><td style="vertical-align:top;width:24.9%;background:#aeaaaa;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Section</b></p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Action</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">6.5.2</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Agreement</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Preamble</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Company</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Preamble</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Company Indemnitees</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">9.2</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Company Patents</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">6.4.5</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Company Tech Transfer Materials</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">2.7</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Cure Period</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">10.2.2</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Development Support</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">3.1.2(c)</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Device Manufacturer</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">2.4</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Disputes</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">11.1</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Effective Date</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Preamble</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">First Amendment</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">ICC</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">11.3.1</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">&#8220;<b style="font-weight:bold;">Licensed Rights</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">2.1</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Licensor</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Preamble</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Licensor Development Activities</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">3.1.2(a)</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Licensor Indemnitees</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">9.1</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Licensor Relevant Action</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">6.5.2</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Licensor Technology Transfer Plan</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">2.3</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Losses</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">9.1</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Non-Specific Licensor Patents</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">6.4.2</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Original Product Agreement</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Party</b>&#8221; and &#8220;<b style="font-weight:bold;">Parties</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Preamble</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Product Agreement</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">Recitals</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Regulatory Support</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">4.3</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Representatives</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">3.1.2(c)</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Right of First Refusal</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">10.6.2</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Right of First Refusal Notice Period</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">10.6.2(b)</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Rules</b>&#8221; </p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">11.3.1</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Second Device Option</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">2.6</p></td></tr></table></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:78.5%;" align="center"><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Specific Licensor Patents</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">6.4.1</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Subcontractor</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">3.4</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Supply Agreement</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">3.3.1</p></td></tr><tr><td style="vertical-align:top;width:75.09%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">&#8220;<b style="font-weight:bold;">Term</b>&#8221;</p></td><td style="vertical-align:top;width:24.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">10.1</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="text-transform:uppercase;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE 2</font><a name="_Toc138665346"></a><b style="font-variant:small-caps;font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><a name="_Toc178261175"></a><b style="font-variant:small-caps;font-weight:bold;">L</b>icenses AND OTHER RIGHTS</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref338866567"></a><a name="_Ref338867078"></a><a name="_Ref338867083"></a><a name="_Ref338867095"></a><a name="_Ref338867104"></a><a name="_Ref338867358"></a><a name="_Ref338868632"></a><a name="_Ref338868681"></a><a name="_Ref131777294"></a><a name="_Toc138665347"></a><a name="_Ref170912382"></a><a name="_Toc178261176"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Grant of License to Company</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Subject to the terms and conditions of this Agreement, Licensor hereby grants to Company and its Affiliates (a) an exclusive (even as to Licensor), royalty-bearing right and license (with the right to sublicense, subject to the provisions of </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">) under the Licensor Technology to Develop, have Developed, manufacture, have manufactured, use and Commercialize Devices and Device Products in the Field in the Territory and (b) a non-exclusive right and license (with the right to sublicense, subject to the provisions of </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">) under the Licensor Technology to Develop, have Developed (but not seek MAA), manufacture, have manufactured and use (but not Commercialize) Devices and Device Products in the Field outside the Territory for the sole purpose of exploiting its right and license under clause (a) (clauses (a) and (b) collectively, the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Licensed Rights</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;).</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Notwithstanding the scope of the Licensed Rights as set forth above, Company shall not Develop, have Developed, manufacture, have manufactured, use or Commercialize the PN2[***] Device or PN1[***] Device for any product other than the Existing Product. In any event, except as expressly set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.6</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> and </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.3.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, Licensor shall not, and shall not permit or authorize any of its Affiliates or sublicensees or any Third Party to, practice or use any Licensor Technology within the scope of the Licensed Rights that has been exclusively licensed to Company under </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.1</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> (a)</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> above.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref338866559"></a><a name="_Ref136435242"></a><a name="_Ref_ContractCompanion_9kb9Ur1BI"></a><a name="_Ref136805686"></a><a name="_Toc138665348"></a><a name="_Toc178261177"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Grant of Sublicense by Company</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;Company shall have the right, in its sole discretion, to grant sublicenses, in whole or in part, through multiple tiers, under the Licensed Rights to Third Parties; provided, however, that (a) the granting by Company of a sublicense shall not relieve Company of any of its obligations hereunder; (b) Licensor&#8217;s obligations to such Third Party will be no broader than Licensor&#8217;s obligations were to Company under this Agreement prior to the grant of such a sublicense, (c) the rights granted to such Third Party under the Licensor Technology will be consistent with the rights granted to Company under </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> applicable to the scope of the sublicense granted to such Third Party, (d) Company shall provide a copy of each sublicense (and any sub-sublicense) agreement to Licensor within thirty (30) Business Days after execution of such sublicense (subject to reasonable redactions), (e) the terms of each sublicense (and any sub-sublicense) agreement shall be consistent with all applicable terms of this Agreement, and (f) Company remains primarily responsible for the actions or omissions of its Sublicensees.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;In no event shall Company grant a sublicense in whole of the Licensed Rights (including the entire Field and entire Territory) to any single Third Party and/or its Affiliates without the prior written consent of Licensor, such consent not to be unreasonably withheld, conditioned or delayed.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref338866680"></a><a name="_Ref135227165"></a><a name="_Toc138665349"></a><a name="_Toc178261178"></a><a name="_Ref135652350"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Licensor Technology Transfer</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;As soon as reasonably practicable after the Effective Date and subject to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.5</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> and the Licensor technology transfer plan (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Licensor Technology Transfer Plan</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;) set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, Licensor will transfer to Company, at Licensor&#8217;s cost and expense, all Licensor Know-How pursuant to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.5</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">For the avoidance of doubt, nothing in this Agreement shall be in any way interpreted that Licensor is transferring its ownership or proprietary right to Licensor Technology.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref167689997"></a><a name="_Toc178261179"></a><a name="_Ref135065766"></a><a name="_Toc138665351"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Manufacturing Technology Transfer</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Upon Company&#8217;s request, Licensor shall transfer to Company all Licensor Know-How for the manufacture of Devices and provide reasonable technical assistance to Company, its Affiliates or any Third Party contract manufacturer for Devices (a </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Device Manufacturer</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;) at reasonable, mutually agreed upon charges with respect to Company&#8217;s and its Affiliate&#8217;s (and any Device Manufacturer&#8217;s) receipt, adoption and establishment of the manufacturing process, including: (a) making available a reasonable number of appropriately trained personnel to provide, on a mutually convenient timetable, technical assistance with respect to such transfer, including technical and design details of all equipment used in the process of manufacturing a Device, (b) using Commercially Reasonable Efforts to promptly assist Company and its Affiliates (and any Device Manufacturer) in obtaining all necessary Regulatory Approvals or modifying existing Regulatory Approvals for the manufacture of Devices by Company, its Affiliate or a Device Manufacturer, (c) allowing Company and its Affiliates (and any Device Manufacturer) to cross reference Licensor&#8217;s (and its Affiliate&#8217;s) regulatory filings (including, but not limited to, a drug master file) and such other regulatory submissions controlled by Licensor (or its Affiliates) applicable to Devices, as the case may be, (d) supplying analytical test methods and other testing Know-How including method validation required to perform release testing or other testing as may be required by the applicable Regulatory Authority, and (e) upon request by Company, providing Company and its Affiliates (and any Device Manufacturer) with appropriate quantities of reference standards related to Product in order to facilitate its testing.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.5</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref167694213"></a><a name="_Toc178261180"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Procedures for Licensor Technology Transfer</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;The technology transfers set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> and </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.4</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> shall occur in an orderly fashion and in a manner such that the value, usefulness and confidentiality of the transferred Licensor Know-How are preserved in all material respects in accordance with the Licensor Technology Transfer Plan. &#160;During the Term, Licensor shall provide to Company full and prompt disclosure, but in no event less frequently than semi-annually, of any Licensor Technology that becomes Controlled by Licensor or any of its Affiliates after the Effective Date and that is necessary or useful to Company to conduct its activities or exercise its rights as contemplated hereunder and shall, promptly following such disclosure, transfer to Company such Licensor Know-How.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;background:#00ffff;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.6</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Second Device Option.</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">  Licensor shall, and hereby does, grant to Company and its Affiliates an exclusive and sole right of first option (the &#8220;Second Device Option&#8221;), at Company&#8217;s election, to include the PN1[***] Device as a Device under this Agreement.  Company may exercise the Second Device Option at any time during the Term upon written notice of such exercise to Licensor. Company shall submit to Licensor payment of an exercise fee in the amount [***] to Licensor within [***] days of receipt of an invoice for such exercise fee.  Notwithstanding anything in this Agreement to the contrary, following Company&#8217;s exercise of the Second Device Option: (a) Licensor shall retain the right, and such right shall be sublicensable to Third Parties, to Develop, have Developed, manufacture, have manufactured, use and Commercialize the PN1[***] Device in the Field in the Territory under the Licensed Technology, provided that in no event shall Licensor, its Affiliates or their respective sublicensees have the right to Develop, have Developed, manufacture, have manufactured, use or Commercialize the PN1[***] Device in connection with treprostinil in the Territory; and (b) Licensor shall have the right, and such right shall be sublicensable to Third Parties, to Develop, have Developed, manufacture, have manufactured, use and Commercialize the PN2[***] Device in the Field in the Territory under the Licensed Technology, provided that in no event shall Licensor, its Affiliates or any of their respective sublicensees have the right to Develop, have Developed, manufacture, have manufactured, use or Commercialize the PN2[***] Device in connection with treprostinil in the Territory.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref338867275"></a><a name="_Toc138665352"></a><a name="_Toc178261182"></a></font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">2.7</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Company Technology Transfer</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">.  During the Term and upon Licensor&#8217;s reasonable written request (but no more frequently than twice each Calendar Year), Company shall provide to Licensor copies of all technical information, data, reports and regulatory dossiers generated by or on behalf of Company during the Development and Commercialization of the Device and Device </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Product that are necessary for Licensor to seek Regulatory Approvals for the Device and Device Product in the Field outside the Territory (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Company Tech Transfer Materials</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">&#8221;) at no cost to Licensor.  Licensor shall have the right to incorporate, and sublicense such right to any Third Party to which Licensor licenses the right of development, manufacture or commercialization to such Third Party in any country outside of the Territory, any such Company Tech Transfer Materials into its regulatory filings for Regulatory Approvals for the Device and Device Product in the Field outside of the Territory; provided, however, that, notwithstanding any permitted assignment or transfer pursuant to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">12.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, in no event shall the Company Tech Transfer Materials (including any rights with respect thereto) be assignable, licensable or otherwise transferable to a Third Party, including any Third Party licensee or successor-in-interest to Licensor&#8217;s business to which this Agreement relates, that is a Company Competitor (as such term defined in the Original Product Agreement) in the Territory.</font></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE 3</font><a name="_Toc138665360"></a><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc178261183"></a>DEVELOPMENT, COMMERCIALIZATION and Manufacture OF DEVICES</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665361"></a><a name="_Toc178261184"></a><a name="_Ref209535774"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Development</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;"> </b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.1.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref167978301"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">General</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Subject to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.1.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, Company shall have the exclusive right, and sole responsibility and decision-making authority, at Company&#8217;s cost and expense, to Develop Devices and Device Products and to conduct (either itself or through its Affiliates, agents, Subcontractors and/or Sublicensees) all Clinical Trials and non-clinical studies Company believes appropriate to obtain Regulatory Approval for Devices and Device Products in the Field in the Territory.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref209535785"></a><a name="_Toc338873023"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> Each Party will notify the other, via the joint steering committee under the Product Agreement, if such notifying Party reasonably believes or expects that any Development of a Device or Device Product conducted by or on behalf of such notifying Party would reasonably be expected to have a material adverse effect on the other Party&#8217;s Development of a Device or Device Product, and the joint steering committee will review and discuss such matter.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.1.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref131777185"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensor Development and Support</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;</font></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:0pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;white-space:nowrap;">(a)</font><a name="_Ref167977304"></a><i style="font-style:italic;">Licensor Development</i>. &#160;Unless and until Company exercises its Second Device Option, Licensor shall, at its sole cost and expense, be responsible for all pre-clinical and manufacturing development of the PN2[***] Device to meet the minimum design requirements for such Device (separately or for Device Products, as applicable) for Company to exploit the Licensed Rights (collectively, the &#8220;<b style="font-weight:bold;">Licensor Development Activities</b>&#8221;). &#160;The minimum design requirements shall include (x) the specifications set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule 1.38</u>, (y) any specifications (including changes thereto) that are reasonably necessary for Company to either obtain or maintain Regulatory Approval of a Device or Device Product in the Territory or avoid infringement or misappropriation of any intellectual property right of a Third Party, and (z) any other specifications established by the JSC pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.1.2(b)</u> (provided the incremental cost incurred for such JSC-approved specifications under this clause (z) shall be borne by Company in accordance with a mutually agreed upon budget for such development activities). &#160;Licensor shall perform the Licensor Development Activities in accordance with a development plan established pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.1.2(b)</u>. &#160;If Company exercises its Second Device Option, (i) the Parties shall cooperate to transition all Licensor Development Activities with respect to the PN1[***] Device to Company; and (ii) Licensor shall have no further obligation to perform Licensor Development Activities (and, for clarity, unless otherwise agreed by the Parties in writing, no obligation to perform any Development activities for Company with </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:0pt;text-transform:none;">respect to the PN2[***] Device). Licensor shall collaborate with Company in connection with Licensor&#8217;s performance of the Licensor Development Activities in accordance with any reasonable direction provided by Company and shall provide Company with regular progress updates on all Licensor Development Activities. &#160; &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:0pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;white-space:nowrap;">(b)</font><a name="_Ref173147524"></a><a name="_Ref173147524_1"></a><a name="_Ref167689653"></a><i style="font-style:italic;">Minimum Design Requirements and Development Plan</i>. &#160;The JSC (as defined in the Product Agreement) under the Product Agreement shall meet from time to time in accordance with Article 3 of the Product Agreement to determine the minimum design requirements and the development plan for the conduct of the Licensor Development Activities for the applicable Device under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.1.2(a)</u>. &#160;Accordingly, the Parties hereby agree that the responsibilities of the JSC under Section 3.3 of the Product Agreement shall include (i) discussing, establishing, reviewing, and, as may be applicable from time to time, amending the minimum design requirements and the development plan for the conduct of the Licensor Development Activities for a Device and (ii) monitoring the progress of the Licensor Development Activities against the development plan. From time to time after the first Regulatory Approval of a MAA (as such term is defined in the Original Product Agreement, as amended) for a Device in the United States, Licensor may identify a nebulizer device owned or controlled by Licensor (or otherwise developed by or on behalf of Licensor) and request confirmation from Company that such nebulizer device will not be deemed a future generation of such Device. &#160;In the event that the Parties are unable to agree as to whether such identified device constitutes a future generation of the PN2[***] Device or PN1[***] Device, then either Party shall have the right to escalate such matter to an independent expert, reasonably acceptable to the other Party, with at least ten (10) years of relevant experience in the field of pharmaceutical nebulizers by providing written notice to the other Party. &#160;If the Parties cannot agree on such independent expert within fifteen (15) Business Days of receipt of such notice, each Party shall select one (1) expert, and the two (2) selected experts shall mutually agree upon the third expert, each expert to have the experience set forth in the preceding sentence. &#160;Within ten (10) Business Days from selection of the expert(s), each Party shall deliver to the expert(s) and the other Party its position as to why the identified device does or does not constitute a &#8220;future generation&#8221; of the applicable Device and a memorandum in support thereof. &#160;Within ten (10) Business Days after receipt of the other Party&#8217;s support memorandum, each Party may submit to the expert(s), with a copy to the other Party, a response to the other Party&#8217;s support memorandum. &#160;Within thirty (30) days following receipt by the expert(s) of the Parties&#8217; reply memoranda, the expert(s) will make a determination as to whether the identified device is or is not a future generation of an applicable Device hereunder.&#160; The decision of the expert(s) shall be final and binding. &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;text-align:justify;text-indent:0pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;white-space:nowrap;">(c)</font><i style="font-style:italic;">Licensor Support</i>. &#160;Licensor shall make its employees, consultants, contractors, advisors and agents (&#8220;<b style="font-weight:bold;">Representatives</b>&#8221;) that are knowledgeable regarding the Licensor Technology and a Device (including the properties and functions thereof), available to Company for scientific and technical explanations, advice, on-site support (limited to once a year and one (1) week for each on-site support) and meetings with Regulatory Authorities that may reasonably be required by Company (provided Company shall consider in good faith Licensor&#8217;s requests regarding when such meetings are scheduled) relating to the Development of such Device (the &#8220;<b style="font-weight:bold;">Development Support</b>&#8221;). &#160;The Development Support shall be provided by Licensor<b style="color:#0000ff;font-weight:bold;"> </b>free-of-charge<font style="color:#0000ff;"> </font>during the Term except for reasonable Out-of-Pocket Expenses. &#160;</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.1.3</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Acknowledgement</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;The Parties acknowledge that Company intends as of the Effective Date to Develop the PN2[***] Device; however, upon exercise of the Second Device </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Option, Company shall have the right to transition its exercise of its development rights under </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.1.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> from the PN2[***] Device to the PN1[***] Device. &#160;For clarity, following its exercise of the Second Device Option, Company shall have the right, but not the obligation, to Develop the PN2[***] Device at its cost and expense. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665362"></a><a name="_Toc178261185"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Commercialization</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;Except for Licensor&#8217;s rights under Section </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">2.6</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a) and Section </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">2.6</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(b) to Commercialize Devices in the Field in the Territory under the Licensed Rights other than in connection with treprostinil, Company shall have the exclusive right, and sole responsibility and decision-making authority, to Commercialize Devices in the Field in the Territory itself or through one (1) or more Affiliates or Sublicensees or other Third Parties selected by Company and shall have the sole decision-making authority and responsibility in all matters relating to the Commercialization of Devices in the Field in the Territory.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc178261186"></a><a name="_Ref135236329"></a><a name="_Toc138665363"></a><a name="_Ref338866754"></a><a name="_Ref131777252"></a><a name="_Ref209535989"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Manufacturing</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.3.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref171436934"></a><a name="_Ref167689911"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensor Supply</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Until either (a) Company and a Device Manufacturer execute a supply agreement governing the manufacture and supply of Devices to Company or (b) Licensor assigns to Company, and Company assumes, a supply agreement, by and between Licensor and a Device Manufacturer, governing the manufacture and supply of Devices (in either case, a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Supply Agreement</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;), Licensor shall supply, under the terms of this Agreement, Company with all of its requirements for such Devices (including, without limitation, the full nebulizer kit including the body, consumables and packaging) at a supply price equal to [***] of Manufacturing Cost for non-commercial supply and at a supply price equal to the Manufacturing Cost for commercial supply under the terms and conditions of this Agreement. &#160;Notwithstanding the foregoing, upon Company&#8217;s written request, the Parties will negotiate and enter into a separate supply agreement for the manufacture and supply of such Devices by Licensor to Company on terms and conditions consistent with the terms and conditions of this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.3.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> and, to the extent reasonably applicable, the terms and conditions of that certain Non-Commercial Supply Agreement, dated as of December 18, 2023, by and between the Parties.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.3.2</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Device Manufacturer Supply</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Upon execution by Company and a Device Manufacturer, or assignment from Licensor to Company, of a Supply Agreement, as the case may be, and in accordance with the terms thereof, Company shall purchase Devices directly from a Device Manufacturer. &#160;Licensor shall cooperate in the transition of its manufacturing and supply responsibility to Company and Device Manufacturer(s) (including performance of a manufacturing technology transfer in accordance with </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.4</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">). &#160;Licensor shall use best efforts to assist Company in effectuating a Supply Agreement on commercially reasonable terms, including purchasing Devices at a fixed amount for the Development, to facilitate the development of a business relationship between Company and the Device Manufacturer, and to inform Company of discussions and communications with a Device Manufacturer until such time as such Supply Agreement has been executed between Company and such Device Manufacturer or such Supply Agreement has been assigned by Licensor and assumed by Company. </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Company shall use Commercially Reasonable Efforts to sign such Supply Agreement with the Device Manufacturer no later than [***]</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">months prior to the first commercial sale of a Device. </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref338867365"></a><a name="_Toc138665364"></a><a name="_Ref167689895"></a><a name="_Toc178261187"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Right to Subcontract of Company</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Company may exercise any of its rights, or perform any of its obligations, under this Agreement (including any of the Licensed Rights) by subcontracting the exercise or performance of any portion of such rights and obligations on Company&#8217;s behalf to a Third Party that has entered into a subcontract agreement to provide services to Company for the purpose of fulfilling Company&#8217;s obligations hereunder (a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Subcontractor</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;); provided that (a) any subcontract granted or entered into by Company as contemplated by this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.4</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> of the exercise or performance of any portion of the rights or obligations that Company may have under this Agreement shall not relieve Company from any of its obligations under this Agreement, (b) the terms of each subcontract agreement shall be consistent with all applicable terms of this Agreement and (c) Company shall remain primarily responsible for the actions or omissions of its Subcontractors. </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> In no event shall Company subcontract all of its obligations under this Agreement to a single Third Party and/or its Affiliates, other than in connection with a sublicense as permitted pursuant to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, without the prior written consent of Licensor, such consent not to be unreasonably withheld, conditioned or delayed.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.5</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref209538247"></a><a name="_Toc138665365"></a><a name="_Toc178261188"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Trademarks</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> As between Licensor and Company, Company shall have the sole authority to select trademarks for the Device and shall own all such trademarks.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE 4</font><a name="_Toc138665366"></a><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc178261189"></a>REGULATORY MATTERS</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665367"></a><a name="_Toc178261190"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Regulatory Filings</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;A</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">s between Company and Licensor, Company shall make, own and maintain all regulatory filings and Regulatory Approvals for the Device in the Territory and the regulatory filings and Regulatory Approvals for the Clinical Trials for the Device or Device Product conducted outside the Territory at its cost after the Effective Date. &#160;Company shall provide a copy of (a) any substantive written communications, notices, or other materials received from any Regulatory Authorities regarding any of the foregoing regulatory filings for Regulatory Approvals and Regulatory Approvals, (b) any substantive written communications with any Regulatory Authority regarding any of the foregoing regulatory filings for Regulatory Approvals, and (c) any proposed significant written communications with any Regulatory Authority regarding any of the foregoing regulatory filings for Regulatory Approval reasonably in advance of submission and, with respect to clause (c), shall consider all of Licensor&#8217;s comments thereto in good faith.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref_ContractCompanion_9kb9Ur19I"></a><a name="_Ref_ContractCompanion_9kb9Ur25B"></a><a name="_Toc138665368"></a><a name="_Toc178261191"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Communications with Authorities</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Company (or one of its Affiliates or Sublicensees) shall be responsible, and act as the sole point of contact, for communications with all Regulatory Authorities in the Territory in connection with the Development, Commercialization, and manufacturing of Device. &#160;Following the Effective Date, Licensor shall not initiate, with respect to Device, any meetings or contact with any Regulatory Authorities in the Territory without Company&#8217;s prior written consent. &#160;To the extent Licensor receives any written or oral communication from any Regulatory Authority in the Territory relating to Device, Licensor shall (a) refer such Regulatory Authority to Company, and (b) as soon as reasonably practicable (but in any event within twenty-four (24) hours), notify Company and provide Company with a copy of any written communication received by Licensor or, if applicable, complete and accurate minutes of such oral communication. &#160;At the request of Company, Licensor shall make available to Company, free of charge, a qualified representative who shall, together with the representatives of Company, participate in and contribute to meetings with the Regulatory Authorities with respect to regulatory matters relating to the Licensor Technology.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref338866841"></a><a name="_Toc138665369"></a><a name="_Toc178261192"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Licensor Support in Regulatory Matters</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Licensor shall make its Representatives that are knowledgeable regarding the Licensor Technology or Device available to Company upon Company&#8217;s request for regulatory explanations, advice and on-site support, that may reasonably be </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">required by Company relating regulatory matters (including preparation and filing for any Regulatory Approvals) for Devices (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Regulatory Support</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;). &#160;The Regulatory Support</font><font style="color:#0000ff;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">shall be provided by Licensor free-of-charge during the Term.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref338867400"></a><a name="_Toc138665371"></a><a name="_Toc178261193"></a><a name="_Ref_ContractCompanion_9kb9Ur2BF"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Adverse Event Reporting</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;The Parties agree to comply with any and all Laws that are applicable as of the Effective Date and thereafter during the Term in connection with Device safety data collection and reporting. &#160;If Licensor has or receives any information regarding any Adverse Event which may be related to the use of Device, then Licensor shall provide Company with all such information in English within such reasonable timelines which enable Company to comply with all Laws and relevant regulations and requirements. &#160;Company shall report to Licensor any Adverse Event culminating in death or permanent disability of a patient or subject who is administered Device. &#160;The information exchanged between the Parties pursuant to this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.4</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> shall be transmitted by e-mail or overnight courier to the following address:</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 12pt 36pt;">Transmission to Licensor:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 36pt;">Weishu Lu</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 36pt;">Pharmosa Biopharm Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 36pt;">11F, No. 508, Section 7, Zhongxiao East Road, Nangang District, Taipei City 115, Taiwan </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 36pt;">Tel: + 886-2-2782-7561#107</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 36pt;">Fax: +886-2-2782-9013</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 36pt;"><font style="white-space:pre-wrap;">Email:  </font>Weishu.lu@pharmosa.com.tw</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 36pt;">Transmission to Company:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 36pt;">Jennifer Weidman</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 36pt;">Liquidia Technologies, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 36pt;">419 Davis Drive, Suite 100</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 36pt;">Morrisville, NC 27560</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 36pt;">USA</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 36pt;">Tel: 919-704-5916</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 36pt;"><font style="white-space:pre-wrap;">Email:  jennifer.weidman@liquidia.com </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.5</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref321653875"></a><a name="_Toc138665372"></a><a name="_Toc178261194"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Safety Data Exchange Agreement</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Without limitation of </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.4</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, the Parties shall, as soon as practical following the Effective Date, negotiate in good faith and enter into a safety data exchange agreement, which shall set forth standard operating procedures governing the collection, investigation, reporting, and exchange of information concerning adverse drug reactions or other adverse events (including Adverse Events) sufficient to permit each Party to comply with its regulatory and other legal obligations within applicable timeframes.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">4.6</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665373"></a><a name="_Toc178261195"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Recalls</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Company shall have the sole right to determine whether and how to implement a recall or other market withdrawal of any Device in the Territory. &#160;Company shall, to the extent allowed by Law and reasonably practicable, provide written notice to Licensor of any such recall or market withdrawal and consider Licensor&#8217;s comments in good faith, provided, however, that in no event shall Company be obligated to delay any such recall or market withdrawal. &#160;Licensor shall take all actions requested by Company in connection with such recall or other market withdrawal.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE 5</font><a name="_Ref_ContractCompanion_9kb9Ur26A"></a><a name="_Ref_ContractCompanion_9kb9Ur26C"></a><a name="_Ref_ContractCompanion_9kb9Ur26E"></a><a name="_Ref_ContractCompanion_9kb9Ur277"></a><a name="_Toc138665374"></a><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc178261196"></a>CONSIDERATION</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_DV_M162"></a><a name="_Toc178261197"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Consideration</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;The Parties acknowledge and agree that the initial fee payable under the First Amendment and the royalties payable on sales of Devices and Device Products under the Product Agreement constitute fair and adequate consideration for the rights granted to Company in this Agreement.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">5.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc178261198"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">No Double-Counting</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Notwithstanding anything in this Agreement, the Product Agreement (including the First Amendment) or any other agreement between the Parties or their Affiliates, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Hlk167803930"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(a) there will be no double counting of any costs or expenses in the calculation of any amounts due from Company or its Affiliates to Licensor or its Affiliates under this Agreement, the Product Agreement or any other agreement between the Parties or their Affiliates, and (b) in no event shall sales (including the calculation of Net Sales under the Product Agreement) of any Device or Product be double-counted under this Agreement, the Product Agreement or any other agreement between the Parties or their Affiliates, including with respect to the calculation of royalties due under any such agreements or the achievement of any threshold for sales milestones (including Sales Milestones under the Product Agreement) under any such agreements.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE 6</font><a name="_Toc138665387"></a><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc178261199"></a>INTELLECTUAL PROPERTY MATTERS</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665388"></a><a name="_Toc178261200"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Certification Under Drug Price Competition and Patent Restoration Act</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Each Party shall immediately give written notice to the other Party of any certification of which they become aware filed pursuant to 21 U.S.C. Section 355(b)(2)(A) or 21 U.S.C. Section 355(j)(2)(A) (or any amendments or successor statutes thereto) claiming that any Licensor Patents Covering a Device Product, or the manufacture or use of each of the foregoing, are invalid or unenforceable, or that infringement will not arise from the manufacture, use or sale of a product by a Third Party.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665389"></a><a name="_Toc178261201"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Listing of Patents</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Notwithstanding any Licensor Patent prosecution rights of Licensor under this Agreement, Company shall have the sole right to determine which of the Licensor Patents, if any, shall be listed for inclusion in the Approved Drug Product with Therapeutic Equivalence Evaluations pursuant to 21 U.S.C. Section 355, or any successor Law in the United States, together with any comparable Laws in any other country in the Territory.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665390"></a><a name="_Toc178261202"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Further Assurances</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Licensor shall require all of its employees, and use its Commercially Reasonable Efforts to require its contractors and agents, and any Affiliates and Third Parties working on its behalf under this Agreement (and their respective employees, contractors and agents), to assign to Licensor any Licensor Technology.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref_ContractCompanion_9kb9Ur28E"></a><a name="_Toc138665391"></a><a name="_Toc178261203"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Patent Prosecution and Maintenance</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.4.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref136861183"></a><a name="_Ref_ContractCompanion_9kb9Ur28A"></a><a name="_Ref_ContractCompanion_9kb9Ur17E"></a><a name="_Ref_ContractCompanion_9kb9Ur17F"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Specific Licensor Patents</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;With respect to Licensor Patents in the Territory that Cover or are directed to only (a) a Device (including the composition of matter, manufacture, or method of use thereof) and (b) treprostinil (or its class of compounds) (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Specific Licensor Patents</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;), including the Licensor Patents identified as such in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">1.30</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> (as may be updated by Company from time to time), Company shall have the first right, and the obligation, to file, prosecute (including initiating or defending any reexamination and reissue proceedings) and maintain, using counsel of Company&#8217;s choosing, such Specific Licensor Patents in Licensor&#8217;s name in the Territory. &#160;Company shall bear all costs and expenses of filing, prosecuting and maintaining Specific Licensor Patents in the Territory. &#160;Company shall keep Licensor informed of the status of the filing and prosecution of </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Specific Licensor Patents by promptly forwarding to Licensor copies of all official correspondence (including, but not limited to, applications, office actions, and responses) relating thereto. &#160;Licensor shall have the right, and Company shall provide Licensor a reasonable opportunity, to comment on and advise Company as to the conduct of such filing, prosecution and maintenance of Specific Licensor Patents, provided, however, that Company shall have the final decision-making right for all matters associated with such filing, prosecution and maintenance. &#160;At Company&#8217;s request, Licensor will provide Company with reasonable free-of-charge assistance in prosecuting Specific Licensor Patents to the extent possible, including providing such data in Licensor&#8217;s Control that is, in Company&#8217;s reasonable judgment, needed to support the prosecution of a Specific Licensor Patent.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">For clarity, (i) any Licensor Patents that satisfy clause (a) and (b) above with respect to the PN2[***] Device shall be deemed Specific Licensor Patents until such time as Company exercises the Second Device Option at which time such Licensor Patents shall be deemed Non-Specific Licensor Patents, and (ii) any Licensor Patents that satisfy clause (a) and (b) above with respect to PN1[***] Device shall be deemed Non-Specific Licensor Patents until such time as Company exercises the Second Device Option at which time such Licensor Patents shall be deemed Specific Licensor Patents. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.4.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref_ContractCompanion_9kb9Ur28C"></a><a name="_Ref167998217"></a><a name="_Ref136861262"></a><a name="_Ref136861138"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Non-Specific Licensor Patents</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Subject to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.4.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, with respect to all Licensor Patents in the Territory other than Specific Licensor Patents (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Non-Specific Licensor Patents</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;) as listed in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">1.30</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> (as may be updated from time to time by Company), Licensor shall have the first right, and the obligation, to file, prosecute (including initiating or defending any reexamination and reissue proceedings) and maintain, using counsel of Licensor&#8217;s choosing, such Non-Specific Licensor Patents in Licensor&#8217;s name. &#160;Licensor shall bear all costs and expenses of filing, prosecuting and maintaining Non-Specific Licensor Patents. &#160;Licensor shall keep Company informed of the status of the filing and prosecution of Non-Specific Licensor Patents by promptly forwarding to Company copies of all official material correspondence (including, but not limited to, applications, office actions, and responses) relating thereto. &#160;Company shall have the right, and Licensor shall provide Company a reasonable opportunity, to comment on and advise Licensor as to the conduct of such filing, prosecution and maintenance of Non-Specific Licensor Patents, and Licensor shall incorporate all reasonable comments of Company, provided, however, that Licensor shall have the final decision-making right for all matters associated with such filing, prosecution and maintenance.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> Notwithstanding the foregoing of this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.4.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, in the event that Licensor or Company wishes to file any continuation or divisional with respect to any Non-Specific Licensor Patent that claims treprostinil as the explicit and sole active pharmaceutical ingredient, then the prosecution and maintenance of any such continuation or divisional shall be governed by </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.4.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.4.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_DV_M755"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Election Not to File and Prosecute Licensor Patents</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;If either Party elects not to file or to continue to prosecute or maintain a Licensor Patent in the Territory where it is permitted to do so pursuant to </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.4.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> and </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.4.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> above, as applicable, or fails to do so after receipt of notice from the other Party, then it shall notify the other Party in writing at least ninety (90) days before any deadline applicable to the filing, prosecution or maintenance of such Licensor Patent, as the case may be, or any other date by which an action must be taken to establish or preserve such Licensor Patent in such country or possession. &#160;In such case, the other Party shall have the right to pursue the filing or support the continued prosecution or maintenance of such Licensor Patent. &#160; &#160; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.4.4</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent Term Extension</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Notwithstanding any Licensor Patent prosecution rights of Licensor under this Agreement, Company shall be responsible, in Licensor&#8217;s name, for </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">obtaining patent term extensions or supplemental protection certificates or comparable extensions in any other country in the Territory, wherever available for Specific Licensor Patents in the Territory. &#160;Licensor shall provide Company with all relevant information, documentation and assistance in this respect as may reasonably be requested by Company. &#160;Any such assistance, supply of information and consultation shall be provided promptly and in a manner that will ensure that all patent term extensions for Specific Licensor Patents are obtained wherever legally permissible, and to the maximum extent available. &#160;In the event that any election with respect to obtaining patent term extensions is to be made, Company shall have the right to make such elections, and Licensor shall abide by all such elections.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.4.5</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref320542756"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Ownership; Company Patents</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Each Party shall own all right, title, and interest in and to all Know-How developed by such Party or any of its Affiliates or a Third Party on behalf of such Party (and all Patent Rights claiming or covering such Know-How). The Parties shall jointly own and have an undivided one-half interest in and to all Know-How developed jointly by or on behalf of the Parties (and all Patent Rights claiming or covering such Know-How) with respect to Devices, Device Products or Products, and each Party hereby grants to the other Party a perpetual, irrevocable, fully paid-up, worldwide, fully sublicensable, non-exclusive license under its interest in and to such Know-How and Patent Rights. All determinations of inventorship under this Agreement shall be made in accordance with United States patent law. For avoidance of doubt, Company shall own any Know-How and Patent Rights developed by Company or any of its Affiliates or a Third Party on behalf of Company and shall have the right, but not the obligation, to file, prosecute and maintain any such Patent Rights (collectively, &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Company Patents</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;). &#160;Company shall bear all costs and expenses of filing, prosecuting and maintaining Company Patents and Licensor shall have no right, title or interest in or to Company Patents.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.5</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref338868000"></a><a name="_Toc138665392"></a><a name="_Toc178261204"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Enforcement</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.5.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref135077141"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;padding-left:36pt;text-align:justify;text-indent:-36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>If either Party believes that an infringement, unauthorized use, misappropriation or ownership claim or threatened infringement or other such activity by a Third Party with respect to any Licensor Technology, or if a Third Party claims that any Licensor Patent is invalid or unenforceable, in each case in the Territory, the Party possessing such knowledge or belief shall notify the other Party and provide it with details of such infringement or claim that are known by such Party.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;padding-left:36pt;text-align:justify;text-indent:-36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>In the event that Licensor believes that a Company Patent, if any, is being infringed by a Third Party or if a Third Party claims that any Company Patent is invalid or unenforceable, Licensor shall notify Company and provide it with details of such infringement or claim.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.5.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref18467700"></a><a name="_Ref131777125"></a><a name="_Ref136864334"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Actions</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Company shall have the exclusive right, at its own cost (subject to the indemnity obligations set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">), to attempt to resolve any infringement or claim, including by filing an infringement suit, defending against such claim or taking other similar action, with respect to a Licensor Patent in the Territory (each, an &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Action</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;) and to compromise or settle any such infringement or claim; provided that the compromise or settlement shall require Licensor&#8217;s prior written consent if the compromise or settlement will have an adverse impact on Licensor&#8217;s business outside the Territory or ownership of the Licensor Technology, such consent not to be unreasonably withheld, conditioned or </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">delayed. &#160;At Company&#8217;s request, Licensor shall immediately provide Company with all relevant documentation (as may be requested by Company) evidencing that Company is validly empowered by Licensor to take such an Action. &#160;Licensor shall join Company in such Action upon Company&#8217;s written request. &#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Licensor shall provide reasonable assistance to Company, at the Company&#8217;s cost, including providing access to relevant documents and other evidence and making its employees available. &#160;All amounts recovered by Company shall be allocated, first, to the costs and expenses of the Parties incurred to enforce the Licensor Patents and, second, to Company (provided that such remaining amounts after deduction of the costs and expenses of the Action shall be deemed Net Sales for royalty calculation purposes under the Product Agreement).</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;In the event that Company does not bring such Action against the Third Party infringer within ninety (90) days of the notice delivered under </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.5.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, Licensor may request in writing that Company bring an Action, and Company shall consider such request in good faith. &#160;Notwithstanding the foregoing, in the event that a Third Party institutes a re-examination action or </font><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:normal;">inter partes </i><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">review proceeding or brings an action where the sole relief sought is declaratory judgment, in each case seeking to have a Licensor Patent declared invalid or unenforceable &#160;or if the Action involves a Non Specific Licensor Patent (a &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Licensor Relevant Action</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;), and Company does not elect to defend or initiate such Licensor Relevant Action within thirty (30) days following Licensor&#8217;s request pursuant to the preceding sentence, Licensor or its licensees shall be free to defend or initiate the Licensor Relevant Action, at its own expense, and retain any award or settlement in its entirety. &#160;If necessary, Company shall join or be joined as a party to the Licensor Relevant Action, but shall be under no obligation to participate, except to the extent that such participation is required as a result of being named a party to the Licensor Relevant Action. &#160;Company shall offer reasonable assistance in connection therewith, at no charge to Licensor, except for reimbursement of reasonable Out-of-Pocket Expenses.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.5.3</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Company Patents</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Company shall have the sole right and authority, but not the obligation, to enforce Company Patents against any Third Party infringer; provided, however, that Licensor shall provide reasonable assistance to Company with respect thereto, including providing access to relevant documents and other evidence and making its employees available, subject to Company&#8217;s reimbursement of any Out-of-Pocket Expenses incurred on an on-going basis in providing such assistance.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.6</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_DV_C1007"></a><a name="_Toc138665393"></a><a name="_Toc178261205"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Third Party Actions Claiming Infringement</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_DV_C1008"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.6.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_DV_C1009"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;If Company becomes aware of any Third Party Action against Company, Company shall promptly notify Licensor thereof in writing, setting for the facts of such claim in reasonable detail.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_DV_C1010"></a></font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.6.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_DV_C1011"></a><a name="_Ref338868062"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right to Defend</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;As between the Parties, Company shall have the exclusive right, at its sole expense and with counsel of its sole choice, but not the obligation, to defend a Third Party Action described in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.6.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_DV_C1012"></a><a name="_Ref88643671"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and to compromise or settle such Third Party Action</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_DV_C1013"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">; provided, however, that Company shall not enter into a settlement, consent judgment or other voluntary disposition of any such Third Party Action without consent by Licensor if the settlement, consent judgment or voluntary disposition will have an adverse impact on Licensor&#8217;s business outside of the Territory or Licensor Technology or involve the admission of liability on the part of Licensor.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;Licensor shall provide reasonable assistance to Company, at the Company&#8217;s cost (subject to the indemnity obligations set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">), including providing access to relevant documents and other evidence and making its employees available. &#160; </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE 7</font><a name="_Ref_ContractCompanion_9kb9Ur178"></a><a name="_Toc138665394"></a><a name="_Ref_ContractCompanion_9kb9Ur27D"></a><a name="_Ref_ContractCompanion_9kb9Ur27B"></a><a name="_Ref_ContractCompanion_9kb9Ur279"></a><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Ref167693004"></a><a name="_Toc178261206"></a>CONFIDENTIALITY</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">7.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref338868102"></a><a name="_Toc138665395"></a><a name="_Toc178261207"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Confidentiality Obligations</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Each Party agrees that, for the Term and for five (5) years thereafter, such Party shall, and shall ensure that its Representatives hold in confidence all Confidential Information disclosed to it by the other Party pursuant to this Agreement, unless such information:</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">is or becomes generally available to the public other than as a result of disclosure by the recipient;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">is already known by or in the possession of the recipient at the time of disclosure by the disclosing Party;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">is independently developed by recipient without use of or reference to the disclosing Party&#8217;s Confidential Information; or</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">is obtained by recipient from a Third Party that has not breached any obligations of confidentiality.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The recipient shall not disclose any of the Confidential Information, except to Representatives of the recipient who need to know the Confidential Information for the purpose of performing the recipient&#8217;s obligations, or exercising its rights, under this Agreement and who are bound by obligations of non-use and non-disclosure substantially similar to those set forth herein. &#160;The recipient shall be responsible for any disclosure or use of the Confidential Information by such Representatives. &#160;The recipient shall protect Confidential Information using not less than the same care with which it treats its own confidential information, but at all times shall use at least reasonable care. &#160;Each Party shall: (i) implement and maintain appropriate security measures to prevent unauthorized access to, or disclosure of, the other Party&#8217;s Confidential Information; (ii) promptly notify the other Party of any unauthorized access or disclosure of such other Party&#8217;s Confidential Information; and (iii) cooperate with such other Party in the investigation and remediation of any such unauthorized access or disclosure.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">7.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref133938631"></a><a name="_Toc138665396"></a><a name="_Toc178261208"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Use</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Notwithstanding </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">7.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, a Party may use the Confidential Information of the other Party for the purpose of performing its obligations, or exercising its rights, under this Agreement, including for purposes of:</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">filing or prosecuting patent applications, subject to the terms of </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.4</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">prosecuting or defending litigation;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">conducting pre-clinical studies or Clinical Trials pursuant to this Agreement or the Product Agreement;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">seeking or maintaining Regulatory Approval of the Device or Device Product; or</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(e)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">complying with Law, including securities Law and the rules of any securities exchange or market on which a Party&#8217;s securities are listed or traded.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">In addition to the foregoing, Company may, in furtherance of its rights under this Agreement, disclose Confidential Information of Licensor to any Third Party, provided that such Third Party is bound by obligations of confidentiality at least as stringent as the ones herein.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">In making any disclosures pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">7.2</u>, the disclosing Party shall, where reasonably practicable, give such advance notice to the other Party of such disclosure requirement as is reasonable under the circumstances and will use its Commercially Reasonable Efforts to cooperate with the other Party in order to secure confidential treatment of such Confidential Information required to be disclosed. &#160;In addition, in connection with any permitted filing by either Party of this Agreement with any Governmental Body the filing Party shall endeavor to obtain confidential treatment of economic, trade secret information and such other information as may be requested by the other Party, and shall provide the other Party with the proposed confidential treatment request with reasonable time for such other Party to provide comments, and shall include in such confidential treatment request all reasonable comments of the other Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">For the avoidance of doubt and notwithstanding anything in this Agreement to the contrary, in no event may Licensor use or reference any Confidential Information of Company, including any information reported by Company to Licensor in connection with this Agreement, to engage in any Competitive Action (as defined in the Product Agreement).</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">7.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref133938648"></a><a name="_Toc138665397"></a><a name="_Toc178261209"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Required Disclosure</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;The recipient may disclose the Confidential Information to the extent required by Law or court order; provided, however, that the recipient promptly provides to the disclosing party prior written notice of such disclosure and provides reasonable assistance in obtaining an order or other remedy protecting the Confidential Information from public disclosure. &#160;If the recipient is required to make a disclosure as described in this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">7.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, the recipient will furnish only that portion of the Confidential Information that is legally required.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">7.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665398"></a><a name="_Toc178261210"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Publications</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Licensor shall not publish any information relating to a Device without the prior written consent of Company (which consent may be withheld or given in Company&#8217;s sole discretion), unless such information has already been publicly disclosed either prior to the Effective Date or after the Effective Date through no fault of Licensor or otherwise not in violation of this Agreement. &#160;Company shall have the right to make such publications as it chooses, in its sole discretion, without the approval of Licensor. &#160;Licensor shall submit to Company for Company&#8217;s written approval (which approval be granted or denied in Company&#8217;s sole discretion) any publication or presentation (including in any seminars, symposia or otherwise) of information related directly or indirectly to the Device for review and approval at least ninety (90) days prior to submission for the proposed date of publication or presentation.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">7.5</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665399"></a><a name="_Toc178261211"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Press Releases and Disclosure</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">7.5.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref167998345"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial Press Release</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. The proposed joint public announcement by Licensor and Company of the execution of this Agreement is set forth on </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">7.5.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> hereto.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">7.5.2</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Public Disclosures by Licensor</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_413"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Except as provided in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">7.5.4</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Licensor may not make any subsequent press release or public </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_415"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">announcement </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">regarding </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_416"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the terms of </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">this Agreement or any matter covered by this Agreement, including the Development or Commercialization of Devices or Device Products, without the prior written consent of Company.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">7.5.3</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Public Disclosures by Company</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_422"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Except as provided in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">7.5.4</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, Company may not make any subsequent press release or public announcement regarding the terms of this Agreement</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_424"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">; provided, however, that </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Company shall have the right to make such press releases as it chooses, in its sole discretion, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_425"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">regarding the status of its Development or Commercialization of Devices or Device Products </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">without the approval of Licensor, provided further, that, to the extent practicable, Company shall use Commercially </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Reasonable Efforts to notify Licensor in advance of any such press release that would reasonably be expected to trigger any securities filing obligations for Licensor.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">7.5.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref132559160"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exceptions</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Notwithstanding the foregoing, </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_427"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">either Party </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">shall have the right, without the approval </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_429"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of the other Party, (a) </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">to make securities filings that </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_431"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">such Party </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">determines are required under applicable securities laws and regulations </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_432"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(provided, that to the extent practicable, it </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_433"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">provides the text of such planned disclosure to </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_434"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the non-disclosing Party no less than two (2</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_4_435"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">) days prior to disclosure, and has used Commercially Reasonable Efforts to incorporate all reasonable comments of </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_cp_text_1_436"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the non-disclosing Party regarding such disclosure); and (b) to make disclosures of information that has been previously published or released in accordance with the terms and conditions of this Agreement.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Licensor may disclose the terms and conditions of this Agreement to its licensees of devices and device products to clarify the scope of license to Company of the Devices and Device Products, provided that Licensor shall redact all of the financial terms and conditions set forth in this Agreement prior to such disclosure and further provided that Licensor shall provide the text of such planned disclosure to Company no less than two (2) days prior to disclosure and shall incorporate all reasonable comments of Company regarding such disclosure. </font></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE 8</font><a name="_Toc138665400"></a><a name="_Ref_ContractCompanion_9kb9Ur29B"></a><a name="_Ref_ContractCompanion_9kb9Ur299"></a><a name="_Ref_ContractCompanion_9kb9Ur28G"></a><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc178261212"></a>REPRESENTATIONS, WARRANTIES AND COVENANTS</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">8.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665401"></a><a name="_Toc178261213"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Representations and Warranties</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Each Party represents and warrants to the other Party that, as of the Effective Date:</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">such Party is duly organized and validly existing under the Laws of the jurisdiction of its incorporation;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">such Party has taken all action necessary to authorize the execution and delivery of this Agreement and the performance of its obligations under this Agreement;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">this Agreement is a legal and valid obligation of such Party, binding upon such Party and enforceable against such Party in accordance with the terms of this Agreement, except as enforcement may be limited by applicable bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors&#8217; rights generally and by general equitable principles. &#160;The execution, delivery and performance of this Agreement by such Party does not conflict with, breach or create in any Third Party the right to accelerate, terminate or modify any agreement or instrument to which such Party is a party or by which such Party is bound, and does not violate any Law of any Governmental Body having authority over such Party; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">such Party has all right, power and authority to enter into this Agreement, to perform its obligations under this Agreement.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">8.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref136541658"></a><a name="_Toc138665402"></a><a name="_Toc178261214"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Additional Representations and Warranties of Licensor</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Licensor represents and warrants to Company that, as of the Effective Date:</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">no consent by any Third Party or Governmental Body is required with respect to the execution and delivery of this Agreement by Licensor or the consummation by Licensor of the transactions contemplated hereby;</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">no claims have been asserted or threatened by any Person, nor to Licensor&#8217;s Knowledge, are there any valid grounds for any claim of any such kind, (i) challenging the validity, effectiveness, or ownership of Licensor Technology, and/or (ii) to the effect that the use, reproduction, modification, manufacturing, distribution, licensing, sublicensing, sale or any other exercise of rights in any of Licensor Technology infringes or will infringe on any intellectual property right of any Person; &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">to Licensor&#8217;s Knowledge, there is no unauthorized use, infringement or misappropriation of any of Licensor Technology by any employee or former employee of Licensor, or any other Third Party in the Territory;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the Licensor Patents are subsisting </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and all registration, renewal, maintenance and other official fees with respect to the </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Licensor Patents</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> due on or before the date of this Agreement have been paid in full. &#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Licensor is the sole assignee and owner of each item listed on </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">1.30</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;To Licensor&#8217;s Knowledge, the Licensor Patents are not the subject of any litigation procedure, discovery process, interference, reissue, reexamination, opposition, appeal proceedings or any other legal dispute;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(e)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the Licensor Patents (i) constitute all Patent Rights owned or Controlled by Licensor as of the Effective Date that are directly related to, necessary or useful for, or used in, the Development, Regulatory Approval, manufacture, use, marketing, sale, offer for sale, import, export or Commercialization of the PN2[***] Device or PN1[***] Device in the Territory and (ii) listed on </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">1.30</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;hereto constitute all Patent Rights that are directly related to, necessary or useful for, or used in, the Development, Regulatory Approval, manufacture, use, marketing sale, offer for sale, import, export or Commercialization of the PN2[***] Device or the PN1[***] in the Territory;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(f)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_DV_C433"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the Licensor Know-How (i) constitutes all Know-How owned or Controlled by Licensor as of the Effective Date that is directly related to, or are necessary or useful for, the Development, manufacture, use or Commercialization of the PN2[***] Device or the PN1[***] Device under the Licensed Rights and (ii) to Licensor&#8217;s Knowledge, constitutes all Know-How that is directly related to, or are necessary or useful for, the Development, manufacture, use or Commercialization of the PN2[***] Device or PN1[***] Device under the Licensed Rights; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(g)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">all of the Licensor Technology is owned by Licensor or its Affiliates and Licensor has not in-licensed, or otherwise obtained any rights, from a Third Party with respect to the PN2[***] Device or PN1[***] Device or the Licensor Technology; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(h)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Licensor has not licensed to a Third Party the right to develop the PN2[***] Device or PN1[***] Device;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(i)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">no Third Party has filed, pursued or maintained or threatened in writing to file, pursue or maintain any claim, lawsuit, charge, complaint or other action alleging that any Licensor Patent is invalid or unenforceable;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(j)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">to Licensor&#8217;s Knowledge, Company&#8217;s and its Affiliates&#8217; and Sublicensees&#8217; practice and use of the inventions claimed in the Licensor Patents under the Licensed Rights as permitted herein (including the sale, offer for sale, Commercialization or Regulatory Approval of the PN2[***] Device or PN1[***] Device) will not infringe any intellectual property rights of any Third Party; </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(k)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">all Representatives of Licensor who have performed any activities on its behalf in connection with Development regarding the PN2[***] Device or PN1[***] Device have assigned to Licensor the whole of their rights in any intellectual property made, discovered or developed by them as a result of such Development, and no Third Party has any rights to any such intellectual property; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(l)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Licensor has all right, title and interest in and to the Licensor Technology and Licensor Technology is free and clear of any liens, charges, encumbrances or rights of others to possession or use; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(m)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Licensor has not previously licensed, assigned, transferred, or otherwise conveyed any right, title or interest in and to the Licensor Technology to any Third Party in the Territory, including any rights with respect to the PN2[***] Device or the PN1[***] Device;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(n)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">to Licensor&#8217;s Knowledge, the Licensor Technology constitutes all of the intellectual property which could reasonably be expected to be necessary or useful for, or used in, the Development, manufacture, Regulatory Approval, import, export, use, marketing, sale, offer for sale or Commercialization of the PN2[***] Device or PN1[***] Device; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(o)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref338868161"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the PN2[***] Device and PN1[***] Device each fall within the scope of at least one Valid Claim of at least one of the Licensor Patents listed on </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">1.30</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(p)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">to Licensor&#8217;s Knowledge, there is no additional Third Party licenses that have to be taken now or in the future to guarantee freedom-to-operate to Develop, manufacture and Commercialize the PN2[***] Device or PN1[***] Device without any limitation;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(q)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the Existing Third Party Agreements constitute all agreements that were entered into by Licensor or its Affiliates with Third Parties for the development or manufacture or supply of the PN2[***] Device or the PN1[***] Device. &#160;Licensor has provided to Company an accurate, true and complete copy of each of the Existing Third Party Agreements, as amended to date, and each of the Existing Third Party Agreements is in full force and effect. &#160;Licensor is not, and to Licensor&#8217;s Knowledge no other party to any Existing Third Party Agreement is, in breach or default in the performance of its obligations under any of the Existing Third Party Agreements. &#160;Licensor has not received any notice from any Third Party of any breach, default or non-compliance of Licensor under the terms of any of the Existing Third Party Agreements. &#160;There have been no amendments or other modification to any Existing Third Party Agreements, except as have been disclosed to Company in writing;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(r)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">all tangible information and data provided by or on behalf of Licensor to Company on or before the Effective Date in contemplation of this Agreement was and is true, accurate and complete in all material respects, and Licensor has not failed to disclose, or cause to be disclosed, any information or data that would cause the information and data that has been disclosed to be misleading in any material respect; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(s)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Licensor (and its Affiliates) has not employed or otherwise used in any capacity, and will not employ or otherwise use in any capacity, the services of any Person debarred under any Law, including under Section 21 USC 335a or any foreign equivalent thereof, with respect to the Licensor Technology or a Device; </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(t)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">all Development related to the PN2[***] Device and PN1[***] Device prior to the Effective Date has been conducted in accordance with all Laws; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">8.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665403"></a><a name="_Toc178261215"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Licensor Covenants</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Licensor covenants to Company that:</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Licensor shall fulfill all of its obligations, including but not limited to its payment obligations, under each Existing Third Party Agreement;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Licensor shall fulfill all of its obligations, including but not limited to its payment obligations, under each Supply Agreement that related to periods prior to the effectuation or assignment to Company of any such agreement;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Licensor shall fulfill all of its obligations, including but not limited to its payment obligations, under any Third Party License Agreement; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Licensor shall not amend or waive, or take any action or omit to taking any action that would alter, any of Licensor&#8217;s rights under any Existing Third Party Agreement, Third Party License Agreement or Supply Agreement in any manner that adversely affects, or would reasonably be expected to adversely affect, Company&#8217;s rights and benefits under this Agreement. &#160;Licensor shall promptly notify Company of any default under, termination or amendment of, any Third Party License Agreement or Supply Agreement; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(e)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">with respect to each Supply Agreement that is to be assigned to Company hereunder, until such time as such Supply Agreement has been assigned to, and assumed by, Company, (i) Licensor shall not amend or terminate such Supply Agreement, or waive, or take any action or omit to take any action that would alter, any of Licensor&#8217;s rights under any Supply Agreement, and (ii) Licensor shall promptly notify Company of any default under, or termination or amendment of, any Supply Agreement. &#160;In the case of any default by Licensor under a Supply Agreement, Licensor shall provide Company a reasonable opportunity to cure such default.</font></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE 9</font><a name="_Toc138665404"></a><a name="_Ref_ContractCompanion_9kb9Ur29F"></a><a name="_Ref_ContractCompanion_9kb9Ur29D"></a><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc178261216"></a>INDEMNIFICATION AND INSURANCE</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">9.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref338866743"></a><a name="_Ref338868291"></a><a name="_Ref338868309"></a><a name="_Toc138665405"></a><a name="_Ref_ContractCompanion_9kb9Ur16D"></a><a name="_Toc178261217"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Indemnification by Company</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Company shall indemnify, defend and hold Licensor and its Affiliates and each of their respective employees, officers, directors and agents (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Licensor Indemnitees</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;) harmless from and against any and all liability, damage, loss, cost or expense (including reasonable attorneys&#8217; fees) (collectively, the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Losses</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;) to the extent arising out of Third Party claims or suits to the extent arising out of: (a) the Development, sale, offer for sale, import, export and other Commercialization of a Device by or on behalf of Company, its Affiliates or Sublicensees after the Effective Date; (b) Company&#8217;s gross negligence or willful misconduct; (c) Company&#8217;s breach of its obligations under this Agreement; or (d) breach by Company of its representations or warranties set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">; except, in each case (a)-(d), to the extent such Losses arise out of (i) any activities set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.2</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(a)-(d)</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> for which Licensor is obligated to indemnify any Company Indemnitee under </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> or (ii) any liability for which Licensor is responsible under the Supply Agreement or any other agreement between Licensor and Company.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">9.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref338866787"></a><a name="_Toc138665406"></a><a name="_Toc178261218"></a><a name="_Ref_ContractCompanion_9kb9Ur16F"></a><a name="_Ref_ContractCompanion_9kb9Ur17G"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Indemnification by Licensor</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Licensor shall indemnify, defend and hold Company and its Affiliates and each of their respective agents, employees, officers and directors (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Company Indemnitees</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;) harmless from and against any and all Losses to the extent arising out of Third Party claims or suits to the extent arising out of: (a) Licensor&#8217;s Development, manufacture, use or </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Commercialization of the Licensor Technology and Devices prior to the Effective Date; (b) Licensor&#8217;s gross negligence or willful misconduct; (c) Licensor&#8217;s breach of its obligations under this Agreement; or (d) breach by Licensor of its representations, warranties or covenants set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">; except, in each case (a)-(d), to the extent such Losses arise out of any activities set forth in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.1</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(a)-(d)</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> for which Company is obligated to indemnify any Licensor Indemnitee under </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">9.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref135653493"></a><a name="_Toc138665407"></a><a name="_Toc178261219"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">No Consequential Damages</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;EXCEPT WITH RESPECT TO EACH PARTY&#8217;S INDEMNIFICATION OBLIGATIONS UNDER </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> OR </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, AS APPLICABLE, IN NO EVENT SHALL EITHER PARTY OR ANY OF ITS AFFILIATES BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING LOSS OF PROFITS, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREIN OR ANY BREACH HEREOF. &#160;NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS AGREEMENT SHALL LIMIT EITHER PARTY FROM SEEKING OR OBTAINING ANY REMEDY AVAILABLE UNDER LAW FOR ANY BREACH OF BY THE OTHER PARTY OF ITS CONFIDENTIALITY OBLIGATIONS UNDER </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ARTICLE 7</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">9.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665408"></a><a name="_Toc178261220"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Notification of Claims; Conditions to Indemnification Obligations</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;As a condition to a Party&#8217;s right to receive indemnification under this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, it shall: (a) promptly notify the other Party as soon as it becomes aware of a claim or suit for which indemnification may be sought pursuant hereto; (b) cooperate, and cause the individual indemnitees to cooperate, with the indemnifying Party in the defense, settlement or compromise of such claim or suit; and (c) permit indemnifying Party to control the defense, settlement or compromise of such claim or suit, including the right to select defense counsel. &#160;In no event, however, may the indemnifying Party compromise or settle any claim or suit in a manner which admits fault or negligence on the part of the indemnified Party or any indemnitee without the prior written consent of the indemnified Party. &#160;Each Party shall reasonably cooperate with the other Party and its counsel in the course of the defense of any such suit, claim or demand, such cooperation to include without limitation using Commercially Reasonable Efforts to provide or make available documents, information and witnesses. &#160;The indemnifying Party shall have no liability under this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> with respect to claims or suits settled or compromised without its prior written consent.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">9.5</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref338868338"></a><a name="_Toc138665409"></a><a name="_Toc178261221"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Insurance</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;During the Term, each Party shall obtain and maintain, at its sole cost and expense, insurance (including any self-insured arrangements) in types and amounts, that are reasonable and customary in the United States and Taiwan, as applicable, pharmaceutical and biotechnology industry for companies engaged in comparable activities. &#160;It is understood and agreed that this insurance shall not be construed to limit either Party&#8217;s liability with respect to its indemnification obligations hereunder. &#160;Each Party will, except to the extent self-insured, provide to the other Party upon request a certificate evidencing the insurance such Party is required to obtain and keep in force under this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.5</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE 10</font><a name="_Toc138665410"></a><a name="_Ref_ContractCompanion_9kb9Ur29H"></a><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc178261222"></a>TERM AND TERMINATION</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">10.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref338867060"></a><a name="_Toc138665411"></a><a name="_Toc178261223"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Term and Expiration</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;The term of this Agreement (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Term</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;) shall commence on the Effective Date and, unless earlier terminated as provided in this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10</u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">,</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> shall continue in full force and effect, on a country-by-country basis until expiration or termination of the Product Agreement for </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the Existing Product in such country, at which time this Agreement shall expire in its entirety in such country and the terms of </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.5.2(a)</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> shall apply.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref338867351"></a></font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">10.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665412"></a><a name="_Toc178261224"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Termination upon Material Breach</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">10.2.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref338867197"></a><a name="_Ref_ContractCompanion_9kb9Ur19G"></a><a name="_Ref_ContractCompanion_9kb9Ur2AA"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Material Breach</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;If a Party breaches any of its material obligations under this Agreement, the Party not in default may give to the breaching Party a written notice specifying the nature of the default, requiring it to cure such breach, and stating its intention to terminate this Agreement if such breach is not cured within [***] days. &#160;If such breach is not cured within [***] days after the receipt of such notice, the Party not in default shall be entitled to terminate this Agreement immediately by written notice to the other Party. &#160;For clarity, such material obligations may apply to the performance of either: (a) this Agreement in its entirety, in which case this provision shall apply to the entire Agreement; (b) a specific Device or Device(s), in which case this provision shall apply only to such affected Device or Device(s); or (c) a specific country or countries within the Territory, in which case this provision shall apply only to such affected country or countries.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;For the avoidance of doubt, in no event shall a breach of any material obligation under this Agreement be deemed a breach of any material obligation under the Product Agreement or be deemed to give rise to a right of termination under the Product Agreement. &#160;Termination of this Agreement shall not be deemed to result in termination of the Product Agreement. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">10.2.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref338866723"></a><a name="_Ref_ContractCompanion_9kb9Ur19E"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensor Cure Period</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;If Licensor is the defaulting party and a material breach by Licensor is not cured within [***] days of receipt following a notice from Company under </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.2.1</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Cure Period</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;), Company may elect not to terminate this Agreement and, instead, during the period commencing at the end of the Cure Period and continuing until the end of the last Royalty Term in all countries, reduce the Development Milestone payments under Section 6.2 of the Product Agreement, the Sales Milestone payments under Section 6.3 of the Product Agreement and the then-applicable royalty rates under Section </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">6.4.1</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> of the Product Agreement by [***]; provided, that such reduction shall not be Company&#8217;s sole remedy with respect to the breach by Licensor.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">10.2.3</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Material Breach Dispute</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Any Dispute regarding an alleged material breach of this Agreement shall be resolved in accordance with </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">11</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;In such event, termination will be tolled and the termination will become effective only if such material breach remains uncured for the applicable cure period after the final resolution of the Dispute through such dispute resolution procedures.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">10.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref_ContractCompanion_9kb9Ur2AE"></a><a name="_Toc138665413"></a><a name="_Ref_ContractCompanion_9kb9Ur179"></a><a name="_Toc178261225"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Bankruptcy Event Termination</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;This Agreement may be terminated by written notice by a Party at any time during the Term in the event of a Bankruptcy Event of the other Party.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">10.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665414"></a><a name="_Toc178261226"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Mutual Termination</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;The Parties may terminate this Agreement in its entirety or on a country-by-country or Device-by-Device basis upon mutual written agreement.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">10.5</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665415"></a><a name="_Toc178261227"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Effects of Termination</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">10.5.1</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;padding-left:36pt;text-align:justify;text-indent:-36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>Notwithstanding the expiration or termination of this Agreement, the following provisions shall survive: &#160;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Articles 1</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">7</u> (solely with respect to the time period set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 7.1</u>) and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">11</u>; and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections 3.5</u> (with respect to trademark ownership), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.1</u> (with respect to ownership of regulatory filings and Regulatory </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;padding-left:36pt;text-align:justify;text-indent:0pt;text-transform:none;">Approvals), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.6</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.2</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.4.5</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.1-9.4</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.5-10.7</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">12.1</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">12.2.1-12.2.4</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">12.2.5</u> (for so long as Company has a continuing license hereunder), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">12.3</u>, and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">12.4-12.17</u>. </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;padding-left:36pt;text-align:justify;text-indent:-36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>Expiration or termination of this Agreement shall not relieve the Parties of any liability that accrued hereunder prior to the effective date of such termination. &#160;In addition, termination of this Agreement shall not preclude either Party from pursuing all rights and remedies it may have hereunder or at Law or in equity with respect to any breach of this Agreement nor prejudice either Party&#8217;s right to obtain performance of any obligation.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">10.5.2</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licenses</u><b style="border-bottom-style:solid;border-bottom-width:0.5pt;color:#0000ff;font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-decoration-line:underline;text-decoration-style:double;">.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;padding-left:36pt;text-align:justify;text-indent:-36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref338868371"></a>As of the effective date of expiration of the Term with respect to a given country, the Licensed Rights shall convert to a fully paid, royalty free, irrevocable, perpetual, exclusive, and sublicensable license under the Licensor Technology to Develop, manufacture, have manufactured, use and Commercialize Devices and Device Products in the Field in such country.</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;padding-left:36pt;text-align:justify;text-indent:-36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>Upon termination of this Agreement by Licensor pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.2.1</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.3</u>, the following terms and conditions shall apply with respect to such Device(s) or Device Product(s) and country(ies) as are the subject of such termination:</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:108pt;text-align:justify;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(i)</font>all licenses granted to Company under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.1</u> shall terminate;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:108pt;text-align:justify;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(ii)</font>Company shall, upon written request by Licensor and within three (3) months therefrom, and subject to Licensor assuming legal responsibility for any Clinical Trials of a Device or Device Product then ongoing, transfer to Licensor or its Third Party designee at no cost to Licensor (except in any such case where Licensor is seeking a claim for damages from Company with respect to any such breach or termination of this Agreement) ownership and control of<font style="color:#008000;"> </font>all regulatory filings, Regulatory Approvals and Device or Device Product data prepared or obtained by or on behalf of Company prior to the date of such termination, to the extent solely related to the Device or Device Product and country(ies) and transferable, and Company shall take any actions reasonably necessary to effect such transfer, provided Company shall have the right to retain one copy of such transferred regulatory filings, Regulatory Approvals and Device or Device Product data for record-keeping purposes; </div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:108pt;text-align:justify;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iii)</font>Company shall, upon written request of Licensor, return to Licensor or, at Company&#8217;s option, destroy, at Company&#8217;s cost and expense, all relevant records and materials in its possession or control containing or comprising the Licensor Know-How, or such other Confidential Information of Licensor, to the extent solely related to such Device(s) or Device Product(s) and country(ies); provided, however, that Company shall have the right to retain one copy of such Licensor Know-How and such other Confidential Information of Licensor for archival purpose;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:108pt;text-align:justify;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(iv)</font>Company shall, at Licensor&#8217;s election within thirty (30) days following termination, sell such materials (in whole or in part) to Licensor at a price equal to Company&#8217;s costs of goods. &#160;Any clinical supplies of such Device(s), Device Product(s) or other materials purchased by Licensor from Company shall </div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:108pt;text-align:justify;text-indent:0pt;text-transform:none;">be purchased on an &#8220;as is&#8221; basis with no representations or warranties. &#160;In the event that Licensor does not make an election within such thirty (30) day period or elects not to purchase such materials, Company shall have the right to (A) destroy or retain any and all chemical, biological or physical materials relating to or comprising such Device(s) or Device Product(s), including clinical supplies of such Device(s) or Device Product(s), that are Controlled by Company to the extent solely related to such country(ies) or (B) sell such materials to a Third Party; &#160;</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:108pt;text-align:justify;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(v)</font>To the extent not prohibited by Law, Company shall wind down any ongoing Clinical Trials to the extent solely related to such Device(s) or Device Product(s) and country(ies);</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:108pt;text-align:justify;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(vi)</font>Company and its Affiliates and Sublicensees shall be entitled, during the [***] month period following such termination, to sell any commercial inventory of such Device(s) or Device Product(s) which remains on hand as of the date of the termination, so long as Company pays to Licensor the royalties applicable to said subsequent sales in accordance with the terms and conditions set forth in this Agreement. &#160;Any commercial inventory remaining following [***] month period shall be offered for sale to Licensor<font style="color:#ff0000;"> </font>at a price equal to Company&#8217;s costs of goods; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:108pt;text-align:justify;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(vii)</font>Upon any termination of this Agreement, each of Company&#8217;s Sublicensees shall continue to have the rights and license set forth in its sublicense agreements, which agreements shall be automatically assigned to Licensor, to the extent solely related to such Device(s) or Device Product(s) and country(ies); provided, however, that such Sublicensee is not then in breach of any of its material obligations under its sublicense agreement.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">10.6</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665416"></a><a name="_Toc178261228"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Additional Effects of Termination for a Licensor Bankruptcy Event</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">10.6.1</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Continuing Rights</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;The Parties agree that Company, as licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. &#160;The Parties further agree that, in the event of a Licensor Bankruptcy Event, Company shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, which, if not already in Company&#8217;s possession, shall be promptly delivered to it (a)&#160;following any such commencement of a bankruptcy proceeding upon Company&#8217;s written request therefor, unless Licensor elects to continue to perform all of its obligations under this Agreement or (b)&#160;if not delivered under clause&#160;(a), following the rejection of this Agreement by Licensor upon written request therefor by Company.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">10.6.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref338867048"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right of First Refusal</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;In addition to the foregoing, in the event of a Licensor Bankruptcy Event, Company shall, to the extent allowed by Law (including to the extent enforceable under the Laws of Taiwan), have a right of first refusal to purchase all of Licensor&#8217;s interest in the Device or Device Product and the Licensor Technology (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Right of First Refusal</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;). &#160;The Right of First Refusal shall operate as follows:</font></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;padding-left:36pt;text-align:justify;text-indent:-36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>Licensor (or other authorized representative of Licensor, including a bankruptcy trustee) shall promptly send to Company a reasonably detailed written notification of any Licensor Bankruptcy Event.</div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;margin-left:72pt;padding-left:36pt;text-align:justify;text-indent:-36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref338867053"></a>Licensor (or other authorized representative of Licensor, including a bankruptcy trustee) shall promptly send to Company a written notification of any Third Party offer made on Device, Device Product or Licensor Technology. &#160;For a period of up to [***] days after Company receives such notice (such period, the &#8220;<b style="font-weight:bold;">Right of First Refusal Notice Period</b>&#8221;), it shall notify Licensor of its intention to exercise its Rights of First Refusal. &#160;In the event Company exercises its Right of First Refusal, the terms of the Third Party offer shall become binding upon Company and Licensor. &#160;For the avoidance of doubt, Licensor shall not enter into any agreement with a Third Party relating to Licensor&#8217;s interest in the Devices, Device Products or Licensor Technology during the Right of First Refusal Notice Period.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">10.7</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665417"></a><a name="_Toc178261229"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Other Remedies</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Termination of this Agreement for any reason shall not release either Party from any liability or obligation that already has accrued prior to such termination. &#160;Termination of this Agreement for any reason shall not constitute a waiver or release of, or otherwise be deemed to prejudice or adversely affect or limit, any rights or remedies that otherwise may be available at Law or in equity.</font></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE 11</font><a name="_Toc138665418"></a><a name="_Ref_ContractCompanion_9kb9Ur24C"></a><a name="_Ref_ContractCompanion_9kb9Ur24A"></a><a name="_Ref_ContractCompanion_9kb9Ur248"></a><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc178261230"></a>DISPUTE RESOLUTION</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">11.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref131777201"></a><a name="_Toc138665419"></a><a name="_Toc178261231"></a><a name="_Ref338866817"></a><a name="_Ref338868737"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">General</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;The Parties recognize that disputes (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Disputes</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;) as to certain matters may from time to time arise during the Term which relate to either Party&#8217;s rights and/or obligations hereunder. &#160;It is the objective of the Parties to establish under this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">11</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> procedures to facilitate the resolution of Disputes arising under this Agreement in an expedient manner by mutual cooperation and without resort to litigation.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">11.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665420"></a><a name="_Toc178261232"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Escalation to Executive Officers</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Either Party may, by written notice to the other Party, request that a Dispute that remains unresolved by the Parties for a period of thirty (30) days be submitted to the Executive Officers for resolution. &#160;If the Executive Officers cannot resolve such Dispute within thirty (30) days after referral of such Dispute to them, then, at any time after such thirty (30) day period, either Party may refer such Dispute to arbitration by submitting a written notice of such request to the other Party.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">11.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665421"></a><a name="_Toc178261233"></a><a name="_Ref_ContractCompanion_9kb9Ur2AI"></a><a name="_Ref_ContractCompanion_9kb9Ur2BB"></a><a name="_Ref_ContractCompanion_9kb9Ur2BD"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Arbitration</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">11.3.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref118744644"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disputes</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;The </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_9kMH8HQ7aXv5BC9DHeIrBJ"></a><a name="_9kMH8HQ7aXv5BC9DIfIrBJ"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Parties</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> hereby agree that, except as otherwise expressly set forth herein, in the event the </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_9kMI0zH7aXv5BC9DHeIrBJ"></a><a name="_9kMI0zH7aXv5BC9DIfIrBJ"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Parties</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> are unable to resolve any Dispute after referring such Dispute to the Executive Officers, the </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_9kMKJ5YVt39A6DKSCy69Ez"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Dispute</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> shall be settled by binding arbitration administered by the </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_9kR3WTr2664ENXK2ut3nu3z5srUI0G8797KkWIQ"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">International </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Chamber of Commerce (&#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_9kR3WTr1784EHRjfv"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">IC</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">C</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;) in accordance with its </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_9kR3WTr2664EMWK2ut3nu3z5srST1tCM47GCIwy"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Rules</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> of Arbitration (the &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_9kR3WTr2445AGea1mu"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Rules</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;). &#160;Either Party may refer any Dispute to arbitration by submitting a written notice of such request to the other Party.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">11.3.2</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Arbitrators</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Any arbitration shall be presided over by three (3) arbitrators. &#160;Each </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_9kMI00I7aXv5BC9DHeIrBJ"></a><a name="_9kMI00I7aXv5BC9DIfIrBJ"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Party</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> shall select one </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="DocXTextRef277"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(1)</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> arbitrator, and such selected arbitrators shall mutually agree upon the third arbitrator who shall act as the chairman of the arbitration panel. &#160;If either Party fails or both Parties fail to choose an arbitrator or arbitrators within thirty (30) days after receiving notice of commencement of arbitration or if the two (2) arbitrators fail to choose a third arbitrator within thirty (30) days after their appointment, then either or both Parties shall immediately request that the ICC select the remaining number of arbitrators to be selected. &#160;The arbitrators shall be neutral and independent of the Parties and their respective Affiliates, and may not be current or former directors, officers or employees of the Parties </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">or their respective Affiliates. &#160;No Party may have any </font><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:normal;">ex parte</i><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> discussion with any potential arbitrator, except for confirming if such arbitrator is willing and able to serve on the arbitration panel. &#160;All arbitrators shall have ten (10) or more years of experience in the pharmaceutical and biotechnology industries, shall have appropriate experience with respect to the matter(s) to be arbitrated, and shall have some experience in mediating or arbitrating issues relating to such agreements. &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">11.3.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref117474804"></a><a name="_Ref_ContractCompanion_9kb9Ur2AG"></a></font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Arbitration Process</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;The seat of the arbitration shall be New York, New York, USA. &#160;The arbitrators shall set a date for a hearing that shall be held no later than sixty (60) days following the appointment of the last of such three (3) arbitrators. &#160;The Parties shall have the right to be represented by counsel. &#160;No less than thirty (30) days prior to the hearing, each Party shall submit the following to the other Party and the arbitration panel: (a) a copy of all exhibits on which such Party intends to rely in any oral or written presentation to the panel; (b) a list of any witnesses such Party intends to call at the hearing, and a short summary of the anticipated testimony of each witness; and (c) a brief in support of such Party&#8217;s proposed rulings and remedies; provided that the brief shall not exceed twenty-five (25) pages. &#160;This page limitation shall apply regardless of the number of issues raised in the arbitration proceeding. &#160;The arbitrators shall determine what discovery will be permitted in accordance with the Rules, consistent with the goal of reasonably controlling the cost and time that the </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_9kMI04M7aXv5BC9DHeIrBJ"></a><a name="_9kMI04M7aXv5BC9DIfIrBJ"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Parties</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> must expend for discovery; provided, however, that the arbitrators shall permit discovery as they deem proportionate to the issues in </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_9kMIH5YVt4666DLTCy69Ez"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">dispute</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;The arbitration panel shall have sole discretion regarding the admissibility of any evidence, except statements made during settlement negotiations and affidavits prepared for the purposes of the hearing shall not be admissible. &#160;Within ten (10) days following completion of the hearing, each Party may submit to the other Party and the panel a post-hearing brief in support of its proposed rulings and remedies; provided that such brief shall not contain or discuss any new evidence and shall not exceed ten (10) pages. &#160;This page limitation shall apply regardless of the number of issues raised in the proceeding.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">11.3.4</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Decision of Arbitrators</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;The arbitrators shall use their best efforts to rule on each disputed issue within thirty (30) days after completion of the hearing described in </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">11.3.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. The determination of the arbitrators as to the resolution of any Dispute shall be binding and conclusive upon the Parties, absent manifest error. &#160;All rulings of the arbitrators shall be in writing and shall be delivered to the Parties as soon as is reasonably possible.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">11.3.5</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Awards</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Any award to be paid by one Party to the other Party as determined by the arbitrators as set forth above under this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">11.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> be promptly paid in USD free of any Tax, deduction or offset, and any costs, fees or Taxes incident to enforcing the award shall, to the maximum extent permitted by Law, be charged against the Party resisting enforcement. &#160;Each Party agrees to abide by the award rendered in any arbitration conducted pursuant to this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">11.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, and agrees that, subject to the Federal Arbitration Act, judgment may be entered upon the final award in a court of competent jurisdiction and that other courts may award full faith and credit to such judgment in order to enforce such award. &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">11.3.6</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Costs and Expenses</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;The </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_9kMI06O7aXv5BC9DHeIrBJ"></a><a name="_9kMI06O7aXv5BC9DIfIrBJ"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Parties</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> agree that they shall share equally in the joint costs associated with the arbitration hearing(s) and any procedural conferences (location, stenographer and similar), the fees and expenses of any independent expert retained by the arbitrators, if any, and the fees and expenses of the arbitrators (as set forth above) and administrative fees and expenses of ICC. &#160;Each </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_9kMI07P7aXv5BC9DHeIrBJ"></a><a name="_9kMI07P7aXv5BC9DIfIrBJ"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Party</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> shall bear its own costs and attorneys&#8217; and witnesses&#8217; fees and associated costs and expenses. &#160;The existence and substance of the </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">arbitration proceedings and the decision of the arbitrators shall be kept confidential by the </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_9kMI08Q7aXv5BC9DHeIrBJ"></a><a name="_9kMI08Q7aXv5BC9DIfIrBJ"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Parties</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> and the arbitrators except to the extent disclosure may be necessary to conduct the arbitration, or in connection with a court application for a preliminary remedy, a judicial </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_9kMHG5YVt46668COAfkwqtwo"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">challenge</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> to an award or its enforcement, or unless otherwise required by law or judicial decision.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">11.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665422"></a><a name="_Toc178261234"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Injunctive Relief</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Notwithstanding anything to the contrary in this </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_9kMH28N7aXv5BC89EP9xwktuwC"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Agreement</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, either </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_9kMI10H7aXv5BC9DHeIrBJ"></a><a name="_9kMI10H7aXv5BC9DIfIrBJ"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Party</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> will have the right to seek temporary injunctive or preliminary equitable relief pending final resolution of any </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_9kMLK5YVt39A6DKSCy69Ez"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Dispute</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> under </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">11.3</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">, in any court of competent jurisdiction as may be available to such </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_9kMI11I7aXv5BC9DHeIrBJ"></a><a name="_9kMI11I7aXv5BC9DIfIrBJ"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Party</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> under </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_9kMI7N6ZWu4BC78HSH30umffrvWN5O"></a><a name="_cp_text_1_691"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Law</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">in such jurisdiction with respect to any matters arising out of the other </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_9kMI12J7aXv5BC9DHeIrBJ"></a><a name="_9kMI12J7aXv5BC9DIfIrBJ"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Party&#8217;s</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> performance or breach of its obligations under this </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_9kMH29O7aXv5BC89EP9xwktuwC"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Agreement</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE 12</font><a name="_Toc138665423"></a><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><a name="_Toc178261235"></a>MISCELLANEOUS PROVISIONS</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.1</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665424"></a><a name="_Toc178261236"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Relationship of the Parties</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Nothing in this Agreement is intended or shall be deemed, for financial, Tax, legal or other purposes, to constitute a partnership, agency, joint venture or employer-employee relationship between the Parties.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.2</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref338868755"></a><a name="_Ref338868760"></a><a name="_Toc138665425"></a><a name="_Toc178261237"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Assignment</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.2.1</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment Generally</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Except as expressly provided herein, neither this Agreement nor any interest hereunder shall be assignable, nor any other obligation delegable, by Licensor without the prior written consent of Company (not to be unreasonably withheld or delayed). &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.2.2</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment by Company</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Except as expressly provided herein, neither this Agreement nor any interest hereunder shall be assignable, nor any other obligation delegable, by Company without the prior written consent of Licensor (not to be unreasonably withheld, conditioned or delayed); provided, however, that Company may, without the prior written consent of Licensor, assign this Agreement to an Affiliate or to any Third Party in connection with a Change of Control or sale of all or substantially all of its assets to which this Agreement relates.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.2.3</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Continuing Obligations</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;No assignment under this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">12.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> shall relieve the assigning Party of any of its responsibilities or obligations hereunder and, as a condition of such assignment, the assignee shall agree in writing to be bound by all obligations of the assigning Party hereunder. &#160;This Agreement shall be binding upon the successors and permitted assigns of the Parties.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.2.4</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Void Assignments</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Any assignment not in accordance with this </font><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">12.2</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> shall be void.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.2.5</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment of Licensor Technology</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Licensor shall not assign or transfer any Licensor Technology to any of its Affiliates without the prior written consent of Company unless such Affiliate agrees in writing to be bound by all obligations of Licensor.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665426"></a><a name="_Toc178261238"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Performance and Exercise by Affiliates</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Company shall have the right to have any of its obligations hereunder performed, or its rights hereunder exercised, by, any of its Affiliates and the performance of such obligations by any such Affiliate shall be deemed to be performance by Company; provided, however, that Company shall be responsible for ensuring the performance of its obligations under this Agreement and that any failure of any Affiliate performing obligations of Company hereunder shall be deemed to be a failure by Company to perform such obligations. &#160;For </font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">clarity, the foregoing means that Company may designate an Affiliate to perform its obligations hereunder or to be the recipient of Licensor&#8217;s performance obligations hereunder.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.4</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665428"></a><a name="_Toc178261239"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Further Actions</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Each Party agrees to execute, acknowledge and deliver such further instruments and to do all such other acts as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Ref89939456"></a></font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.5</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665429"></a><a name="_Toc178261240"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Accounting Procedures</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Each Party shall calculate all amounts, and perform other accounting procedures required, under this Agreement and applicable to it in accordance with GAAP.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.6</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665430"></a><a name="_Toc178261241"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Force Majeure</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Neither Party shall be liable to the other Party or be deemed to have breached or defaulted under this Agreement for failure or delay in the performance of any of its obligations under this Agreement for the time and to the extent such failure or delay is caused by or results from acts of God, earthquake, riot, civil commotion, terrorism, war, strikes or other labor disputes, fire, flood, failure or delay of transportation, omissions or delays in acting by a governmental authority, acts of a government or an agency thereof or judicial orders or decrees or restrictions or any other reason which is beyond the control of the respective Party. &#160;The Party affected by force majeure shall provide the other Party with full particulars thereof as soon as it becomes aware of the same (including its best estimate of the likely extent and duration of the interference with its activities) and will use Commercially Reasonable Efforts to overcome the difficulties created thereby and to resume performance of its obligations hereunder as soon as practicable.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.7</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665431"></a><a name="_Toc178261242"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">No Trademark Rights</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;No right, express or implied, is granted by this Agreement to a Party to use in any manner the name or any other trade name or trademark of the other Party in connection with the performance of this Agreement or otherwise.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.8</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665432"></a><a name="_Toc178261243"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Entire Agreement of the Parties; Amendments</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;This Agreement and the Schedules and Exhibits hereto, together with the Product Agreement (including the First Amendment) and the schedules and exhibits thereto (as incorporated herein), constitute and contain the entire understanding and agreement of the Parties respecting the subject matter hereof and cancel and supersede any and all prior negotiations, correspondence, understandings and agreements between the Parties, whether oral or written, regarding such subject matter. &#160;No waiver, modification or amendment of any provision of this Agreement shall be valid or effective unless made in a writing referencing this Agreement and signed by a duly authorized officer of each Party.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.9</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665433"></a><a name="_Toc178261244"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Captions</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;The captions to this Agreement are for convenience only, and are to be of no force or effect in construing or interpreting any of the provisions of this Agreement.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.10</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665434"></a><a name="_Toc178261245"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Governing Law</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;This Agreement shall be governed by and interpreted in accordance with the laws of the State of New York, USA, excluding application of any conflict of laws principles that would require application of the Law of a jurisdiction outside of State of New York, USA.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.11</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665435"></a><a name="_Toc178261246"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Notices and Deliveries</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Any notice, request, approval or consent required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been sufficiently given if delivered in person or transmitted by express courier service (signature required) to the Party to which it is directed at its address shown below or such other address as such Party shall have last given by notice to the other Party.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 12pt 36pt;">If to Company, addressed to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:72pt;margin:0pt 0pt 0pt 36pt;">Liquidia Technologies, Inc.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 108pt;">419 Davis Drive, Suite 100</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 108pt;">Morrisville, North Carolina 27560</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 108pt;">USA</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 108pt;">Attention: General Counsel</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 12pt 108pt;">Email: legal@liquidia.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 12pt 36pt;"><a name="_Hlk138445450"></a>With a copy, which shall not constitute notice, to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 108pt;">DLA Piper LLP (US)</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 108pt;">51 John F. Kennedy Parkway, Suite 120</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 108pt;">Short Hills, New Jersey 07078</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 108pt;">USA</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 108pt;">Attention: Andrew P. Gilbert</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>Email: andrew.gilbert@us.dlapiper.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 12pt 36pt;">If to Licensor, addressed to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 108pt;"><a name="_Hlk138445750"></a>Pharmosa Biopharm Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 108pt;">11F, No. 508, Section 7, Zhongxiao East Road</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 108pt;">Nangang District, Taipei City 11502 </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 108pt;">Taiwan </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 108pt;">Attention: Pei Kan/ Weishu Lu</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 108pt;">Email: peikan@pharmosa.com.tw/ Weishu.lu@pharmosa.com.tw</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 36pt;">With a copy, which shall not constitute notice, to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 108pt;"><a name="_Hlk138445804"></a>K&amp;L Gates </p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 108pt;">30F, No. 95. Dun Hua S. Road, Section 2</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 108pt;">Ta-an District, Taipei City 106</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 108pt;">Taiwan</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 108pt;">Attention: Jacqueline Fu</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 108pt;">Email: jacqueline.fu@klgates.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 12pt 108pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.12</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665436"></a><a name="_Toc178261247"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Language. &#160;</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">The official language of this Agreement and between the Parties for all correspondence shall be the English language.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.13</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665437"></a><a name="_Toc178261248"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Waiver</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;A waiver by either Party of any of the terms and conditions of this Agreement in any instance shall not be deemed or construed to be a waiver of such term or condition for the future, or of any other term or condition hereof. &#160;All rights, remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative and none of them shall be in limitation of any other remedy, right, undertaking, obligation or agreement of either Party.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.14</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665438"></a><a name="_Toc178261249"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Severability</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;When possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under Law, but if any provision of this Agreement is held to be prohibited by or invalid under Law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement. &#160;The Parties shall make a good faith effort to replace the invalid or unenforceable provision with a valid one which in its economic effect is most consistent with the invalid or unenforceable provision.</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.15</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665439"></a><a name="_Toc178261250"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">No Implied License</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;No right or license is granted to Licensor hereunder by implication, estoppel, or otherwise to any know-how, patent or other intellectual property right owned or controlled by Company or its Affiliates.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.16</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Toc138665440"></a><a name="_Toc178261251"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Interpretation</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;The words &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation.&#8221; &#160;All references herein to Articles, Sections, Schedules and Exhibits shall be deemed references to Articles and Sections of, and Schedules and Exhibits to, this Agreement unless the context shall otherwise require. &#160;Except as otherwise expressly provided herein, all terms of an accounting or financial nature shall be construed in accordance with GAAP. &#160;Unless the context otherwise requires, countries shall include territories.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:12pt;table-layout:fixed;text-align:justify;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-transform:none;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">12.17</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="TCEntryText"></a><a name="_Toc138665441"></a><a name="_Toc178261119"></a><a name="_Toc178261252"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Counterparts</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="TCEntryEnd"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> &#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"><a name="_Hlk133942094"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">This Agreement may be executed in counterparts, each of which will be deemed an original, and all of which together will be deemed to be one and the same instrument. &#160;A facsimile or a portable document format (PDF) copy of this Agreement, including the signature pages, will be deemed an original.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">[</b><b style="font-weight:bold;text-transform:uppercase;">signature page follows</b><b style="font-weight:bold;">]</b></p><p style="display:none;font-size:11pt;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>IN WITNESS WHEREOF, duly authorized representatives of the Parties have executed this Agreement as of the Effective Date.</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;table-layout:auto;width:107.85%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;">/s/s</p></div></div></td><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:8.1pt;"><td style="vertical-align:top;width:50.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">PHARMOSA BIOPHARM INC.</b></p></td><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">LIQUIDIA TECHNOLOGIES, INC.</b></p></td></tr><tr><td style="vertical-align:top;width:50.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:12pt 0pt 0pt 0pt;"><a name="_Hlk133942554"></a>Signature:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:26.79pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u>/s/ Pei Kan</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:23.72pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:12pt 0pt 0pt 0pt;">Signature:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:26.79pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u>/s/ Roger Jeffs</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:8.45pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td></tr><tr><td style="vertical-align:top;width:50.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:12pt 0pt 0pt 0pt;">Printed Name:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:8.15pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u>Pei Kan</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:0.87pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:12pt 0pt 0pt 0pt;">Printed Name:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:8.15pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u>Roger Jeffs</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:21.6pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td></tr><tr><td style="vertical-align:top;width:50.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:12pt 0pt 0pt 0pt;">Title:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> President</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:4.49pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p></td><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:12pt 0pt 0pt 0pt;">Title:<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> CEO</u></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;font-size:11pt;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">1.21</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Existing Third Party Agreements</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><a name="_Hlk169531247"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">1.28</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensor Know-How</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">[***]</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">1.29</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensor&#8217;s Knowledge Individuals</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">1.30</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensor Patents</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">1.37</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PN1</u>[***]<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> Device Specification</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">[***]</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">1.38</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PN2</u>[***]<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> Device Specification</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">2.3</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensor Technology Transfer Plan</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:justify;margin:0pt;"> <font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Schedule </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">7.5.1</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial Press Release</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;text-align:center;background:#ffffff;margin:0pt;"><a name="_Hlk136531746"></a><a name="_Hlk136531991"></a><b style="font-family:'Aptos';font-weight:bold;">Liquidia and Pharmosa Biopharm Expand Collaboration </b><b style="font-family:'Aptos';font-weight:bold;">to Develop </b><b style="font-family:'Aptos';font-weight:bold;"><br></b><b style="font-family:'Aptos';font-weight:bold;">Sustained Release Inhaled Treprostinil (L606)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Aptos';margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Aptos';font-size:11pt;font-style:normal;font-weight:normal;">Liquidia amends exclusive license to include key markets in Europe, Japan and elsewhere </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Aptos';font-size:11pt;font-style:normal;font-weight:normal;">Liquidia also obtains rights to Pharmosa&#8217;s next-generation nebulizers for use with L606</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Aptos';font-size:11pt;font-style:normal;font-weight:normal;">Pharmosa to receive $3.5 million upfront and up to $157.75 million in additional development and sales milestones tied to commercial sales outside of North America</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0pt 18pt;"><font style="font-family:'Aptos';margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><b style="font-family:'Aptos';font-weight:bold;">MORRISVILLE, N.C.,&#160;[October 2], 2024&#160;</b><font style="font-family:'Aptos';">&#8211;&#160;</font><font style="font-family:'Aptos';">Liquidia Corporation</font><font style="font-family:'Aptos';"> (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases,&#160;and </font><font style="font-family:'Aptos';">Pharmosa Biopharm</font><font style="font-family:'Aptos';"> (Pharmosa) today announced that they have amended the current exclusive licensing agreement for the development and commercialization of L606, an inhaled, sustained-release formulation of treprostinil currently being evaluated in a clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The amended agreement expands Liquidia&#8217;s licensed territory beyond North America to include key markets in Europe, Japan and elsewhere. Pharmosa will retain certain territories, including</font><font style="font-family:'Aptos';"> China, Korea, Taiwan, Middle East, North Africa, Turkey and Southeast Asia</font><font style="font-family:'Aptos';">. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Aptos';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Aptos';">Liquidia has also obtained certain rights to Pharmosa&#8217;s next-generation smart-technology nebulizers for use with its proprietary liposomal drug formulations. Unlike current nebulized treatments for PAH and PH-ILD, these palm-sized, lightweight, virtually silent nebulizers provide portability like a dry-powder inhaler and rapidly deliver a dose using breath-actuated smart technology that adapts to a patient&#8217;s normal breathing pattern.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Aptos';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Aptos';">Dr. Rajeev Saggar, Chief Medical Officer of Liquidia, stated: &#8220;This is a great example of our approach to research and development in pulmonary hypertension. This partnership has the potential to be transformational for people living with PAH and PH-ILD, as it will combine Liquidia&#8217;s expertise as a leader in the field of pulmonary hypertension with Pharmosa&#8217;s deep experience in inhaled liposomal formulations. We are delighted by the interest from the global medical and patient communities, many of which lack access to inhaled formulations of treprostinil, as we prepare to initiate the L606 pivotal study in PH-ILD later this year. We are also encouraged by the recent scientific advice from the European Medicines Agency that supports our plan to proceed with the study as designed.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Aptos';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Aptos';">Pei Kan, Ph.D., President of Pharmosa, added: &#8220;This expanded partnership with Liquidia is a strong endorsement for our L606 programs and our contribution to the fight against </font><font style="font-family:'Aptos';">pulmonary hypertension including </font><font style="font-family:'Aptos';">PAH and PH-ILD. With more than </font><font style="font-family:'Aptos';">10</font><font style="font-family:'Aptos';">0,000 PAH and PH-ILD patients in the </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Aptos';">major countries outside North America, improvements of the treatment strategies in this region are essential</font><font style="font-family:'Aptos';"> since there is no approved treatment for PH-ILD outside the U.S</font><font style="font-family:'Aptos';">. </font><font style="font-family:'Aptos';">We believe </font><font style="font-family:'Aptos';">Liquidia</font><font style="font-family:'Aptos';">&#8217;s</font><font style="font-family:'Aptos';"> commit</font><font style="font-family:'Aptos';">ment</font><font style="font-family:'Aptos';"> to move quickly and execute its global clinical program will accelerate the potential for long-term value creation for both parties in this partnership.&#8221; </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Aptos';"> </font><font style="font-family:'Aptos';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Aptos';">Consistent with the agreement from June 2023, Liquidia will be responsible for the development, regulatory and commercial activities of L606 in the expanded territory. Pharmosa will continue to manufacture clinical and commercial supplies of L606. In consideration for these incremental exclusive rights, Liquidia will pay Pharmosa an upfront payment of $3.5 million and up to $157.75 million in additional milestone payments for the development of PAH and PH-ILD indications and commercial sales outside of North America. Royalties payable by Liquidia to Pharmosa on global net sales of L606 have not changed and remain two tiers of low, double-digit royalties as set forth in the original agreement. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Aptos';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Aptos';">Clinically, L606 continues to generate encouraging data in an open-label safety study in the United States in both PAH and PH-ILD. As reported in a </font><font style="font-family:'Aptos';">poster presentation</font><font style="font-family:'Aptos';"> at the 2024 American Thoracic Society International Conference, the tolerability and titratability profile of L606 observed to date has been favorable up to the maximum dose allowed in the study of 378 mcg twice daily, a dosage comparable to 26 to 28 breaths of Tyvaso administered four times daily. Pharmacokinetic studies in healthy volunteers demonstrated therapeutic levels of L606 up to 12 hours and 7-times lower peak plasma concentration compared to Tyvaso&#174;. The increased apparent half-life of L606, in concert with comparable systemic exposure and clearance rate, suggests that L606 provides controlled, continuous drug coverage during sleeping and waking hours, and supports twice-daily administration using a breath-actuated, smart-technology nebulizer.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-family:'Aptos';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;padding-bottom:8pt;background:#ffffff;margin:0pt;"><b style="font-family:'Aptos';font-weight:bold;">About L606 (liposomal treprostinil) Inhalation Suspension</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;padding-bottom:8pt;background:#ffffff;margin:0pt;"><font style="font-family:'Aptos';">L606 is an investigational, liposomal formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer. The L606 suspension uses Pharmosa&#8217;s proprietary liposomal formulation to encapsulate treprostinil which can be released slowly at a controlled rate into the lung, enhancing drug exposure over an extended period and reducing local irritation of the upper respiratory tract. L606 is currently being evaluated in an open-label study in the United States for treatment of pulmonary arterial hypertension (PAH) with a planned pivotal study for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;padding-bottom:8pt;background:#ffffff;margin:0pt;"><b style="font-family:'Aptos';font-weight:bold;">About Pulmonary Arterial Hypertension (PAH) </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;padding-bottom:8pt;background:#ffffff;margin:0pt;"><font style="font-family:'Aptos';">Pulmonary arterial hypertension (PAH) is a rare, chronic, progressive disease caused by hardening and narrowing of the pulmonary arteries that can lead to right heart failure and eventually death. Currently, an estimated 45,000 patients are diagnosed and treated in the United States. There is currently no cure for PAH, so the goals of existing treatments are to alleviate symptoms, maintain or improve functional class, delay disease progression, and improve quality of life.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;padding-bottom:8pt;background:#ffffff;margin:0pt;"><b style="font-family:'Aptos';font-weight:bold;">About Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)</b></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;padding-bottom:8pt;background:#ffffff;margin:0pt;"><font style="font-family:'Aptos';">Pulmonary hypertension (PH) associated with interstitial lung disease (ILD) includes a diverse collection of up to 150 different pulmonary diseases, including interstitial pulmonary fibrosis, chronic hypersensitivity pneumonitis, connective tissue disease related ILD, and sarcoidosis among others. Any level of PH in ILD patients is associated with poor 3-year survival between 30 to 35%. A current estimate of PH-ILD prevalence in the United States is greater than 60,000 patients, though population growth in many of these underlying ILD diseases is not yet known due to factors including underdiagnosis and lack of approved treatments until March 2021 with inhaled treprostinil. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;padding-bottom:8pt;background:#ffffff;margin:0pt;"><b style="font-family:'Aptos';font-weight:bold;">About Liquidia Corporation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;padding-bottom:8pt;background:#ffffff;margin:0pt;"><font style="color:#202124;font-family:'Aptos';">Liquidia Corporation&#160;is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company&#8217;s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT</font><sup style="color:#202124;font-family:'Aptos';font-size:8.25pt;vertical-align:top;">&#174;</sup><font style="color:#202124;font-family:'Aptos';">&#160;Technology. PRINT enabled the creation of Liquidia&#8217;s lead candidate, YUTREPIA&#8482; (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).&#160; The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit&#160;</font><font style="font-family:'Aptos';">https://www.liquidia.com</font><font style="color:#202124;font-family:'Aptos';">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;padding-bottom:8pt;background:#ffffff;margin:0pt;"><b style="font-family:'Aptos';font-weight:bold;">About Pharmosa Biopharm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;padding-bottom:8pt;background:#ffffff;margin:0pt;"><font style="font-family:'Aptos';">Pharmosa Biopharm Inc. (PBI) is a Taiwan-based biotechnology company focused on developing new drugs by exploiting its proprietary liposomal formulations and manufacturing technology. With regional and global strategic partnerships, PBI develops products through 505(b)(2) or hybrid applications to regulatory authorities with the intent to expand the clinical potential of existing drugs by exploiting innovative delivery formulations and medical devices. For more information, please visit </font><font style="font-family:'Aptos';">https://www.pharmosa.com.tw</font><u style="color:#0000ff;font-family:'Aptos';text-decoration-color:#0000ff;text-decoration-line:underline;text-decoration-style:solid;">.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-bottom:14pt;background:#ffffff;margin:0pt;"><font style="color:#202124;font-family:'Aptos';">Tyvaso</font><sup style="color:#202124;font-family:'Aptos';font-size:8.25pt;vertical-align:top;">&#174;</sup><font style="color:#202124;font-family:'Aptos';">&#160;is a registered trademark of United Therapeutics Corporation</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;background:#ffffff;margin:0pt;"><b style="font-family:'Aptos';font-weight:bold;">Cautionary Statements Regarding Forward-Looking Statements&#160;</b><b style="font-family:'Aptos';font-weight:bold;"><br></b><font style="font-family:'Aptos';">This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements. </font><font style="color:#202124;font-family:'Aptos';">Such forward-looking statements, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related submission contents and timelines, and our ability to execute on our strategic or financial initiatives, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein.&#160;</font><font style="font-family:'Aptos';"> The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;would,&#8221; and similar </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-bottom:14pt;background:#ffffff;margin:0pt;"><font style="font-family:'Aptos';">expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our filings with the</font><font style="font-family:'Arial','Helvetica','sans-serif';">&#8239;</font><font style="font-family:'Aptos';">SEC, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.&#160;</font><b style="font-family:'Aptos';font-weight:bold;"><br></b><font style="font-family:'Aptos';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-bottom:14pt;background:#ffffff;margin:0pt;"><b style="font-family:'Aptos';font-weight:bold;">Contact Information</b><b style="font-family:'Aptos';font-weight:bold;"><br><br></b><b style="font-family:'Aptos';font-weight:bold;">Investors:</b><b style="font-family:'Aptos';font-weight:bold;"><br></b><font style="font-family:'Aptos';">Jason Adair</font><font style="font-family:'Aptos';"><br></font><font style="font-family:'Aptos';">919.328.4350</font><font style="font-family:'Aptos';"><br></font><font style="font-family:'Aptos';">jason.adair@liquidia.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;background:#ffffff;margin:0pt;"><b style="font-family:'Aptos';font-weight:bold;">Media:</b><b style="font-family:'Aptos';font-weight:bold;"><br></b><font style="font-family:'Aptos';">Patrick Wallace</font><font style="font-family:'Aptos';"><br></font><font style="font-family:'Aptos';">919.328.4383</font><font style="font-family:'Aptos';"><br></font><font style="font-family:'Aptos';">patrick.wallace@liquidia.com</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>3
<FILENAME>lqda-20240930xex10d5.htm
<DESCRIPTION>EX-10.5
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 11/13/2024 03:22:36 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:28.8pt;min-height:43.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-style:italic;font-weight:bold;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.5</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FIRST AMENDMENT TO THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">LICENSE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="font-size:11pt;">This First Amendment to the License Agreement (this &#8220;</font><b style="font-size:11pt;font-weight:bold;">First Amendment</b><font style="font-size:11pt;">&#8221;) is entered into as of October 2, 2024 (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">First Amendment Effective Date</b><font style="font-size:11pt;">&#8221;) by and between Pharmosa Biopharm Inc., a corporation incorporated under the laws of Taiwan having a place of business at 11F.-3, No. 508, Section 7, Zhongxiao East Road, Nangang District, Taipei City 115, Taiwan (&#8220;</font><b style="font-size:11pt;font-weight:bold;">Licensor</b><font style="font-size:11pt;">&#8221;), and Liquidia Technologies, Inc., a corporation incorporated under the laws of the State of Delaware, USA having a place of business at 419 Davis Drive, Suite 100, Morrisville, NC 27560, USA (&#8220;</font><b style="font-size:11pt;font-weight:bold;">Company</b><font style="font-size:11pt;">&#8221;), for the purpose of amending that certain License Agreement, dated as of June 28, 2023, by and between Licensor and Company (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Agreement</b><font style="font-size:11pt;">&#8221;). &#160;Licensor and Company may be referred to herein as a &#8220;</font><b style="font-size:11pt;font-weight:bold;">Party</b><font style="font-size:11pt;">&#8221; or, collectively, as the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Parties</b><font style="font-size:11pt;">&#8221;. &#160;Capitalized terms used and not otherwise defined in First Amendment shall have the meanings ascribed to such terms in the Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><b style="font-size:11pt;font-weight:bold;">WHEREAS</b><font style="font-size:11pt;">, the Parties entered into the Agreement, pursuant to which, </font><i style="font-size:11pt;font-style:italic;">inter alia</i><font style="font-size:11pt;">, Licensor granted to Company an exclusive license under the Licensor Technology to Develop, have Developed, manufacture, have manufactured, use and Commercialize Products in the Field in the Territory, as more fully set forth therein;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><b style="font-size:11pt;font-weight:bold;">WHEREAS</b><font style="font-size:11pt;">, pursuant to Section 13.9 of the Agreement, the Parties desire to amend the Agreement to, </font><i style="font-size:11pt;font-style:italic;">inter alia</i><font style="font-size:11pt;">, (a) expand the Territory, (b) amend the Development Milestones and Sales Milestones and (c) waive the terms of certain provisions in the Agreement, as more fully set forth herein; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><b style="font-size:11pt;font-weight:bold;">WHEREAS</b><font style="font-size:11pt;">, concurrently with the execution of First Amendment, the Parties are entering into that certain Device License Agreement, dated as of the First Amendment Effective Date (the &#8220;</font><b style="font-size:11pt;font-weight:bold;">Device License</b><font style="font-size:11pt;">&#8221;), pursuant to which, </font><i style="font-size:11pt;font-style:italic;">inter alia</i><font style="font-size:11pt;">, Licensor is granting to Company certain rights and licenses under certain intellectual property rights controlled by Licensor to develop, have developed, manufacture, have manufactured, use and commercialize Devices and Device Products (each as defined in the Device License), as more fully set forth therein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><b style="font-size:11pt;font-weight:bold;">NOW</b><font style="font-size:11pt;">, </font><b style="font-size:11pt;font-weight:bold;">THEREFORE</b><font style="font-size:11pt;">, in consideration of the foregoing and the mutual covenants and agreement set forth herein, set forth in the Agreement and set forth in the Device License, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Amendments</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;The Agreement is hereby amended as follows:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Section 1.42 (&#8220;Net Sales&#8221;) of the Agreement is hereby amended by adding the following language to the end of such Section:</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 72pt;">Sales of Devices and Device Products made pursuant to the Device License, which sales, if for Product, would otherwise constitute sales subject to the &#8220;Net Sales&#8221; definition under this Agreement, shall be included in the calculation of Net Sales under this Agreement in accordance with the terms and conditions of this definition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Section 1.60 (&#8220;Territory&#8221;) of the Agreement is hereby amended and restated as follows:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:28.8pt;min-height:43.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="height:0pt;position:relative;width:100%;"><div style="height:20.15pt;left:0%;position:absolute;top:0pt;width:201.6pt;z-index:-251658240;"><img src="lqda-20240930xex10d5001.jpg" alt="Graphic" style="left:0pt;position:absolute;width:100%;z-index:-1;"><div style="height:20.15pt;left:0pt;position:relative;top:0pt;width:201.6pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;line-height:10pt;width:100%;margin:0pt;">802475447.3 </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;line-height:10pt;width:100%;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:28.8pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">1.60</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;">Territory</b><font style="font-size:11pt;">&#8221; means all of the countries, jurisdictions and territories in the world, except China (including Hong Kong and Macao), North Korea, the Republic of Korea, Taiwan, Kingdom of Saudi Arabia, United Arab Emirates, Kuwait, Qatar, Oman, Bahrain, Iraq, Egypt, Lebanon, Jordan, Morocco, Algeria, Iran, Tunisia, Sudan, Yemen, Libya, Syria, Turkey, Malaysia, Indonesia, Thailand, Philippines, Singapore, Brunei, Vietnam, Lao, Cambodia and Myanmar.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Article 1 (Definitions) of the Agreement is hereby amended by adding the following definitions to the end of such Article:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">1.68</font></font>&#8220;<b style="font-weight:bold;">Device</b>&#8221; means a Device (as defined in the Device License).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">1.69</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;">Device License</b><font style="font-size:11pt;">&#8221; means that certain Device License Agreement, dated as of October 2, 2024, by and between Licensor and Company, as may be amended from time to time.</font><font style="display:inline-block;width:16.09pt;"></font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">1.70</font></font>&#8220;<b style="font-weight:bold;">Device Product</b>&#8221; means a Combination Product containing a Device.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">1.71</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;">EMA</b><font style="font-size:11pt;">&#8221; means the European Medicines Agency and any successor Regulatory Authority thereto.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">1.73</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;">European Union</b><font style="font-size:11pt;">&#8221; means the organization of the member states of the European Union, as it may be constituted from time to time during the Term. &#160;For purposes of this Agreement, the United Kingdom shall continue to be treated as being part of the European Union, notwithstanding the withdrawal of it from the EU. &#160;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">1.74</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">&#8220;</font><b style="font-size:11pt;font-weight:bold;">PMDA</b><font style="font-size:11pt;">&#8221; means the Pharmaceuticals and Medical Devices Agency in Japan or any successor Regulatory Authority thereto.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_Hlk167374988"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Section 6.2 (Development Milestones) of the Agreement is hereby amended by including the following additional one-time Development Milestones to the table set forth therein:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:77.4pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:80.76%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.66%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:14.05pt;"><td style="vertical-align:bottom;width:66.66%;background:#aeaaaa;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">Development Milestone</b></p></td><td style="vertical-align:bottom;width:33.33%;background:#aeaaaa;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">Milestone Payment USD</b></p></td></tr><tr style="height:14.05pt;"><td style="vertical-align:middle;width:66.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Initiation (i.e., first dosing of the first patient) of the first Phase III Clinical Trial of a Device Product in the European Union (in PH-ILD) &#160;</p></td><td style="vertical-align:middle;width:33.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:3pt 7.2pt 7.19pt 7.2pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:14.05pt;"><td style="vertical-align:middle;width:66.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">MAA approval by the EMA for a Product (in PAH and/or PH-ILD)</p></td><td style="vertical-align:middle;width:33.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:3pt 7.2pt 7.19pt 7.2pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:14.05pt;"><td style="vertical-align:middle;width:66.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">MAA approval by the EMA for a Product (in each Indication other than PAH or PH-ILD)*</p></td><td style="vertical-align:middle;width:33.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:3pt 7.2pt 7.19pt 7.2pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:14.05pt;"><td style="vertical-align:middle;width:66.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">MAA approval by the PMDA for a Product (in the first (1st) Indication between PAH and PH-ILD)</p></td><td style="vertical-align:middle;width:33.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:3pt 7.2pt 7.19pt 7.2pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:14.05pt;"><td style="vertical-align:middle;width:66.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Approval by the PMDA of an NDA for a Product (in the second (2nd) Indication between PAH and PH-ILD)</p></td><td style="vertical-align:middle;width:33.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:3pt 7.2pt 7.19pt 7.2pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:14.05pt;"><td style="vertical-align:middle;width:66.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Approval by the PMDA of an NDA for a Product (in each Indication other than PAH or PH-ILD)*</p></td><td style="vertical-align:middle;width:33.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:3pt 7.2pt 7.19pt 7.2pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div></div><div style="clear:both;margin-bottom:28.8pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:28.8pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="padding-left:77.4pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:80.76%;"><tr style="height:14.05pt;"><td style="vertical-align:middle;width:66.66%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">Regulatory Approval by an applicable Regulatory Authority for a Product in the first Indication in the first country outside of North America, the European Union, or Japan</p></td><td style="vertical-align:middle;width:33.33%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:3pt 7.2pt 7.19pt 7.2pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">e.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Section 6.3 (Sales Milestones) of the Agreement is hereby amended and restated in its entirety as follows:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:72pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.3</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_Toc138665377"></a><a name="_Ref_ContractCompanion_9kb9Ur25D"></a><a name="_Ref_ContractCompanion_9kb9Ur266"></a></font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Sales Milestones</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Company shall pay Licensor the following one-time, non-refundable, non-creditable amounts for the first achievement of the following sales event milestone events (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Sales Milestones</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;).</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:107.75pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:75%;"><tr style="height:14.05pt;"><td style="vertical-align:bottom;width:70.51%;background:#aeaaaa;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">Sales Milestones</b></p></td><td style="vertical-align:bottom;width:29.48%;background:#aeaaaa;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">Milestone Payment USD</b></p></td></tr><tr style="height:14.05pt;"><td style="vertical-align:bottom;width:70.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">The first Calendar Year in which annual Net Sales of the Products in North America exceed [***] (the &#8220;<b style="font-weight:bold;">First NA Sales Milestone</b>&#8221;)</p></td><td style="vertical-align:bottom;width:29.48%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">[***]</p></td></tr><tr style="height:14.05pt;"><td style="vertical-align:top;width:70.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">The first Calendar Year in which annual Net Sales of the Products in North America exceed [***] (the &#8220;<b style="font-weight:bold;">Second NA Sales Milestone</b>&#8221;)</p></td><td style="vertical-align:bottom;width:29.48%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">[***]</p></td></tr><tr style="height:14.05pt;"><td style="vertical-align:top;width:70.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">The first Calendar Year in which annual Net Sales of the Products in North America exceed [***] (the &#8220;<b style="font-weight:bold;">Third NA Sales Milestone</b>&#8221;)</p></td><td style="vertical-align:bottom;width:29.48%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">[***]</p></td></tr><tr style="height:14.05pt;"><td style="vertical-align:top;width:70.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">The first Calendar Year in which annual Net Sales of the Products in North America exceed [***] (together with the First NA Sales Milestone, the Second NA Sales Milestone and the Third NA Sales Milestone, the &#8220;<b style="font-weight:bold;">NA Sales Milestones</b>&#8221;)</p></td><td style="vertical-align:bottom;width:29.48%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">[***]</p></td></tr><tr style="height:14.05pt;"><td style="vertical-align:top;width:70.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">The first Calendar Year in which annual Net Sales of the Products in the Territory (other than North America) exceed [***] (the &#8220;<b style="font-weight:bold;">First Ex-NA Sales Milestone</b>&#8221;)</p></td><td style="vertical-align:top;width:29.48%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">[***]</p></td></tr><tr style="height:14.05pt;"><td style="vertical-align:top;width:70.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">The first Calendar Year in which annual Net Sales of the Products in the Territory (other than North America) exceed [***] (the &#8220;<b style="font-weight:bold;">Second Ex-NA Sales Milestone</b>&#8221;)</p></td><td style="vertical-align:top;width:29.48%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">[***]</p></td></tr><tr style="height:14.05pt;"><td style="vertical-align:top;width:70.51%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">First Calendar Year in which annual Net Sales of the Products in the Territory (other than North America) exceed [***] (together with the First Ex-NA Sales Milestone and the Second Ex-NA Sales Milestone, the &#8220;<b style="font-weight:bold;">Ex-NA Sales Milestones</b>&#8221;)</p></td><td style="vertical-align:top;width:29.48%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">[***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">Company shall deliver written notice to Licensor within sixty (60) days following the end of the Calendar Year in which a Sales Milestone occurs and Licensor shall issue Company an invoice for the amount of the corresponding Sales Milestone payment, which invoice Company shall pay within [***] days following receipt of such invoice. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:28.8pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:28.8pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">For the avoidance of doubt, each aforementioned Sales Milestone payment shall be made only once and only with respect to Net Sales of the Products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">The achievement of a higher NA Sales Milestone or Ex-NA Sales Milestone, as applicable, shall trigger the payment of a lower NA Sales Milestone or Ex-NA Sales Milestone, respectively, in addition to the payment of the Milestone Payment for such higher Sales Milestone, in the event such lower Sales Milestone had not been triggered prior to achievement of the higher Sales Milestone. &#160;For the avoidance of doubt, in no event shall the achievement of any NA Sales Milestone trigger the payment of an Ex-NA Sales Milestone or vice versa. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">For the avoidance of doubt, the total maximum Sales Milestones payable under this Section 6.3 shall not exceed [***].</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 108pt;">For clarity, Net Sales of Devices and Device Products shall be included in calculating whether a Sales Milestone has been achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 144pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">f.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Section 6.4 (Royalty Payments for Product) of the Agreement is hereby amended by including the following text after the heading of Section 6.4. &#160;For clarity, the remaining provision of Section 6.4, including Sections 6.4.1 and 6.4.2, shall remain in effect.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:72pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">6.4</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-size:11pt;font-weight:bold;">Royalty Payments for Product</b><font style="font-size:11pt;">. For the purposes of all royalty calculations, rights, and obligations in this Section 6.4, all references to &#8220;Product&#8221; shall include Devices and Device Products.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 108pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">g.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Section 6.5 (Compulsory License) of the Agreement is hereby amended by including the following at the end of such Section:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 72pt;">In the case of any Compulsory License and Compulsory License Compensation (each as defined in the Device License) with respect to a Device or Device Product, the terms of this Section 6.5 shall apply to the calculation of Net Sales on such Device or Device Product <i style="font-style:italic;">mutatis mutandis</i>. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">h.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Section 6.6 (Third Party License Agreements and Device Agreement) of the Agreement is hereby amended by amending and restating the first sentence of such Section in its entirety as follows:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 72pt;">In the event that, to avoid infringement of the Third Party&#8217;s intellectual property rights by either (a) (i) use of the Licensor Technology under the Licensed Rights under this Agreement or (ii) use the Licensor Technology under the Licensed Rights (each as defined in the Device License) under the Device License or (b) Developing, manufacturing or Commercializing the Existing Product, Devices, or Device Products, it is reasonably necessary for Company to make payments to a Thid Party with respect to a license under such Third Party&#8217;s intellectual property rights, to develop, manufacture, use, or sell a Product, Device or Device Product in the Field in the Territory, Company will be entitled to deduct an amount equal to [***] of any such amounts due to such Third Party for such license from any amounts payable to Licensor under Section 6.4.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">i.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Section 6.9 (Royalty Reports and Records Retention) is hereby amended to replace each reference to &#8220;Product&#8221; with &#8220;Product, Device or Device Product&#8221;. </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_Ref338867808"></a></font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:28.8pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:28.8pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">j.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Section 11.2.1 (Material Breach) of the Agreement is hereby amended by adding the following sentences at the end of such Section:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt 0pt 0pt 72pt;">For the avoidance of doubt, in no event shall a breach of any material obligation under this Agreement be deemed a breach of any material obligation under the Device License or be deemed to give rise to a right of termination under the Device License. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Additional Acknowledgements and Agreements</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Double-Counting</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;Notwithstanding anything in First Amendment, the Agreement (including as amended hereunder), the Device License or any other agreement between the Parties or their Affiliates, (i) there will be no double counting of any costs or expenses in the calculation of any amounts due from Company or its Affiliates to Licensor or its Affiliates under the Agreement, the Device License or any other agreement between the Parties or their Affiliates, and (ii) in no event shall sales (including the calculation of Net Sales) of any Device or Product be double-counted under this Agreement, the Device License or any other agreement between the Parties or their Affiliates, including with respect to the calculation of royalties due under any such agreements or the achievement of any threshold for sales milestones (including Sales Milestones) under any such agreements. &#160;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;"> </b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limited Waiver of Section 6.6</u><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;For the avoidance of doubt, Section 6.6 of the Agreement shall not apply with respect to any payments made by Company to Licensor pursuant to the Agreement as of the Amendment Effective Date. Section 6.6 of the Agreement shall also not apply with respect to any payments made by Company to manufacturers of a Device so long as the milestone payments and royalties payable by Company to such manufacturers do not exceed [***]. &#160;In the event that the milestone payments and royalties payable by Company to such manufacturers do exceed [***], Section 6.6 of the Agreement shall apply only to the excess. &#160;It is the Parties&#8217; understanding that Licensor&#8217;s agreement to permit Company to deduct milestone payments and royalties due to a manufacturer from amounts payable to Licensor under Section 6.6 of the Agreement is conditioned upon Company&#8217;s good faith cooperation in obtaining reasonable payment terms from such manufacturer, including allowing Licensor to be the only party communicating with such manufacturer (until such time that Company enters into, or has assigned to it by Licensor, a Device Agreement); provided, however, that (a) Licensor shall not execute a supply agreement with such manufacturer without the prior written consent of Company and (b) Licensor shall subsequently take reasonable action, such as assignment of such agreement to Company to the extent permitted (in which event it shall be deemed a Device Agreement), to allow Company to order directly from such manufacturer. Section 6.6 of the Agreement shall also not apply with respect to any payments made by Company to any other manufacturer unless and until Company reasonably determines that reasonable doubt has arisen as to whether the Devices are viable development candidates, at which time any payments made to any such entity may be deducted pursuant to Section 6.6 of the Agreement.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Amendment Fee</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;As partial consideration for the rights granted in this First Amendment and the Device License, Company shall pay, or cause to be paid, to Licensor a non-refundable and non-creditable fee of [***] within thirty (30) days following Company&#8217;s receipt of an invoice from Licensor following the First Amendment Effective Date.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:28.8pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:28.8pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">No Other Amendments</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;All other terms and conditions of the Agreement shall remain in full force and effect. &#160;This First Amendment, together with the Agreement and the Device License (as incorporated into this First Amendment and the Agreement herein), constitutes the entire agreement between the Parties with respect to the subject matter hereof.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Counterparts</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">. &#160;This First Amendment may be executed in counterparts, each of which will be deemed an original, and all of which together will be deemed to be one and the same instrument. &#160;A facsimile or a portable document format (PDF) copy of this First Amendment, including the signature pages, will be deemed an original.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt;">[Signature Page Follows]</p></div><div style="clear:both;margin-bottom:28.8pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:28.8pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="font-size:11pt;">IN WITNESS WHEREOF, the Parties have executed First Amendment through their authorized representatives as of the First Amendment Effective Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:103.07%;"><tr style="height:1pt;"><td style="vertical-align:top;width:54.29%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="white-space:pre-wrap;"> </font>Roger</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:45.7%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:54.29%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">PHARMOSA BIOPHARM INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">By:__<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Pei Kan</u>________________________________</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Name:</font></font>Pei Kan</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Title:</font></font>President</p></td><td style="vertical-align:top;width:45.7%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">LIQUIDIA TECHNOLOGIES, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;">By:_<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Roger Jeffs</u>_____________________</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Name:</font></font>Roger Jeffs</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Title:</font></font>CEO</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:28.8pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>lqda-20240930xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 11/13/2024 03:22:36 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7pt;">I, Roger A. Jeffs, Ph.D., certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">I have reviewed this Quarterly Report on Form 10-Q of Liquidia Corporation;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18.6pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.4pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:38.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.8pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November 13, 2024</p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Roger A. Jeffs, Ph.D.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:44.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Roger A. Jeffs, Ph.D.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>lqda-20240930xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 11/13/2024 03:22:36 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7pt;">I, Michael Kaseta, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:19.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">I have reviewed this Quarterly Report on Form 10-Q of Liquidia Corporation;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:19.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:19.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:19.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:46.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:46.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:46.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:46.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:19.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:46.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:46.95pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November 13, 2024</p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Michael Kaseta</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:44.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael Kaseta</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer and Chief Operating Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>lqda-20240930xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 11/13/2024 03:22:47 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 20pt;">In connection with the Quarterly Report of Liquidia Corporation, a Delaware corporation (the &#8220;Company&#8221;), on Form 10-Q for the nine months ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Roger A. Jeffs, Ph.D., Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:19.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:19.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November 13, 2024</p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Roger A. Jeffs, Ph.D.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:44.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Roger A. Jeffs, Ph.D.</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>lqda-20240930xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 11/13/2024 03:22:48 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 20pt;">In connection with the Quarterly Report of Liquidia Corporation, a Delaware corporation (the &#8220;Company&#8221;), on Form 10-Q for the nine months ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Michael Kaseta, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:19.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.75pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:19.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November 13, 2024</p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Michael Kaseta</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:44.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael Kaseta</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer and Chief Operating Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>lqda-20240930x10q002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lqda-20240930x10q002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  "  (# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]):*** /_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>lqda-20240930xex10d5001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lqda-20240930xex10d5001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  I 90# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
G **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>lqda-20240930.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/13/2024 3:23:02 AM-->
<!--Modified on: 11/13/2024 3:23:02 AM-->
<xsd:schema xmlns:srt="http://fasb.org/srt/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:us-gaap="http://fasb.org/us-gaap/2023" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://liquidia.com/20240930" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:lqda="http://liquidia.com/20240930" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2023">
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" id="StatementCondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>995200100 - Statement - Condensed Consolidated Balance Sheets (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited">
        <link:definition>995200200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" id="StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>995200400 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureInventoryDetails" id="DisclosureInventoryDetails">
        <link:definition>99940301 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" id="DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails">
        <link:definition>99940401 - Disclosure - Property, Plant, and Equipment - Schedule of Property, plant and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>99940701 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureLeasesCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2" id="DisclosureLeasesCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2">
        <link:definition>41203 - Disclosure - Leases, Commitments and Contingencies - Future Minimum Lease Payments (Details) Calc 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableExpectedAnnualPaymentsDetails" id="DisclosureRevenueInterestFinancingPayableExpectedAnnualPaymentsDetails">
        <link:definition>99941203 - Disclosure - Revenue Interest Financing Payable - Expected Annual Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>995200090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParentheticals" id="StatementCondensedConsolidatedBalanceSheetsUnauditedParentheticals">
        <link:definition>995200105 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" id="StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited">
        <link:definition>995200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureLegalProceedings" id="DisclosureLegalProceedings">
        <link:definition>995211401 - Disclosure - Legal Proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsTables" id="DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsTables">
        <link:definition>99930203 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>99930903 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureBusinessLiquidityDetails" id="DisclosureBusinessLiquidityDetails">
        <link:definition>99940101 - Disclosure - Business - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails" id="DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails">
        <link:definition>99940201 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements - Other (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsCommonStockEquivalentSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" id="DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsCommonStockEquivalentSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails">
        <link:definition>99940202 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements - Common Stock Equivalent Shares Excluded From Calculation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsFairValueOfFinancialAssetsAndFinancialLiabilitiesDetails" id="DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsFairValueOfFinancialAssetsAndFinancialLiabilitiesDetails">
        <link:definition>99940203 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements - Fair Value of Financial Assets and Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentExpenseDetails" id="DisclosurePropertyPlantAndEquipmentExpenseDetails">
        <link:definition>99940402 - Disclosure - Property, Plant, and Equipment - Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetOtherDetails" id="DisclosureContractAcquisitionCostsAndIntangibleAssetOtherDetails">
        <link:definition>99940502 - Disclosure - Contract Acquisition Costs and Intangible Asset - Other (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureIndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDetails" id="DisclosureIndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDetails">
        <link:definition>99940601 - Disclosure - Indemnification Asset with Related Party and Litigation Finance Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
        <link:definition>99940801 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails" id="DisclosureStockBasedCompensationOtherDetails">
        <link:definition>99940901 - Disclosure - Stock-Based Compensation - Other (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>99940902 - Disclosure - Stock-Based Compensation - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureStockBasedCompensationUnamortizedCompensationExpenseDetails" id="DisclosureStockBasedCompensationUnamortizedCompensationExpenseDetails">
        <link:definition>99940903 - Disclosure - Stock-Based Compensation - Unamortized Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails" id="DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails">
        <link:definition>99940904 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options Granted and Purchase Rights Issued under the ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" id="DisclosureStockBasedCompensationStockOptionActivityDetails">
        <link:definition>99940905 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" id="DisclosureStockBasedCompensationRestrictedStockUnitsDetails">
        <link:definition>99940906 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureRevenueFromContractsWithCustomersDetails" id="DisclosureRevenueFromContractsWithCustomersDetails">
        <link:definition>99941001 - Disclosure - Revenue From Contracts With Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureLeasesOtherDetails" id="DisclosureLeasesOtherDetails">
        <link:definition>99941101 - Disclosure - Leases - Other (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureLeasesCostDetails" id="DisclosureLeasesCostDetails">
        <link:definition>99941102 - Disclosure - Leases - Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails" id="DisclosureRevenueInterestFinancingPayableTermsDetails">
        <link:definition>99941201 - Disclosure - Revenue Interest Financing Payable - Terms (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>99941301 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureLegalProceedingsDetails" id="DisclosureLegalProceedingsDetails">
        <link:definition>99941401 - Disclosure - Legal Proceedings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureBusiness" id="DisclosureBusiness">
        <link:definition>995210101 - Disclosure - Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurements" id="DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurements">
        <link:definition>995210201 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureInventory" id="DisclosureInventory">
        <link:definition>995210301 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosurePropertyPlantAndEquipment" id="DisclosurePropertyPlantAndEquipment">
        <link:definition>995210401 - Disclosure - Property, Plant, and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAsset" id="DisclosureContractAcquisitionCostsAndIntangibleAsset">
        <link:definition>995210501 - Disclosure - Contract Acquisition Costs and Intangible Asset</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureIndemnificationAssetWithRelatedPartyAndLitigationFinancePayable" id="DisclosureIndemnificationAssetWithRelatedPartyAndLitigationFinancePayable">
        <link:definition>995210601 - Disclosure - Indemnification Asset with Related Party and Litigation Finance Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>995210701 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>995210801 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>995210901 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureRevenueFromContractsWithCustomers" id="DisclosureRevenueFromContractsWithCustomers">
        <link:definition>995211001 - Disclosure - Revenue From Contracts With Customers</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>995211101 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureRevenueInterestFinancingPayable" id="DisclosureRevenueInterestFinancingPayable">
        <link:definition>995211201 - Disclosure - Revenue Interest Financing Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995211301 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995211501 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsPolicies" id="DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsPolicies">
        <link:definition>99920202 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureInventoryTables" id="DisclosureInventoryTables">
        <link:definition>99930303 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentTables" id="DisclosurePropertyPlantAndEquipmentTables">
        <link:definition>99930403 - Disclosure - Property, Plant, and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetTables" id="DisclosureContractAcquisitionCostsAndIntangibleAssetTables">
        <link:definition>99930503 - Disclosure - Contract Acquisition Costs and Intangible Asset (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>99930703 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>99930803 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>99931103 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTables" id="DisclosureRevenueInterestFinancingPayableTables">
        <link:definition>99931203 - Disclosure - Revenue Interest Financing Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetSummaryDetails" id="DisclosureContractAcquisitionCostsAndIntangibleAssetSummaryDetails">
        <link:definition>99940501 - Disclosure - Contract Acquisition Costs and Intangible Asset - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureLeasesRemainingLeaseTermAndDiscountRatesDetails" id="DisclosureLeasesRemainingLeaseTermAndDiscountRatesDetails">
        <link:definition>99941103 - Disclosure - Leases - Remaining Lease Term and Discount Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" id="DisclosureLeasesFutureMinimumLeasePaymentsDetails">
        <link:definition>99941104 - Disclosure - Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableSummaryDetails" id="DisclosureRevenueInterestFinancingPayableSummaryDetails">
        <link:definition>99941202 - Disclosure - Revenue Interest Financing Payable - Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lqda-20240930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lqda-20240930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lqda-20240930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lqda-20240930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" />
  <xsd:element abstract="true" id="lqda_AgreementWithLGMPharmaLLCMember" name="AgreementWithLGMPharmaLLCMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="lqda_BusinessCombinationContractAcquisitionCostsNet" name="BusinessCombinationContractAcquisitionCostsNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="lqda_ClassOfWarrantOrRightExercisedDuringPeriod" name="ClassOfWarrantOrRightExercisedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="lqda_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lqda_LabAndBuildToSuitEquipmentMember" name="LabAndBuildToSuitEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="lqda_LeaseLiability" name="LeaseLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="lqda_LeaseLiabilityMaturityTableTextBlock" name="LeaseLiabilityMaturityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="lqda_LeaseLiabilityPaymentsDueNextTwelveMonths" name="LeaseLiabilityPaymentsDueNextTwelveMonths" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="lqda_LeaseLiabilityPaymentsDueTotal" name="LeaseLiabilityPaymentsDueTotal" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="lqda_LeaseLiabilityPaymentsDueYearTwo" name="LeaseLiabilityPaymentsDueYearTwo" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="lqda_LeaseLiabilityUndiscountedExcessAmount" name="LeaseLiabilityUndiscountedExcessAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="lqda_LiquidiaPAHAndSandozMember" name="LiquidiaPAHAndSandozMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="lqda_MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties" name="MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="lqda_NoncashPortionOfLeaseExpense" name="NoncashPortionOfLeaseExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="lqda_OperatingLeaseLiabilitiesCashPaid" name="OperatingLeaseLiabilitiesCashPaid" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lqda_PBMMember" name="PBMMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="lqda_ProceedsFromIssuanceOfCommonStockNet" name="ProceedsFromIssuanceOfCommonStockNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts" name="ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts" name="ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lqda_SandozMember" name="SandozMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="lqda_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" name="StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="lqda_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" name="StockIssuedDuringPeriodValueCommonStockWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lqda_The2020PlanMember" name="The2020PlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lqda_UTCAndSmithsMedicalLitigationMember" name="UTCAndSmithsMedicalLitigationMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lqda_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="lqda_WarrantsToPurchaseCommonStockMember" name="WarrantsToPurchaseCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="lqda_BusinessAbstract" name="BusinessAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="lqda_OtherWarrantsMember" name="OtherWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="lqda_LeaseLiabilityPaymentsDueRemainderOfFiscalYear" name="LeaseLiabilityPaymentsDueRemainderOfFiscalYear" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="lqda_IncreaseInIndemnificationAssetThroughAccountsPayable" name="IncreaseInIndemnificationAssetThroughAccountsPayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="lqda_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" name="StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="lqda_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" name="StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="lqda_IndemnificationAssetRelatedParty" name="IndemnificationAssetRelatedParty" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="lqda_PromotionAgreementPayment" name="PromotionAgreementPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract" name="ContractAcquisitionCostsAndIntangibleAssetAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="lqda_ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock" name="ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="lqda_IndemnificationAssetAndLitigationFinancePayableAbstract" name="IndemnificationAssetAndLitigationFinancePayableAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="lqda_IndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDisclosureTextBlock" name="IndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="lqda_PercentageOfRevenueFromPromotionAgreement" name="PercentageOfRevenueFromPromotionAgreement" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="lqda_CustomerOneMember" name="CustomerOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="lqda_SvbWarrantTermBAndTermCTranchesMember" name="SvbWarrantTermBAndTermCTranchesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="lqda_SvbWarrantInitialTrancheMember" name="SvbWarrantInitialTrancheMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="InducementPlan2022Member" id="lqda_InducementPlan2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfCustomers" id="lqda_NumberOfCustomers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RelatedPartyTransactionMajorStockholderOwnershipPercentageInCompany" id="lqda_RelatedPartyTransactionMajorStockholderOwnershipPercentageInCompany" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="EmployeeStockPurchasePlan2020Member" id="lqda_EmployeeStockPurchasePlan2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EmployeePurchaseRightsMember" id="lqda_EmployeePurchaseRightsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AgreementExpirationTerm" id="lqda_AgreementExpirationTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="BoardOfDirectorsMember" id="lqda_BoardOfDirectorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Mr.PaulB.ManningMember" id="lqda_Mr.PaulB.ManningMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LargestStockholderAndMemberOfBoardOfDirectorsMember" id="lqda_LargestStockholderAndMemberOfBoardOfDirectorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CaliganPartnersLPMember" id="lqda_CaliganPartnersLPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ArSiliconValleyBankTermLoansMember" id="lqda_ArSiliconValleyBankTermLoansMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ArSvbWarrantsInitialTrancheMember" id="lqda_ArSvbWarrantsInitialTrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LeaseDisclosureTextBlock" id="lqda_LeaseDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" id="lqda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AccruedExpensesAndOtherLiabilitiesCurrent" id="lqda_AccruedExpensesAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" id="lqda_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock" id="lqda_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AccruedResearchAndDevelopmentExpenses" id="lqda_AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LegalProceedingsDisclosureAbstract" id="lqda_LegalProceedingsDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NetSalesEarnedRelatingToPaymentOfFutureContingentRoyalties" id="lqda_NetSalesEarnedRelatingToPaymentOfFutureContingentRoyalties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ScheduleOfContractAcquisitionCostsAndIntangibleAssetsTableTextBlock" id="lqda_ScheduleOfContractAcquisitionCostsAndIntangibleAssetsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RevenueInterestFinancingAgreementMaximumInvestmentAmount" id="lqda_RevenueInterestFinancingAgreementMaximumInvestmentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RevenueInterestFinancingAgreementInitialInvestmentAmount" id="lqda_RevenueInterestFinancingAgreementInitialInvestmentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RevenueInterestFinancingAgreementMember" id="lqda_RevenueInterestFinancingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RevenueInterestFinancingAgreementHardCapPercentage" id="lqda_RevenueInterestFinancingAgreementHardCapPercentage" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RevenueInterestFinancingAgreementInternalRateOfReturn" id="lqda_RevenueInterestFinancingAgreementInternalRateOfReturn" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PercentageOfInvestmentAmountToBeRepaidOnFinalApproval" id="lqda_PercentageOfInvestmentAmountToBeRepaidOnFinalApproval" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PercentageOfInvestmentAmountToBePaid" id="lqda_PercentageOfInvestmentAmountToBePaid" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MinimumCashAndCashEquivalentsRequiredToBeMaintainedDuringYearTwo" id="lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedDuringYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MinimumCashAndCashEquivalentsRequiredToBeMaintainedAfterYearTwo" id="lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedAfterYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="RevenueInterestFinancingPayableAbstract" id="lqda_RevenueInterestFinancingPayableAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RevenueInterestFinancingPayableTextBlock" id="lqda_RevenueInterestFinancingPayableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ScheduleOfActivityOfRevenueInterestFinancingAgreementTableTextBlock" id="lqda_ScheduleOfActivityOfRevenueInterestFinancingAgreementTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RevenueInterestFinancingPayableTable" id="lqda_RevenueInterestFinancingPayableTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RevenueInterestFinancingPayableLineItems" id="lqda_RevenueInterestFinancingPayableLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RevenueInterestFinancingAgreement" id="lqda_RevenueInterestFinancingAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RevenueInterestFinancingAgreementIssuanceCosts" id="lqda_RevenueInterestFinancingAgreementIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RevenueInterestFinancingAgreementAmortizationOfDebtDiscount" id="lqda_RevenueInterestFinancingAgreementAmortizationOfDebtDiscount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="RevenueInterestFinancingPayableCurrent" id="lqda_RevenueInterestFinancingPayableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RevenueInterestFinancingPayableNoncurrent" id="lqda_RevenueInterestFinancingPayableNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ProceedsFromRevenueInterestFinancingNet" id="lqda_ProceedsFromRevenueInterestFinancingNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="RevenueInterestFinancingAgreementEffectiveAnnualInterestRate" id="lqda_RevenueInterestFinancingAgreementEffectiveAnnualInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding" id="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuance" id="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAvailableForIssuance" id="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAvailableForIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PaymentsOnRevenueInterestFinancingLiability" id="lqda_PaymentsOnRevenueInterestFinancingLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ChasmTechnologiesAgreementMember" id="lqda_ChasmTechnologiesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PharmosaLicenseAgreementMember" id="lqda_PharmosaLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MaximumPotentialDevelopmentMilestonePayments" id="lqda_MaximumPotentialDevelopmentMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="MaximumPotentialSalesMilestones" id="lqda_MaximumPotentialSalesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche" id="lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="HealthcareRoyaltyPartnersIvL.pMember" id="lqda_HealthcareRoyaltyPartnersIvL.pMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember" id="lqda_SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MilestonePaymentsPayable" id="lqda_MilestonePaymentsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember" id="lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommercialManufacturingServicesAndSupplyAgreementInitialTerm" id="lqda_CommercialManufacturingServicesAndSupplyAgreementInitialTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection" id="lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay" id="lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures" id="lqda_PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ReimbursementOfCapitalExpenditureIncurredBySupplier" id="lqda_ReimbursementOfCapitalExpenditureIncurredBySupplier" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="TermOfSubmissionOfQuarterlyForecastOfExpectedProduction" id="lqda_TermOfSubmissionOfQuarterlyForecastOfExpectedProduction" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder" id="lqda_InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AcquiredInProcessResearchAndDevelopment" id="lqda_AcquiredInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="RevenueInterestFinancingAgreementAmountFunded" id="lqda_RevenueInterestFinancingAgreementAmountFunded" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccruedResearchAndDevelopmentExpensePolicyTextBlock" id="lqda_AccruedResearchAndDevelopmentExpensePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RevenueInterestFinancingAgreementNumberOfTranches" id="lqda_RevenueInterestFinancingAgreementNumberOfTranches" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AccretionAndNonCashInterestExpense" id="lqda_AccretionAndNonCashInterestExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="RevenueInterestFinancingAgreementAccretion" id="lqda_RevenueInterestFinancingAgreementAccretion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="FourthAmendmentToRevenueInterestFinancingAgreementMember" id="lqda_FourthAmendmentToRevenueInterestFinancingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="InventoryCapitalizedCost" id="lqda_InventoryCapitalizedCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ForCalendarYearBeginningOnJanuary12024Member" id="lqda_ForCalendarYearBeginningOnJanuary12024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained" id="lqda_RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="RevenueInterestFinancingPayablePolicyPolicyTextBlock" id="lqda_RevenueInterestFinancingPayablePolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OperatingAndFinanceLeaseLiabilityCurrent" id="lqda_OperatingAndFinanceLeaseLiabilityCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OperatingAndFinanceLeaseLiabilityNoncurrent" id="lqda_OperatingAndFinanceLeaseLiabilityNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccruedInventoryCosts" id="lqda_AccruedInventoryCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts" id="lqda_NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PerformanceBasedRestrictedStockUnitsMember" id="lqda_PerformanceBasedRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear" id="lqda_RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RevenueInterestFinancingAgreementExpectedPaymentsYearOne" id="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearOne" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RevenueInterestFinancingAgreementExpectedPaymentsYearTwo" id="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RevenueInterestFinancingAgreementExpectedPaymentsYearThree" id="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RevenueInterestFinancingAgreementExpectedPaymentsYearFour" id="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RevenueInterestFinancingAgreementExpectedPaymentsTotal" id="lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ScheduleOfExpectedAnnualPaymentsOnRevenueInterestFinancingAgreement" id="lqda_ScheduleOfExpectedAnnualPaymentsOnRevenueInterestFinancingAgreement" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AfterCalendarYearEndingOnDecember312024Member" id="lqda_AfterCalendarYearEndingOnDecember312024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FifthAmendmentToRevenueInterestFinancingAgreementMember" id="lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RightOfUseAssetObtainedInExchangeForLeaseLiability" id="lqda_RightOfUseAssetObtainedInExchangeForLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="InventoryCurrentAndNonCurrent" id="lqda_InventoryCurrentAndNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CapitalizedCostsOfInventory" id="lqda_CapitalizedCostsOfInventory" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="BreachOfContractClaimMember" id="lqda_BreachOfContractClaimMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PaymentForUpfrontLicenseFee" id="lqda_PaymentForUpfrontLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccruedAdditionalUpfrontLicenseFee" id="lqda_AccruedAdditionalUpfrontLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OtherThenNorthAmericaMember" id="lqda_OtherThenNorthAmericaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OnFirstFundedPortionOfInvestmentAmountMember" id="lqda_OnFirstFundedPortionOfInvestmentAmountMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OnSecondPortionOfFundedInvestmentAmountMember" id="lqda_OnSecondPortionOfFundedInvestmentAmountMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentAnnualIncreaseInCapitalShareReservedForFutureIssuance" id="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentAnnualIncreaseInCapitalShareReservedForFutureIssuance" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OfferingCostsIncurredIncludedInAccruedExpenses" id="lqda_OfferingCostsIncurredIncludedInAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RevenueInterestFinancingAgreementExpectedPaymentsYearFiveAndThereafter" id="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFiveAndThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>lqda-20240930_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/13/2024 3:23:02 AM-->
<!--Modified on: 11/13/2024 3:23:02 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#StatementCondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" roleURI="http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureInventoryDetails" roleURI="http://liquidia.com/role/DisclosureInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" roleURI="http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureLeasesCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2" roleURI="http://liquidia.com/role/DisclosureLeasesCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureRevenueInterestFinancingPayableExpectedAnnualPaymentsDetails" roleURI="http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableExpectedAnnualPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" xlink:title="995200100 - Statement - Condensed Consolidated Balance Sheets (unaudited)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638670649779769488" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638670649779769488" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638670649779769488" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638670649779769488" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638670649779769488" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638670649779769488" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638670649779769488" xlink:to="us-gaap_AccountsReceivableNetCurrent_638670649779769488" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638670649779769488" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638670649779769488" xlink:to="us-gaap_InventoryNet_638670649779769488" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638670649779779446" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638670649779769488" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638670649779779446" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638670649779779446" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638670649779779446" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638670649779779446" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638670649779779446" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_IndemnificationAssetRelatedParty" xlink:label="lqda_IndemnificationAssetRelatedParty_638670649779779446" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="lqda_IndemnificationAssetRelatedParty_638670649779779446" order="4" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_BusinessCombinationContractAcquisitionCostsNet" xlink:label="lqda_BusinessCombinationContractAcquisitionCostsNet_638670649779779446" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="lqda_BusinessCombinationContractAcquisitionCostsNet_638670649779779446" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638670649779779446" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638670649779779446" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_638670649779779446" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill_638670649779779446" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638670649779789469" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638670649779789469" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638670649779789469" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638670649779789469" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserveNoncurrent" xlink:label="us-gaap_LitigationReserveNoncurrent_638670649779789469" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638670649779789469" xlink:to="us-gaap_LitigationReserveNoncurrent_638670649779789469" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingPayableNoncurrent" xlink:label="lqda_RevenueInterestFinancingPayableNoncurrent_638670649779789469" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638670649779789469" xlink:to="lqda_RevenueInterestFinancingPayableNoncurrent_638670649779789469" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="lqda_OperatingAndFinanceLeaseLiabilityNoncurrent_638670649779799465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638670649779789469" xlink:to="lqda_OperatingAndFinanceLeaseLiabilityNoncurrent_638670649779799465" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638670649779799465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638670649779789469" xlink:to="us-gaap_LiabilitiesCurrent_638670649779799465" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638670649779799465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638670649779799465" xlink:to="us-gaap_AccountsPayableCurrent_638670649779799465" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="lqda_AccruedExpensesAndOtherLiabilitiesCurrent_638670649779799465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638670649779799465" xlink:to="lqda_AccruedExpensesAndOtherLiabilitiesCurrent_638670649779799465" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingPayableCurrent" xlink:label="lqda_RevenueInterestFinancingPayableCurrent_638670649779799465" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638670649779799465" xlink:to="lqda_RevenueInterestFinancingPayableCurrent_638670649779799465" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_OperatingAndFinanceLeaseLiabilityCurrent" xlink:label="lqda_OperatingAndFinanceLeaseLiabilityCurrent_638670649779809467" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638670649779799465" xlink:to="lqda_OperatingAndFinanceLeaseLiabilityCurrent_638670649779809467" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638670649779809467" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638670649779809467" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638670649779809467" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638670649779809467" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638670649779809467" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638670649779809467" xlink:to="us-gaap_CommonStockValue_638670649779809467" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638670649779809467" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638670649779809467" xlink:to="us-gaap_PreferredStockValue_638670649779809467" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638670649779879469" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638670649779809467" xlink:to="us-gaap_AdditionalPaidInCapital_638670649779879469" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638670649779879469" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638670649779809467" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638670649779879469" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="extended" xlink:title="995200200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638670649779879469" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_638670649779879469" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638670649779879469" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638670649779879469" xlink:to="us-gaap_CostsAndExpenses_638670649779879469" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638670649779889112" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638670649779879469" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638670649779889112" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638670649779889112" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638670649779879469" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638670649779889112" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638670649779889112" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses_638670649779879469" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638670649779889112" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638670649779889112" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638670649779879469" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638670649779889112" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638670649779889112" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense_638670649779889112" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638670649779889112" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638670649779889112" xlink:to="us-gaap_InvestmentIncomeInterest_638670649779889112" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638670649779889112" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638670649779889112" xlink:to="us-gaap_InterestExpense_638670649779889112" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638670649779899498" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638670649779889112" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638670649779899498" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" xlink:title="995200400 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638670649779899498" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638670649779899498" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_638670649779899498" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638670649779899498" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_638670649779899498" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638670649779899498" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638670649779899498" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638670649779899498" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638670649779909135" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638670649779899498" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638670649779909135" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638670649779909135" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638670649779909135" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_638670649779909135" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638670649779909135" xlink:to="us-gaap_ProceedsFromStockPlans_638670649779909135" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638670649779909135" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638670649779909135" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638670649779909135" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PaymentsOnRevenueInterestFinancingLiability" xlink:label="lqda_PaymentsOnRevenueInterestFinancingLiability_638670649779909135" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638670649779909135" xlink:to="lqda_PaymentsOnRevenueInterestFinancingLiability_638670649779909135" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_638670649779909135" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638670649779909135" xlink:to="us-gaap_RepaymentsOfLongTermDebt_638670649779909135" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638670649779909135" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638670649779909135" xlink:to="us-gaap_RepaymentsOfDebt_638670649779909135" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ProceedsFromRevenueInterestFinancingNet" xlink:label="lqda_ProceedsFromRevenueInterestFinancingNet_638670649779919120" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638670649779909135" xlink:to="lqda_ProceedsFromRevenueInterestFinancingNet_638670649779919120" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638670649779919120" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638670649779909135" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638670649779919120" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyReceivableProceeds" xlink:label="us-gaap_LossContingencyReceivableProceeds_638670649779919120" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638670649779909135" xlink:to="us-gaap_LossContingencyReceivableProceeds_638670649779919120" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638670649779919120" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638670649779919120" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_NoncashPortionOfLeaseExpense" xlink:label="lqda_NoncashPortionOfLeaseExpense_638670649779919120" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638670649779919120" xlink:to="lqda_NoncashPortionOfLeaseExpense_638670649779919120" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AcquiredInProcessResearchAndDevelopment" xlink:label="lqda_AcquiredInProcessResearchAndDevelopment_638670649779929167" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638670649779919120" xlink:to="lqda_AcquiredInProcessResearchAndDevelopment_638670649779929167" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets_638670649779929167" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638670649779919120" xlink:to="us-gaap_GainLossOnDispositionOfAssets_638670649779929167" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables_638670649779929167" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638670649779919120" xlink:to="us-gaap_IncreaseDecreaseInReceivables_638670649779929167" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638670649779929167" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638670649779919120" xlink:to="us-gaap_IncreaseDecreaseInInventories_638670649779929167" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638670649779929167" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638670649779919120" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638670649779929167" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638670649779929167" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638670649779919120" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638670649779929167" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638670649779939438" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638670649779919120" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638670649779939438" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_638670649779939438" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638670649779919120" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_638670649779939438" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="lqda_IncreaseDecreaseInOperatingLeaseLiabilities_638670649779939438" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638670649779919120" xlink:to="lqda_IncreaseDecreaseInOperatingLeaseLiabilities_638670649779939438" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638670649779939438" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638670649779919120" xlink:to="us-gaap_ShareBasedCompensation_638670649779939438" order="11" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638670649779939438" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638670649779919120" xlink:to="us-gaap_ProfitLoss_638670649779939438" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638670649779949572" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638670649779919120" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638670649779949572" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638670649779949572" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638670649779919120" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638670649779949572" order="14" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AccretionAndNonCashInterestExpense" xlink:label="lqda_AccretionAndNonCashInterestExpense_638670649779949572" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638670649779919120" xlink:to="lqda_AccretionAndNonCashInterestExpense_638670649779949572" order="15" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://liquidia.com/role/DisclosureInventoryDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Inventory (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_InventoryCurrentAndNonCurrent" xlink:label="lqda_InventoryCurrentAndNonCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_638670649779959117" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lqda_InventoryCurrentAndNonCurrent" xlink:to="us-gaap_InventoryRawMaterials_638670649779959117" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_638670649779959117" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lqda_InventoryCurrentAndNonCurrent" xlink:to="us-gaap_InventoryWorkInProcess_638670649779959117" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Property, Plant, and Equipment - Schedule of Property, plant and equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638670649779959117" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638670649779959117" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638670649779959117" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638670649779959117" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="lqda_AccruedExpensesAndOtherLiabilitiesCurrent_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638670649779969439" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lqda_AccruedExpensesAndOtherLiabilitiesCurrent_1" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638670649779969439" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AccruedResearchAndDevelopmentExpenses" xlink:label="lqda_AccruedResearchAndDevelopmentExpenses_638670649779969439" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lqda_AccruedExpensesAndOtherLiabilitiesCurrent_1" xlink:to="lqda_AccruedResearchAndDevelopmentExpenses_638670649779969439" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AccruedInventoryCosts" xlink:label="lqda_AccruedInventoryCosts_638670649779969439" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lqda_AccruedExpensesAndOtherLiabilitiesCurrent_1" xlink:to="lqda_AccruedInventoryCosts_638670649779969439" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638670649779969439" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lqda_AccruedExpensesAndOtherLiabilitiesCurrent_1" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638670649779969439" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://liquidia.com/role/DisclosureLeasesCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2" xlink:type="extended" xlink:title="41203 - Disclosure - Leases, Commitments and Contingencies - Future Minimum Lease Payments (Details) Calc 2" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638670649779969439" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiability_638670649779969439" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638670649779969439" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638670649779969439" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LeaseLiabilityPaymentsDueTotal" xlink:label="lqda_LeaseLiabilityPaymentsDueTotal" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LeaseLiability" xlink:label="lqda_LeaseLiability_638670649779979129" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lqda_LeaseLiabilityPaymentsDueTotal" xlink:to="lqda_LeaseLiability_638670649779979129" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LeaseLiabilityUndiscountedExcessAmount" xlink:label="lqda_LeaseLiabilityUndiscountedExcessAmount_638670649779979129" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lqda_LeaseLiabilityPaymentsDueTotal" xlink:to="lqda_LeaseLiabilityUndiscountedExcessAmount_638670649779979129" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638670649779979129" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638670649779979129" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638670649779979129" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability_638670649779979129" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableExpectedAnnualPaymentsDetails" xlink:type="extended" xlink:title="99941203 - Disclosure - Revenue Interest Financing Payable - Expected Annual Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal_1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFiveAndThereafter" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFiveAndThereafter_638670649779979129" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal_1" xlink:to="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFiveAndThereafter_638670649779979129" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFour" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFour_638670649779989468" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal_1" xlink:to="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFour_638670649779989468" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearThree" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearThree_638670649779989468" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal_1" xlink:to="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearThree_638670649779989468" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearTwo" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearTwo_638670649779989468" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal_1" xlink:to="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearTwo_638670649779989468" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearOne" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearOne_638670649779989468" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal_1" xlink:to="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearOne_638670649779989468" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear_638670649779989468" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal_1" xlink:to="lqda_RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear_638670649779989468" order="6" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>lqda-20240930_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/13/2024 3:23:02 AM-->
<!--Modified on: 11/13/2024 3:23:02 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" roleURI="http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureStockBasedCompensationTables" roleURI="http://liquidia.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureBusinessLiquidityDetails" roleURI="http://liquidia.com/role/DisclosureBusinessLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails" roleURI="http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsCommonStockEquivalentSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" roleURI="http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsCommonStockEquivalentSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsFairValueOfFinancialAssetsAndFinancialLiabilitiesDetails" roleURI="http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsFairValueOfFinancialAssetsAndFinancialLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureInventoryDetails" roleURI="http://liquidia.com/role/DisclosureInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" roleURI="http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureIndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDetails" roleURI="http://liquidia.com/role/DisclosureIndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureStockholdersEquityDetails" roleURI="http://liquidia.com/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureStockBasedCompensationOtherDetails" roleURI="http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://liquidia.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureStockBasedCompensationUnamortizedCompensationExpenseDetails" roleURI="http://liquidia.com/role/DisclosureStockBasedCompensationUnamortizedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails" roleURI="http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureStockBasedCompensationRestrictedStockUnitsDetails" roleURI="http://liquidia.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureRevenueFromContractsWithCustomersDetails" roleURI="http://liquidia.com/role/DisclosureRevenueFromContractsWithCustomersDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureLeasesCostDetails" roleURI="http://liquidia.com/role/DisclosureLeasesCostDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureRevenueInterestFinancingPayableTermsDetails" roleURI="http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureLegalProceedingsDetails" roleURI="http://liquidia.com/role/DisclosureLegalProceedingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://liquidia.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="lqda-20240930.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:definitionLink xlink:role="http://liquidia.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis_1" xlink:title="srt_LitigationCaseAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_1" xlink:title="srt_LitigationCaseTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_LitigationCaseAxis_1" xlink:to="srt_LitigationCaseTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_LitigationCaseAxis_1 To srt_LitigationCaseTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis_1" xlink:title="us-gaap_LitigationStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain_1" xlink:title="us-gaap_LitigationStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LitigationStatusAxis_1" xlink:to="us-gaap_LitigationStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LitigationStatusAxis_1 To us-gaap_LitigationStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_1" xlink:title="us-gaap_BusinessAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:title="us-gaap_BusinessAcquisitionAcquireeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BusinessAcquisitionAxis_1" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BusinessAcquisitionAxis_1 To us-gaap_BusinessAcquisitionAcquireeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis_1" xlink:title="us-gaap_ConversionOfStockByUniqueDescriptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain_1" xlink:title="us-gaap_ConversionOfStockNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis_1" xlink:to="us-gaap_ConversionOfStockNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConversionOfStockByUniqueDescriptionAxis_1 To us-gaap_ConversionOfStockNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1" xlink:title="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1" xlink:title="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1 To us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:title="us-gaap_ConcentrationRiskByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_1" xlink:title="us-gaap_ConcentrationRiskTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:to="us-gaap_ConcentrationRiskTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByTypeAxis_1 To us-gaap_ConcentrationRiskTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByBenchmarkAxis_1 To us-gaap_ConcentrationRiskBenchmarkDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_1" xlink:title="us-gaap_FairValueByMeasurementBasisAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" xlink:title="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_1" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementBasisAxis_1 To us-gaap_PortionAtFairValueFairValueDisclosureMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_1" xlink:title="us-gaap_ContingentConsiderationByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_1" xlink:title="us-gaap_ContingentConsiderationTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ContingentConsiderationByTypeAxis_1" xlink:to="us-gaap_ContingentConsiderationTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ContingentConsiderationByTypeAxis_1 To us-gaap_ContingentConsiderationTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_1" xlink:title="srt_OwnershipAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_1" xlink:title="srt_OwnershipDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_OwnershipAxis_1" xlink:to="srt_OwnershipDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_OwnershipAxis_1 To srt_OwnershipDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_1" xlink:title="us-gaap_LeaseContractualTermAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_1" xlink:title="us-gaap_LeaseContractualTermDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LeaseContractualTermAxis_1" xlink:to="us-gaap_LeaseContractualTermDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LeaseContractualTermAxis_1 To us-gaap_LeaseContractualTermDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis_1" xlink:title="us-gaap_OtherCommitmentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain_1" xlink:title="us-gaap_OtherCommitmentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_OtherCommitmentsAxis_1" xlink:to="us-gaap_OtherCommitmentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_OtherCommitmentsAxis_1 To us-gaap_OtherCommitmentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_1" xlink:title="us-gaap_VariableRateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_1" xlink:title="us-gaap_VariableRateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VariableRateAxis_1" xlink:to="us-gaap_VariableRateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VariableRateAxis_1 To us-gaap_VariableRateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended" xlink:title="Individuals" />
  <definitionLink xlink:role="http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:type="extended" xlink:title="995200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" xlink:label="lqda_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" xlink:label="lqda_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:label="lqda_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:label="lqda_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://liquidia.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="99930903 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_EmployeeStockPurchasePlan2020Member" xlink:label="lqda_EmployeeStockPurchasePlan2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="lqda_EmployeeStockPurchasePlan2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://liquidia.com/role/DisclosureBusinessLiquidityDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - Business - Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementMember" xlink:label="lqda_RevenueInterestFinancingAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lqda_RevenueInterestFinancingAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember" xlink:label="lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_HealthcareRoyaltyPartnersIvL.pMember" xlink:label="lqda_HealthcareRoyaltyPartnersIvL.pMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lqda_HealthcareRoyaltyPartnersIvL.pMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ForCalendarYearBeginningOnJanuary12024Member" xlink:label="lqda_ForCalendarYearBeginningOnJanuary12024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="lqda_ForCalendarYearBeginningOnJanuary12024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AfterCalendarYearEndingOnDecember312024Member" xlink:label="lqda_AfterCalendarYearEndingOnDecember312024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="lqda_AfterCalendarYearEndingOnDecember312024Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained" xlink:label="lqda_RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="lqda_RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche" xlink:label="lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementAmountFunded" xlink:label="lqda_RevenueInterestFinancingAgreementAmountFunded" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="lqda_RevenueInterestFinancingAgreementAmountFunded" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts" xlink:label="lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts" xlink:label="lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements - Other (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_CustomerOneMember" xlink:label="lqda_CustomerOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="lqda_CustomerOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_NumberOfCustomers" xlink:label="lqda_NumberOfCustomers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_NumberOfCustomers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_InventoryCapitalizedCost" xlink:label="lqda_InventoryCapitalizedCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_InventoryCapitalizedCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportingUnits" xlink:label="us-gaap_NumberOfReportingUnits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NumberOfReportingUnits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsCommonStockEquivalentSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="99940202 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements - Common Stock Equivalent Shares Excluded From Calculation of Diluted Net Loss Per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsFairValueOfFinancialAssetsAndFinancialLiabilitiesDetails" xlink:type="extended" xlink:title="99940203 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements - Fair Value of Financial Assets and Financial Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://liquidia.com/role/DisclosureInventoryDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Inventory (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryCurrentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryRawMaterials" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryWorkInProcess" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_InventoryCurrentAndNonCurrent" xlink:label="lqda_InventoryCurrentAndNonCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_InventoryLineItems" xlink:to="lqda_InventoryCurrentAndNonCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_CapitalizedCostsOfInventory" xlink:label="lqda_CapitalizedCostsOfInventory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_InventoryLineItems" xlink:to="lqda_CapitalizedCostsOfInventory" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Property, Plant, and Equipment - Schedule of Property, plant and equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LabAndBuildToSuitEquipmentMember" xlink:label="lqda_LabAndBuildToSuitEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lqda_LabAndBuildToSuitEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://liquidia.com/role/DisclosureIndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Indemnification Asset with Related Party and Litigation Finance Payable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PBMMember" xlink:label="lqda_PBMMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="lqda_PBMMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RelatedPartyTransactionMajorStockholderOwnershipPercentageInCompany" xlink:label="lqda_RelatedPartyTransactionMajorStockholderOwnershipPercentageInCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="lqda_RelatedPartyTransactionMajorStockholderOwnershipPercentageInCompany" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://liquidia.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Stockholders' Equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_UnderwrittenPublicOfferingMember" xlink:label="lqda_UnderwrittenPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lqda_UnderwrittenPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ArSvbWarrantsInitialTrancheMember" xlink:label="lqda_ArSvbWarrantsInitialTrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lqda_ArSvbWarrantsInitialTrancheMember" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_SvbWarrantInitialTrancheMember" xlink:label="lqda_SvbWarrantInitialTrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lqda_SvbWarrantInitialTrancheMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_SvbWarrantTermBAndTermCTranchesMember" xlink:label="lqda_SvbWarrantTermBAndTermCTranchesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lqda_SvbWarrantTermBAndTermCTranchesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_OtherWarrantsMember" xlink:label="lqda_OtherWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lqda_OtherWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_WarrantsToPurchaseCommonStockMember" xlink:label="lqda_WarrantsToPurchaseCommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lqda_WarrantsToPurchaseCommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_BoardOfDirectorsMember" xlink:label="lqda_BoardOfDirectorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lqda_BoardOfDirectorsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LargestStockholderAndMemberOfBoardOfDirectorsMember" xlink:label="lqda_LargestStockholderAndMemberOfBoardOfDirectorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lqda_LargestStockholderAndMemberOfBoardOfDirectorsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_CaliganPartnersLPMember" xlink:label="lqda_CaliganPartnersLPMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lqda_CaliganPartnersLPMember" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_Mr.PaulB.ManningMember" xlink:label="lqda_Mr.PaulB.ManningMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lqda_Mr.PaulB.ManningMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ProceedsFromIssuanceOfCommonStockNet" xlink:label="lqda_ProceedsFromIssuanceOfCommonStockNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_ProceedsFromIssuanceOfCommonStockNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="lqda_ClassOfWarrantOrRightExercisedDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_ClassOfWarrantOrRightExercisedDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts" xlink:label="lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts" xlink:label="lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Stock-Based Compensation - Other (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_The2020PlanMember" xlink:label="lqda_The2020PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="lqda_The2020PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_InducementPlan2022Member" xlink:label="lqda_InducementPlan2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="lqda_InducementPlan2022Member" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_EmployeeStockPurchasePlan2020Member" xlink:label="lqda_EmployeeStockPurchasePlan2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="lqda_EmployeeStockPurchasePlan2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PerformanceBasedRestrictedStockUnitsMember" xlink:label="lqda_PerformanceBasedRestrictedStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lqda_PerformanceBasedRestrictedStockUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentAnnualIncreaseInCapitalShareReservedForFutureIssuance" xlink:label="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentAnnualIncreaseInCapitalShareReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentAnnualIncreaseInCapitalShareReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding" xlink:label="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuance" xlink:label="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAvailableForIssuance" xlink:label="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAvailableForIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAvailableForIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://liquidia.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - Stock-Based Compensation - Stock-based Compensation Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://liquidia.com/role/DisclosureStockBasedCompensationUnamortizedCompensationExpenseDetails" xlink:type="extended" xlink:title="99940903 - Disclosure - Stock-Based Compensation - Unamortized Compensation Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails" xlink:type="extended" xlink:title="99940904 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options Granted and Purchase Rights Issued under the ESPP (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_EmployeeStockPurchasePlan2020Member" xlink:label="lqda_EmployeeStockPurchasePlan2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="lqda_EmployeeStockPurchasePlan2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_EmployeePurchaseRightsMember" xlink:label="lqda_EmployeePurchaseRightsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lqda_EmployeePurchaseRightsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://liquidia.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="99940906 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://liquidia.com/role/DisclosureRevenueFromContractsWithCustomersDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Revenue From Contracts With Customers (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_SandozMember" xlink:label="lqda_SandozMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lqda_SandozMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PromotionAgreementPayment" xlink:label="lqda_PromotionAgreementPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_PromotionAgreementPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerRefundLiability" xlink:label="us-gaap_ContractWithCustomerRefundLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerRefundLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PercentageOfRevenueFromPromotionAgreement" xlink:label="lqda_PercentageOfRevenueFromPromotionAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_PercentageOfRevenueFromPromotionAgreement" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://liquidia.com/role/DisclosureLeasesCostDetails" xlink:type="extended" xlink:title="99941102 - Disclosure - Leases - Cost (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_InterestExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_FinanceLeaseInterestExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseCost" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - Revenue Interest Financing Payable - Terms (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingPayableTable" xlink:label="lqda_RevenueInterestFinancingPayableTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="lqda_RevenueInterestFinancingPayableTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementMember" xlink:label="lqda_RevenueInterestFinancingAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lqda_RevenueInterestFinancingAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember" xlink:label="lqda_SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lqda_SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_FourthAmendmentToRevenueInterestFinancingAgreementMember" xlink:label="lqda_FourthAmendmentToRevenueInterestFinancingAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lqda_FourthAmendmentToRevenueInterestFinancingAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember" xlink:label="lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="lqda_RevenueInterestFinancingPayableTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ArSiliconValleyBankTermLoansMember" xlink:label="lqda_ArSiliconValleyBankTermLoansMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="lqda_ArSiliconValleyBankTermLoansMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="lqda_RevenueInterestFinancingPayableTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_OnSecondPortionOfFundedInvestmentAmountMember" xlink:label="lqda_OnSecondPortionOfFundedInvestmentAmountMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="lqda_OnSecondPortionOfFundedInvestmentAmountMember" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_OnFirstFundedPortionOfInvestmentAmountMember" xlink:label="lqda_OnFirstFundedPortionOfInvestmentAmountMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="lqda_OnFirstFundedPortionOfInvestmentAmountMember" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingPayableLineItems" xlink:label="lqda_RevenueInterestFinancingPayableLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="lqda_RevenueInterestFinancingPayableLineItems" xlink:to="lqda_RevenueInterestFinancingPayableTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementMaximumInvestmentAmount" xlink:label="lqda_RevenueInterestFinancingAgreementMaximumInvestmentAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="lqda_RevenueInterestFinancingPayableLineItems" xlink:to="lqda_RevenueInterestFinancingAgreementMaximumInvestmentAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementNumberOfTranches" xlink:label="lqda_RevenueInterestFinancingAgreementNumberOfTranches" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="lqda_RevenueInterestFinancingPayableLineItems" xlink:to="lqda_RevenueInterestFinancingAgreementNumberOfTranches" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementInitialInvestmentAmount" xlink:label="lqda_RevenueInterestFinancingAgreementInitialInvestmentAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="lqda_RevenueInterestFinancingPayableLineItems" xlink:to="lqda_RevenueInterestFinancingAgreementInitialInvestmentAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="lqda_RevenueInterestFinancingPayableLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="lqda_RevenueInterestFinancingPayableLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche" xlink:label="lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="lqda_RevenueInterestFinancingPayableLineItems" xlink:to="lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementHardCapPercentage" xlink:label="lqda_RevenueInterestFinancingAgreementHardCapPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="lqda_RevenueInterestFinancingPayableLineItems" xlink:to="lqda_RevenueInterestFinancingAgreementHardCapPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementInternalRateOfReturn" xlink:label="lqda_RevenueInterestFinancingAgreementInternalRateOfReturn" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="lqda_RevenueInterestFinancingPayableLineItems" xlink:to="lqda_RevenueInterestFinancingAgreementInternalRateOfReturn" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PercentageOfInvestmentAmountToBeRepaidOnFinalApproval" xlink:label="lqda_PercentageOfInvestmentAmountToBeRepaidOnFinalApproval" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="lqda_RevenueInterestFinancingPayableLineItems" xlink:to="lqda_PercentageOfInvestmentAmountToBeRepaidOnFinalApproval" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PercentageOfInvestmentAmountToBePaid" xlink:label="lqda_PercentageOfInvestmentAmountToBePaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="lqda_RevenueInterestFinancingPayableLineItems" xlink:to="lqda_PercentageOfInvestmentAmountToBePaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedDuringYearTwo" xlink:label="lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedDuringYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="lqda_RevenueInterestFinancingPayableLineItems" xlink:to="lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedDuringYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedAfterYearTwo" xlink:label="lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedAfterYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="lqda_RevenueInterestFinancingPayableLineItems" xlink:to="lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedAfterYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementAmountFunded" xlink:label="lqda_RevenueInterestFinancingAgreementAmountFunded" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="lqda_RevenueInterestFinancingPayableLineItems" xlink:to="lqda_RevenueInterestFinancingAgreementAmountFunded" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementIssuanceCosts" xlink:label="lqda_RevenueInterestFinancingAgreementIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="lqda_RevenueInterestFinancingPayableLineItems" xlink:to="lqda_RevenueInterestFinancingAgreementIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementEffectiveAnnualInterestRate" xlink:label="lqda_RevenueInterestFinancingAgreementEffectiveAnnualInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="lqda_RevenueInterestFinancingPayableLineItems" xlink:to="lqda_RevenueInterestFinancingAgreementEffectiveAnnualInterestRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="99941301 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PharmosaLicenseAgreementMember" xlink:label="lqda_PharmosaLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="lqda_PharmosaLicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ChasmTechnologiesAgreementMember" xlink:label="lqda_ChasmTechnologiesAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="lqda_ChasmTechnologiesAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AgreementWithLGMPharmaLLCMember" xlink:label="lqda_AgreementWithLGMPharmaLLCMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="lqda_AgreementWithLGMPharmaLLCMember" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember" xlink:label="lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember" xlink:label="srt_NorthAmericaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_NorthAmericaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_OtherThenNorthAmericaMember" xlink:label="lqda_OtherThenNorthAmericaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="lqda_OtherThenNorthAmericaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PaymentForUpfrontLicenseFee" xlink:label="lqda_PaymentForUpfrontLicenseFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_PaymentForUpfrontLicenseFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AccruedAdditionalUpfrontLicenseFee" xlink:label="lqda_AccruedAdditionalUpfrontLicenseFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_AccruedAdditionalUpfrontLicenseFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_MaximumPotentialDevelopmentMilestonePayments" xlink:label="lqda_MaximumPotentialDevelopmentMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_MaximumPotentialDevelopmentMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_MaximumPotentialSalesMilestones" xlink:label="lqda_MaximumPotentialSalesMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_MaximumPotentialSalesMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_MilestonePaymentsPayable" xlink:label="lqda_MilestonePaymentsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_MilestonePaymentsPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties" xlink:label="lqda_MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_NetSalesEarnedRelatingToPaymentOfFutureContingentRoyalties" xlink:label="lqda_NetSalesEarnedRelatingToPaymentOfFutureContingentRoyalties" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_NetSalesEarnedRelatingToPaymentOfFutureContingentRoyalties" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_CommercialManufacturingServicesAndSupplyAgreementInitialTerm" xlink:label="lqda_CommercialManufacturingServicesAndSupplyAgreementInitialTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_CommercialManufacturingServicesAndSupplyAgreementInitialTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection" xlink:label="lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay" xlink:label="lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures" xlink:label="lqda_PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ReimbursementOfCapitalExpenditureIncurredBySupplier" xlink:label="lqda_ReimbursementOfCapitalExpenditureIncurredBySupplier" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_ReimbursementOfCapitalExpenditureIncurredBySupplier" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_TermOfSubmissionOfQuarterlyForecastOfExpectedProduction" xlink:label="lqda_TermOfSubmissionOfQuarterlyForecastOfExpectedProduction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_TermOfSubmissionOfQuarterlyForecastOfExpectedProduction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder" xlink:label="lqda_InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts" xlink:label="lqda_NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AgreementExpirationTerm" xlink:label="lqda_AgreementExpirationTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="lqda_AgreementExpirationTerm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://liquidia.com/role/DisclosureLegalProceedingsDetails" xlink:type="extended" xlink:title="99941401 - Disclosure - Legal Proceedings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LossContingenciesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LiquidiaPAHAndSandozMember" xlink:label="lqda_LiquidiaPAHAndSandozMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="lqda_LiquidiaPAHAndSandozMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_LitigationCaseAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_UTCAndSmithsMedicalLitigationMember" xlink:label="lqda_UTCAndSmithsMedicalLitigationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="lqda_UTCAndSmithsMedicalLitigationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_BreachOfContractClaimMember" xlink:label="lqda_BreachOfContractClaimMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="lqda_BreachOfContractClaimMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LitigationStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PendingLitigationMember" xlink:label="us-gaap_PendingLitigationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_PendingLitigationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="us-gaap_ProceedsFromLegalSettlements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ProceedsFromLegalSettlements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>lqda-20240930_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/13/2024 3:23:02 AM-->
<!--Modified on: 11/13/2024 3:23:02 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Balance Sheets (unaudited)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognized as: Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_AssetsCurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease right-of-use assets, net</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_IndemnificationAssetRelatedParty" xlink:label="lqda_IndemnificationAssetRelatedParty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_IndemnificationAssetRelatedParty" xlink:to="lqda_IndemnificationAssetRelatedParty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_IndemnificationAssetRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of indemnification asset, related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_IndemnificationAssetRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indemnification Asset, Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_IndemnificationAssetRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indemnification asset, related party</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_BusinessCombinationContractAcquisitionCostsNet" xlink:label="lqda_BusinessCombinationContractAcquisitionCostsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_BusinessCombinationContractAcquisitionCostsNet" xlink:to="lqda_BusinessCombinationContractAcquisitionCostsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_BusinessCombinationContractAcquisitionCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents net amount of contract acquisition costs in a business acquisition.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_BusinessCombinationContractAcquisitionCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract acquisition costs, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_BusinessCombinationContractAcquisitionCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract acquisition costs, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible asset, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible asset, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible asset, Net Carrying Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="lqda_AccruedExpensesAndOtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:to="lqda_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents carrying value as of the balance sheet date of accrued expenses and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses And Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lqda_AccruedExpensesAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingPayableCurrent" xlink:label="lqda_RevenueInterestFinancingPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingPayableCurrent" xlink:to="lqda_RevenueInterestFinancingPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of revenue interest financing payable, current portion as of balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lqda_RevenueInterestFinancingPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: current portion of revenue interest financing payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_RevenueInterestFinancingPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue interest financing payable, current</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_OperatingAndFinanceLeaseLiabilityCurrent" xlink:label="lqda_OperatingAndFinanceLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_OperatingAndFinanceLeaseLiabilityCurrent" xlink:to="lqda_OperatingAndFinanceLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_OperatingAndFinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lessee's discounted obligation for lease payments from operating and finance leases, classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_OperatingAndFinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating and Finance Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_OperatingAndFinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating and finance lease liabilities, current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_LiabilitiesCurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserveNoncurrent" xlink:label="us-gaap_LitigationReserveNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationReserveNoncurrent" xlink:to="us-gaap_LitigationReserveNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationReserveNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation finance payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationReserveNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation finance payable</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingPayableNoncurrent" xlink:label="lqda_RevenueInterestFinancingPayableNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingPayableNoncurrent" xlink:to="lqda_RevenueInterestFinancingPayableNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingPayableNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of revenue interest financing payable, noncurrent portion as of balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingPayableNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Payable, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_RevenueInterestFinancingPayableNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term portion of revenue interest financing payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lqda_RevenueInterestFinancingPayableNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue interest financing payable, noncurrent</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="lqda_OperatingAndFinanceLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:to="lqda_OperatingAndFinanceLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_OperatingAndFinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lessee's discounted obligation for lease payments from operating and finance leases, classified as noncurrent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_OperatingAndFinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating and Finance Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_OperatingAndFinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating and finance lease liabilities, noncurrent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 15)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 13)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock - 10,000,000 shares authorized as of June 30, 2021 and December 31, 2020, 0 shares issued and outstanding as of June 30, 2021 and December 31, 2020</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock - 10,000,000 shares authorized, none outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock - $0.001 par value, 80,000,000 shares authorized as of June 30, 2021 and December 31, 2020, 51,975,049 and 43,336,277 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock - $0.001 par value, 115,000,000 and 100,000,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively, 84,545,409 and 68,629,575 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_StockholdersEquity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_LiabilitiesAndStockholdersEquity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs and expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_CostsAndExpenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total costs and expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_OperatingIncomeLoss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_InterestExpense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on extinguishment of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (loss) on extinguishment of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on extinguishment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_NonoperatingIncomeExpense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income (expense), net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss and comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per common share, basic (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per common share, diluted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding, basic (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding, diluted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Statements of Stockholders' Equity (unaudited)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of stock options (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised, number of shares (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" xlink:label="lqda_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" xlink:to="lqda_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The value of common shares issued under vesting of restricted stock units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Vesting of Restricted Stock Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon vesting of restricted stock units</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" xlink:label="lqda_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" xlink:to="lqda_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of common shares issued under vesting of restricted stock units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Vesting of Restricted Stock Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon vesting of restricted stock units (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock under employee stock purchase plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock under employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock under employee stock purchase plan (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock under employee stock purchase plan (in shares)</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:label="lqda_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:to="lqda_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued as a result of common stock warrants exercised during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of common stock warrants (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:label="lqda_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:to="lqda_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock issued as a result of the exercise of common stock warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of common stock warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock upon exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of common stock, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of common stock, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of common stock, net (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of common stock, net (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Condensed Consolidated Statements of Cash Flows (unaudited)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AcquiredInProcessResearchAndDevelopment" xlink:label="lqda_AcquiredInProcessResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_AcquiredInProcessResearchAndDevelopment" xlink:to="lqda_AcquiredInProcessResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_AcquiredInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired in-process research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_AcquiredInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired In Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_AcquiredInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired in-process research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_ShareBasedCompensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_NoncashPortionOfLeaseExpense" xlink:label="lqda_NoncashPortionOfLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_NoncashPortionOfLeaseExpense" xlink:to="lqda_NoncashPortionOfLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_NoncashPortionOfLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of non cash portion of lease expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_NoncashPortionOfLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash lease expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_NoncashPortionOfLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_GainLossOnDispositionOfAssets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss (gain) on disposal of property and equipment</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AccretionAndNonCashInterestExpense" xlink:label="lqda_AccretionAndNonCashInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_AccretionAndNonCashInterestExpense" xlink:to="lqda_AccretionAndNonCashInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_AccretionAndNonCashInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion and non-cash interest expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_AccretionAndNonCashInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion and Non-Cash Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_AccretionAndNonCashInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion and non-cash interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_IncreaseDecreaseInReceivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other noncurrent assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_IncreaseDecreaseInAccountsPayable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="lqda_IncreaseDecreaseInOperatingLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lqda_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the reporting period in operating lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Operating Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_NetCashProvidedByUsedInOperatingActivities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of in-process research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the sale of property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_NetCashProvidedByUsedInInvestingActivities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing activities</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ProceedsFromRevenueInterestFinancingNet" xlink:label="lqda_ProceedsFromRevenueInterestFinancingNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_ProceedsFromRevenueInterestFinancingNet" xlink:to="lqda_ProceedsFromRevenueInterestFinancingNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_ProceedsFromRevenueInterestFinancingNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from revenue interest financing, net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_ProceedsFromRevenueInterestFinancingNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Revenue Interest Financing Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_ProceedsFromRevenueInterestFinancingNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from revenue interest financing, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_RepaymentsOfLongTermDebt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal payments on long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_RepaymentsOfDebt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for debt prepayment and extinguishment costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of debt repaid with initial investment from RIFA</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PaymentsOnRevenueInterestFinancingLiability" xlink:label="lqda_PaymentsOnRevenueInterestFinancingLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_PaymentsOnRevenueInterestFinancingLiability" xlink:to="lqda_PaymentsOnRevenueInterestFinancingLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_PaymentsOnRevenueInterestFinancingLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow from payments on revenue interest financing liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_PaymentsOnRevenueInterestFinancingLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments On Revenue Interest Financing Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lqda_PaymentsOnRevenueInterestFinancingLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lqda_PaymentsOnRevenueInterestFinancingLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments on revenue interest financing liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_FinanceLeasePrincipalPayments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal payments on finance leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyReceivableProceeds" xlink:label="us-gaap_LossContingencyReceivableProceeds" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyReceivableProceeds" xlink:to="us-gaap_LossContingencyReceivableProceeds_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyReceivableProceeds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipts from litigation financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyReceivableProceeds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipts from litigation financing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sale of common stock, net of underwriting fees and commissions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sale of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock under stock incentive plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock under stock incentive plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_NetCashProvidedByUsedInFinancingActivities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase (decrease) in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of cash flow information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for interest</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_OperatingLeaseLiabilitiesCashPaid" xlink:label="lqda_OperatingLeaseLiabilitiesCashPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_OperatingLeaseLiabilitiesCashPaid" xlink:to="lqda_OperatingLeaseLiabilitiesCashPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_OperatingLeaseLiabilitiesCashPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash paid for operating lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_OperatingLeaseLiabilitiesCashPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for operating lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_OperatingLeaseLiabilitiesCashPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_OfferingCostsIncurredIncludedInAccruedExpenses" xlink:label="lqda_OfferingCostsIncurredIncludedInAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_OfferingCostsIncurredIncludedInAccruedExpenses" xlink:to="lqda_OfferingCostsIncurredIncludedInAccruedExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_OfferingCostsIncurredIncludedInAccruedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering costs incurred, but not paid included in accrued expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_OfferingCostsIncurredIncludedInAccruedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering Costs Incurred, Included in Accrued Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_OfferingCostsIncurredIncludedInAccruedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering costs incurred, but not paid included in accrued expenses</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:label="lqda_RightOfUseAssetObtainedInExchangeForLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:to="lqda_RightOfUseAssetObtainedInExchangeForLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RightOfUseAssetObtainedInExchangeForLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase in right-of-use asset obtained in exchange for lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RightOfUseAssetObtainedInExchangeForLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right Of Use Asset Obtained In Exchange For Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_RightOfUseAssetObtainedInExchangeForLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right of use assets obtained through lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in purchases of property and equipment in accounts payable and accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash increase in property, plant and equipment through accounts payable</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_IncreaseInIndemnificationAssetThroughAccountsPayable" xlink:label="lqda_IncreaseInIndemnificationAssetThroughAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_IncreaseInIndemnificationAssetThroughAccountsPayable" xlink:to="lqda_IncreaseInIndemnificationAssetThroughAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_IncreaseInIndemnificationAssetThroughAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in indemnification asset through accounts payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_IncreaseInIndemnificationAssetThroughAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in Indemnification Asset Through Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_IncreaseInIndemnificationAssetThroughAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash increase in indemnification asset through accounts payable</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_BusinessAbstract" xlink:label="lqda_BusinessAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_BusinessAbstract" xlink:to="lqda_BusinessAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_BusinessAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_BusinessAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation, Significant Accounting Policies and Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation, Significant Accounting Policies and Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant, and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant, and Equipment</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract" xlink:label="lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract" xlink:to="lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Acquisition Costs and Intangible Asset [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Acquisition Costs and Intangible Asset</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock" xlink:label="lqda_ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock" xlink:to="lqda_ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for contract acquisition costs and intangible asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Acquisition Costs and Intangible Asset Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Acquisition Costs and Intangible Asset</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_IndemnificationAssetAndLitigationFinancePayableAbstract" xlink:label="lqda_IndemnificationAssetAndLitigationFinancePayableAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_IndemnificationAssetAndLitigationFinancePayableAbstract" xlink:to="lqda_IndemnificationAssetAndLitigationFinancePayableAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_IndemnificationAssetAndLitigationFinancePayableAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indemnification Asset and Litigation Finance Payable [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_IndemnificationAssetAndLitigationFinancePayableAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indemnification Asset with Related Party and Litigation Finance Payable</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_IndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDisclosureTextBlock" xlink:label="lqda_IndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_IndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDisclosureTextBlock" xlink:to="lqda_IndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_IndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for indemnification asset with related party and litigation finance payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_IndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indemnification Asset with Related Party and Litigation Finance Payable Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_IndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indemnification Asset with Related Party and Litigation Finance Payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses and Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" xlink:label="lqda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" xlink:to="lqda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for accrued expenses and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses and Other Current Liabilities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses and Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue From Contracts With Customers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue From Contracts With Customers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LeaseDisclosureTextBlock" xlink:label="lqda_LeaseDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_LeaseDisclosureTextBlock" xlink:to="lqda_LeaseDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of information about leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_LeaseDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingPayableAbstract" xlink:label="lqda_RevenueInterestFinancingPayableAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingPayableAbstract" xlink:to="lqda_RevenueInterestFinancingPayableAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingPayableAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Payable [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingPayableAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Payable</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingPayableTextBlock" xlink:label="lqda_RevenueInterestFinancingPayableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingPayableTextBlock" xlink:to="lqda_RevenueInterestFinancingPayableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingPayableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for revenue interest financing payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingPayableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Payable [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_RevenueInterestFinancingPayableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LegalProceedingsDisclosureAbstract" xlink:label="lqda_LegalProceedingsDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_LegalProceedingsDisclosureAbstract" xlink:to="lqda_LegalProceedingsDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_LegalProceedingsDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Proceedings Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_LegalProceedingsDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Proceedings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Matters and Contingencies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Proceedings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock" xlink:label="lqda_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock" xlink:to="lqda_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for cash and cash equivalents and concentration of credit risk the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents And Concentration of Credit Risk [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, and Concentration of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prelaunch Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingPayablePolicyPolicyTextBlock" xlink:label="lqda_RevenueInterestFinancingPayablePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingPayablePolicyPolicyTextBlock" xlink:to="lqda_RevenueInterestFinancingPayablePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingPayablePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for revenue interest financing payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingPayablePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Payable Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_RevenueInterestFinancingPayablePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AccruedResearchAndDevelopmentExpensePolicyTextBlock" xlink:label="lqda_AccruedResearchAndDevelopmentExpensePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_AccruedResearchAndDevelopmentExpensePolicyTextBlock" xlink:to="lqda_AccruedResearchAndDevelopmentExpensePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_AccruedResearchAndDevelopmentExpensePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for accrued research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_AccruedResearchAndDevelopmentExpensePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Research and Development Expense [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_AccruedResearchAndDevelopmentExpensePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Research and Development Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of calculation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of financial assets and liabilities measured at fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ScheduleOfContractAcquisitionCostsAndIntangibleAssetsTableTextBlock" xlink:label="lqda_ScheduleOfContractAcquisitionCostsAndIntangibleAssetsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_ScheduleOfContractAcquisitionCostsAndIntangibleAssetsTableTextBlock" xlink:to="lqda_ScheduleOfContractAcquisitionCostsAndIntangibleAssetsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_ScheduleOfContractAcquisitionCostsAndIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of contract acquisition costs and intangible assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_ScheduleOfContractAcquisitionCostsAndIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Contract Acquisition Costs And Intangible Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_ScheduleOfContractAcquisitionCostsAndIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of contract acquisition costs and intangible asset</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="lqda_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="lqda_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure for Accrued Expenses and Other Current Liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Expenses and Other Current Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of outstanding warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_EmployeeStockPurchasePlan2020Member" xlink:label="lqda_EmployeeStockPurchasePlan2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_EmployeeStockPurchasePlan2020Member" xlink:to="lqda_EmployeeStockPurchasePlan2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_EmployeeStockPurchasePlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to 2020 employee stock purchase plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_EmployeeStockPurchasePlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan 2020 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_EmployeeStockPurchasePlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock-based compensation expense recognized for employees and non-employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of unamortized compensation expense and weighted average remaining recognition period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of assumptions used for estimating the fair value of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of unvested RSU awards outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of lease cost</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LeaseLiabilityMaturityTableTextBlock" xlink:label="lqda_LeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_LeaseLiabilityMaturityTableTextBlock" xlink:to="lqda_LeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_LeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of undiscounted cash flows of lessee's operating lease liability and finance lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_LeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Liability Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_LeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ScheduleOfActivityOfRevenueInterestFinancingAgreementTableTextBlock" xlink:label="lqda_ScheduleOfActivityOfRevenueInterestFinancingAgreementTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_ScheduleOfActivityOfRevenueInterestFinancingAgreementTableTextBlock" xlink:to="lqda_ScheduleOfActivityOfRevenueInterestFinancingAgreementTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_ScheduleOfActivityOfRevenueInterestFinancingAgreementTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of changes in the liability related to the revenue interest financing agreement (RIFA).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_ScheduleOfActivityOfRevenueInterestFinancingAgreementTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Activity of Revenue Interest Financing Agreement [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_ScheduleOfActivityOfRevenueInterestFinancingAgreementTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of changes in the liability related to RIFA</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ScheduleOfExpectedAnnualPaymentsOnRevenueInterestFinancingAgreement" xlink:label="lqda_ScheduleOfExpectedAnnualPaymentsOnRevenueInterestFinancingAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_ScheduleOfExpectedAnnualPaymentsOnRevenueInterestFinancingAgreement" xlink:to="lqda_ScheduleOfExpectedAnnualPaymentsOnRevenueInterestFinancingAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_ScheduleOfExpectedAnnualPaymentsOnRevenueInterestFinancingAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the expected annual payments on the revenue interest financing payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_ScheduleOfExpectedAnnualPaymentsOnRevenueInterestFinancingAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Expected Annual Payments on Revenue Interest Financing Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_ScheduleOfExpectedAnnualPaymentsOnRevenueInterestFinancingAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of expected annual payments on the revenue interest financing payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementMember" xlink:label="lqda_RevenueInterestFinancingAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingAgreementMember" xlink:to="lqda_RevenueInterestFinancingAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to royalty interest financing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_RevenueInterestFinancingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Agreement</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember" xlink:label="lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember" xlink:to="lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the Fifth Amendment to the Revenue Interest Financing Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fifth Amendment to Revenue Interest Financing Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fifth Amendment to Revenue Interest Financing Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_HealthcareRoyaltyPartnersIvL.pMember" xlink:label="lqda_HealthcareRoyaltyPartnersIvL.pMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_HealthcareRoyaltyPartnersIvL.pMember" xlink:to="lqda_HealthcareRoyaltyPartnersIvL.pMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_HealthcareRoyaltyPartnersIvL.pMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to HealthCare Royalty Partners IV, L.P.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_HealthcareRoyaltyPartnersIvL.pMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">HealthCare Royalty Partners IV, L.P [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_HealthcareRoyaltyPartnersIvL.pMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">HCR</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ForCalendarYearBeginningOnJanuary12024Member" xlink:label="lqda_ForCalendarYearBeginningOnJanuary12024Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_ForCalendarYearBeginningOnJanuary12024Member" xlink:to="lqda_ForCalendarYearBeginningOnJanuary12024Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_ForCalendarYearBeginningOnJanuary12024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to period, calendar year beginning on January 1, 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_ForCalendarYearBeginningOnJanuary12024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">For Calendar Year Beginning on January 1, 2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_ForCalendarYearBeginningOnJanuary12024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">For Calendar Year Beginning on January 1, 2024</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AfterCalendarYearEndingOnDecember312024Member" xlink:label="lqda_AfterCalendarYearEndingOnDecember312024Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_AfterCalendarYearEndingOnDecember312024Member" xlink:to="lqda_AfterCalendarYearEndingOnDecember312024Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_AfterCalendarYearEndingOnDecember312024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to period, after the calendar year ending on December 31, 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_AfterCalendarYearEndingOnDecember312024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">After Calendar Year Ending on December 31 , 2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_AfterCalendarYearEndingOnDecember312024Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">After Calendar Year Ending on December 31 , 2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained" xlink:label="lqda_RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained" xlink:to="lqda_RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum amount of cash and cash equivalent to be maintained per the cash covenants of the revenue interest financing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Agreement, Minimum Cash and Cash Equivalent to be Maintained</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lqda_RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash covenants, minimum cash and cash equivalents to be maintained</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche" xlink:label="lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche" xlink:to="lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount funded under the second tranche per the revenue financing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Agreement, Amount Funded Under Second Tranche</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount funded under the second tranche</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second tranche funding, net of fees</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementAmountFunded" xlink:label="lqda_RevenueInterestFinancingAgreementAmountFunded" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingAgreementAmountFunded" xlink:to="lqda_RevenueInterestFinancingAgreementAmountFunded_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingAgreementAmountFunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The total amount funded under the revenue interest financing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingAgreementAmountFunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Agreement, Amount Funded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_RevenueInterestFinancingAgreementAmountFunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RIFA, total amount funded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lqda_RevenueInterestFinancingAgreementAmountFunded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total funding</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts" xlink:label="lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts" xlink:to="lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from the issuance of common stock, net of costs incurred directly with the issuance of the common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from issuance of common stock in public offering</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts" xlink:label="lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts" xlink:to="lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow associated with the amount net of issuance costs received from entity's raising of capital via private rather than public placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from issuance of common stock in private offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditConcentrationRiskMember" xlink:to="us-gaap_CreditConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Concentration Risk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Credit Concentration Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer [Domain]</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_CustomerOneMember" xlink:label="lqda_CustomerOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_CustomerOneMember" xlink:to="lqda_CustomerOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_CustomerOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to customer one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_CustomerOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_CustomerOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customer One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_NumberOfOperatingSegments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segments</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_NumberOfCustomers" xlink:label="lqda_NumberOfCustomers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_NumberOfCustomers" xlink:to="lqda_NumberOfCustomers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_NumberOfCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of customers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_NumberOfCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Customers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_NumberOfCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of customers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Percentage1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration risk, percentage</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_InventoryCapitalizedCost" xlink:label="lqda_InventoryCapitalizedCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_InventoryCapitalizedCost" xlink:to="lqda_InventoryCapitalizedCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_InventoryCapitalizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">the amount of Inventory, Capitalized Cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_InventoryCapitalizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Capitalized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_InventoryCapitalizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Capitalized Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long-Lived Assets Held-for-use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of long-lived assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportingUnits" xlink:label="us-gaap_NumberOfReportingUnits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportingUnits" xlink:to="us-gaap_NumberOfReportingUnits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportingUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Reporting Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportingUnits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of reporting units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill, Impairment Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of goodwill</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Anti-dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, by Balance Sheet Grouping [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market mutual funds (cash equivalents)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds (cash equivalents)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Basis [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Portion at Fair Value Measurement [Member] [Default]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimate of Fair Value Measurement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reported Value Measurement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryCurrentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryCurrentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Current [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentAssetsMember" xlink:to="us-gaap_OtherNoncurrentAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Noncurrent Assets [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncurrentAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Raw Materials, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raw materials</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Work in Process, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Work in process</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_InventoryCurrentAndNonCurrent" xlink:label="lqda_InventoryCurrentAndNonCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_InventoryCurrentAndNonCurrent" xlink:to="lqda_InventoryCurrentAndNonCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_InventoryCurrentAndNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of current and non current inventory.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_InventoryCurrentAndNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory Current And Non Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lqda_InventoryCurrentAndNonCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNoncurrent" xlink:to="us-gaap_InventoryNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognized as: Other assets</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_CapitalizedCostsOfInventory" xlink:label="lqda_CapitalizedCostsOfInventory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_CapitalizedCostsOfInventory" xlink:to="lqda_CapitalizedCostsOfInventory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_CapitalizedCostsOfInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of capitalized cost of inventory.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_CapitalizedCostsOfInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized Costs Of Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_CapitalizedCostsOfInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LabAndBuildToSuitEquipmentMember" xlink:label="lqda_LabAndBuildToSuitEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_LabAndBuildToSuitEquipmentMember" xlink:to="lqda_LabAndBuildToSuitEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_LabAndBuildToSuitEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related to lab and build-to-suit equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_LabAndBuildToSuitEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lab and build-to-suit equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_LabAndBuildToSuitEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lab and build-to-suit equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and fixtures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and fixtures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer and other equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction-in-progress</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction-in-progress</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_DepreciationAndAmortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostGross" xlink:to="us-gaap_CapitalizedContractCostGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedContractCostGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Acquisition Costs, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalizedContractCostGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract acquisition costs, Gross Carrying Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAccumulatedAmortization" xlink:label="us-gaap_CapitalizedContractCostAccumulatedAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostAccumulatedAmortization" xlink:to="us-gaap_CapitalizedContractCostAccumulatedAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedContractCostAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Acquisition Costs, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CapitalizedContractCostAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract acquisition costs, Accumulated Amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostNet" xlink:to="us-gaap_CapitalizedContractCostNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Acquisition Costs Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract acquisition costs, Net Carrying Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Gross (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible asset, Gross Carrying Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible asset, Accumulated Amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Business Acquisitions, by Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Acquisition Costs and Intangible Asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostAmortization" xlink:to="us-gaap_CapitalizedContractCostAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedContractCostAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination, Amortization Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalizedContractCostAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Acquisition Costs, Amortization Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_AmortizationOfIntangibleAssets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Asset, Amortization Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PBMMember" xlink:label="lqda_PBMMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_PBMMember" xlink:to="lqda_PBMMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_PBMMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to PBM.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_PBMMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PBM [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_PBMMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PBM</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Indemnification Asset with Related Party and Litigation Finance Payable</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RelatedPartyTransactionMajorStockholderOwnershipPercentageInCompany" xlink:label="lqda_RelatedPartyTransactionMajorStockholderOwnershipPercentageInCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RelatedPartyTransactionMajorStockholderOwnershipPercentageInCompany" xlink:to="lqda_RelatedPartyTransactionMajorStockholderOwnershipPercentageInCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RelatedPartyTransactionMajorStockholderOwnershipPercentageInCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage ownership by a major stockholder in the Company, which also controls a specific entity in which the Company entered into a Litigation Funding and Indemnification Agreement with.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RelatedPartyTransactionMajorStockholderOwnershipPercentageInCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Major Stockholder Ownership Percentage in Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_RelatedPartyTransactionMajorStockholderOwnershipPercentageInCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major stockholder ownership percentage of Liquidia Corporation Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AccruedResearchAndDevelopmentExpenses" xlink:label="lqda_AccruedResearchAndDevelopmentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_AccruedResearchAndDevelopmentExpenses" xlink:to="lqda_AccruedResearchAndDevelopmentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of accrued research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Research and Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_AccruedResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued research and development expenses</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AccruedInventoryCosts" xlink:label="lqda_AccruedInventoryCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_AccruedInventoryCosts" xlink:to="lqda_AccruedInventoryCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_AccruedInventoryCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of accrued inventory costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_AccruedInventoryCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Inventory Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_AccruedInventoryCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued inventory costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued other expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_UnderwrittenPublicOfferingMember" xlink:label="lqda_UnderwrittenPublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_UnderwrittenPublicOfferingMember" xlink:to="lqda_UnderwrittenPublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information related to underwritten public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwritten Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwritten Public Offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ArSvbWarrantsInitialTrancheMember" xlink:label="lqda_ArSvbWarrantsInitialTrancheMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_ArSvbWarrantsInitialTrancheMember" xlink:to="lqda_ArSvbWarrantsInitialTrancheMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_ArSvbWarrantsInitialTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to A&amp;R SVB Warrants - initial tranche.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_ArSvbWarrantsInitialTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A&amp;R SVB Warrants Initial Tranche</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lqda_ArSvbWarrantsInitialTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants, Expiration, January 6, 2032</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_SvbWarrantInitialTrancheMember" xlink:label="lqda_SvbWarrantInitialTrancheMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_SvbWarrantInitialTrancheMember" xlink:to="lqda_SvbWarrantInitialTrancheMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_SvbWarrantInitialTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to SVB Warrant - Initial Tranche.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_SvbWarrantInitialTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SVB Warrant Initial Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lqda_SvbWarrantInitialTrancheMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants, Initial Tranche, Expiration, February 26, 2031</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_SvbWarrantTermBAndTermCTranchesMember" xlink:label="lqda_SvbWarrantTermBAndTermCTranchesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_SvbWarrantTermBAndTermCTranchesMember" xlink:to="lqda_SvbWarrantTermBAndTermCTranchesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_SvbWarrantTermBAndTermCTranchesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to SVB Warrant - Term B and Term C Tranches.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_SvbWarrantTermBAndTermCTranchesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SVB Warrant - Term B and Term C Tranches</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lqda_SvbWarrantTermBAndTermCTranchesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants, Other Tranches, Expiration, February 26, 2031</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_OtherWarrantsMember" xlink:label="lqda_OtherWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_OtherWarrantsMember" xlink:to="lqda_OtherWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_OtherWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to other warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_OtherWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lqda_OtherWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants, Expiration, December 31, 2026</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_WarrantsToPurchaseCommonStockMember" xlink:label="lqda_WarrantsToPurchaseCommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_WarrantsToPurchaseCommonStockMember" xlink:to="lqda_WarrantsToPurchaseCommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents warrants to purchase common stock shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to Purchase Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_BoardOfDirectorsMember" xlink:label="lqda_BoardOfDirectorsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_BoardOfDirectorsMember" xlink:to="lqda_BoardOfDirectorsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_BoardOfDirectorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to board of directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_BoardOfDirectorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Board of Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_BoardOfDirectorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Board of Directors</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LargestStockholderAndMemberOfBoardOfDirectorsMember" xlink:label="lqda_LargestStockholderAndMemberOfBoardOfDirectorsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_LargestStockholderAndMemberOfBoardOfDirectorsMember" xlink:to="lqda_LargestStockholderAndMemberOfBoardOfDirectorsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_LargestStockholderAndMemberOfBoardOfDirectorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents collective information pertaining to the largest stockholder and a member of Board of Directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_LargestStockholderAndMemberOfBoardOfDirectorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Caligan and Paul B. Manning [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_LargestStockholderAndMemberOfBoardOfDirectorsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Caligan and Paul B. Manning</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_CaliganPartnersLPMember" xlink:label="lqda_CaliganPartnersLPMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_CaliganPartnersLPMember" xlink:to="lqda_CaliganPartnersLPMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_CaliganPartnersLPMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to Caligan Partners LP ("Caligan").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_CaliganPartnersLPMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Caligan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_CaliganPartnersLPMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Caligan</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_Mr.PaulB.ManningMember" xlink:label="lqda_Mr.PaulB.ManningMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_Mr.PaulB.ManningMember" xlink:to="lqda_Mr.PaulB.ManningMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_Mr.PaulB.ManningMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to Mr. Paul B. Manning.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_Mr.PaulB.ManningMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mr. Paul B. Manning [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_Mr.PaulB.ManningMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mr. Paul B. Manning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Executive Officer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Roger Jeffs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Executive Officer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_SharesIssuedPricePerShare</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Private Placement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Before deducting offering costs</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ProceedsFromIssuanceOfCommonStockNet" xlink:label="lqda_ProceedsFromIssuanceOfCommonStockNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_ProceedsFromIssuanceOfCommonStockNet" xlink:to="lqda_ProceedsFromIssuanceOfCommonStockNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_ProceedsFromIssuanceOfCommonStockNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from the additional capital contribution to the entity, net of offering costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_ProceedsFromIssuanceOfCommonStockNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds From Issuance Of Common Stock Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_ProceedsFromIssuanceOfCommonStockNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_PaymentsOfStockIssuanceCosts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for offering costs</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="lqda_ClassOfWarrantOrRightExercisedDuringPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:to="lqda_ClassOfWarrantOrRightExercisedDuringPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_ClassOfWarrantOrRightExercisedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of warrants or rights exercised during period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_ClassOfWarrantOrRightExercisedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right Exercised During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_ClassOfWarrantOrRightExercisedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercised During Period (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_ClassOfWarrantOrRightOutstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_ProceedsFromIssuanceOfCommonStock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_The2020PlanMember" xlink:label="lqda_The2020PlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_The2020PlanMember" xlink:to="lqda_The2020PlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_The2020PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related to the 2020 plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_The2020PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The 2020 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_The2020PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The 2020 Plan</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_InducementPlan2022Member" xlink:label="lqda_InducementPlan2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_InducementPlan2022Member" xlink:to="lqda_InducementPlan2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_InducementPlan2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining 2022 to inducement plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_InducementPlan2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inducement Plan 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_InducementPlan2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022 Inducement Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Tranche One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Tranche One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Tranche Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Tranche Two</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PerformanceBasedRestrictedStockUnitsMember" xlink:label="lqda_PerformanceBasedRestrictedStockUnitsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_PerformanceBasedRestrictedStockUnitsMember" xlink:to="lqda_PerformanceBasedRestrictedStockUnitsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_PerformanceBasedRestrictedStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to performance-based restricted stock units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_PerformanceBasedRestrictedStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Based Restricted Stock Units [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_PerformanceBasedRestrictedStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Based Restricted Stock Units</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentAnnualIncreaseInCapitalShareReservedForFutureIssuance" xlink:label="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentAnnualIncreaseInCapitalShareReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentAnnualIncreaseInCapitalShareReservedForFutureIssuance" xlink:to="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentAnnualIncreaseInCapitalShareReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentAnnualIncreaseInCapitalShareReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percent increase in number of shares reserved for future issuance under a share-based compensation arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentAnnualIncreaseInCapitalShareReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Percent Annual Increase In Capital Share Reserved For Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentAnnualIncreaseInCapitalShareReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation arrangement by share-based payment award, percent annual increase in capital shares reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation arrangement by share-based payment award, number of additional shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation arrangement by share-based payment award, number of shares available for grant (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, capital shares reserved for future issuance (in shares)</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding" xlink:label="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding" xlink:to="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold increase in shares available for issuance as a percentage of shares issued and outstanding under the share based payment award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Threshold Increase In Shares Available For Issuance, As A Percentage Of Stock Issued And Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the number of shares of common stock issued and outstanding</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuance" xlink:label="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuance" xlink:to="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold increase in shares available for issuance under the share based payment award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Threshold Increase In Shares Available For Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common stock shares outstanding</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAvailableForIssuance" xlink:label="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAvailableForIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAvailableForIssuance" xlink:to="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAvailableForIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAvailableForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in shares available for issuance under the share based payment award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAvailableForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Increase In Shares Available For Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAvailableForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available of issuance under the ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation arrangement by share-based payment award, purchase price of common stock, percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted, weighted average exercise price (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted, weighted average exercise price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation arrangement by share-based payment award, award vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_SharePrice</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted, number (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted, number (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation arrangement by share-based payment award, award vesting rights, percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Sales [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based awards, unamortized expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unamortized Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based awards, weighted average remaining recognition period (Year)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Recognition Period (Years)</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_EmployeePurchaseRightsMember" xlink:label="lqda_EmployeePurchaseRightsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_EmployeePurchaseRightsMember" xlink:to="lqda_EmployeePurchaseRightsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_EmployeePurchaseRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to employees purchase rights awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_EmployeePurchaseRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Purchase Rights [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_EmployeePurchaseRightsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Purchase Rights</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate, maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected Volatility, minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected Volatility, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected Volatility, maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected Volatility, maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected life (years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected life (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average fair value for options granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, number of shares (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, number of shares (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, weighted average exercise price (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, weighted average exercise price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted, number of shares (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted, number of shares (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised, weighted average exercise price (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised, weighted average exercise price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled, number of shares (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled, weighted average exercise price (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cancelled, weighted average exercise price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, weighted average contractual term (Year)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, weighted average contractual term (Year)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, aggregate intrinsic value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, aggregate intrinsic value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable, number of shares (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable, number of shares (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable, weighted average exercise price (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable, weighted average exercise price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable, weighted average contractual term (Year)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable, weighted average contractual term (Year)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable, aggregate intrinsic value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable, aggregate intrinsic value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest, number of shares (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest, number of shares (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest, weighted average exercise price (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest, weighted average exercise price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest, weighted average contractual term (Year)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest, weighted average contractual term (Year)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest, aggregate intrinsic value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest, aggregate intrinsic value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested , number (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested, number (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested , weighted average grant date fair value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested , weighted average grant date fair value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted , weighted average grant date fair value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted , weighted average grant date fair value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested , number (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested , weighted average grant date fair value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested , weighted average grant date fair value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited, number (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited , weighted average grant date fair value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited , weighted average grant date fair value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_SandozMember" xlink:label="lqda_SandozMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_SandozMember" xlink:to="lqda_SandozMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_SandozMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related to Sandoz.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_SandozMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sandoz [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_SandozMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sandoz</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PromotionAgreementPayment" xlink:label="lqda_PromotionAgreementPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_PromotionAgreementPayment" xlink:to="lqda_PromotionAgreementPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_PromotionAgreementPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount paid by the Company at the inception of the Promotion Agreement, in consideration for the right to conduct promotional activities for the product.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_PromotionAgreementPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Promotion Agreement, Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_PromotionAgreementPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Promotion Agreement, Payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerRefundLiability" xlink:label="us-gaap_ContractWithCustomerRefundLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerRefundLiability" xlink:to="us-gaap_ContractWithCustomerRefundLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerRefundLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Refund Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerRefundLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Refund Liability</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PercentageOfRevenueFromPromotionAgreement" xlink:label="lqda_PercentageOfRevenueFromPromotionAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_PercentageOfRevenueFromPromotionAgreement" xlink:to="lqda_PercentageOfRevenueFromPromotionAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_PercentageOfRevenueFromPromotionAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of revenue from Promotion Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_PercentageOfRevenueFromPromotionAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Revenue from Promotion Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_PercentageOfRevenueFromPromotionAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Revenue from Promotion Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseDiscountRate" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_LesseeFinanceLeaseDiscountRate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Finance Lease, Discount Rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Commitment, Remaining Minimum Amount Committed</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AgreementExpirationTerm" xlink:label="lqda_AgreementExpirationTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_AgreementExpirationTerm" xlink:to="lqda_AgreementExpirationTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_AgreementExpirationTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration term of the agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_AgreementExpirationTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement Expiration Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_AgreementExpirationTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration term of agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Renewal term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseMember" xlink:to="us-gaap_InterestExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of lease assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest on lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Lease Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining lease term, Operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining lease term, Finance leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average discount rate, Operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average discount rate, Finance leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024 (three months remaining)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating leases, 2021</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating leases, 2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating leases, Total minimum lease payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating leases, Present value of lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, Payment, Due [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024 (three months remaining)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, 2021</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, 2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Total minimum lease payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance Lease, Present value of lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LeaseLiabilityPaymentsDueRemainderOfFiscalYear" xlink:label="lqda_LeaseLiabilityPaymentsDueRemainderOfFiscalYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_LeaseLiabilityPaymentsDueRemainderOfFiscalYear" xlink:to="lqda_LeaseLiabilityPaymentsDueRemainderOfFiscalYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_LeaseLiabilityPaymentsDueRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of lessee's undiscounted obligation for lease payments, to be paid in remainder of current fiscal year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_LeaseLiabilityPaymentsDueRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Liability Payments Due, Remainder of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_LeaseLiabilityPaymentsDueRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024 (three months remaining)</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="lqda_LeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_LeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lqda_LeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_LeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of lessee's undiscounted obligation for lease payments, due in next fiscal year following latest fiscal year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_LeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Liability Payments Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_LeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LeaseLiabilityPaymentsDueYearTwo" xlink:label="lqda_LeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_LeaseLiabilityPaymentsDueYearTwo" xlink:to="lqda_LeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_LeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of lessee's undiscounted obligation for lease payments for operating lease and finance lease, due in second fiscal year following latest fiscal year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_LeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Liability Payments Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_LeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LeaseLiabilityPaymentsDueTotal" xlink:label="lqda_LeaseLiabilityPaymentsDueTotal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_LeaseLiabilityPaymentsDueTotal" xlink:to="lqda_LeaseLiabilityPaymentsDueTotal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_LeaseLiabilityPaymentsDueTotal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of lessee's undiscounted obligation for lease payments for operating lease and finance lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_LeaseLiabilityPaymentsDueTotal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Liability Payments Due Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lqda_LeaseLiabilityPaymentsDueTotal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LeaseLiabilityUndiscountedExcessAmount" xlink:label="lqda_LeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_LeaseLiabilityUndiscountedExcessAmount" xlink:to="lqda_LeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_LeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_LeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Liability Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lqda_LeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: interest</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LeaseLiability" xlink:label="lqda_LeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_LeaseLiability" xlink:to="lqda_LeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_LeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lessee's discounted obligation for lease payments from operating lease and finance lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_LeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_LeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingPayableTable" xlink:label="lqda_RevenueInterestFinancingPayableTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingPayableTable" xlink:to="lqda_RevenueInterestFinancingPayableTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingPayableTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A table or schedule providing information pertaining to revenue interest financing payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingPayableTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Payable [Table]</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember" xlink:label="lqda_SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember" xlink:to="lqda_SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Second and Third Amendments to Revenue Interest Financing Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second and Third Amendments to Revenue Interest Financing Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Second and Third Amendments to Revenue Interest Financing Agreement</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_FourthAmendmentToRevenueInterestFinancingAgreementMember" xlink:label="lqda_FourthAmendmentToRevenueInterestFinancingAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_FourthAmendmentToRevenueInterestFinancingAgreementMember" xlink:to="lqda_FourthAmendmentToRevenueInterestFinancingAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_FourthAmendmentToRevenueInterestFinancingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the Fourth Amendment to the Revenue Interest Financing Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_FourthAmendmentToRevenueInterestFinancingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fourth Amendment to Revenue Interest Financing Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_FourthAmendmentToRevenueInterestFinancingAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fourth Amendment to Revenue Interest Financing Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ArSiliconValleyBankTermLoansMember" xlink:label="lqda_ArSiliconValleyBankTermLoansMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_ArSiliconValleyBankTermLoansMember" xlink:to="lqda_ArSiliconValleyBankTermLoansMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_ArSiliconValleyBankTermLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to A&amp;R Silicon Valley bank term loans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_ArSiliconValleyBankTermLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A&amp;R Silicon Valley Bank Term Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_ArSiliconValleyBankTermLoansMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A&amp;R Silicon Valley Bank Term Loan</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_OnFirstFundedPortionOfInvestmentAmountMember" xlink:label="lqda_OnFirstFundedPortionOfInvestmentAmountMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_OnFirstFundedPortionOfInvestmentAmountMember" xlink:to="lqda_OnFirstFundedPortionOfInvestmentAmountMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_OnFirstFundedPortionOfInvestmentAmountMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to first funded portion of investment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_OnFirstFundedPortionOfInvestmentAmountMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">On First Funded Portion of Investment Amount [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_OnFirstFundedPortionOfInvestmentAmountMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">On first funded portion of investment amount</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_OnSecondPortionOfFundedInvestmentAmountMember" xlink:label="lqda_OnSecondPortionOfFundedInvestmentAmountMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_OnSecondPortionOfFundedInvestmentAmountMember" xlink:to="lqda_OnSecondPortionOfFundedInvestmentAmountMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_OnSecondPortionOfFundedInvestmentAmountMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to second portion of funded investment amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_OnSecondPortionOfFundedInvestmentAmountMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">On Second Portion of Funded Investment Amount [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_OnSecondPortionOfFundedInvestmentAmountMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">On second portion of funded investment amount</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingPayableLineItems" xlink:label="lqda_RevenueInterestFinancingPayableLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingPayableLineItems" xlink:to="lqda_RevenueInterestFinancingPayableLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingPayableLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingPayableLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Payable [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_RevenueInterestFinancingPayableLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Payable</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementMaximumInvestmentAmount" xlink:label="lqda_RevenueInterestFinancingAgreementMaximumInvestmentAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingAgreementMaximumInvestmentAmount" xlink:to="lqda_RevenueInterestFinancingAgreementMaximumInvestmentAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingAgreementMaximumInvestmentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The investment amount received upfront under the revenue interest financing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingAgreementMaximumInvestmentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Agreement, Maximum Investment Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_RevenueInterestFinancingAgreementMaximumInvestmentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RIFA, maximum investment amount</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementNumberOfTranches" xlink:label="lqda_RevenueInterestFinancingAgreementNumberOfTranches" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingAgreementNumberOfTranches" xlink:to="lqda_RevenueInterestFinancingAgreementNumberOfTranches_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingAgreementNumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of tranches of the revenue interest financing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingAgreementNumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Agreement, Number of Tranches</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_RevenueInterestFinancingAgreementNumberOfTranches_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RIFA, number of tranches</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementInitialInvestmentAmount" xlink:label="lqda_RevenueInterestFinancingAgreementInitialInvestmentAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingAgreementInitialInvestmentAmount" xlink:to="lqda_RevenueInterestFinancingAgreementInitialInvestmentAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingAgreementInitialInvestmentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The initial investment amount received  under the revenue interest financing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingAgreementInitialInvestmentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Agreement, Initial Investment Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_RevenueInterestFinancingAgreementInitialInvestmentAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RIFA, initial investment amount</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementHardCapPercentage" xlink:label="lqda_RevenueInterestFinancingAgreementHardCapPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingAgreementHardCapPercentage" xlink:to="lqda_RevenueInterestFinancingAgreementHardCapPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingAgreementHardCapPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The hard cap expressed as percentage to terminate the interest revenue payment agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingAgreementHardCapPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Agreement, Hard Cap Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_RevenueInterestFinancingAgreementHardCapPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RIFA, Hard Cap percentage</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementInternalRateOfReturn" xlink:label="lqda_RevenueInterestFinancingAgreementInternalRateOfReturn" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingAgreementInternalRateOfReturn" xlink:to="lqda_RevenueInterestFinancingAgreementInternalRateOfReturn_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingAgreementInternalRateOfReturn_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Internal rate of return on investment amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingAgreementInternalRateOfReturn_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Agreement, Internal rate of Return</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_RevenueInterestFinancingAgreementInternalRateOfReturn_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RIFA, internal rate of return</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PercentageOfInvestmentAmountToBeRepaidOnFinalApproval" xlink:label="lqda_PercentageOfInvestmentAmountToBeRepaidOnFinalApproval" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_PercentageOfInvestmentAmountToBeRepaidOnFinalApproval" xlink:to="lqda_PercentageOfInvestmentAmountToBeRepaidOnFinalApproval_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_PercentageOfInvestmentAmountToBeRepaidOnFinalApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of investment amount to be repaid under the agreement on receiving approval from food and drug administration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_PercentageOfInvestmentAmountToBeRepaidOnFinalApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Investment Amount to be Repaid on Final Approval</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_PercentageOfInvestmentAmountToBeRepaidOnFinalApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of investment amount to be repaid on final approval</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PercentageOfInvestmentAmountToBePaid" xlink:label="lqda_PercentageOfInvestmentAmountToBePaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_PercentageOfInvestmentAmountToBePaid" xlink:to="lqda_PercentageOfInvestmentAmountToBePaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_PercentageOfInvestmentAmountToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of investment amount to be paid when payment has not been made in full on approval from FDA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_PercentageOfInvestmentAmountToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Investment Amount to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_PercentageOfInvestmentAmountToBePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of investment amount to be paid</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedDuringYearTwo" xlink:label="lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedDuringYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedDuringYearTwo" xlink:to="lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedDuringYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedDuringYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash and cash equivalents to be maintained during year two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedDuringYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Cash and Cash Equivalents Required to be Maintained During Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedDuringYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum cash and cash equivalents required to be maintained during next year</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedAfterYearTwo" xlink:label="lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedAfterYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedAfterYearTwo" xlink:to="lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedAfterYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedAfterYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash and cash equivalents to be maintained after year two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedAfterYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Cash and Cash Equivalents Required to be Maintained After Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedAfterYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum cash and cash equivalents required to be maintained after December 31, 2024</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementIssuanceCosts" xlink:label="lqda_RevenueInterestFinancingAgreementIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingAgreementIssuanceCosts" xlink:to="lqda_RevenueInterestFinancingAgreementIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingAgreementIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance costs related to the revenue interest financing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingAgreementIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Agreement, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lqda_RevenueInterestFinancingAgreementIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_RevenueInterestFinancingAgreementIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance costs</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementEffectiveAnnualInterestRate" xlink:label="lqda_RevenueInterestFinancingAgreementEffectiveAnnualInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingAgreementEffectiveAnnualInterestRate" xlink:to="lqda_RevenueInterestFinancingAgreementEffectiveAnnualInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingAgreementEffectiveAnnualInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The effective annual interest rate under revenue interest financing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingAgreementEffectiveAnnualInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Agreement, Effective Annual Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_RevenueInterestFinancingAgreementEffectiveAnnualInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective annual interest rate</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreement" xlink:label="lqda_RevenueInterestFinancingAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingAgreement" xlink:to="lqda_RevenueInterestFinancingAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of revenue interest financing payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lqda_RevenueInterestFinancingAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lqda_RevenueInterestFinancingAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementAccretion" xlink:label="lqda_RevenueInterestFinancingAgreementAccretion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingAgreementAccretion" xlink:to="lqda_RevenueInterestFinancingAgreementAccretion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingAgreementAccretion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion expense related to the revenue interest financing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingAgreementAccretion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Agreement, Accretion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_RevenueInterestFinancingAgreementAccretion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementAmortizationOfDebtDiscount" xlink:label="lqda_RevenueInterestFinancingAgreementAmortizationOfDebtDiscount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingAgreementAmortizationOfDebtDiscount" xlink:to="lqda_RevenueInterestFinancingAgreementAmortizationOfDebtDiscount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingAgreementAmortizationOfDebtDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of amortization of debt discount related to the revenue interest financing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingAgreementAmortizationOfDebtDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Agreement, Amortization of Debt Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_RevenueInterestFinancingAgreementAmortizationOfDebtDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of issuance costs</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear" xlink:to="lqda_RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expected payments on the revenue interest financing payable in remainder of current fiscal year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Agreement, Expected Payments, Remainder of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024 (three months remaining)</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearOne" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearOne" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearOne" xlink:to="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearOne_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expected payments on the revenue interest financing payable in next fiscal year following current fiscal year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Agreement, Expected Payments, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearOne_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearTwo" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearTwo" xlink:to="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expected payments on the revenue interest financing payable in second fiscal year following current fiscal year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Agreement, Expected Payments, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearThree" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearThree" xlink:to="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expected payments on the revenue interest financing payable in third fiscal year following current fiscal year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Agreement, Expected Payments, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFour" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFour" xlink:to="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expected payments on the revenue interest financing payable in fourth fiscal year following current fiscal year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Agreement, Expected Payments, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2028</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFiveAndThereafter" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFiveAndThereafter" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFiveAndThereafter" xlink:to="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFiveAndThereafter_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFiveAndThereafter_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expected payments on the revenue interest financing payable in fifth fiscal year and thereafter following current fiscal year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFiveAndThereafter_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Agreement, Expected Payments, Year Five and Thereafter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFiveAndThereafter_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal" xlink:to="lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of total expected payments on the revenue interest financing payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Interest Financing Agreement, Expected Payments, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Domain]</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PharmosaLicenseAgreementMember" xlink:label="lqda_PharmosaLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_PharmosaLicenseAgreementMember" xlink:to="lqda_PharmosaLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_PharmosaLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the license agreement with Pharmosa Biopharm Inc. ("Pharmosa").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_PharmosaLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pharmosa License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_PharmosaLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pharmosa License Agreement</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ChasmTechnologiesAgreementMember" xlink:label="lqda_ChasmTechnologiesAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_ChasmTechnologiesAgreementMember" xlink:to="lqda_ChasmTechnologiesAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_ChasmTechnologiesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to the agreement with Chasm Technologies, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_ChasmTechnologiesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chasm Technologies [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_ChasmTechnologiesAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chasm Technologies</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AgreementWithLGMPharmaLLCMember" xlink:label="lqda_AgreementWithLGMPharmaLLCMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_AgreementWithLGMPharmaLLCMember" xlink:to="lqda_AgreementWithLGMPharmaLLCMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_AgreementWithLGMPharmaLLCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related to agreement with LGM Pharma, LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_AgreementWithLGMPharmaLLCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement With LGM Pharma, LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_AgreementWithLGMPharmaLLCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreement With LGM Pharma, LLC</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember" xlink:label="lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember" xlink:to="lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Amended and Restated Commercial Manufacturing Services and Supply Agreement with Lonza Tampa LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amended and Restated Commercial Manufacturing Services and Supply Agreement with Lonza Tampa LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amended and Restated Commercial Manufacturing Services and Supply Agreement with Lonza Tampa LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember" xlink:label="srt_NorthAmericaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NorthAmericaMember" xlink:to="srt_NorthAmericaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NorthAmericaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">North America [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_NorthAmericaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">North America</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_OtherThenNorthAmericaMember" xlink:label="lqda_OtherThenNorthAmericaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_OtherThenNorthAmericaMember" xlink:to="lqda_OtherThenNorthAmericaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_OtherThenNorthAmericaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to countries other than North America.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_OtherThenNorthAmericaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Then North America [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_OtherThenNorthAmericaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other then North America</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PaymentForUpfrontLicenseFee" xlink:label="lqda_PaymentForUpfrontLicenseFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_PaymentForUpfrontLicenseFee" xlink:to="lqda_PaymentForUpfrontLicenseFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_PaymentForUpfrontLicenseFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cash outflow for upfront license fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_PaymentForUpfrontLicenseFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment for Upfront License fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_PaymentForUpfrontLicenseFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront license fee to be paid</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AccruedAdditionalUpfrontLicenseFee" xlink:label="lqda_AccruedAdditionalUpfrontLicenseFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_AccruedAdditionalUpfrontLicenseFee" xlink:to="lqda_AccruedAdditionalUpfrontLicenseFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_AccruedAdditionalUpfrontLicenseFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of accrued additional upfront license fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_AccruedAdditionalUpfrontLicenseFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Additional Upfront License Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_AccruedAdditionalUpfrontLicenseFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued additional upfront license fee</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_MaximumPotentialDevelopmentMilestonePayments" xlink:label="lqda_MaximumPotentialDevelopmentMilestonePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_MaximumPotentialDevelopmentMilestonePayments" xlink:to="lqda_MaximumPotentialDevelopmentMilestonePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_MaximumPotentialDevelopmentMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum potential development milestone payments per the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_MaximumPotentialDevelopmentMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Potential Development Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_MaximumPotentialDevelopmentMilestonePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum potential development milestone payments</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_MaximumPotentialSalesMilestones" xlink:label="lqda_MaximumPotentialSalesMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_MaximumPotentialSalesMilestones" xlink:to="lqda_MaximumPotentialSalesMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_MaximumPotentialSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum potential sales milestones to be paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_MaximumPotentialSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Potential Sales Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_MaximumPotentialSalesMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum potential sales milestones</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_MilestonePaymentsPayable" xlink:label="lqda_MilestonePaymentsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_MilestonePaymentsPayable" xlink:to="lqda_MilestonePaymentsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_MilestonePaymentsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of milestone payments payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_MilestonePaymentsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payments Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_MilestonePaymentsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments Pharmosa is to receive per terms of the license agreement</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties" xlink:label="lqda_MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties" xlink:to="lqda_MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum net sales amount that is used as the basis in determining the payment of future contingent royalties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">lqda_MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Net Sales Threshold As Basis For Payment Of Future Contingent Royalties</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_NetSalesEarnedRelatingToPaymentOfFutureContingentRoyalties" xlink:label="lqda_NetSalesEarnedRelatingToPaymentOfFutureContingentRoyalties" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_NetSalesEarnedRelatingToPaymentOfFutureContingentRoyalties" xlink:to="lqda_NetSalesEarnedRelatingToPaymentOfFutureContingentRoyalties_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_NetSalesEarnedRelatingToPaymentOfFutureContingentRoyalties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of net sales earned by the entity relating to payment of future contingent royalties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_NetSalesEarnedRelatingToPaymentOfFutureContingentRoyalties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Sales Earned Relating To Payment Of Future Contingent Royalties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_NetSalesEarnedRelatingToPaymentOfFutureContingentRoyalties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net sales earned relating to payment of future contingent royalties</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_CommercialManufacturingServicesAndSupplyAgreementInitialTerm" xlink:label="lqda_CommercialManufacturingServicesAndSupplyAgreementInitialTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_CommercialManufacturingServicesAndSupplyAgreementInitialTerm" xlink:to="lqda_CommercialManufacturingServicesAndSupplyAgreementInitialTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_CommercialManufacturingServicesAndSupplyAgreementInitialTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial term of commercial manufacturing services and supply agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_CommercialManufacturingServicesAndSupplyAgreementInitialTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Manufacturing Services and Supply Agreement, Initial Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_CommercialManufacturingServicesAndSupplyAgreementInitialTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial term</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection" xlink:label="lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection" xlink:to="lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term term upon written notice in the event of application for regulatory approval is rejected by the FDA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Manufacturing Services and Supply Agreement, Termination Term for FDA Rejection</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination term for FDA rejection</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay" xlink:label="lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay" xlink:to="lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term term upon written notice in the event of application for regulatory approval is not received by FDA within the specified period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Manufacturing Services and Supply Agreement, Termination Term for FDA Delay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination term for FDA delay</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures" xlink:label="lqda_PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures" xlink:to="lqda_PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of reimbursement of documented out of pocket expenditures for any capital equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Reimbursement of Documented Out of Pocket Expenditures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of reimburse</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ReimbursementOfCapitalExpenditureIncurredBySupplier" xlink:label="lqda_ReimbursementOfCapitalExpenditureIncurredBySupplier" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_ReimbursementOfCapitalExpenditureIncurredBySupplier" xlink:to="lqda_ReimbursementOfCapitalExpenditureIncurredBySupplier_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_ReimbursementOfCapitalExpenditureIncurredBySupplier_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The aggregate amount of reimbursement capital expenditure incurred by the supplier after the effective date of agreement to perform the services for the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_ReimbursementOfCapitalExpenditureIncurredBySupplier_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursement of Capital Expenditure Incurred by Supplier</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_ReimbursementOfCapitalExpenditureIncurredBySupplier_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate exceed</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_TermOfSubmissionOfQuarterlyForecastOfExpectedProduction" xlink:label="lqda_TermOfSubmissionOfQuarterlyForecastOfExpectedProduction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_TermOfSubmissionOfQuarterlyForecastOfExpectedProduction" xlink:to="lqda_TermOfSubmissionOfQuarterlyForecastOfExpectedProduction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_TermOfSubmissionOfQuarterlyForecastOfExpectedProduction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of submission of quarterly forecast of expected production.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_TermOfSubmissionOfQuarterlyForecastOfExpectedProduction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of Submission of Quarterly Forecast of Expected Production</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_TermOfSubmissionOfQuarterlyForecastOfExpectedProduction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of submission</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder" xlink:label="lqda_InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder" xlink:to="lqda_InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial term of submission of quarterly forecast of expected production considered as binding firm order.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Term of Submission of Quarterly Forecast of Expected Production, Binding Firm Order</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial term</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts" xlink:label="lqda_NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts" xlink:to="lqda_NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of non-cancelable future commitments for product manufacturing and supply costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Cancelable Future Commitment For Product Manufacturing And Supply Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cancelable commitments for product manufacturing and supply costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LiquidiaPAHAndSandozMember" xlink:label="lqda_LiquidiaPAHAndSandozMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_LiquidiaPAHAndSandozMember" xlink:to="lqda_LiquidiaPAHAndSandozMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_LiquidiaPAHAndSandozMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related to Liquidia PAH and Sandoz.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_LiquidiaPAHAndSandozMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidia PAH and Sandoz [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_LiquidiaPAHAndSandozMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidia PAH and Sandoz</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation Case [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="srt_LitigationCaseTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation Case [Domain]</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_UTCAndSmithsMedicalLitigationMember" xlink:label="lqda_UTCAndSmithsMedicalLitigationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_UTCAndSmithsMedicalLitigationMember" xlink:to="lqda_UTCAndSmithsMedicalLitigationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_UTCAndSmithsMedicalLitigationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related to UTC and Smiths Medical litigation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_UTCAndSmithsMedicalLitigationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">UTC and Smiths Medical Litigation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_UTCAndSmithsMedicalLitigationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">UTC and Smiths Medical Litigation</label>
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_BreachOfContractClaimMember" xlink:label="lqda_BreachOfContractClaimMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="lqda_BreachOfContractClaimMember" xlink:to="lqda_BreachOfContractClaimMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lqda_BreachOfContractClaimMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to breach of contract claim.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lqda_BreachOfContractClaimMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Breach of Contract Claim [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lqda_BreachOfContractClaimMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Breach of contract claim</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationStatusAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_LitigationStatusDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationStatusDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PendingLitigationMember" xlink:label="us-gaap_PendingLitigationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PendingLitigationMember" xlink:to="us-gaap_PendingLitigationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PendingLitigationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pending Litigation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PendingLitigationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pending Litigation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Proceedings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="us-gaap_ProceedsFromLegalSettlements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLegalSettlements" xlink:to="us-gaap_ProceedsFromLegalSettlements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLegalSettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">us-gaap_ProceedsFromLegalSettlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLegalSettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Legal Settlements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation Settlement, Amount Awarded from Other Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Judgement amount awarded from other party</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>lqda-20240930_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/13/2024 3:23:02 AM-->
<!--Modified on: 11/13/2024 3:23:02 AM-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://liquidia.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#StatementCondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#StatementCondensedConsolidatedBalanceSheetsUnauditedParentheticals" roleURI="http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParentheticals" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" roleURI="http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" roleURI="http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureBusiness" roleURI="http://liquidia.com/role/DisclosureBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurements" roleURI="http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureInventory" roleURI="http://liquidia.com/role/DisclosureInventory" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosurePropertyPlantAndEquipment" roleURI="http://liquidia.com/role/DisclosurePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureContractAcquisitionCostsAndIntangibleAsset" roleURI="http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureIndemnificationAssetWithRelatedPartyAndLitigationFinancePayable" roleURI="http://liquidia.com/role/DisclosureIndemnificationAssetWithRelatedPartyAndLitigationFinancePayable" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities" roleURI="http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureStockholdersEquity" roleURI="http://liquidia.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureStockBasedCompensation" roleURI="http://liquidia.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureRevenueFromContractsWithCustomers" roleURI="http://liquidia.com/role/DisclosureRevenueFromContractsWithCustomers" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureLeases" roleURI="http://liquidia.com/role/DisclosureLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureRevenueInterestFinancingPayable" roleURI="http://liquidia.com/role/DisclosureRevenueInterestFinancingPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://liquidia.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureLegalProceedings" roleURI="http://liquidia.com/role/DisclosureLegalProceedings" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureSubsequentEvents" roleURI="http://liquidia.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsPolicies" roleURI="http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsTables" roleURI="http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureInventoryTables" roleURI="http://liquidia.com/role/DisclosureInventoryTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosurePropertyPlantAndEquipmentTables" roleURI="http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureContractAcquisitionCostsAndIntangibleAssetTables" roleURI="http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureStockholdersEquityTables" roleURI="http://liquidia.com/role/DisclosureStockholdersEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureStockBasedCompensationTables" roleURI="http://liquidia.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureLeasesTables" roleURI="http://liquidia.com/role/DisclosureLeasesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureRevenueInterestFinancingPayableTables" roleURI="http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureBusinessLiquidityDetails" roleURI="http://liquidia.com/role/DisclosureBusinessLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails" roleURI="http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsCommonStockEquivalentSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" roleURI="http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsCommonStockEquivalentSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsFairValueOfFinancialAssetsAndFinancialLiabilitiesDetails" roleURI="http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsFairValueOfFinancialAssetsAndFinancialLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureInventoryDetails" roleURI="http://liquidia.com/role/DisclosureInventoryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" roleURI="http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosurePropertyPlantAndEquipmentExpenseDetails" roleURI="http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureContractAcquisitionCostsAndIntangibleAssetSummaryDetails" roleURI="http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureContractAcquisitionCostsAndIntangibleAssetOtherDetails" roleURI="http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetOtherDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureIndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDetails" roleURI="http://liquidia.com/role/DisclosureIndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureStockholdersEquityDetails" roleURI="http://liquidia.com/role/DisclosureStockholdersEquityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureStockBasedCompensationOtherDetails" roleURI="http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://liquidia.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureStockBasedCompensationUnamortizedCompensationExpenseDetails" roleURI="http://liquidia.com/role/DisclosureStockBasedCompensationUnamortizedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails" roleURI="http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureStockBasedCompensationStockOptionActivityDetails" roleURI="http://liquidia.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureStockBasedCompensationRestrictedStockUnitsDetails" roleURI="http://liquidia.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureRevenueFromContractsWithCustomersDetails" roleURI="http://liquidia.com/role/DisclosureRevenueFromContractsWithCustomersDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureLeasesOtherDetails" roleURI="http://liquidia.com/role/DisclosureLeasesOtherDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureLeasesCostDetails" roleURI="http://liquidia.com/role/DisclosureLeasesCostDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureLeasesRemainingLeaseTermAndDiscountRatesDetails" roleURI="http://liquidia.com/role/DisclosureLeasesRemainingLeaseTermAndDiscountRatesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureLeasesFutureMinimumLeasePaymentsDetails" roleURI="http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureRevenueInterestFinancingPayableTermsDetails" roleURI="http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureRevenueInterestFinancingPayableSummaryDetails" roleURI="http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureRevenueInterestFinancingPayableExpectedAnnualPaymentsDetails" roleURI="http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableExpectedAnnualPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="lqda-20240930.xsd#DisclosureLegalProceedingsDetails" roleURI="http://liquidia.com/role/DisclosureLegalProceedingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://liquidia.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="995200090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638670649780929140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638670649780929140" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_638670649780929140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_638670649780929140" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638670649780929140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638670649780929140" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638670649780929140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638670649780929140" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638670649780929140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638670649780929140" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638670649780929140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638670649780929140" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638670649780929140" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638670649780929140" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638670649780939291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638670649780939291" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638670649780939291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638670649780939291" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638670649780939291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638670649780939291" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638670649780939291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638670649780939291" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638670649780939291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638670649780939291" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638670649780939291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638670649780939291" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638670649780939291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638670649780939291" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638670649780939291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638670649780939291" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638670649780949231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638670649780949231" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638670649780949231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638670649780949231" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638670649780949231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638670649780949231" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638670649780949231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638670649780949231" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638670649780949231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638670649780949231" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638670649780949231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638670649780949231" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638670649780949231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638670649780949231" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638670649780949231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638670649780949231" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638670649780959470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638670649780959470" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638670649780959470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638670649780959470" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638670649780959470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638670649780959470" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638670649780959470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638670649780959470" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638670649780959470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638670649780959470" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638670649780959470" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638670649780959470" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended" xlink:title="995200100 - Statement - Condensed Consolidated Balance Sheets (unaudited)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638670649780969133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_638670649780969133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638670649780969133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638670649780969133" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638670649780969133" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638670649780969133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638670649780969133" xlink:to="us-gaap_AccountsReceivableNetCurrent_638670649780969133" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638670649780969133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638670649780969133" xlink:to="us-gaap_InventoryNet_638670649780969133" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638670649780969133" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638670649780969133" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638670649780969133" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638670649780979143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638670649780969133" xlink:to="us-gaap_AssetsCurrent_638670649780979143" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638670649780979143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638670649780969133" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638670649780979143" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638670649780979143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638670649780969133" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638670649780979143" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_IndemnificationAssetRelatedParty" xlink:label="lqda_IndemnificationAssetRelatedParty_638670649780979143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638670649780969133" xlink:to="lqda_IndemnificationAssetRelatedParty_638670649780979143" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_BusinessCombinationContractAcquisitionCostsNet" xlink:label="lqda_BusinessCombinationContractAcquisitionCostsNet_638670649780979143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638670649780969133" xlink:to="lqda_BusinessCombinationContractAcquisitionCostsNet_638670649780979143" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638670649780979143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638670649780969133" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638670649780979143" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_638670649780979143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638670649780969133" xlink:to="us-gaap_Goodwill_638670649780979143" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638670649780979143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638670649780969133" xlink:to="us-gaap_OtherAssetsNoncurrent_638670649780979143" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638670649780979143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638670649780969133" xlink:to="us-gaap_Assets_638670649780979143" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638670649780989474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638670649780989474" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638670649780989474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638670649780989474" xlink:to="us-gaap_AccountsPayableCurrent_638670649780989474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="lqda_AccruedExpensesAndOtherLiabilitiesCurrent_638670649780989474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638670649780989474" xlink:to="lqda_AccruedExpensesAndOtherLiabilitiesCurrent_638670649780989474" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingPayableCurrent" xlink:label="lqda_RevenueInterestFinancingPayableCurrent_638670649780989474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638670649780989474" xlink:to="lqda_RevenueInterestFinancingPayableCurrent_638670649780989474" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_OperatingAndFinanceLeaseLiabilityCurrent" xlink:label="lqda_OperatingAndFinanceLeaseLiabilityCurrent_638670649780989474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638670649780989474" xlink:to="lqda_OperatingAndFinanceLeaseLiabilityCurrent_638670649780989474" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638670649780989474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638670649780989474" xlink:to="us-gaap_LiabilitiesCurrent_638670649780989474" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserveNoncurrent" xlink:label="us-gaap_LitigationReserveNoncurrent_638670649780989474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638670649780989474" xlink:to="us-gaap_LitigationReserveNoncurrent_638670649780989474" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingPayableNoncurrent" xlink:label="lqda_RevenueInterestFinancingPayableNoncurrent_638670649780999475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638670649780989474" xlink:to="lqda_RevenueInterestFinancingPayableNoncurrent_638670649780999475" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_OperatingAndFinanceLeaseLiabilityNoncurrent" xlink:label="lqda_OperatingAndFinanceLeaseLiabilityNoncurrent_638670649780999475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638670649780989474" xlink:to="lqda_OperatingAndFinanceLeaseLiabilityNoncurrent_638670649780999475" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638670649780999475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638670649780989474" xlink:to="us-gaap_Liabilities_638670649780999475" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638670649780999475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638670649780989474" xlink:to="us-gaap_CommitmentsAndContingencies_638670649780999475" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638670649780999475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_638670649780999475" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638670649780999475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638670649780999475" xlink:to="us-gaap_PreferredStockValue_638670649780999475" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638670649780999475" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638670649780999475" xlink:to="us-gaap_CommonStockValue_638670649780999475" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638670649781009286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638670649780999475" xlink:to="us-gaap_AdditionalPaidInCapital_638670649781009286" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638670649781009286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638670649780999475" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638670649781009286" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638670649781009286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638670649780999475" xlink:to="us-gaap_StockholdersEquity_638670649781009286" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638670649781009286" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638670649780999475" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638670649781009286" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParentheticals" xlink:type="extended" xlink:title="995200105 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parentheticals)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638670649781019496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638670649781019496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638670649781019496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638670649781019496" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638670649781019496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638670649781019496" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638670649781019496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638670649781019496" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638670649781019496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638670649781019496" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638670649781019496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638670649781019496" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited" xlink:type="extended" xlink:title="995200200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638670649781019496" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638670649781019496" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract_638670649781029149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_638670649781029149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638670649781029149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638670649781029149" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638670649781029149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638670649781029149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638670649781029149" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638670649781029149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638670649781029149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638670649781029149" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638670649781029149" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses_638670649781029149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638670649781029149" xlink:to="us-gaap_CostsAndExpenses_638670649781029149" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638670649781029149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract_638670649781029149" xlink:to="us-gaap_OperatingIncomeLoss_638670649781029149" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638670649781029149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638670649781029149" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638670649781029149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638670649781029149" xlink:to="us-gaap_InvestmentIncomeInterest_638670649781029149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638670649781029149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638670649781029149" xlink:to="us-gaap_InterestExpense_638670649781029149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638670649781039143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638670649781029149" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638670649781039143" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638670649781039143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638670649781029149" xlink:to="us-gaap_NonoperatingIncomeExpense_638670649781039143" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638670649781039143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638670649781029149" xlink:to="us-gaap_NetIncomeLoss_638670649781039143" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638670649781039143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638670649781029149" xlink:to="us-gaap_EarningsPerShareBasic_638670649781039143" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638670649781039143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638670649781029149" xlink:to="us-gaap_EarningsPerShareDiluted_638670649781039143" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638670649781039143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638670649781029149" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638670649781039143" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638670649781039143" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638670649781029149" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638670649781039143" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:type="extended" xlink:title="995200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638670649781049186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638670649781049186" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638670649781049186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781049186" xlink:to="us-gaap_StatementEquityComponentsAxis_638670649781049186" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638670649781049186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638670649781049186" xlink:to="us-gaap_CommonStockMember_638670649781049186" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638670649781049186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638670649781049186" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638670649781049186" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638670649781049186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638670649781049186" xlink:to="us-gaap_RetainedEarningsMember_638670649781049186" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638670649781049186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638670649781049186" xlink:to="us-gaap_EquityComponentDomain_638670649781049186" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638670649781049186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781049186" xlink:to="us-gaap_StatementLineItems_638670649781049186" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638670649781059147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781049186" xlink:to="us-gaap_StockholdersEquity_638670649781059147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638670649781059147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781049186" xlink:to="us-gaap_SharesOutstanding_638670649781059147" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638670649781059147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781049186" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638670649781059147" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638670649781059147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781049186" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638670649781059147" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits" xlink:label="lqda_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits_638670649781059147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781049186" xlink:to="lqda_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits_638670649781059147" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits" xlink:label="lqda_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits_638670649781059147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781049186" xlink:to="lqda_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits_638670649781059147" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638670649781059147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781049186" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638670649781059147" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638670649781069195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781049186" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638670649781069195" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised" xlink:label="lqda_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_638670649781069195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781049186" xlink:to="lqda_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised_638670649781069195" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_StockIssuedDuringPeriodValueCommonStockWarrantsExercised" xlink:label="lqda_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_638670649781069195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781049186" xlink:to="lqda_StockIssuedDuringPeriodValueCommonStockWarrantsExercised_638670649781069195" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638670649781069195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781049186" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638670649781069195" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638670649781069195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781049186" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638670649781069195" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638670649781069195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781049186" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638670649781069195" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638670649781069195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781049186" xlink:to="us-gaap_NetIncomeLoss_638670649781069195" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638670649781079447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781049186" xlink:to="us-gaap_StockholdersEquity_638670649781079447" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638670649781079447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781049186" xlink:to="us-gaap_SharesOutstanding_638670649781079447" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="extended" xlink:title="995200400 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638670649781079447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638670649781079447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638670649781079447" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638670649781079447" xlink:to="us-gaap_ProfitLoss_638670649781079447" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638670649781089250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638670649781089250" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AcquiredInProcessResearchAndDevelopment" xlink:label="lqda_AcquiredInProcessResearchAndDevelopment_638670649781089250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638670649781089250" xlink:to="lqda_AcquiredInProcessResearchAndDevelopment_638670649781089250" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638670649781089250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638670649781089250" xlink:to="us-gaap_ShareBasedCompensation_638670649781089250" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638670649781089250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638670649781089250" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638670649781089250" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_NoncashPortionOfLeaseExpense" xlink:label="lqda_NoncashPortionOfLeaseExpense_638670649781089250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638670649781089250" xlink:to="lqda_NoncashPortionOfLeaseExpense_638670649781089250" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets_638670649781089250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638670649781089250" xlink:to="us-gaap_GainLossOnDispositionOfAssets_638670649781089250" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638670649781089250" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638670649781089250" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638670649781089250" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AccretionAndNonCashInterestExpense" xlink:label="lqda_AccretionAndNonCashInterestExpense_638670649781099205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638670649781089250" xlink:to="lqda_AccretionAndNonCashInterestExpense_638670649781099205" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638670649781099205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638670649781099205" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables_638670649781099205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638670649781099205" xlink:to="us-gaap_IncreaseDecreaseInReceivables_638670649781099205" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638670649781099205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638670649781099205" xlink:to="us-gaap_IncreaseDecreaseInInventories_638670649781099205" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638670649781099205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638670649781099205" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638670649781099205" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638670649781099205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638670649781099205" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_638670649781099205" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638670649781099205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638670649781099205" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638670649781099205" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_638670649781099205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638670649781099205" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_638670649781099205" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="lqda_IncreaseDecreaseInOperatingLeaseLiabilities_638670649781109138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638670649781099205" xlink:to="lqda_IncreaseDecreaseInOperatingLeaseLiabilities_638670649781109138" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638670649781109138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638670649781099205" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638670649781109138" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638670649781109138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638670649781109138" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_638670649781109138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638670649781109138" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_638670649781109138" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638670649781109138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638670649781109138" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638670649781109138" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638670649781109138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638670649781109138" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638670649781109138" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638670649781119462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638670649781109138" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638670649781119462" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638670649781119462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638670649781119462" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ProceedsFromRevenueInterestFinancingNet" xlink:label="lqda_ProceedsFromRevenueInterestFinancingNet_638670649781119462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638670649781119462" xlink:to="lqda_ProceedsFromRevenueInterestFinancingNet_638670649781119462" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_638670649781119462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638670649781119462" xlink:to="us-gaap_RepaymentsOfLongTermDebt_638670649781119462" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638670649781119462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638670649781119462" xlink:to="us-gaap_RepaymentsOfDebt_638670649781119462" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PaymentsOnRevenueInterestFinancingLiability" xlink:label="lqda_PaymentsOnRevenueInterestFinancingLiability_638670649781119462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638670649781119462" xlink:to="lqda_PaymentsOnRevenueInterestFinancingLiability_638670649781119462" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638670649781129123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638670649781119462" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638670649781129123" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyReceivableProceeds" xlink:label="us-gaap_LossContingencyReceivableProceeds_638670649781129123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638670649781119462" xlink:to="us-gaap_LossContingencyReceivableProceeds_638670649781129123" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638670649781129123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638670649781119462" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638670649781129123" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_638670649781129123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638670649781119462" xlink:to="us-gaap_ProceedsFromStockPlans_638670649781129123" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638670649781129123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638670649781119462" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638670649781129123" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638670649781129123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638670649781119462" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638670649781129123" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638670649781139115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638670649781119462" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638670649781139115" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6386706497811391151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638670649781119462" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_6386706497811391151" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract_638670649781139115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract_638670649781139115" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638670649781139115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract_638670649781139115" xlink:to="us-gaap_InterestPaidNet_638670649781139115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_OperatingLeaseLiabilitiesCashPaid" xlink:label="lqda_OperatingLeaseLiabilitiesCashPaid_638670649781139115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract_638670649781139115" xlink:to="lqda_OperatingLeaseLiabilitiesCashPaid_638670649781139115" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_OfferingCostsIncurredIncludedInAccruedExpenses" xlink:label="lqda_OfferingCostsIncurredIncludedInAccruedExpenses_638670649781139115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract_638670649781139115" xlink:to="lqda_OfferingCostsIncurredIncludedInAccruedExpenses_638670649781139115" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:label="lqda_RightOfUseAssetObtainedInExchangeForLeaseLiability_638670649781149075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract_638670649781139115" xlink:to="lqda_RightOfUseAssetObtainedInExchangeForLeaseLiability_638670649781149075" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638670649781149075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract_638670649781139115" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638670649781149075" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_IncreaseInIndemnificationAssetThroughAccountsPayable" xlink:label="lqda_IncreaseInIndemnificationAssetThroughAccountsPayable_638670649781149075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowElementsAbstract_638670649781139115" xlink:to="lqda_IncreaseInIndemnificationAssetThroughAccountsPayable_638670649781149075" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureBusiness" xlink:type="extended" xlink:title="995210101 - Disclosure - Business" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_BusinessAbstract" xlink:label="lqda_BusinessAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_638670649781159093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_BusinessAbstract" xlink:to="us-gaap_NatureOfOperations_638670649781159093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurements" xlink:type="extended" xlink:title="995210201 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638670649781159093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638670649781159093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureInventory" xlink:type="extended" xlink:title="995210301 - Disclosure - Inventory" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_638670649781159093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock_638670649781159093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosurePropertyPlantAndEquipment" xlink:type="extended" xlink:title="995210401 - Disclosure - Property, Plant, and Equipment" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638670649781169100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638670649781169100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAsset" xlink:type="extended" xlink:title="995210501 - Disclosure - Contract Acquisition Costs and Intangible Asset" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract" xlink:label="lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock" xlink:label="lqda_ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock_638670649781169100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract" xlink:to="lqda_ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock_638670649781169100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureIndemnificationAssetWithRelatedPartyAndLitigationFinancePayable" xlink:type="extended" xlink:title="995210601 - Disclosure - Indemnification Asset with Related Party and Litigation Finance Payable" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_IndemnificationAssetAndLitigationFinancePayableAbstract" xlink:label="lqda_IndemnificationAssetAndLitigationFinancePayableAbstract" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_IndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDisclosureTextBlock" xlink:label="lqda_IndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDisclosureTextBlock_638670649781169100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_IndemnificationAssetAndLitigationFinancePayableAbstract" xlink:to="lqda_IndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDisclosureTextBlock_638670649781169100" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" xlink:title="995210701 - Disclosure - Accrued Expenses and Other Current Liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock" xlink:label="lqda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_638670649781179093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="lqda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock_638670649781179093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="995210801 - Disclosure - Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638670649781179093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638670649781179093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="995210901 - Disclosure - Stock-Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638670649781179093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638670649781179093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureRevenueFromContractsWithCustomers" xlink:type="extended" xlink:title="995211001 - Disclosure - Revenue From Contracts With Customers" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_638670649781189125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_638670649781189125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureLeases" xlink:type="extended" xlink:title="995211101 - Disclosure - Leases" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LeaseDisclosureTextBlock" xlink:label="lqda_LeaseDisclosureTextBlock_638670649781189125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="lqda_LeaseDisclosureTextBlock_638670649781189125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureRevenueInterestFinancingPayable" xlink:type="extended" xlink:title="995211201 - Disclosure - Revenue Interest Financing Payable" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingPayableAbstract" xlink:label="lqda_RevenueInterestFinancingPayableAbstract" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingPayableTextBlock" xlink:label="lqda_RevenueInterestFinancingPayableTextBlock_638670649781189125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableAbstract" xlink:to="lqda_RevenueInterestFinancingPayableTextBlock_638670649781189125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="995211301 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638670649781199075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638670649781199075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureLegalProceedings" xlink:type="extended" xlink:title="995211401 - Disclosure - Legal Proceedings" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LegalProceedingsDisclosureAbstract" xlink:label="lqda_LegalProceedingsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_638670649781199075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_LegalProceedingsDisclosureAbstract" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock_638670649781199075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="995211501 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638670649781199075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638670649781199075" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsPolicies" xlink:type="extended" xlink:title="99920202 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637635605880135114" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638670649781209071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637635605880135114" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638670649781209071" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638670649781209071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637635605880135114" xlink:to="us-gaap_UseOfEstimates_638670649781209071" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638670649781209071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637635605880135114" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638670649781209071" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638670649781209071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637635605880135114" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638670649781209071" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock" xlink:label="lqda_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock_638670649781209071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637635605880135114" xlink:to="lqda_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock_638670649781209071" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_638670649781209071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637635605880135114" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_638670649781209071" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock_638670649781219120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637635605880135114" xlink:to="us-gaap_InventoryPolicyTextBlock_638670649781219120" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638670649781219120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637635605880135114" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638670649781219120" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_638670649781219120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637635605880135114" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_638670649781219120" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingPayablePolicyPolicyTextBlock" xlink:label="lqda_RevenueInterestFinancingPayablePolicyPolicyTextBlock_638670649781219120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637635605880135114" xlink:to="lqda_RevenueInterestFinancingPayablePolicyPolicyTextBlock_638670649781219120" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638670649781219120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637635605880135114" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638670649781219120" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638670649781219120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637635605880135114" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638670649781219120" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AccruedResearchAndDevelopmentExpensePolicyTextBlock" xlink:label="lqda_AccruedResearchAndDevelopmentExpensePolicyTextBlock_638670649781219120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637635605880135114" xlink:to="lqda_AccruedResearchAndDevelopmentExpensePolicyTextBlock_638670649781219120" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638670649781219120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637635605880135114" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638670649781219120" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638670649781219120" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637635605880135114" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638670649781219120" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638670649781229106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637635605880135114" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_638670649781229106" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsTables" xlink:type="extended" xlink:title="99930203 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638670649781229106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638670649781229106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_638670649781229106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_638670649781229106" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureInventoryTables" xlink:type="extended" xlink:title="99930303 - Disclosure - Inventory (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638670649781229106" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_2" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638670649781229106" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentTables" xlink:type="extended" xlink:title="99930403 - Disclosure - Property, Plant, and Equipment (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638670649781239115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638670649781239115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetTables" xlink:type="extended" xlink:title="99930503 - Disclosure - Contract Acquisition Costs and Intangible Asset (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract" xlink:label="lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract_1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ScheduleOfContractAcquisitionCostsAndIntangibleAssetsTableTextBlock" xlink:label="lqda_ScheduleOfContractAcquisitionCostsAndIntangibleAssetsTableTextBlock_638670649781239115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract_1" xlink:to="lqda_ScheduleOfContractAcquisitionCostsAndIntangibleAssetsTableTextBlock_638670649781239115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" xlink:title="99930703 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract_2" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="lqda_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_638670649781239115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_2" xlink:to="lqda_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_638670649781239115" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="99930803 - Disclosure - Stockholders' Equity (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638670649781249263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638670649781249263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="99930903 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638670649781249263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable_638670649781249263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638670649781249263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781249263" xlink:to="us-gaap_PlanNameAxis_638670649781249263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638670649781249263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638670649781249263" xlink:to="us-gaap_PlanNameDomain_638670649781249263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_EmployeeStockPurchasePlan2020Member" xlink:label="lqda_EmployeeStockPurchasePlan2020Member_638670649781249263" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638670649781249263" xlink:to="lqda_EmployeeStockPurchasePlan2020Member_638670649781249263" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638670649781259103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781249263" xlink:to="us-gaap_StatementLineItems_638670649781259103" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638670649781259103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781259103" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638670649781259103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_638670649781259103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781259103" xlink:to="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_638670649781259103" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638670649781259103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781259103" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638670649781259103" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638670649781259103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781259103" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638670649781259103" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_638670649781259103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781259103" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_638670649781259103" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="99931103 - Disclosure - Leases (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638670649781269195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_4" xlink:to="us-gaap_LeaseCostTableTextBlock_638670649781269195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LeaseLiabilityMaturityTableTextBlock" xlink:label="lqda_LeaseLiabilityMaturityTableTextBlock_638670649781269195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_4" xlink:to="lqda_LeaseLiabilityMaturityTableTextBlock_638670649781269195" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTables" xlink:type="extended" xlink:title="99931203 - Disclosure - Revenue Interest Financing Payable (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingPayableAbstract" xlink:label="lqda_RevenueInterestFinancingPayableAbstract_1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ScheduleOfActivityOfRevenueInterestFinancingAgreementTableTextBlock" xlink:label="lqda_ScheduleOfActivityOfRevenueInterestFinancingAgreementTableTextBlock_638670649781269195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableAbstract_1" xlink:to="lqda_ScheduleOfActivityOfRevenueInterestFinancingAgreementTableTextBlock_638670649781269195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ScheduleOfExpectedAnnualPaymentsOnRevenueInterestFinancingAgreement" xlink:label="lqda_ScheduleOfExpectedAnnualPaymentsOnRevenueInterestFinancingAgreement_638670649781269195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableAbstract_1" xlink:to="lqda_ScheduleOfExpectedAnnualPaymentsOnRevenueInterestFinancingAgreement_638670649781269195" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureBusinessLiquidityDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - Business - Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_BusinessAbstract" xlink:label="lqda_BusinessAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638670649781269195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_BusinessAbstract" xlink:to="us-gaap_DebtInstrumentTable_638670649781269195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638670649781269195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638670649781269195" xlink:to="us-gaap_TypeOfArrangementAxis_638670649781269195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638670649781279176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638670649781269195" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638670649781279176" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementMember" xlink:label="lqda_RevenueInterestFinancingAgreementMember_638670649781279176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638670649781279176" xlink:to="lqda_RevenueInterestFinancingAgreementMember_638670649781279176" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember" xlink:label="lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember_638670649781279176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638670649781279176" xlink:to="lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember_638670649781279176" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638670649781279176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638670649781269195" xlink:to="srt_CounterpartyNameAxis_638670649781279176" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638670649781279176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638670649781279176" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638670649781279176" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_HealthcareRoyaltyPartnersIvL.pMember" xlink:label="lqda_HealthcareRoyaltyPartnersIvL.pMember_638670649781279176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638670649781279176" xlink:to="lqda_HealthcareRoyaltyPartnersIvL.pMember_638670649781279176" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638670649781279176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638670649781269195" xlink:to="srt_StatementScenarioAxis_638670649781279176" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638670649781279176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638670649781279176" xlink:to="srt_ScenarioUnspecifiedDomain_638670649781279176" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ForCalendarYearBeginningOnJanuary12024Member" xlink:label="lqda_ForCalendarYearBeginningOnJanuary12024Member_638670649781279176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638670649781279176" xlink:to="lqda_ForCalendarYearBeginningOnJanuary12024Member_638670649781279176" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AfterCalendarYearEndingOnDecember312024Member" xlink:label="lqda_AfterCalendarYearEndingOnDecember312024Member_638670649781279176" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638670649781279176" xlink:to="lqda_AfterCalendarYearEndingOnDecember312024Member_638670649781279176" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638670649781289181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638670649781269195" xlink:to="us-gaap_DebtInstrumentLineItems_638670649781289181" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638670649781289181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638670649781289181" xlink:to="us-gaap_NetIncomeLoss_638670649781289181" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638670649781289181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638670649781289181" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638670649781289181" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained" xlink:label="lqda_RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained_638670649781289181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638670649781289181" xlink:to="lqda_RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained_638670649781289181" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche" xlink:label="lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche_638670649781289181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638670649781289181" xlink:to="lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche_638670649781289181" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementAmountFunded" xlink:label="lqda_RevenueInterestFinancingAgreementAmountFunded_638670649781289181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638670649781289181" xlink:to="lqda_RevenueInterestFinancingAgreementAmountFunded_638670649781289181" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts" xlink:label="lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts_638670649781289181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638670649781289181" xlink:to="lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts_638670649781289181" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts" xlink:label="lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts_638670649781289181" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638670649781289181" xlink:to="lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts_638670649781289181" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements - Other (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638670649781299251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable_638670649781299251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_638670649781299251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781299251" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_638670649781299251" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_638670649781299251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_638670649781299251" xlink:to="us-gaap_ConcentrationRiskTypeDomain_638670649781299251" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember_638670649781299251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_638670649781299251" xlink:to="us-gaap_CreditConcentrationRiskMember_638670649781299251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_638670649781299251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781299251" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_638670649781299251" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_638670649781299251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_638670649781299251" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_638670649781299251" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember_638670649781299251" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638670649781299251" xlink:to="us-gaap_AccountsReceivableMember_638670649781299251" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_638670649781309182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781299251" xlink:to="srt_MajorCustomersAxis_638670649781309182" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638670649781309182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_638670649781309182" xlink:to="srt_NameOfMajorCustomerDomain_638670649781309182" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_CustomerOneMember" xlink:label="lqda_CustomerOneMember_638670649781309182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638670649781309182" xlink:to="lqda_CustomerOneMember_638670649781309182" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638670649781309182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781299251" xlink:to="us-gaap_StatementLineItems_638670649781309182" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638670649781309182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781309182" xlink:to="us-gaap_NumberOfOperatingSegments_638670649781309182" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_NumberOfCustomers" xlink:label="lqda_NumberOfCustomers_638670649781309182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781309182" xlink:to="lqda_NumberOfCustomers_638670649781309182" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_638670649781309182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781309182" xlink:to="us-gaap_ConcentrationRiskPercentage1_638670649781309182" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_InventoryCapitalizedCost" xlink:label="lqda_InventoryCapitalizedCost_638670649781319209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781309182" xlink:to="lqda_InventoryCapitalizedCost_638670649781319209" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_638670649781319209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781309182" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_638670649781319209" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportingUnits" xlink:label="us-gaap_NumberOfReportingUnits_638670649781319209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781309182" xlink:to="us-gaap_NumberOfReportingUnits_638670649781319209" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss_638670649781319209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781309182" xlink:to="us-gaap_GoodwillImpairmentLoss_638670649781319209" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsCommonStockEquivalentSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="99940202 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements - Common Stock Equivalent Shares Excluded From Calculation of Diluted Net Loss Per Share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638670649781319209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable_638670649781319209" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638670649781319209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781319209" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638670649781319209" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638670649781329200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638670649781319209" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638670649781329200" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638670649781329200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638670649781329200" xlink:to="us-gaap_EmployeeStockOptionMember_638670649781329200" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638670649781329200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638670649781329200" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638670649781329200" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638670649781329200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638670649781329200" xlink:to="us-gaap_WarrantMember_638670649781329200" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638670649781329200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781319209" xlink:to="us-gaap_StatementLineItems_638670649781329200" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638670649781329200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781329200" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638670649781329200" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsFairValueOfFinancialAssetsAndFinancialLiabilitiesDetails" xlink:type="extended" xlink:title="99940203 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements - Fair Value of Financial Assets and Financial Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_638670649781329200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_638670649781329200" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638670649781329200" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_638670649781329200" xlink:to="us-gaap_FinancialInstrumentAxis_638670649781329200" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638670649781339154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638670649781329200" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638670649781339154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638670649781339154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638670649781339154" xlink:to="us-gaap_MoneyMarketFundsMember_638670649781339154" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638670649781339154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_638670649781329200" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638670649781339154" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638670649781339154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638670649781339154" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638670649781339154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638670649781339154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638670649781339154" xlink:to="us-gaap_FairValueInputsLevel1Member_638670649781339154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_638670649781339154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_638670649781329200" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_638670649781339154" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_638670649781339154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_638670649781339154" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_638670649781339154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_638670649781339154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember_638670649781339154" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_638670649781339154" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_638670649781339154" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember_638670649781339154" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_638670649781339154" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_638670649781349146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_638670649781329200" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_638670649781349146" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638670649781349146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_638670649781349146" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638670649781349146" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureInventoryDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Inventory (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable_638670649781349146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract_3" xlink:to="us-gaap_InventoryCurrentTable_638670649781349146" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_638670649781349146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable_638670649781349146" xlink:to="us-gaap_BalanceSheetLocationAxis_638670649781349146" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_638670649781349146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_638670649781349146" xlink:to="us-gaap_BalanceSheetLocationDomain_638670649781349146" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember_638670649781349146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_638670649781349146" xlink:to="us-gaap_OtherNoncurrentAssetsMember_638670649781349146" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems_638670649781349146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable_638670649781349146" xlink:to="us-gaap_InventoryLineItems_638670649781349146" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_638670649781349146" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638670649781349146" xlink:to="us-gaap_InventoryRawMaterials_638670649781349146" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_638670649781359239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638670649781349146" xlink:to="us-gaap_InventoryWorkInProcess_638670649781359239" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_InventoryCurrentAndNonCurrent" xlink:label="lqda_InventoryCurrentAndNonCurrent_638670649781359239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638670649781349146" xlink:to="lqda_InventoryCurrentAndNonCurrent_638670649781359239" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638670649781359239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638670649781349146" xlink:to="us-gaap_InventoryNet_638670649781359239" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNoncurrent" xlink:label="us-gaap_InventoryNoncurrent_638670649781359239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638670649781349146" xlink:to="us-gaap_InventoryNoncurrent_638670649781359239" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_CapitalizedCostsOfInventory" xlink:label="lqda_CapitalizedCostsOfInventory_638670649781359239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems_638670649781349146" xlink:to="lqda_CapitalizedCostsOfInventory_638670649781359239" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Property, Plant, and Equipment - Schedule of Property, plant and equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637563329478017070" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638670649781359239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637563329478017070" xlink:to="us-gaap_StatementTable_638670649781359239" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638670649781359239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781359239" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638670649781359239" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638670649781369159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638670649781359239" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638670649781369159" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LabAndBuildToSuitEquipmentMember" xlink:label="lqda_LabAndBuildToSuitEquipmentMember_638670649781369159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638670649781369159" xlink:to="lqda_LabAndBuildToSuitEquipmentMember_638670649781369159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_638670649781369159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638670649781369159" xlink:to="us-gaap_OfficeEquipmentMember_638670649781369159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638670649781369159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638670649781369159" xlink:to="us-gaap_FurnitureAndFixturesMember_638670649781369159" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_638670649781369159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638670649781369159" xlink:to="us-gaap_ComputerEquipmentMember_638670649781369159" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638670649781369159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638670649781369159" xlink:to="us-gaap_LeaseholdImprovementsMember_638670649781369159" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_638670649781379262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638670649781369159" xlink:to="us-gaap_ConstructionInProgressMember_638670649781379262" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638670649781379262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781359239" xlink:to="us-gaap_StatementLineItems_638670649781379262" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638670649781379262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781379262" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638670649781379262" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638670649781379262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781379262" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638670649781379262" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638670649781379262" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781379262" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638670649781379262" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentExpenseDetails" xlink:type="extended" xlink:title="99940402 - Disclosure - Property, Plant, and Equipment - Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_638670649781389147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization_638670649781389147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetSummaryDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Contract Acquisition Costs and Intangible Asset - Summary (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract" xlink:label="lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross_638670649781389147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract_2" xlink:to="us-gaap_CapitalizedContractCostGross_638670649781389147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAccumulatedAmortization" xlink:label="us-gaap_CapitalizedContractCostAccumulatedAmortization_638670649781389147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract_2" xlink:to="us-gaap_CapitalizedContractCostAccumulatedAmortization_638670649781389147" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet_638670649781389147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract_2" xlink:to="us-gaap_CapitalizedContractCostNet_638670649781389147" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_638670649781389147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract_2" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_638670649781389147" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638670649781389147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract_2" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638670649781389147" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638670649781389147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract_2" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638670649781389147" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetOtherDetails" xlink:type="extended" xlink:title="99940502 - Disclosure - Contract Acquisition Costs and Intangible Asset - Other (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract" xlink:label="lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization_638670649781459199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract" xlink:to="us-gaap_CapitalizedContractCostAmortization_638670649781459199" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638670649781459199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638670649781459199" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureIndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Indemnification Asset with Related Party and Litigation Finance Payable (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_IndemnificationAssetAndLitigationFinancePayableAbstract" xlink:label="lqda_IndemnificationAssetAndLitigationFinancePayableAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638670649781459199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_IndemnificationAssetAndLitigationFinancePayableAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638670649781459199" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638670649781459199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638670649781459199" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638670649781459199" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638670649781469152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638670649781459199" xlink:to="us-gaap_RelatedPartyDomain_638670649781469152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PBMMember" xlink:label="lqda_PBMMember_638670649781469152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638670649781469152" xlink:to="lqda_PBMMember_638670649781469152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638670649781469152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638670649781459199" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638670649781469152" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RelatedPartyTransactionMajorStockholderOwnershipPercentageInCompany" xlink:label="lqda_RelatedPartyTransactionMajorStockholderOwnershipPercentageInCompany_638670649781469152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638670649781469152" xlink:to="lqda_RelatedPartyTransactionMajorStockholderOwnershipPercentageInCompany_638670649781469152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638670649781469152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_1" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638670649781469152" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AccruedResearchAndDevelopmentExpenses" xlink:label="lqda_AccruedResearchAndDevelopmentExpenses_638670649781469152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_1" xlink:to="lqda_AccruedResearchAndDevelopmentExpenses_638670649781469152" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AccruedInventoryCosts" xlink:label="lqda_AccruedInventoryCosts_638670649781469152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_1" xlink:to="lqda_AccruedInventoryCosts_638670649781469152" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_638670649781469152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_1" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_638670649781469152" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AccruedExpensesAndOtherLiabilitiesCurrent" xlink:label="lqda_AccruedExpensesAndOtherLiabilitiesCurrent_638670649781469152" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract_1" xlink:to="lqda_AccruedExpensesAndOtherLiabilitiesCurrent_638670649781469152" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Stockholders' Equity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638670649781479142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StatementTable_638670649781479142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638670649781479142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781479142" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638670649781479142" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638670649781479142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638670649781479142" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638670649781479142" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_638670649781479142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638670649781479142" xlink:to="us-gaap_PrivatePlacementMember_638670649781479142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_UnderwrittenPublicOfferingMember" xlink:label="lqda_UnderwrittenPublicOfferingMember_638670649781479142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638670649781479142" xlink:to="lqda_UnderwrittenPublicOfferingMember_638670649781479142" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638670649781479142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781479142" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638670649781479142" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638670649781479142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638670649781479142" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638670649781479142" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ArSvbWarrantsInitialTrancheMember" xlink:label="lqda_ArSvbWarrantsInitialTrancheMember_638670649781479142" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638670649781479142" xlink:to="lqda_ArSvbWarrantsInitialTrancheMember_638670649781479142" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_SvbWarrantInitialTrancheMember" xlink:label="lqda_SvbWarrantInitialTrancheMember_638670649781489198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638670649781479142" xlink:to="lqda_SvbWarrantInitialTrancheMember_638670649781489198" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_SvbWarrantTermBAndTermCTranchesMember" xlink:label="lqda_SvbWarrantTermBAndTermCTranchesMember_638670649781489198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638670649781479142" xlink:to="lqda_SvbWarrantTermBAndTermCTranchesMember_638670649781489198" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_OtherWarrantsMember" xlink:label="lqda_OtherWarrantsMember_638670649781489198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638670649781479142" xlink:to="lqda_OtherWarrantsMember_638670649781489198" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_WarrantsToPurchaseCommonStockMember" xlink:label="lqda_WarrantsToPurchaseCommonStockMember_638670649781489198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638670649781479142" xlink:to="lqda_WarrantsToPurchaseCommonStockMember_638670649781489198" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638670649781489198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781479142" xlink:to="srt_TitleOfIndividualAxis_638670649781489198" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638670649781489198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638670649781489198" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638670649781489198" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_BoardOfDirectorsMember" xlink:label="lqda_BoardOfDirectorsMember_638670649781489198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638670649781489198" xlink:to="lqda_BoardOfDirectorsMember_638670649781489198" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LargestStockholderAndMemberOfBoardOfDirectorsMember" xlink:label="lqda_LargestStockholderAndMemberOfBoardOfDirectorsMember_638670649781489198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638670649781489198" xlink:to="lqda_LargestStockholderAndMemberOfBoardOfDirectorsMember_638670649781489198" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_CaliganPartnersLPMember" xlink:label="lqda_CaliganPartnersLPMember_638670649781489198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638670649781489198" xlink:to="lqda_CaliganPartnersLPMember_638670649781489198" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_Mr.PaulB.ManningMember" xlink:label="lqda_Mr.PaulB.ManningMember_638670649781499147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638670649781489198" xlink:to="lqda_Mr.PaulB.ManningMember_638670649781499147" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_638670649781499147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638670649781489198" xlink:to="srt_ChiefExecutiveOfficerMember_638670649781499147" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638670649781499147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781479142" xlink:to="srt_RangeAxis_638670649781499147" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638670649781499147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638670649781499147" xlink:to="srt_RangeMember_638670649781499147" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638670649781499147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638670649781499147" xlink:to="srt_MaximumMember_638670649781499147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638670649781499147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781479142" xlink:to="us-gaap_StatementLineItems_638670649781499147" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638670649781499147" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781499147" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638670649781499147" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_638670649781509237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781499147" xlink:to="us-gaap_SharesIssuedPricePerShare_638670649781509237" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_638670649781509237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781499147" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_638670649781509237" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638670649781509237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781499147" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638670649781509237" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ProceedsFromIssuanceOfCommonStockNet" xlink:label="lqda_ProceedsFromIssuanceOfCommonStockNet_638670649781509237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781499147" xlink:to="lqda_ProceedsFromIssuanceOfCommonStockNet_638670649781509237" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638670649781509237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781499147" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638670649781509237" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638670649781509237" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781499147" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638670649781509237" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="lqda_ClassOfWarrantOrRightExercisedDuringPeriod_638670649781519195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781499147" xlink:to="lqda_ClassOfWarrantOrRightExercisedDuringPeriod_638670649781519195" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638670649781519195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781499147" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638670649781519195" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638670649781519195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781499147" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638670649781519195" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts" xlink:label="lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts_638670649781519195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781499147" xlink:to="lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts_638670649781519195" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts" xlink:label="lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts_638670649781519195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781499147" xlink:to="lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts_638670649781519195" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638670649781519195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781499147" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638670649781519195" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Stock-Based Compensation - Other (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638670649781529149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable_638670649781529149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638670649781529149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781529149" xlink:to="us-gaap_PlanNameAxis_638670649781529149" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638670649781529149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638670649781529149" xlink:to="us-gaap_PlanNameDomain_638670649781529149" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_The2020PlanMember" xlink:label="lqda_The2020PlanMember_638670649781529149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638670649781529149" xlink:to="lqda_The2020PlanMember_638670649781529149" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_InducementPlan2022Member" xlink:label="lqda_InducementPlan2022Member_638670649781529149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638670649781529149" xlink:to="lqda_InducementPlan2022Member_638670649781529149" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_EmployeeStockPurchasePlan2020Member" xlink:label="lqda_EmployeeStockPurchasePlan2020Member_638670649781529149" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638670649781529149" xlink:to="lqda_EmployeeStockPurchasePlan2020Member_638670649781529149" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638670649781539244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781529149" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638670649781539244" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638670649781539244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638670649781539244" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638670649781539244" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638670649781539244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638670649781539244" xlink:to="us-gaap_EmployeeStockOptionMember_638670649781539244" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638670649781539244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781529149" xlink:to="us-gaap_VestingAxis_638670649781539244" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638670649781539244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638670649781539244" xlink:to="us-gaap_VestingDomain_638670649781539244" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638670649781539244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638670649781539244" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638670649781539244" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638670649781539244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638670649781539244" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638670649781539244" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638670649781539244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781529149" xlink:to="us-gaap_StatementEquityComponentsAxis_638670649781539244" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638670649781539244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638670649781539244" xlink:to="us-gaap_EquityComponentDomain_638670649781539244" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638670649781549185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_638670649781539244" xlink:to="us-gaap_CommonStockMember_638670649781549185" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638670649781549185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781529149" xlink:to="us-gaap_AwardTypeAxis_638670649781549185" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638670649781549185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638670649781549185" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638670649781549185" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638670649781549185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638670649781549185" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638670649781549185" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PerformanceBasedRestrictedStockUnitsMember" xlink:label="lqda_PerformanceBasedRestrictedStockUnitsMember_638670649781549185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638670649781549185" xlink:to="lqda_PerformanceBasedRestrictedStockUnitsMember_638670649781549185" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638670649781549185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781529149" xlink:to="us-gaap_StatementLineItems_638670649781549185" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentAnnualIncreaseInCapitalShareReservedForFutureIssuance" xlink:label="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentAnnualIncreaseInCapitalShareReservedForFutureIssuance_638670649781549185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781549185" xlink:to="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentAnnualIncreaseInCapitalShareReservedForFutureIssuance_638670649781549185" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638670649781549185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781549185" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_638670649781549185" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638670649781559245" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781549185" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638670649781559245" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638670649781559245" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781549185" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638670649781559245" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding" xlink:label="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding_638670649781559245" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781549185" xlink:to="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding_638670649781559245" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuance" xlink:label="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuance_638670649781559245" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781549185" xlink:to="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuance_638670649781559245" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAvailableForIssuance" xlink:label="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAvailableForIssuance_638670649781559245" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781549185" xlink:to="lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAvailableForIssuance_638670649781559245" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638670649781559245" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781549185" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_638670649781559245" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638670649781559245" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781549185" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638670649781559245" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638670649781569659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781549185" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638670649781569659" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638670649781569659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781549185" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638670649781569659" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638670649781569659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781549185" xlink:to="us-gaap_SharePrice_638670649781569659" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638670649781569659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781549185" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638670649781569659" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638670649781569659" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781549185" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638670649781569659" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - Stock-Based Compensation - Stock-based Compensation Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638670649781579162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable_638670649781579162" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638670649781579162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781579162" xlink:to="us-gaap_IncomeStatementLocationAxis_638670649781579162" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638670649781579162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638670649781579162" xlink:to="us-gaap_IncomeStatementLocationDomain_638670649781579162" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_638670649781579162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638670649781579162" xlink:to="us-gaap_CostOfSalesMember_638670649781579162" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638670649781579162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638670649781579162" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638670649781579162" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638670649781579162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638670649781579162" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638670649781579162" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638670649781579162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781579162" xlink:to="us-gaap_StatementLineItems_638670649781579162" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638670649781589280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781579162" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638670649781589280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureStockBasedCompensationUnamortizedCompensationExpenseDetails" xlink:type="extended" xlink:title="99940903 - Disclosure - Stock-Based Compensation - Unamortized Compensation Expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638670649781589280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable_638670649781589280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638670649781589280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781589280" xlink:to="us-gaap_AwardTypeAxis_638670649781589280" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638670649781589280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638670649781589280" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638670649781589280" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638670649781589280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638670649781589280" xlink:to="us-gaap_EmployeeStockOptionMember_638670649781589280" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638670649781589280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638670649781589280" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638670649781589280" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638670649781589280" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781589280" xlink:to="us-gaap_StatementLineItems_638670649781589280" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638670649781599199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781589280" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638670649781599199" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638670649781599199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781589280" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638670649781599199" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails" xlink:type="extended" xlink:title="99940904 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options Granted and Purchase Rights Issued under the ESPP (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638670649781599199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_StatementTable_638670649781599199" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638670649781599199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781599199" xlink:to="us-gaap_PlanNameAxis_638670649781599199" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638670649781599199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638670649781599199" xlink:to="us-gaap_PlanNameDomain_638670649781599199" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_EmployeeStockPurchasePlan2020Member" xlink:label="lqda_EmployeeStockPurchasePlan2020Member_638670649781599199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638670649781599199" xlink:to="lqda_EmployeeStockPurchasePlan2020Member_638670649781599199" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638670649781599199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781599199" xlink:to="us-gaap_AwardTypeAxis_638670649781599199" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638670649781599199" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638670649781599199" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638670649781599199" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638670649781609456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638670649781599199" xlink:to="us-gaap_EmployeeStockOptionMember_638670649781609456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_EmployeePurchaseRightsMember" xlink:label="lqda_EmployeePurchaseRightsMember_638670649781609456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638670649781599199" xlink:to="lqda_EmployeePurchaseRightsMember_638670649781609456" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638670649781609456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781599199" xlink:to="srt_RangeAxis_638670649781609456" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638670649781609456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638670649781609456" xlink:to="srt_RangeMember_638670649781609456" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638670649781609456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638670649781609456" xlink:to="srt_MinimumMember_638670649781609456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638670649781609456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638670649781609456" xlink:to="srt_MaximumMember_638670649781609456" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638670649781609456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781599199" xlink:to="us-gaap_StatementLineItems_638670649781609456" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638670649781609456" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781609456" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638670649781609456" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638670649781619139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781609456" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638670649781619139" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638670649781619139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781609456" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638670649781619139" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638670649781619139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781609456" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638670649781619139" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638670649781619139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781609456" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_638670649781619139" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638670649781619139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781609456" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_638670649781619139" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638670649781619139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781609456" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638670649781619139" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638670649781619139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781609456" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638670649781619139" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638670649781619139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781609456" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638670649781619139" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="99940905 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638670649781629285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638670649781629285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638670649781629285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638670649781629285" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638670649781629285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638670649781629285" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638670649781629285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638670649781629285" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638670649781629285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638670649781629285" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638670649781629285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638670649781629285" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_638670649781639278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_638670649781639278" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_638670649781639278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_638670649781639278" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638670649781639278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638670649781639278" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638670649781639278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638670649781639278" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638670649781639278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638670649781639278" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638670649781639278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638670649781639278" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638670649781639278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638670649781639278" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638670649781639278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638670649781639278" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638670649781639278" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638670649781639278" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638670649781649462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638670649781649462" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638670649781649462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638670649781649462" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638670649781649462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638670649781649462" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638670649781649462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638670649781649462" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_638670649781649462" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_638670649781649462" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="99940906 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638670649781659137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable_638670649781659137" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638670649781659137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781659137" xlink:to="us-gaap_AwardTypeAxis_638670649781659137" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638670649781659137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638670649781659137" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638670649781659137" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638670649781659137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638670649781659137" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638670649781659137" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638670649781659137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781659137" xlink:to="us-gaap_StatementLineItems_638670649781659137" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638670649781659137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781659137" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638670649781659137" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638670649781659137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781659137" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638670649781659137" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638670649781659137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781659137" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638670649781659137" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638670649781659137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781659137" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638670649781659137" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638670649781659137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781659137" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638670649781659137" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638670649781669256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781659137" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638670649781669256" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638670649781669256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781659137" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638670649781669256" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638670649781669256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781659137" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638670649781669256" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638670649781669256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781659137" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638670649781669256" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638670649781669256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781659137" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638670649781669256" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureRevenueFromContractsWithCustomersDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Revenue From Contracts With Customers (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638670649781669256" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_StatementTable_638670649781669256" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638670649781679458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781669256" xlink:to="srt_CounterpartyNameAxis_638670649781679458" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638670649781679458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638670649781679458" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638670649781679458" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_SandozMember" xlink:label="lqda_SandozMember_638670649781679458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638670649781679458" xlink:to="lqda_SandozMember_638670649781679458" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638670649781679458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781669256" xlink:to="us-gaap_StatementLineItems_638670649781679458" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PromotionAgreementPayment" xlink:label="lqda_PromotionAgreementPayment_638670649781679458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781679458" xlink:to="lqda_PromotionAgreementPayment_638670649781679458" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerRefundLiability" xlink:label="us-gaap_ContractWithCustomerRefundLiability_638670649781679458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781679458" xlink:to="us-gaap_ContractWithCustomerRefundLiability_638670649781679458" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PercentageOfRevenueFromPromotionAgreement" xlink:label="lqda_PercentageOfRevenueFromPromotionAgreement_638670649781679458" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781679458" xlink:to="lqda_PercentageOfRevenueFromPromotionAgreement_638670649781679458" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureLeasesOtherDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - Leases - Other (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeaseDiscountRate" xlink:label="us-gaap_LesseeFinanceLeaseDiscountRate_638670649781689151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_LesseeFinanceLeaseDiscountRate_638670649781689151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_638670649781689151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_638670649781689151" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AgreementExpirationTerm" xlink:label="lqda_AgreementExpirationTerm_638670649781689151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="lqda_AgreementExpirationTerm_638670649781689151" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638670649781689151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638670649781689151" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638670649781689151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638670649781689151" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureLeasesCostDetails" xlink:type="extended" xlink:title="99941102 - Disclosure - Leases - Cost (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638670649781689151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638670649781689151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638670649781689151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638670649781689151" xlink:to="us-gaap_IncomeStatementLocationAxis_638670649781689151" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638670649781689151" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638670649781689151" xlink:to="us-gaap_IncomeStatementLocationDomain_638670649781689151" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638670649781699474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638670649781689151" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638670649781699474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638670649781699474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638670649781689151" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638670649781699474" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember_638670649781699474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638670649781689151" xlink:to="us-gaap_InterestExpenseMember_638670649781699474" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638670649781699474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638670649781689151" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638670649781699474" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638670649781699474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638670649781699474" xlink:to="us-gaap_OperatingLeaseCost_638670649781699474" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638670649781699474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638670649781699474" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638670649781699474" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense_638670649781699474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638670649781699474" xlink:to="us-gaap_FinanceLeaseInterestExpense_638670649781699474" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_638670649781699474" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638670649781699474" xlink:to="us-gaap_LeaseCost_638670649781699474" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureLeasesRemainingLeaseTermAndDiscountRatesDetails" xlink:type="extended" xlink:title="99941103 - Disclosure - Leases - Remaining Lease Term and Discount Rates (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638670649781709472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_5" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638670649781709472" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638670649781709472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_5" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638670649781709472" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638670649781709472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_5" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638670649781709472" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638670649781709472" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_5" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638670649781709472" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended" xlink:title="99941104 - Disclosure - Leases - Future Minimum Lease Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638670649781719136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_3" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638670649781719136" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_638670649781719136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638670649781719136" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_638670649781719136" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638670649781719136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638670649781719136" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638670649781719136" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638670649781719136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638670649781719136" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638670649781719136" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638670649781719136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638670649781719136" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638670649781719136" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638670649781719136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638670649781719136" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638670649781719136" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638670649781719136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638670649781719136" xlink:to="us-gaap_OperatingLeaseLiability_638670649781719136" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638670649781719136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_3" xlink:to="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638670649781719136" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_638670649781719136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638670649781719136" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_638670649781719136" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638670649781729455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638670649781719136" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638670649781729455" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638670649781729455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638670649781719136" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638670649781729455" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_638670649781729455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638670649781719136" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_638670649781729455" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638670649781729455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638670649781719136" xlink:to="us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_638670649781729455" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638670649781729455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_638670649781719136" xlink:to="us-gaap_FinanceLeaseLiability_638670649781729455" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract_638670649781729455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_3" xlink:to="us-gaap_LesseeDisclosureAbstract_638670649781729455" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LeaseLiabilityPaymentsDueRemainderOfFiscalYear" xlink:label="lqda_LeaseLiabilityPaymentsDueRemainderOfFiscalYear_638670649781729455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_638670649781729455" xlink:to="lqda_LeaseLiabilityPaymentsDueRemainderOfFiscalYear_638670649781729455" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="lqda_LeaseLiabilityPaymentsDueNextTwelveMonths_638670649781729455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_638670649781729455" xlink:to="lqda_LeaseLiabilityPaymentsDueNextTwelveMonths_638670649781729455" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LeaseLiabilityPaymentsDueYearTwo" xlink:label="lqda_LeaseLiabilityPaymentsDueYearTwo_638670649781729455" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_638670649781729455" xlink:to="lqda_LeaseLiabilityPaymentsDueYearTwo_638670649781729455" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LeaseLiabilityPaymentsDueTotal" xlink:label="lqda_LeaseLiabilityPaymentsDueTotal_638670649781739244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_638670649781729455" xlink:to="lqda_LeaseLiabilityPaymentsDueTotal_638670649781739244" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LeaseLiabilityUndiscountedExcessAmount" xlink:label="lqda_LeaseLiabilityUndiscountedExcessAmount_638670649781739244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_638670649781729455" xlink:to="lqda_LeaseLiabilityUndiscountedExcessAmount_638670649781739244" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LeaseLiability" xlink:label="lqda_LeaseLiability_638670649781739244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract_638670649781729455" xlink:to="lqda_LeaseLiability_638670649781739244" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - Revenue Interest Financing Payable - Terms (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingPayableAbstract" xlink:label="lqda_RevenueInterestFinancingPayableAbstract_2" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingPayableTable" xlink:label="lqda_RevenueInterestFinancingPayableTable_638670649781739244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableAbstract_2" xlink:to="lqda_RevenueInterestFinancingPayableTable_638670649781739244" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638670649781739244" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableTable_638670649781739244" xlink:to="us-gaap_TypeOfArrangementAxis_638670649781739244" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638670649781749567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638670649781739244" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638670649781749567" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementMember" xlink:label="lqda_RevenueInterestFinancingAgreementMember_638670649781749567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638670649781749567" xlink:to="lqda_RevenueInterestFinancingAgreementMember_638670649781749567" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember" xlink:label="lqda_SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember_638670649781749567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638670649781749567" xlink:to="lqda_SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember_638670649781749567" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_FourthAmendmentToRevenueInterestFinancingAgreementMember" xlink:label="lqda_FourthAmendmentToRevenueInterestFinancingAgreementMember_638670649781749567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638670649781749567" xlink:to="lqda_FourthAmendmentToRevenueInterestFinancingAgreementMember_638670649781749567" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember" xlink:label="lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember_638670649781749567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638670649781749567" xlink:to="lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember_638670649781749567" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638670649781749567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableTable_638670649781739244" xlink:to="us-gaap_DebtInstrumentAxis_638670649781749567" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638670649781749567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638670649781749567" xlink:to="us-gaap_DebtInstrumentNameDomain_638670649781749567" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ArSiliconValleyBankTermLoansMember" xlink:label="lqda_ArSiliconValleyBankTermLoansMember_638670649781749567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638670649781749567" xlink:to="lqda_ArSiliconValleyBankTermLoansMember_638670649781749567" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638670649781749567" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableTable_638670649781739244" xlink:to="srt_StatementScenarioAxis_638670649781749567" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638670649781759194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638670649781749567" xlink:to="srt_ScenarioUnspecifiedDomain_638670649781759194" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_OnFirstFundedPortionOfInvestmentAmountMember" xlink:label="lqda_OnFirstFundedPortionOfInvestmentAmountMember_638670649781759194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638670649781759194" xlink:to="lqda_OnFirstFundedPortionOfInvestmentAmountMember_638670649781759194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_OnSecondPortionOfFundedInvestmentAmountMember" xlink:label="lqda_OnSecondPortionOfFundedInvestmentAmountMember_638670649781759194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638670649781759194" xlink:to="lqda_OnSecondPortionOfFundedInvestmentAmountMember_638670649781759194" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingPayableLineItems" xlink:label="lqda_RevenueInterestFinancingPayableLineItems_638670649781759194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableTable_638670649781739244" xlink:to="lqda_RevenueInterestFinancingPayableLineItems_638670649781759194" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementMaximumInvestmentAmount" xlink:label="lqda_RevenueInterestFinancingAgreementMaximumInvestmentAmount_638670649781759194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableLineItems_638670649781759194" xlink:to="lqda_RevenueInterestFinancingAgreementMaximumInvestmentAmount_638670649781759194" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementNumberOfTranches" xlink:label="lqda_RevenueInterestFinancingAgreementNumberOfTranches_638670649781759194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableLineItems_638670649781759194" xlink:to="lqda_RevenueInterestFinancingAgreementNumberOfTranches_638670649781759194" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementInitialInvestmentAmount" xlink:label="lqda_RevenueInterestFinancingAgreementInitialInvestmentAmount_638670649781759194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableLineItems_638670649781759194" xlink:to="lqda_RevenueInterestFinancingAgreementInitialInvestmentAmount_638670649781759194" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638670649781759194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableLineItems_638670649781759194" xlink:to="us-gaap_RepaymentsOfDebt_638670649781759194" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638670649781759194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableLineItems_638670649781759194" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638670649781759194" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche" xlink:label="lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche_638670649781769137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableLineItems_638670649781759194" xlink:to="lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche_638670649781769137" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementHardCapPercentage" xlink:label="lqda_RevenueInterestFinancingAgreementHardCapPercentage_638670649781769137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableLineItems_638670649781759194" xlink:to="lqda_RevenueInterestFinancingAgreementHardCapPercentage_638670649781769137" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementInternalRateOfReturn" xlink:label="lqda_RevenueInterestFinancingAgreementInternalRateOfReturn_638670649781769137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableLineItems_638670649781759194" xlink:to="lqda_RevenueInterestFinancingAgreementInternalRateOfReturn_638670649781769137" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PercentageOfInvestmentAmountToBeRepaidOnFinalApproval" xlink:label="lqda_PercentageOfInvestmentAmountToBeRepaidOnFinalApproval_638670649781769137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableLineItems_638670649781759194" xlink:to="lqda_PercentageOfInvestmentAmountToBeRepaidOnFinalApproval_638670649781769137" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PercentageOfInvestmentAmountToBePaid" xlink:label="lqda_PercentageOfInvestmentAmountToBePaid_638670649781769137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableLineItems_638670649781759194" xlink:to="lqda_PercentageOfInvestmentAmountToBePaid_638670649781769137" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedDuringYearTwo" xlink:label="lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedDuringYearTwo_638670649781769137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableLineItems_638670649781759194" xlink:to="lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedDuringYearTwo_638670649781769137" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedAfterYearTwo" xlink:label="lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedAfterYearTwo_638670649781769137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableLineItems_638670649781759194" xlink:to="lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedAfterYearTwo_638670649781769137" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementAmountFunded" xlink:label="lqda_RevenueInterestFinancingAgreementAmountFunded_638670649781769137" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableLineItems_638670649781759194" xlink:to="lqda_RevenueInterestFinancingAgreementAmountFunded_638670649781769137" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementIssuanceCosts" xlink:label="lqda_RevenueInterestFinancingAgreementIssuanceCosts_638670649781779301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableLineItems_638670649781759194" xlink:to="lqda_RevenueInterestFinancingAgreementIssuanceCosts_638670649781779301" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementEffectiveAnnualInterestRate" xlink:label="lqda_RevenueInterestFinancingAgreementEffectiveAnnualInterestRate_638670649781779301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableLineItems_638670649781759194" xlink:to="lqda_RevenueInterestFinancingAgreementEffectiveAnnualInterestRate_638670649781779301" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableSummaryDetails" xlink:type="extended" xlink:title="99941202 - Disclosure - Revenue Interest Financing Payable - Summary (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingPayableAbstract" xlink:label="lqda_RevenueInterestFinancingPayableAbstract_3" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreement" xlink:label="lqda_RevenueInterestFinancingAgreement_638670649781779301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableAbstract_3" xlink:to="lqda_RevenueInterestFinancingAgreement_638670649781779301" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementIssuanceCosts" xlink:label="lqda_RevenueInterestFinancingAgreementIssuanceCosts_638670649781779301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableAbstract_3" xlink:to="lqda_RevenueInterestFinancingAgreementIssuanceCosts_638670649781779301" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche" xlink:label="lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche_638670649781789159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableAbstract_3" xlink:to="lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche_638670649781789159" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_638670649781789159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableAbstract_3" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_638670649781789159" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementAccretion" xlink:label="lqda_RevenueInterestFinancingAgreementAccretion_638670649781789159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableAbstract_3" xlink:to="lqda_RevenueInterestFinancingAgreementAccretion_638670649781789159" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementAmortizationOfDebtDiscount" xlink:label="lqda_RevenueInterestFinancingAgreementAmortizationOfDebtDiscount_638670649781789159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableAbstract_3" xlink:to="lqda_RevenueInterestFinancingAgreementAmortizationOfDebtDiscount_638670649781789159" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PaymentsOnRevenueInterestFinancingLiability" xlink:label="lqda_PaymentsOnRevenueInterestFinancingLiability_638670649781789159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableAbstract_3" xlink:to="lqda_PaymentsOnRevenueInterestFinancingLiability_638670649781789159" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreement" xlink:label="lqda_RevenueInterestFinancingAgreement_638670649781789159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableAbstract_3" xlink:to="lqda_RevenueInterestFinancingAgreement_638670649781789159" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingPayableCurrent" xlink:label="lqda_RevenueInterestFinancingPayableCurrent_638670649781789159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableAbstract_3" xlink:to="lqda_RevenueInterestFinancingPayableCurrent_638670649781789159" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingPayableNoncurrent" xlink:label="lqda_RevenueInterestFinancingPayableNoncurrent_638670649781789159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableAbstract_3" xlink:to="lqda_RevenueInterestFinancingPayableNoncurrent_638670649781789159" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableExpectedAnnualPaymentsDetails" xlink:type="extended" xlink:title="99941203 - Disclosure - Revenue Interest Financing Payable - Expected Annual Payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingPayableAbstract" xlink:label="lqda_RevenueInterestFinancingPayableAbstract_4" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear_638670649781789159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableAbstract_4" xlink:to="lqda_RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear_638670649781789159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearOne" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearOne_638670649781799150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableAbstract_4" xlink:to="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearOne_638670649781799150" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearTwo" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearTwo_638670649781799150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableAbstract_4" xlink:to="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearTwo_638670649781799150" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearThree" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearThree_638670649781799150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableAbstract_4" xlink:to="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearThree_638670649781799150" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFour" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFour_638670649781799150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableAbstract_4" xlink:to="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFour_638670649781799150" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFiveAndThereafter" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFiveAndThereafter_638670649781799150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableAbstract_4" xlink:to="lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFiveAndThereafter_638670649781799150" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal" xlink:label="lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal_638670649781799150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_RevenueInterestFinancingPayableAbstract_4" xlink:to="lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal_638670649781799150" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="99941301 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638670649781799150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_StatementTable_638670649781799150" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis_638670649781799150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781799150" xlink:to="us-gaap_OtherCommitmentsAxis_638670649781799150" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain_638670649781799150" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis_638670649781799150" xlink:to="us-gaap_OtherCommitmentsDomain_638670649781799150" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PharmosaLicenseAgreementMember" xlink:label="lqda_PharmosaLicenseAgreementMember_638670649781809489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain_638670649781799150" xlink:to="lqda_PharmosaLicenseAgreementMember_638670649781809489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ChasmTechnologiesAgreementMember" xlink:label="lqda_ChasmTechnologiesAgreementMember_638670649781809489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain_638670649781799150" xlink:to="lqda_ChasmTechnologiesAgreementMember_638670649781809489" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AgreementWithLGMPharmaLLCMember" xlink:label="lqda_AgreementWithLGMPharmaLLCMember_638670649781809489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain_638670649781799150" xlink:to="lqda_AgreementWithLGMPharmaLLCMember_638670649781809489" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember" xlink:label="lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember_638670649781809489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain_638670649781799150" xlink:to="lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember_638670649781809489" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638670649781809489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781799150" xlink:to="srt_StatementGeographicalAxis_638670649781809489" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638670649781809489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638670649781809489" xlink:to="srt_SegmentGeographicalDomain_638670649781809489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember" xlink:label="srt_NorthAmericaMember_638670649781809489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638670649781809489" xlink:to="srt_NorthAmericaMember_638670649781809489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_OtherThenNorthAmericaMember" xlink:label="lqda_OtherThenNorthAmericaMember_638670649781809489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638670649781809489" xlink:to="lqda_OtherThenNorthAmericaMember_638670649781809489" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638670649781809489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638670649781799150" xlink:to="us-gaap_StatementLineItems_638670649781809489" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PaymentForUpfrontLicenseFee" xlink:label="lqda_PaymentForUpfrontLicenseFee_638670649781809489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781809489" xlink:to="lqda_PaymentForUpfrontLicenseFee_638670649781809489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AccruedAdditionalUpfrontLicenseFee" xlink:label="lqda_AccruedAdditionalUpfrontLicenseFee_638670649781819139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781809489" xlink:to="lqda_AccruedAdditionalUpfrontLicenseFee_638670649781819139" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_MaximumPotentialDevelopmentMilestonePayments" xlink:label="lqda_MaximumPotentialDevelopmentMilestonePayments_638670649781819139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781809489" xlink:to="lqda_MaximumPotentialDevelopmentMilestonePayments_638670649781819139" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_MaximumPotentialSalesMilestones" xlink:label="lqda_MaximumPotentialSalesMilestones_638670649781819139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781809489" xlink:to="lqda_MaximumPotentialSalesMilestones_638670649781819139" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_MilestonePaymentsPayable" xlink:label="lqda_MilestonePaymentsPayable_638670649781819139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781809489" xlink:to="lqda_MilestonePaymentsPayable_638670649781819139" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties" xlink:label="lqda_MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties_638670649781819139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781809489" xlink:to="lqda_MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties_638670649781819139" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_NetSalesEarnedRelatingToPaymentOfFutureContingentRoyalties" xlink:label="lqda_NetSalesEarnedRelatingToPaymentOfFutureContingentRoyalties_638670649781819139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781809489" xlink:to="lqda_NetSalesEarnedRelatingToPaymentOfFutureContingentRoyalties_638670649781819139" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_CommercialManufacturingServicesAndSupplyAgreementInitialTerm" xlink:label="lqda_CommercialManufacturingServicesAndSupplyAgreementInitialTerm_638670649781819139" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781809489" xlink:to="lqda_CommercialManufacturingServicesAndSupplyAgreementInitialTerm_638670649781819139" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection" xlink:label="lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection_638670649781829451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781809489" xlink:to="lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection_638670649781829451" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay" xlink:label="lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay_638670649781829451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781809489" xlink:to="lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay_638670649781829451" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures" xlink:label="lqda_PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures_638670649781829451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781809489" xlink:to="lqda_PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures_638670649781829451" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_ReimbursementOfCapitalExpenditureIncurredBySupplier" xlink:label="lqda_ReimbursementOfCapitalExpenditureIncurredBySupplier_638670649781829451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781809489" xlink:to="lqda_ReimbursementOfCapitalExpenditureIncurredBySupplier_638670649781829451" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_TermOfSubmissionOfQuarterlyForecastOfExpectedProduction" xlink:label="lqda_TermOfSubmissionOfQuarterlyForecastOfExpectedProduction_638670649781829451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781809489" xlink:to="lqda_TermOfSubmissionOfQuarterlyForecastOfExpectedProduction_638670649781829451" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder" xlink:label="lqda_InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder_638670649781829451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781809489" xlink:to="lqda_InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder_638670649781829451" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_638670649781829451" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781809489" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_638670649781829451" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts" xlink:label="lqda_NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts_638670649781839465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781809489" xlink:to="lqda_NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts_638670649781839465" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_AgreementExpirationTerm" xlink:label="lqda_AgreementExpirationTerm_638670649781839465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638670649781809489" xlink:to="lqda_AgreementExpirationTerm_638670649781839465" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://liquidia.com/role/DisclosureLegalProceedingsDetails" xlink:type="extended" xlink:title="99941401 - Disclosure - Legal Proceedings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LegalProceedingsDisclosureAbstract" xlink:label="lqda_LegalProceedingsDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable_638670649781839465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="lqda_LegalProceedingsDisclosureAbstract_1" xlink:to="us-gaap_LossContingenciesTable_638670649781839465" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638670649781839465" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638670649781839465" xlink:to="dei_LegalEntityAxis_638670649781839465" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638670649781849195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638670649781839465" xlink:to="dei_EntityDomain_638670649781849195" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_LiquidiaPAHAndSandozMember" xlink:label="lqda_LiquidiaPAHAndSandozMember_638670649781849195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638670649781849195" xlink:to="lqda_LiquidiaPAHAndSandozMember_638670649781849195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis_638670649781849195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638670649781839465" xlink:to="srt_LitigationCaseAxis_638670649781849195" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_638670649781849195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis_638670649781849195" xlink:to="srt_LitigationCaseTypeDomain_638670649781849195" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_UTCAndSmithsMedicalLitigationMember" xlink:label="lqda_UTCAndSmithsMedicalLitigationMember_638670649781849195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain_638670649781849195" xlink:to="lqda_UTCAndSmithsMedicalLitigationMember_638670649781849195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="lqda-20240930.xsd#lqda_BreachOfContractClaimMember" xlink:label="lqda_BreachOfContractClaimMember_638670649781849195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain_638670649781849195" xlink:to="lqda_BreachOfContractClaimMember_638670649781849195" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis_638670649781849195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638670649781839465" xlink:to="us-gaap_LitigationStatusAxis_638670649781849195" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain_638670649781849195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusAxis_638670649781849195" xlink:to="us-gaap_LitigationStatusDomain_638670649781849195" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PendingLitigationMember" xlink:label="us-gaap_PendingLitigationMember_638670649781849195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusDomain_638670649781849195" xlink:to="us-gaap_PendingLitigationMember_638670649781849195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems_638670649781849195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_638670649781839465" xlink:to="us-gaap_LossContingenciesLineItems_638670649781849195" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="us-gaap_ProceedsFromLegalSettlements_638670649781849195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638670649781849195" xlink:to="us-gaap_ProceedsFromLegalSettlements_638670649781849195" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_638670649781859184" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_638670649781849195" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_638670649781859184" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262514150784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Oct. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIQUIDIA CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1710962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">419 Davis Drive, Suite&#160;100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Morrisville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">328-4400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LQDA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,636,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001819576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262513682016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 204,368<span></span>
</td>
<td class="nump">$ 83,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">4,202<span></span>
</td>
<td class="nump">4,061<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,604<span></span>
</td>
<td class="nump">2,159<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">214,212<span></span>
</td>
<td class="nump">89,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">7,784<span></span>
</td>
<td class="nump">4,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">1,371<span></span>
</td>
<td class="nump">1,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_IndemnificationAssetRelatedParty', window );">Indemnification asset, related party</a></td>
<td class="nump">7,206<span></span>
</td>
<td class="nump">6,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_BusinessCombinationContractAcquisitionCostsNet', window );">Contract acquisition costs, net</a></td>
<td class="nump">7,433<span></span>
</td>
<td class="nump">7,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible asset, net</a></td>
<td class="nump">3,219<span></span>
</td>
<td class="nump">3,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,903<span></span>
</td>
<td class="nump">3,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">7,758<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">252,886<span></span>
</td>
<td class="nump">118,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,298<span></span>
</td>
<td class="nump">1,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_AccruedExpensesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">17,039<span></span>
</td>
<td class="nump">13,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingPayableCurrent', window );">Revenue interest financing payable, current</a></td>
<td class="nump">13,252<span></span>
</td>
<td class="nump">2,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_OperatingAndFinanceLeaseLiabilityCurrent', window );">Operating and finance lease liabilities, current</a></td>
<td class="nump">1,249<span></span>
</td>
<td class="nump">1,139<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">33,838<span></span>
</td>
<td class="nump">18,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveNoncurrent', window );">Litigation finance payable</a></td>
<td class="nump">7,196<span></span>
</td>
<td class="nump">6,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingPayableNoncurrent', window );">Revenue interest financing payable, noncurrent</a></td>
<td class="nump">99,892<span></span>
</td>
<td class="nump">43,418<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_OperatingAndFinanceLeaseLiabilityNoncurrent', window );">Operating and finance lease liabilities, noncurrent</a></td>
<td class="nump">1,442<span></span>
</td>
<td class="nump">2,364<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">142,368<span></span>
</td>
<td class="nump">71,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - 10,000,000 shares authorized, none outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $0.001 par value, 115,000,000 and 100,000,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively, 84,545,409 and 68,629,575 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">631,556<span></span>
</td>
<td class="nump">476,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(521,123)<span></span>
</td>
<td class="num">(429,098)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">110,518<span></span>
</td>
<td class="nump">47,293<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 252,886<span></span>
</td>
<td class="nump">$ 118,332<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_AccruedExpensesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents carrying value as of the balance sheet date of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_AccruedExpensesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_BusinessCombinationContractAcquisitionCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents net amount of contract acquisition costs in a business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_BusinessCombinationContractAcquisitionCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_IndemnificationAssetRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of indemnification asset, related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_IndemnificationAssetRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_OperatingAndFinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating and finance leases, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_OperatingAndFinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_OperatingAndFinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating and finance leases, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_OperatingAndFinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue interest financing payable, current portion as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingPayableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue interest financing payable, noncurrent portion as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingPayableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262514459056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (unaudited) (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Condensed Consolidated Balance Sheets (unaudited)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">115,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">84,545,409<span></span>
</td>
<td class="nump">68,629,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">84,545,409<span></span>
</td>
<td class="nump">68,629,575<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262513656608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 4,448<span></span>
</td>
<td class="nump">$ 3,678<span></span>
</td>
<td class="nump">$ 11,079<span></span>
</td>
<td class="nump">$ 12,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">1,565<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="nump">4,525<span></span>
</td>
<td class="nump">1,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">11,890<span></span>
</td>
<td class="nump">7,440<span></span>
</td>
<td class="nump">31,367<span></span>
</td>
<td class="nump">30,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">20,182<span></span>
</td>
<td class="nump">10,559<span></span>
</td>
<td class="nump">60,374<span></span>
</td>
<td class="nump">27,597<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">33,637<span></span>
</td>
<td class="nump">18,569<span></span>
</td>
<td class="nump">96,266<span></span>
</td>
<td class="nump">59,905<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(29,189)<span></span>
</td>
<td class="num">(14,891)<span></span>
</td>
<td class="num">(85,187)<span></span>
</td>
<td class="num">(46,948)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1,815<span></span>
</td>
<td class="nump">862<span></span>
</td>
<td class="nump">5,550<span></span>
</td>
<td class="nump">2,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2,996)<span></span>
</td>
<td class="num">(1,761)<span></span>
</td>
<td class="num">(8,120)<span></span>
</td>
<td class="num">(4,311)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of debt</a></td>
<td class="nump">7,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,268)<span></span>
</td>
<td class="num">(2,311)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">6,034<span></span>
</td>
<td class="num">(899)<span></span>
</td>
<td class="num">(6,838)<span></span>
</td>
<td class="num">(4,104)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (23,155)<span></span>
</td>
<td class="num">$ (15,790)<span></span>
</td>
<td class="num">$ (92,025)<span></span>
</td>
<td class="num">$ (51,052)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share, basic (in dollars per share)</a></td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (1.20)<span></span>
</td>
<td class="num">$ (0.79)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (1.20)<span></span>
</td>
<td class="num">$ (0.79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic (in shares)</a></td>
<td class="nump">78,316,820<span></span>
</td>
<td class="nump">64,857,508<span></span>
</td>
<td class="nump">76,719,990<span></span>
</td>
<td class="nump">64,767,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">78,316,820<span></span>
</td>
<td class="nump">64,857,508<span></span>
</td>
<td class="nump">76,719,990<span></span>
</td>
<td class="nump">64,767,893<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262515534128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 64<span></span>
</td>
<td class="nump">$ 440,954<span></span>
</td>
<td class="num">$ (350,596)<span></span>
</td>
<td class="nump">$ 90,422<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">64,517,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">21,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits', window );">Issuance of common stock upon vesting of restricted stock units</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="nump">89,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="nump">81,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,552<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,745)<span></span>
</td>
<td class="num">(11,745)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">443,919<span></span>
</td>
<td class="num">(362,341)<span></span>
</td>
<td class="nump">81,643<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">64,710,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 64<span></span>
</td>
<td class="nump">440,954<span></span>
</td>
<td class="num">(350,596)<span></span>
</td>
<td class="nump">90,422<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">64,517,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(51,052)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">449,589<span></span>
</td>
<td class="num">(401,648)<span></span>
</td>
<td class="nump">48,006<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2023</a></td>
<td class="nump">64,899,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">443,919<span></span>
</td>
<td class="num">(362,341)<span></span>
</td>
<td class="nump">81,643<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">64,710,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">10,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits', window );">Issuance of common stock upon vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="nump">19,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,499<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,517)<span></span>
</td>
<td class="num">(23,517)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">446,450<span></span>
</td>
<td class="num">(385,858)<span></span>
</td>
<td class="nump">60,657<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">64,740,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">79,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits', window );">Issuance of common stock upon vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="nump">19,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="nump">59,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,487<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,790)<span></span>
</td>
<td class="num">(15,790)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">449,589<span></span>
</td>
<td class="num">(401,648)<span></span>
</td>
<td class="nump">48,006<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2023</a></td>
<td class="nump">64,899,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">476,322<span></span>
</td>
<td class="num">(429,098)<span></span>
</td>
<td class="nump">47,293<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">68,629,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">23,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits', window );">Issuance of common stock upon vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="nump">383,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="nump">67,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="nump">946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_StockIssuedDuringPeriodValueCommonStockWarrantsExercised', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">74,861<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">74,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net (in shares)</a></td>
<td class="nump">7,182,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,524<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,928)<span></span>
</td>
<td class="num">(40,928)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">556,210<span></span>
</td>
<td class="num">(470,026)<span></span>
</td>
<td class="nump">86,260<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2024</a></td>
<td class="nump">76,287,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">476,322<span></span>
</td>
<td class="num">(429,098)<span></span>
</td>
<td class="nump">$ 47,293<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">68,629,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">351,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (92,025)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2024</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">631,556<span></span>
</td>
<td class="num">(521,123)<span></span>
</td>
<td class="nump">110,518<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2024</a></td>
<td class="nump">84,545,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">556,210<span></span>
</td>
<td class="num">(470,026)<span></span>
</td>
<td class="nump">86,260<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2024</a></td>
<td class="nump">76,287,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">10,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits', window );">Issuance of common stock upon vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="nump">116,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,372<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,942)<span></span>
</td>
<td class="num">(27,942)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">560,614<span></span>
</td>
<td class="num">(497,968)<span></span>
</td>
<td class="nump">62,722<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2024</a></td>
<td class="nump">76,414,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,548<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">317,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits', window );">Issuance of common stock upon vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="nump">116,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">844<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="nump">104,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="nump">8,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_StockIssuedDuringPeriodValueCommonStockWarrantsExercised', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">63,669<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">63,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net (in shares)</a></td>
<td class="nump">7,584,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,881<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,155)<span></span>
</td>
<td class="num">(23,155)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2024</a></td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 631,556<span></span>
</td>
<td class="num">$ (521,123)<span></span>
</td>
<td class="nump">$ 110,518<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2024</a></td>
<td class="nump">84,545,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued as a result of common stock warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of common shares issued under vesting of restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_StockIssuedDuringPeriodValueCommonStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_StockIssuedDuringPeriodValueCommonStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of common shares issued under vesting of restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262513999056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (92,025)<span></span>
</td>
<td class="num">$ (51,052)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,777<span></span>
</td>
<td class="nump">7,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,679<span></span>
</td>
<td class="nump">1,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_NoncashPortionOfLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361<span></span>
</td>
<td class="nump">289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss (gain) on disposal of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">$ (7,215)<span></span>
</td>
<td class="nump">$ 11,500<span></span>
</td>
<td class="nump">4,268<span></span>
</td>
<td class="nump">2,311<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_AccretionAndNonCashInterestExpense', window );">Accretion and non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,114<span></span>
</td>
<td class="nump">4,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(141)<span></span>
</td>
<td class="nump">1,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,445)<span></span>
</td>
<td class="num">(2,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,471)<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(222)<span></span>
</td>
<td class="num">(556)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,291<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(760)<span></span>
</td>
<td class="num">(660)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72,609)<span></span>
</td>
<td class="num">(25,582)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Purchase of in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,661)<span></span>
</td>
<td class="num">(1,084)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,661)<span></span>
</td>
<td class="num">(11,082)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_ProceedsFromRevenueInterestFinancingNet', window );">Proceeds from revenue interest financing, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,460<span></span>
</td>
<td class="nump">41,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments on long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payments for debt prepayment and extinguishment costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,190)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_PaymentsOnRevenueInterestFinancingLiability', window );">Payments on revenue interest financing liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,731)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal payments on finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="num">(155)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyReceivableProceeds', window );">Receipts from litigation financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from sale of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from issuance of common stock under stock incentive plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,928<span></span>
</td>
<td class="nump">1,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,959<span></span>
</td>
<td class="nump">19,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,689<span></span>
</td>
<td class="num">(17,058)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,679<span></span>
</td>
<td class="nump">83,679<span></span>
</td>
<td class="nump">93,283<span></span>
</td>
<td class="nump">93,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">$ 204,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,368<span></span>
</td>
<td class="nump">76,225<span></span>
</td>
<td class="nump">$ 83,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_OperatingLeaseLiabilitiesCashPaid', window );">Cash paid for operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">985<span></span>
</td>
<td class="nump">956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_OfferingCostsIncurredIncludedInAccruedExpenses', window );">Offering costs incurred, but not paid included in accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RightOfUseAssetObtainedInExchangeForLeaseLiability', window );">Right of use assets obtained through lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Non-cash increase in property, plant and equipment through accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_IncreaseInIndemnificationAssetThroughAccountsPayable', window );">Non-cash increase in indemnification asset through accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 499<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_AccretionAndNonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion and non-cash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_AccretionAndNonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in-process research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_IncreaseInIndemnificationAssetThroughAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in indemnification asset through accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_IncreaseInIndemnificationAssetThroughAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_NoncashPortionOfLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of non cash portion of lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_NoncashPortionOfLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_OfferingCostsIncurredIncludedInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering costs incurred, but not paid included in accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_OfferingCostsIncurredIncludedInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_OperatingLeaseLiabilitiesCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash paid for operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_OperatingLeaseLiabilitiesCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_PaymentsOnRevenueInterestFinancingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from payments on revenue interest financing liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_PaymentsOnRevenueInterestFinancingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_ProceedsFromRevenueInterestFinancingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from revenue interest financing, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_ProceedsFromRevenueInterestFinancingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RightOfUseAssetObtainedInExchangeForLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RightOfUseAssetObtainedInExchangeForLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyReceivableProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the collection of receivables related to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyReceivableProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262515966848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_BusinessAbstract', window );"><strong>Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Description of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are a biopharmaceutical company focused on the development, manufacture, and commercialization of products that address unmet patient needs, with current focus directed towards rare cardiopulmonary diseases such as pulmonary arterial hypertension (&#8220;PAH&#8221;) and pulmonary hypertension associated with interstitial lung disease (&#8220;PH-ILD&#8221;). We operate through our wholly owned operating subsidiaries, Liquidia Technologies, Inc. (&#8220;Liquidia Technologies&#8221;) and Liquidia PAH, LLC (&#8220;Liquidia PAH&#8221;), formerly known as RareGen, LLC (&#8220;RareGen&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We currently generate revenue pursuant to a promotion agreement between Liquidia PAH and Sandoz Inc. (&#8220;Sandoz&#8221;), dated as of August&#160;1, 2018, as amended (the &#8220;Promotion Agreement&#8221;), sharing profit derived from the sale of Sandoz&#8217;s substitutable generic treprostinil injection (&#8220;Treprostinil Injection&#8221;) in the United States. Liquidia PAH has the exclusive rights to conduct commercial activities to encourage the appropriate use of Treprostinil Injection. We employ a targeted sales force calling on physicians and hospital pharmacies involved in the treatment of PAH and PH-ILD in the United States, as well as key stakeholders involved in the distribution and reimbursement of medicines to treat these patients. We established our commercial presence in the field to support Treprostinil Injection and have since expanded our presence to support the potential launch of YUTREPIA (treprostinil) inhalation powder (&#8220;YUTREPIA&#8221;), further validating our reputation as a company committed to supporting PAH and PH-ILD patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">We conduct research, development and manufacturing of novel products by applying our subject matter expertise in cardiopulmonary diseases and our proprietary PRINT</span><span style="font-size:7.5pt;letter-spacing:0.15pt;">&#174;</span><span style="font-size:10pt;">&#160;technology, a particle engineering platform, to enable precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Through development of our own products and research with third parties, we have experience applying PRINT across multiple routes of administration and drug payloads including inhaled therapies, vaccines, biologics, nucleic acids and ophthalmic implants, among others.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, low effort dry-powder inhaler (&#8220;DPI&#8221;) and by achieving higher dose levels than the labeled doses of current inhaled therapies. On August&#160;16, 2024, the United States Food and Drug Administration (the &#8220;FDA&#8221;) (i)&#160;granted tentative approval for our New Drug Application (&#8220;NDA&#8221;) for YUTREPIA for the treatment of PAH and PH-ILD and (ii)&#160;simultaneously determined that Tyvaso DPI, approved on May&#160;23, 2022, qualifies for a three-year New Clinical Investigation exclusivity for the chronic use of dry powder formulations of treprostinil for the approved indications. As a result, final approval of YUTREPIA for PAH and PH-ILD is currently delayed until after expiry of the three-year regulatory exclusivity for Tyvaso DPI on May&#160;23, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are also developing L606, an investigational, liposomal formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer, which we licensed from Pharmosa Biopharm Inc. (&#8220;Pharmosa&#8221;). L606 is currently being evaluated in an open-label study in the United States for treatment of PAH and PH-ILD with a planned pivotal study for the treatment of PH-ILD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We are subject to risks and uncertainties common to companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on third parties and key personnel, protection of proprietary technology, compliance with government regulations, and the ability to secure additional capital to fund operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The current global macro-economic environment is volatile, which may result in supply chain constraints and elevated rates of inflation. In addition, we operate in a dynamic and highly competitive industry and believe that changes in any of the following areas could have a material adverse effect on our future financial position, results of operations, or cash flows: the ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval, market acceptance and third-party payor coverage for our products; development of sales channels; certain strategic relationships; litigation or claims against us, including claims related to intellectual property, product, regulatory, or other matters; and our ability to attract and retain employees necessary to support our growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Product candidates we develop require approval from the FDA and/or other international regulatory agencies prior to commercial sales. There can be no assurance that our product candidates will receive the necessary approvals or, if we do, the indications for which our products will be approved. If we are denied approval, approval is delayed, approval is for less than all of the indications we are seeking, or we are unable to maintain approval, it could have a material adverse impact on our business, financial position and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We rely on single source manufacturers and suppliers for the supply of our product candidates, adding to the manufacturing risks we face. In the event of any failure by a supplier, we could be left without backup facilities. Any disruption from these manufacturers or suppliers could have a negative impact on our business, financial position and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We have financed our growth and operations through a combination of funds generated from revenues, the issuance of convertible preferred stock and common stock, bank borrowings, bank borrowings with warrants, the issuance of convertible notes and warrants, and revenue interest financing. Since inception, we have incurred recurring losses, including a net loss of $92.0 million for the nine months ended September&#160;30,&#160;2024. As of September&#160;30,&#160;2024, we had an accumulated deficit of $521.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We expect to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates through clinical trials, seek regulatory approval of such product candidates and pursue commercialization of any approved product candidates. These efforts require significant amounts of capital, adequate personnel and infrastructure, and extensive compliance-reporting capabilities. Even if our development efforts are successful, it is uncertain when, if ever, we will realize significant revenue from product sales. Additionally, the Revenue Interest Financing Agreement with HealthCare Royalty Partners IV, L.P. (&#8220;HCR&#8221;) dated January 9, 2023, as amended (the &#8220;RIFA&#8221;) contains fixed quarterly payments and minimum cash covenants that require us to maintain cash and cash equivalents in an amount at least equal to $7.5 million during the calendar year beginning on January 1, 2024 and at least equal to $15.0 million for the remainder of the payment term after the calendar year ended December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In September 2024, we entered into the Fifth Amendment to the RIFA pursuant to which HCR funded an additional $32.5 million on September 12, 2024, for total funding of $100 million. Additionally, payments due under the RIFA were amended such that the one-time fixed payment previously due in July 2025 is now due in equal payments in January and July 2026. See Note 12&#160;for further information.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On September 12, 2024, we sold shares of our common stock in an underwritten registered public offering for net proceeds of approximately $53.7 million and sold shares of our common stock for net proceeds of approximately $10.0 million in a private offering. See Note 8 for further information.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our future funding requirements will be heavily determined by the timing of the potential commercialization of YUTREPIA and the resources needed to support development of our product candidates. Based on our current plans, we expect that we will require additional capital to fund operations as well as to pursue in-licenses or acquisitions of other product candidates. If we are unable to obtain additional funding, we could be required to delay, reduce, or eliminate research and development programs, product portfolio expansion, or future commercialization efforts, which could adversely affect our business prospects, or we may be unable to continue operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Although we expect to continue to generate operating losses for the foreseeable future, we believe that as a result of the recent Fifth Amendment to the RIFA and net proceeds from the sale of common stock described above, excluding any future YUTREPIA product revenue, our cash and cash equivalents will be sufficient to fund operations, capital expenditures, and RIFA payments and allow us to remain in compliance with our minimum cash covenants pursuant to the RIFA for at least twelve months from the issuance date of these condensed consolidated financial statements. If we have not received full FDA approval and generated sufficient cash from product sales of YUTREPIA or are unable to access additional capital by the date of issuance of our fiscal year 2024 consolidated financial statements, we expect there would be substantial doubt about our ability to continue as a going concern as of that date. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect, which would have a material impact on our operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_BusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_BusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262513849632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Significant Accounting Policies and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Basis of Presentation, Significant Accounting Policies and Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation, Significant Accounting Policies and Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Basis of Presentation, Significant Accounting Policies and Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The unaudited interim condensed consolidated financial statements as of September&#160;30,&#160;2024 and for the three and nine months ended September&#160;30,&#160;2024 and 2023 have been prepared pursuant to the rules&#160;and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for interim financial reporting. These condensed consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal recurring adjustments and accruals) necessary for a fair statement of the results for the periods presented in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The year-end condensed consolidated balance sheet data was derived from our audited consolidated financial statements but does not include all disclosures required by GAAP. Operating results for the three and nine months ended September&#160;30,&#160;2024 are not necessarily indicative of the results that may be expected for the fiscal&#160;year ending December&#160;31,&#160;2024. Certain information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with GAAP have been omitted in accordance with the SEC&#8217;s rules&#160;and regulations for interim reporting. <span style="background:#ffffff;">Certain amounts have been reclassified from the prior year presentation to conform to current presentation, specifically in relation to the balance sheet presentation of finance and operating leases. </span>Our financial position, results of operations and cash flows are presented in U.S. Dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with our audited consolidated financial statements for the&#160;year ended December&#160;31,&#160;2023, which are included in our 2023 Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31,&#160;2023 (the &#8220;2023 Annual Report on Form 10-K&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the period. These estimates are based on historical experience and various other assumptions believed to be reasonable under the circumstances. We evaluate our estimates on an ongoing basis, including those related to the valuation of stock-based awards, certain accruals, the revenue interest financing payable, and intangible and contract acquisition cost amortization, and make changes to the estimates and related disclosures as our experience develops or new information becomes known. Actual results will most likely differ from those estimates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">GAAP requires segmentation based on an entity&#8217;s internal organization and reporting of revenue and operating income based upon internal accounting methods commonly referred to as the &#8220;management approach.&#8221; Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources and in assessing performance. Our CODM is our Chief Executive Officer. We have determined that we have one&#160;operating and reporting segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our significant accounting policies are disclosed in Note&#160;2 of the consolidated financial statements for the&#160;years ended December&#160;31, 2023 and 2022, which are included in our 2023 Annual Report on Form 10-K. There have been no material changes to our significant accounting policies during the nine months ended September&#160;30,&#160;2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board under its accounting standards codifications (ASC) or other standard setting bodies and are adopted by us as of the specified effective date. For the nine months ended September&#160;30,&#160;2024, there were no newly adopted accounting pronouncements that had a material impact on our condensed consolidated financial statements. As of September&#160;30,&#160;2024, there are no recently issued but not yet adopted accounting pronouncements that are expected to materially impact our condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash, Cash Equivalents, and Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We consider all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject us to concentrations of credit risk consist of cash and cash equivalents. We are exposed to credit risk, subject to federal deposit insurance, in the event of default by the financial institutions holding our cash and cash equivalents to the extent of amounts recorded on the condensed consolidated balance sheet. Our cash and cash equivalents are held at multiple accredited financial institutions. We have not experienced any losses on such accounts and do not believe that we are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Such deposits have exceeded and will continue to exceed federally insured limits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accounts Receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accounts receivable are stated at net realizable value and net of an allowance for credit losses as of each balance sheet date, if applicable. One customer accounted for 96% and 99% of our accounts receivable, net at September&#160;30,&#160;2024 and December&#160;31,&#160;2023, respectively. As of September&#160;30,&#160;2024 and December&#160;31,&#160;2023, we have not recorded an allowance for credit losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Prelaunch Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We capitalize prelaunch inventory prior to receiving regulatory approval if regulatory approval and subsequent commercialization of a product is probable and we also expect future economic benefit from the sales of the product to be realized. Prior to this conclusion, we expense prelaunch inventory as research and development expense in the period incurred. For prelaunch inventory that is capitalized, we consider a number of specific facts and circumstances, including the product&#8217;s shelf life, the product's current status in the development and regulatory approval process, results from related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential obstacles to the approval process, viability of commercialization and market trends. In late 2023, based on our assessment of the legal and regulatory process related to YUTREPIA, we concluded that we met the criteria to capitalize expenditures for prelaunch inventory. We capitalized $7.4 million of prelaunch inventory as of September&#160;30,&#160;2024 and none as of December&#160;31,&#160;2023. If either regulatory approval or market acceptance post-approval of YUTREPIA do not occur at all or on a timely basis prior to the inventory shelf-life expiration,&#160;we may be required to write-off some or all prelaunch inventory, which could affect our financial condition and financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;">We review long-lived assets, including definite-life intangible assets, for realizability on an ongoing basis. Changes in depreciation and amortization, generally accelerated depreciation and variable amortization, are determined and recorded when estimates of the remaining useful lives or residual values of long-term assets change. We also review </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 12pt 0pt;">for impairment when conditions exist that indicate the carrying amount of the assets may not be fully recoverable. In those circumstances, we perform undiscounted operating cash flow analyses to determine if an impairment exists. When testing for asset impairment, we group assets and liabilities at the lowest level for which cash flows are separately identifiable. Any impairment loss is calculated as the excess of the asset&#8217;s carrying value over its estimated fair value. Fair value is estimated based on the discounted cash flows for the asset group over the remaining useful life or based on the expected cash proceeds for the asset less costs of disposal. Any impairment losses would be recorded in the consolidated statements of operations. To date, no such impairments have occurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Goodwill</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 12pt 0pt;">We assess goodwill for impairment at least annually as of July 1 or whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. For example, significant and unanticipated changes or our inability to obtain or maintain regulatory approvals for our product candidates, including the NDA for YUTREPIA, could trigger testing of our goodwill for impairment at an interim date. We have one reporting unit. We have the option to first assess qualitative factors to determine whether events or circumstances indicate it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, in which case a quantitative impairment test is not required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Per ASC 350, <i style="font-style:italic;">Intangibles Goodwill and Other, </i>the quantitative goodwill impairment test is performed by comparing the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not impaired. An impairment loss is recognized for any excess of the carrying amount of the reporting unit&#8217;s goodwill over the fair value up to the amount of goodwill allocated to the reporting unit. Income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit are considered when measuring the goodwill impairment loss, if applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30,&#160;2024, we concluded there were no events or changes in circumstances which indicated that the carrying amount of goodwill was not recoverable. We completed our annual impairment test as of July 1, 2024 and concluded that no impairments had occurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Interest Financing Payable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recognized a liability related to amounts received in January 2023, July 2023, and January 2024 pursuant to the RIFA under ASC 470-10, <i style="font-style:italic;">Debt</i> and ASC 835-30, <i style="font-style:italic;">Interest - Imputation of Interest</i>. The liability will be accreted under the effective interest method based upon the estimated amount of future payments to be made pursuant to the RIFA. If the timing or amounts of any estimated future payments change, we will prospectively adjust the effective interest and the related amortization of the liability and related issuance costs. A significant increase or decrease in these estimates could materially impact the liability balance and related interest expense.<b style="font-weight:bold;"> </b>Amendments are assessed under ASC 470 to determine appropriate treatment as troubled debt restructurings, extinguishments or modifications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recognize revenue in accordance with ASC 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;). The core principle of ASC 606 is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:16.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Step 1: Identify the contract with the customer</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:16.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Step 2: Identify the performance obligations in the contract</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:16.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Step 3: Determine the transaction price</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:16.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Step 4: Allocate the transaction price to the performance obligations in the contract</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:16.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Step 5: Recognize revenue when the company satisfies a performance obligation</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In order to identify the performance obligations in a contract with a customer, we assess the promised goods or services in the contract and identify each promised good or service that is distinct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If a good or service is not distinct, the good or service is combined with other promised goods or services until a bundle of goods or services is identified that is distinct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. We evaluate any non-cash consideration, consideration payable to the customer, potential returns and refunds, and whether consideration contains a significant financing element in determining the transaction price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Revenue is measured based on consideration specified in a contract with a customer. We recognize revenue when it satisfies a performance obligation by transferring control over a service to a customer. The amount of revenue recognized reflects estimates for refunds and returns, which are presented as a reduction of accounts receivable where the right of setoff exists.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred in accordance with ASC 730,&#160;<i style="font-style:italic;">Research and Development</i> and include facility-related costs related to research and development activities, direct costs from third parties, such as contract research organizations (&#8220;CROs&#8221;), contract manufacturing organizations (CMOs&#8221;), and consultants, as well as employee-related expenses, including salaries, benefits, and stock-based compensation. Research and development expenses also include costs of acquired product licenses and related technology rights where there is no alternative future use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accrued Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As part of the process of preparing the condensed consolidated financial statements, we are required to estimate accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our condensed consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of these estimates with the service providers and make adjustments if necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The significant estimates in our accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities. The financial terms of our agreements with CROs and CMOs are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from such estimate, we adjust the accrual or prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We estimate the grant date fair value of stock-based awards and amortize this fair value to compensation expense over the requisite service period or the vesting period of the respective award. In arriving at stock-based compensation expense, we estimate the number of stock-based awards that will be forfeited due to employee turnover. The forfeiture assumption is based primarily on turn-over historical experience. If the actual forfeiture rate is higher than the estimated forfeiture rate, then an adjustment will be made to increase the estimated forfeiture rate, which will result in a decrease to the expense recognized in our financial statements. If the actual forfeiture rate is lower than the&#160;estimated forfeiture rate, then an adjustment will be made to lower the&#160;estimated forfeiture rate, which will result in an increase to expense recognized in our financial statements. The expense we recognize in future periods will be affected by changes in the&#160;estimated forfeiture rate and may differ from amounts recognized in the current period. See Note 9.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. Due to their anti-dilutive effect, the calculation of diluted net loss per share excludes the following common stock equivalent shares:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,113,427</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,573,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,372,790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,494,833</p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted Stock Units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,131,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,704,353</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,062,498</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,689,998</p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 450,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 450,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 450,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 450,000</p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,695,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,728,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,885,288</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,634,831</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Certain common stock warrants are included in the calculation of basic and diluted net loss per share since their exercise price is de minimis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ASC 825,<span style="font-family:'Calibri','Helvetica','sans-serif';"> </span><i style="font-style:italic;">Financial Instruments</i> defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants (an exit price). As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. ASC 825 establishes a three-tiered approach for valuation of financial instruments, which requires that fair value measurements be classified and disclosed in one of three tiers, whether or not recognized on our condensed consolidated balance sheets at fair value. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Level 1&#160;&#8212; Quoted prices in active markets for identical assets or liabilities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Level 2&#160;&#8212; Inputs other than quoted prices included in active markets that are observable for the asset or liability, either directly or indirectly; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Level 3&#160;&#8212; Unobservable inputs for the asset and liability used to measure fair value, to the extent that observable inputs are not available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following table presents the placement in the fair value hierarchy of financial assets and liabilities measured at fair value as of September&#160;30,&#160;2024 and December&#160;31,&#160;2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Money market funds (cash equivalents)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198,565</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198,565</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds (cash equivalents)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79,912</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Money market funds are included in cash and cash equivalents on our condensed consolidated balance sheet and are classified within Level 1 of the fair value hierarchy since they are valued using quoted market prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts reflected in our condensed consolidated balance sheets for cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their short-term nature. The carrying value of the revenue interest financing payable approximate fair value as the respective interest rates are reflective of current market rates on debt with similar terms and conditions. In addition, the revenue interest financing payable is <span style="background:#ffffff;">updated with the expected amount to be paid back each reporting period based on the contractual terms and current projections.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262513830832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">3. Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">Inventories are stated at the lower of average cost or net realizable value and consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,835</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,442</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Recognized as:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Prelaunch Inventory</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the nine months ended September&#160;30,&#160;2024, we capitalized costs of $7.4 million associated with the production of YUTREPIA as a result of our determination that regulatory approval and subsequent commercialization is probable, and we also expect future economic benefit from the sales of YUTREPIA to be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Amounts recognized as <i style="font-style:italic;">Other Assets</i> are comprised entirely of raw materials and work in process inventories not expected to be sold within one year of the balance sheet date<span style="white-space:pre-wrap;">.  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262515777600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant, and Equipment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant, and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant, and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Property, Plant, and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property, plant and equipment consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lab and build-to-suit equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,834</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 241</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 241</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer and other equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 740</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 487</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,450</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,409</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Construction-in-progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,315</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 804</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,718</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,794</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,934)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,314)</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, plant and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,480</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recorded depreciation and amortization expense related to property, plant and equipment of $0.3 million and $0.3 million for the three months ended September&#160;30,&#160;2024 and 2023, respectively, and of $0.8 million and $0.9 million for the nine months ended September&#160;30,&#160;2024 and 2023, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262515292016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Acquisition Costs and Intangible Asset<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract', window );"><strong>Contract Acquisition Costs and Intangible Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock', window );">Contract Acquisition Costs and Intangible Asset</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Contract Acquisition Costs and Intangible Asset</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Contract acquisition costs and intangible asset are summarized as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:25.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:25.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross Carrying Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net Carrying Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross Carrying Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net Carrying Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract acquisition costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,980</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,547)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,433</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,980</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,058)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,922</p></td></tr><tr><td style="vertical-align:bottom;width:46.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,401)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,190)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,430</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are amortizing the value of the contract acquisition costs and intangible asset on a pro-rata basis based on the estimated total revenue or net profits to be recognized over the period from November 18, 2020 through December 2032, the termination date of the Promotion Agreement (see Note 2-Revenue Recognition for our accounting policies). Amortization of contract acquisition costs is recorded as a reduction of revenue, and amortization of the intangible asset is recorded as cost of revenue. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recorded amortization related to the contract acquisition costs of $0.2 million and $0.1 million for the three months ended September&#160;30,&#160;2024 and 2023, respectively, and of $0.5 million and $0.5 million for the nine months ended September&#160;30,&#160;2024 and 2023, respectively. We recorded amortization related to the intangible asset of $0.1 million and $0.1 million for the three months ended September&#160;30,&#160;2024 and 2023, respectively, and of $0.2 million and $0.2 million for the nine months ended September&#160;30,&#160;2024 and 2023, respectively. Annual amortization over the next five years is expected to immaterially fluctuate from the 2024 amounts, consistent with changes to net profits to be recognized pursuant to the Promotion Agreement over the period.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Acquisition Costs and Intangible Asset [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for contract acquisition costs and intangible asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262514086528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indemnification Asset with Related Party and Litigation Finance Payable<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_IndemnificationAssetAndLitigationFinancePayableAbstract', window );"><strong>Indemnification Asset with Related Party and Litigation Finance Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_IndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDisclosureTextBlock', window );">Indemnification Asset with Related Party and Litigation Finance Payable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Indemnification Asset with Related Party and Litigation Finance Payable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On June 3, 2020, Liquidia PAH entered into a litigation financing arrangement (the &#8220;Financing Agreement&#8221;) with Henderson SPV, LLC (&#8220;Henderson&#8221;). Liquidia PAH, along with Sandoz (collectively the &#8220;Plaintiffs&#8221;), are pursuing litigation against United Therapeutics Corporation (&#8220;United Therapeutics&#8221;) (the &#8220;RareGen Litigation&#8221;). Under the Financing Agreement, Henderson will fund Liquidia PAH&#8217;s legal and litigation expenses (referred to as &#8220;Deployments&#8221;) in exchange for a share of certain litigation or settlement proceeds. Deployments received from Henderson are recorded as a Litigation finance payable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Litigation proceeds will be split equally between Liquidia PAH and Sandoz. Unless there is an event of default by Henderson, litigation proceeds received by Liquidia PAH must be applied first to repayment of total Deployments received. Litigation proceeds in excess of Deployments received are split between Liquidia PAH and Henderson according to a formula. Unless there is an event of default by PBM (as defined below), all proceeds received by Liquidia PAH are due to PBM as described further below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On November 17, 2020, Liquidia PAH entered into a Litigation Funding and Indemnification Agreement (&#8220;Indemnification Agreement&#8221;) with PBM RG Holdings, LLC (&#8220;PBM&#8221;). PBM is considered to be a related party as it is controlled by a major stockholder (which beneficially owns approximately 7.9% of Liquidia Corporation common stock as of October 30, 2024), who is also a member of our Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Indemnification Agreement, PBM now controls the litigation, with Liquidia PAH&#8217;s primary responsibility being to cooperate to support the litigation proceedings as needed. The Indemnification Agreement provides that Liquidia PAH and its affiliates will not be entitled to any proceeds resulting from, or bear any financial or other liability for, the RareGen Litigation unless there is an event of default by PBM. Any Liquidia PAH litigation expenses not reimbursed by Henderson under the Financing Agreement will be reimbursed by PBM. Any proceeds received which Henderson is not entitled to under the Financing Agreement will be due to PBM.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Indemnification Asset is increased as we record third party legal and litigation expenses related to the RareGen litigation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30,&#160;2024 and December&#160;31,&#160;2023, the Indemnification Asset and Litigation Finance Payable were classified as long-term assets and liabilities, respectively, as it is considered unlikely that the RareGen Litigation would conclude prior to September&#160;30, 2025.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_IndemnificationAssetAndLitigationFinancePayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indemnification Asset and Litigation Finance Payable [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_IndemnificationAssetAndLitigationFinancePayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_IndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for indemnification asset with related party and litigation finance payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_IndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262513857120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. Accrued Expenses and Other Current Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses and other current liabilities consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,488</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,544</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,381</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,902</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued inventory costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,954</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,039</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,400</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262514690496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Issuance of Common Stock on September 11, 2024 from an Underwritten Public Offering and Private Placement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In September 2024, we sold 6,460,674 shares of our common stock in an underwritten registered public offering at an offering price of $8.90 per share (the &#8220;2024 Offering&#8221;) for gross proceeds of approximately $57.5 million, before deducting offering costs of approximately $3.8 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A fund affiliated with Paul B. Manning, a member of our Board of Directors, participated in the 2024 Offering and purchased shares of common stock in an aggregate amount of approximately $3.0 million at the public offering price per share and on the same terms as the other purchasers in the 2024 Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Concurrently with the 2024 Offering referenced above, we entered into a common stock purchase agreement with funds managed by Caligan Partners LP (&#8220;Caligan&#8221;), our largest stockholder, for the sale by us in a private placement of an </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">aggregate of 1,123,595 shares of our common stock at a purchase price of $8.90 per share for gross and net proceeds of approximately $10.0 million (the &#8220;Caligan 2024 Private Placement&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Issuance of Common Stock on January 4, 2024 from a Private Placement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On January 4, 2024, we entered into a common stock purchase agreement with Legend Aggregator, LP for the sale by us in a private placement (the &#8220;2024 Private Placement&#8221;) of an aggregate of 7,182,532 shares of our common stock at a purchase price of $10.442 per share. The 2024 Private Placement closed on January 8, 2024, and we received gross proceeds of approximately $75.0 million, before deducting offering costs of less than $0.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Issuance of Common Stock on December 12, 2023 from an Underwritten Public Offering and Private Placement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In December 2023, we sold 3,491,620 shares of our common stock in an underwritten registered public offering at an offering price of $7.16 per share (the &#8220;2023 Offering&#8221;) for net proceeds of approximately $25.0 million, before deducting offering costs of approximately $1.9 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Caligan and Paul B. Manning, participated in the 2023 Offering and purchased shares of common stock in an aggregate amount of approximately $10.0<span style="white-space:pre-wrap;"> million at the public offering price per share and on the same terms as the other purchasers in the 2023 Offering.  Caligan purchased </span>1,117,318 shares of common stock in the 2023 Offering for an aggregate purchase price of $8.0 million and Paul B. Manning purchased 279,330 shares of common stock in the 2023 Offering for an aggregate purchase price of $2.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Concurrently with the 2023 Offering referenced above, we entered into a common stock purchase agreement with Roger Jeffs, our Chief Executive Officer, for the sale by us in a private placement of an aggregate of 139,665 shares of our common stock at a purchase price of $7.16 per share for gross proceeds of approximately $1.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the nine months ended September&#160;30,&#160;2024 and 2023, 9,175 and no warrants to purchase shares of common stock were exercised, respectively. Outstanding warrants consisted of the following as of September&#160;30,&#160;2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:35.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:30.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration Date</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">January 6, 2032</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">February 26, 2031</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">n/a<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">February 26, 2031</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56,397</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">December 31, 2026</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">These warrants were issued on February 26, 2021, in connection with our previously outstanding debt with Silicon Valley Bank. These warrants only became exercisable if there was additional funding under the loan agreement, and the exercise price of these warrants was to be set upon such potential additional funding. The additional funding never occurred, and the loan agreement has since been repaid and terminated. While these warrants technically remain outstanding, they are not, and will never be, exercisable.</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262515794432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2020 Long-Term Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;">Our 2020 Long-Term Incentive Plan (the &#8220;2020 Plan&#8221;) provides for the granting of stock appreciation rights, stock awards, stock units, and other stock-based awards and for accelerated vesting under certain change of control transactions. The number of shares of our common stock available for issuance under the 2020 plan will automatically increase on January 1 of each year through 2030, by an amount equal to the smaller of (a) 4% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by the Board of Directors (the &#8220;Evergreen Provision&#8221;). On January 1, 2024, the number of shares of common stock </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 12pt 0pt;">available for issuance under the 2020 Plan automatically increased by 2,745,183 shares pursuant to the Evergreen Provision. As of September&#160;30,&#160;2024, there were 900,518 shares available for future grants under the 2020 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The 2020 Plan replaced all prior equity award plans and such plans have been discontinued. However, the awards outstanding under the prior equity award plans will continue to remain in effect in accordance with their terms. Awards that are forfeited under these prior plans upon cancellation, termination or expiration will not be available for grant under the 2020 Plan. As of September&#160;30,&#160;2024, a total of 473,076 shares of common stock were reserved for issuance related to the remaining outstanding equity awards granted under the prior plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2022 Inducement Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On January 25, 2022, the Board of Directors approved the adoption of our 2022 Inducement Plan (the &#8220;2022 Inducement Plan&#8221;). The 2022 Inducement Plan was recommended for approval by the Compensation Committee of the Board (the &#8220;Compensation Committee&#8221;), and subsequently approved and adopted by the Board of Directors without stockholder approval pursuant to Rule 5635(c)(4) of the rules and regulations of The Nasdaq Stock Market, LLC (the &#8220;Nasdaq Listing Rules&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">310,000 shares of our common stock were reserved for issuance pursuant to equity awards that may be granted under the 2022 Inducement Plan, and the 2022 Inducement Plan will be administered by the Compensation Committee. In accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules, equity awards under the 2022 Inducement Plan may only be made to an employee who has not previously been an employee or member of the Board of Directors, or following a bona fide period of non-employment by us, if he or she is granted such equity awards in connection with his or her commencement of employment with us and such grant is an inducement material to his or her entering into employment with us. As of September&#160;30,&#160;2024, a total of 27,608 shares were available for issuance under the 2022 Inducement Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employee Stock Purchase Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In November 2020, stockholders approved the Liquidia Corporation 2020 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The number of shares of our common stock available for issuance under the ESPP will automatically increase on January 1 of each year through 2030, by the lesser of (a) 1.0% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, (b) 150,000 shares, or (c) an amount determined by the Board of Directors. On January 1, 2024, the number of shares of common stock available for issuance under the ESPP increased by 150,000 shares. As of September&#160;30,&#160;2024, a total of 534,742 shares of common stock are reserved for issuance under the ESPP. The ESPP allows eligible employees to purchase shares of our common stock at a discount through payroll deductions, subject to plan limitations. Unless otherwise determined by the administrator, the common stock will be purchased for the accounts of employees participating in the ESPP at a price per share that is 85% of the lesser of the fair market value of our common stock on the first and last trading day of the offering period. During the nine months ended September&#160;30,&#160;2024 and 2023, 172,395 and 140,922 shares were issued under the ESPP, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation Valuation and Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We account for employee stock-based compensation plans using the fair value method. The fair value method requires us to estimate the grant-date fair value of stock-based awards and amortize this fair value to compensation expense over the requisite service period or vesting term. The fair value of each option grant is estimated using a Black-Scholes option-pricing model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For restricted stock units (&#8220;RSUs&#8221;), the grant-date fair value is based upon the market price of our common stock on the date of the grant. This fair value is then amortized to compensation expense over the requisite service period or vesting term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Total stock-based compensation expense recognized for employees and non-employees was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">By Expense Category:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 839</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 555</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,676</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,932</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,935</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,487</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,777</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,538</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table summarizes the unamortized compensation expense and the remaining&#160;years over which such expense would be expected to be recognized, on a weighted average basis, by type of award:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;September&#160;30,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Recognition</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unamortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Period</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,789</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.6</p></td></tr><tr><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted and performance stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.5</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fair Value of <i><img alt="Graphic" src="lqda-20240930x10q002.jpg" style="display:inline-block;height:0.65pt;width:0.65pt;"/></i>Stock Options Granted and Purchase Rights Issued under the ESPP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We use the Black-Scholes option-pricing model to determine the fair value of stock options granted and purchase rights issued under the ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the assumptions used for estimating the fair value of stock options granted under the Black-Scholes option-pricing model:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_fljXNZJ780WhJZl0xfbOZw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_KgzYt7L2DEmD5XrMEpBoAQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.98%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.46% - 4.62%</p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">90%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">91% - 95%</p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.8 - 6.1</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The weighted average fair value for options granted during the nine months ended September&#160;30,&#160;2024 and 2023 was $9.84 and $5.09 per share, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the assumptions used for estimating the fair value of purchase rights granted to employees under the ESPP under the Black-Scholes option-pricing model:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_od59HwKFmkW8EjvwzxxZHg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden__L855O1ENEa44A4aGasXbw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">4.80% - 5.27%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.20% - 5.47%</p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">62% - 72%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">60% - 64%</p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.50</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Option Activity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Options generally vest over a four-year period in multiple tranches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table summarizes stock option activity during the nine months ended September&#160;30,&#160;2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding as of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,573,937</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (351,653)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (179,926)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding as of September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,049,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,835</p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,649,860</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,106</p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and expected to vest as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,772,869</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,661</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of stock options in the table above represents the difference between the $10.00 closing price of our common stock as of September&#160;30,&#160;2024 and the exercise price of outstanding, exercisable, and vested and expected to vest in-the-money stock options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Stock Units</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Restricted stock units (&#8220;RSUs&#8221;) represent the right to receive shares of our common stock at the end of a specified time period and/or upon the achievement of a specific milestone. RSUs can only be settled in shares of our common stock. RSUs generally vest over a four-year period similar to stock options granted to employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The tax withholding method used for most RSUs is the sell-to-cover method, in which shares with a market value equivalent to the tax withholding obligation are sold on behalf of the holder of the RSUs upon vesting and settlement to cover the tax withholding liability and the cash proceeds from such sales are remitted to taxing authorities by us. In circumstances where the sell-to-cover method is not used, the holder of the RSUs is required to remit cash to us to cover the tax withholding liability and the cash is then remitted to taxing authorities by us.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A summary of unvested RSU awards outstanding as of September&#160;30,&#160;2024 and changes during the nine months ended September&#160;30,&#160;2024 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant-Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(per&#160;RSU)</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,657,978</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.41</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,146,517</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.57</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (615,827)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.48</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (94,047)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.52</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,094,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.64</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;"><span style="font-size:1pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">RSUs granted during the nine months ended September&#160;30,&#160;2024, included 520,526 performance-based RSUs granted to our executive officers. These performance-based RSUs vest upon the later of (a) time-based vesting conditions and (b) the first commercial sale of YUTREPIA in the United States and are considered probable of vesting. The time-based vesting condition means 25% of the performance-based RSUs vest one year after grant date and quarterly thereafter for three years, subject to the executive&#8217;s continued service.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262515718112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue From Contracts With Customers<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue From Contracts With Customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue From Contracts With Customers</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. Revenue From Contracts With Customers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In August 2018, we entered into a Promotion Agreement with Sandoz under which we have the exclusive rights to conduct commercial activities to encourage the appropriate use of Treprostinil Injection for the treatment of patients with PAH in the United States. We paid Sandoz $20 million at the inception of the Promotion Agreement in consideration for these rights. In exchange for conducting these commercial activities, we are entitled to receive a share of Net Profits (as defined within the Promotion Agreement) based on specified profit levels. The share of Net Profits received is subject to adjustments from Sandoz for certain items, such as distributor chargebacks, rebates, inventory returns, inventory write-offs and other adjustments. We expect to refund certain amounts to Sandoz through a reduction of the cash received from future Net Profits generated under the Promotion Agreement. As of September&#160;30,&#160;2024, a $0.5 million refund liability is offset against accounts receivable from Sandoz related to expected refund amounts. Approximately 98% and 98% of revenue during the three and nine months ended September&#160;30,&#160;2024, respectively, was generated from the Promotion Agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262515677104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_LeaseDisclosureTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">We are party to a non-cancelable operating lease for our laboratory and office space in Morrisville, North Carolina. The lease expires on October 31, 2026 with an option to </span><span style="background:#ffffff;">extend</span><span style="background:#ffffff;"> for an additional period of </span><span style="background:#ffffff;">five years</span><span style="background:#ffffff;"> with appropriate notice. We have not included the optional extension period in the measurement of lease liabilities because it is not reasonably certain that we will exercise the option to extend. The payments under this lease are subject to escalation clauses. Operating lease cost is allocated between research and development and general and administrative expenses based on the usage of the leased facilities. The related right-of-use assets are amortized on a straight-line basis over the lesser of the lease term or the estimated useful life of the asset.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Finance Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">We lease specialized laboratory equipment under finance leases. We do not have access to certain inputs used by our lessors to calculate the rate implicit in our finance leases and, as such, use our estimated incremental borrowing rate at the time of lease inception for the discount rate applied to our finance leases. The incremental borrowing rate used on finance leases was </span><span style="background:#ffffff;">6.5%</span><span style="background:#ffffff;">. Certain finance leases also include options to purchase the leased property. We recognize all such purchase options as part of our right-of-use assets and lease liabilities if we are reasonably certain that such purchase options will be exercised.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Lease Balances, Costs, and Future Minimum Payments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Leases with an initial term of 12 months or less are not recorded on the balance sheet. As of September&#160;30,&#160;2024, we have not entered into any short-term leases. For lease agreements entered into or reassessed after the adoption of ASC 842</span><i style="font-style:italic;background:#ffffff;"> Leases</i><span style="background:#ffffff;">, we combine lease and non-lease components, if any. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">Our lease cost is reflected in the accompanying condensed statements of operations and comprehensive loss as follows</span>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:23.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Fixed lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 175</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 527</p></td></tr><tr><td style="vertical-align:bottom;width:23.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Fixed lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 59</p></td></tr><tr><td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 74</p></td></tr><tr><td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13</p></td></tr><tr><td style="vertical-align:bottom;width:23.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total Lease Cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 220</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 659</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 673</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The weighted average remaining lease term and discount rates as of September&#160;30,&#160;2024 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:88.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:88.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining lease term (years):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average discount rate:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:88.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The discount rate for leases was estimated based upon market rates of collateralized loan obligations of comparable companies on comparable terms at the time of lease inception.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The future minimum lease payments as of September&#160;30,&#160;2024 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Year ending December&#160;31:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024 (three months remaining)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 367</p></td></tr><tr><td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,434</p></td></tr><tr><td style="vertical-align:bottom;width:65.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,169</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,169</p></td></tr><tr><td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,877</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,970</p></td></tr><tr><td style="vertical-align:bottom;width:65.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (278)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (280)</p></td></tr><tr><td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,599</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,690</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_LeaseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information about leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_LeaseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262513762768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Interest Financing Payable<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingPayableAbstract', window );"><strong>Revenue Interest Financing Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingPayableTextBlock', window );">Revenue Interest Financing Payable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Revenue Interest Financing Payable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On January 9, 2023, we entered into the RIFA with HCR and HealthCare Royalty Management, LLC, pursuant to which and subject to the terms and conditions contained therein, HCR agreed to pay us an aggregate investment amount of up to </span><span style="background:#ffffff;">$100.0</span><span style="background:#ffffff;"> million (the &#8220;Investment Amount&#8221;) in </span><span style="background:#ffffff;">four</span><span style="background:#ffffff;"> tranches.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">On January 27, 2023, </span><span style="background:#ffffff;">$32.5</span><span style="background:#ffffff;"> million of the Investment Amount was funded from the first tranche, </span><span style="background:#ffffff;">$22.2</span><span style="background:#ffffff;"> million of which was used to satisfy existing obligations due to Silicon Valley Bank. This repayment resulted in a loss on extinguishment during the year ended December&#160;31,&#160;2023 of&#160;</span><span style="background:#ffffff;">$2.3</span><span style="background:#ffffff;">&#160;million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On June 28, 2023 and July 27, 2023, we entered into the Second Amendment to the RIFA and Third Amendment to the RIFA, respectively, pursuant to which HCR funded $10.0 million from the second tranche on July 27, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On January 3, 2024, we entered into the Fourth Amendment to the RIFA pursuant to which HCR funded an additional $25.0 million from the second tranche on January 5, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On September 11, 2024 we entered into the Fifth Amendment to the RIFA pursuant to which HCR funded an additional $32.5 million from the second tranche on September 12, 2024 and eliminated the third and fourth tranches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As consideration for the Investment Amount and pursuant to the RIFA, we have agreed to pay HCR according to a fixed quarterly payment schedule.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">As of  September&#160;30,&#160;2024, we were required to pay </span>$13.3 million within one year of the balance sheet date, which is classified as current in our condensed consolidated balance sheet.<span style="background:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Aggregate payments to HCR are capped at 175% of funded portion of the Investment Amount (the &#8220;Hard Cap&#8221;), plus an amount, if any, that HCR would need to receive to yield an internal rate of return of (i) 18% on the first $67.5 million funded and (ii) 16% on the last $32.5 million funded (the &#8220;IRR True-Up Payment&#8221;), unless the RIFA is earlier terminated. If a change of control occurs or upon the occurrence of an event of default, HCR may accelerate payments due under the RIFA up to the Hard Cap, plus the IRR True-Up Payment, plus any other obligations payable under the RIFA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The RIFA contains customary affirmative and negative covenants and customary events of default and other events that would cause acceleration, including, among other things, the occurrence of certain material adverse events or the material breach of certain representations and warranties and specified covenants, in which event HCR may elect to terminate the RIFA and require us to make payments to HCR equal to the lesser of (a) the Hard Cap, plus any other obligations payable under the RIFA, or (b) the funded portion of the Investment Amount, minus payments received by HCR in respect of the Revenue Interests, plus the IRR True-Up Payment. If the FDA grants final approval to an inhaled treprostinil product therapeutically equivalent to YUTREPIA and HCR has not received 100% of the amount funded by HCR to date, then we will be required to make payments to HCR equal to 100% of the amount funded by HCR to date, minus payments received by HCR in respect of the Revenue Interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The RIFA contains certain restrictions on our ability, among other things, to incur additional debt, grant or permit additional liens, make investments and acquisitions, dispose of assets, pay dividends and distributions, subject to certain exceptions.&#160;<span style="background:#ffffff;">In addition, the RIFA contains a financial covenant that requires us to maintain cash and cash equivalents in an </span>amount at least equal to $7.5 million during the calendar year beginning on January 1, 2024 and at least equal to $15.0 million for the remainder of the payment term after the calendar year ended December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of the filing date of these condensed consolidated financial statements, we are not aware of any breach of covenants, or the occurrence of any material adverse event, nor have we received any notice of event of default from HCR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Fourth Amendment to the RIFA qualifies as a debt extinguishment and issuance of a new debt instrument in accordance with ASC 405-20, Extinguishments of Liabilities. We recorded a loss on extinguishment during the quarter ended March 31, 2024 of $11.5 million, equal to the fair value of the amended RIFA less the carrying value of the existing RIFA on January 5, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Fifth Amendment to the RIFA qualifies as a debt extinguishment and issuance of a new debt instrument in accordance with ASC 405-20, Extinguishments of Liabilities. We recorded a gain on extinguishment during the quarter ended September 30, 2024 of $7.2 million, equal to the fair value of the amended RIFA less the carrying value of the existing RIFA on September 12, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recorded the total funds received from HCR under the terms of the RIFA as a liability. The issuance costs, consisting primarily of legal fees, totaled $0.9 million and were recorded as a deduction of the carrying amount of the liability and are being amortized under the effective interest method over the estimated period the liability will be repaid. We estimated the total amount of payments over the life of the RIFA to determine the interest expense to record to accrete the liability to the amount ultimately due. For the three and nine months ended September&#160;30,&#160;2024, we estimated an&#160;effective annual interest rate of approximately&#160;15.2%. Over the course of the RIFA, the effective annual interest rate may be affected by potential changes in forecasted payments. On a quarterly&#160;basis, we will reassess the expected amount and timing of payments, recalculate the amortization and effective interest&#160;rate and adjust the accounting prospectively as needed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table presents the changes in the RIFA payable during the nine months ended September&#160;30,&#160;2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,033</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Second tranche funding, net of fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,975</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of January 5, 2024, prior to extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 71,117</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss on extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,483</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of January 5, 2024, after extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82,600</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,161</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,731)</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Second tranche funding, net of fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,485</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of September 12, 2024, prior to extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 119,515</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Gain) on extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,215)</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of September 12, 2024, after extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 112,300</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 844</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 113,144</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: current portion of revenue interest financing payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,252)</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term portion of revenue interest financing payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 99,892</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The expected annual payments on the revenue interest financing payable as of September&#160;30,&#160;2024 are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Year ending December&#160;31:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024 (three months remaining)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,122</p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,017</p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,724</p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,962</p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,962</p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,828</p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 170,615</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Interest Financing Payable [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue interest financing payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262513892192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. Commitments and Contingencies </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Pharmosa License Agreement and Device License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June 2023, we entered into a License Agreement with Pharmosa Biopharm Inc. (&#8220;Pharmosa&#8221;) pursuant to which we were granted an exclusive license in North America to develop and commercialize L606, an inhaled, sustained-release formulation of treprostinil currently being evaluated in a clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), and a non-exclusive license for the manufacture, development and use (but not commercialization) of such licensed product in most countries outside North America (the &#8220;Pharmosa License Agreement&#8221;). On October 2, 2024, we and Pharmosa entered into a First Amendment to the Pharmosa License Agreement (the &#8220;First Amendment&#8221;) which, among other things, expands our licensed territory beyond North America to include key markets in Europe, Japan and elsewhere.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;">Concurrently with the execution of the First Amendment, we and Pharmosa also entered into a Device License Agreement (the &#8220;Device License Agreement&#8221;). Pursuant to the terms of the Device License Agreement, Pharmosa will provide (i) an exclusive license to Liquidia Technologies for the right to develop, manufacture, use and commercialize Pharmosa&#8217;s next-generation smart-technology nebulizers (the &#8220;Device&#8221;) for use with L606 in most countries (subject to certain exceptions) (the &#8220;Territory&#8221;) and (ii) a non-exclusive license to Liquidia Technologies for the right to develop, manufacture and use (but not commercialize) the Device outside of the Territory.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Pharmosa License Agreement, as amended, we will be responsible for development, regulatory and commercial activities of L606 in the Territory. Pharmosa will manufacture clinical and commercial supplies of the liposomal formulation through its global supply chain and support us in establishing a redundant global supply chain. In consideration for these exclusive rights, we paid Pharmosa an upfront license fee of $10 million and paid an additional $3.5 million upfront license fee in October 2024 in <span style="color:#212529;">connection with the rights granted in the First Amendment and the Device License Agreement. In addition to the upfront fees, we </span>will pay Pharmosa potential development milestone payments tied to clinical development and approvals in PAH and/or PH-ILD of up to $37.75 million, potential sales milestones of up to $185 million in North America and $150 million outside North American and two tiers of low, double-digit royalties on all net sales of L606. Pharmosa will also receive a $10 million milestone payment for each additional indication approved after PAH and PH-ILD and each additional product approved under the license. We also retain the first right to negotiate for development and commercialization of L606 in Europe and other territories should Pharmosa seek a partner, subject to satisfaction of certain conditions as set forth in the Pharmosa License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Mainbridge Health Care Device Development and Supply Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2022, we entered into a Device Development and Supply Agreement (the &#8220;Pump Development Agreement&#8221;) with Mainbridge Health Partners, LLC (&#8220;Mainbridge&#8221;) and Sandoz Inc. (&#8220;Sandoz&#8221;). The Pump Development Agreement provides for the cooperation between us, Sandoz and Mainbridge to develop a new pump that is suitable for the subcutaneous administration of Treprostinil Injection. Mainbridge will perform all development, validation and testing activities required for the pump and related consumables in anticipation of submitting a 510(k)&#160;clearance application for the pump to the FDA. In connection with the Pump Development Agreement, we and Sandoz have agreed to pay Mainbridge certain future contingent milestone payments in accordance with the terms and conditions set forth therein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">UNC License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We perform research under a license agreement with The University of North Carolina at Chapel Hill (&#8220;UNC&#8221;) as amended to date (the &#8220;UNC License Agreement&#8221;). As part of the UNC License Agreement, we hold an exclusive license to certain research and development technologies and processes in various stages of patent pursuit, for use in our research and development and commercial activities, with a term until the expiration date of the last to expire patent subject to the UNC License Agreement, subject to industry standard contractual compliance. Under the UNC License Agreement, we are obligated to pay UNC royalties equal to a low single digit&#160;percentage of all net sales of drug products whose manufacture, use or sale includes any use of the technology or patent rights covered by the UNC License </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Agreement, including YUTREPIA. We may grant sublicenses of UNC licensed intellectual property in return for specified payments based on a&#160;percentage of any fee, royalty or other consideration received.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Chasm Technologies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In March 2012, we entered into an agreement, as amended, with Chasm Technologies, Inc. for manufacturing consulting services related to our manufacturing capabilities during the term of the agreement. We agreed to pay future contingent milestones and royalties on net sales totaling no more than $1.5 million, $0.2 million of which has been accrued as of September&#160;30,&#160;2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employment Agreements and Executive Severance and Change in Control Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have agreements with certain employees and an Executive Severance and Change in Control Plan which covers certain other employees which require payments if certain events, such as a change in control or termination without cause, occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Purchase Obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We enter into contracts in the normal course of business with contract service providers to assist in the performance of research and development and manufacturing activities. Subject to required notice periods and obligations under binding purchase orders, we can elect to discontinue the work under these agreements at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On July 14, 2023, we entered into an Amended and Restated Commercial Manufacturing Services and Supply Agreement with Lonza Tampa LLC (&#8220;Lonza&#8221;) (the &#8220;CSA&#8221;). Lonza is our sole supplier for encapsulation and packaging services for YUTREPIA. <span style="background:#ffffff;">Pursuant to the terms of the CSA, we deliver bulk treprostinil powder, manufactured using our proprietary PRINT</span><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;background:#ffffff;">&#174;</sup><span style="background:#ffffff;">&#160;technology, and Lonza encapsulates and packages it. </span>The CSA was effective upon signing and will be in effect for an initial term of 5 years from receipt of regulatory approval of YUTREPIA by the FDA (&#8220;Regulatory Approval&#8221;) absent termination by either party in accordance with the terms of the CSA.<span style="background:#ffffff;"> We may terminate the CSA upon </span><span style="background:#ffffff;">60 days</span><span style="background:#ffffff;">&#8217; written notice to Lonza in the event that the application for regulatory approval is rejected by the FDA and such FDA decision is not caused by the fault of the Company (the &#8220;Termination for FDA Rejection&#8221;). Lonza may terminate the CSA upon </span><span style="background:#ffffff;">120 days</span><span style="background:#ffffff;"> written notice if we do not receive regulatory approval by December&#160;31, 2024 (the &#8220;Termination for FDA Delay&#8221;). </span>Upon any Termination for FDA Rejection or Termination for FDA Delay, we would reimburse Lonza for 50% of its documented out-of-pocket expenditures for any capital equipment that is purchased by Lonza after the effective date of the Agreement to perform the services for us, not to exceed $2.5 million in the aggregate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">We are required to provide Lonza with quarterly forecasts of our expected production requirements for the following </span><span style="background:#ffffff;">24-month</span><span style="background:#ffffff;"> period, the first </span><span style="background:#ffffff;">twelve months</span><span style="background:#ffffff;"> of which is considered a binding, firm order. We are required to purchase certain minimum annual order quantities, which may be adjusted by us after the thirteenth month after receipt of regulatory approval (as defined in the CSA). The CSA provides for tiered pricing depending upon the batch size ordered. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, we are party to a multi-year supply agreement with LGM Pharma, LLC (LGM) to supply active pharmaceutical ingredients for YUTREPIA. Under the supply agreement with LGM, we are required to provide rolling forecasts, a portion of which will be considered a binding, firm order, subject to an annual minimum purchase commitment of $2.7 million for the term of the agreement. The agreement expires five&#160;years from the first marketing authorization approval of YUTREPIA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30,&#160;2024, we have non-cancelable commitments for product manufacturing and supply costs of approximately $14.7 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Contingencies and Commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">From time-to-time we are subject to claims and litigation in the normal course of business, none of which do we believe represent a risk of material loss or exposure. See Note&#160;14 for further discussion of pending legal proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition to the commitments described above, we are party to other commitments, including non-cancelable leases and long-term debt, which are described elsewhere in these notes to the condensed consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262514089744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_LegalProceedingsDisclosureAbstract', window );"><strong>Legal Proceedings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Proceedings</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14. Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">YUTREPIA-Related Litigation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In 2020, United Therapeutics filed a complaint for patent infringement against the Company in the U.S. District Court for the District of Delaware (the &#8220;Original Hatch-Waxman Litigation&#8221;), asserting infringement by the Company of U.S. Patent Nos. 9,604,901, entitled &#8220;Process to Prepare Treprostinil, the Active Ingredient in Remodulin&#174;&#8221; (the &#8220;&#8216;901 Patent&#8221;), 9,593,066, entitled &#8220;Process to Prepare Treprostinil, the Active Ingredient in Remodulin&#174;&#8221; (the &#8220;&#8216;066 Patent&#8221;), and 10,716,793, entitled &#8220;Treprostinil Administration by Inhalation&#8221; (the &#8220;&#8216;793 Patent&#8221;) relating to United Therapeutics&#8217; Tyvaso&#174;, a nebulized treprostinil solution for the treatment of PAH. United Therapeutics&#8217; complaint was in response to the Company&#8217;s NDA for YUTREPIA, filed with the FDA, requesting approval to market YUTREPIA, a dry powder formulation of treprostinil for the treatment of PAH. The YUTREPIA NDA was filed under the 505(b)(2) regulatory pathway with Tyvaso&#174; as the reference listed drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In December 2021, United Therapeutics filed a stipulation of partial judgment with respect to the &#8216;901 Patent under which United Therapeutics agreed to the entry of judgment of the Company&#8217;s non-infringement of the &#8217;901 Patent.  In August 2022, Judge Andrews, who was presiding over the Original Hatch-Waxman Litigation, issued an opinion that claims 1, 2, 3, 6 and 9 of the &#8216;066 Patent were invalid, that the remaining asserted claims of the &#8216;066 Patent were not infringed by the Company.  In January 2021, the Company filed a petition for </span><i style="font-style:italic;">inter partes</i><span style="white-space:pre-wrap;"> review with the Patent Trial and Appeal Board (the &#8220;PTAB&#8221;) relating to the &#8216;793 Patent, seeking a determination that the claims in the &#8216;793 Patent are invalid. In July 2022, the PTAB ruled in the Company&#8217;s favor, concluding that based on the preponderance of the evidence, all the claims of the &#8217;793 Patent have been shown to be unpatentable. These decisions related to the &#8216;901 Patent, the &#8216;066 Patent and the &#8216;793 Patent have all been affirmed on appeal and are not subject to further appeal.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In connection with an amendment to the Company&#8217;s NDA filed in July 2023 to add PH-ILD as an indication for YUTREPIA, the Company provided a new notice of the paragraph IV certification to United Therapeutics as the owner of the patents that are the subject of the certification to which the NDA for YUTREPIA refers. As a result, in September 2023, United Therapeutics filed a second complaint for patent infringement against the Company in the U.S. District Court for the District of Delaware (Case No. 1:23-cv-00975-RGA) (the &#8220;New Hatch-Waxman Litigation&#8221;), again asserting infringement by the Company of the &#8216;793 Patent.  In November 2023, the U.S. Patent and Trademark Office (the &#8220;USPTO&#8221;) issued U.S. Patent No. 11,826,327, or the &#8216;327 Patent, entitled &#8220;Treatment for Interstitial Lung Disease&#8221;, to United Therapeutics. On November 30, 2023, United Therapeutics filed an amended complaint in the New Hatch-Waxman Litigation asserting infringement of the &#8216;327 Patent by the practice of YUTREPIA based on the amended NDA.  In January 2024, the Company filed an answer, counterclaims and a partial motion to dismiss the claims related to the &#8216;793 Patent as a result of the decision by the United States Court of Appeals for the Federal Circuit to affirm the PTAB&#8217;s finding that the &#8217;793 patent is unpatentable.  In February 2024, United Therapeutics stipulated to the dismissal of the claims in the New Hatch-Waxman Litigation related to the &#8216;793 Patent.  In February 2024, United Therapeutics also filed a motion seeking a preliminary injunction to prevent the Company from manufacturing, marketing, storing, importing, distributing, offering for sale, and/or selling YUTREPIA for the treatment of PH-ILD.  Judge Andrews denied the motion for a preliminary injunction in May 2024. Discovery in the case remains ongoing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FDA Litigation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In February 2024, United Therapeutics filed a complaint against the FDA in the U.S. District Court for the District of Columbia (the &#8220;D.C. District Court&#8221;), challenging the FDA&#8217;s acceptance of the Company&#8217;s amended NDA for review (the &#8220;Original FDA Litigation&#8221;).  The Company intervened and became a party to the lawsuit in March 2024.  </span><span style="letter-spacing:0.2pt;">In March&#160;2024, United Therapeutics filed a motion for a temporary restraining order and preliminary injunction in the FDA Litigation, seeking to enjoin the FDA from approving the Company&#8217;s NDA for YUTREPIA with respect to the indication to treat PH-ILD. United Therapeutics&#8217; motion was denied in March&#160;2024. On August&#160;20, 2024, United Therapeutics voluntarily dismissed its complaint, without prejudice.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On August 21, 2024, the Company filed a lawsuit in the D.C. District Court to challenge the decision by the FDA to grant three-year regulatory exclusivity to Tyvaso DPI (the &#8220;New FDA Litigation&#8221;). The D.C. District Court has granted the parties&#8217; motion for an expedited summary judgment briefing schedule, with briefing to be completed on or before November 15, 2024 and a summary judgment hearing scheduled for December 5, 2024.  On September 16, 2024, United Therapeutics filed a cross claim in the New FDA Litigation, re-asserting its challenge to FDA&#8217;s acceptance of the Company&#8217;s amended NDA for review.  The Company intervened and became a party with respect to the cross claim on November 5, 2024.  United Therapeutics has filed a motion for an expedited summary judgment briefing schedule for its cross claim.  That motion remains pending.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Trade Secret Litigation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In December 2021, United Therapeutics filed a complaint in the Superior Court in Durham County, North Carolina, alleging that the Company and Robert Roscigno (&#8220;Dr. Roscigno&#8221;) a former United Therapeutics employee, who later joined the Company as an employee many years after terminating his employment with United Therapeutics, conspired to misappropriate certain trade secrets of United Therapeutics and engaged in unfair or deceptive trade practices. In January 2024, Dr. Roscigno filed a motion for summary judgment with respect to all claims, but the motion was denied in July 2024.  In addition, in July 2024, the Company filed a motion for summary judgment with respect to all claims.  A hearing on the Company&#8217;s motion for summary judgment has been scheduled for December 19, 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">In May 2024, United Therapeutics filed a second complaint in the Superior Court in Durham County, North Carolina, against Dr. Roscigno, alleging that he breached prior employment agreements with United Therapeutics by failing to assign to United Therapeutics his interest in patents obtained by the Company that relied upon or benefitted from certain inventions, discoveries, materials, authorship, derivatives and results developed by Dr. Roscigno while he was employed by United Therapeutics. The Company was also named as a defendant in this new lawsuit. As part of the lawsuit, United Therapeutics alleges that Dr. Roscigno misappropriated certain intellectual property of United Therapeutics which led to the development of YUTREPIA. The complaint also seeks declaratory judgement such that all right, title and interest in and to any patentable or unpatentable inventions, discoveries, and ideas made or conceived by Dr. Roscigno while employed by the Company should be assigned and transferred to United Therapeutics because they involved the use of United Therapeutics&#8217; confidential information. On July 30, 2024, the Company filed a motion to dismiss all claims.  A hearing on the Company&#8217;s motion to dismiss has been scheduled for December 19, 2024.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RareGen Litigation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In April 2019, Sandoz and Liquidia PAH (then known as RareGen) filed a complaint against United Therapeutics and Smiths Medical (now ICU Medical) in the District Court of New Jersey (Case No. No. 3:19 cv 10170), (the &#8220;RareGen Litigation&#8221;), alleging that United Therapeutics and Smiths Medical violated the Sherman Antitrust Act of 1890, state law antitrust statutes and unfair competition statutes by engaging in anticompetitive acts regarding the drug treprostinil for the treatment of PAH. In March 2020, Sandoz and Liquidia PAH filed a first amended complaint adding a claim that United Therapeutics breached a settlement agreement that was entered into in 2015, in which United Therapeutics agreed to not interfere with Sandoz&#8217;s efforts to launch its generic treprostinil, by taking calculated steps to restrict and interfere with the launch of Sandoz&#8217;s competing generic product. United Therapeutics developed treprostinil under the brand name Remodulin&#174; and Smiths Medical manufactured a pump and cartridges that are used to inject treprostinil into patients continuously throughout the day. Sandoz and Liquidia PAH allege that United Therapeutics and Smiths Medical entered into anticompetitive agreements (i) whereby Smiths Medical placed restrictions on the cartridges such that they can only be used with United Therapeutics&#8217; branded Remodulin&#174; product and (ii) requiring Smiths Medical to enter into agreements with specialty pharmacies to sell the cartridges only for use with Remodulin&#174;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In November 2020, Sandoz and Liquidia PAH entered into a binding term sheet (the &#8220;Term Sheet&#8221;) with Smiths Medical in order to resolve the outstanding RareGen Litigation solely with respect to disputes between Smiths Medical, Liquidia PAH and Sandoz. In April 2021, Liquidia PAH and Sandoz entered into a Long Form Settlement Agreement (the &#8220;Settlement Agreement&#8221;) with Smiths Medical to further detail the terms of the settlement among such parties as reflected in the Term Sheet. Pursuant to the Term Sheet and the Settlement Agreement, the former RareGen members and Sandoz received a payment of $4.25 million that was evenly split between the parties. In addition, pursuant to the Term Sheet and Settlement Agreement, Smiths Medical disclosed and made available to Sandoz and Liquidia PAH </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">certain specifications and other information related to the cartridge that Smiths Medical developed and manufactures for use with the CADD-MS 3 infusion pump (the &#8220;CADD-MS 3 Cartridge&#8221;). Pursuant to the Settlement Agreement, Smiths Medical also granted Liquidia PAH and Sandoz a non-exclusive, royalty-free license in the United States to Smiths Medical&#8217;s patents and copyrights associated with the CADD-MS 3 Cartridge and certain other information for use of the CADD-MS 3 pump and the CADD-MS 3 Cartridges. Smiths also agreed in the Settlement Agreement to provide information and assistance in support of Liquidia PAH&#8217;s efforts to receive FDA clearance for the RG 3ml Medication Cartridge (the &#8220;RG Cartridge&#8221;) and to continue to service certain CADD-MS 3 pumps that are available for use with the Treprostinil Injection through January 1, 2025. Liquidia PAH and Sandoz agreed, among other things, to indemnify Smiths from certain liabilities related to the RG Cartridge.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">In September 2021, United Therapeutics filed a motion for summary judgment with respect to all of the claims brought by Sandoz and Liquidia PAH against United Therapeutics. At the same time, Sandoz filed a motion for summary judgment with respect to the breach of contract claim. In March 2022, the Court issued an order granting partial summary judgment to United Therapeutics with respect to the antitrust and unfair competition claims, denying summary judgment to United Therapeutics with respect to the breach of contract claim, and granting partial summary judgment to Sandoz with respect to the breach of contract claim. A trial to determine the amount of damages due from United Therapeutics to Sandoz with respect to the breach of contract claim was held from late April to early May 2024, and closing arguments were held in June 2024.  On November 1, 2024, the Court entered a judgment in the amount of </span>$70.6<span style="white-space:pre-wrap;"> million.  United Therapeutics has filed a notice of its intent to appeal the decision.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Under the Promotion Agreement, all proceeds from the litigation will be divided evenly between Sandoz and Liquidia PAH. Under the litigation finance agreements that Liquidia PAH has entered into with Henderson and PBM, any net proceeds received by Liquidia PAH with respect to the RareGen Litigation will be divided between Henderson and PBM.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_LegalProceedingsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal Proceedings Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_LegalProceedingsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262515232752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">15. Subsequent Event</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On October 2, 2024, we and Pharmosa entered into a First Amendment to the Pharmosa License Agreement (the &#8220;First Amendment&#8221;) and concurrently entered into a <span style="color:#212529;">Device License Agreement with Pharmosa. See Note 13 for additional information.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262513272352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (23,155)<span></span>
</td>
<td class="num">$ (27,942)<span></span>
</td>
<td class="num">$ (40,928)<span></span>
</td>
<td class="num">$ (15,790)<span></span>
</td>
<td class="num">$ (23,517)<span></span>
</td>
<td class="num">$ (11,745)<span></span>
</td>
<td class="num">$ (92,025)<span></span>
</td>
<td class="num">$ (51,052)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262513738704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262509431200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Significant Accounting Policies and Fair Value Measurements (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Basis of Presentation, Significant Accounting Policies and Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The unaudited interim condensed consolidated financial statements as of September&#160;30,&#160;2024 and for the three and nine months ended September&#160;30,&#160;2024 and 2023 have been prepared pursuant to the rules&#160;and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for interim financial reporting. These condensed consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal recurring adjustments and accruals) necessary for a fair statement of the results for the periods presented in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). The year-end condensed consolidated balance sheet data was derived from our audited consolidated financial statements but does not include all disclosures required by GAAP. Operating results for the three and nine months ended September&#160;30,&#160;2024 are not necessarily indicative of the results that may be expected for the fiscal&#160;year ending December&#160;31,&#160;2024. Certain information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with GAAP have been omitted in accordance with the SEC&#8217;s rules&#160;and regulations for interim reporting. <span style="background:#ffffff;">Certain amounts have been reclassified from the prior year presentation to conform to current presentation, specifically in relation to the balance sheet presentation of finance and operating leases. </span>Our financial position, results of operations and cash flows are presented in U.S. Dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with our audited consolidated financial statements for the&#160;year ended December&#160;31,&#160;2023, which are included in our 2023 Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31,&#160;2023 (the &#8220;2023 Annual Report on Form 10-K&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the period. These estimates are based on historical experience and various other assumptions believed to be reasonable under the circumstances. We evaluate our estimates on an ongoing basis, including those related to the valuation of stock-based awards, certain accruals, the revenue interest financing payable, and intangible and contract acquisition cost amortization, and make changes to the estimates and related disclosures as our experience develops or new information becomes known. Actual results will most likely differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segment Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">GAAP requires segmentation based on an entity&#8217;s internal organization and reporting of revenue and operating income based upon internal accounting methods commonly referred to as the &#8220;management approach.&#8221; Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources and in assessing performance. Our CODM is our Chief Executive Officer. We have determined that we have one&#160;operating and reporting segment.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board under its accounting standards codifications (ASC) or other standard setting bodies and are adopted by us as of the specified effective date. For the nine months ended September&#160;30,&#160;2024, there were no newly adopted accounting pronouncements that had a material impact on our condensed consolidated financial statements. As of September&#160;30,&#160;2024, there are no recently issued but not yet adopted accounting pronouncements that are expected to materially impact our condensed consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock', window );">Cash, Cash Equivalents, and Concentration of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash, Cash Equivalents, and Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We consider all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject us to concentrations of credit risk consist of cash and cash equivalents. We are exposed to credit risk, subject to federal deposit insurance, in the event of default by the financial institutions holding our cash and cash equivalents to the extent of amounts recorded on the condensed consolidated balance sheet. Our cash and cash equivalents are held at multiple accredited financial institutions. We have not experienced any losses on such accounts and do not believe that we are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Such deposits have exceeded and will continue to exceed federally insured limits.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accounts Receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accounts receivable are stated at net realizable value and net of an allowance for credit losses as of each balance sheet date, if applicable. One customer accounted for 96% and 99% of our accounts receivable, net at September&#160;30,&#160;2024 and December&#160;31,&#160;2023, respectively. As of September&#160;30,&#160;2024 and December&#160;31,&#160;2023, we have not recorded an allowance for credit losses.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Prelaunch Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Prelaunch Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We capitalize prelaunch inventory prior to receiving regulatory approval if regulatory approval and subsequent commercialization of a product is probable and we also expect future economic benefit from the sales of the product to be realized. Prior to this conclusion, we expense prelaunch inventory as research and development expense in the period incurred. For prelaunch inventory that is capitalized, we consider a number of specific facts and circumstances, including the product&#8217;s shelf life, the product's current status in the development and regulatory approval process, results from related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential obstacles to the approval process, viability of commercialization and market trends. In late 2023, based on our assessment of the legal and regulatory process related to YUTREPIA, we concluded that we met the criteria to capitalize expenditures for prelaunch inventory. We capitalized $7.4 million of prelaunch inventory as of September&#160;30,&#160;2024 and none as of December&#160;31,&#160;2023. If either regulatory approval or market acceptance post-approval of YUTREPIA do not occur at all or on a timely basis prior to the inventory shelf-life expiration,&#160;we may be required to write-off some or all prelaunch inventory, which could affect our financial condition and financial results.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;">We review long-lived assets, including definite-life intangible assets, for realizability on an ongoing basis. Changes in depreciation and amortization, generally accelerated depreciation and variable amortization, are determined and recorded when estimates of the remaining useful lives or residual values of long-term assets change. We also review </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 12pt 0pt;">for impairment when conditions exist that indicate the carrying amount of the assets may not be fully recoverable. In those circumstances, we perform undiscounted operating cash flow analyses to determine if an impairment exists. When testing for asset impairment, we group assets and liabilities at the lowest level for which cash flows are separately identifiable. Any impairment loss is calculated as the excess of the asset&#8217;s carrying value over its estimated fair value. Fair value is estimated based on the discounted cash flows for the asset group over the remaining useful life or based on the expected cash proceeds for the asset less costs of disposal. Any impairment losses would be recorded in the consolidated statements of operations. To date, no such impairments have occurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Goodwill</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 12pt 0pt;">We assess goodwill for impairment at least annually as of July 1 or whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. For example, significant and unanticipated changes or our inability to obtain or maintain regulatory approvals for our product candidates, including the NDA for YUTREPIA, could trigger testing of our goodwill for impairment at an interim date. We have one reporting unit. We have the option to first assess qualitative factors to determine whether events or circumstances indicate it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, in which case a quantitative impairment test is not required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Per ASC 350, <i style="font-style:italic;">Intangibles Goodwill and Other, </i>the quantitative goodwill impairment test is performed by comparing the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not impaired. An impairment loss is recognized for any excess of the carrying amount of the reporting unit&#8217;s goodwill over the fair value up to the amount of goodwill allocated to the reporting unit. Income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit are considered when measuring the goodwill impairment loss, if applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of September&#160;30,&#160;2024, we concluded there were no events or changes in circumstances which indicated that the carrying amount of goodwill was not recoverable. We completed our annual impairment test as of July 1, 2024 and concluded that no impairments had occurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingPayablePolicyPolicyTextBlock', window );">Revenue Interest Financing Payable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Interest Financing Payable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recognized a liability related to amounts received in January 2023, July 2023, and January 2024 pursuant to the RIFA under ASC 470-10, <i style="font-style:italic;">Debt</i> and ASC 835-30, <i style="font-style:italic;">Interest - Imputation of Interest</i>. The liability will be accreted under the effective interest method based upon the estimated amount of future payments to be made pursuant to the RIFA. If the timing or amounts of any estimated future payments change, we will prospectively adjust the effective interest and the related amortization of the liability and related issuance costs. A significant increase or decrease in these estimates could materially impact the liability balance and related interest expense.<b style="font-weight:bold;"> </b>Amendments are assessed under ASC 470 to determine appropriate treatment as troubled debt restructurings, extinguishments or modifications.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We recognize revenue in accordance with ASC 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;). The core principle of ASC 606 is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:16.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Step 1: Identify the contract with the customer</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:16.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Step 2: Identify the performance obligations in the contract</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:16.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Step 3: Determine the transaction price</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:16.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Step 4: Allocate the transaction price to the performance obligations in the contract</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:16.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Step 5: Recognize revenue when the company satisfies a performance obligation</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In order to identify the performance obligations in a contract with a customer, we assess the promised goods or services in the contract and identify each promised good or service that is distinct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If a good or service is not distinct, the good or service is combined with other promised goods or services until a bundle of goods or services is identified that is distinct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. We evaluate any non-cash consideration, consideration payable to the customer, potential returns and refunds, and whether consideration contains a significant financing element in determining the transaction price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Revenue is measured based on consideration specified in a contract with a customer. We recognize revenue when it satisfies a performance obligation by transferring control over a service to a customer. The amount of revenue recognized reflects estimates for refunds and returns, which are presented as a reduction of accounts receivable where the right of setoff exists.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred in accordance with ASC 730,&#160;<i style="font-style:italic;">Research and Development</i> and include facility-related costs related to research and development activities, direct costs from third parties, such as contract research organizations (&#8220;CROs&#8221;), contract manufacturing organizations (CMOs&#8221;), and consultants, as well as employee-related expenses, including salaries, benefits, and stock-based compensation. Research and development expenses also include costs of acquired product licenses and related technology rights where there is no alternative future use.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_AccruedResearchAndDevelopmentExpensePolicyTextBlock', window );">Accrued Research and Development Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Accrued Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As part of the process of preparing the condensed consolidated financial statements, we are required to estimate accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our condensed consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of these estimates with the service providers and make adjustments if necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The significant estimates in our accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities. The financial terms of our agreements with CROs and CMOs are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from such estimate, we adjust the accrual or prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We estimate the grant date fair value of stock-based awards and amortize this fair value to compensation expense over the requisite service period or the vesting period of the respective award. In arriving at stock-based compensation expense, we estimate the number of stock-based awards that will be forfeited due to employee turnover. The forfeiture assumption is based primarily on turn-over historical experience. If the actual forfeiture rate is higher than the estimated forfeiture rate, then an adjustment will be made to increase the estimated forfeiture rate, which will result in a decrease to the expense recognized in our financial statements. If the actual forfeiture rate is lower than the&#160;estimated forfeiture rate, then an adjustment will be made to lower the&#160;estimated forfeiture rate, which will result in an increase to expense recognized in our financial statements. The expense we recognize in future periods will be affected by changes in the&#160;estimated forfeiture rate and may differ from amounts recognized in the current period. See Note 9.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. Due to their anti-dilutive effect, the calculation of diluted net loss per share excludes the following common stock equivalent shares:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,113,427</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,573,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,372,790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,494,833</p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted Stock Units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,131,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,704,353</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,062,498</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,689,998</p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 450,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 450,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 450,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 450,000</p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,695,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,728,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,885,288</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,634,831</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Certain common stock warrants are included in the calculation of basic and diluted net loss per share since their exercise price is de minimis.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">ASC 825,<span style="font-family:'Calibri','Helvetica','sans-serif';"> </span><i style="font-style:italic;">Financial Instruments</i> defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants (an exit price). As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. ASC 825 establishes a three-tiered approach for valuation of financial instruments, which requires that fair value measurements be classified and disclosed in one of three tiers, whether or not recognized on our condensed consolidated balance sheets at fair value. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Level 1&#160;&#8212; Quoted prices in active markets for identical assets or liabilities;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Level 2&#160;&#8212; Inputs other than quoted prices included in active markets that are observable for the asset or liability, either directly or indirectly; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Level 3&#160;&#8212; Unobservable inputs for the asset and liability used to measure fair value, to the extent that observable inputs are not available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following table presents the placement in the fair value hierarchy of financial assets and liabilities measured at fair value as of September&#160;30,&#160;2024 and December&#160;31,&#160;2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Money market funds (cash equivalents)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198,565</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198,565</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds (cash equivalents)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79,912</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Money market funds are included in cash and cash equivalents on our condensed consolidated balance sheet and are classified within Level 1 of the fair value hierarchy since they are valued using quoted market prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts reflected in our condensed consolidated balance sheets for cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their short-term nature. The carrying value of the revenue interest financing payable approximate fair value as the respective interest rates are reflective of current market rates on debt with similar terms and conditions. In addition, the revenue interest financing payable is <span style="background:#ffffff;">updated with the expected amount to be paid back each reporting period based on the contractual terms and current projections.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_AccruedResearchAndDevelopmentExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_AccruedResearchAndDevelopmentExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents and concentration of credit risk the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingPayablePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue interest financing payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingPayablePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262515778592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Significant Accounting Policies and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Basis of Presentation, Significant Accounting Policies and Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of calculation of diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,113,427</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,573,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,372,790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,494,833</p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted Stock Units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,131,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,704,353</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,062,498</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,689,998</p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 450,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 450,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 450,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 450,000</p></td></tr><tr><td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,695,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,728,033</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,885,288</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,634,831</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of financial assets and liabilities measured at fair value</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Money market funds (cash equivalents)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198,565</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198,565</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Prices&#160;in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Markets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Money market funds (cash equivalents)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79,912</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79,912</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262513749200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-size:13.5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Work in process</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,835</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,442</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Recognized as:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262515964528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant, and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant, and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, plant and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lab and build-to-suit equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,834</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 241</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 241</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer and other equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 740</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 487</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,450</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,409</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Construction-in-progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,315</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 804</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23,718</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,794</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,934)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,314)</p></td></tr><tr><td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property, plant and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,480</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262513850912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Acquisition Costs and Intangible Asset (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract', window );"><strong>Contract Acquisition Costs and Intangible Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_ScheduleOfContractAcquisitionCostsAndIntangibleAssetsTableTextBlock', window );">Schedule of contract acquisition costs and intangible asset</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:25.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:25.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross Carrying Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net Carrying Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross Carrying Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated Amortization</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Net Carrying Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract acquisition costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,980</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,547)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,433</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,980</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,058)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,922</p></td></tr><tr><td style="vertical-align:bottom;width:46.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,401)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,219</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,190)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,430</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Acquisition Costs and Intangible Asset [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_ScheduleOfContractAcquisitionCostsAndIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contract acquisition costs and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_ScheduleOfContractAcquisitionCostsAndIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262515711840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Accrued expenses and other current liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,488</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,544</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,381</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,902</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued inventory costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,954</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,039</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,400</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for Accrued Expenses and Other Current Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262513860240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of outstanding warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:35.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:30.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration Date</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 250,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">January 6, 2032</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">February 26, 2031</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">n/a<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">1</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">February 26, 2031</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 56,397</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">December 31, 2026</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262514684784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense recognized for employees and non-employees</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">By Expense Category:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 839</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 555</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,676</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,932</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,935</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,487</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,777</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,538</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock', window );">Schedule of unamortized compensation expense and weighted average remaining recognition period</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of&#160;September&#160;30,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Recognition</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unamortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Period</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,789</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.6</p></td></tr><tr><td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted and performance stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.5</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used for estimating the fair value of stock options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_fljXNZJ780WhJZl0xfbOZw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_KgzYt7L2DEmD5XrMEpBoAQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.98%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.46% - 4.62%</p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">90%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">91% - 95%</p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.8 - 6.1</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding as of December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,573,937</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.86</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (351,653)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (179,926)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.24</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Outstanding as of September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,049,858</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.76</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 47,835</p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,649,860</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 37,106</p></td></tr><tr><td style="vertical-align:bottom;width:53.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested and expected to vest as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,772,869</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,661</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of unvested RSU awards outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant-Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">RSUs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(per&#160;RSU)</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested as of December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,657,978</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.41</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,146,517</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.57</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (615,827)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.48</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (94,047)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.52</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,094,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10.64</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lqda_EmployeeStockPurchasePlan2020Member', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used for estimating the fair value of stock options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_od59HwKFmkW8EjvwzxxZHg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden__L855O1ENEa44A4aGasXbw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">4.80% - 5.27%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.20% - 5.47%</p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">62% - 72%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">60% - 64%</p></td></tr><tr><td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected life (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.50</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (i)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lqda_EmployeeStockPurchasePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lqda_EmployeeStockPurchasePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262513889552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of lease cost</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:23.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Fixed lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 175</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 527</p></td></tr><tr><td style="vertical-align:bottom;width:23.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Fixed lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 59</p></td></tr><tr><td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:23.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 74</p></td></tr><tr><td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13</p></td></tr><tr><td style="vertical-align:bottom;width:23.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total Lease Cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 220</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 659</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 673</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The weighted average remaining lease term and discount rates as of September&#160;30,&#160;2024 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:88.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:88.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average remaining lease term (years):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average discount rate:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:88.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:88.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Finance leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_LeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum lease payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The future minimum lease payments as of September&#160;30,&#160;2024 were as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Finance</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Year ending December&#160;31:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024 (three months remaining)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 367</p></td></tr><tr><td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 64</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,434</p></td></tr><tr><td style="vertical-align:bottom;width:65.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,169</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,169</p></td></tr><tr><td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,877</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,970</p></td></tr><tr><td style="vertical-align:bottom;width:65.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (278)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (280)</p></td></tr><tr><td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,599</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,690</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_LeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability and finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_LeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262517042224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Interest Financing Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingPayableAbstract', window );"><strong>Revenue Interest Financing Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_ScheduleOfActivityOfRevenueInterestFinancingAgreementTableTextBlock', window );">Schedule of changes in the liability related to RIFA</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 46,033</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Second tranche funding, net of fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,975</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of January 5, 2024, prior to extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 71,117</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss on extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,483</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of January 5, 2024, after extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82,600</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,161</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,731)</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Second tranche funding, net of fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,485</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of September 12, 2024, prior to extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 119,515</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Gain) on extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,215)</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of September 12, 2024, after extinguishment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 112,300</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accretion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 844</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance as of September&#160;30,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 113,144</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: current portion of revenue interest financing payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,252)</p></td></tr><tr><td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Long-term portion of revenue interest financing payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 99,892</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_ScheduleOfExpectedAnnualPaymentsOnRevenueInterestFinancingAgreement', window );">Schedule of expected annual payments on the revenue interest financing payable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The expected annual payments on the revenue interest financing payable as of September&#160;30,&#160;2024 are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Year ending December&#160;31:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024 (three months remaining)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,122</p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,017</p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,724</p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,962</p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,962</p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 31,828</p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 170,615</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Interest Financing Payable [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_ScheduleOfActivityOfRevenueInterestFinancingAgreementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the liability related to the revenue interest financing agreement (RIFA).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_ScheduleOfActivityOfRevenueInterestFinancingAgreementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_ScheduleOfExpectedAnnualPaymentsOnRevenueInterestFinancingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the expected annual payments on the revenue interest financing payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_ScheduleOfExpectedAnnualPaymentsOnRevenueInterestFinancingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262513229632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business - Liquidity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 12, 2024</div></th>
<th class="th"><div>Jan. 04, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 11, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,155<span></span>
</td>
<td class="nump">$ 27,942<span></span>
</td>
<td class="nump">$ 40,928<span></span>
</td>
<td class="nump">$ 15,790<span></span>
</td>
<td class="nump">$ 23,517<span></span>
</td>
<td class="nump">$ 11,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,025<span></span>
</td>
<td class="nump">$ 51,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 521,123<span></span>
</td>
<td class="nump">521,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">521,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 429,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche', window );">Amount funded under the second tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts', window );">Net proceeds from issuance of common stock in public offering</a></td>
<td class="nump">$ 53,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts', window );">Net proceeds from issuance of common stock in private offering</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lqda_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementAmountFunded', window );">Total funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lqda_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement | HCR | For Calendar Year Beginning on January 1, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained', window );">Cash covenants, minimum cash and cash equivalents to be maintained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lqda_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement | HCR | After Calendar Year Ending on December 31 , 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained', window );">Cash covenants, minimum cash and cash equivalents to be maintained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember', window );">Fifth Amendment to Revenue Interest Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche', window );">Amount funded under the second tranche</a></td>
<td class="nump">$ 32,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, net of costs incurred directly with the issuance of the common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount net of issuance costs received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingAgreementAmountFunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount funded under the revenue interest financing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingAgreementAmountFunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount funded under the second tranche per the revenue financing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of cash and cash equivalent to be maintained per the cash covenants of the revenue interest financing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lqda_RevenueInterestFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lqda_RevenueInterestFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lqda_HealthcareRoyaltyPartnersIvL.pMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lqda_HealthcareRoyaltyPartnersIvL.pMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=lqda_ForCalendarYearBeginningOnJanuary12024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=lqda_ForCalendarYearBeginningOnJanuary12024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=lqda_AfterCalendarYearEndingOnDecember312024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=lqda_AfterCalendarYearEndingOnDecember312024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262513693952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Significant Accounting Policies and Fair Value Measurements - Other (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>customer </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_InventoryCapitalizedCost', window );">Inventory, Capitalized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember', window );">Credit Concentration Risk | Accounts Receivable | Customer One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_NumberOfCustomers', window );">Number of customers | customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_InventoryCapitalizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>the amount of Inventory, Capitalized Cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_InventoryCapitalizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=lqda_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=lqda_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262508946992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Significant Accounting Policies and Fair Value Measurements - Common Stock Equivalent Shares Excluded From Calculation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (in shares)</a></td>
<td class="nump">12,695,261<span></span>
</td>
<td class="nump">11,728,033<span></span>
</td>
<td class="nump">12,885,288<span></span>
</td>
<td class="nump">11,634,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (in shares)</a></td>
<td class="nump">9,113,427<span></span>
</td>
<td class="nump">9,573,680<span></span>
</td>
<td class="nump">9,372,790<span></span>
</td>
<td class="nump">9,494,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (in shares)</a></td>
<td class="nump">3,131,834<span></span>
</td>
<td class="nump">1,704,353<span></span>
</td>
<td class="nump">3,062,498<span></span>
</td>
<td class="nump">1,689,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (in shares)</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262515259872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation, Significant Accounting Policies and Fair Value Measurements - Fair Value of Financial Assets and Financial Liabilities (Details) - Money market funds (cash equivalents) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Reported Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value of Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 198,565<span></span>
</td>
<td class="nump">$ 79,912<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Fair Value, Inputs, Level 1 | Estimate of Fair Value Measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value of Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 198,565<span></span>
</td>
<td class="nump">$ 79,912<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262512976832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 2,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">4,835<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_InventoryCurrentAndNonCurrent', window );">Inventory</a></td>
<td class="nump">7,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Recognized as: Inventory</a></td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_CapitalizedCostsOfInventory', window );">Capitalized costs</a></td>
<td class="nump">7,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Recognized as: Other assets</a></td>
<td class="nump">$ 7,404<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_CapitalizedCostsOfInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of capitalized cost of inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_CapitalizedCostsOfInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_InventoryCurrentAndNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and non current inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_InventoryCurrentAndNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262513661936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant, and Equipment - Schedule of Property, plant and equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 23,718<span></span>
</td>
<td class="nump">$ 19,794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(15,934)<span></span>
</td>
<td class="num">(15,314)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">7,784<span></span>
</td>
<td class="nump">4,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lqda_LabAndBuildToSuitEquipmentMember', window );">Lab and build-to-suit equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">6,953<span></span>
</td>
<td class="nump">6,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer and other equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">740<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">11,450<span></span>
</td>
<td class="nump">11,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment</a></td>
<td class="nump">$ 4,315<span></span>
</td>
<td class="nump">$ 804<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lqda_LabAndBuildToSuitEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=lqda_LabAndBuildToSuitEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262513493248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant, and Equipment - Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant, and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262515079648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Contract Acquisition Costs and Intangible Asset - Summary (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract', window );"><strong>Contract Acquisition Costs and Intangible Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Contract acquisition costs, Gross Carrying Amount</a></td>
<td class="nump">$ 12,980<span></span>
</td>
<td class="nump">$ 12,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAccumulatedAmortization', window );">Contract acquisition costs, Accumulated Amortization</a></td>
<td class="num">(5,547)<span></span>
</td>
<td class="num">(5,058)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Contract acquisition costs, Net Carrying Amount</a></td>
<td class="nump">7,433<span></span>
</td>
<td class="nump">7,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible asset, Gross Carrying Amount</a></td>
<td class="nump">5,620<span></span>
</td>
<td class="nump">5,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible asset, Accumulated Amortization</a></td>
<td class="num">(2,401)<span></span>
</td>
<td class="num">(2,190)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible asset, Net Carrying Amount</a></td>
<td class="nump">$ 3,219<span></span>
</td>
<td class="nump">$ 3,430<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Acquisition Costs and Intangible Asset [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262517156560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Acquisition Costs and Intangible Asset - Other (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract', window );"><strong>Contract Acquisition Costs and Intangible Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Contract Acquisition Costs, Amortization Expense</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible Asset, Amortization Expense</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Acquisition Costs and Intangible Asset [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262512746688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Indemnification Asset with Related Party and Litigation Finance Payable (Details)<br></strong></div></th>
<th class="th"><div>Oct. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=lqda_PBMMember', window );">PBM</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Indemnification Asset with Related Party and Litigation Finance Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RelatedPartyTransactionMajorStockholderOwnershipPercentageInCompany', window );">Major stockholder ownership percentage of Liquidia Corporation Common Stock</a></td>
<td class="nump">7.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RelatedPartyTransactionMajorStockholderOwnershipPercentageInCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage ownership by a major stockholder in the Company, which also controls a specific entity in which the Company entered into a Litigation Funding and Indemnification Agreement with.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RelatedPartyTransactionMajorStockholderOwnershipPercentageInCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=lqda_PBMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=lqda_PBMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262515497616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 8,488<span></span>
</td>
<td class="nump">$ 8,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_AccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">2,381<span></span>
</td>
<td class="nump">2,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_AccruedInventoryCosts', window );">Accrued inventory costs</a></td>
<td class="nump">1,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other expenses</a></td>
<td class="nump">4,254<span></span>
</td>
<td class="nump">1,954<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_AccruedExpensesAndOtherLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 17,039<span></span>
</td>
<td class="nump">$ 13,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_AccruedExpensesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents carrying value as of the balance sheet date of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_AccruedExpensesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_AccruedInventoryCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued inventory costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_AccruedInventoryCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262514921072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 12, 2024</div></th>
<th class="th"><div>Jan. 08, 2024</div></th>
<th class="th"><div>Jan. 04, 2024</div></th>
<th class="th"><div>Dec. 12, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,677<span></span>
</td>
<td class="nump">$ 74,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts', window );">Net proceeds from issuance of common stock in private offering</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts', window );">Net proceeds from issuance of common stock in public offering</a></td>
<td class="nump">$ 53,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lqda_ArSvbWarrantsInitialTrancheMember', window );">Warrants, Expiration, January 6, 2032</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.14<span></span>
</td>
<td class="nump">$ 5.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lqda_SvbWarrantInitialTrancheMember', window );">Warrants, Initial Tranche, Expiration, February 26, 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lqda_SvbWarrantTermBAndTermCTranchesMember', window );">Warrants, Other Tranches, Expiration, February 26, 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lqda_OtherWarrantsMember', window );">Warrants, Expiration, December 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,397<span></span>
</td>
<td class="nump">56,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=lqda_WarrantsToPurchaseCommonStockMember', window );">Warrants to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Class of Warrant or Right, Exercised During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,175<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,182,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,123,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.90<span></span>
</td>
<td class="nump">8.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Before deducting offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Roger Jeffs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lqda_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,491,620<span></span>
</td>
<td class="nump">6,460,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.16<span></span>
</td>
<td class="nump">$ 8.90<span></span>
</td>
<td class="nump">$ 8.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_ProceedsFromIssuanceOfCommonStockNet', window );">Proceeds from Issuance of Common Stock, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments for offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lqda_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering | Board of Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lqda_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering | Caligan and Paul B. Manning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lqda_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering | Caligan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,117,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lqda_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering | Mr. Paul B. Manning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights exercised during period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_ProceedsFromIssuanceOfCommonStockNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_ProceedsFromIssuanceOfCommonStockNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, net of costs incurred directly with the issuance of the common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount net of issuance costs received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lqda_ArSvbWarrantsInitialTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lqda_ArSvbWarrantsInitialTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lqda_SvbWarrantInitialTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lqda_SvbWarrantInitialTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lqda_SvbWarrantTermBAndTermCTranchesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lqda_SvbWarrantTermBAndTermCTranchesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lqda_OtherWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lqda_OtherWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=lqda_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=lqda_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lqda_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lqda_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=lqda_BoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=lqda_BoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=lqda_LargestStockholderAndMemberOfBoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=lqda_LargestStockholderAndMemberOfBoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=lqda_CaliganPartnersLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=lqda_CaliganPartnersLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=lqda_Mr.PaulB.ManningMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=lqda_Mr.PaulB.ManningMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262514223456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Other (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jan. 25, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding', window );">Percentage of the number of shares of common stock issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuance', window );">Number of common stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based compensation arrangement by share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,146,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lqda_PerformanceBasedRestrictedStockUnitsMember', window );">Performance Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">520,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,413<span></span>
</td>
<td class="nump">67,982<span></span>
</td>
<td class="nump">59,641<span></span>
</td>
<td class="nump">81,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Share-based Payment Arrangement, Tranche One | Performance Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based compensation arrangement by share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based compensation arrangement by share-based payment award, award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Share-based Payment Arrangement, Tranche Two | Performance Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based compensation arrangement by share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based compensation arrangement by share-based payment award, award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lqda_The2020PlanMember', window );">The 2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentAnnualIncreaseInCapitalShareReservedForFutureIssuance', window );">Share-based compensation arrangement by share-based payment award, percent annual increase in capital shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-based compensation arrangement by share-based payment award, number of additional shares authorized (in shares)</a></td>
<td class="nump">2,745,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based compensation arrangement by share-based payment award, number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">473,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">473,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lqda_InducementPlan2022Member', window );">2022 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lqda_EmployeeStockPurchasePlan2020Member', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAvailableForIssuance', window );">Available of issuance under the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share-based compensation arrangement by share-based payment award, purchase price of common stock, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,395<span></span>
</td>
<td class="nump">140,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in shares available for issuance under the share based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentAnnualIncreaseInCapitalShareReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percent increase in number of shares reserved for future issuance under a share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentAnnualIncreaseInCapitalShareReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold increase in shares available for issuance under the share based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold increase in shares available for issuance as a percentage of shares issued and outstanding under the share based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lqda_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lqda_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lqda_The2020PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lqda_The2020PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lqda_InducementPlan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lqda_InducementPlan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lqda_EmployeeStockPurchasePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lqda_EmployeeStockPurchasePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262518556064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,881<span></span>
</td>
<td class="nump">$ 2,487<span></span>
</td>
<td class="nump">$ 13,777<span></span>
</td>
<td class="nump">$ 7,538<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">839<span></span>
</td>
<td class="nump">555<span></span>
</td>
<td class="nump">2,676<span></span>
</td>
<td class="nump">1,714<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,997<span></span>
</td>
<td class="nump">$ 1,932<span></span>
</td>
<td class="nump">$ 10,935<span></span>
</td>
<td class="nump">$ 5,824<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262514855104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Unamortized Compensation Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unamortized Expense</a></td>
<td class="nump">$ 9,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted Average Remaining Recognition Period (Years)</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unamortized Expense</a></td>
<td class="nump">$ 26,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted Average Remaining Recognition Period (Years)</a></td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262513009200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Fair Value of Stock Options Granted and Purchase Rights Issued under the ESPP (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value for options granted (in dollars per share)</a></td>
<td class="nump">$ 9.84<span></span>
</td>
<td class="nump">$ 5.09<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lqda_EmployeeStockPurchasePlan2020Member', window );">Employee Stock Purchase Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.46%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.62%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.98%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected Volatility, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected Volatility, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lqda_EmployeeStockPurchasePlan2020Member', window );">Employee Stock Purchase Plan | Employee Stock Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lqda_EmployeeStockPurchasePlan2020Member', window );">Employee Stock Purchase Plan | Employee Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lqda_EmployeeStockPurchasePlan2020Member', window );">Employee Stock Purchase Plan | Employee Purchase Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">5.27%<span></span>
</td>
<td class="nump">5.47%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected Volatility, minimum</a></td>
<td class="nump">62.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected Volatility, maximum</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lqda_EmployeeStockPurchasePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lqda_EmployeeStockPurchasePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lqda_EmployeePurchaseRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lqda_EmployeePurchaseRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262508876928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, number of shares (in shares)</a></td>
<td class="nump">9,573,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, number of shares (in shares)</a></td>
<td class="nump">7,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 12.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, number of shares (in shares)</a></td>
<td class="num">(351,653)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled, number of shares (in shares)</a></td>
<td class="num">(179,926)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 7.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, number of shares (in shares)</a></td>
<td class="nump">9,049,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average contractual term (Year)</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 47,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, number of shares (in shares)</a></td>
<td class="nump">6,649,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, weighted average contractual term (Year)</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 37,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, number of shares (in shares)</a></td>
<td class="nump">8,772,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 4.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, weighted average contractual term (Year)</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, aggregate intrinsic value</a></td>
<td class="nump">$ 46,661<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262517153648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Units (Details) - Restricted Stock Units<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, number (in shares) | shares</a></td>
<td class="nump">1,657,978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested , weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, number (in shares) | shares</a></td>
<td class="nump">2,146,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted , weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested , number (in shares) | shares</a></td>
<td class="num">(615,827)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested , weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited, number (in shares) | shares</a></td>
<td class="num">(94,047)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited , weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested , number (in shares) | shares</a></td>
<td class="nump">3,094,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested , weighted average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.64<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262518450896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue From Contracts With Customers (Details) - Sandoz - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_PromotionAgreementPayment', window );">Promotion Agreement, Payment</a></td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerRefundLiability', window );">Contract with Customer, Refund Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_PercentageOfRevenueFromPromotionAgreement', window );">Percentage of Revenue from Promotion Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_PercentageOfRevenueFromPromotionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue from Promotion Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_PercentageOfRevenueFromPromotionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_PromotionAgreementPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount paid by the Company at the inception of the Promotion Agreement, in consideration for the right to conduct promotional activities for the product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_PromotionAgreementPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerRefundLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerRefundLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lqda_SandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lqda_SandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262513345776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Other (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDiscountRate', window );">Lessee, Finance Lease, Discount Rate</a></td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of finance lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262515493328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total Lease Cost</a></td>
<td class="nump">$ 221<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 659<span></span>
</td>
<td class="nump">$ 673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Fixed lease cost</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="nump">527<span></span>
</td>
<td class="nump">527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of lease assets</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Fixed lease cost</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262518453856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Remaining Lease Term and Discount Rates (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term, Operating leases</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term, Finance leases</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate, Operating leases</a></td>
<td class="nump">10.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate, Finance leases</a></td>
<td class="nump">6.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262513787936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2024 (three months remaining)</a></td>
<td class="nump">$ 338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">1,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">1,169<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">2,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="num">(278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">2,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2024 (three months remaining)</a></td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_LeaseLiabilityPaymentsDueRemainderOfFiscalYear', window );">2024 (three months remaining)</a></td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_LeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">1,434<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_LeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">1,169<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_LeaseLiabilityPaymentsDueTotal', window );">Total minimum lease payments</a></td>
<td class="nump">2,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_LeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="num">(280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_LeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 2,690<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease and finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_LeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_LeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_LeaseLiabilityPaymentsDueRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments, to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_LeaseLiabilityPaymentsDueRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_LeaseLiabilityPaymentsDueTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease and finance lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_LeaseLiabilityPaymentsDueTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_LeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease and finance lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_LeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_LeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_LeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262509439952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Interest Financing Payable - Terms (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 12, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 05, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 04, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 27, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 27, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 09, 2023 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 11, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingPayableLineItems', window );"><strong>Revenue Interest Financing Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Amount of debt repaid with initial investment from RIFA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment</a></td>
<td class="num">$ (7,215)<span></span>
</td>
<td class="nump">$ 11,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,215<span></span>
</td>
<td class="num">$ (11,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,268)<span></span>
</td>
<td class="num">$ (2,311)<span></span>
</td>
<td class="num">$ (2,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche', window );">Amount funded under the second tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lqda_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingPayableLineItems', window );"><strong>Revenue Interest Financing Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementMaximumInvestmentAmount', window );">RIFA, maximum investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementNumberOfTranches', window );">RIFA, number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementInitialInvestmentAmount', window );">RIFA, initial investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementHardCapPercentage', window );">RIFA, Hard Cap percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_PercentageOfInvestmentAmountToBeRepaidOnFinalApproval', window );">Percentage of investment amount to be repaid on final approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_PercentageOfInvestmentAmountToBePaid', window );">Percentage of investment amount to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedDuringYearTwo', window );">Minimum cash and cash equivalents required to be maintained during next year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedAfterYearTwo', window );">Minimum cash and cash equivalents required to be maintained after December 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementAmountFunded', window );">RIFA, total amount funded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementEffectiveAnnualInterestRate', window );">Effective annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lqda_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement | On first funded portion of investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingPayableLineItems', window );"><strong>Revenue Interest Financing Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementInternalRateOfReturn', window );">RIFA, internal rate of return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementAmountFunded', window );">RIFA, total amount funded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lqda_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement | On second portion of funded investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingPayableLineItems', window );"><strong>Revenue Interest Financing Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementInternalRateOfReturn', window );">RIFA, internal rate of return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementAmountFunded', window );">RIFA, total amount funded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lqda_RevenueInterestFinancingAgreementMember', window );">Revenue Interest Financing Agreement | A&amp;R Silicon Valley Bank Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingPayableLineItems', window );"><strong>Revenue Interest Financing Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Amount of debt repaid with initial investment from RIFA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lqda_SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember', window );">Second and Third Amendments to Revenue Interest Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingPayableLineItems', window );"><strong>Revenue Interest Financing Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche', window );">Amount funded under the second tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lqda_FourthAmendmentToRevenueInterestFinancingAgreementMember', window );">Fourth Amendment to Revenue Interest Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingPayableLineItems', window );"><strong>Revenue Interest Financing Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche', window );">Amount funded under the second tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember', window );">Fifth Amendment to Revenue Interest Financing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingPayableLineItems', window );"><strong>Revenue Interest Financing Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche', window );">Amount funded under the second tranche</a></td>
<td class="nump">$ 32,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedAfterYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents to be maintained after year two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedAfterYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedDuringYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents to be maintained during year two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedDuringYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_PercentageOfInvestmentAmountToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of investment amount to be paid when payment has not been made in full on approval from FDA.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_PercentageOfInvestmentAmountToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_PercentageOfInvestmentAmountToBeRepaidOnFinalApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of investment amount to be repaid under the agreement on receiving approval from food and drug administration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_PercentageOfInvestmentAmountToBeRepaidOnFinalApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingAgreementAmountFunded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount funded under the revenue interest financing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingAgreementAmountFunded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount funded under the second tranche per the revenue financing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingAgreementEffectiveAnnualInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effective annual interest rate under revenue interest financing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingAgreementEffectiveAnnualInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingAgreementHardCapPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The hard cap expressed as percentage to terminate the interest revenue payment agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingAgreementHardCapPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingAgreementInitialInvestmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The initial investment amount received  under the revenue interest financing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingAgreementInitialInvestmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingAgreementInternalRateOfReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Internal rate of return on investment amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingAgreementInternalRateOfReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingAgreementIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance costs related to the revenue interest financing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingAgreementIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingAgreementMaximumInvestmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The investment amount received upfront under the revenue interest financing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingAgreementMaximumInvestmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingAgreementNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of tranches of the revenue interest financing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingAgreementNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingPayableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingPayableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lqda_RevenueInterestFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lqda_RevenueInterestFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=lqda_OnFirstFundedPortionOfInvestmentAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=lqda_OnFirstFundedPortionOfInvestmentAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=lqda_OnSecondPortionOfFundedInvestmentAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=lqda_OnSecondPortionOfFundedInvestmentAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lqda_ArSiliconValleyBankTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lqda_ArSiliconValleyBankTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lqda_SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lqda_SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lqda_FourthAmendmentToRevenueInterestFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lqda_FourthAmendmentToRevenueInterestFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262519829792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Interest Financing Payable - Summary (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 12, 2024</div></th>
<th class="th"><div>Jan. 05, 2024</div></th>
<th class="th"><div>Jan. 04, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 11, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingPayableAbstract', window );"><strong>Revenue Interest Financing Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreement', window );">Beginning balance</a></td>
<td class="nump">$ 119,515<span></span>
</td>
<td class="nump">$ 71,117<span></span>
</td>
<td class="nump">$ 46,033<span></span>
</td>
<td class="nump">$ 112,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,033<span></span>
</td>
<td class="nump">$ 82,600<span></span>
</td>
<td class="nump">$ 46,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche', window );">Second tranche funding, net of fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment</a></td>
<td class="num">(7,215)<span></span>
</td>
<td class="nump">11,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,215<span></span>
</td>
<td class="num">$ (11,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,268)<span></span>
</td>
<td class="num">$ (2,311)<span></span>
</td>
<td class="num">$ (2,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementAccretion', window );">Accretion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementAmortizationOfDebtDiscount', window );">Amortization of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_PaymentsOnRevenueInterestFinancingLiability', window );">Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,731)<span></span>
</td>
<td class="num">(2,731)<span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreement', window );">Ending balance</a></td>
<td class="nump">$ 112,300<span></span>
</td>
<td class="nump">$ 82,600<span></span>
</td>
<td class="nump">$ 71,117<span></span>
</td>
<td class="nump">113,144<span></span>
</td>
<td class="nump">113,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,515<span></span>
</td>
<td class="nump">113,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingPayableCurrent', window );">Less: current portion of revenue interest financing payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,252)<span></span>
</td>
<td class="num">(13,252)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,252)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,615)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingPayableNoncurrent', window );">Long-term portion of revenue interest financing payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,892<span></span>
</td>
<td class="nump">$ 99,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,418<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_PaymentsOnRevenueInterestFinancingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from payments on revenue interest financing liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_PaymentsOnRevenueInterestFinancingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue interest financing payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingAgreementAccretion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accretion expense related to the revenue interest financing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingAgreementAccretion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingAgreementAmortizationOfDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortization of debt discount related to the revenue interest financing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingAgreementAmortizationOfDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount funded under the second tranche per the revenue financing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Interest Financing Payable [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue interest financing payable, current portion as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingPayableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue interest financing payable, noncurrent portion as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingPayableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262508787488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue Interest Financing Payable - Expected Annual Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingPayableAbstract', window );"><strong>Revenue Interest Financing Payable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear', window );">2024 (three months remaining)</a></td>
<td class="nump">$ 2,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearOne', window );">2025</a></td>
<td class="nump">18,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearTwo', window );">2026</a></td>
<td class="nump">52,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearThree', window );">2027</a></td>
<td class="nump">32,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFour', window );">2028</a></td>
<td class="nump">32,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFiveAndThereafter', window );">Thereafter</a></td>
<td class="nump">31,828<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal', window );">Total</a></td>
<td class="nump">$ 170,615<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected payments on the revenue interest financing payable in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of total expected payments on the revenue interest financing payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFiveAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected payments on the revenue interest financing payable in fifth fiscal year and thereafter following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFiveAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected payments on the revenue interest financing payable in fourth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected payments on the revenue interest financing payable in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected payments on the revenue interest financing payable in third fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected payments on the revenue interest financing payable in second fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_RevenueInterestFinancingPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Interest Financing Payable [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_RevenueInterestFinancingPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262513664736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 14, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts', window );">Non-cancelable commitments for product manufacturing and supply costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=lqda_PharmosaLicenseAgreementMember', window );">Pharmosa License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_PaymentForUpfrontLicenseFee', window );">Upfront license fee to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_AccruedAdditionalUpfrontLicenseFee', window );">Accrued additional upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_MaximumPotentialDevelopmentMilestonePayments', window );">Maximum potential development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_MilestonePaymentsPayable', window );">Milestone payments Pharmosa is to receive per terms of the license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=lqda_PharmosaLicenseAgreementMember', window );">Pharmosa License Agreement | North America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_MaximumPotentialSalesMilestones', window );">Maximum potential sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=lqda_PharmosaLicenseAgreementMember', window );">Pharmosa License Agreement | Other then North America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_MaximumPotentialSalesMilestones', window );">Maximum potential sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=lqda_ChasmTechnologiesAgreementMember', window );">Chasm Technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties', window );">Maximum Net Sales Threshold As Basis For Payment Of Future Contingent Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_NetSalesEarnedRelatingToPaymentOfFutureContingentRoyalties', window );">Net sales earned relating to payment of future contingent royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=lqda_AgreementWithLGMPharmaLLCMember', window );">Agreement With LGM Pharma, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Purchase Commitment, Remaining Minimum Amount Committed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_AgreementExpirationTerm', window );">Expiration term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember', window );">Amended and Restated Commercial Manufacturing Services and Supply Agreement with Lonza Tampa LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_CommercialManufacturingServicesAndSupplyAgreementInitialTerm', window );">Initial term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection', window );">Termination term for FDA rejection</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay', window );">Termination term for FDA delay</a></td>
<td class="text">120 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures', window );">Percentage of reimburse</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_ReimbursementOfCapitalExpenditureIncurredBySupplier', window );">Aggregate exceed</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_TermOfSubmissionOfQuarterlyForecastOfExpectedProduction', window );">Term of submission</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lqda_InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder', window );">Initial term</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_AccruedAdditionalUpfrontLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued additional upfront license fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_AccruedAdditionalUpfrontLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_AgreementExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration term of the agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_AgreementExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_CommercialManufacturingServicesAndSupplyAgreementInitialTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial term of commercial manufacturing services and supply agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_CommercialManufacturingServicesAndSupplyAgreementInitialTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term term upon written notice in the event of application for regulatory approval is not received by FDA within the specified period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term term upon written notice in the event of application for regulatory approval is rejected by the FDA.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial term of submission of quarterly forecast of expected production considered as binding firm order.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum net sales amount that is used as the basis in determining the payment of future contingent royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_MaximumPotentialDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum potential development milestone payments per the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_MaximumPotentialDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_MaximumPotentialSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum potential sales milestones to be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_MaximumPotentialSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_MilestonePaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_MilestonePaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_NetSalesEarnedRelatingToPaymentOfFutureContingentRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net sales earned by the entity relating to payment of future contingent royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_NetSalesEarnedRelatingToPaymentOfFutureContingentRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of non-cancelable future commitments for product manufacturing and supply costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_PaymentForUpfrontLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for upfront license fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_PaymentForUpfrontLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reimbursement of documented out of pocket expenditures for any capital equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_ReimbursementOfCapitalExpenditureIncurredBySupplier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of reimbursement capital expenditure incurred by the supplier after the effective date of agreement to perform the services for the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_ReimbursementOfCapitalExpenditureIncurredBySupplier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lqda_TermOfSubmissionOfQuarterlyForecastOfExpectedProduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of submission of quarterly forecast of expected production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lqda_TermOfSubmissionOfQuarterlyForecastOfExpectedProduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lqda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=lqda_PharmosaLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=lqda_PharmosaLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=lqda_OtherThenNorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=lqda_OtherThenNorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=lqda_ChasmTechnologiesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=lqda_ChasmTechnologiesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=lqda_AgreementWithLGMPharmaLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=lqda_AgreementWithLGMPharmaLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46262517151424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings (Details) - Liquidia PAH and Sandoz - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2024</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=lqda_LiquidiaPAHAndSandozMember', window );">UTC and Smiths Medical Litigation | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal Proceedings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLegalSettlements', window );">Proceeds from Legal Settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=lqda_LiquidiaPAHAndSandozMember', window );">Breach of contract claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal Proceedings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Judgement amount awarded from other party</a></td>
<td class="nump">$ 70,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for the settlement of litigation during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lqda_LiquidiaPAHAndSandozMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lqda_LiquidiaPAHAndSandozMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lqda_UTCAndSmithsMedicalLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lqda_UTCAndSmithsMedicalLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lqda_BreachOfContractClaimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lqda_BreachOfContractClaimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>77
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MDE#*]$I=BS2$\[N>ZEP+N]E(H_%BV#+Q1#&A0SM"_>W(ZZ+H1E@H>^8LZ43
M,,MJ 670>9SHF*DICJ(Q1SKDPB2F4],L'9H/ZF\^H'=M-VU_/E#PE<B%DT2H
MW4^<1 1C,IX:78(AR8)L@@[IT'I0?^O14XER5"LG8+NIP#B(L'50:\N%"<DF
MQERZ=Z;L[SXLXNL2^=GH'<?,KD'3(><<-!=[+T7,&ZF_6',G*@7-Q H4@],$
M_&_ZESS]C99U]Y[D5FHM-]WEFC. ;03@]Y4$4MS>F%<ONU=MR_\!4$L#!!0
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M'*HY;IN*D94[L>ZDP?//%0N\H8"R =B_DM(\5NPAV-UYTG]02P,$%     @
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MYB]Z[+#N!*UV0O*R,U8S*/.J_9\\=4(<&2@_L 'I#(AIX \8>)V!]](1_,[
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MP+]?,U8=/X@*3D<"+O\'4$L#!!0    ( ,T[;5G9*BFP^Q   *LK   8
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MTM=!<72GP88>#S?]G^0'@'LUYH=5G,@N#J2(U(T]S!*CN_Q. S::(UH:%FS
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M7Y3?$,*FR<?;H[.35R^.Y&N=]$?O.OX<<^7ZWK7\$U46J(,6X/W:H9;&/^B
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M^7A\^.+FW15_.GKQ X,>Z-$C3E#8!D0_ .F<?ARIFI38!-"(3F X[<+4 (;
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MWI+#ET[(>1>CX]8=^U,83@N%Y6DLE$15Q-9 *B6PSKG<7I&GOE[ZQ0RPT&Q
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MYU-IPC2 MO*ZG<#EW;!+')J* ^?Y..:1NB1I@U![SF)08-6$OH#I%BUZ=AQ
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MRKDW]D@.!=UP<R]WWZ#-9VCY,LFU^Y)=$YN./))MM)%5"T8%%1/-2)_:.O0
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M=D_&1=,I7\*;]^:6JC43FG H$!H.1D./J*:'-X:1M>N;*VFP"[MIB<\>*!N
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M$C2&6 [L<MO45%QL*+  9(5,LQR!",TU,.W>2/I1+3ZE=]K@4^B*I%2*XHQ
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MR-P]KI 1I78"?5]((J$>V 7:V[;S_P!02P,$%     @ S3MM6=RL52^+#@
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M<4T2;V.\ >NIUJX9L('V@^7M'U!+ P04    " #-.VU9Q_\8ELT*  !K'P
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MA]+LLZ(<@,=P$FO03S^2 2O,(\\CLJE2W!CRS:'DHPP*$4 ^]-*AC8?UYX>
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M87!0)_W@QL)O0YYT'8NO8!3V:5+LKTS4&UH<I3%A.#4*2HXYE%6NAE?TO C
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M<C8 ;$";%]<K6:M"?* 4B.D.!;J22&V&\Q+1'!3E3EV[0KER\(KU$?YWKN9
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MZP6DA_<*!^5_DDYEG'Y30J-M4DXIQ3I4""A1+$IP-:+.96N,\ 35[\X3XF)
M)'^P$%RCGUO-M.QESYO1]?;#78Y/T8;FJE@XA^=-VT"0:8J"%T.J;:P0)0WF
MQ^/2P8E%7T.! ]>#=76OIB%2P?D%J%FEV,%GDTWP=-0Z2R',9C*HX<Y0M_'7
MP_KN.0$J.IR1#(5$@P[=@?W24,]$3.QWDF"DN!L)D0->5?%'&:WBV' -;5#V
M]_KCP?XN EUTA;R_=?L#S;J7F=HL'PY;^OL<]6C) 26NX6-(>T8#&?KT1<0
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M?&4TF."6DSJHFNUAV1X\?1B$85 )7%XN7&9NBKG4AN(9N0T^3^-K1R= >3L
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M0>0$H<#,.@*CQQ8O40@'(AE/'3/H2[K$W?,K_<;W3KVLF,%+)7[SW!;3X#R
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MJ#00SU>$\-U$.JC[Z. ?4$L#!!0    ( ,T[;5D >H^K0P(  (H&   9
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M"_.S &D#S/-,"'V:V WZWT_R!U!+ P04    " #-.VU9XR6ZA@L:  #*5@
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M.B98#%]/<>1.4/%%,:86DX=VV\..<])2G85#4H26)8LCB^V5*7#'Q#XA#+"
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MC&&&+R+T%+?6Y(A2O(P7C"ALD@TF]5QN8LB#B)VAD^'&SMNT)O N29F_YYI
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M"5%,2+(257'32D&XV^C:]0A7DA,%6VW4L0K=.<_ADK?O?W]*.W]0^'MJ?-P
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MXR9;ZJT';+@/]R42*9%Z*#^DF-E6JCM= !CRM>1"SYW"F.K4\W1:0$GUB:Q
MX$HN54D-BFKCZ4H!S1JCDGNA[X^]DC+A+&:-;JD6,UD;S@0L%=%U65+U< %<
M;N=.X.P4UVQ3&*OP%K.*;F %YK9:*I2\WDO&2A":24$4Y'/G/#B]&-G]S89/
M#+9Z;TYL)&LI[ZSP(9L[O@4$'%)C/5 <[N$2.+>.$,:7SJ?3'VD-]^<[[^^:
MV#&6-=5P*?EGEIEB[B0.R2"G-3?7<OL>NG@:@*GDNODEVVZO[Y"TUD:6G3$B
M*)EH1_JUNX>?,0@[@[#!W1[4H'Q+#5W,E-P297>C-SMI0FVL$1P3]J.LC,)5
MAG9F<4$UTT3F9*E @S#4WI5+5FPC6,Y2*@PY3U-9"\/$ABPE9RD#3:C(R#O*
M%/E$>0WD"JBN%>#',IJ\OJ%K#OK-S#,(T![CI1V8BQ9,^ 28*;F2PA2:_"$R
MR [M/0RLCR[<17<1#CI<075"(M\EH1_& _ZB_K:BQE_TVV[KV"6U&.+C&&R6
MGNJ*IC!W*HM"W8.S>/4B&/MG Q'&?83QD/?%JDU.&V-*>5KS)D0K9HS7!C(B
ML%)PJ36I ).[H J.Q3!\RJL72>A'9^17C3>% C@@4[_T%T(YOK(;D30&RC5&
M9YDSK-V-EE_[0C2PLC(RO2,?*WNQFDS=((C<.)S@;#2)W''BXRR:A.YD:F?Q
M-':3*"+7H(UBJ?T"K8-;P3#9(C>( MP0D\"=^+$;C2+4^>,0#1/4C9.I.\79
M9ZH4M=FY@Q*/?-?W_6?+-])03H+0'4]';C@.2( 'AXGK(T;4)@EJD\1JQY%%
M'@R0<M23<O2SI,R9H")E"(%J#:;-+<[HFG%F;*Z5;7)EA!J2VYR[MSEWC*+#
M9_YJBCXU_EW+YAOOE93GNE@B3_ FF.@U'TV!Q.VI_"]\GS>OYZ/#M2T\ML[W
MJELAOU?^:+RBZ@[V6/E!5/73XB62^,%6UL-D/$BQUW_"/2!!WWRK";_31(^:
MKC!+ 0_XNEI,)*]%AH]92G5!X$O-D$>V8#_:O"3!-'%'X]&>QLZ"\&Q0\ZW5
M_PS[#S+L+:0=P0+WL*#_3H)-L'@'X3/YU1H=*[O>7I]8@MHTW; F3</2MHR]
MMF^XS]L^\W%[VZWCM6X8/E\<<C3U3R98357; ;>"D573=:ZEP1ZVF1;XIP&4
MW8#KN406=H(]H/\;LO@'4$L#!!0    ( ,T[;5F!*B<B=0(  )\&   9
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MI+$%S7=S^X* <@EV?BVEV05N@?9-2OX 4$L#!!0    ( ,T[;5E@?T7I^0(
M $0'   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;*55;6_3,!#^*U9
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M2_P=@;(.>+Z2TO0;FV#XP65_ 5!+ P04    " #-.VU9O%;")'D"  #R!0
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MQ?&^=XYVZK!"O0[=QD"N&FF[DNQ7^X9VV=7QG_"N&]XQO>;2@,"5H]+!R8B
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MD']S'WE5\*T-YEL-ZAI1*3"P"SRZ6I[I5,!4PV0'R N#44Q,UU= 9*S76!Y
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M"ZM^S:K?AKYXP.R*RQ0(7Y%4,R01E^H4RW:<]V_&@1=>DO_K]S$1  =7A&"
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MP?\5(/0&7%]QKO:"/J#^I[+X!U!+ P04    " #-.VU9)J=20MH#  #8"@
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M+>1*8IX:K; "12N7>'8AD:AFB"\ ]J"&X21+GX7^.Y<M:A))N]8*2:.%TJZ
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MCH?O>_0/CKPA\TP4S@7[FZ9Z,PUN TAQ34JFG\3N#ZP)#2Q>(IAR_["K;:,
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M&AQ/],$1;35J.XK7M@+<<:7KB6V6NH*#, OT_(ISM>L8 ?>?(/L#4$L#!!0
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MJ2H0/QX+CQ/)2G.RVC*ISFEFF*FC-.8:H.ZGC,GGB3ZL-8?SY4]02P,$%
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MWKQ 34>RRESB2R;5DV":N7JT@>L -;]B3+YT]+O0_0U(_@%02P,$%     @
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M0FD.E$9+VNEAD$G?&)_7 ]3,A=)\*(U!:1Q%4^NA,G--O9G[H\>/H,XME.9
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M3C;-^(L@>NRHRHTT==[;7Z1[NF97(]Z=IRQY8J/KG_ZESI3_=.D!"3-*V+*
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MH5A/G*$#(5ZB320>Z>XOG!/J*;P%C;C^A5T^UG-@L>&"QKFQ]" F2?:/WO)
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MHS@4Q[^*Q8Y6K=0&;,*MFT3J979W'D933:>SVD<73A)4P*SM).VWW\.ED$Z
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M$U96]_BJHD5>WIT?A,:;>%E< X] %AWP^5((_5(I)FB^IBS^!U!+ P04
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MQ5H^4=4I54?QTM8&<ZYTI6&;F:[M0)@%>G[!N=IV3("F6IS\!5!+ P04
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M!XI\)FA*N4"SD!$6A&R+[L@/\AA1=($>BGI#'STJ2!CQ3_+:MP</??SP"7U
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M7";&K^SNU:ZA1>/NLH70YF9TU<H\12#M!#.^%$*_->SUV#]N^6]02P,$%
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MT:,M)(O70-'0(K<7ZKW0=#W;:DP/*)1F HTOA-";AEF@>I*-?@-02P,$%
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M#^QBXL&)!=CNYV'@<:Y<61O76H@AR3$(LSKFVBG,Q^+&RG!7Q:FU$KM>\]]
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M]1GN^ZROC*QV+]7M7@C\^ ]02P,$%     @ S3MM6?5)DLP! @  7B0  !H
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MU2BR:A19-8JL,Q199_\IZZ.UJS^.'Y]%9YK^,Y^-_^VY>@=02P$"% ,4
M" #-.VU9!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( ,T[;5GUXB.Q[0   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( ,T[;5F97)PC
M$ 8  )PG   3              "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ S3MM61-BI(+7!0  _1X  !@              ("!# @
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( ,T[;5DAER5T
ME@8  '8;   8              " @1D.  !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4    " #-.VU9Y[I:V<,"  #_"   &
M@('E%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ S3MM
M66XYE*6E!0  A!D  !@              ("!WA<  'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0    ( ,T[;5GA4#3YH@P  &=T   8
M      " @;D=  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M" #-.VU9/'4B3;@*   >4   &               @(&1*@  >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#%     @ S3MM6=DJ*;#[$   JRL  !@
M             ("!?S4  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0    ( ,T[;5FB[NCB3!D  $]0   8              " @;!&  !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " #-.VU9Q7W2?W #  "?
M"   &               @($R8   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#%     @ S3MM64V!CV!; P  T @  !D              ("!V&,
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #-.VU9!?;/
MLRT$  #)#   &0              @(%J9P  >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0    ( ,T[;5DO"P?MV 4  .D/   9
M  " @<YK  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @
MS3MM6:\!?N>P @  5 <  !D              ("!W7$  'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4    " #-.VU9I43IP8(&  !Y$P  &0
M            @('$=   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0    ( ,T[;5G<K%4OBPX  !LP   9              " @7U[  !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ S3MM63+@0N\<!
MD@D  !D              ("!/XH  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4    " #-.VU9VXMVMF@'  "\%   &0              @(&2
MC@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( ,T[;5G'
M_QB6S0H  &L?   9              " @3&6  !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#%     @ S3MM64OT4$0F#0  02,  !D
M     ("!-:$  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,T[;5GC);J&"QH  ,I6   9              "
M@1W(  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ S3MM
M6:N(X92_ P  D@P  !D              ("!7^(  'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6Q02P$"% ,4    " #-.VU9@2HG(G4"  "?!@  &0
M        @(%5Y@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0
M   ( ,T[;5E@?T7I^0(  $0'   9              " @0'I  !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ S3MM6:=D7URH @  < <
M !D              ("!,>P  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q0
M2P$"% ,4    " #-.VU9C1Z3*:P"  #L!@  &0              @($0[P
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( ,T[;5F\5L(D
M>0(  /(%   9              " @?/Q  !X;"]W;W)K<VAE971S+W-H965T
M,S N>&UL4$L! A0#%     @ S3MM690.K/+F!0  ^A0  !D
M ("!H_0  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #-
M.VU9[@+C'_X#  "U#   &0              @(' ^@  >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( ,T[;5DFIU)"V@,  -@*   9
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M970S-RYX;6Q02P$"% ,4    " #-.VU9!]YJCJ4"   ?"   &0
M    @(&J%0$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (
M ,T[;5EW#/(BI@,  *@/   9              " @888 0!X;"]W;W)K<VAE
M971S+W-H965T,SDN>&UL4$L! A0#%     @ S3MM68.?-]6, @  Y <  !D
M             ("!8QP! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"
M% ,4    " #-.VU9A$E9F,P"  #S"   &0              @($F'P$ >&PO
M=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( ,T[;5E5W-!PL0(
M  P)   9              " @2DB 0!X;"]W;W)K<VAE971S+W-H965T-#(N
M>&UL4$L! A0#%     @ S3MM60I<5]PW @  +04  !D              ("!
M$24! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " #-.VU9
M%RB\C+H"   2"   &0              @(%_)P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0T+GAM;%!+ 0(4 Q0    ( ,T[;5D:X_9=!@L  #.%   9
M      " @7 J 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%
M  @ S3MM64FDJ]>A"0  K&X  !D              ("!K34! 'AL+W=O<FMS
M:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " #-.VU9+(KE-%H#  !.#@
M&0              @(&%/P$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+
M 0(4 Q0    ( ,T[;5EWOFIXKP(  &$'   9              " @19# 0!X
M;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ S3MM61[JA]*1
M!   O18  !D              ("!_$4! 'AL+W=O<FMS:&5E=',O<VAE970T
M.2YX;6Q02P$"% ,4    " #-.VU9Z,?4Z#0$  !9$0  &0
M@('$2@$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( ,T[
M;5D^(D@P\P(  #D*   9              " @2]/ 0!X;"]W;W)K<VAE971S
M+W-H965T-3$N>&UL4$L! A0#%     @ S3MM68S9#:*[ @  'P@  !D
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M=#4V+GAM;%!+ 0(4 Q0    ( ,T[;5E2,T<1J L  !VH   9
M  " @1AB 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @
MS3MM64(JEL!V!0  OR0  !D              ("!]VT! 'AL+W=O<FMS:&5E
M=',O<VAE970U."YX;6Q02P$"% ,4    " #-.VU9(!N[&8@"  #H!@  &0
M            @(&D<P$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4
M Q0    ( ,T[;5E!-8VG) 8  &HB   9              " @6-V 0!X;"]W
M;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ S3MM60T+JSSL @
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M2P$"% ,4    " #-.VU9]4F2S $"  !>)   &@              @ %*B0$
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #-.VU9UDS
MDN !  #C(P  $P              @ &#BP$ 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     10!% -H2  "4C0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>190</ContextCount>
  <ElementCount>341</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>69</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995200090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995200100 - Statement - Condensed Consolidated Balance Sheets (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995200105 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995200200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995200400 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995210101 - Disclosure - Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureBusiness</Role>
      <ShortName>Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995210201 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurements</Role>
      <ShortName>Basis of Presentation, Significant Accounting Policies and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995210301 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureInventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995210401 - Disclosure - Property, Plant, and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosurePropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant, and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995210501 - Disclosure - Contract Acquisition Costs and Intangible Asset</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAsset</Role>
      <ShortName>Contract Acquisition Costs and Intangible Asset</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995210601 - Disclosure - Indemnification Asset with Related Party and Litigation Finance Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureIndemnificationAssetWithRelatedPartyAndLitigationFinancePayable</Role>
      <ShortName>Indemnification Asset with Related Party and Litigation Finance Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995210701 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995210801 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995210901 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995211001 - Disclosure - Revenue From Contracts With Customers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureRevenueFromContractsWithCustomers</Role>
      <ShortName>Revenue From Contracts With Customers</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995211101 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995211201 - Disclosure - Revenue Interest Financing Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureRevenueInterestFinancingPayable</Role>
      <ShortName>Revenue Interest Financing Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995211301 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995211401 - Disclosure - Legal Proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureLegalProceedings</Role>
      <ShortName>Legal Proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995211501 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>99920202 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsPolicies</Role>
      <ShortName>Basis of Presentation, Significant Accounting Policies and Fair Value Measurements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>99930203 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsTables</Role>
      <ShortName>Basis of Presentation, Significant Accounting Policies and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>99930303 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureInventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://liquidia.com/role/DisclosureInventory</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>99930403 - Disclosure - Property, Plant, and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, Plant, and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://liquidia.com/role/DisclosurePropertyPlantAndEquipment</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>99930503 - Disclosure - Contract Acquisition Costs and Intangible Asset (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetTables</Role>
      <ShortName>Contract Acquisition Costs and Intangible Asset (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAsset</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>99930703 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>99930803 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://liquidia.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>99930903 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://liquidia.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>99931103 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://liquidia.com/role/DisclosureLeases</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>99931203 - Disclosure - Revenue Interest Financing Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTables</Role>
      <ShortName>Revenue Interest Financing Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://liquidia.com/role/DisclosureRevenueInterestFinancingPayable</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>99940101 - Disclosure - Business - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureBusinessLiquidityDetails</Role>
      <ShortName>Business - Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>99940201 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements - Other (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails</Role>
      <ShortName>Basis of Presentation, Significant Accounting Policies and Fair Value Measurements - Other (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>99940202 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements - Common Stock Equivalent Shares Excluded From Calculation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsCommonStockEquivalentSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Basis of Presentation, Significant Accounting Policies and Fair Value Measurements - Common Stock Equivalent Shares Excluded From Calculation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>99940203 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements - Fair Value of Financial Assets and Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsFairValueOfFinancialAssetsAndFinancialLiabilitiesDetails</Role>
      <ShortName>Basis of Presentation, Significant Accounting Policies and Fair Value Measurements - Fair Value of Financial Assets and Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>99940301 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureInventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://liquidia.com/role/DisclosureInventoryTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>99940401 - Disclosure - Property, Plant, and Equipment - Schedule of Property, plant and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant, and Equipment - Schedule of Property, plant and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>99940402 - Disclosure - Property, Plant, and Equipment - Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentExpenseDetails</Role>
      <ShortName>Property, Plant, and Equipment - Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>99940501 - Disclosure - Contract Acquisition Costs and Intangible Asset - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetSummaryDetails</Role>
      <ShortName>Contract Acquisition Costs and Intangible Asset - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>99940502 - Disclosure - Contract Acquisition Costs and Intangible Asset - Other (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetOtherDetails</Role>
      <ShortName>Contract Acquisition Costs and Intangible Asset - Other (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>99940601 - Disclosure - Indemnification Asset with Related Party and Litigation Finance Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureIndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDetails</Role>
      <ShortName>Indemnification Asset with Related Party and Litigation Finance Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://liquidia.com/role/DisclosureIndemnificationAssetWithRelatedPartyAndLitigationFinancePayable</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>99940701 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>99940801 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureStockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://liquidia.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>99940901 - Disclosure - Stock-Based Compensation - Other (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails</Role>
      <ShortName>Stock-Based Compensation - Other (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>99940902 - Disclosure - Stock-Based Compensation - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>99940903 - Disclosure - Stock-Based Compensation - Unamortized Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureStockBasedCompensationUnamortizedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Unamortized Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>99940904 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options Granted and Purchase Rights Issued under the ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails</Role>
      <ShortName>Stock-Based Compensation - Fair Value of Stock Options Granted and Purchase Rights Issued under the ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>99940905 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>99940906 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>99941001 - Disclosure - Revenue From Contracts With Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureRevenueFromContractsWithCustomersDetails</Role>
      <ShortName>Revenue From Contracts With Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://liquidia.com/role/DisclosureRevenueFromContractsWithCustomers</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>99941101 - Disclosure - Leases - Other (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureLeasesOtherDetails</Role>
      <ShortName>Leases - Other (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>99941102 - Disclosure - Leases - Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureLeasesCostDetails</Role>
      <ShortName>Leases - Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>99941103 - Disclosure - Leases - Remaining Lease Term and Discount Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureLeasesRemainingLeaseTermAndDiscountRatesDetails</Role>
      <ShortName>Leases - Remaining Lease Term and Discount Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>99941104 - Disclosure - Leases - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>99941201 - Disclosure - Revenue Interest Financing Payable - Terms (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails</Role>
      <ShortName>Revenue Interest Financing Payable - Terms (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>99941202 - Disclosure - Revenue Interest Financing Payable - Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableSummaryDetails</Role>
      <ShortName>Revenue Interest Financing Payable - Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>99941203 - Disclosure - Revenue Interest Financing Payable - Expected Annual Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableExpectedAnnualPaymentsDetails</Role>
      <ShortName>Revenue Interest Financing Payable - Expected Annual Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>99941301 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://liquidia.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="lqda-20240930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>99941401 - Disclosure - Legal Proceedings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://liquidia.com/role/DisclosureLegalProceedingsDetails</Role>
      <ShortName>Legal Proceedings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://liquidia.com/role/DisclosureLegalProceedings</ParentRole>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>lqda-20240930.xsd</File>
    <File>lqda-20240930_cal.xml</File>
    <File>lqda-20240930_def.xml</File>
    <File>lqda-20240930_lab.xml</File>
    <File>lqda-20240930_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="lqda-20240930x10q.htm">lqda-20240930x10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>lqda-20240930x10q002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="567">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>84
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lqda-20240930x10q.htm": {
   "nsprefix": "lqda",
   "nsuri": "http://liquidia.com/20240930",
   "dts": {
    "schema": {
     "local": [
      "lqda-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "lqda-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lqda-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "lqda-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lqda-20240930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "lqda-20240930x10q.htm"
     ]
    }
   },
   "keyStandard": 244,
   "keyCustom": 97,
   "axisStandard": 28,
   "axisCustom": 0,
   "memberStandard": 30,
   "memberCustom": 37,
   "hidden": {
    "total": 11,
    "http://fasb.org/us-gaap/2023": 6,
    "http://xbrl.sec.gov/dei/2023": 5
   },
   "contextCount": 190,
   "entityCount": 1,
   "segmentCount": 69,
   "elementCount": 599,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 567,
    "http://xbrl.sec.gov/dei/2023": 29,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://liquidia.com/role/DocumentDocumentAndEntityInformation",
     "longName": "995200090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
     "longName": "995200100 - Statement - Condensed Consolidated Balance Sheets (unaudited)",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParentheticals",
     "longName": "995200105 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parentheticals)",
     "shortName": "Condensed Consolidated Balance Sheets (unaudited) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
     "longName": "995200200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
     "longName": "995200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited)",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aaTdBw1wLEmeLLnJDiO8qg",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_z8Y4XLDSWUyq3w7U4D0TuQ",
      "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
     "longName": "995200400 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://liquidia.com/role/DisclosureBusiness",
     "longName": "995210101 - Disclosure - Business",
     "shortName": "Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurements",
     "longName": "995210201 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements",
     "shortName": "Basis of Presentation, Significant Accounting Policies and Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://liquidia.com/role/DisclosureInventory",
     "longName": "995210301 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://liquidia.com/role/DisclosurePropertyPlantAndEquipment",
     "longName": "995210401 - Disclosure - Property, Plant, and Equipment",
     "shortName": "Property, Plant, and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAsset",
     "longName": "995210501 - Disclosure - Contract Acquisition Costs and Intangible Asset",
     "shortName": "Contract Acquisition Costs and Intangible Asset",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "lqda:ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "lqda:ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://liquidia.com/role/DisclosureIndemnificationAssetWithRelatedPartyAndLitigationFinancePayable",
     "longName": "995210601 - Disclosure - Indemnification Asset with Related Party and Litigation Finance Payable",
     "shortName": "Indemnification Asset with Related Party and Litigation Finance Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "lqda:IndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "lqda:IndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "longName": "995210701 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "lqda:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "lqda:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://liquidia.com/role/DisclosureStockholdersEquity",
     "longName": "995210801 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://liquidia.com/role/DisclosureStockBasedCompensation",
     "longName": "995210901 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://liquidia.com/role/DisclosureRevenueFromContractsWithCustomers",
     "longName": "995211001 - Disclosure - Revenue From Contracts With Customers",
     "shortName": "Revenue From Contracts With Customers",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://liquidia.com/role/DisclosureLeases",
     "longName": "995211101 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "lqda:LeaseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "lqda:LeaseDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayable",
     "longName": "995211201 - Disclosure - Revenue Interest Financing Payable",
     "shortName": "Revenue Interest Financing Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "lqda:RevenueInterestFinancingPayableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "lqda:RevenueInterestFinancingPayableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://liquidia.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "995211301 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://liquidia.com/role/DisclosureLegalProceedings",
     "longName": "995211401 - Disclosure - Legal Proceedings",
     "shortName": "Legal Proceedings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://liquidia.com/role/DisclosureSubsequentEvents",
     "longName": "995211501 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R23": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsPolicies",
     "longName": "99920202 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements (Policies)",
     "shortName": "Basis of Presentation, Significant Accounting Policies and Fair Value Measurements (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsTables",
     "longName": "99930203 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements (Tables)",
     "shortName": "Basis of Presentation, Significant Accounting Policies and Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://liquidia.com/role/DisclosureInventoryTables",
     "longName": "99930303 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentTables",
     "longName": "99930403 - Disclosure - Property, Plant, and Equipment (Tables)",
     "shortName": "Property, Plant, and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetTables",
     "longName": "99930503 - Disclosure - Contract Acquisition Costs and Intangible Asset (Tables)",
     "shortName": "Contract Acquisition Costs and Intangible Asset (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "lqda:ScheduleOfContractAcquisitionCostsAndIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "lqda:ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "lqda:ScheduleOfContractAcquisitionCostsAndIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "lqda:ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "99930703 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "lqda:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "lqda:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "lqda:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "lqda:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://liquidia.com/role/DisclosureStockholdersEquityTables",
     "longName": "99930803 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://liquidia.com/role/DisclosureStockBasedCompensationTables",
     "longName": "99930903 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://liquidia.com/role/DisclosureLeasesTables",
     "longName": "99931103 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTables",
     "longName": "99931203 - Disclosure - Revenue Interest Financing Payable (Tables)",
     "shortName": "Revenue Interest Financing Payable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "lqda:ScheduleOfActivityOfRevenueInterestFinancingAgreementTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "lqda:ScheduleOfActivityOfRevenueInterestFinancingAgreementTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://liquidia.com/role/DisclosureBusinessLiquidityDetails",
     "longName": "99940101 - Disclosure - Business - Liquidity (Details)",
     "shortName": "Business - Liquidity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails",
     "longName": "99940201 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements - Other (Details)",
     "shortName": "Basis of Presentation, Significant Accounting Policies and Fair Value Measurements - Other (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_segment_5Yg_HHT1gEGJPlsg-11Qtw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_segment_5Yg_HHT1gEGJPlsg-11Qtw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsCommonStockEquivalentSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
     "longName": "99940202 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements - Common Stock Equivalent Shares Excluded From Calculation of Diluted Net Loss Per Share (Details)",
     "shortName": "Basis of Presentation, Significant Accounting Policies and Fair Value Measurements - Common Stock Equivalent Shares Excluded From Calculation of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsFairValueOfFinancialAssetsAndFinancialLiabilitiesDetails",
     "longName": "99940203 - Disclosure - Basis of Presentation, Significant Accounting Policies and Fair Value Measurements - Fair Value of Financial Assets and Financial Liabilities (Details)",
     "shortName": "Basis of Presentation, Significant Accounting Policies and Fair Value Measurements - Fair Value of Financial Assets and Financial Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_ANzvLLeodEu35lLZjmLNlw",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_ANzvLLeodEu35lLZjmLNlw",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://liquidia.com/role/DisclosureInventoryDetails",
     "longName": "99940301 - Disclosure - Inventory (Details)",
     "shortName": "Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails",
     "longName": "99940401 - Disclosure - Property, Plant, and Equipment - Schedule of Property, plant and equipment (Details)",
     "shortName": "Property, Plant, and Equipment - Schedule of Property, plant and equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentExpenseDetails",
     "longName": "99940402 - Disclosure - Property, Plant, and Equipment - Expense (Details)",
     "shortName": "Property, Plant, and Equipment - Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetSummaryDetails",
     "longName": "99940501 - Disclosure - Contract Acquisition Costs and Intangible Asset - Summary (Details)",
     "shortName": "Contract Acquisition Costs and Intangible Asset - Summary (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg",
      "name": "us-gaap:CapitalizedContractCostGross",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "lqda:ScheduleOfContractAcquisitionCostsAndIntangibleAssetsTableTextBlock",
       "lqda:ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg",
      "name": "us-gaap:CapitalizedContractCostGross",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "lqda:ScheduleOfContractAcquisitionCostsAndIntangibleAssetsTableTextBlock",
       "lqda:ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetOtherDetails",
     "longName": "99940502 - Disclosure - Contract Acquisition Costs and Intangible Asset - Other (Details)",
     "shortName": "Contract Acquisition Costs and Intangible Asset - Other (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q",
      "name": "us-gaap:CapitalizedContractCostAmortization",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "lqda:ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q",
      "name": "us-gaap:CapitalizedContractCostAmortization",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "lqda:ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://liquidia.com/role/DisclosureIndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDetails",
     "longName": "99940601 - Disclosure - Indemnification Asset with Related Party and Litigation Finance Payable (Details)",
     "shortName": "Indemnification Asset with Related Party and Litigation Finance Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "As_Of_10_30_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lqda_PBMMember_BakiyxxweE66bApftnb0xA",
      "name": "lqda:RelatedPartyTransactionMajorStockholderOwnershipPercentageInCompany",
      "unitRef": "Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_10_30_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lqda_PBMMember_BakiyxxweE66bApftnb0xA",
      "name": "lqda:RelatedPartyTransactionMajorStockholderOwnershipPercentageInCompany",
      "unitRef": "Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "99940701 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "lqda:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "lqda:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "lqda:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "lqda:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://liquidia.com/role/DisclosureStockholdersEquityDetails",
     "longName": "99940801 - Disclosure - Stockholders' Equity (Details)",
     "shortName": "Stockholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_WarrantsToPurchaseCommonStockMember_nREMiBhLNEmIWUNmI18Y6Q",
      "name": "lqda:ClassOfWarrantOrRightExercisedDuringPeriod",
      "unitRef": "Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails",
     "longName": "99940901 - Disclosure - Stock-Based Compensation - Other (Details)",
     "shortName": "Stock-Based Compensation - Other (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "Duration_11_1_2020_To_11_30_2020_lTtrHrdNKk2SU5Ol2ar1-w",
      "name": "lqda:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding",
      "unitRef": "Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_11_1_2020_To_11_30_2020_lTtrHrdNKk2SU5Ol2ar1-w",
      "name": "lqda:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding",
      "unitRef": "Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://liquidia.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
     "longName": "99940902 - Disclosure - Stock-Based Compensation - Stock-based Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation - Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://liquidia.com/role/DisclosureStockBasedCompensationUnamortizedCompensationExpenseDetails",
     "longName": "99940903 - Disclosure - Stock-Based Compensation - Unamortized Compensation Expense (Details)",
     "shortName": "Stock-Based Compensation - Unamortized Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2wjFZ4y_OU6vooFOFqzXIQ",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2wjFZ4y_OU6vooFOFqzXIQ",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails",
     "longName": "99940904 - Disclosure - Stock-Based Compensation - Fair Value of Stock Options Granted and Purchase Rights Issued under the ESPP (Details)",
     "shortName": "Stock-Based Compensation - Fair Value of Stock Options Granted and Purchase Rights Issued under the ESPP (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://liquidia.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
     "longName": "99940905 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://liquidia.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
     "longName": "99940906 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details)",
     "shortName": "Stock-Based Compensation - Restricted Stock Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_kteGXRriH0alvhRWw4-p7w",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_kteGXRriH0alvhRWw4-p7w",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://liquidia.com/role/DisclosureRevenueFromContractsWithCustomersDetails",
     "longName": "99941001 - Disclosure - Revenue From Contracts With Customers (Details)",
     "shortName": "Revenue From Contracts With Customers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "Duration_8_1_2018_To_8_31_2018_srt_CounterpartyNameAxis_lqda_SandozMember_bR-PCAVcsEa0W4IuOAk7hQ",
      "name": "lqda:PromotionAgreementPayment",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_8_1_2018_To_8_31_2018_srt_CounterpartyNameAxis_lqda_SandozMember_bR-PCAVcsEa0W4IuOAk7hQ",
      "name": "lqda:PromotionAgreementPayment",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://liquidia.com/role/DisclosureLeasesOtherDetails",
     "longName": "99941101 - Disclosure - Leases - Other (Details)",
     "shortName": "Leases - Other (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg",
      "name": "us-gaap:LesseeFinanceLeaseDiscountRate",
      "unitRef": "Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "lqda:LeaseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg",
      "name": "us-gaap:LesseeFinanceLeaseDiscountRate",
      "unitRef": "Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "lqda:LeaseDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://liquidia.com/role/DisclosureLeasesCostDetails",
     "longName": "99941102 - Disclosure - Leases - Cost (Details)",
     "shortName": "Leases - Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q",
      "name": "us-gaap:LeaseCost",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q",
      "name": "us-gaap:LeaseCost",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://liquidia.com/role/DisclosureLeasesRemainingLeaseTermAndDiscountRatesDetails",
     "longName": "99941103 - Disclosure - Leases - Remaining Lease Term and Discount Rates (Details)",
     "shortName": "Leases - Remaining Lease Term and Discount Rates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails",
     "longName": "99941104 - Disclosure - Leases - Future Minimum Lease Payments (Details)",
     "shortName": "Leases - Future Minimum Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "lqda:LeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "lqda:LeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails",
     "longName": "99941201 - Disclosure - Revenue Interest Financing Payable - Terms (Details)",
     "shortName": "Revenue Interest Financing Payable - Terms (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ",
      "name": "us-gaap:RepaymentsOfDebt",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_9_2023_To_1_9_2023_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_fo6QHS2lUkOEV604PgAJ-g",
      "name": "lqda:RevenueInterestFinancingAgreementMaximumInvestmentAmount",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableSummaryDetails",
     "longName": "99941202 - Disclosure - Revenue Interest Financing Payable - Summary (Details)",
     "shortName": "Revenue Interest Financing Payable - Summary (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "As_Of_9_11_2024_Ev9Bn70vFE2agHiszGrR1Q",
      "name": "lqda:RevenueInterestFinancingAgreement",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "lqda:ScheduleOfActivityOfRevenueInterestFinancingAgreementTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_1_4_2024_lOhuZ940QEqjnjbxJodNUA",
      "name": "lqda:RevenueInterestFinancingAgreementAccretion",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "lqda:ScheduleOfActivityOfRevenueInterestFinancingAgreementTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableExpectedAnnualPaymentsDetails",
     "longName": "99941203 - Disclosure - Revenue Interest Financing Payable - Expected Annual Payments (Details)",
     "shortName": "Revenue Interest Financing Payable - Expected Annual Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg",
      "name": "lqda:RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "lqda:ScheduleOfExpectedAnnualPaymentsOnRevenueInterestFinancingAgreement",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg",
      "name": "lqda:RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "lqda:ScheduleOfExpectedAnnualPaymentsOnRevenueInterestFinancingAgreement",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "longName": "99941301 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg",
      "name": "lqda:NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg",
      "name": "lqda:NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://liquidia.com/role/DisclosureLegalProceedingsDetails",
     "longName": "99941401 - Disclosure - Legal Proceedings (Details)",
     "shortName": "Legal Proceedings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2021_To_4_30_2021_dei_LegalEntityAxis_lqda_LiquidiaPAHAndSandozMember_srt_LitigationCaseAxis_lqda_UTCAndSmithsMedicalLitigationMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_HugoVmm5y0mmurW4-YSz7g",
      "name": "us-gaap:ProceedsFromLegalSettlements",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2021_To_4_30_2021_dei_LegalEntityAxis_lqda_LiquidiaPAHAndSandozMember_srt_LitigationCaseAxis_lqda_UTCAndSmithsMedicalLitigationMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_HugoVmm5y0mmurW4-YSz7g",
      "name": "us-gaap:ProceedsFromLegalSettlements",
      "unitRef": "Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lqda-20240930x10q.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation, Significant Accounting Policies and Fair Value Measurements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r642"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable",
        "terseLabel": "Accounts Receivable",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215"
     ]
    },
    "lqda_AccretionAndNonCashInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "AccretionAndNonCashInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion and non-cash interest expense.",
        "label": "Accretion and Non-Cash Interest Expense",
        "terseLabel": "Accretion and non-cash interest expense"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_AccruedAdditionalUpfrontLicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "AccruedAdditionalUpfrontLicenseFee",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued additional upfront license fee.",
        "label": "Accrued Additional Upfront License Fee",
        "terseLabel": "Accrued additional upfront license fee"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_AccruedExpensesAndOtherCurrentLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accrued expenses and other current liabilities.",
        "label": "Accrued Expenses and Other Current Liabilities [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_AccruedExpensesAndOtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "AccruedExpensesAndOtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents carrying value as of the balance sheet date of accrued expenses and other current liabilities.",
        "label": "Accrued Expenses And Other Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_AccruedInventoryCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "AccruedInventoryCosts",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "lqda_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued inventory costs.",
        "label": "Accrued Inventory Costs",
        "terseLabel": "Accrued inventory costs"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_AccruedResearchAndDevelopmentExpensePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "AccruedResearchAndDevelopmentExpensePolicyTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accrued research and development expenses.",
        "label": "Accrued Research and Development Expense [Policy Text Block]",
        "terseLabel": "Accrued Research and Development Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_AccruedResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "lqda_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued research and development expenses.",
        "label": "Accrued Research and Development Expenses",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
        "negatedLabel": "Accumulated depreciation and amortization",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r140",
      "r506"
     ]
    },
    "lqda_AcquiredInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "AcquiredInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired in-process research and development.",
        "label": "Acquired In Process Research and Development",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r642",
      "r826"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r390",
      "r391",
      "r524",
      "r752",
      "r753",
      "r754",
      "r806",
      "r828"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r53",
      "r353"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Before deducting offering costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r106"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_AfterCalendarYearEndingOnDecember312024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "AfterCalendarYearEndingOnDecember312024Member",
     "presentation": [
      "http://liquidia.com/role/DisclosureBusinessLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to period, after the calendar year ending on December 31, 2024.",
        "label": "After Calendar Year Ending on December 31 , 2024 [Member]",
        "terseLabel": "After Calendar Year Ending on December 31 , 2024"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r663",
      "r674",
      "r684",
      "r709"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r666",
      "r677",
      "r687",
      "r712"
     ]
    },
    "lqda_AgreementExpirationTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "AgreementExpirationTerm",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://liquidia.com/role/DisclosureLeasesOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration term of the agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Agreement Expiration Term",
        "terseLabel": "Expiration term of agreement"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_AgreementWithLGMPharmaLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "AgreementWithLGMPharmaLLCMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to agreement with LGM Pharma, LLC.",
        "label": "Agreement With LGM Pharma, LLC [Member]",
        "terseLabel": "Agreement With LGM Pharma, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r670",
      "r678",
      "r688",
      "r705",
      "r713",
      "r717",
      "r725"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "terseLabel": "Total stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r396"
     ]
    },
    "lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Amended and Restated Commercial Manufacturing Services and Supply Agreement with Lonza Tampa LLC.",
        "label": "Amended and Restated Commercial Manufacturing Services and Supply Agreement with Lonza Tampa LLC [Member]",
        "terseLabel": "Amended and Restated Commercial Manufacturing Services and Supply Agreement with Lonza Tampa LLC"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AmortizationOfIntangibleAssets",
        "terseLabel": "Intangible Asset, Amortization Expense",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r37",
      "r39"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsCommonStockEquivalentSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Anti-dilutive Shares Excluded from Calculation of Diluted Net Loss Per Share (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsCommonStockEquivalentSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsCommonStockEquivalentSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "lqda_ArSiliconValleyBankTermLoansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "ArSiliconValleyBankTermLoansMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to A&amp;R Silicon Valley bank term loans.",
        "label": "A&amp;R Silicon Valley Bank Term Loan [Member]",
        "terseLabel": "A&amp;R Silicon Valley Bank Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_ArSvbWarrantsInitialTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "ArSvbWarrantsInitialTrancheMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to A&amp;R SVB Warrants - initial tranche.",
        "label": "A&amp;R SVB Warrants Initial Tranche",
        "verboseLabel": "Warrants, Expiration, January 6, 2032"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureBusinessLiquidityDetails",
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Assets",
        "totalLabel": "Total assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r144",
      "r162",
      "r190",
      "r204",
      "r208",
      "r249",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r403",
      "r407",
      "r423",
      "r500",
      "r551",
      "r642",
      "r654",
      "r774",
      "r775",
      "r814"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r147",
      "r162",
      "r249",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r403",
      "r407",
      "r423",
      "r642",
      "r774",
      "r775",
      "r814"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationUnamortizedCompensationExpenseDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://liquidia.com/role/DisclosureInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation, Significant Accounting Policies and Fair Value Measurements",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "lqda_BoardOfDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "BoardOfDirectorsMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to board of directors.",
        "label": "Board of Directors [Member]",
        "terseLabel": "Board of Directors"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_BreachOfContractClaimMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "BreachOfContractClaimMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureLegalProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to breach of contract claim.",
        "label": "Breach of Contract Claim [Member]",
        "terseLabel": "Breach of contract claim"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_BusinessAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "BusinessAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business [Abstract]",
        "label": "Business"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_BusinessCombinationContractAcquisitionCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "BusinessCombinationContractAcquisitionCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents net amount of contract acquisition costs in a business acquisition.",
        "label": "Contract acquisition costs, net",
        "terseLabel": "Contract acquisition costs, net"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_CaliganPartnersLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "CaliganPartnersLPMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to Caligan Partners LP (\"Caligan\").",
        "label": "Caligan [Member]",
        "terseLabel": "Caligan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in purchases of property and equipment in accounts payable and accrued expenses",
        "verboseLabel": "Non-cash increase in property, plant and equipment through accounts payable",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_CapitalizedContractCostAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedContractCostAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Acquisition Costs, Accumulated Amortization",
        "negatedLabel": "Contract acquisition costs, Accumulated Amortization",
        "documentation": "Amount of accumulated amortization of asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedContractCostAmortization",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Amortization Expense",
        "terseLabel": "Contract Acquisition Costs, Amortization Expense",
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "us-gaap_CapitalizedContractCostGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedContractCostGross",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Acquisition Costs, Gross",
        "terseLabel": "Contract acquisition costs, Gross Carrying Amount",
        "documentation": "Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "us-gaap_CapitalizedContractCostNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedContractCostNet",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Acquisition Costs Net",
        "terseLabel": "Contract acquisition costs, Net Carrying Amount",
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "lqda_CapitalizedCostsOfInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "CapitalizedCostsOfInventory",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of capitalized cost of inventory.",
        "label": "Capitalized Costs Of Inventory",
        "terseLabel": "Capitalized costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsFairValueOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reported Value Measurement",
        "documentation": "Measured as reported on the statement of financial position (balance sheet)."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58"
     ]
    },
    "lqda_CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents and concentration of credit risk the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents And Concentration of Credit Risk [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents, and Concentration of Credit Risk"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r138",
      "r613"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsFairValueOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r92",
      "r160"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r92"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "lqda_ChasmTechnologiesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "ChasmTechnologiesAgreementMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the agreement with Chasm Technologies, Inc.",
        "label": "Chasm Technologies [Member]",
        "terseLabel": "Chasm Technologies"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer",
        "terseLabel": "Roger Jeffs",
        "verboseLabel": "Chief Executive Officer"
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
        "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "lqda_ClassOfWarrantOrRightExercisedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "ClassOfWarrantOrRightExercisedDuringPeriod",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights exercised during period.",
        "label": "Class Of Warrant Or Right Exercised During Period",
        "terseLabel": "Class of Warrant or Right, Exercised During Period (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ClassOfWarrantOrRightOutstanding",
        "terseLabel": "Class of Warrant or Right, Outstanding (in shares)",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "lqda_CommercialManufacturingServicesAndSupplyAgreementInitialTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "CommercialManufacturingServicesAndSupplyAgreementInitialTerm",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial term of commercial manufacturing services and supply agreement.",
        "label": "Commercial Manufacturing Services and Supply Agreement, Initial Term",
        "terseLabel": "Initial term"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay": {
     "xbrltype": "durationItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term term upon written notice in the event of application for regulatory approval is not received by FDA within the specified period.",
        "label": "Commercial Manufacturing Services and Supply Agreement, Termination Term for FDA Delay",
        "terseLabel": "Termination term for FDA delay"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection": {
     "xbrltype": "durationItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term term upon written notice in the event of application for regulatory approval is rejected by the FDA.",
        "label": "Commercial Manufacturing Services and Supply Agreement, Termination Term for FDA Rejection",
        "terseLabel": "Termination term for FDA rejection"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Note 15)",
        "terseLabel": "Commitments and contingencies (Note 13)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r67",
      "r501",
      "r538"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r273",
      "r274",
      "r599",
      "r769"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
        "terseLabel": "Common stock, capital shares reserved for future issuance (in shares)",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails",
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r644",
      "r645",
      "r646",
      "r648",
      "r649",
      "r650",
      "r651",
      "r752",
      "r753",
      "r806",
      "r825",
      "r828"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r539"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r74",
      "r539",
      "r557",
      "r828",
      "r829"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock - $0.001 par value, 80,000,000 shares authorized as of June 30, 2021 and December 31, 2020, 51,975,049 and 43,336,277 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively",
        "terseLabel": "Common stock - $0.001 par value, 115,000,000 and 100,000,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively, 84,545,409 and 68,629,575 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r503",
      "r642"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer equipment",
        "terseLabel": "Computer and other equipment",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r59",
      "r60",
      "r213",
      "r598"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r59",
      "r60",
      "r213",
      "r518",
      "r598"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r59",
      "r60",
      "r213",
      "r598",
      "r733"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Percentage1",
        "terseLabel": "Concentration risk, percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r59",
      "r60",
      "r213"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r59",
      "r60",
      "r213",
      "r598"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction-in-progress",
        "terseLabel": "Construction-in-progress",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "lqda_ContractAcquisitionCostsAndIntangibleAssetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "ContractAcquisitionCostsAndIntangibleAssetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Acquisition Costs and Intangible Asset [Abstract]",
        "label": "Contract Acquisition Costs and Intangible Asset"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAsset"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for contract acquisition costs and intangible asset.",
        "label": "Contract Acquisition Costs and Intangible Asset Disclosure [Text Block]",
        "terseLabel": "Contract Acquisition Costs and Intangible Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerRefundLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerRefundLiability",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Refund Liability",
        "terseLabel": "Contract with Customer, Refund Liability",
        "documentation": "Amount of liability for consideration received or receivable from customer which is not included in transaction price, when consideration is expected to be refunded to customer."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of revenue",
        "terseLabel": "Cost of revenue",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r483"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of Revenue",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_CostsAndExpenses",
        "totalLabel": "Total costs and expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureBusinessLiquidityDetails",
      "http://liquidia.com/role/DisclosureRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r293",
      "r309",
      "r448",
      "r615",
      "r617"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditConcentrationRiskMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Concentration Risk",
        "terseLabel": "Credit Concentration Risk",
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "lqda_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to customer one.",
        "label": "Customer One [Member]",
        "terseLabel": "Customer One"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r70",
      "r71",
      "r113",
      "r114",
      "r165",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r431",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r750"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://liquidia.com/role/DisclosureBusinessLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "verboseLabel": "Business",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r431",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r750"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r165",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r431",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r750"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://liquidia.com/role/DisclosureBusinessLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r45",
      "r46",
      "r61",
      "r62",
      "r64",
      "r68",
      "r104",
      "r105",
      "r165",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r431",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r750"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DepreciationAndAmortization",
        "terseLabel": "Depreciation and amortization expense",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r41"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r195"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r354",
      "r385",
      "r386",
      "r388",
      "r638"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share, basic (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r180",
      "r182",
      "r184",
      "r185",
      "r186",
      "r188",
      "r418",
      "r419",
      "r497",
      "r511",
      "r619"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share, diluted (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r182",
      "r184",
      "r185",
      "r186",
      "r188",
      "r418",
      "r419",
      "r497",
      "r511",
      "r619"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30"
     ]
    },
    "lqda_EmployeePurchaseRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "EmployeePurchaseRightsMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to employees purchase rights awards.",
        "label": "Employee Purchase Rights [Member]",
        "terseLabel": "Employee Purchase Rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "lqda_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued compensation",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationUnamortizedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based awards, unamortized expense",
        "verboseLabel": "Unamortized Expense",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationUnamortizedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based awards, weighted average remaining recognition period (Year)",
        "terseLabel": "Weighted Average Remaining Recognition Period (Years)",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsCommonStockEquivalentSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationUnamortizedCompensationExpenseDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "lqda_EmployeeStockPurchasePlan2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "EmployeeStockPurchasePlan2020Member",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to 2020 employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan 2020 [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://liquidia.com/role/DisclosureLegalProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails",
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r133",
      "r150",
      "r151",
      "r152",
      "r166",
      "r167",
      "r168",
      "r170",
      "r176",
      "r178",
      "r189",
      "r250",
      "r251",
      "r322",
      "r389",
      "r390",
      "r391",
      "r399",
      "r400",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r417",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r445",
      "r513",
      "r514",
      "r515",
      "r524",
      "r580"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r663",
      "r674",
      "r684",
      "r709"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r660",
      "r671",
      "r681",
      "r706"
     ]
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsFairValueOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimate of Fair Value Measurement",
        "documentation": "Measured as an estimate of fair value."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r422",
      "r627",
      "r628"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsFairValueOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsFairValueOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r58"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsFairValueOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r420",
      "r454",
      "r455",
      "r456",
      "r627",
      "r628",
      "r634",
      "r635",
      "r636"
     ]
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementBasisAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsFairValueOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Basis [Axis]",
        "documentation": "Information by measurement basis."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r56",
      "r298",
      "r627",
      "r628"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsFairValueOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r343",
      "r348",
      "r420",
      "r454",
      "r634",
      "r635",
      "r636"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "terseLabel": "Summary of financial assets and liabilities measured at fair value",
        "documentation": "Tabular disclosure of liabilities measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r110"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsFairValueOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r454",
      "r455",
      "r456",
      "r627",
      "r628",
      "r634",
      "r635",
      "r636"
     ]
    },
    "lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "FifthAmendmentToRevenueInterestFinancingAgreementMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureBusinessLiquidityDetails",
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Fifth Amendment to the Revenue Interest Financing Agreement.",
        "label": "Fifth Amendment to Revenue Interest Financing Agreement [Member]",
        "terseLabel": "Fifth Amendment to Revenue Interest Financing Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest on lease liabilities",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r439",
      "r641"
     ]
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/DisclosureLeasesCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Present value of lease liabilities",
        "terseLabel": "Present value of lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r444"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/DisclosureLeasesCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Total minimum lease payments",
        "totalLabel": "Total minimum lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, 2021",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, 2022",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2024 (three months remaining)",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/DisclosureLeasesCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount",
        "negatedLabel": "Less: interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FinanceLeasePrincipalPayments",
        "negatedLabel": "Principal payments on finance leases",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r441"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of lease assets",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r439",
      "r641"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesRemainingLeaseTermAndDiscountRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent",
        "verboseLabel": "Weighted average discount rate, Finance leases",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r641"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesRemainingLeaseTermAndDiscountRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1",
        "terseLabel": "Weighted average remaining lease term, Finance leases",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r641"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsFairValueOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r306",
      "r319",
      "r415",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r510",
      "r624",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r758",
      "r759",
      "r760",
      "r761"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Intangible asset, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r270"
     ]
    },
    "lqda_ForCalendarYearBeginningOnJanuary12024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "ForCalendarYearBeginningOnJanuary12024Member",
     "presentation": [
      "http://liquidia.com/role/DisclosureBusinessLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to period, calendar year beginning on January 1, 2024.",
        "label": "For Calendar Year Beginning on January 1, 2024 [Member]",
        "terseLabel": "For Calendar Year Beginning on January 1, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r667",
      "r678",
      "r688",
      "r713"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r667",
      "r678",
      "r688",
      "r713"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r667",
      "r678",
      "r688",
      "r713"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r667",
      "r678",
      "r688",
      "r713"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r667",
      "r678",
      "r688",
      "r713"
     ]
    },
    "lqda_FourthAmendmentToRevenueInterestFinancingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "FourthAmendmentToRevenueInterestFinancingAgreementMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Fourth Amendment to the Revenue Interest Financing Agreement.",
        "label": "Fourth Amendment to Revenue Interest Financing Agreement [Member]",
        "terseLabel": "Fourth Amendment to Revenue Interest Financing Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and fixtures",
        "terseLabel": "Furniture and fixtures",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_GainLossOnDispositionOfAssets",
        "negatedLabel": "Loss (gain) on disposal of property and equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r749",
      "r766",
      "r767"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      },
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableSummaryDetails",
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails",
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of debt",
        "terseLabel": "Gain (loss) on extinguishment of debt",
        "verboseLabel": "Loss on extinguishment",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r43",
      "r44"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r561"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesCostDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r266",
      "r496",
      "r625",
      "r642",
      "r764",
      "r765"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r269",
      "r625"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment of goodwill",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r267",
      "r268",
      "r269",
      "r625"
     ]
    },
    "lqda_HealthcareRoyaltyPartnersIvL.pMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "HealthcareRoyaltyPartnersIvL.pMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureBusinessLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to HealthCare Royalty Partners IV, L.P.",
        "label": "HealthCare Royalty Partners IV, L.P [Member]",
        "terseLabel": "HCR"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets Held-for-use",
        "terseLabel": "Impairment of long-lived assets",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r40",
      "r99"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r100"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesCostDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r564"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesCostDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r564"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInAccountsPayable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in operating lease liabilities.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets",
        "negatedLabel": "Other noncurrent assets",
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInReceivables",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_IncreaseDecreaseInReceivables",
        "negatedLabel": "Accounts receivable, net",
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "lqda_IncreaseInIndemnificationAssetThroughAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "IncreaseInIndemnificationAssetThroughAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in indemnification asset through accounts payable.",
        "label": "Increase in Indemnification Asset Through Accounts Payable",
        "terseLabel": "Non-cash increase in indemnification asset through accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_IndemnificationAssetAndLitigationFinancePayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "IndemnificationAssetAndLitigationFinancePayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indemnification Asset and Litigation Finance Payable [Abstract]",
        "label": "Indemnification Asset with Related Party and Litigation Finance Payable"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_IndemnificationAssetRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "IndemnificationAssetRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of indemnification asset, related party.",
        "label": "Indemnification Asset, Related Party",
        "terseLabel": "Indemnification asset, related party"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_IndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "IndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDisclosureTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureIndemnificationAssetWithRelatedPartyAndLitigationFinancePayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for indemnification asset with related party and litigation finance payable.",
        "label": "Indemnification Asset with Related Party and Litigation Finance Payable Disclosure [Text Block]",
        "terseLabel": "Indemnification Asset with Related Party and Litigation Finance Payable"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r670",
      "r678",
      "r688",
      "r705",
      "r713",
      "r717",
      "r725"
     ]
    },
    "lqda_InducementPlan2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "InducementPlan2022Member",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining 2022 to inducement plan.",
        "label": "Inducement Plan 2022 [Member]",
        "terseLabel": "2022 Inducement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder": {
     "xbrltype": "durationItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial term of submission of quarterly forecast of expected production considered as binding firm order.",
        "label": "Initial Term of Submission of Quarterly Forecast of Expected Production, Binding Firm Order",
        "terseLabel": "Initial term"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r659",
      "r729"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r659",
      "r729"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r659",
      "r729"
     ]
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Intangible asset, Gross Carrying Amount",
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetSummaryDetails",
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible asset, net",
        "terseLabel": "Intangible asset, net",
        "verboseLabel": "Intangible asset, Net Carrying Amount",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r38"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_InterestExpense",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r118",
      "r153",
      "r194",
      "r430",
      "r565",
      "r652",
      "r827"
     ]
    },
    "us-gaap_InterestExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest Expense",
        "documentation": "Primary financial statement caption encompassing interest expense."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "terseLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r158",
      "r159"
     ]
    },
    "lqda_InventoryCapitalizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "InventoryCapitalizedCost",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "the amount of Inventory, Capitalized Cost.",
        "label": "Inventory, Capitalized Cost",
        "terseLabel": "Inventory, Capitalized Cost"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_InventoryCurrentAndNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "InventoryCurrentAndNonCurrent",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/DisclosureInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and non current inventory.",
        "label": "Inventory Current And Non Current",
        "totalLabel": "Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryCurrentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryCurrentTable",
     "presentation": [
      "http://liquidia.com/role/DisclosureInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Current [Table]",
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureInventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r260"
     ]
    },
    "us-gaap_InventoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryLineItems",
     "presentation": [
      "http://liquidia.com/role/DisclosureInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureInventoryDetails",
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "verboseLabel": "Recognized as: Inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r614",
      "r642"
     ]
    },
    "us-gaap_InventoryNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Noncurrent",
        "terseLabel": "Recognized as: Other assets",
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Prelaunch Inventory",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r137",
      "r145",
      "r260",
      "r261",
      "r262",
      "r482",
      "r618"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/DisclosureInventoryDetails": {
       "parentTag": "lqda_InventoryCurrentAndNonCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/DisclosureInventoryDetails": {
       "parentTag": "lqda_InventoryCurrentAndNonCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "terseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r193"
     ]
    },
    "lqda_LabAndBuildToSuitEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "LabAndBuildToSuitEquipmentMember",
     "presentation": [
      "http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to lab and build-to-suit equipment.",
        "label": "Lab and build-to-suit equipment [Member]",
        "terseLabel": "Lab and build-to-suit equipment"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_LargestStockholderAndMemberOfBoardOfDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "LargestStockholderAndMemberOfBoardOfDirectorsMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents collective information pertaining to the largest stockholder and a member of Board of Directors.",
        "label": "Caligan and Paul B. Manning [Member]",
        "terseLabel": "Caligan and Paul B. Manning"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Lease Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r641"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of lease cost",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "lqda_LeaseDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "LeaseDisclosureTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of information about leases.",
        "label": "Lease Disclosure [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_LeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "LeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/DisclosureLeasesCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "parentTag": "lqda_LeaseLiabilityPaymentsDueTotal",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease and finance lease.",
        "label": "Lease Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_LeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "LeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability and finance lease liability.",
        "label": "Lease Liability Maturity [Table Text Block]",
        "terseLabel": "Schedule of future minimum lease payments"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_LeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "LeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments, due in next fiscal year following latest fiscal year.",
        "label": "Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2025"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_LeaseLiabilityPaymentsDueRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "LeaseLiabilityPaymentsDueRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments, to be paid in remainder of current fiscal year.",
        "label": "Lease Liability Payments Due, Remainder of Fiscal Year",
        "terseLabel": "2024 (three months remaining)"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_LeaseLiabilityPaymentsDueTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "LeaseLiabilityPaymentsDueTotal",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/DisclosureLeasesCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease and finance lease",
        "label": "Lease Liability Payments Due Total",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_LeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "LeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease and finance lease, due in second fiscal year following latest fiscal year.",
        "label": "Lease Liability Payments Due Year Two",
        "terseLabel": "2026"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_LeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "LeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/DisclosureLeasesCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "parentTag": "lqda_LeaseLiabilityPaymentsDueTotal",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Lease Liability Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold improvements",
        "terseLabel": "Leasehold improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureLegalProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LegalMattersAndContingenciesTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureLegalProceedings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "Legal Proceedings",
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "lqda_LegalProceedingsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "LegalProceedingsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Proceedings Disclosure [Abstract]",
        "label": "Legal Proceedings"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeDisclosureAbstract",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]",
        "terseLabel": "Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeaseDiscountRate",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeFinanceLeaseDiscountRate",
        "terseLabel": "Lessee, Finance Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of finance lease payments."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Leases",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/DisclosureLeasesCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases, Total minimum lease payments",
        "totalLabel": "Total minimum lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases, 2021",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases, 2022",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2024 (three months remaining)",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/DisclosureLeasesCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
        "negatedLabel": "Less: interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r162",
      "r249",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r404",
      "r407",
      "r408",
      "r423",
      "r537",
      "r620",
      "r654",
      "r774",
      "r814",
      "r815"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r116",
      "r505",
      "r642",
      "r751",
      "r762",
      "r807"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r136",
      "r162",
      "r249",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r404",
      "r407",
      "r408",
      "r423",
      "r642",
      "r774",
      "r814",
      "r815"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_LiquidiaPAHAndSandozMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "LiquidiaPAHAndSandozMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureLegalProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to Liquidia PAH and Sandoz.",
        "label": "Liquidia PAH and Sandoz [Member]",
        "terseLabel": "Liquidia PAH and Sandoz"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureLegalProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://liquidia.com/role/DisclosureLegalProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationReserveNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationReserveNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation finance payable",
        "terseLabel": "Litigation finance payable",
        "documentation": "Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r770"
     ]
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureLegalProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Settlement, Amount Awarded from Other Party",
        "terseLabel": "Judgement amount awarded from other party",
        "documentation": "Amount awarded from other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationStatusAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureLegalProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Status [Axis]",
        "documentation": "Information by status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "us-gaap_LitigationStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationStatusDomain",
     "presentation": [
      "http://liquidia.com/role/DisclosureLegalProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Status [Domain]",
        "documentation": "Status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://liquidia.com/role/DisclosureLegalProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Line Items]",
        "verboseLabel": "Legal Proceedings",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r280",
      "r771",
      "r772"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://liquidia.com/role/DisclosureLegalProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r280",
      "r771",
      "r772"
     ]
    },
    "us-gaap_LossContingencyReceivableProceeds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyReceivableProceeds",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receipts from litigation financing",
        "terseLabel": "Receipts from litigation financing",
        "documentation": "Amount of cash inflow from the collection of receivables related to a loss contingency."
       }
      }
     },
     "auth_ref": [
      "r747",
      "r773"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r213",
      "r633",
      "r777",
      "r823",
      "r824"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails",
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r350",
      "r481",
      "r512",
      "r529",
      "r530",
      "r586",
      "r588",
      "r590",
      "r591",
      "r593",
      "r609",
      "r610",
      "r623",
      "r631",
      "r637",
      "r643",
      "r776",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821"
     ]
    },
    "lqda_MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum net sales amount that is used as the basis in determining the payment of future contingent royalties.",
        "label": "lqda_MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties",
        "terseLabel": "Maximum Net Sales Threshold As Basis For Payment Of Future Contingent Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_MaximumPotentialDevelopmentMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "MaximumPotentialDevelopmentMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum potential development milestone payments per the agreement.",
        "label": "Maximum Potential Development Milestone Payments",
        "terseLabel": "Maximum potential development milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_MaximumPotentialSalesMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "MaximumPotentialSalesMilestones",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum potential sales milestones to be paid.",
        "label": "Maximum Potential Sales Milestones",
        "terseLabel": "Maximum potential sales milestones"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "lqda_MilestonePaymentsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "MilestonePaymentsPayable",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payments payable.",
        "label": "Milestone Payments Payable",
        "terseLabel": "Milestone payments Pharmosa is to receive per terms of the license agreement"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedAfterYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "MinimumCashAndCashEquivalentsRequiredToBeMaintainedAfterYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash and cash equivalents to be maintained after year two.",
        "label": "Minimum Cash and Cash Equivalents Required to be Maintained After Year Two",
        "terseLabel": "Minimum cash and cash equivalents required to be maintained after December 31, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_MinimumCashAndCashEquivalentsRequiredToBeMaintainedDuringYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "MinimumCashAndCashEquivalentsRequiredToBeMaintainedDuringYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash and cash equivalents to be maintained during year two.",
        "label": "Minimum Cash and Cash Equivalents Required to be Maintained During Year Two",
        "terseLabel": "Minimum cash and cash equivalents required to be maintained during next year"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r350",
      "r481",
      "r512",
      "r529",
      "r530",
      "r586",
      "r588",
      "r590",
      "r591",
      "r593",
      "r609",
      "r610",
      "r623",
      "r631",
      "r637",
      "r643",
      "r776",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsFairValueOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money market mutual funds (cash equivalents)",
        "terseLabel": "Money market funds (cash equivalents)",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "lqda_Mr.PaulB.ManningMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "Mr.PaulB.ManningMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to Mr. Paul B. Manning.",
        "label": "Mr. Paul B. Manning [Member]",
        "terseLabel": "Mr. Paul B. Manning"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r213",
      "r633",
      "r777",
      "r823",
      "r824"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://liquidia.com/role/DisclosureBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Business",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r131"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r94"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureBusinessLiquidityDetails",
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited",
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net loss",
        "totalLabel": "Net loss and comprehensive loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r94",
      "r117",
      "r134",
      "r148",
      "r149",
      "r152",
      "r162",
      "r169",
      "r171",
      "r172",
      "r173",
      "r174",
      "r177",
      "r178",
      "r183",
      "r190",
      "r203",
      "r207",
      "r209",
      "r249",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r419",
      "r423",
      "r509",
      "r559",
      "r578",
      "r579",
      "r621",
      "r652",
      "r774"
     ]
    },
    "lqda_NetSalesEarnedRelatingToPaymentOfFutureContingentRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "NetSalesEarnedRelatingToPaymentOfFutureContingentRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net sales earned by the entity relating to payment of future contingent royalties.",
        "label": "Net Sales Earned Relating To Payment Of Future Contingent Royalties",
        "terseLabel": "Net sales earned relating to payment of future contingent royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "lqda_NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of non-cancelable future commitments for product manufacturing and supply costs.",
        "label": "Non Cancelable Future Commitment For Product Manufacturing And Supply Costs",
        "terseLabel": "Non-cancelable commitments for product manufacturing and supply costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r667",
      "r678",
      "r688",
      "r705",
      "r713"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "lqda_NoncashPortionOfLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "NoncashPortionOfLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of non cash portion of lease expense.",
        "label": "Non-cash lease expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NonoperatingIncomeExpense",
        "totalLabel": "Total other income (expense), net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NorthAmericaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NorthAmericaMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "North America [Member]",
        "terseLabel": "North America"
       }
      }
     },
     "auth_ref": [
      "r830",
      "r831",
      "r832",
      "r833"
     ]
    },
    "lqda_NumberOfCustomers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "NumberOfCustomers",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of customers.",
        "label": "Number of Customers",
        "terseLabel": "Number of customers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_NumberOfOperatingSegments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_NumberOfReportingUnits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportingUnits",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units",
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "lqda_OfferingCostsIncurredIncludedInAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "OfferingCostsIncurredIncludedInAccruedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering costs incurred, but not paid included in accrued expenses.",
        "label": "Offering Costs Incurred, Included in Accrued Expenses",
        "terseLabel": "Offering costs incurred, but not paid included in accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office equipment",
        "terseLabel": "Office equipment",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "lqda_OnFirstFundedPortionOfInvestmentAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "OnFirstFundedPortionOfInvestmentAmountMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to first funded portion of investment.",
        "label": "On First Funded Portion of Investment Amount [Member]",
        "terseLabel": "On first funded portion of investment amount"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_OnSecondPortionOfFundedInvestmentAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "OnSecondPortionOfFundedInvestmentAmountMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to second portion of funded investment amount.",
        "label": "On Second Portion of Funded Investment Amount [Member]",
        "terseLabel": "On second portion of funded investment amount"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_OperatingAndFinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "OperatingAndFinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating and finance leases, classified as current.",
        "label": "Operating and Finance Lease, Liability, Current",
        "terseLabel": "Operating and finance lease liabilities, current"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_OperatingAndFinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "OperatingAndFinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating and finance leases, classified as noncurrent.",
        "label": "Operating and Finance Lease, Liability, Noncurrent",
        "terseLabel": "Operating and finance lease liabilities, noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingIncomeLoss",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r203",
      "r207",
      "r209",
      "r621"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease cost",
        "verboseLabel": "Fixed lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r641"
     ]
    },
    "lqda_OperatingLeaseLiabilitiesCashPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "OperatingLeaseLiabilitiesCashPaid",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash paid for operating lease liabilities.",
        "label": "Cash paid for operating lease liabilities",
        "terseLabel": "Cash paid for operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/DisclosureLeasesCommitmentsAndContingenciesFutureMinimumLeasePaymentsDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating leases, Present value of lease liabilities",
        "terseLabel": "Present value of lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets, net",
        "terseLabel": "Operating lease right-of-use assets, net",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesRemainingLeaseTermAndDiscountRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent",
        "verboseLabel": "Weighted average discount rate, Operating leases",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r641"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesRemainingLeaseTermAndDiscountRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1",
        "terseLabel": "Weighted average remaining lease term, Operating leases",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r442",
      "r641"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "parentTag": "lqda_AccruedExpensesAndOtherLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other expenses",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Domain]",
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncurrentAssetsMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other assets",
        "documentation": "Primary financial statement caption encompassing other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "lqda_OtherThenNorthAmericaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "OtherThenNorthAmericaMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to countries other than North America.",
        "label": "Other Then North America [Member]",
        "terseLabel": "Other then North America"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_OtherWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "OtherWarrantsMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to other warrants.",
        "label": "Other Warrants",
        "verboseLabel": "Warrants, Expiration, December 31, 2026"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r665",
      "r676",
      "r686",
      "r711"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r668",
      "r679",
      "r689",
      "r714"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r668",
      "r679",
      "r689",
      "r714"
     ]
    },
    "lqda_PBMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "PBMMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureIndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to PBM.",
        "label": "PBM [Member]",
        "terseLabel": "PBM"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_PaymentForUpfrontLicenseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "PaymentForUpfrontLicenseFee",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for upfront license fee.",
        "label": "Payment for Upfront License fee",
        "terseLabel": "Upfront license fee to be paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsOfStockIssuanceCosts",
        "terseLabel": "Payments for offering costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "lqda_PaymentsOnRevenueInterestFinancingLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "PaymentsOnRevenueInterestFinancingLiability",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableSummaryDetails",
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from payments on revenue interest financing liability.",
        "label": "Payments On Revenue Interest Financing Liability",
        "negatedLabel": "Payments",
        "negatedTerseLabel": "Payments on revenue interest financing liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire in Process Research and Development",
        "negatedLabel": "Purchase of in-process research and development",
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
        "negatedLabel": "Purchases of property, plant and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_PendingLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PendingLitigationMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureLegalProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pending Litigation",
        "terseLabel": "Pending Litigation",
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process."
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "lqda_PercentageOfInvestmentAmountToBePaid": {
     "xbrltype": "pureItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "PercentageOfInvestmentAmountToBePaid",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of investment amount to be paid when payment has not been made in full on approval from FDA.",
        "label": "Percentage of Investment Amount to be Paid",
        "terseLabel": "Percentage of investment amount to be paid"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_PercentageOfInvestmentAmountToBeRepaidOnFinalApproval": {
     "xbrltype": "pureItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "PercentageOfInvestmentAmountToBeRepaidOnFinalApproval",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of investment amount to be repaid under the agreement on receiving approval from food and drug administration.",
        "label": "Percentage of Investment Amount to be Repaid on Final Approval",
        "terseLabel": "Percentage of investment amount to be repaid on final approval"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures": {
     "xbrltype": "percentItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of reimbursement of documented out of pocket expenditures for any capital equipment.",
        "label": "Percentage of Reimbursement of Documented Out of Pocket Expenditures",
        "terseLabel": "Percentage of reimburse"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_PercentageOfRevenueFromPromotionAgreement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "PercentageOfRevenueFromPromotionAgreement",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenue from Promotion Agreement.",
        "label": "Percentage of Revenue from Promotion Agreement",
        "terseLabel": "Percentage of Revenue from Promotion Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_PerformanceBasedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "PerformanceBasedRestrictedStockUnitsMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to performance-based restricted stock units.",
        "label": "Performance Based Restricted Stock Units [Member]",
        "terseLabel": "Performance Based Restricted Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_PharmosaLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "PharmosaLicenseAgreementMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the license agreement with Pharmosa Biopharm Inc. (\"Pharmosa\").",
        "label": "Pharmosa License Agreement [Member]",
        "terseLabel": "Pharmosa License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805"
     ]
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsFairValueOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Portion at Fair Value Measurement [Member] [Default]",
        "documentation": "Measured at fair value for financial reporting purposes."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r539"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnauditedParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r539",
      "r557",
      "r828",
      "r829"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock - 10,000,000 shares authorized as of June 30, 2021 and December 31, 2020, 0 shares issued and outstanding as of June 30, 2021 and December 31, 2020",
        "terseLabel": "Preferred stock - 10,000,000 shares authorized, none outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r502",
      "r642"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement",
        "terseLabel": "Private Placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from sale of common stock, net of underwriting fees and commissions",
        "terseLabel": "Proceeds from sale of common stock, net of issuance costs",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromIssuanceOfCommonStock",
        "terseLabel": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "lqda_ProceedsFromIssuanceOfCommonStockNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "ProceedsFromIssuanceOfCommonStockNet",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity, net of offering costs.",
        "label": "Proceeds From Issuance Of Common Stock Net",
        "terseLabel": "Proceeds from Issuance of Common Stock, Net"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureBusinessLiquidityDetails",
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, net of costs incurred directly with the issuance of the common stock.",
        "label": "lqda_ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts",
        "terseLabel": "Net proceeds from issuance of common stock in public offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromIssuanceOfPrivatePlacement",
        "terseLabel": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureBusinessLiquidityDetails",
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount net of issuance costs received from entity's raising of capital via private rather than public placement.",
        "label": "lqda_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts",
        "terseLabel": "Net proceeds from issuance of common stock in private offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLegalSettlements",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureLegalProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ProceedsFromLegalSettlements",
        "terseLabel": "Proceeds from Legal Settlements",
        "documentation": "Cash received for the settlement of litigation during the current period."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "lqda_ProceedsFromRevenueInterestFinancingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "ProceedsFromRevenueInterestFinancingNet",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from revenue interest financing, net.",
        "label": "Proceeds From Revenue Interest Financing Net",
        "terseLabel": "Proceeds from revenue interest financing, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from the sale of property, plant and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ProceedsFromStockPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockPlans",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock under stock incentive plans",
        "terseLabel": "Proceeds from issuance of common stock under stock incentive plans",
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r148",
      "r149",
      "r156",
      "r162",
      "r169",
      "r177",
      "r178",
      "r190",
      "r203",
      "r207",
      "r209",
      "r249",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r402",
      "r405",
      "r406",
      "r419",
      "r423",
      "r498",
      "r508",
      "r523",
      "r559",
      "r578",
      "r579",
      "r621",
      "r639",
      "r640",
      "r653",
      "r745",
      "r774"
     ]
    },
    "lqda_PromotionAgreementPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "PromotionAgreementPayment",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount paid by the Company at the inception of the Promotion Agreement, in consideration for the right to conduct promotional activities for the product.",
        "label": "Promotion Agreement, Payment",
        "terseLabel": "Promotion Agreement, Payment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosurePropertyPlantAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "Property, Plant, and Equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r126",
      "r129",
      "r130"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total property, plant and equipment",
        "terseLabel": "Total property, plant and equipment",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r139",
      "r507"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails",
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment, net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r499",
      "r507",
      "r642"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property, plant and equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://liquidia.com/role/DisclosureLeasesOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted",
        "terseLabel": "Purchase Commitment, Remaining Minimum Amount Committed",
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r115"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails",
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r342",
      "r350",
      "r380",
      "r381",
      "r382",
      "r457",
      "r481",
      "r512",
      "r529",
      "r530",
      "r586",
      "r588",
      "r590",
      "r591",
      "r593",
      "r609",
      "r610",
      "r623",
      "r631",
      "r637",
      "r643",
      "r646",
      "r768",
      "r776",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails",
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r276",
      "r277",
      "r278",
      "r279",
      "r342",
      "r350",
      "r380",
      "r381",
      "r382",
      "r457",
      "r481",
      "r512",
      "r529",
      "r530",
      "r586",
      "r588",
      "r590",
      "r591",
      "r593",
      "r609",
      "r610",
      "r623",
      "r631",
      "r637",
      "r643",
      "r646",
      "r768",
      "r776",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r660",
      "r671",
      "r681",
      "r706"
     ]
    },
    "lqda_ReimbursementOfCapitalExpenditureIncurredBySupplier": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "ReimbursementOfCapitalExpenditureIncurredBySupplier",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of reimbursement capital expenditure incurred by the supplier after the effective date of agreement to perform the services for the company.",
        "label": "Reimbursement of Capital Expenditure Incurred by Supplier",
        "terseLabel": "Aggregate exceed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://liquidia.com/role/DisclosureIndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r446",
      "r447",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r556",
      "r558",
      "r585"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://liquidia.com/role/DisclosureIndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Indemnification Asset with Related Party and Litigation Finance Payable",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r563",
      "r564"
     ]
    },
    "lqda_RelatedPartyTransactionMajorStockholderOwnershipPercentageInCompany": {
     "xbrltype": "percentItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RelatedPartyTransactionMajorStockholderOwnershipPercentageInCompany",
     "presentation": [
      "http://liquidia.com/role/DisclosureIndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage ownership by a major stockholder in the Company, which also controls a specific entity in which the Company entered into a Litigation Funding and Indemnification Agreement with.",
        "label": "Related Party Transaction, Major Stockholder Ownership Percentage in Company",
        "terseLabel": "Major stockholder ownership percentage of Liquidia Corporation Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureIndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r446",
      "r447",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r556",
      "r558",
      "r585",
      "r813"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails",
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_RepaymentsOfDebt",
        "negatedLabel": "Payments for debt prepayment and extinguishment costs",
        "verboseLabel": "Amount of debt repaid with initial investment from RIFA",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_RepaymentsOfLongTermDebt",
        "negatedLabel": "Principal payments on long-term debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r521"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://liquidia.com/role/DisclosureBusinessLiquidityDetails",
      "http://liquidia.com/role/DisclosureRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r293",
      "r309",
      "r448",
      "r616",
      "r617"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "terseLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r398",
      "r822"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureLeasesCostDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r661",
      "r672",
      "r682",
      "r707"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r662",
      "r673",
      "r683",
      "r708"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r669",
      "r680",
      "r690",
      "r715"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsCommonStockEquivalentSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationUnamortizedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units",
        "terseLabel": "Restricted Stock Units",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureBusinessLiquidityDetails",
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r106",
      "r504",
      "r516",
      "r517",
      "r522",
      "r540",
      "r642"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r166",
      "r167",
      "r168",
      "r170",
      "r176",
      "r178",
      "r250",
      "r251",
      "r389",
      "r390",
      "r391",
      "r399",
      "r400",
      "r409",
      "r411",
      "r412",
      "r414",
      "r417",
      "r513",
      "r515",
      "r524",
      "r828"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Contracts With Customers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue",
        "terseLabel": "Revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r192",
      "r202",
      "r205",
      "r206",
      "r210",
      "r211",
      "r213",
      "r339",
      "r340",
      "r483"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r611"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueFromContractsWithCustomers"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue From Contracts With Customers",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r341"
     ]
    },
    "lqda_RevenueInterestFinancingAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingAgreement",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue interest financing payable.",
        "label": "Revenue Interest Financing Agreement",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingAgreementAccretion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingAgreementAccretion",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion expense related to the revenue interest financing agreement.",
        "label": "Revenue Interest Financing Agreement, Accretion",
        "terseLabel": "Accretion"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingAgreementAmortizationOfDebtDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingAgreementAmortizationOfDebtDiscount",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of amortization of debt discount related to the revenue interest financing agreement.",
        "label": "Revenue Interest Financing Agreement, Amortization of Debt Discount",
        "terseLabel": "Amortization of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingAgreementAmountFunded": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingAgreementAmountFunded",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureBusinessLiquidityDetails",
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount funded under the revenue interest financing agreement.",
        "label": "Revenue Interest Financing Agreement, Amount Funded",
        "terseLabel": "RIFA, total amount funded",
        "verboseLabel": "Total funding"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureBusinessLiquidityDetails",
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableSummaryDetails",
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount funded under the second tranche per the revenue financing agreement.",
        "label": "Revenue Interest Financing Agreement, Amount Funded Under Second Tranche",
        "terseLabel": "Amount funded under the second tranche",
        "verboseLabel": "Second tranche funding, net of fees"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingAgreementEffectiveAnnualInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingAgreementEffectiveAnnualInterestRate",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective annual interest rate under revenue interest financing agreement.",
        "label": "Revenue Interest Financing Agreement, Effective Annual Interest Rate",
        "terseLabel": "Effective annual interest rate"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableExpectedAnnualPaymentsDetails": {
       "parentTag": "lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableExpectedAnnualPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected payments on the revenue interest financing payable in remainder of current fiscal year.",
        "label": "Revenue Interest Financing Agreement, Expected Payments, Remainder of Fiscal Year",
        "terseLabel": "2024 (three months remaining)"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingAgreementExpectedPaymentsTotal",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableExpectedAnnualPaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableExpectedAnnualPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of total expected payments on the revenue interest financing payable.",
        "label": "Revenue Interest Financing Agreement, Expected Payments, Total",
        "totalLabel": "Total"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFiveAndThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingAgreementExpectedPaymentsYearFiveAndThereafter",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableExpectedAnnualPaymentsDetails": {
       "parentTag": "lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableExpectedAnnualPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected payments on the revenue interest financing payable in fifth fiscal year and thereafter following current fiscal year.",
        "label": "Revenue Interest Financing Agreement, Expected Payments, Year Five and Thereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingAgreementExpectedPaymentsYearFour",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableExpectedAnnualPaymentsDetails": {
       "parentTag": "lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableExpectedAnnualPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected payments on the revenue interest financing payable in fourth fiscal year following current fiscal year.",
        "label": "Revenue Interest Financing Agreement, Expected Payments, Year Four",
        "terseLabel": "2028"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingAgreementExpectedPaymentsYearOne",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableExpectedAnnualPaymentsDetails": {
       "parentTag": "lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableExpectedAnnualPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected payments on the revenue interest financing payable in next fiscal year following current fiscal year.",
        "label": "Revenue Interest Financing Agreement, Expected Payments, Year One",
        "terseLabel": "2025"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingAgreementExpectedPaymentsYearThree",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableExpectedAnnualPaymentsDetails": {
       "parentTag": "lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableExpectedAnnualPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected payments on the revenue interest financing payable in third fiscal year following current fiscal year.",
        "label": "Revenue Interest Financing Agreement, Expected Payments, Year Three",
        "terseLabel": "2027"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingAgreementExpectedPaymentsYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingAgreementExpectedPaymentsYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableExpectedAnnualPaymentsDetails": {
       "parentTag": "lqda_RevenueInterestFinancingAgreementExpectedPaymentsTotal",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableExpectedAnnualPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected payments on the revenue interest financing payable in second fiscal year following current fiscal year.",
        "label": "Revenue Interest Financing Agreement, Expected Payments, Year Two",
        "terseLabel": "2026"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingAgreementHardCapPercentage": {
     "xbrltype": "pureItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingAgreementHardCapPercentage",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The hard cap expressed as percentage to terminate the interest revenue payment agreement.",
        "label": "Revenue Interest Financing Agreement, Hard Cap Percentage",
        "terseLabel": "RIFA, Hard Cap percentage"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingAgreementInitialInvestmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingAgreementInitialInvestmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The initial investment amount received  under the revenue interest financing agreement.",
        "label": "Revenue Interest Financing Agreement, Initial Investment Amount",
        "terseLabel": "RIFA, initial investment amount"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingAgreementInternalRateOfReturn": {
     "xbrltype": "percentItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingAgreementInternalRateOfReturn",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internal rate of return on investment amount.",
        "label": "Revenue Interest Financing Agreement, Internal rate of Return",
        "terseLabel": "RIFA, internal rate of return"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingAgreementIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingAgreementIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableSummaryDetails",
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance costs related to the revenue interest financing agreement.",
        "label": "Revenue Interest Financing Agreement, Issuance Costs",
        "negatedLabel": "Issuance costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingAgreementMaximumInvestmentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingAgreementMaximumInvestmentAmount",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The investment amount received upfront under the revenue interest financing agreement.",
        "label": "Revenue Interest Financing Agreement, Maximum Investment Amount",
        "terseLabel": "RIFA, maximum investment amount"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingAgreementMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureBusinessLiquidityDetails",
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to royalty interest financing agreement.",
        "label": "Revenue Interest Financing Agreement [Member]",
        "terseLabel": "Revenue Interest Financing Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureBusinessLiquidityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of cash and cash equivalent to be maintained per the cash covenants of the revenue interest financing agreement.",
        "label": "Revenue Interest Financing Agreement, Minimum Cash and Cash Equivalent to be Maintained",
        "verboseLabel": "Cash covenants, minimum cash and cash equivalents to be maintained"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingAgreementNumberOfTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingAgreementNumberOfTranches",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of tranches of the revenue interest financing agreement.",
        "label": "Revenue Interest Financing Agreement, Number of Tranches",
        "terseLabel": "RIFA, number of tranches"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Interest Financing Payable [Abstract]",
        "label": "Revenue Interest Financing Payable"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableSummaryDetails",
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue interest financing payable, current portion as of balance sheet date.",
        "label": "Revenue Interest Financing Payable, Current",
        "negatedLabel": "Less: current portion of revenue interest financing payable",
        "terseLabel": "Revenue interest financing payable, current"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingPayableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingPayableLineItems",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue Interest Financing Payable [Line Items]",
        "terseLabel": "Revenue Interest Financing Payable"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingPayableNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingPayableNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableSummaryDetails",
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue interest financing payable, noncurrent portion as of balance sheet date.",
        "label": "Revenue Interest Financing Payable, Noncurrent",
        "terseLabel": "Long-term portion of revenue interest financing payable",
        "verboseLabel": "Revenue interest financing payable, noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingPayablePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingPayablePolicyPolicyTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue interest financing payable.",
        "label": "Revenue Interest Financing Payable Policy [Policy Text Block]",
        "terseLabel": "Revenue Interest Financing Payable"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingPayableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingPayableTable",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to revenue interest financing payable.",
        "label": "Revenue Interest Financing Payable [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RevenueInterestFinancingPayableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RevenueInterestFinancingPayableTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for revenue interest financing payable.",
        "label": "Revenue Interest Financing Payable [Text Block]",
        "terseLabel": "Revenue Interest Financing Payable"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_RightOfUseAssetObtainedInExchangeForLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for lease liability.",
        "label": "Right Of Use Asset Obtained In Exchange For Lease Liability",
        "terseLabel": "Right of use assets obtained through lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "lqda_SandozMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "SandozMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueFromContractsWithCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to Sandoz.",
        "label": "Sandoz [Member]",
        "terseLabel": "Sandoz"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://liquidia.com/role/DisclosureBusinessLiquidityDetails",
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r179",
      "r351",
      "r731",
      "r755"
     ]
    },
    "lqda_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for Accrued Expenses and Other Current Liabilities.",
        "label": "Schedule of Accrued Expenses and Other Current Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued expenses and other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_ScheduleOfActivityOfRevenueInterestFinancingAgreementTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "ScheduleOfActivityOfRevenueInterestFinancingAgreementTableTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in the liability related to the revenue interest financing agreement (RIFA).",
        "label": "Schedule of Activity of Revenue Interest Financing Agreement [Table Text Block]",
        "terseLabel": "Schedule of changes in the liability related to RIFA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of calculation of diluted net loss per share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "lqda_ScheduleOfContractAcquisitionCostsAndIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "ScheduleOfContractAcquisitionCostsAndIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureContractAcquisitionCostsAndIntangibleAssetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contract acquisition costs and intangible assets.",
        "label": "Schedule of Contract Acquisition Costs And Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of contract acquisition costs and intangible asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense recognized for employees and non-employees",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "lqda_ScheduleOfExpectedAnnualPaymentsOnRevenueInterestFinancingAgreement": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "ScheduleOfExpectedAnnualPaymentsOnRevenueInterestFinancingAgreement",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the expected annual payments on the revenue interest financing payable.",
        "label": "Schedule of Expected Annual Payments on Revenue Interest Financing Agreement",
        "terseLabel": "Schedule of expected annual payments on the revenue interest financing payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureInventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventory",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r80",
      "r81",
      "r82"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of unvested RSU awards outstanding",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://liquidia.com/role/DisclosureIndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r562",
      "r563",
      "r564"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r49"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used for estimating the fair value of stock options",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of outstanding warrants",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost [Table Text Block]",
        "terseLabel": "Schedule of unamortized compensation expense and weighted average remaining recognition period",
        "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "lqda_SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Second and Third Amendments to Revenue Interest Financing Agreement.",
        "label": "Second and Third Amendments to Revenue Interest Financing Agreement [Member]",
        "terseLabel": "Second and Third Amendments to Revenue Interest Financing Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r211",
      "r212",
      "r526",
      "r527",
      "r528",
      "r587",
      "r589",
      "r592",
      "r594",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r612",
      "r632",
      "r646",
      "r777",
      "r823"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r211",
      "r622"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensation",
        "verboseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, award vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
        "negatedLabel": "Forfeited, number (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited , weighted average grant date fair value (in dollars per share)",
        "terseLabel": "Forfeited , weighted average grant date fair value (in dollars per share)",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, number (in shares)",
        "verboseLabel": "Granted, number (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted , weighted average grant date fair value (in dollars per share)",
        "terseLabel": "Granted , weighted average grant date fair value (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
        "periodEndLabel": "Unvested , number (in shares)",
        "periodStartLabel": "Unvested, number (in shares)",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
        "periodEndLabel": "Unvested , weighted average grant date fair value (in dollars per share)",
        "periodStartLabel": "Unvested , weighted average grant date fair value (in dollars per share)",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
        "negatedLabel": "Vested , number (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested , weighted average grant date fair value (in dollars per share)",
        "terseLabel": "Vested , weighted average grant date fair value (in dollars per share)",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r371"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected dividend yield",
        "verboseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r381"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected Volatility, maximum",
        "terseLabel": "Expected Volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected Volatility, minimum",
        "terseLabel": "Expected Volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
        "terseLabel": "Risk-free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
        "terseLabel": "Risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAvailableForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAvailableForIssuance",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in shares available for issuance under the share based payment award.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Increase In Shares Available For Issuance",
        "terseLabel": "Available of issuance under the ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, number of additional shares authorized (in shares)",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, number of shares available for grant (in shares)",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, number of shares (in shares)",
        "terseLabel": "Exercisable, number of shares (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, weighted average exercise price (in dollars per share)",
        "terseLabel": "Exercisable, weighted average exercise price (in dollars per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
        "negatedLabel": "Cancelled, number of shares (in shares)",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cancelled, weighted average exercise price (in dollars per share)",
        "terseLabel": "Cancelled, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, number of shares (in shares)",
        "verboseLabel": "Granted, number of shares (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
        "terseLabel": "Weighted average fair value for options granted (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r373"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding, aggregate intrinsic value",
        "terseLabel": "Outstanding, aggregate intrinsic value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
        "periodEndLabel": "Outstanding, number of shares (in shares)",
        "periodStartLabel": "Outstanding, number of shares (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
        "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)",
        "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested and expected to vest, aggregate intrinsic value",
        "terseLabel": "Vested and expected to vest, aggregate intrinsic value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested and expected to vest, number of shares (in shares)",
        "terseLabel": "Vested and expected to vest, number of shares (in shares)",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested and expected to vest, weighted average exercise price (in dollars per share)",
        "terseLabel": "Vested and expected to vest, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentAnnualIncreaseInCapitalShareReservedForFutureIssuance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentAnnualIncreaseInCapitalShareReservedForFutureIssuance",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percent increase in number of shares reserved for future issuance under a share-based compensation arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Percent Annual Increase In Capital Share Reserved For Future Issuance",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, percent annual increase in capital shares reserved for future issuance"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuance",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold increase in shares available for issuance under the share based payment award.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Threshold Increase In Shares Available For Issuance",
        "terseLabel": "Number of common stock shares outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold increase in shares available for issuance as a percentage of shares issued and outstanding under the share based payment award.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Threshold Increase In Shares Available For Issuance, As A Percentage Of Stock Issued And Outstanding",
        "terseLabel": "Percentage of the number of shares of common stock issued and outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationUnamortizedCompensationExpenseDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercised, weighted average exercise price (in dollars per share)",
        "terseLabel": "Exercised, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r364"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted, weighted average exercise price (in dollars per share)",
        "terseLabel": "Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price (in dollars per share)",
        "verboseLabel": "Granted, weighted average exercise price (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Tranche One",
        "terseLabel": "Share-based Payment Arrangement, Tranche One",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Tranche Two",
        "terseLabel": "Share-based Payment Arrangement, Tranche Two",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r358",
      "r377",
      "r378",
      "r379",
      "r380",
      "r383",
      "r392",
      "r393",
      "r394",
      "r395"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharePrice",
        "terseLabel": "Share Price (in dollars per share)",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, award vesting rights, percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected life (years)",
        "terseLabel": "Expected life (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r379"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, aggregate intrinsic value",
        "terseLabel": "Exercisable, aggregate intrinsic value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercisable, weighted average contractual term (Year)",
        "terseLabel": "Exercisable, weighted average contractual term (Year)",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding, weighted average contractual term (Year)",
        "terseLabel": "Outstanding, weighted average contractual term (Year)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested and expected to vest, weighted average contractual term (Year)",
        "terseLabel": "Vested and expected to vest, weighted average contractual term (Year)",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r375"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, purchase price of common stock, percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_SharesIssuedPricePerShare",
        "terseLabel": "Shares Issued, Price Per Share (in dollars per share)",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails",
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r20",
      "r133",
      "r150",
      "r151",
      "r152",
      "r166",
      "r167",
      "r168",
      "r170",
      "r176",
      "r178",
      "r189",
      "r250",
      "r251",
      "r322",
      "r389",
      "r390",
      "r391",
      "r399",
      "r400",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r417",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r445",
      "r513",
      "r514",
      "r515",
      "r524",
      "r580"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r211",
      "r212",
      "r526",
      "r527",
      "r528",
      "r587",
      "r589",
      "r592",
      "r594",
      "r597",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r612",
      "r632",
      "r646",
      "r777",
      "r823"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsCommonStockEquivalentSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails",
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails",
      "http://liquidia.com/role/DisclosureRevenueFromContractsWithCustomersDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationTables",
      "http://liquidia.com/role/DisclosureStockBasedCompensationUnamortizedCompensationExpenseDetails",
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails",
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r189",
      "r483",
      "r519",
      "r525",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r539",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r558",
      "r560",
      "r561",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r580",
      "r647"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Cash Flows (unaudited)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Balance Sheets (unaudited)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Stockholders' Equity (unaudited)"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureBusinessLiquidityDetails",
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r179",
      "r351",
      "r731",
      "r732",
      "r755"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsCommonStockEquivalentSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails",
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsOtherDetails",
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://liquidia.com/role/DisclosurePropertyPlantAndEquipmentScheduleOfPropertyPlantAndEquipmentDetails",
      "http://liquidia.com/role/DisclosureRevenueFromContractsWithCustomersDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationFairValueOfStockOptionsGrantedAndPurchaseRightsIssuedUnderEsppDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://liquidia.com/role/DisclosureStockBasedCompensationTables",
      "http://liquidia.com/role/DisclosureStockBasedCompensationUnamortizedCompensationExpenseDetails",
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails",
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r189",
      "r483",
      "r519",
      "r525",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r539",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r558",
      "r560",
      "r561",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r580",
      "r647"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r664",
      "r675",
      "r685",
      "r710"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "lqda_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "StockIssuedDuringPeriodSharesCommonStockWarrantsExercised",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued as a result of common stock warrants exercised during the current period.",
        "label": "Issuance of common stock upon exercise of common stock warrants (in shares)",
        "terseLabel": "Issuance of common stock upon exercise of warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails",
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock under employee stock purchase plan (in shares)",
        "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r73",
      "r74",
      "r106"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails",
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of common stock, net (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)",
        "verboseLabel": "Sale of common stock, net (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r73",
      "r74",
      "r106",
      "r520",
      "r580",
      "r595"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon exercise of stock options (in shares)",
        "negatedLabel": "Exercised, number of shares (in shares)",
        "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r73",
      "r74",
      "r106",
      "r364"
     ]
    },
    "lqda_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of common shares issued under vesting of restricted stock units.",
        "label": "Stock Issued During Period, Shares, Vesting of Restricted Stock Units",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_StockIssuedDuringPeriodValueCommonStockWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "StockIssuedDuringPeriodValueCommonStockWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of common stock warrants.",
        "label": "Issuance of common stock upon exercise of common stock warrants",
        "terseLabel": "Issuance of common stock upon exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock under employee stock purchase plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r73",
      "r74",
      "r106"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails",
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of common stock, net",
        "terseLabel": "Sale of common stock, net",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r73",
      "r74",
      "r106",
      "r524",
      "r580",
      "r595",
      "r653"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock upon exercise of stock options",
        "terseLabel": "Issuance of common stock upon exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r20",
      "r106"
     ]
    },
    "lqda_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits",
     "crdr": "credit",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of common shares issued under vesting of restricted stock units.",
        "label": "Stock Issued During Period, Value, Vesting of Restricted Stock Units",
        "terseLabel": "Issuance of common stock upon vesting of restricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_StockholdersEquity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r78",
      "r96",
      "r541",
      "r557",
      "r581",
      "r582",
      "r642",
      "r654",
      "r751",
      "r762",
      "r807",
      "r828"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r161",
      "r307",
      "r308",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r322",
      "r416",
      "r583",
      "r584",
      "r596"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://liquidia.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r450"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowElementsAbstract",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_SvbWarrantInitialTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "SvbWarrantInitialTrancheMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to SVB Warrant - Initial Tranche.",
        "label": "SVB Warrant Initial Tranche [Member]",
        "verboseLabel": "Warrants, Initial Tranche, Expiration, February 26, 2031"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_SvbWarrantTermBAndTermCTranchesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "SvbWarrantTermBAndTermCTranchesMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to SVB Warrant - Term B and Term C Tranches.",
        "label": "SVB Warrant - Term B and Term C Tranches",
        "verboseLabel": "Warrants, Other Tranches, Expiration, February 26, 2031"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "lqda_TermOfSubmissionOfQuarterlyForecastOfExpectedProduction": {
     "xbrltype": "durationItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "TermOfSubmissionOfQuarterlyForecastOfExpectedProduction",
     "presentation": [
      "http://liquidia.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of submission of quarterly forecast of expected production.",
        "label": "Term of Submission of Quarterly Forecast of Expected Production",
        "terseLabel": "Term of submission"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_The2020PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "The2020PlanMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to the 2020 plan.",
        "label": "The 2020 Plan [Member]",
        "terseLabel": "The 2020 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r757",
      "r812"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r216",
      "r217",
      "r218"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://liquidia.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsFairValueOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r306",
      "r319",
      "r415",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r510",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r758",
      "r759",
      "r760",
      "r761"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureBusinessLiquidityDetails",
      "http://liquidia.com/role/DisclosureRevenueInterestFinancingPayableTermsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "lqda_UTCAndSmithsMedicalLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "UTCAndSmithsMedicalLitigationMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureLegalProceedingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to UTC and Smiths Medical litigation.",
        "label": "UTC and Smiths Medical Litigation [Member]",
        "terseLabel": "UTC and Smiths Medical Litigation"
       }
      }
     },
     "auth_ref": []
    },
    "lqda_UnderwrittenPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "UnderwrittenPublicOfferingMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to underwritten public offering.",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Underwritten Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r124",
      "r125",
      "r127",
      "r128"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockBasedCompensationOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureBasisOfPresentationSignificantAccountingPoliciesAndFairValueMeasurementsCommonStockEquivalentSharesExcludedFromCalculationOfDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r644",
      "r645",
      "r648",
      "r649",
      "r650",
      "r651"
     ]
    },
    "lqda_WarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://liquidia.com/20240930",
     "localname": "WarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://liquidia.com/role/DisclosureStockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents warrants to purchase common stock shares.",
        "label": "Warrants to Purchase Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r186"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://liquidia.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding, basic (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r186"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-20/tableOfContent"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-27"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>85
<FILENAME>0001558370-24-015433-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-015433-xbrl.zip
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M^';U>)2<9BKL;7K"^T]A!7AW]90L>);G\*DFV1 R-P"[J_7UPJ=X#I>JLBF
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MZ;QTTX\NZ]/Y=#Z'[.X13UH3R:M5-PX4(3"56BOZ[,ANAJE13U@FL<_UJ8L
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MO@E?8# A!";D%Q@%5P@_$EG@V+"M \><9C/#D!YWA+>QL'=PA3!;ND15UW7
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MQ!EVP2R>\K>6FIP:=P3RD=)/;A AD$SCRR\L&2L-R8)AJY2003N+=8XZB\R
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M$>Y#I'=G3U; 6,M0/;CMY&T3UNJI.!19_]:*K&?Y;E<(/ZXH78P*OLVY@L*
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MR;NAS'GF:\4Y-8Z2)%01D#/9IWHK("/!,K/9TS72[%,YJ/WD4[G.B+E=QGX
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M2,\.QZS:SL8YCR4VZZ! GW &%KWTGE'L4+_X&K\7UO4X]#KX#K>7-20<[55
MS9X'_7^YEV0T"9]OZ2Y.VO(Z>4O\?B71[M#%#IKA]C:9L*,=KR),!&5[3GA#
MDR#VSR/_C,VI.E0_;(?? 5LU.W2_1B/<SM<NZFC7$V39[,,G0-CB )IX41K
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MU!4G:.KHW]S5[>^'=[XV2'K]=*!D4F8"KN9H+TM=I0UC)PHS-OLC<DL^#KK
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MNDQT\T%^P,G)L9[I]:\6 7:M:CJ*Y[+L\"WECU=?[=<6E0W526)N4=YOC^Z
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MF I>X!BAB_;14LZRN!#6@BC(9@H.+'2,+ICF"'>K#?7SD%ZOW^5I$-$TK>6
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M#*:9-%D%7OC>B_*UM\IX-?4[FCRQY"UE+>_RW2Y\;EH@CO[T[KWMSKL*5QV
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M9I+EADAI2",.Z;/BC)"AS/(YRE.:B&-!G-DJLPL4LZ@A#@_SK:2#@CTIY*'
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M/DQ/1&>EY;LJNGI"OE5[UFEY;&?5]+YDT"0DL8LB5;PX[?KU"_ BD2)Q)4@
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MOIH*MH<@BBWO_[EKXAJHJ;"9NJ1#*#1I@-<&V9AI""R,[LI_-D9;U$X7^C'
M-X-2@GH/R\#';^QWBQBC)Z:.%[HRP GS!.PDA-P;'[X\HY.;!EWM%C%&5TP=
M+W1E@!<F/Q=\>E^]!%Z#HBI_KX(]GAP>::HE>J\+%1G@<2DH=_UF+]'A+<91
MUE3,&(4Q=[[0FS%>E/S>0^9=1YR$ D\B[/*PN;@Q>N0&4>C3&!]*&@5DH:!C
M<&7%5@Z5X/)L*FZ8/CE %/HTQIN"SE/"2[@K76394_''19M2AFF/WO?B<-T8
M#\K3RO*\4G+C9J552AFF-'K?"Z49XR:Y7H%P 6>#7\+@>[Q$-QDL'S_B&DL;
MID1V#(4R#?"4Y/Q< L^CZ;!<R##54;M>:,P WTF^*-LF)<E2D<R2&+UN@C9*
M^.4HH5)5+">3XS.M#VRYH10:-L#CDB,$Z'J4AZZFO_U?@!^6.^5,TR-#[PO5
M&>" R1?3-VYD6]X_@17B(P9Q18U1(!> 0H<&>&B*8+HML!OXFZ:%*::D,1KD
MZ7^A0 -<-55864PKFPI+90U5(@U!H48#/#13B,I)D7E6TYJF\G=CU$7O=:$B
MF4Z7OWW>O>W3X@J0X'MN):$3KP2-#]"5H,U'X,^;[XS*'QKE7QIEGQK])2D^
M]A\_]'!+:&Y%+VE[2?1I85GK_+Z7%T?%;[9TSG_Q;0.JE(WN(<@BMC'7B?BJ
MBH]'$3A9(KU\'4#I?V/9*O]/)^.C(R6C5D0_:$#S@]/EYI*(NM'K:>C"*/S/
M-A%F-(TOK3!\A_NN-.4)1OU,=76C [M:ZY00!RR)(C$((W"7\60-%P7H0"Z]
M]=&SC<A2=4:/P 90"B\>N =Q\SD+2Y4A480;IZ1K<YHP8Y.N]![@F% N,B3-
M4W%)NF;7K.EQWYI^",':<HLD@D4.P8H ,01@J#DD7HC"E72EKTP7A2M)EA5D
M50QGD_&QN5JG Y-T#S .8LM3HE]L5F*\[2=5&9+VN7%*NEVH;K#GCW?G2;?2
M'(BS^==H\TAJ$QN(=89$!WZ@DFXB"O.AGM('_>9;4T[E<C[E'44SU1F"HL6!
M2KJ@*&=1B-%Z$>1R&:Q>7-_*,HTW)Q^OFWZ!%@;#" FP)5U]5#<Q[.2B1T"S
M%U90U$T0.-]=;S>JG:?J$+C2&J^L^Y7J6$)APA"US:11F0[#GA>$VUWN?>#;
MQ%U@8]DAZ9H=H*P+F9IXB3+,Q,W_D/1,0"3K)J>Z_7[I81"VXT%\A:J$SB?'
M9\=&GA%R(M0E15Z;,Y\\I2[;:4^UL&Y:Y]0>_K"' 68'!X RMG:8IX#JDFG:
MU3%7'HSB)<#N]+Q/TH:?DDZ;0 FVFL/B0PO,6AT)8LBP<5YN'M?,7ALHA/9.
MH -KW6$1HA7J#H[]%*[_J1,)ON!@.,$)T?ASP>V+BH]02>$KH.[_"34&R (^
MK*I/!L66"%B5\U6N2F0")7)BIO8EP)9T)/@*PI= X6J!S R.ZL/B1EO@6ITC
MREPVT-<+@R$"*S999X+*5@B$QXIPH>;X&H-3/R]6\T__ZF\T4R_.X"KHQ@91
MSS(G0EV>\!",),ZZF&(F73AI**F?OKGT5E<\*\9.;Y0<JI@1\M0/Q!M'.\4&
MIWTF@)VZD'M7_=1QW S @^4ZM_ZEM79C"Q<)@BE=EM/XX&!R>'YJ-A%X<';@
M1>Z7 H_H/4<?.-=6B-[MC::VG:R2-'+R"LQ=V\6M ^@5!T<,0<C&WR:I"XYY
M;3@X#C!"'( G>;.5@CLA9@;0J@V.#T* 93F6=]FA/"W%0RKP)8A=V_(V#@6F
M)!4G;9-4C/Y2_?I'U@H5>\@L>]PTB9=P4?OG5MO$[>1NI>J@&4^.)ZJMA)@G
M00"ER0DMFN#B\R@RUAHR%V@P30Y:+&VGH5V>A:G<G'1G_0#"%#_=TX"K.112
MB$(UV>=82S5*G2P(-09(!)YI0GGV52D$N(VBA%WY6>G!*IX 3Y?GBZ4HG;XP
M8,U)/"CU,RX)9.9][7'7N/EK-)OG81?PK^E1ZPI^;PDKN*_@+HB$,AT>LF8Z
MW'9C%,Q'VXZ,H.!'E:Z,4%],2(6(7EQ>@0TPRCX26[IOYW,:E74#AU)Q.?LW
M-UY>)E$,NQ=N;N"BNUWP_SO/UAO6&\W=DFXFA*+!JB-:#EK5-V,DS"I1&JFQ
MN1!"ICVN>%4XZ$7RB2E4X()D]GXR@I,KNKF=.EI!^.K:('H*//S"$5=!-W5S
MZ;"9 AQ C1_T*'@;"A>E [V"AM +TO1.N?"P\P.ASL#XP(^U@ZB&GG-8 !^N
MX3R(>.JL7-]%\D(/LI%)0:DU,%J(H#4^O&%79HP+@X&IG@F>K# %94?6FSC^
M;/F$=FX8=3>4')C&61$:'Z=P'_A!%6N1[96\%:#6TXT0''L",6PFGRF@!-!1
M&K>?X2WN>6'='\W%==.YF"+KA.#":_S^H$!'7OSME!JNZNDPVR[_)YG&?;!
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M-OS7=#XOMZWE(,8*@S*4&>KU'N39W"'V <[31'54G$[&!VK?"V#6XTZP9SO
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MS6DY>>_"IN;4P17O.RU0M1_4XS)<>5V&**L^JLE_>$"9[%Z2==6O^#OCX)Y
MWAT<=G_C;_27HM1_Z&HG)%[^@^P\.STZ.3TX.3\_&!^=P"6.HON .WU\S_Z7
M\>8?I7)E#!X>P#&H-M,=IS[JUJ8%[$Y-SV'?Y/D:@=G\.HK=E15CLT57"PV.
M# SP.D@[I5#I3V"!3/4C6 <AK\%@JCLXBHBC[B =5=^YYK^7Q!<&/OS1+JU
M&'G#V\S@*"1% )UFJ#J1<^20)X3=20.;[;=M@ Z24:=G\TO86S=^=*/?R0R2
MT^A@^-2A."2EK-(D_]ES:#F@B*8NTBV5WB5*!8*Q5DQU!T.I]J@[S535^_IH
MDU2 ;6K#%:]*:CR!TC*;'UQ .WA\2:$QN5VM+3=,DUF'12+S[)G6._<5..E=
MKHB1+@)-#8]*LH30P5M."BW/+T'@?'<]KWY/.2K^1)RWF.L/CE#MD,MZO4D*
MB\1">5@V8\+M#(8N<B4@[5$C/28Y2L0OV_3&U\A@B"41OJSW@,BG6SVR*@)0
M 6B_>@6%XP5IHI[\NBMQ-F.H.4#^B&&6]4*.[)<1\MO-#+!8KH3S-#,8:D@5
M0,$3/=Y':'^4L;FS5K[5-EOGB3QO4V\8W%&DC\$2C8U 2X-AF&P9%"3KQD_=
M^PQV;84^BC)[ &$J(;:%$*76X,@C@K<@2C<NY]Z)TA2GPW-(QER_*LS#R?C@
MU&SRM$->T,C,EQ(DQ8,]IQEG6*/!C@X.#X[ZB ;+NK4/L6"]KWWL)7 2#\SF
M4]@?Q_42-#<_ 3L)TWQ!UV_9NUG97G2U3N+\5'#74E-C/J1_R!S[U;A,ZD<>
MJI\YE#<=EI)8Y<;!F?F/2%[HL3=HT.X#/RS^F1JA9]+M1.GMFTW';L70U8N+
M7;]AP#L='M6GPTU;VL]B4E\T^-9_0.+&H&ZZE:>_8[(#K-5U&^84'9 F'@&@
M)E\YQ.9[YQWEQ_513G[^0/NA/_QW$(1?/\",!_7/Y<I]\X ,T^1ASY[&G=<.
MG-3M .=C!UT;!LU>/?@FZ>GC[13&W@?R;D!6L[H8B18*VCDSZDHH)IL4]FS+
MG!;EK&Y1^-*,Z[_2D)EOG'N30;4G?)IEM":"C>IB2Q@5@;4;,N&;;#7J:9MY
MS<-YW3PT92G7W@@,(5WYAM[-_?K-"D.XQ(YFX:.[6#+D8Q!MKSI,CB>'I\:E
M,Y<*O9>KU;VF-^>U$A.,E6C(<:Z]I?A(=@X'%.S4QDV%-8[E0KK9!/FIR!GP
M2C($GHI#+^2>N;=68/KFXO(IE(OHIF\&[32XIFB AJ#0JV!EN3Y%I5DAW91*
MU0]>I01 "I6*V0Q>K]9>\ ZRR?@A">TE-$H("<I]] 6L7D"XHS_6:KIJE*">
MG4V=*$CCHQ V%@TNZ\ M_!%GENL%JP(YF8P/##3.C+ DG?,K,=';;<B&Y2!\
M=6W0'- \]=)NI"$YC\ .%K[[)UR[ +A7R!8T[#L^R=_3EG!D[I VAGU(J!?7
MD@(V?T7A.KDPRN)"(KD/_%<0P27X]+L5.FP!4Q):'B!#Y<JBTU1A"KE8>QTJ
ME4BZFL@NB$0H!JUXV3999;_CI*6,CPR0H9V)I8/L9)J1M3R@RP*;VK'[6OCQ
M10C*U_"@22E!%)TF-E-(Q,W\\0C_-W1M^%,JH:^^&XMR4*#- =)/EA1Z27K6
MZ4MEG(<,XW']D"%K2/LC!8%WR[[UGH\Y_3Y:.S(-:TSI*E5/)^.)3H^<?6N\
MP\<#1:L=&^FQNB+&X?V+%:/K/61CS5S/)/VV ]7+?DC-DW:\AK?AQB7]73M%
M<:;=/W G/Z*TF/61#ZFY"]-%"+8.5.88,,%F=1GDO%HAA(/)E(0)<T#)C_FV
M!FB1.?7]Q/**@VYTOXXB"3*YA)L='+GD2L+D:><BB>"V*(KNLC+Q^Q6(+==C
MGFF.#QI>)"X:1:O]HMW17_*6>YY<BKZ09I%ZF7Z7\5?@);[UX;<36@!/0TFM
M!B=.VN6U.RL&DP,YGF';< Y#$8F+U' 00G0:R^JB55ZEU=7-#L]DA9?P1=GM
M=VO[FV?X4P1' W)4-H:&"+92E>+99'RF]I(QNZKK-)$!7;\H(>J" A\IQ%A5
M-P[(T./.NJV-)%2'%&%X<>/.X^44]MU)Q1*TX(E@4WO &YF2Z2HU2;L)*@KC
MTN0$_[6=F. _OEVBS"X@A,*/WS%QPKABNM&#?_W!A4R[B#2*9A_!.@^KW)!W
M%VMC##%775TXP*7)*@':8=5O/?$/8'GQTH:B>@S>X8_O#Q"&#XW*[>O=CVO\
M),%23R=UM]/;SCP@#%[UXD'(-&S.NY]L .=0-\!8_<9RNG"@G=EGAR8I**DW
MNU\ ^NI':V"[<Q<X6#N/+:N+DOE4M:-B+G#Z&?*;(+Q$+^DY5OA/8(478.'Z
M*%_CS/\ORT^L\'V,ZA!6_1SUM=(WE]YV%_1M0:LVZ+B'"^:PQ3*R:]])85T!
M.P5S1&$#5P.#H4-[U'KNZH1/#NXHMXXPI:NB.9^,S]4^+BGN:^8!*"D,]!6$
M+X&R]Y(A6CM8@;L@PNF\4D9O39/U5=<V'5I;>S_)=.R#!;J 7CN;/>U;X8_H
M"-4'3I'<>6K;R2I);\=?@;EKN[A 17K%85%#$&_;^4 R7X0/%5S?726KQI>;
MGX,+\ 7*)I./V,$#<_/#(%4O4I&T$ZU.1])CE*A2F*Z0F^8F0=$B7^'_A$_
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MC:QYD?ZKY25 <#]3K3L8HHBCS1ESI@5C<"=U37%)UV\@M-VH"KCQ\(ZY=E5
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M2YE4SKC+Y*@Y7 IP(9:[?WSNSPC0-3]<#9,TV<UNKQC4W3[]5]SSSK:XKK^
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MV7%H+;DN\FL:= IY,&8&JMA9W1J67YBE$,S7$M6O6=(?LXBG,F]T!Q)0^PG
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MC]'[8@*_SLS,:231GQM\AE9R3#O]-"QQT]ZMRZRO8&87)O>QR^RGEG/1D@9
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MW_^38NGH7QL4Z)>:KN.Y.&<HL2VB/M!S0-@1%TTPDQ1,QCD:0):+B0++I40
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MY*$,5@!O#KZ@$+Q[V;Y,5*(#Z]@HMSX7^Z[6OOOO#Z[86P/L%?#8 ^NR%Y?
MD_IV57>$Q&H<RJJY5I[[;"N:KMK146RI37&3;R Q%8\P289.)]C7L?@B!V(#
M*$/?4H3)@J:0C4BBUZB*;4BF()%<F%@SWEO\I)@Q!:KT3'[_>6MB]>/:=/!D
MZUN$+=]U[KIWE'>]LT'MKQFJH=W]^2:DV3LV?GN8OCX+R@B" 4W3^T]-4B&S
M83^C08VU6BV[5*@VJF*/RS_5V'&;B[XI"&-,FLH#A$<J;TA+^)WJVI(%/0<0
M35]./@9"ZV-_RKB]N>5XQ6GXK17BZRWN'/JS:?2TE;KC_K)C44Y9YV"7!HMY
MOJ;41:ZTF+ZQL.N:@83J4I+ETTKN:]]^ITYL&G^%%>#-"E$7FD8+-2:I_*YG
M4)"D:5]>=N6"77<JR4?P5''R;^TRDRP%5 X8"&(J"$V T 1X#QA;&D*^/);T
M/4OTD3/EX3*96,R;-BU'XK"B)KDVSO+_!AC99#SQAIC]I51_;Q:QFM\RT&J6
M="!3A37D;1Q@1S5%$9^5#I7\X&H5?R#L4QC\;ZKRZ;OX5I/G-1D/^I]OT6]G
M$13[C+]XI-L=&DPW)OF725E0AOI,4R&E$@? =PIA6+9QURC$WP$:I@#OJ5>7
M_!_7#LG"6D0&=6;+H=S-Q6<EVQA5BO/YL!-;E*W^,+D6WA*6:2;];OWASU/Z
MPT5'6-,0;%J8#D=;J#&-9<!,>^C1.:[5[T]6_"S;>VNS,,JF(K'86_;.2XSX
MEC'^NJ;T([.);WQ=%-WT.O^CB'1;:!!\?2>*+OH!/$$%5,%_Y$9GN7H4#K-"
MBU^D^!E.$XCX-U9-*1F8%F60")1#]GC9&(=S]W(_-39[KU-=)-,-R9)0#09A
MI-! TZ3;AFGC/6]+HU )S 4\;P/[Q\0+-$&Z 0X>R?#6_1?L?K]OJSN>BO(\
M%"&73DQ27 S"&)<"#.!2, 63@LC$X['TX2:N/8O5^_5.S2XHT\CZ<?3 9?FV
MOVVQ5U(0\KI2-J-J0=*RPS1?849:"Y=D#DOV6O5L3^FO8;_Y6#>GZD/2R18S
MG@/ZU]X8CL;OF%>5OYUS'SOU:ZA.4=96/I7]WQ$<5W<_0?)S'EFA>7KS](ZG
M])&&_:)@@JPCV[K.B9%+[W"2DSG>O\_71EGZ+ID.I_VSIST6NZ.CX;1?;MI?
MT&GHN\2[MB$\+G3VP2SWY-G+[[US:*^?[&+T=;#<,#W)<H\!0L#/*!XG+WJO
ME>OQE;,G\D8GR@#$:'0CC/]XO\?#XP._^#3YP9($3G#M*MN4IE*KF82>;!7+
M-VT4^BX:S.7\U0;@%<UTSP1P&'9"&,/&7;JF9Y6U%JVTYD/5?N@M$]'G26;E
M!GNZ^<O0T#5^_IWZ_^D[FF8H'1C4$L@VQ''D%#ER_K-.^\OQF5^8@AZ;<KG4
MAGR.TVK$)<"G"G8L;G;L5+^[;&/R(;.DULYG?I8TE^-MP2+-X1X:9FA7V3[S
M%U[!XYC;@'I$/7,]U1X35=F<L[.%8R8&^6:D[L5/]Y#=W0"F !84R2!(X5.1
MT*)JM=P;?K'/=V_$OLZ]X9[=I#?'2,JJ@&-<(#5Q*'X&T;SA:TV0D((DP E[
M,XQMN/\?C.?HF &3$B49"A209<]MA+TE"UO"OA)+HR;0*X JWG>71'%@U,[I
M',]ILN-U\8F/'2E8AI+CB +)24N*Z@;D(5%"&-:M@YPA-*D_4,T(JI1I(Q%K
MSC1R%M$[OV/-@'4XGA78[S3NL?NQ-Z0_OQ,WVA_LSK@G"/6HT.0)C0I_1,JC
M+W%_O,I(0C/2$])=[%I+TVX- G#,NT\XI9.S#;QKZYXIPXS0 I9M[KB;GZK9
M97_$54$A A^ZSG14'[8J[6__/N*4*/L+AGK_@;/-T5BJH7W@\]BU?7SOPSTF
M.Z*X@N_>%"@H(\H;FHJ%@.Q0$ D$AR(7J^!;L9>0R@,+N*>R#E;$MHY=;V+'
MEKW I1@=]P[8V+(;>-:-]*@_\,OD7VR4O?,*6#/)Q/Y;'9^S^925X?9\@W5H
M_OD9(-Z95#RG'J9W0)Q?.[-*%BI.8;',+E0Z2H\%)?.[@/@J)Z&^?+$A: -*
M1M]#"O \6FP&SE%.4&=@=GSR*84H'3GYPE30*D6M&#XG1$!5T&B=[U@.H>H0
MM\9]G5)30UM9,__U'9)(D/1-@**D$G\1V?W'<\;2?[W40_*:^<LO]F:!%_OG
ME\,"R"O[0E?]DI*ZPTN0Z1)A*4^X[DK4NYN"XR_E_2='X5T;+AZ0R-)+Q7OL
M#"UVEW[5O1Z.+AS=U4ZZ!7/UU8BPR.S( JP>&C^M5 29KK_7:-]RF!!]EB@
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M;\'F+<S<!7*ID>E[_G CQ*O@,Q+\C6OY>5TP?)WD.R4B^21OJO>70C&?H?Y
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ML 6LW_SY2?-^B(Q7B? 'L4 TVT0Z'=+L/$^-.<-Z&7&?(JW5_84/Y?RYH4]
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M_)%.U>? =)(.X3I>Q"*U1 &%#@K==0O=B8^BLYZ\C_?.J/U))=V7, 5EBN[
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M,BW=_B.)@71Z(]C _A0;*+J_^)Y>;(";(@?CR;<=P]<O"SDF[;* PS/S4+*
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M>3'P\X60FH(S.0YP96CF+2Q?>GSKF<G?53U5<N5Y'.Y2(KO?=):@!BST\<*
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M,D_,4\?YSSW?"R"$DW@K/D\(IL*)5DLW*&/5=/AQ@(J[' 8(@?GVDT(R>(Z
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M!/H]1QYIIYXA!_^U+_^5[N8N8-/_Z;<++UFT\=\C\HEXTMP_-MR_[_U'$?@
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M;LJ#H<DEL#$^6!"5N8RT!Z(BE=M*&\U'8U_@;J0WD+R>.9X@Z@CA#;TUR2_
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ML0R)P_P7F/]R8?DOEZRT_@G<#Q:"2(+]EY):P!5_U1XT!T: AEE.P4L$9X<
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MK0$URDL51-H.FJ7AH#CQAY$A@ ._%)V)] &8< ,3;F#"#8P\7GV^0@K./2C
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MO'I3'@%[!.P1\+<EX)L#_WB^G%?4MM]J)=8P*^U1N]3CYWESDVI."T(HJ$]
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M9_^<R+I$-:W?*%C&;F420X=,$889PT];>*,(E,V.2<%:][ "UP92&.E)4.5
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M=?<IX GY[21,2"UF)CX^:(&ZH&W,&2*(9D$"D HK< ?OD@U:/T6E>%:J4+N
M:^X?$ 4#^BH*BO&7"\5-L]''P-G.//<Z&06#VD<*Q2LTR6 U8^RT8,R2NK37
M3X2]\%CB68A0SL*&$4(I+)I_L:^;<Y@[#"67B @1'*!#/IEL[%.5@8[AR@X@
M@BD\N_4C02'S,:8(D<M4\&T$X[#F$KD V3F\?FZ0_RIIX&/1S(,SD; 2@15@
M4.OVS@6L>,"D'WQ.T]^3K?Q][M"I?F6?(+B4;(S[&AV?G*,7C&S%!>TYE"I
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M:P"%60:+E[@WCKG<).8.@%1@C;I-]I%\4=9%:V&0?%A6?Y#5?"'"9#\;C1:
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MU-,B"!?@A,2$9UQ+U!P8=3^&WUWA>8PD"*5#"670A&&BM)";@R5PRE%):"P
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M2)(YR.H:[ V UU?@6.WNUO+NKDW["=,@+JW7;!LB;4SHT&K3E_B2C+FLH$.
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M9P"9:]2K6 SK+@9;)K^8"RQL>3;V>8F2$\ID45/D6K8QZ=8&>6N 6I[UL^$
M;%"L+ H\46G$]$Z#D4"S,4P$C)TRR?&<%"F,KBY[ IO3&AH[&2;/6[8:1<[
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M+7[)L/@SLM/[A<4/IJ<C95 96]-4AN_JQE2J"'HU4W(M,8GRTS@9TJV==B.
M;@V1!/C$:NAP.>(,6@JJ Q =%?I%?/.,=C#I *)H0DQL,5.PA<A(L&0+_0LD
M] EZ(+!LJ (>99LMJ!$3+(&&WF<B'ESTU;$,'V[KD9%'!C?17/H"A$WA/L"
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M1Y]3N02#]BRL5XOE8WF;=AG]/J(\Q/"%1?FT.YMFBFAEP78'=KO5M$?E$=Z
M&(Z=%>7?*RKVW5HA?!O]%?SH06B[!K%0^)Q2X\=2V:H5%(+-E00IOAH[5,X
M(N]4LY?0.PDJAL\I-;P_B'&;0G?!UNI69;84:T*B,/GU)W&VG4\H\$.!?W^!
M_R 6;M#$P3F!S_:2Z6I&7!<99].5.Y;"U=OJ$@C\T(=Y( R?$_BS:05 J;K
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MBKX6A(NRWNOD?J#0]JTPT?V?KUYL;H4L)7LZ!6P+)9@JV%-P'@> #:(#475
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M(DZ"Z/FTV[@X< P5+R7"C_G#; H5/&>]K<.!P6Y8'@N.YD$'!G,,/V7*B]_
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M''5\YE.M57Y?S)(*V&$O;DT'ZWCW& H60"S? PPP%3$$@Y?Y%["I]0$ C.=
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MYE.6)O<V&*HH*CY/XM'U= FXV;W)(9-OWN1L!^-=>PS>WL+=NL\,Q3L:K_Y
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MNJ05N]^F<^4&X!,,")83%O0[$84 9E$@@OZ&1 0U/H']^[PAQ-N1^SG^[S^
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MJXGP@">IILD;HF)I+8LETWRC&!LEDND$#9PP(G*<@O(IJO%,(D@ECN59-1;
MB26N$0% "-XE(?H(>(:<9Q.-@4$)UOAP1SS (Q#R$:0]E6!K=/]8X"?+46S7
M@$,X1-$M"P'? +@'SW0D:^HN&CLF? 6DRK4_/ 5\X^7LE.=)]E&PYVVJQ?VI
M%G\F6F(8]7_C>UFR.%TODJQJ1:U)+SJP&I//TTD.F*!6&4!/L&H:<P"]'>$
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M$6M86!I-Y?1L371*<1A7C)XPKW>, V/8P"G2-=_I\9WW$:? !!_$F@H"\(P
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MYRGRGXKY/(%>\Q($_&OB+<A*#OVBXK:N_VO0V?M]L%O]]>/JPEW[?7FU^6O
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M2HAC&E$2Q9;K,V<-R)%9L"(J/XFG1G['(1N'000HXGJRM-R;&CV&";CLTO)
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MO1&L'/4%UL'ZT@[&25ATV BMM(C1'9)3[@:K;I$NFSLXF@]@T[W0=0;,^,"
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M^FWGP5W"EY<&SH9SN;^(1JFC:3GW(I6&@<I-#/P]JUWP'Y)4U=LQNI@2C X
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MN7SE1/;'XD-UTF4A;NJKH51TO%AJ=Y6P3,H:=I"2WN@T95_Z6^?%L3-7F^;
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M2F[<!MX#STI]I1AMH[G#)-0^T^:&^4[6?6H[632QDE;):R>1I@D#_EI8]9^
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M*<<(#\P[Q5)_&SH''#5!VA%+Q=:52KH4P;,(%#\\NL3=IRSW264TO\\]GX3
M&X&@;Q^QQB?_:E>\6L#M+;59!Y"'+LTTZ_-!7M@13#S)>Y[Q\AQ"(VS"1Z,
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M87W7=KD=TZIK.6++";#LY4T%.E@$YS':9K-=-=N=IA$-06F)I!M!QT)43>!
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M;^K^]([SLPG<P8U\1-,XU:-6+PHP%OG(_*-8KM&#MU<==!'VT&G3]48)B!4
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M]L/3VY)FR#BAO;N#MLHDF!G.C4(,<VO1=SRV;V>(U&W'*;V406U&WTO[LL&
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M,F/AL*X(F,R_/X1%&+VFX>/B2U@)$E7148#]]^PQP6^G78 5W9<'\NW%;@<
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MQTL^_$>/[MY+F0LTK>&_..>\B48+$5DK)I?4<[[BIH22X4ZS; &@@*2"#=V
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MQ&<^)))FS\,);SLZQMKI/. BF*1PDL+W][84T:W$55S.@1LDDSITQD]G0YN
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M3+G3%+[QKQ!&!4T?.A7RS\-7A[-UOF+/+UVAZ9%A(M+:@#TW7 B.2U\[T?&
M>8"B875ED3RT<PG3O!M24LGJ=%5T#3HYR33ST!H8\M&%.IYNP?0N-+-(*Q-O
M['#VBOY>DM9O>NL3];]@E!A[AO"/N3G1K2*ZQW^XFOMO\IB>R#'C+GK#+;)@
M9.=2 ''3"I22@G=;8SH#T^P 1_;5!WU3V\?,F\<WA7 #2V[R$[XF/45HB?!,
M _2L@X8)@X!(=I8.:%>RHEV-',:D7YKW5 (=C[=R]?H3@'%D%FAHH [[7S?)
M$75OPEZ#?2[5O, &P'GEFH=Q-!$6$:%P-LX8QLUNP:<:N7^9B[PSY76.5 2Y
M=5INHSNS:>L[BBP$&A!<YE\I=F@Q9L,)AH5>J61@_2Y\NAE!^!;!Z=L,VS*G
MMT??JH3Z?"9=9]BAU[2P)[V6?_Y1+]K9XR6'9&2^'\YRZ*-*WA?R\T%_DZ>-
M6&VO(>"6$WKYM.&A1,,.;NC7$RA#VY%5-\798IM(\:+>@J*#@6%S91!P$TJR
M#5K9K1:1W$U)@<ZL#V]=-VZ=H51OC+Q"C;K3XR.^#"YU=/_:%T+]HECE8QU#
MSZK$797-9U'\OF;;NZ;01C$GG#-JX1&UNO%X2R_I9>1KX<#98-@MJ>-O(3-&
M'_QS37Y;PR\P[=2FT+6I,TLG-/DV5X8$]F/Q4[B\<WV)F+LG) _TZ8.Y@D(#
M G7P9JXG >_W#@[IG\9_<B':@D%YK-!RK6>![X3\2 ,+YE6FUX/#D)US(V16
MR7D-AX'N]K@_0>M1/ G/JK76]UZR<'-OF9T%VJ?SK+6KS[61::2PIB6PE4Y8
M/[K_O\AUY=B5P7]6TF5]H!FKU:]]NX>(P.P]:""L.LXS'EULJ-DXNJ"(:3SH
MXS7GXU%L)Y\C4[C[N[7[A'O>=7)AB:;:(VO-Q5RS6G;EH?&T*R=)J?%,6VI3
MS1[?C"9-N$>\6SA7ORSB;X.E@A&E'<:I$<H3DKRWILG,BIYE#88[26**CG]G
MK02/2^!C3M@L+W#RSW)Y469-C!1""_?!/1%@1-;67%V=*Y@?RF(!_U,PRIJO
M=)>+%_"(P^ +*8JUS,\R=?.=0>1X1M3$^!<88I!2=X@?K1+%+!?#-*><"P&]
M@Y](+'P69UJIYR!4*<SR/XQQ5G:0'8J;EU;B726!Q"@QW/ZT[V7"^$76V.[?
MF6IL4XUMJK%]V&8Z1B,S!-C(VJS->%'4HW.:%3!1U3L :>TVKI6A@W^3T-WX
MU@MMJ0B_]6J.T7W)O$ X$-RT0C$94M;#-H#Y7H:6P'O^D>PP\Z[LDN6][YXZ
M<I.Q45/MK-^"IH"W"ANR9""7VY'(\^Z BYU-VQ%C9WAL#JX[VNQJ!_ZYA\%
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MW4T^N19UV15/38IHV#7(S#'-!D/SE"J20]^NL,+TG@WD7%J@[M%RPH<0F'F
M[H]=;;?U'EOJWOTE*XY4M](CYYGC!_(UE%C)XG"Y,Q8<U 50=!0;(?>DC?P
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MZ&*EG-8YHG'W9O^00<@K([3>9S^&#IW-4Q>"!M6XG&0HEK/.7T0H3!HN6^Q
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M(0R.'I,JW])QJ6H\?!_1^P@C;+YHJ-='V(_G'JVXKQ%!& WD+0?=$SN,':?
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M( AYX8_^T-,":*> -3K4!^/'^C9?-&YR]&4O3GD!K(8!"A>=X=W@67ZEB#]
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MWSEEA7;?#8781:(;DWK0W"D"-_;&C:Q5T9:B,(;;^DG4;D]E(E11^14H"FB
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MC79063?)_O<F*I<$LCG1J5OM!EYE<]F[1F<9^H]:VKN"R>XB919?CS8\9Z"
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M$U(F]?*YAQL,,-Q^-OF6U%83RYH7!JYN]5J-%KLUPDWF@5GQS 83HFN=WA;
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M9VE.?LVV;NEXE%??8?_5#[]<%-V#.Q.*;D+132BZ=S"%EWDBJC)_>OJ8=48
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M4]/TU#0]-4V/G(;*S0+W03G<!9<2D1@OY>AZ_.!L0W^M.)/99QHQ=Y>4X@F
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M!></==/*QR?G'^QEQ$0RLL[^9MO4O-6CDSQZ95TJ1?5,<$;DP]BZXB.0K[V
M3M-NSOU%U? 86K@+Z=%B^,/9!SOBR&,EDX)*@Y$JH->Q*,O5 %K9T )'D#B3
M^0^S'%<YL";D>DQ:9TU7J:77D][.\1&MR8J')N[I/<1W,!2SLFTU%I]NMLH6
M,4DH&9WV 8*[7,MJ,,& 49:J:_LM\SQ\+*Q)]_GD.'*7651Y[4>5;0*1XI3&
M.3G9Z6W .]C1R]4@\J;]YS>Q54*MTN^OIFBTO!4.1!'%QY>S_Z88H"PD"+V^
MI ]>:W94^@JFN*"2OIJ#"]X$L*'X"!20I]V@'\]N0K:UYE=.)"WMZ[P\U7I=
M\K JF>T182+43]4CSM=Q%CYM?HHCT=P,S B!3]OL1'=9;>4Y^T04./ +NH\G
M_(+$Q*-E5?&\Z#N:.G-)\%'%30[%%.L.F8<X*_:OK\FLZ&W]N&Y:<JUL.,=.
M5[+=*U&<._Y^49)&6#O@+4QDBYUCF4%&%D>27[YZ\&#V<T..9O97(<>)E#C.
MWKC?^V)=TLJ5V^ ^XQ[M&84V$N0G:*W"9&G-F65@:5[,3<*DTW&\@VZW-'K,
M>OX2&?FT"X^?D5O\*C/!N ZMX@_X.4*B8>"WC_)^KFZ8.#S<:IM6V0<JN'ZD
M;C;;-3U%0K.GEZ&^6/8Q<#KR1O\^>THA&>VABRS0FB]Z"CA"TR=[3S#HUW[S
M/ZM_U;R5M1OP]<^>_FOVLR:)7-^H+YID:6F2.-9'&&?YY/OOSWY^-7M<\'_.
M_A$N4";!)_E7KYHUS]VLF*-@MNTWVVYZDQS;&OGSPO7D?Z!N68.P*+&)L%4T
M(N(CV%J]RWT7#(GLCJSER?)O<Y=9'<1;W02]&;VKO0UG&56+F:"]Q]G/K\X>
M.]#I-0I6=/)<A7@-1UB;(O5H X/W'$D/G%AEZGL&L2;/P>MY<3AO6O%P:B3.
MQ1;''_ V^YD.Z#E;LF.A<EVUE:##^$9^W\YFF,MV7:I"K5NJX0@G'ZB"L$5
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M#\M!@4^X["!6@"BDB"F:-$A]DG:L=HH2E7V/3?"(QG>XX@J,59H*^7REAA4
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MIJU=I.3R\Y6S"C( 7L(YI]3=;BX-Z7Q8]!9D\)QLJ 5 T37QD)XH1MO5E+A
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M]QN=L13M%#P68AF%XK5J'"4BSM1>010 OW2'D&$2?<0@)3[1UDC4=>HD^8*
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M1,DQ7ZI;5Y2<T#JL<^Y)(=; --0Z+"] 2MUDZRQ8$!W[,R:SL<:(!IL#ZI;
M1(,ZNYUFY:<*]*-[G[Y?JRV'*Y-=NPJ';V<,A70FGC:4V'K?*7;GW6_O@QBC
M:YS>N !1^H4>]2_T&((HLE:GY8'= J%*+[(2N4CGHMQ*KT4+O)Z]/U]9S;(T
MFK%)!WE1PDTJ$Z'IR_PX3?ZMD21<RG[3OUS%Y^$,J9H8'Z>$H6LTH8EW[ODF
M(S'WL9Z2=E1C@!KT!3#@*G\%/XKR'[^&A*ZXVY;1^^C5)&%S6CV1V::7%7FQ
M6,L/]E9NMH?M9*&KMPD!PJ\;=NDM2$FEKALE [(_]?0>"4$B969/MMIOMRS?
M'9OC_P;(0@S3<6WEWW^G2O&'S=(G-$SB*-R\%#;W07C 9;J88NB*\W_'SL51
M]\:X< %3[-M80Z%GY@4QP(:5TG7%Z&YLK\;!4/U+C+EK:"G$+S&?V1F5ST0>
MHQ?<.XT:%3G$>$\08(=0WV>:17@*.:'(0ZY4'*J8756M".'L2L/,%_$1P;[?
M,/D*&K!,6YRO,. "K0#O.ZF3-(MFK4F"TH;;C=H+(>,+\F%Y6&$A**]C5U=U
M@>C.FAHW3/<G!1H;;HU_JI.M,HZG;U<3V'+&ZO((RG8+5G<N$6:K:?(/ R=@
M>+G67%B&^#C.@*77;?G2>C=8 _<>Z)?-!>=P0X8EV:S1T>8NE"TB117J,S']
MWD7@#KT 8Q(*&_Y&#@\C(2=2N+74A&C;OY& M NERD@Z1F+3-7:G@_)FD9>Q
MT<]-0]?J4:7B0"O9 ^_DF(B:\2>*^+'/<'^L+GX9UM55R,6FN--)STNI=LN;
M9]JMY+[$'!5RK+ZM]1U)5JC3=)2C)VU5NUV7PXJ^$Y<2::\P3X1<)AOM "2F
MOH!LEA*;:E$O2.2,7R" YOIK3Z];;T&?R]V% /44IG=9;=7\M_0#(5:ZI%=&
M/U@((I357)7]PH/-MN6>\5,Q?I<6-9L)DW-=@1OLHHSF(PZ&ETS"9+;<.OVN
MB(S8]"2,$1F0@\@ZZ,:A:&+XZ[X]<IY4J[1I#7'B"0(2\[=99-4Q<5W9I711
M B@/H/Z(NVB/3UVT4Q?MU$6[;89E?)F[/!6VR".%.:Z!0Y&RQ!G\@RY4_Y'(
M(]/&;(9'NOA3+J96\U[B(=;8-&B(UG?2L5_,%M5519%?68_OA\X02?;=;SD'
M;GE&<6W/,&":E0-)A.;D5+,5Z'6T/*DZ[U3@;:B-.,_@(_<FOWF>+9Y)*<%C
MMJ7"W7]N6HI2KD!I-&203,2/;;_5*T@:28O=1VH[SDTJ')U+T=6J$3#1<M.+
M+1$E.61(CR88Y9.40G+_U%;\!I3AP KN+*_Y65^M1$@MZ^R\^_H-[$R2.B&J
MA3+N#&I1EPV7(GE@@GD=Z1^U:.#2?3 F6DP6&O>82%FMFX8BBTNZ.]@:Z!(H
M3+FD<.M-2.ML2R^LG/F::\PH.46.>LI"J4$ZU;B;OPQKKG_V<<>DJP@?$2R&
M0_D>$*>U3,P*5%UVE6BM#M[K[-E..4$\)]*8+&N6>BT(6)3OTP'&A3BG#BF%
M8P:U1C#"PLM35BHKNEV7VI=-"5]KY#WXE7MK(["O<JOFS\_KN)Q\_\;SD+%[
MQ?";JR^(UY4EB)'R$B1Z/*17L9O&+]\$64ZW!?V*.B;*:3.GHDC'&9Y$K,<,
MR_5O1H Z/$0B!;+EY.3 &R"=>'O)YV/QV]T5&^*@.2=O/'V"WSPZ^&NZRYK/
MS_A0<0WIS."KYC" SC>C-%EQ-]?7_/8"=Z?DM%LW3)LN5A38):CM*V.4<Q[-
MH*0CO\+^C0MM>PI/N<]?1_$6CO)=Y7<_\>Y\9O4K7PYF@#YW3[60$>=.5E9Y
ML_G04HJH(SVJ"W1ZK),S*#?,^_4;T1R*S#LR[,)^_W5979<0H5I#3?#BTFH2
MUTW[1AT<A40EJ^-Q806ODJ,<N;/%)4_\)=XMN2!O[$NR:O/AD7D*N0OS ,_#
M[AJ;5_Z [_SI)3-'I[0O59-E)))5O/E[M?E29''0)#5Q]%93O1M9KX_/J.]5
MAQ<+](,Q?MZO'BZF6[D*PIIT;Q G+6=,-GK3"$I$X(_Z!]KM8)  %^RDOA0/
M&/L:LH(.)=VUSQ*D+HS()]05CZW6I2&?5.O/"6GM&.?!V*_15>]48WAJ_S2#
M<%Y<C17@$A>S-FLOVN::PE'7JQULS,M*4[ V,$RMZRM1A;1'Q>^XD+>";J3C
ME+W=<MHH'9V29XA"SF??2\RB559M,2TE8X@Q"#Q?(3AUA@_&P#AY'KW3,")T
M\0R-6D:KFF'3.7?>41B*CF)*7WEQE87.&,*XNESM^K3N%XC2:N%CU(+ID*!F
MU7B*L:AI[C1*./PIUS&X,Z!4LK!!J(8Y=.8[:6[SXEVW<MSUK#8,8Y"PUWM4
M=%:TJZ#M%2YE CUAL^[(TA<MO0*Y^R+=>J'W%7G\Y-+!/Q*/0F@X.-R]FX#4
M)VUD7IQ=*#>69X1681@1395UR=R$?H6FDQPUWL5TG+HEH>OI_>XWQ3%GHMTL
MI"D4'+]LZ,EG_T7KKJ.<=)R&U>R'WWBVBA;[.0NYMH>8= _</Z-'2KC\Q#:
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M6]91HE]S7.!#_7(..1SCUL4&F0>N^*4G0!2Q2F.R8Z/\ -;X;.6V'\H<E='
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MAL&UHU&&(D_MF5W4W86XC"Z$-VG\F_&_X[<_>4]==G*1B]M4G=4QR_F<WH,
M(7"F\?<J14\J2CRAE1*F#U0DFM;&Y/%SH(/M5OQC8&43L774T0$)%YT[QG74
MQ:4VAM6NW 23UQR=7!?PQF2:GW6?%V3/72DCU9N"C*1E4#$YWJ97%9X\8S(
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M%M?EAVQ$+2-)C!V3A)V7M+5.A&GZ35HCR#D5^+1,%)<CW==X>I[/?L9''<$
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M=ZZ)PZJ$>"EC5\("%P%T$%HTQK\06ZJ7$//&=6"&S,.W'<[9,)QV6H(WL2&
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M"[/CAID9\TL]L5BHA1=>AT"XI&4@Q3M$*"FG.C'BB%7L)!<P^P8 ?--2*'V
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MZ%Q<WHS>O!F=W7PX?>.\OWKW?G1U8Q/_K'%E=8_.ZAZ'G32N9)SZ$Y42XWR
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M-9!-T$ LWG49[SKH#S]-$G\:SFV*I,4QBV,6Q^Z'8QUT<;^'5XT_"EVIJ&G
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M@:VV77@<9M2=RP!>2FP+(2S86;"S8/>-8-?!4H@W(IQF8BJQC+OM@E$+'*N
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MN<!7DE\@+ /,,_%!<(H"F:6#ZD>4)2@WYWZBZK1(OJ;B(Z!R8@"'5E3A"OC
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M?"K.H#\"RI%2<1F,FE&08R=;%&*<]>I'72L8R9:WC3ZB)!4A9LR"AH(W5WJ
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MOL7Y.[?6P.;+Q$X7YFFM?F7*',C+-45[^\^V:$^SSG1)3":NCQ@&@$P0@QT
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MYG=('"C:00;%^"F^AEL1D#">1QX@(5XO=39^XZ6?T0Z*3).*Q">!WS1:SL6
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M";8;*(;A'!(__L1ATE@L@,3*-6;9CDM$R<[=+-(]-=-HRKS<^:$K7YN41K/
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M1:(9+JA^PX8[0J5)YG(*"ZT:(>T73+V@SI1F7G"M2AU$ <'I=$07@>E*/HJ
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MS=/RUMV'!_L[AP>+X;SWMW>7N(#V&W,!]66#"A -R[U!=B9^.T!$E_B%=&N
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M6V2*;[A[4SF"T;/#%]H9;>LPU2T'-=!%,WOF)MQ_ADUI3HODG*>A (H:49]
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M:M6N_O7MX/3BW-G9J6A?UDT^+M_DI;#J^Z?/>[S_O,?59!Y50Q&2CZ_"CY/
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M]"%2-P)) 81T$HEY*C,]%-0K)Z6H#S6%6)?(C*'(QF:PXBLE/JAP5SY,,]6
MQLYEZ)+_N^3_3G]<@^3_^CPK75?D^%;0;*%;_0Y3%"C%W9=I\"V"9 &Q<OP$
M.*["4VT1/HVJ:Z7\2SQQF8U2;.B*"1-AG.:);H 3"4SOQ>Q&;IE-O>A*>EM/
M=L6!KR/I9I'MRMAXQSP)U?Y.@@0#ZPLP\)3,.;D#]2J'VO<$#2+9%$'=WJLD
MJ>/33_W1W</OV4/<+!UY>$M%-&X.U(GZTDG/2LS*C.69)$*0'=<-RAM66P82
MW"GD%DKZI!5/ZF)O*X@?_%BN27/7U\(/WBT+" L_N 3@^9I84-%O><3U>=?
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M'!-*'(RB &7(.BR[NV9-RF7#AM_)I\[P6]B%Y\_9C7QW23?R7=4HRA[NY1J
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M=+%"^IV/]?N)J)?<^/_YRU_^\K\-$?/+T^YR3EF1;J_+_#LQWXGYU1?SA;J
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M4-2_K.1D"2&C4>K @ZDZ0;70!;&">EMNBR]@X+[4BFIUJ%Y5_^G);"@JOJ!
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M*?"DX_W/T..^S2UE-<G(@^X 0ZO:3+L7GF.7,>F&@:9U,N0N)25ERZ$OXHN
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M2"3#(F69(:%BU$#IC)N$C&2>TXR\9TIQ(<A;Q:,)(Z33;KUN=;J[K;;G'1Y
M7X.RD<P"TNGXG9[?;7=W2+L7=+M![S7IOR=;EZ/!MC4_.AN,_CD?NG'/+]^>
M' ](P_/]__0&OG\T.G(5.ZUVAXP4S30W7&94^/[PM$$:B3%YX/NSV:PUZ[6D
MFOBC"S\QJ=CQA92:M2(3-0X/L 1^,AH='J3,4!(F5&EFWC0N1^^\/; PW AV
M>.!7OYWM6$;SPX.(3XDV<\'>-%*J)CSSC,R#7CLW^]#2A^H;-M?>C$<F"3KM
M]J_[.8TBGDT\P6(3[+;V]I9%BD^219ET4PL4$]3P*<.^:[V&@E$5C*5)]F\.
ML*YE7K6+96:\F*9<S(-7(YXR34[9C%S(E&:OFJX$?FNF>/QJWUIK_C\&7</T
M#+LV'A5\ IVCK_MN_D$Y]?'*(#-FIS.6(H+*X77"Q]R07J?5.?#'L$[Y8WFU
MZ@165MU.N89!!3?S(.%1Q#(P^/<O>]UV;__ 1\/'=*.V."%PA:D'K,Y@>#$Z
M?G<\Z(^.ST[)V3LR^GU(SB^.3P?'Y_T3,OQ[.+@<'?\UA"JP&EX\\@I^C>OG
MEQ<?+ONG(S(Z(Q^& SN!7KM;3>)#_^)M_W3XP3O[^V3X#^D/1EC3;;>[/R8*
MEFZ0ZO]OUJ7C)O0P88KT6^0/%L>Z2<Z3UE&K24*F#(_GQ"34!)NT(H:.!2-C
MJ2*FWC3:#?!4B'*S6ESKG(;E-;10\#^JABDWI;W6:W"A;%>YXYNH;CK%-0BI
M*%%H 0F[ZOXLX89Y. 8+,CE3%(JJ7G=N]_J8"^?!YFID&M1*<)]W(W5:=H5N
MS.*YO#DF"9TRHMB4LQDHK4FX)G\65 &5Q9Q<L%PJ _I+WDF5@D![?Q(9DQ/^
ML> 1IV0@%1A0%(W]Y;1\O)F^Q< +(C<=D;4=_+^%QNT$!N]N$$C7.OB6:AL7
MDG1.KF Q!8,(LNG@JQQH(PE^9!)"3QB0\HS0;$Z*S*B"@>,05]JX%-!,20I7
MBE-!8AI"D2(RA8##2&=WRR!C(=.:JCF:I/2*P;BU/C641> ,#"E0[W ,- BY
M@F 8S" \UN )()$ )L*$Z )_+-O/F&)E)SB!E&N(V7#I7?BLF,Y9:!W$?G-P
M348P30 >+,IX7E^&%UI^G[1L'/8VB(.?(!PC,<\ TLB.)82;P#8PAVI5J^=9
M##)BY0+^#D4109] DQI>FT QCM*3 \J1H$A<R!$7#"S!KV\,#22/;/+21(M"
M@ '03@(W['#:^A-2G9!8R)FN.*G8A&L#Z: A% N=W^!ELT8M73ESR]L7=GVO
M[-K9*':-5J"(=[+SV[XN^5-&^;C]RSCF<&E!>DRH8I8. &^.-QI@2YC&F\YU
M@N9HEH+TH?SA=<1U**0NH!V*HI+"\2)7,F01%&NR!32(&/#*87UX'28TFS#2
M![VY* 18='K4Z^QNL6W;M+,;N2MWR3$'S!P?L7^"HE2CJ:,-^G+O@>*5@6(8
M".=YD[Q@@9%L\#,0LK?7ZCX)(?>>D9!T>Y,(><0TK!I TX9FG^=-$Z/&D!;Z
M_DTP?!LSX$ YD@L(9:&@ ] =1!2J&5BQS/:#6?Y2!^M:ZL[K@%1E1+@D1K/4
M6:SDH(G@BY:"1_9851=CC6F<XC@![N)6J^X9]E1HC"7M'J1MX&FU3VH&#AG0
M6FR44T19(2A*-DS+.K&,2:&%BW#K@3G\-69H"*H*[5GT4ZCH#TG:\0:3]MY2
M=(N[]Q>Q>U,8:#_E$3*3:IE90%$-K,9<$.E*5511!\C,J8,E1JGKAL6-Q++,
M$LCM 2NFM5S2!@77Y83R0N5 8&VCZC $2%L';%8Y81D$RP)X##4LQPT"32!C
M=ER%C83GH,LO;/T^V;KV'"7<( *O=7 XI:*P:H6 9W$,N1^? E3UFAQN$3C?
M0WW=Y?JTSE(8&H)R:I<\CF5A[O;@/O$!75@SS(SCSQ_=D'&5<]M=B;F5P*-6
M[/R%A=\E"QN'T091#C330?<V!?"TM$S);,U:GCU *3%XE6%8* 1Z+5)<TVLJ
MM8%R?* (?6FXM^2C>R1!MNYH$@-C0<-N6)>.A\ C>]"+9\!9L?!KVWF54+T(
MJU']+,-99,,"NQZE9,^)X%=,E*>^-^R;7[U$/PVK?\CSI-T?X#S)/@J,J@VA
MN=0?E,,Z*9=2A+1Z0*!]*S]=N$8A1S52Z45L:PN@RS3EQC#V";$?2XB>L3[B
MX)_M9 NH"]JJ4;OA-V;*U7[#/A8<W+=[2Y&%]G!X^^78Z'M5T\TZ-NH+R+U@
MW3C0"H\E\8 SY QX4$:<B^.;&:-7&$*Z7,P&D3:+M$\?JZ<6#V)7>=+B#H77
M2!:-H*%F"\6ZDXEE[@E-@$Z N::+8S4$L;I(8<ZP(G8R9:2P]OG.3Z-F/R2K
M-NM<IP^A:*Q $)J <68U#%ABGXR7=&JZ2(YG4RFF#,.YC$[*!_RJE#V6YD+.
M&=3.$NFTCJZ0%<CU*+%N:[-A;]\R==@O&SH*>*$4@N::!=4?]:$Q8DO<ZWOX
MUBBN :QN=:_L*ZFT,+(J<"^DVI*5UU;;2U"7-EA2>P>U02Q%WC3<ZX26=)6?
MY?@=-_6[V24K%NU"A[7UNH'?VCNQM9[QKN(CXFH-JVL/V1F,86N]\F:P8)]]
MSW913\=:BL*P_0K1]>D^/2QJAE!Y3Y"X=Y'+GY_>RY:KW=KKO:SWMUOOG9U6
MY_7+@C_2@MNM>E7@OW!?>8+Y'H'.!>04;E4Z!M'I])H$OX18)])?3,\G</OM
M/'B0BR6B2STJ0X).?DWL,TOR2]O^^[9S\+6__O7K&RJ_J=#YDA!A@R%U2E/V
M-:#"+>J9$?6"IHU!TP@_TOHB.'U3-P<)9S$97K.P0!TF9^[8[@4SSX&9IYS.
M<X!KZ]P]VH<4]A;"MN](95W<M"F+6POEDD6R.*;AU43)(HLPL94JJ/;ZVO>/
MJQ5EC(RG.8)GS"NO*W6H?W>YDN6N%"T^Z,SIA'DNFJ8Q9+(!G4H>E?=Y;Z_5
MW5EHDBMKVW,C]Z&H_?+T\/]02P,$%     @ S3MM60#R4:<T"0  ;#L  !@
M  !L<61A+3(P,C0P.3,P>&5X,S%D,BYH=&WM6W]3VSH6_2K:O-DMS,1Q?D#+
M,Y29-(1YS&N!1\/LOC\56XZUR)8KR0G93[_W2G;B0-K2%DJ@, /$TI5T)9^C
M<Z_L'/S#\X990K.01>2/T8?W)))AD;+,D% Q:J!TQDU"1C+/:48^,*6X$.2=
MXM&$$=)IMUZW.MW=5MOS#@^@KT'92&8!Z73\3L_OMKL[I-T+NMV@]YKT/Y"M
MR]%@VYH?G0U&?Y\/W;CGE^_>GPQ(P_/]?_<&OG\T.G(5.ZUVAXP4S30W7&94
M^/[PM$$:B3%YX/NSV:PUZ[6DFOBC"S\QJ=CQA92:M2(3-0X/L 3^,AH='J3,
M4!(F5&EFWC8N1\?>'E@8;@0[//"K_\YV+*/YX4'$IT2;N6!O&RE5$YYY1N9!
MKYV;?6CI0_4-FVMOQB.3!)UV^Y_[.8TBGDT\P6(3[+;V]I9%BD^219ET4PL4
M$]3P*<.^:[V&@E$5C*5)]F\.L*YE7K6+96:\F*9<S(-7(YXR34[9C%S(E&:O
MFJX$_FNF>/QJWUIK_C\&7</T#+LV'A5\ IVCK_MN_D$Y]?'*(#-FIS.6(H+*
MX77"Q]R07J?5/?#'L$[Y?7FUZ@165MU.N89!!3?S(.%1Q#(P^-=O>]UV;__
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MV'#I7>RLF,Y9:!W$?G-P348P34 >+,IX7E^&%V(^56(V#GL;Q,(O4(Z1F&<
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MQ;3Y\RR=K)N<=,KIC'$_???T,((F;4,@T X,?FCW;E_Z[>ZMU?_),$9I3-*
MAO#>/S^#4 3KA*8* DF)0NJ&J1A\D64DA7,J)>,<3B0+5Q3 L<TCTW$/3=LP
MCOLH:UAM$JD'CF,Y'<NUW0.P.Y[K>@==&)S#WJ4_W"^6G\Z&_L>+4:GWXO+D
M;#*$EF%9OW6&EG7JGY:, ]-VP)<DS9EB(B7<LD;3%K1BI3+/LC:;C;GIF$*N
M+']NQ2KA!Q87(J=FJ,+6<5]3\)V2\+B?4$4@B(G,J7K7NO3'1A=7**8X/>Y;
M]6>Y=BG"[7$_9%>0JRVG[UH)D2N6&DID7L?.5 ]W6LB^L^;:V+!0Q9YCVS_W
M,A*&+%T9G$;*.S2[W1N29*MX1Q.E:YZDG"AV1;7LAM2 4R*]I5!Q[ZZ"+^W,
MZGV12)41D83QK??:9PG-84HW,!<)25^W2PI^YE2RZ'6O6)VS/RB*1O<4O58&
MX6R%PK6MO=)_KW)]>4O)AA;N+ 4/D3FZCMF2*>BXIMNWEABG[*&LNFV$9M9B
MKUB.2CE36R]F84A37/#+JZYK=WI]2R]\2#,:P0DP5ZC\AN@,1W-_,IX,!_YD
M-H79&/SW([B83Z;#R<7@#,:3Z0"_XK?9&%>-Y@\<P>\Q_>)ROK@<3'WP9[ 8
M#0L'WMI'M1.+P?QD,!TMC-GO9Z./,!CZFN/:]O\4!3=F0/UR2YLF*00B36F@
MD[.LH"JF\&%-)$:<;V%.,R$5B C.V.<U"QF!H9!((WI'&PB<8D9OB*0H:$>'
M/2U%^^/:O:%(L"1OBRNGM]_&F@MC(1,LRL8'B(0L5*8LI9"@W7$.- VQ-"]H
MIFBRI!(Z=AMT>49U.42,U\5>[UO08"VQMF! 2!K"Z!K+9HHE'[4F+,^U,?BO
M5X98\"&FDJ(S3?M*%V_,F[3AG*$4RN%7@@68M&$8,QK!F*78?QCA,(LB%J!A
M*$D+JCQL%]*76T"68A%>9VN9KPG>=27 Z<*EN3"')NIUCM[TP.D<VH5')!29
M[D7-U8OJEFC45EH61"Y)2G-C=LWI%@9!<5LT:MO()\6V9 N?4K'!"*VH]YR
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M/G>[IGNP:U0ES2Y^*BH?_!5/$H__!%!+ 0(4 Q0    ( ,T[;5D4^JZ;Y1<
M .<0 0 1              "  0    !L<61A+3(P,C0P.3,P+GAS9%!+ 0(4
M Q0    ( ,T[;5E@DG\ & X  #;    5              "  108  !L<61A
M+3(P,C0P.3,P7V-A;"YX;6Q02P$"% ,4    " #-.VU9^.?06 @R  #=]@(
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M,#(T,#DS,'@Q,'$N:'1M4$L! A0#%     @ S3MM6?NVJ^VS 0  =P(  !@
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M,BYH=&U02P$"% ,4    " #-.VU9C?C88- %   8'0  &
M@ &O9@4 ;'%D82TR,#(T,#DS,'AE>#,R9#$N:'1M4$L! A0#%     @ S3MM
M62;:WD+1!0  'QT  !@              ( !M6P% &QQ9&$M,C R-# Y,S!X
@97@S,F0R+FAT;5!+!08     #0 - '@#  "\<@4    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>lqda-20240930x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lqda="http://liquidia.com/20240930"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lqda-20240930.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2024_To_9_30_2024_srt_TitleOfIndividualAxis_lqda_BoardOfDirectorsMember_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_k0mS-FrErEGcCSQNS7upnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lqda:BoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lqda:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_12_12_2023_To_12_12_2023_srt_TitleOfIndividualAxis_lqda_LargestStockholderAndMemberOfBoardOfDirectorsMember_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_gnFwleLvT02Zo7EgTUlKNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lqda:LargestStockholderAndMemberOfBoardOfDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lqda:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-12</startDate>
            <endDate>2023-12-12</endDate>
        </period>
    </context>
    <context id="Duration_1_4_2024_To_1_4_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_rWhTZuGpl06hF6C5gOgr0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-04</startDate>
            <endDate>2024-01-04</endDate>
        </period>
    </context>
    <context id="Duration_12_12_2023_To_12_12_2023_srt_TitleOfIndividualAxis_lqda_Mr.PaulB.ManningMember_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_ET_kOfe7OUyGZnegoThYVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lqda:Mr.PaulB.ManningMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lqda:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-12</startDate>
            <endDate>2023-12-12</endDate>
        </period>
    </context>
    <context id="Duration_12_12_2023_To_12_12_2023_srt_TitleOfIndividualAxis_lqda_CaliganPartnersLPMember_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_yy0o7xFcx0aREDaZ1VnfRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">lqda:CaliganPartnersLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lqda:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-12</startDate>
            <endDate>2023-12-12</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_glcrSVianU6a1o46EeXtNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TAyoFb0K3kegpTygRfEduw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TmKhLmYzCECUkE-NW019MQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ScrF8tr1w0-MxUBmw2dweg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5u8PMn6XnUeumeLh8ydfDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_FQbXKficgEeFRZOCIK6Svw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AFsBC1pdhU25u5j1c2Q6ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_UnpCcNxeWkirPc8V7uSOcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_bmSEVHYEX0GyBAzQZDTzxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zXAQdDuaAUShk1iCOS3LQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sg-6UkrcA0mC1Q9jWG_gTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_FtiVafAv4UWr8JRCklLjuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uAdhr2xcg06h66-QEsr0Rw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fVis6Rc0lU24mViOdhLPQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0jwCrvtl9UmljYaJoSpv6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_caIrfeIWIUSr-5YM1URrGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2PLVLFxMP0GKVplKYm4eUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VaQV6KiTs0uXI_fEPfZBIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_D-bH4JsxuEqUTMaVgHIQIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_T0JQS0-8iUiQm5svY1pKoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_C8mVC4eTakmAXbazP4Sw7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7AEtKY-q0EKpSlxBuo5Tpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fCrJtKAilUWF6oakyV0Nxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7E3fQ6q_00GZ5N7nqYsJJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GIpJ2QgtfkiSIOYQwZQCIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HrYg36StAUevt9it2sHW4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vBNSpOjO0k-ci40DF_S6vQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aaTdBw1wLEmeLLnJDiO8qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_6YbY13rlnk2AxDHTatb6fA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_0Q4e0dBgsk2MRpxDh6fJYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lqda:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_1_4_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VFjgbZY-JEy1XAWMuIb9qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-04</instant>
        </period>
    </context>
    <context id="As_Of_12_12_2023_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_ZMC_KO-DIESEKNwQeHuFPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-12</instant>
        </period>
    </context>
    <context id="As_Of_12_12_2023_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_n5jOtXbc5063nwGCNNyeNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lqda:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-12</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MBzkjBjqCku_2H2dhAQG9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_lqda_The2020PlanMember_CEMyV83-zUCOMl6DTROCNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:The2020PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_c3RkhmYjMUymom-OGSSabQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_Y_FZ3m3A40qqKnWMJKMAEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_WDRn4vkaQU-_GJyXGW7r-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_3f2n43cTpEKLLf2BEff-rw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lqda:EmployeePurchaseRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_CfxUqp13dkiX5pxqnNfcWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_58oqF0uKeUmLTXXZbeZuOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lqda:EmployeePurchaseRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_kteGXRriH0alvhRWw4-p7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_PerformanceBasedRestrictedStockUnitsMember_Yv0caJPQY0mJtH96769LWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lqda:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_PerformanceBasedRestrictedStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ObYqzytTmk-rYw5p78JFbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lqda:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_PerformanceBasedRestrictedStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_h6JlHh_6Hk2OCYyiU3MA8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lqda:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_m7APsiBNMkuX9fDgBs78Wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_27_2023_To_1_27_2023_us-gaap_DebtInstrumentAxis_lqda_ArSiliconValleyBankTermLoansMember_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_lBeKdvCPDUmyLAg_84HrDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lqda:ArSiliconValleyBankTermLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-27</startDate>
            <endDate>2023-01-27</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_OtherCommitmentsAxis_lqda_AgreementWithLGMPharmaLLCMember_a_fkJlyRgkS7OKPppsJs0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">lqda:AgreementWithLGMPharmaLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_NBou6jkXCUKIl86emqBNpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_VYpHUurxNEuWKkqyAiGjGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_HhiaPNdxpU2kL50_8kQ28g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_iPwI9W-yukKJZYkZvhU5ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember__bkosJSnNUKdzQ6jMHMqOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_lqda_LabAndBuildToSuitEquipmentMember_vbQ7hgEZXU2QQ8szN1HAtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lqda:LabAndBuildToSuitEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_u0t7q0rYoUCrtJJgFwTvrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_vuK9MdKws0WBj-FZvfK_jA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_P6CllWvurEyyz948ZgWhnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_W1eYleOODEWnNYcNk76J4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_JDWBnuimj0OiMbqSGdD8Ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_lqda_LabAndBuildToSuitEquipmentMember_3By5Ws9wr0KTAbJFyx2jow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lqda:LabAndBuildToSuitEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_4_30_2021_dei_LegalEntityAxis_lqda_LiquidiaPAHAndSandozMember_srt_LitigationCaseAxis_lqda_UTCAndSmithsMedicalLitigationMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_HugoVmm5y0mmurW4-YSz7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lqda:UTCAndSmithsMedicalLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lqda:LiquidiaPAHAndSandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_RIO6XDdLvUCyictd22yGPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_8_2024_To_1_8_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_ud0mQkQYWkGjIgetbIuylw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-08</startDate>
            <endDate>2024-01-08</endDate>
        </period>
    </context>
    <context id="Duration_12_12_2023_To_12_12_2023_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_CQWWEiOLTEaaVRh41M4MgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-12</startDate>
            <endDate>2023-12-12</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_lZWG9RJZDEmZsvf2PUlu_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lqda:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2024_To_11_1_2024_dei_LegalEntityAxis_lqda_LiquidiaPAHAndSandozMember_srt_LitigationCaseAxis_lqda_BreachOfContractClaimMember_dVqpqeHTvEyS2ITxDkE5Vw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lqda:BreachOfContractClaimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lqda:LiquidiaPAHAndSandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_xRg1wcXNfk271ht3s4kIeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_7_1_2024_XRrRRtHXS0yYWbSCULb-5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-01</endDate>
        </period>
    </context>
    <context id="Duration_1_5_2024_To_1_5_2024_viljKiMR20eRuvibROMGtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <startDate>2024-01-05</startDate>
            <endDate>2024-01-05</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_cXF6Jhyv9Ums3sgX3ZsQgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_4sm_WwX1i06DJVradQbuAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_rJo_5hCZZ0eoAsQBkZvmzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_icDoJJYujESK_TgeFGGuBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_seQD86Gg-k-g0j-4Yfw1cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_uwLnN9HvMUyPs1gUVBzqIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1P_inS6zXkWNbG-ht9J6vg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_bNNJw9ET4UKPsBG0tkb61Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2wjFZ4y_OU6vooFOFqzXIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_srt_CounterpartyNameAxis_lqda_SandozMember_raO9GBmyIE-5ZvV1IBniiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lqda:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_PlanNameAxis_lqda_The2020PlanMember_q3rF1sbUKU-D4Hw_9Wjf4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:The2020PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_PlanNameAxis_lqda_InducementPlan2022Member_59X93Oj32UqU-HIAb8N6uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:InducementPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_IvI4h9c3EUuyg5PQrrLhMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_1_25_2022_us-gaap_PlanNameAxis_lqda_InducementPlan2022Member_QcdutN2Mc0eer7i2vctGcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:InducementPlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-25</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_SvbWarrantTermBAndTermCTranchesMember_wOo46pKdiUGRSW3RPNRPxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lqda:SvbWarrantTermBAndTermCTranchesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_SvbWarrantInitialTrancheMember_vINmu1l2Ck24QYQ5Ny4zow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lqda:SvbWarrantInitialTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_OtherWarrantsMember_n4R8mkRr-0KRugEMPPOtqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lqda:OtherWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_ArSvbWarrantsInitialTrancheMember_ffU72mNG2UiEuncpq3Bk3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lqda:ArSvbWarrantsInitialTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_6z62s4VwhEOUHWT_u7NrVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_h-v_IaJxz0SgsF5X90JwfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_kMc1M1fUA0aLfEacYxGcNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_ANzvLLeodEu35lLZjmLNlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_RXXfSfHAKUOxB0bjch78SQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_hRZjTb3f50WuaHZvxqO0dQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_9fQbmG5QVECfc_dtjchxWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_bAuPCroLc0CrK6O9kr5tog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_TzBMkys33EuWe4DPMyM4ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_Qb1al7pN5Eum9jNVekDffw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_0ZcXs57SsESdiizR7P7_-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_U5I2QUtyeUKSw5V0JR-EtQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_Ccuko3guq0aS4kOvVeM9WQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_aep-yz_sAU6w4KnoDTuRXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_canxHtd-XkG4uVMvRpE1FQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_XlMlf1imU0CKFBvkuE1IEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_QGpDrn6it0u-SFLEKVzU7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_1muCQV59SEeHsD-Yav1p6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9ztv0G7UzkWrHinKet79MQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_5JpbAcp9g0S1jyEmoVFeoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_9Shl9FOqAEm1xT8OQEZiPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_MRV76XSit0KBbsAP3TiUpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_8RApRitnUUKh4kBFAXN1pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_sVbvNMFieEqahGNDqo00CQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_b9IfscRcGUihtJB5srkY2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_wV-uPH-HE0C8hSHXy_alBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_We2fnt_wf0y9QPYfo6rVXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ynF1uQCSmUyLHWdxX__Sxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_8_2024_To_1_8_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_u77gK6C1w06rKnCiKbNkfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-08</startDate>
            <endDate>2024-01-08</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Xp3560lqZU2xfNzbsFaQdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6Z3BVNcjGUCp4hge4qevNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_9bh_UZq1Z06Lu_r7nFqRFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QZw6OTAtg0azS_m5VGB6bA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_f-rSQLlZh0qWc3XMDnx8Sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_athnGX3vVUWNi8j4p4X8yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oTd2Y4azxE6k0h-MkNkt7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_fj9qXeNqAUyr-FVp6nmzpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_wXfmt2J2LE2WLZnDVgzsJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a9uUf5liUEShuVXaMIN48A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_74IJvwrt6EmcH2m1d12TYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_i3PmmyVMRUO1q-dHTQOURQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4juqE32tLUykVWFmMMpgzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_z8Y4XLDSWUyq3w7U4D0TuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wgxF__1apky0OItCKW6-bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jVVuLhnI7EmDjNeG2Ga_NQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_stBhy-3vH0CN55lEF1pbPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ESYXfJPI-k-Cm-6QGRH6Sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_52Y2y5aCZ06_iOiL1avbmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fl_qDLX5AkK2MTZFNhq5Zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5GOcXOaV5U2T36M6_dQLCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Yh1HtfeM1U6dLWe0U9X_hQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_lTtrHrdNKk2SU5Ol2ar1-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_PlanNameAxis_lqda_The2020PlanMember_WZy6bkl5x06pEBTAbp6atA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:The2020PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_xFqmiRrTOkqulJr1LBWAnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lqda:EmployeeStockPurchasePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_srt_CounterpartyNameAxis_lqda_HealthcareRoyaltyPartnersIvL.pMember_srt_StatementScenarioAxis_lqda_ForCalendarYearBeginningOnJanuary12024Member_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_jT09y22dlU-r4cO26SYVlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lqda:HealthcareRoyaltyPartnersIvL.pMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">lqda:ForCalendarYearBeginningOnJanuary12024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_srt_CounterpartyNameAxis_lqda_HealthcareRoyaltyPartnersIvL.pMember_srt_StatementScenarioAxis_lqda_AfterCalendarYearEndingOnDecember312024Member_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_Eu2lyuSqdUWRsk5xpT6IEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lqda:HealthcareRoyaltyPartnersIvL.pMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">lqda:AfterCalendarYearEndingOnDecember312024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_27_2023_To_1_27_2023_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_ewbpUOaI7UyQVn102NdAXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-27</startDate>
            <endDate>2023-01-27</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_k-djEJags0G4_tYSdX2F1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_9_12_2024_To_9_12_2024_us-gaap_TypeOfArrangementAxis_lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember_90dvyAHXdUi7zLcPG7LSyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:FifthAmendmentToRevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-12</startDate>
            <endDate>2024-09-12</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2024_To_9_30_2024_us-gaap_TypeOfArrangementAxis_lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember_L0sD_tmmekuf3ox2hlAg-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:FifthAmendmentToRevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_5_2024_To_1_5_2024_us-gaap_TypeOfArrangementAxis_lqda_FourthAmendmentToRevenueInterestFinancingAgreementMember_KQa5hA-xwU2M20pCIYuA9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:FourthAmendmentToRevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-05</startDate>
            <endDate>2024-01-05</endDate>
        </period>
    </context>
    <context id="Duration_7_27_2023_To_7_27_2023_us-gaap_TypeOfArrangementAxis_lqda_SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember_JoeWZnLjZ0ynl9XNGamlHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-27</startDate>
            <endDate>2023-07-27</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2024_To_9_30_2024_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_aLJKJ9CWC0enkGwFB_L9fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_9_2023_To_1_9_2023_srt_StatementScenarioAxis_lqda_OnSecondPortionOfFundedInvestmentAmountMember_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_vs2P5tJ_80ax80uJ--MG3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">lqda:OnSecondPortionOfFundedInvestmentAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-09</startDate>
            <endDate>2023-01-09</endDate>
        </period>
    </context>
    <context id="Duration_1_9_2023_To_1_9_2023_srt_StatementScenarioAxis_lqda_OnFirstFundedPortionOfInvestmentAmountMember_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_aXDyEn_Gnkq9Wg0YnjtxyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">lqda:OnFirstFundedPortionOfInvestmentAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-09</startDate>
            <endDate>2023-01-09</endDate>
        </period>
    </context>
    <context id="Duration_9_13_2024_To_9_30_2024_i691B_ItG0GtXHNs1Fzb9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <startDate>2024-09-13</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_1_4_2024_lOhuZ940QEqjnjbxJodNUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-04</endDate>
        </period>
    </context>
    <context id="As_Of_9_12_2024_CIE4XyPuXU-VCdM-JmlrRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <instant>2024-09-12</instant>
        </period>
    </context>
    <context id="As_Of_9_11_2024_Ev9Bn70vFE2agHiszGrR1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <instant>2024-09-11</instant>
        </period>
    </context>
    <context id="As_Of_1_5_2024_3NJ3uFG5A06JS2suMz0vng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <instant>2024-01-05</instant>
        </period>
    </context>
    <context id="As_Of_1_4_2024_bF-IBdhTwk-KlM3yC7Lrpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <instant>2024-01-04</instant>
        </period>
    </context>
    <context id="As_Of_10_30_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lqda_PBMMember_BakiyxxweE66bApftnb0xA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">lqda:PBMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-30</instant>
        </period>
    </context>
    <context id="As_Of_7_14_2023_us-gaap_OtherCommitmentsAxis_lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember_zRac0Pl5b0Geps4g1_aVUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">lqda:AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-14</instant>
        </period>
    </context>
    <context id="Duration_8_1_2018_To_8_31_2018_srt_CounterpartyNameAxis_lqda_SandozMember_bR-PCAVcsEa0W4IuOAk7hQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lqda:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="Duration_9_12_2024_To_9_12_2024_aSxtNfNO5k-96RR4O_eJ5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <startDate>2024-09-12</startDate>
            <endDate>2024-09-12</endDate>
        </period>
    </context>
    <context id="Duration_12_12_2023_To_12_12_2023_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_-VeA1df9x0OIOsIgO9z0NA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lqda:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-12</startDate>
            <endDate>2023-12-12</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_srt_CounterpartyNameAxis_lqda_SandozMember_rx6kg0vHT0uP6yMhTHZMqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lqda:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_srt_CounterpartyNameAxis_lqda_SandozMember_KdRq-SWRhUqv88cPuzMv1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lqda:SandozMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_6_2024_To_9_11_2024_EiDEZtBwZ0mjbahWfp4TWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <startDate>2024-01-06</startDate>
            <endDate>2024-09-11</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_srt_MajorCustomersAxis_lqda_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_VjK3Qv7B0EufQgTVe6t9Mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lqda:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_lqda_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_flP9Ohx3sEW9JMma2AxykA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lqda:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_9_2023_To_1_9_2023_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_fo6QHS2lUkOEV604PgAJ-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">lqda:RevenueInterestFinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-09</startDate>
            <endDate>2023-01-09</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2023_To_6_30_2023_srt_StatementGeographicalAxis_srt_NorthAmericaMember_us-gaap_OtherCommitmentsAxis_lqda_PharmosaLicenseAgreementMember_QWvVbOqoFUaZurD06Zgd0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">lqda:PharmosaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2023_To_6_30_2023_srt_StatementGeographicalAxis_lqda_OtherThenNorthAmericaMember_us-gaap_OtherCommitmentsAxis_lqda_PharmosaLicenseAgreementMember_PWs3djrXF0qDVpc8vjHEMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">lqda:OtherThenNorthAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">lqda:PharmosaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2023_To_6_30_2023_us-gaap_OtherCommitmentsAxis_lqda_PharmosaLicenseAgreementMember_kTOrGdUxVkmmOH0NFjgVRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">lqda:PharmosaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_OtherCommitmentsAxis_lqda_ChasmTechnologiesAgreementMember_17fard0TZkuq54S0aOBFBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">lqda:ChasmTechnologiesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_14_2023_To_7_14_2023_us-gaap_OtherCommitmentsAxis_lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember_9-1NFSrmLU2h8Mehfb8Z0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">lqda:AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-14</startDate>
            <endDate>2023-07-14</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_WarrantsToPurchaseCommonStockMember_nREMiBhLNEmIWUNmI18Y6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lqda:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_lqda_WarrantsToPurchaseCommonStockMember_W3GhsPkTi0ad1ra4mD2y0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">lqda:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_OtherCommitmentsAxis_lqda_AgreementWithLGMPharmaLLCMember_HIEBrzKy8U2iausIsKFPnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">lqda:AgreementWithLGMPharmaLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_OtherCommitmentsAxis_lqda_PharmosaLicenseAgreementMember_74ZGg3byiEqvxeoe8yh5pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">lqda:PharmosaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_10_30_2024_hkahraS0RkyEbsZVtds9bQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <instant>2024-10-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819576</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_customer_rCtGSEdMk0iBBkxQf_23NA">
        <measure>lqda:customer</measure>
    </unit>
    <unit id="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_tranche_wUAWxTjoVkeKHp1IAnkhew">
        <measure>lqda:tranche</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment_5Yg_HHT1gEGJPlsg-11Qtw">
        <measure>lqda:segment</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      id="Hidden_DVKJjtpYYEaK1FOJGf_f5g"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      id="Hidden_G7RdtXnBf0WgJFsdqp6jvA"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tc_k-PF8Ae41U-NhZIAKUenZA_2_1">0001819576</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tc_LowbsVg02k6QBlBfmWdhgg_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tc_Pu1hS3ILIEeXkVRjaod1Tw_4_1">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tc_0e8bLGyIEEC2WQ_3un-YmQ_5_1">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tc_V7IgufauZEqHCTa6f94FJg_6_1">false</dei:AmendmentFlag>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_WDRn4vkaQU-_GJyXGW7r-g"
      id="Hidden_fljXNZJ780WhJZl0xfbOZw"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_CfxUqp13dkiX5pxqnNfcWg"
      id="Hidden_KgzYt7L2DEmD5XrMEpBoAQ"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_3f2n43cTpEKLLf2BEff-rw"
      id="Hidden_od59HwKFmkW8EjvwzxxZHg"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_58oqF0uKeUmLTXXZbeZuOw"
      id="Hidden__L855O1ENEa44A4aGasXbw"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Narr_eBlJJAILukefrQrJJEysSA">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Narr_eos5EDgIEk2xeXyuK4Z9IQ">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Narr_h3hY9j1UjUmFa8-kqR-Cmw">2024-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Narr_l-iXA6wKBk2zR0V2Mbuj-g">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Narr_U7406VX_UU-X3PGvS9WfbA">001-39724</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Narr_hPgZ9BV1O02kSO2eyruK_w">LIQUIDIA CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tc_wevI8ers1E-pQ58UKWyBCA_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tc_K5elnsxmzU2P39Ku3X4vog_1_2">85-1710962</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tc_XVL2tPPuGEKNKfT_DjL2ZQ_3_0">419 Davis Drive, Suite&#160;100</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Narr_u43_mxCeS0aqkDLmMf_Gqg">Morrisville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Narr_diigUlvSlEuMyJ7YajJyDA">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tc_Y_slWv76qkOu0l-5eJn7_Q_4_2">27560</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Narr_UzmBNXJFkkWR4qItUW7xdA">919</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Narr_4o21ahoHT0C_PUUbwchBTw">328-4400</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tc_x0hJxo3JPkWnuHTv63zbAw_2_0">Common stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tc_yyPN5iac8Eu45sRu8USvQw_2_1">LQDA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tc_sxgoY6Klsk2hqys6VDO-MQ_2_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Narr_jKBvUX_KaE-eHSygXMWPJQ">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Narr_DxyhJBemyEqvBqn030ZdmA">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Narr_exTsc8kkq0O2yd_3d7V2Qg">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Narr_7ybVGWW5OEKRj8xR7mTYwA">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Narr_iijZ8Umq9UWSoUdfu-Qhbg">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Narr_PLQwA2UdcUayWSVrc1Mspw">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_10_30_2024_hkahraS0RkyEbsZVtds9bQ"
      decimals="INF"
      id="Narr_AEPazt8UqkOAWz8kxfhCpQ"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">84636621</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc__k7ZwiqYWE283SpY0IhzKA_5_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">204368000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_434QywMtWE2_ePZ4lVFOrA_5_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">83679000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_NlFzQKe92UydYcSVjqY4fw_6_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">4202000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_KxNJXB4XkUWfbrpHYQdFVA_6_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">4061000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_c8F9YFrK2UuQEgwgL0J-EQ_7_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">38000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_QvTXJ_mhx0GFHRAwswYR_w_8_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">5604000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_oyoBQAhsHk-lPcfjpSfTNA_8_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2159000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_U9Rw-zkITkKcqlofB7ZUAw_9_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">214212000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_YDLnp5PCKEmRXMC8NULU8A_9_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">89899000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_qHKc1GvHS0OAq5J7-DglrQ_10_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">7784000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_wB4nKdzuKEC2xwnp_0Ii0A_10_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">4480000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_qsSQ2lyHekeMDjD4s_gX9g_11_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1371000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_wg2Spk-rdkqtimSb2VghVA_11_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1704000</us-gaap:OperatingLeaseRightOfUseAsset>
    <lqda:IndemnificationAssetRelatedParty
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_ppCjovzm90O6apJRBXEWrA_12_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">7206000</lqda:IndemnificationAssetRelatedParty>
    <lqda:IndemnificationAssetRelatedParty
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_UtuilfXCk06I0xTh3WDcCg_12_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">6707000</lqda:IndemnificationAssetRelatedParty>
    <lqda:BusinessCombinationContractAcquisitionCostsNet
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_320CGRAK4k-fDtjQjaUnbA_13_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">7433000</lqda:BusinessCombinationContractAcquisitionCostsNet>
    <lqda:BusinessCombinationContractAcquisitionCostsNet
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc__Nm982K6YE24aQJsAJWEmg_13_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">7922000</lqda:BusinessCombinationContractAcquisitionCostsNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_yRk5Q49TNE6ryF9NDNm9fA_14_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">3219000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_x2Y44X29Rkyoesoo9Emf1Q_14_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">3430000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_2PiVWdLFLEiAhLT8y6FTwQ_15_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">3903000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_eftr8Mzk2U-RwqX00JuQYg_15_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">3903000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_7EidA0en5kKswJTDY8jtWQ_16_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">7758000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_RLRsK-wh90-H3TjtvIUkMw_16_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">287000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_y-ay9O-3xkeXCgjr7rchEg_17_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">252886000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_xLArdtuSlUqTo6lZwMOWug_17_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">118332000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_MFiIwSq1fUie2O7DwX2mhw_20_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2298000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_hjxpbJglM0KVXfpBV9XmLQ_20_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1396000</us-gaap:AccountsPayableCurrent>
    <lqda:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_x4nXw76SMU2qe4gd-EnTvw_21_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">17039000</lqda:AccruedExpensesAndOtherLiabilitiesCurrent>
    <lqda:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_qd4Bdezg5kmLb5n-zQGC7Q_21_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">13400000</lqda:AccruedExpensesAndOtherLiabilitiesCurrent>
    <lqda:RevenueInterestFinancingPayableCurrent
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_SSfIWzV9V0uAfLLzd6xiqA_22_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">13252000</lqda:RevenueInterestFinancingPayableCurrent>
    <lqda:RevenueInterestFinancingPayableCurrent
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_aCW2p3ZQdUOClahpz1YPtA_22_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2615000</lqda:RevenueInterestFinancingPayableCurrent>
    <lqda:OperatingAndFinanceLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_hLpfY10DnU2KE9u5YLRfaA_23_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1249000</lqda:OperatingAndFinanceLeaseLiabilityCurrent>
    <lqda:OperatingAndFinanceLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_p81uTLM24kGWpc9TeLzRCw_23_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1139000</lqda:OperatingAndFinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_S1oRdiOcz0qGHhjWCncGlQ_24_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">33838000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_aPg7akutLUWaQc_FdauxMg_24_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">18550000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LitigationReserveNoncurrent
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_Y1WpZfZVZkOJ8kpQaRdZDw_25_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">7196000</us-gaap:LitigationReserveNoncurrent>
    <us-gaap:LitigationReserveNoncurrent
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_qclzraLzCke6O-ghadNqVg_25_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">6707000</us-gaap:LitigationReserveNoncurrent>
    <lqda:RevenueInterestFinancingPayableNoncurrent
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_5mYf1qerAU6hYqe3cvA6WQ_26_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">99892000</lqda:RevenueInterestFinancingPayableNoncurrent>
    <lqda:RevenueInterestFinancingPayableNoncurrent
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_w_W-v_dnhUa1u9DJ7vFoLw_26_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">43418000</lqda:RevenueInterestFinancingPayableNoncurrent>
    <lqda:OperatingAndFinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_smpgkaz2vUCbqcH70hWGpg_27_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1442000</lqda:OperatingAndFinanceLeaseLiabilityNoncurrent>
    <lqda:OperatingAndFinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_iFlHJAE-q0qt5ck3Q_CoFQ_27_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2364000</lqda:OperatingAndFinanceLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_Kq3mH77CwkWIaoOV67W_rQ_28_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">142368000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_y3_FGT4Tg0WyycBu13kErw_28_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">71039000</us-gaap:Liabilities>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="INF"
      id="Narr_F39jKySA5UKxJd6_-JNYZg"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="INF"
      id="Narr_12s4QOrn7Ui2MGL2ynNoVA"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="INF"
      id="Narr_LWuWzjfzh0insGgPhL5j1Q"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="INF"
      id="Narr_n1fMzCwD6UChavKeJd61Bg"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_PGL4ZB71rkWg2JjC9XZqFg_31_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_Pxh6Ug_Kg0uLe-0EPt3Log_31_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="3"
      id="Narr_LpTJuno240-c8EVrhMDwcQ"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="3"
      id="Narr_owkuqdVu70W8S6mOFA2ldA"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="INF"
      id="Narr_Ucqfcs0APE274bD7t4W-_g"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">115000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="INF"
      id="Narr_gnwou4P7HESn3kr-4Nlh4g"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="INF"
      id="Narr_BTk0JBctG0qUQLaKWtoA5A"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">84545409</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="INF"
      id="Narr_mvSuteEi_UmcSn5OSGwkKQ"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">84545409</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="INF"
      id="Narr_vXrcdJ_SG0ikaS4oayc8lA"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">68629575</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="INF"
      id="Narr_6_XR6f-EhUeRK_F6FOQ-Fg"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">68629575</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_loCn1Im8a0qWjNoXN6rh3w_32_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">85000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_R7Dm2aqHTE2A12vIjsN7Mw_32_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">69000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_8iUhOrH410SAGY0bx_B2Ew_33_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">631556000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_3m2JjAuLoEqA9pNUAoXfaQ_33_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">476322000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_vLLCTXeF-U-irntBP97anA_34_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-521123000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_SMTfdSTGvUezDVO1Mc98ww_34_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-429098000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_x1qOS4Fm3Eee_cRMgSVnIw_35_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">110518000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_UbhyNNU6jUetDd1WGC3kuw_35_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">47293000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_8XMyEULSy0KLodKCfzv7DQ_36_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">252886000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_q3IYQmprVkOwMpUozmzzsQ_36_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">118332000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="-3"
      id="Tc_Vu1d2mLJJk6cbHSHVagG1w_3_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">4448000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA"
      decimals="-3"
      id="Tc_oG9EuTySOk2ayTx_UqOP6g_3_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">3678000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_RoAaS_VQwEuHelAeWiirvQ_3_9"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">11079000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_aNgngLYKDkSq3YPhRMy1Mw_3_12"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">12957000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="-3"
      id="Tc_L0ZRCScwL0qpXzOhouxu1w_5_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1565000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA"
      decimals="-3"
      id="Tc_RQjnnwy_MkS9Rn8aJdytDQ_5_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">570000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_C5XFeB-f3E6PkXzt5VF23A_5_9"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">4525000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_7KS5L2eaq0CZB_utBCw6bQ_5_12"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1895000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="-3"
      id="Tc_GfKGINGn3kG5LLGGK6kpoQ_6_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">11890000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA"
      decimals="-3"
      id="Tc_uQ5s5KGr70OGP7Iqwg0nHg_6_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">7440000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_3fC-9iTps06qrMYE_PtNZQ_6_9"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">31367000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_T3P0ytPGg0aKnrCDhywr8g_6_12"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">30413000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="-3"
      id="Tc_DBGDKSEg3kiFw_e7080yJQ_7_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">20182000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA"
      decimals="-3"
      id="Tc_ELVS3k4Qb0-GyGU-NSR19A_7_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">10559000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_ldE_mNik6kqMoQYu1_z72A_7_9"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">60374000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_L2koxWtYdkeTaZ63auoNUw_7_12"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">27597000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="-3"
      id="Tc_hoOG6eBxf06iuQQQWBSsAA_8_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">33637000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA"
      decimals="-3"
      id="Tc_AqN3x6T1H0aJVOVYVgsTdw_8_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">18569000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_XLRiEoxZ1UmybC2fG05Pfg_8_9"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">96266000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_Et1jF9sJAEeN1GrLuVzmmw_8_12"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">59905000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="-3"
      id="Tc_y2Z5rm2ho0qCBanIhn7oyw_9_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-29189000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA"
      decimals="-3"
      id="Tc_mTryNOVNpEi4BTp4M-rfNg_9_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-14891000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_Pr9awI8sKEWN9Bm23tTbaw_9_9"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-85187000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_0ZeXRbVFfEy-ipHvymbzxg_9_12"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-46948000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="-3"
      id="Tc_omGpBAT0qU2t8zWTXk-uCA_11_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1815000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA"
      decimals="-3"
      id="Tc_11nHhjFMWEyYL8-w6ryjTA_11_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">862000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_mj95ncP9ukyvMyRZh6evXw_11_9"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">5550000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_MpPQM7NkU06fkr-Q6Xc5Kw_11_12"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2518000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="-3"
      id="Tc_wna3WpuN20W0j_N4c52pHA_12_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2996000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA"
      decimals="-3"
      id="Tc_WiE0BKmqe0CXZrnMXUVXzQ_12_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1761000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_1R5PV8ZCq0e_1pgXJgDilg_12_9"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">8120000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_yaWSRkslYke-MAyvSDCadA_12_12"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">4311000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="-3"
      id="Tc_X7UVgW2YBUGOsOb-Y_wjng_13_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">7215000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_LBldoN7QL0yynNfBTMWfRA_13_9"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-4268000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_CRUtrWDOtkew3g4OxnfmJQ_13_12"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-2311000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="-3"
      id="Tc_NFG6XNl2eUix5flSgRCTWg_14_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">6034000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA"
      decimals="-3"
      id="Tc_NYrK4iQrXUmnlx3PTvZywg_14_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-899000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_2dw_g9KNRUehVr0ugFdQGg_14_9"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-6838000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_ydZPtjgVkUSSmFjsCukyKg_14_12"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-4104000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="-3"
      id="Tc_iUAfF4_UYUOgQMwkoUx1eg_15_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-23155000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA"
      decimals="-3"
      id="Tc_pIrSTG3b3Ee63bhiKqymHQ_15_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-15790000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_Z59PncgqMUaFQUSWdrVebA_15_9"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-92025000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_M5TzcYMq306p4R76Y_Z83A_15_12"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-51052000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="2"
      id="Tc_9DmcWEg4XUKJaGGzoG4D9g_16_3"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">-0.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="2"
      id="Tc_9DmcWEg4XUKJaGGzoG4D9g_16_3_2"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">-0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA"
      decimals="2"
      id="Tc_tXOtIRfl7kS22p8G6d0B1g_16_6"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA"
      decimals="2"
      id="Tc_tXOtIRfl7kS22p8G6d0B1g_16_6_2"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="2"
      id="Tc_ApHc9bEkfkCtIBkuNj1U_g_16_9"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">-1.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="2"
      id="Tc_ApHc9bEkfkCtIBkuNj1U_g_16_9_2"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">-1.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="2"
      id="Tc_uXekJ52DYECMmrwnHJv2RQ_16_12"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">-0.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="2"
      id="Tc_uXekJ52DYECMmrwnHJv2RQ_16_12_2"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">-0.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="0"
      id="Tc_gb1Nyy-zV0mw2tD7YavBvg_17_3"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">78316820</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="0"
      id="Tc_gb1Nyy-zV0mw2tD7YavBvg_17_3_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">78316820</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA"
      decimals="0"
      id="Tc_hhDlFayXzEWhE__06UxTSg_17_6"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">64857508</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA"
      decimals="0"
      id="Tc_hhDlFayXzEWhE__06UxTSg_17_6_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">64857508</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="0"
      id="Tc_Yy3ZrCy1W0iCZlKhqsyqZw_17_9"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">76719990</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="0"
      id="Tc_Yy3ZrCy1W0iCZlKhqsyqZw_17_9_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">76719990</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="0"
      id="Tc_wy4IjjZ6xUiUenlmOL_oZA_17_12"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">64767893</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="0"
      id="Tc_wy4IjjZ6xUiUenlmOL_oZA_17_12_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">64767893</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7E3fQ6q_00GZ5N7nqYsJJg"
      decimals="INF"
      id="Tc_39K0hSGG3kCm65lU5ibmqg_5_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">68629575</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7E3fQ6q_00GZ5N7nqYsJJg"
      decimals="-3"
      id="Tc_JrmGohtcH0mbYcprq456dg_5_5"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">69000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_sg-6UkrcA0mC1Q9jWG_gTg"
      decimals="-3"
      id="Tc_gVQzt1uU3UyAI3qv8G8Oyw_5_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">476322000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zXAQdDuaAUShk1iCOS3LQA"
      decimals="-3"
      id="Tc_nMgglAXnfkaGAthiUfwWVg_5_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-429098000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_xZg1P4maDUOAxM1Ngaf1YA_5_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">47293000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Yh1HtfeM1U6dLWe0U9X_hQ"
      decimals="INF"
      id="Tc_qX6RBD5YA0y14yGEUvYfwA_6_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">23247</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QZw6OTAtg0azS_m5VGB6bA"
      decimals="-3"
      id="Tc_AA4UxUiAaEe7snzUF5asJQ_6_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">99000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jVVuLhnI7EmDjNeG2Ga_NQ"
      decimals="-3"
      id="Tc__MpQhHZo8UasC9nDj_siRQ_6_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2024_To_3_31_2024_f-rSQLlZh0qWc3XMDnx8Sw"
      decimals="-3"
      id="Tc_QchZqhX1zk2BP3z5zc4AoQ_6_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">99000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <lqda:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Yh1HtfeM1U6dLWe0U9X_hQ"
      decimals="INF"
      id="Tc_YVER94FSO0GqwMO7uWVlZw_7_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">383133</lqda:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits>
    <lqda:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jVVuLhnI7EmDjNeG2Ga_NQ"
      decimals="-3"
      id="Tc_j9mEdRTatk-V73FtiGRdGA_7_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</lqda:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Yh1HtfeM1U6dLWe0U9X_hQ"
      decimals="INF"
      id="Tc_twVIf7UYdkG4f38x7x6BNA_8_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">67982</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QZw6OTAtg0azS_m5VGB6bA"
      decimals="-3"
      id="Tc_Z6vbt_QBuk61HjA88__o8g_8_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">404000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jVVuLhnI7EmDjNeG2Ga_NQ"
      decimals="-3"
      id="Tc_420pbfQTFkKauR6jb5qm1g_8_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2024_To_3_31_2024_f-rSQLlZh0qWc3XMDnx8Sw"
      decimals="-3"
      id="Tc_iRNJg2k35kqs_-f_th55kg_8_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">404000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <lqda:StockIssuedDuringPeriodSharesCommonStockWarrantsExercised
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Yh1HtfeM1U6dLWe0U9X_hQ"
      decimals="INF"
      id="Tc_pTqwbEQk8EKCuEkp7pdBOA_9_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">946</lqda:StockIssuedDuringPeriodSharesCommonStockWarrantsExercised>
    <lqda:StockIssuedDuringPeriodValueCommonStockWarrantsExercised
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jVVuLhnI7EmDjNeG2Ga_NQ"
      decimals="-3"
      id="Tc_pGLZmfjI802bGHVwoEDMyg_9_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</lqda:StockIssuedDuringPeriodValueCommonStockWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Yh1HtfeM1U6dLWe0U9X_hQ"
      decimals="INF"
      id="Tc_KsZVeCequk6tuejPIs7xQg_10_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">7182532</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Yh1HtfeM1U6dLWe0U9X_hQ"
      decimals="-3"
      id="Tc_C3dtqOVMVku1w-Ed3F4Enw_10_5"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">7000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QZw6OTAtg0azS_m5VGB6bA"
      decimals="-3"
      id="Tc_HGDHWBiexES_sxcs58Kp6g_10_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">74861000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jVVuLhnI7EmDjNeG2Ga_NQ"
      decimals="-3"
      id="Tc_AwLL6mcAyUG9MMaA2mFbhg_10_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_3_31_2024_f-rSQLlZh0qWc3XMDnx8Sw"
      decimals="-3"
      id="Tc_t2Al9vmUXkyt--AIHcQUTQ_10_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">74868000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QZw6OTAtg0azS_m5VGB6bA"
      decimals="-3"
      id="Tc_z1l9Z0g81UG_HuHpXrbzyQ_11_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">4524000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jVVuLhnI7EmDjNeG2Ga_NQ"
      decimals="-3"
      id="Tc_W8NaYdMuYUSNLW4iEF9EOA_11_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_3_31_2024_f-rSQLlZh0qWc3XMDnx8Sw"
      decimals="-3"
      id="Tc_ygk18Vtwx06ajeqGVEMDCg_11_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">4524000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jVVuLhnI7EmDjNeG2Ga_NQ"
      decimals="-3"
      id="Tc_Hpg0nVQv50S3SIhs1merww_12_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-40928000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_f-rSQLlZh0qWc3XMDnx8Sw"
      decimals="-3"
      id="Tc_65kia26Gek-wzRdiME4gqw_12_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-40928000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fCrJtKAilUWF6oakyV0Nxw"
      decimals="INF"
      id="Tc_OeeD-E64ykaXcnHcKwSfbw_13_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">76287415</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fCrJtKAilUWF6oakyV0Nxw"
      decimals="-3"
      id="Tc_2bB5tmpKLU65-HCoiC19tg_13_5"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">76000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_UnpCcNxeWkirPc8V7uSOcA"
      decimals="-3"
      id="Tc_wrgQT2R36EyIBP1Eps5iEg_13_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">556210000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AFsBC1pdhU25u5j1c2Q6ug"
      decimals="-3"
      id="Tc_rH0Uoc2HpU-A4bwlbENjig_13_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-470026000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_bmSEVHYEX0GyBAzQZDTzxQ"
      decimals="-3"
      id="Tc_emKqcyfaLUOQJwBKriat5Q_13_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">86260000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_stBhy-3vH0CN55lEF1pbPw"
      decimals="INF"
      id="Tc_8vHNb4jxHUKA1zJCV5pRrw_14_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">10686</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6Z3BVNcjGUCp4hge4qevNg"
      decimals="-3"
      id="Tc_a1BwgIcMyk2Gl8surrpRQg_14_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">32000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a9uUf5liUEShuVXaMIN48A"
      decimals="-3"
      id="Tc_ExXRqiy_DUGEJWeQRBwX3g_14_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2024_To_6_30_2024_9bh_UZq1Z06Lu_r7nFqRFg"
      decimals="-3"
      id="Tc_Xos9PzXHq0u2D_HoRfccdw_14_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">32000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <lqda:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_stBhy-3vH0CN55lEF1pbPw"
      decimals="INF"
      id="Tc_qDPjqyL_dEmJrdOrgWdK7w_15_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">116447</lqda:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits>
    <lqda:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a9uUf5liUEShuVXaMIN48A"
      decimals="-3"
      id="Tc_efFsCSmeK0Gr1ExBAiQljQ_15_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</lqda:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a9uUf5liUEShuVXaMIN48A"
      decimals="-3"
      id="Tc_zOaP7ghYyk-snys7c8X98Q_16_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6Z3BVNcjGUCp4hge4qevNg"
      decimals="-3"
      id="Tc_Rl6jaaImWEyuST0rRNfDzg_17_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">4372000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a9uUf5liUEShuVXaMIN48A"
      decimals="-3"
      id="Tc_m-J4IzI7tU2oP3fad6JZpA_17_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2024_To_6_30_2024_9bh_UZq1Z06Lu_r7nFqRFg"
      decimals="-3"
      id="Tc_I1GVEurwaUKaefwESv5qXg_17_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">4372000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2024_To_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_a9uUf5liUEShuVXaMIN48A"
      decimals="-3"
      id="Tc_9unPyEbh30W7dl1KuB7ynA_18_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-27942000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2024_To_6_30_2024_9bh_UZq1Z06Lu_r7nFqRFg"
      decimals="-3"
      id="Tc_f9V2yDz5rUWLdhjAE7W06g_18_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-27942000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7AEtKY-q0EKpSlxBuo5Tpw"
      decimals="INF"
      id="Tc_Vl_HFBOoN0yQpO80VRNQeA_19_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">76414548</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7AEtKY-q0EKpSlxBuo5Tpw"
      decimals="-3"
      id="Tc__oq1i5zYEUKz8wVEorQmaA_19_5"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">76000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5u8PMn6XnUeumeLh8ydfDw"
      decimals="-3"
      id="Tc_VX-6EEExAUeaPESzGVej9g_19_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">560614000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ScrF8tr1w0-MxUBmw2dweg"
      decimals="-3"
      id="Tc_5GDni-xw-kygQ5sjG-Jf5w_19_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-497968000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_FQbXKficgEeFRZOCIK6Svw"
      decimals="-3"
      id="Tc_aObeNc3T1EGCiKIBGfS5lA_19_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">62722000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5GOcXOaV5U2T36M6_dQLCw"
      decimals="INF"
      id="Tc_5N4LHVLpo0-0C9yitdGUWQ_20_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">317720</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5GOcXOaV5U2T36M6_dQLCw"
      decimals="-3"
      id="Tc_rJ1Q-cT22km2RKv-wRWVBQ_20_5"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Xp3560lqZU2xfNzbsFaQdQ"
      decimals="-3"
      id="Tc_XotWO4dvxUOXo71HdxEg-Q_20_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1548000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wgxF__1apky0OItCKW6-bw"
      decimals="-3"
      id="Tc_v3tB44oEAEKckbhO74zhXw_20_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="-3"
      id="Tc_l5Qz6E_wH0yq3vUmr78TLA_20_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1549000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <lqda:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5GOcXOaV5U2T36M6_dQLCw"
      decimals="INF"
      id="Tc_R_wL4j9dZ0ywahk3Qag_2A_21_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">116247</lqda:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits>
    <lqda:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wgxF__1apky0OItCKW6-bw"
      decimals="-3"
      id="Tc_KePFAz6aLU-ZQKW3uIghNg_21_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</lqda:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5GOcXOaV5U2T36M6_dQLCw"
      decimals="INF"
      id="Tc_dAxjCxg_wk-ArJeNSS4ndA_22_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">104413</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Xp3560lqZU2xfNzbsFaQdQ"
      decimals="-3"
      id="Tc_txbJhY2lnEiCsjQC26CvzA_22_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">844000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wgxF__1apky0OItCKW6-bw"
      decimals="-3"
      id="Tc_gXbTrFpIPkWIShX4L6vIog_22_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="-3"
      id="Tc_ezXTgmkLoUuj5Huj5GMxbg_22_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">844000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <lqda:StockIssuedDuringPeriodSharesCommonStockWarrantsExercised
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5GOcXOaV5U2T36M6_dQLCw"
      decimals="INF"
      id="Tc_aINV6XBaH0ayVMFWVDZtWA_23_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">8212</lqda:StockIssuedDuringPeriodSharesCommonStockWarrantsExercised>
    <lqda:StockIssuedDuringPeriodValueCommonStockWarrantsExercised
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wgxF__1apky0OItCKW6-bw"
      decimals="-3"
      id="Tc_7rTVN-e9_UCMG0-N8AUXvQ_23_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</lqda:StockIssuedDuringPeriodValueCommonStockWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5GOcXOaV5U2T36M6_dQLCw"
      decimals="INF"
      id="Tc_-60eXiixpE2_YvW5m-vGFA_24_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">7584269</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5GOcXOaV5U2T36M6_dQLCw"
      decimals="-3"
      id="Tc_RwVlTrbgIU-fH5EYappIBQ_24_5"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">8000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Xp3560lqZU2xfNzbsFaQdQ"
      decimals="-3"
      id="Tc_raSxSfYoHE2uz7dKnhd1cg_24_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">63669000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wgxF__1apky0OItCKW6-bw"
      decimals="-3"
      id="Tc_PtjeREtwW0aSKgCyACKI-A_24_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="-3"
      id="Tc_SmJiDZYETEWlUPMZJNssIg_24_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">63677000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Xp3560lqZU2xfNzbsFaQdQ"
      decimals="-3"
      id="Tc_TN8T4XZjNE-SHBEHSFg1FA_25_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">4881000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wgxF__1apky0OItCKW6-bw"
      decimals="-3"
      id="Tc_7oxKHODldEuVio563dVkXA_25_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="-3"
      id="Tc_3e9M6_V_wkSK_vGkoHYUjw_25_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">4881000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wgxF__1apky0OItCKW6-bw"
      decimals="-3"
      id="Tc_TQzmcgJl5kWgw_YIU131tw_26_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-23155000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="-3"
      id="Tc_QuQM5dPrz066TNhBlpeZ8Q_26_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-23155000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MBzkjBjqCku_2H2dhAQG9A"
      decimals="INF"
      id="Tc_fW37x64EGEGomDmBuTIqJg_27_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">84545409</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MBzkjBjqCku_2H2dhAQG9A"
      decimals="-3"
      id="Tc_spvpaziYfk2NRSN_mFoEBA_27_5"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">85000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TmKhLmYzCECUkE-NW019MQ"
      decimals="-3"
      id="Tc_KrmHZDPeuEmlDqQMSU1L6Q_27_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">631556000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TAyoFb0K3kegpTygRfEduw"
      decimals="-3"
      id="Tc_wxNLK9c_hkK-TfvgFeJEsw_27_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-521123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_RvZkv8KbqUSThAFUMs9sxg_27_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">110518000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aaTdBw1wLEmeLLnJDiO8qg"
      decimals="INF"
      id="Tc_DI08rqII0UmOLeU07OmLNA_5_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">64517912</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_aaTdBw1wLEmeLLnJDiO8qg"
      decimals="-3"
      id="Tc_NWPqDrDj1Eu_EgY558fMOA_5_5"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">64000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_C8mVC4eTakmAXbazP4Sw7Q"
      decimals="-3"
      id="Tc_jbZAn1t08U6DCaDGq-GiHA_5_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">440954000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_T0JQS0-8iUiQm5svY1pKoQ"
      decimals="-3"
      id="Tc_z4oZbp79c0637mjRWznoiQ_5_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-350596000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_h-v_IaJxz0SgsF5X90JwfQ"
      decimals="-3"
      id="Tc_BempzZDddUCUvNwi3q_Prg_5_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">90422000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fl_qDLX5AkK2MTZFNhq5Zw"
      decimals="INF"
      id="Tc_aoehAMjQWUWnvmP9q-31Hw_6_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">21447</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_z8Y4XLDSWUyq3w7U4D0TuQ"
      decimals="-3"
      id="Tc_dReJ7psbUUyKGNlbuIV_0Q_6_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">79000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4juqE32tLUykVWFmMMpgzA"
      decimals="-3"
      id="Tc_ROz0OBmrGUSeWOS-8KrKRw_6_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_3_31_2023_wXfmt2J2LE2WLZnDVgzsJQ"
      decimals="-3"
      id="Tc_ZrWNWI1ypkKI9dqwvd5iRw_6_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">79000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <lqda:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fl_qDLX5AkK2MTZFNhq5Zw"
      decimals="INF"
      id="Tc_-bwreN59iUOEgDAeth-FnQ_7_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">89804</lqda:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits>
    <lqda:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fl_qDLX5AkK2MTZFNhq5Zw"
      decimals="-3"
      id="Tc_U_ymZs9SuU2NcGwfyaxf8A_7_5"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1000</lqda:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits>
    <lqda:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_z8Y4XLDSWUyq3w7U4D0TuQ"
      decimals="-3"
      id="Tc_So4IIOAP_U6lLnVitQMyFA_7_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-1000</lqda:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits>
    <lqda:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4juqE32tLUykVWFmMMpgzA"
      decimals="-3"
      id="Tc_HfStrjMLM06ouEMV00LHEg_7_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</lqda:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fl_qDLX5AkK2MTZFNhq5Zw"
      decimals="INF"
      id="Tc_sHdjcETg9UWReSiWTlvHwg_8_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">81281</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_z8Y4XLDSWUyq3w7U4D0TuQ"
      decimals="-3"
      id="Tc_W5pCz5NupEqA017Plw2oDA_8_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">335000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4juqE32tLUykVWFmMMpgzA"
      decimals="-3"
      id="Tc_Qa9u49JM6kKRIrJT0zXCgQ_8_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2023_To_3_31_2023_wXfmt2J2LE2WLZnDVgzsJQ"
      decimals="-3"
      id="Tc_fPDyljRO7EaszykbhkS4pQ_8_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">335000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_z8Y4XLDSWUyq3w7U4D0TuQ"
      decimals="-3"
      id="Tc_xyEMqATEa0WaVHBViMo3bA_9_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2552000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4juqE32tLUykVWFmMMpgzA"
      decimals="-3"
      id="Tc__yaO64TKXEetbXMd6wgXXg_9_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2023_To_3_31_2023_wXfmt2J2LE2WLZnDVgzsJQ"
      decimals="-3"
      id="Tc_AS6uSN5kiEa-2CjGTsm3-A_9_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2552000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4juqE32tLUykVWFmMMpgzA"
      decimals="-3"
      id="Tc_8yn6is_NxEqR-syVvvP_fg_10_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-11745000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_3_31_2023_wXfmt2J2LE2WLZnDVgzsJQ"
      decimals="-3"
      id="Tc_P9Qzp2WcJk6fAuCDtoOLsg_10_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-11745000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vBNSpOjO0k-ci40DF_S6vQ"
      decimals="INF"
      id="Tc_WiI8F1z2pk21xnof6CGOzQ_11_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">64710444</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_vBNSpOjO0k-ci40DF_S6vQ"
      decimals="-3"
      id="Tc_0vPKYxxUVUeSiM8zuP0lCg_11_5"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">65000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_VaQV6KiTs0uXI_fEPfZBIA"
      decimals="-3"
      id="Tc_q_FA8rrDnEmsDMmz_oA1zQ_11_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">443919000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2PLVLFxMP0GKVplKYm4eUw"
      decimals="-3"
      id="Tc_mEzrcXbgakqpcoCI3E2IRw_11_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-362341000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2023_D-bH4JsxuEqUTMaVgHIQIw"
      decimals="-3"
      id="Tc_Caw4skxtq0mPiBHo1qO8EQ_11_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">81643000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_52Y2y5aCZ06_iOiL1avbmQ"
      decimals="INF"
      id="Tc_yM8Y3CAQiUuHZdtJ-uacMQ_12_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">10173</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oTd2Y4azxE6k0h-MkNkt7g"
      decimals="-3"
      id="Tc_-MCByWQcP0aED6hak4TWrA_12_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">32000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_i3PmmyVMRUO1q-dHTQOURQ"
      decimals="-3"
      id="Tc_ncoNmHjl0EGFaup9MldCNw_12_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_4_1_2023_To_6_30_2023_fj9qXeNqAUyr-FVp6nmzpA"
      decimals="-3"
      id="Tc_MMFzcvlxyE61j0zXp-q19Q_12_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">32000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <lqda:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_52Y2y5aCZ06_iOiL1avbmQ"
      decimals="INF"
      id="Tc_RCHstbUp_UeD5cH6ItM_MQ_13_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">19765</lqda:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits>
    <lqda:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_i3PmmyVMRUO1q-dHTQOURQ"
      decimals="-3"
      id="Tc_PtLSbSJV6kGtwBQhHa21rg_13_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</lqda:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oTd2Y4azxE6k0h-MkNkt7g"
      decimals="-3"
      id="Tc_EKha_BUaHkqt-Pe7JZVHrA_14_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2499000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_i3PmmyVMRUO1q-dHTQOURQ"
      decimals="-3"
      id="Tc_cCICtx75HkelT7meIL3kHg_14_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2023_To_6_30_2023_fj9qXeNqAUyr-FVp6nmzpA"
      decimals="-3"
      id="Tc_X1tJQrVdzky4CFb9wXAX9w_14_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2499000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_i3PmmyVMRUO1q-dHTQOURQ"
      decimals="-3"
      id="Tc_FA1wVp94QkC_BAzwT_q9rg_15_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-23517000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_fj9qXeNqAUyr-FVp6nmzpA"
      decimals="-3"
      id="Tc_ia6LiMJjYUyi5HtesItgYA_15_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-23517000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HrYg36StAUevt9it2sHW4Q"
      decimals="INF"
      id="Tc_WWTz3DVNeUyzjOQs6zNULQ_16_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">64740382</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_HrYg36StAUevt9it2sHW4Q"
      decimals="-3"
      id="Tc_VBaGWFbiUkiUUBD1QGlKaQ_16_5"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">65000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_0jwCrvtl9UmljYaJoSpv6Q"
      decimals="-3"
      id="Tc_QmR91FgMA0OYGVNW6tYqRw_16_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">446450000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_fVis6Rc0lU24mViOdhLPQw"
      decimals="-3"
      id="Tc_iKHcbnnQik-cvT_5khfm1A_16_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-385858000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_caIrfeIWIUSr-5YM1URrGA"
      decimals="-3"
      id="Tc_59QIv5ONXkusDrU9Dwz-jA_16_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">60657000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ESYXfJPI-k-Cm-6QGRH6Sw"
      decimals="INF"
      id="Tc_X4xR3dFeaEOqtSUR48UooQ_17_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">79506</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_athnGX3vVUWNi8j4p4X8yg"
      decimals="-3"
      id="Tc_FYhmghzasEWT1AltzBBZzg_17_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">304000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_74IJvwrt6EmcH2m1d12TYQ"
      decimals="-3"
      id="Tc_XMWJmYLCTkGpAul3j76NqA_17_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA"
      decimals="-3"
      id="Tc_dnOwhnrvn0q5amTn0MFe1g_17_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">304000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <lqda:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ESYXfJPI-k-Cm-6QGRH6Sw"
      decimals="INF"
      id="Tc_9xNbYjEzS0e300_fnfJzOw_18_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">19766</lqda:StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnits>
    <lqda:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_74IJvwrt6EmcH2m1d12TYQ"
      decimals="-3"
      id="Tc_6iH_QJgOf0ms-LPeGz7xXQ_18_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</lqda:StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ESYXfJPI-k-Cm-6QGRH6Sw"
      decimals="INF"
      id="Tc_WxtpDjBlk06RPh3I6claMQ_19_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">59641</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_athnGX3vVUWNi8j4p4X8yg"
      decimals="-3"
      id="Tc_eO1CEsKH40WP0XVGbREr2A_19_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">348000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_74IJvwrt6EmcH2m1d12TYQ"
      decimals="-3"
      id="Tc_69kCY1tqBkmxpJY7-FucGw_19_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA"
      decimals="-3"
      id="Tc_-nWaBCKd60-KLJEtKRLPSw_19_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">348000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_athnGX3vVUWNi8j4p4X8yg"
      decimals="-3"
      id="Tc_t0TkCOePGUCk8fcdKxnJ4w_20_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2487000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_74IJvwrt6EmcH2m1d12TYQ"
      decimals="-3"
      id="Tc_02_xQ6JK0UG2wW8Md8B3hw_20_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA"
      decimals="-3"
      id="Tc_yKn8K3PtNEasmxSXFJR0lQ_20_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2487000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_74IJvwrt6EmcH2m1d12TYQ"
      decimals="-3"
      id="Tc_J-GT2cVF50myueNItWoWLQ_21_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-15790000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA"
      decimals="-3"
      id="Tc_YlQPZmDWIU259YUVfJCwgA_21_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-15790000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GIpJ2QgtfkiSIOYQwZQCIw"
      decimals="INF"
      id="Tc_VLWXYVjptkSGm2iqA7rLiw_22_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">64899295</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GIpJ2QgtfkiSIOYQwZQCIw"
      decimals="-3"
      id="Tc_4o-4SDSYkUe4AenURRrUuQ_22_5"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">65000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uAdhr2xcg06h66-QEsr0Rw"
      decimals="-3"
      id="Tc_pURN6t89906ffjurehJawg_22_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">449589000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_FtiVafAv4UWr8JRCklLjuA"
      decimals="-3"
      id="Tc_63k6hQPG8UiFHFvs-3Fdlw_22_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-401648000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_6z62s4VwhEOUHWT_u7NrVQ"
      decimals="-3"
      id="Tc_NuU3TP4GT0Sfs4FhkLJBkA_22_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">48006000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_2neTY6LGJEG1rzKpv6lBkw_4_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-92025000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_xyIhqKKLY0iNxNX3uY070Q_4_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-51052000</us-gaap:ProfitLoss>
    <lqda:AcquiredInProcessResearchAndDevelopment
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_Hu-npCF5MUi-ab8Hz2_aDQ_6_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">10000000</lqda:AcquiredInProcessResearchAndDevelopment>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_tbFQ2V5sL0KNc2dyH7V5xw_7_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">13777000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_t6JyHYzs2UivFKZjdOHxxw_7_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">7538000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_wvErZuL-eUS9BQQft4BYAg_8_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1679000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_eiFdsScpV0GGPPUusXjXyw_8_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1672000</us-gaap:DepreciationDepletionAndAmortization>
    <lqda:NoncashPortionOfLeaseExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_TS-76k4DmEaHC6KBjSpAEw_9_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">361000</lqda:NoncashPortionOfLeaseExpense>
    <lqda:NoncashPortionOfLeaseExpense
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_r7TKJoHRe0qQa4LkF2T6Hw_9_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">289000</lqda:NoncashPortionOfLeaseExpense>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_6Tap0rB9e0yAFsFSnG8OaQ_10_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-3000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_ARwyMnT2QkWT94tyw6BFVQ_10_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_x9yHt2aBS0uqTKCTF68XwA_11_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-4268000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_Jp7WXEONc0-DEhKfhDRNJA_11_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-2311000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <lqda:AccretionAndNonCashInterestExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_9Wn1-Dlf5kqyCm_iQiacyA_12_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">8114000</lqda:AccretionAndNonCashInterestExpense>
    <lqda:AccretionAndNonCashInterestExpense
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_MShoYESliUiNnwQRz6pMQw_12_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">4133000</lqda:AccretionAndNonCashInterestExpense>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_vSTOX6X660Gexlxhz5GkQg_14_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">141000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_Zfep32r040yiF8xD7ctrZQ_14_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-1679000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_sa0_dCMNzUej_5gEuztEBQ_15_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">38000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_Ks5YJf1TPU2eOezVaQqp5g_16_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">3445000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_nItcVe9yoEOqjFth113rlw_16_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2056000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_5hDb6Ilz1EufAn-qB5kqHA_17_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">7471000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_p-EMmwzmRke7b5VUw3WskQ_17_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-20000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_SzpJjOxdsEuMrWXZZmxOgw_18_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-222000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_r4903ElHDUKGjdAyr9azRA_18_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-556000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_E2t_u8cz1EaqYThtO5U7Dw_19_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">3291000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_GdWMG_dWZkqjcRY2r33nMA_19_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1102000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <lqda:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_oxefXs3cdE-RouBUrO0fAA_20_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-760000</lqda:IncreaseDecreaseInOperatingLeaseLiabilities>
    <lqda:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_-MxGKSaSLEKuzvxA3L9saQ_20_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-660000</lqda:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_HikaoKa0P0-d_B9s6_--Kw_21_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-72609000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_PfQggOUWTkWm9ayjQGlrUg_21_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-25582000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_qefaLz_pLEGZbGhEdnN4eA_23_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">10000000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_eVjola2RHU-RFYQX10_gkg_24_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">3661000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_5umKFPA5vUaoLQxYMS0f0Q_24_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1084000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_7lo-J-MtjUu_p5tp1-sR2w_25_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_Sr2Va-_wL0GXDjZh6a_0_A_25_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_SQ1Q8Q393EurLthj7ilDOA_26_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-3661000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_p_hfIuvP5kKdkDLb7S16hw_26_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-11082000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <lqda:ProceedsFromRevenueInterestFinancingNet
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_PM5KEOHY2UCn6Cf6pEoi1A_28_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">57460000</lqda:ProceedsFromRevenueInterestFinancingNet>
    <lqda:ProceedsFromRevenueInterestFinancingNet
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_Ofy0qegt2UOUj7jKjNfWQA_28_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">41744000</lqda:ProceedsFromRevenueInterestFinancingNet>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_uO0kOjFnC06sahzceL_HsQ_29_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">20000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_gvrIZ026D0KfHHO0Bd7c2Q_30_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2190000</us-gaap:RepaymentsOfDebt>
    <lqda:PaymentsOnRevenueInterestFinancingLiability
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_iz2fBEvynE67Rmh1ouIonw_31_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2731000</lqda:PaymentsOnRevenueInterestFinancingLiability>
    <lqda:PaymentsOnRevenueInterestFinancingLiability
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_8y4RLk8snUyxkWm5hKP2Cg_31_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1000000</lqda:PaymentsOnRevenueInterestFinancingLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_WAyJsVeLHEO8ZEcZz-sV4A_32_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">80000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_2GkbReQh1Eak4dMx6XraSQ_32_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">155000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:LossContingencyReceivableProceeds
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_UX8nop6xMk28dU-4cqZ6pQ_33_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">489000</us-gaap:LossContingencyReceivableProceeds>
    <us-gaap:LossContingencyReceivableProceeds
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_mhZ9UMpGpUSRA9Fw4zdohA_33_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">109000</us-gaap:LossContingencyReceivableProceeds>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_dtEEaaloCkaIAGjuccC5YA_34_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">138893000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_y1TroB4zQEGV7mJFMitYHA_35_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2928000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_eAL4U5SOPUC5f3-xRU939w_35_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1098000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_ztmpe-2je0-jNH4lFKQFwA_36_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">196959000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_UgU3HP87kkiP6QgcBlweWQ_36_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">19606000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_zQegfg_YO0mxxh77ZGbZAQ_37_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">120689000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_WvqCAorgWkyrh3Dk0_Tr1g_37_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-17058000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_lnohH7ztNEu7BNYc_eipRQ_38_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">83679000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_12_31_2022_h-v_IaJxz0SgsF5X90JwfQ"
      decimals="-3"
      id="Tc_mLSEJhpujUmrpVeTy_NJeg_38_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">93283000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_qU54A9b3_E6vreMPg99dkg_39_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">204368000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="As_Of_9_30_2023_6z62s4VwhEOUHWT_u7NrVQ"
      decimals="-3"
      id="Tc_vWYBhZrRIkalsP6hif7QmQ_39_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">76225000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_1ZLI4CUJn0us-DlDMpMYJg_41_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_vm_yfubXs0Cd02w8mQcMUw_41_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">360000</us-gaap:InterestPaidNet>
    <lqda:OperatingLeaseLiabilitiesCashPaid
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_jilicfKrrUq4vZWaZGuiRA_42_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">985000</lqda:OperatingLeaseLiabilitiesCashPaid>
    <lqda:OperatingLeaseLiabilitiesCashPaid
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_AmSY-0XnQ0qRMu4vhZpybw_42_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">956000</lqda:OperatingLeaseLiabilitiesCashPaid>
    <lqda:OfferingCostsIncurredIncludedInAccruedExpenses
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_TK3V4_XlIkS4I-6bBazmyQ_43_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">348000</lqda:OfferingCostsIncurredIncludedInAccruedExpenses>
    <lqda:RightOfUseAssetObtainedInExchangeForLeaseLiability
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_JE5NwvLA2UCZSaI6WGanhA_44_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">28000</lqda:RightOfUseAssetObtainedInExchangeForLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_a5taUGk53kaAk-c_AzEWgQ_45_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">625000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <lqda:IncreaseInIndemnificationAssetThroughAccountsPayable
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_3ajaJPsCIEGeNW33sLcvXw_46_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">499000</lqda:IncreaseInIndemnificationAssetThroughAccountsPayable>
    <lqda:IncreaseInIndemnificationAssetThroughAccountsPayable
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_qqwWGPPG3kGWCumFTkaJcQ_46_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">111000</lqda:IncreaseInIndemnificationAssetThroughAccountsPayable>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_WPCAlNncJU2QO3_ky6OPDw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;1. Business&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Description of the Business&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We are a biopharmaceutical company focused on the development, manufacture, and commercialization of products that address unmet patient needs, with current focus directed towards rare cardiopulmonary diseases such as pulmonary arterial hypertension (&#x201c;PAH&#x201d;) and pulmonary hypertension associated with interstitial lung disease (&#x201c;PH-ILD&#x201d;). We operate through our wholly owned operating subsidiaries, Liquidia Technologies, Inc. (&#x201c;Liquidia Technologies&#x201d;) and Liquidia PAH, LLC (&#x201c;Liquidia PAH&#x201d;), formerly known as RareGen, LLC (&#x201c;RareGen&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We currently generate revenue pursuant to a promotion agreement between Liquidia PAH and Sandoz Inc. (&#x201c;Sandoz&#x201d;), dated as of August&#160;1, 2018, as amended (the &#x201c;Promotion Agreement&#x201d;), sharing profit derived from the sale of Sandoz&#x2019;s substitutable generic treprostinil injection (&#x201c;Treprostinil Injection&#x201d;) in the United States. Liquidia PAH has the exclusive rights to conduct commercial activities to encourage the appropriate use of Treprostinil Injection. We employ a targeted sales force calling on physicians and hospital pharmacies involved in the treatment of PAH and PH-ILD in the United States, as well as key stakeholders involved in the distribution and reimbursement of medicines to treat these patients. We established our commercial presence in the field to support Treprostinil Injection and have since expanded our presence to support the potential launch of YUTREPIA (treprostinil) inhalation powder (&#x201c;YUTREPIA&#x201d;), further validating our reputation as a company committed to supporting PAH and PH-ILD patients.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;We conduct research, development and manufacturing of novel products by applying our subject matter expertise in cardiopulmonary diseases and our proprietary PRINT&lt;/span&gt;&lt;span style="font-size:7.5pt;letter-spacing:0.15pt;"&gt;&#xae;&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#160;technology, a particle engineering platform, to enable precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Through development of our own products and research with third parties, we have experience applying PRINT across multiple routes of administration and drug payloads including inhaled therapies, vaccines, biologics, nucleic acids and ophthalmic implants, among others.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Our lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, low effort dry-powder inhaler (&#x201c;DPI&#x201d;) and by achieving higher dose levels than the labeled doses of current inhaled therapies. On August&#160;16, 2024, the United States Food and Drug Administration (the &#x201c;FDA&#x201d;) (i)&#160;granted tentative approval for our New Drug Application (&#x201c;NDA&#x201d;) for YUTREPIA for the treatment of PAH and PH-ILD and (ii)&#160;simultaneously determined that Tyvaso DPI, approved on May&#160;23, 2022, qualifies for a three-year New Clinical Investigation exclusivity for the chronic use of dry powder formulations of treprostinil for the approved indications. As a result, final approval of YUTREPIA for PAH and PH-ILD is currently delayed until after expiry of the three-year regulatory exclusivity for Tyvaso DPI on May&#160;23, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We are also developing L606, an investigational, liposomal formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer, which we licensed from Pharmosa Biopharm Inc. (&#x201c;Pharmosa&#x201d;). L606 is currently being evaluated in an open-label study in the United States for treatment of PAH and PH-ILD with a planned pivotal study for the treatment of PH-ILD.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;"&gt;Risks and Uncertainties&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;We are subject to risks and uncertainties common to companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on third parties and key personnel, protection of proprietary technology, compliance with government regulations, and the ability to secure additional capital to fund operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;The current global macro-economic environment is volatile, which may result in supply chain constraints and elevated rates of inflation. In addition, we operate in a dynamic and highly competitive industry and believe that changes in any of the following areas could have a material adverse effect on our future financial position, results of operations, or cash flows: the ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval, market acceptance and third-party payor coverage for our products; development of sales channels; certain strategic relationships; litigation or claims against us, including claims related to intellectual property, product, regulatory, or other matters; and our ability to attract and retain employees necessary to support our growth.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;Product candidates we develop require approval from the FDA and/or other international regulatory agencies prior to commercial sales. There can be no assurance that our product candidates will receive the necessary approvals or, if we do, the indications for which our products will be approved. If we are denied approval, approval is delayed, approval is for less than all of the indications we are seeking, or we are unable to maintain approval, it could have a material adverse impact on our business, financial position and results of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;We rely on single source manufacturers and suppliers for the supply of our product candidates, adding to the manufacturing risks we face. In the event of any failure by a supplier, we could be left without backup facilities. Any disruption from these manufacturers or suppliers could have a negative impact on our business, financial position and results of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;"&gt;Liquidity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;We have financed our growth and operations through a combination of funds generated from revenues, the issuance of convertible preferred stock and common stock, bank borrowings, bank borrowings with warrants, the issuance of convertible notes and warrants, and revenue interest financing. Since inception, we have incurred recurring losses, including a net loss of $92.0 million for the nine months ended September&#160;30,&#160;2024. As of September&#160;30,&#160;2024, we had an accumulated deficit of $521.1 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;We expect to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates through clinical trials, seek regulatory approval of such product candidates and pursue commercialization of any approved product candidates. These efforts require significant amounts of capital, adequate personnel and infrastructure, and extensive compliance-reporting capabilities. Even if our development efforts are successful, it is uncertain when, if ever, we will realize significant revenue from product sales. Additionally, the Revenue Interest Financing Agreement with HealthCare Royalty Partners IV, L.P. (&#x201c;HCR&#x201d;) dated January 9, 2023, as amended (the &#x201c;RIFA&#x201d;) contains fixed quarterly payments and minimum cash covenants that require us to maintain cash and cash equivalents in an amount at least equal to $7.5 million during the calendar year beginning on January 1, 2024 and at least equal to $15.0 million for the remainder of the payment term after the calendar year ended December 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In September 2024, we entered into the Fifth Amendment to the RIFA pursuant to which HCR funded an additional $32.5 million on September 12, 2024, for total funding of $100 million. Additionally, payments due under the RIFA were amended such that the one-time fixed payment previously due in July 2025 is now due in equal payments in January and July 2026. See Note 12&#160;for further information.&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 12, 2024, we sold shares of our common stock in an underwritten registered public offering for net proceeds of approximately $53.7 million and sold shares of our common stock for net proceeds of approximately $10.0 million in a private offering. See Note 8 for further information.&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Our future funding requirements will be heavily determined by the timing of the potential commercialization of YUTREPIA and the resources needed to support development of our product candidates. Based on our current plans, we expect that we will require additional capital to fund operations as well as to pursue in-licenses or acquisitions of other product candidates. If we are unable to obtain additional funding, we could be required to delay, reduce, or eliminate research and development programs, product portfolio expansion, or future commercialization efforts, which could adversely affect our business prospects, or we may be unable to continue operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Although we expect to continue to generate operating losses for the foreseeable future, we believe that as a result of the recent Fifth Amendment to the RIFA and net proceeds from the sale of common stock described above, excluding any future YUTREPIA product revenue, our cash and cash equivalents will be sufficient to fund operations, capital expenditures, and RIFA payments and allow us to remain in compliance with our minimum cash covenants pursuant to the RIFA for at least twelve months from the issuance date of these condensed consolidated financial statements. If we have not received full FDA approval and generated sufficient cash from product sales of YUTREPIA or are unable to access additional capital by the date of issuance of our fiscal year 2024 consolidated financial statements, we expect there would be substantial doubt about our ability to continue as a going concern as of that date. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect, which would have a material impact on our operations.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-5"
      id="Narr_UVq8c0NGMUScGifRd-w-tw"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-92000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-5"
      id="Narr_2N6-j_hJn063e1Z5udEEYQ"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-521100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <lqda:RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained
      contextRef="As_Of_9_30_2024_srt_CounterpartyNameAxis_lqda_HealthcareRoyaltyPartnersIvL.pMember_srt_StatementScenarioAxis_lqda_ForCalendarYearBeginningOnJanuary12024Member_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_jT09y22dlU-r4cO26SYVlQ"
      decimals="-5"
      id="Narr_HDrj2J1xYEyin6eEB7yM0A"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">7500000</lqda:RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained>
    <lqda:RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained
      contextRef="As_Of_9_30_2024_srt_CounterpartyNameAxis_lqda_HealthcareRoyaltyPartnersIvL.pMember_srt_StatementScenarioAxis_lqda_AfterCalendarYearEndingOnDecember312024Member_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_Eu2lyuSqdUWRsk5xpT6IEw"
      decimals="-5"
      id="Narr_jNgwEI0pxU6rdwnruBTk0Q"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">15000000.0</lqda:RevenueInterestFinancingAgreementMinimumCashAndCashEquivalentToBeMaintained>
    <lqda:RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche
      contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_TypeOfArrangementAxis_lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember_L0sD_tmmekuf3ox2hlAg-g"
      decimals="-5"
      id="Narr_N5YyghIM5EyPnfCgNlgF-A"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">32500000</lqda:RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche>
    <lqda:RevenueInterestFinancingAgreementAmountFunded
      contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_aLJKJ9CWC0enkGwFB_L9fw"
      decimals="-6"
      id="Narr_oLmT7THw3UyMaYL6FteqDA"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">100000000</lqda:RevenueInterestFinancingAgreementAmountFunded>
    <lqda:ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts
      contextRef="Duration_9_12_2024_To_9_12_2024_aSxtNfNO5k-96RR4O_eJ5w"
      decimals="-5"
      id="Narr_RV2q-HygO0yiTRnVE2zJnA"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">53700000</lqda:ProceedsFromIssuanceOfCommonStockNetOfOfferingCosts>
    <lqda:ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts
      contextRef="Duration_9_12_2024_To_9_12_2024_aSxtNfNO5k-96RR4O_eJ5w"
      decimals="-5"
      id="Narr_PLKuk93CwEKmLnew0_gsTQ"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">10000000.0</lqda:ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_W8KMD8D_nkK4bZ62ch8JYA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2. Basis of Presentation, Significant Accounting Policies and Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The unaudited interim condensed consolidated financial statements as of September&#160;30,&#160;2024 and for the three and nine months ended September&#160;30,&#160;2024 and 2023 have been prepared pursuant to the rules&#160;and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) for interim financial reporting. These condensed consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal recurring adjustments and accruals) necessary for a fair statement of the results for the periods presented in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The year-end condensed consolidated balance sheet data was derived from our audited consolidated financial statements but does not include all disclosures required by GAAP. Operating results for the three and nine months ended September&#160;30,&#160;2024 are not necessarily indicative of the results that may be expected for the fiscal&#160;year ending December&#160;31,&#160;2024. Certain information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with GAAP have been omitted in accordance with the SEC&#x2019;s rules&#160;and regulations for interim reporting. &lt;span style="background:#ffffff;"&gt;Certain amounts have been reclassified from the prior year presentation to conform to current presentation, specifically in relation to the balance sheet presentation of finance and operating leases. &lt;/span&gt;Our financial position, results of operations and cash flows are presented in U.S. Dollars.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with our audited consolidated financial statements for the&#160;year ended December&#160;31,&#160;2023, which are included in our 2023 Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31,&#160;2023 (the &#x201c;2023 Annual Report on Form 10-K&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the period. These estimates are based on historical experience and various other assumptions believed to be reasonable under the circumstances. We evaluate our estimates on an ongoing basis, including those related to the valuation of stock-based awards, certain accruals, the revenue interest financing payable, and intangible and contract acquisition cost amortization, and make changes to the estimates and related disclosures as our experience develops or new information becomes known. Actual results will most likely differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Segment Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;GAAP requires segmentation based on an entity&#x2019;s internal organization and reporting of revenue and operating income based upon internal accounting methods commonly referred to as the &#x201c;management approach.&#x201d; Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources and in assessing performance. Our CODM is our Chief Executive Officer. We have determined that we have one&#160;operating and reporting segment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Our significant accounting policies are disclosed in Note&#160;2 of the consolidated financial statements for the&#160;years ended December&#160;31, 2023 and 2022, which are included in our 2023 Annual Report on Form 10-K. There have been no material changes to our significant accounting policies during the nine months ended September&#160;30,&#160;2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board under its accounting standards codifications (ASC) or other standard setting bodies and are adopted by us as of the specified effective date. For the nine months ended September&#160;30,&#160;2024, there were no newly adopted accounting pronouncements that had a material impact on our condensed consolidated financial statements. As of September&#160;30,&#160;2024, there are no recently issued but not yet adopted accounting pronouncements that are expected to materially impact our condensed consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash, Cash Equivalents, and Concentration of Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We consider all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject us to concentrations of credit risk consist of cash and cash equivalents. We are exposed to credit risk, subject to federal deposit insurance, in the event of default by the financial institutions holding our cash and cash equivalents to the extent of amounts recorded on the condensed consolidated balance sheet. Our cash and cash equivalents are held at multiple accredited financial institutions. We have not experienced any losses on such accounts and do not believe that we are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Such deposits have exceeded and will continue to exceed federally insured limits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Accounts Receivable&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Accounts receivable are stated at net realizable value and net of an allowance for credit losses as of each balance sheet date, if applicable. One customer accounted for 96% and 99% of our accounts receivable, net at September&#160;30,&#160;2024 and December&#160;31,&#160;2023, respectively. As of September&#160;30,&#160;2024 and December&#160;31,&#160;2023, we have not recorded an allowance for credit losses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Prelaunch Inventory&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We capitalize prelaunch inventory prior to receiving regulatory approval if regulatory approval and subsequent commercialization of a product is probable and we also expect future economic benefit from the sales of the product to be realized. Prior to this conclusion, we expense prelaunch inventory as research and development expense in the period incurred. For prelaunch inventory that is capitalized, we consider a number of specific facts and circumstances, including the product&#x2019;s shelf life, the product's current status in the development and regulatory approval process, results from related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential obstacles to the approval process, viability of commercialization and market trends. In late 2023, based on our assessment of the legal and regulatory process related to YUTREPIA, we concluded that we met the criteria to capitalize expenditures for prelaunch inventory. We capitalized $7.4 million of prelaunch inventory as of September&#160;30,&#160;2024 and none as of December&#160;31,&#160;2023. If either regulatory approval or market acceptance post-approval of YUTREPIA do not occur at all or on a timely basis prior to the inventory shelf-life expiration,&#160;we may be required to write-off some or all prelaunch inventory, which could affect our financial condition and financial results.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Long-Lived Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;"&gt;We review long-lived assets, including definite-life intangible assets, for realizability on an ongoing basis. Changes in depreciation and amortization, generally accelerated depreciation and variable amortization, are determined and recorded when estimates of the remaining useful lives or residual values of long-term assets change. We also review &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 12pt 0pt;"&gt;for impairment when conditions exist that indicate the carrying amount of the assets may not be fully recoverable. In those circumstances, we perform undiscounted operating cash flow analyses to determine if an impairment exists. When testing for asset impairment, we group assets and liabilities at the lowest level for which cash flows are separately identifiable. Any impairment loss is calculated as the excess of the asset&#x2019;s carrying value over its estimated fair value. Fair value is estimated based on the discounted cash flows for the asset group over the remaining useful life or based on the expected cash proceeds for the asset less costs of disposal. Any impairment losses would be recorded in the consolidated statements of operations. To date, no such impairments have occurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Goodwill&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 12pt 0pt;"&gt;We assess goodwill for impairment at least annually as of July 1 or whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. For example, significant and unanticipated changes or our inability to obtain or maintain regulatory approvals for our product candidates, including the NDA for YUTREPIA, could trigger testing of our goodwill for impairment at an interim date. We have one reporting unit. We have the option to first assess qualitative factors to determine whether events or circumstances indicate it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, in which case a quantitative impairment test is not required.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Per ASC 350, &lt;i style="font-style:italic;"&gt;Intangibles Goodwill and Other, &lt;/i&gt;the quantitative goodwill impairment test is performed by comparing the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not impaired. An impairment loss is recognized for any excess of the carrying amount of the reporting unit&#x2019;s goodwill over the fair value up to the amount of goodwill allocated to the reporting unit. Income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit are considered when measuring the goodwill impairment loss, if applicable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September&#160;30,&#160;2024, we concluded there were no events or changes in circumstances which indicated that the carrying amount of goodwill was not recoverable. We completed our annual impairment test as of July 1, 2024 and concluded that no impairments had occurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Revenue Interest Financing Payable&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We recognized a liability related to amounts received in January 2023, July 2023, and January 2024 pursuant to the RIFA under ASC 470-10, &lt;i style="font-style:italic;"&gt;Debt&lt;/i&gt; and ASC 835-30, &lt;i style="font-style:italic;"&gt;Interest - Imputation of Interest&lt;/i&gt;. The liability will be accreted under the effective interest method based upon the estimated amount of future payments to be made pursuant to the RIFA. If the timing or amounts of any estimated future payments change, we will prospectively adjust the effective interest and the related amortization of the liability and related issuance costs. A significant increase or decrease in these estimates could materially impact the liability balance and related interest expense.&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;Amendments are assessed under ASC 470 to determine appropriate treatment as troubled debt restructurings, extinguishments or modifications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We recognize revenue in accordance with ASC 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;). The core principle of ASC 606 is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:16.5pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.5pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Step 1: Identify the contract with the customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:16.5pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.5pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Step 2: Identify the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:16.5pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.5pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Step 3: Determine the transaction price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:16.5pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.5pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Step 4: Allocate the transaction price to the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:16.5pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.5pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Step 5: Recognize revenue when the company satisfies a performance obligation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In order to identify the performance obligations in a contract with a customer, we assess the promised goods or services in the contract and identify each promised good or service that is distinct.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;If a good or service is not distinct, the good or service is combined with other promised goods or services until a bundle of goods or services is identified that is distinct.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. We evaluate any non-cash consideration, consideration payable to the customer, potential returns and refunds, and whether consideration contains a significant financing element in determining the transaction price.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Revenue is measured based on consideration specified in a contract with a customer. We recognize revenue when it satisfies a performance obligation by transferring control over a service to a customer. The amount of revenue recognized reflects estimates for refunds and returns, which are presented as a reduction of accounts receivable where the right of setoff exists.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Expense&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred in accordance with ASC 730,&#160;&lt;i style="font-style:italic;"&gt;Research and Development&lt;/i&gt; and include facility-related costs related to research and development activities, direct costs from third parties, such as contract research organizations (&#x201c;CROs&#x201d;), contract manufacturing organizations (CMOs&#x201d;), and consultants, as well as employee-related expenses, including salaries, benefits, and stock-based compensation. Research and development expenses also include costs of acquired product licenses and related technology rights where there is no alternative future use.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Accrued Research and Development Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As part of the process of preparing the condensed consolidated financial statements, we are required to estimate accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our condensed consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of these estimates with the service providers and make adjustments if necessary.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The significant estimates in our accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities. The financial terms of our agreements with CROs and CMOs are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from such estimate, we adjust the accrual or prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We estimate the grant date fair value of stock-based awards and amortize this fair value to compensation expense over the requisite service period or the vesting period of the respective award. In arriving at stock-based compensation expense, we estimate the number of stock-based awards that will be forfeited due to employee turnover. The forfeiture assumption is based primarily on turn-over historical experience. If the actual forfeiture rate is higher than the estimated forfeiture rate, then an adjustment will be made to increase the estimated forfeiture rate, which will result in a decrease to the expense recognized in our financial statements. If the actual forfeiture rate is lower than the&#160;estimated forfeiture rate, then an adjustment will be made to lower the&#160;estimated forfeiture rate, which will result in an increase to expense recognized in our financial statements. The expense we recognize in future periods will be affected by changes in the&#160;estimated forfeiture rate and may differ from amounts recognized in the current period. See Note 9.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss Per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. Due to their anti-dilutive effect, the calculation of diluted net loss per share excludes the following common stock equivalent shares:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock Options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,113,427&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,573,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,372,790&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,494,833&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted Stock Units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,131,834&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,704,353&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,062,498&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,689,998&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 450,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 450,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 450,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 450,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,695,261&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,728,033&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,885,288&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,634,831&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Certain common stock warrants are included in the calculation of basic and diluted net loss per share since their exercise price is de minimis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC 825,&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt; &lt;/span&gt;&lt;i style="font-style:italic;"&gt;Financial Instruments&lt;/i&gt; defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants (an exit price). As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. ASC 825 establishes a three-tiered approach for valuation of financial instruments, which requires that fair value measurements be classified and disclosed in one of three tiers, whether or not recognized on our condensed consolidated balance sheets at fair value. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 1&#160;&#x2014; Quoted prices in active markets for identical assets or liabilities;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 2&#160;&#x2014; Inputs other than quoted prices included in active markets that are observable for the asset or liability, either directly or indirectly; and&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 3&#160;&#x2014; Unobservable inputs for the asset and liability used to measure fair value, to the extent that observable inputs are not available.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following table presents the placement in the fair value hierarchy of financial assets and liabilities measured at fair value as of September&#160;30,&#160;2024 and December&#160;31,&#160;2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Money market funds (cash equivalents)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 198,565&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 198,565&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds (cash equivalents)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79,912&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Money market funds are included in cash and cash equivalents on our condensed consolidated balance sheet and are classified within Level 1 of the fair value hierarchy since they are valued using quoted market prices.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying amounts reflected in our condensed consolidated balance sheets for cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their short-term nature. The carrying value of the revenue interest financing payable approximate fair value as the respective interest rates are reflective of current market rates on debt with similar terms and conditions. In addition, the revenue interest financing payable is &lt;span style="background:#ffffff;"&gt;updated with the expected amount to be paid back each reporting period based on the contractual terms and current projections.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_x2MrxE0KR0G4IwrXC1Ve5A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The unaudited interim condensed consolidated financial statements as of September&#160;30,&#160;2024 and for the three and nine months ended September&#160;30,&#160;2024 and 2023 have been prepared pursuant to the rules&#160;and regulations of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) for interim financial reporting. These condensed consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal recurring adjustments and accruals) necessary for a fair statement of the results for the periods presented in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). The year-end condensed consolidated balance sheet data was derived from our audited consolidated financial statements but does not include all disclosures required by GAAP. Operating results for the three and nine months ended September&#160;30,&#160;2024 are not necessarily indicative of the results that may be expected for the fiscal&#160;year ending December&#160;31,&#160;2024. Certain information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with GAAP have been omitted in accordance with the SEC&#x2019;s rules&#160;and regulations for interim reporting. &lt;span style="background:#ffffff;"&gt;Certain amounts have been reclassified from the prior year presentation to conform to current presentation, specifically in relation to the balance sheet presentation of finance and operating leases. &lt;/span&gt;Our financial position, results of operations and cash flows are presented in U.S. Dollars.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying unaudited condensed consolidated financial statements and related notes should be read in conjunction with our audited consolidated financial statements for the&#160;year ended December&#160;31,&#160;2023, which are included in our 2023 Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31,&#160;2023 (the &#x201c;2023 Annual Report on Form 10-K&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_PsFx8PFXE02qI2ZptcBg3Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the period. These estimates are based on historical experience and various other assumptions believed to be reasonable under the circumstances. We evaluate our estimates on an ongoing basis, including those related to the valuation of stock-based awards, certain accruals, the revenue interest financing payable, and intangible and contract acquisition cost amortization, and make changes to the estimates and related disclosures as our experience develops or new information becomes known. Actual results will most likely differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_xpFeg02o5EWh_JTWZaEBIQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Segment Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;GAAP requires segmentation based on an entity&#x2019;s internal organization and reporting of revenue and operating income based upon internal accounting methods commonly referred to as the &#x201c;management approach.&#x201d; Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker (CODM), or decision-making group, in deciding how to allocate resources and in assessing performance. Our CODM is our Chief Executive Officer. We have determined that we have one&#160;operating and reporting segment.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="INF"
      id="Narr_peLBo4XhxEOhwgHsWsY-Fw"
      unitRef="Unit_Standard_segment_5Yg_HHT1gEGJPlsg-11Qtw">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_GCI5zNlh9kqRYt8bHrKC1Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board under its accounting standards codifications (ASC) or other standard setting bodies and are adopted by us as of the specified effective date. For the nine months ended September&#160;30,&#160;2024, there were no newly adopted accounting pronouncements that had a material impact on our condensed consolidated financial statements. As of September&#160;30,&#160;2024, there are no recently issued but not yet adopted accounting pronouncements that are expected to materially impact our condensed consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <lqda:CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_Xf-Dee1Rh0-9Hv7OOB6eZg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash, Cash Equivalents, and Concentration of Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We consider all highly liquid investments with a maturity of three months or less at the date of purchase to be cash equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject us to concentrations of credit risk consist of cash and cash equivalents. We are exposed to credit risk, subject to federal deposit insurance, in the event of default by the financial institutions holding our cash and cash equivalents to the extent of amounts recorded on the condensed consolidated balance sheet. Our cash and cash equivalents are held at multiple accredited financial institutions. We have not experienced any losses on such accounts and do not believe that we are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Such deposits have exceeded and will continue to exceed federally insured limits.&lt;/p&gt;</lqda:CashAndCashEquivalentsAndConcentrationOfCreditRiskPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_ARjFJufJskKaccmncov61Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Accounts Receivable&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Accounts receivable are stated at net realizable value and net of an allowance for credit losses as of each balance sheet date, if applicable. One customer accounted for 96% and 99% of our accounts receivable, net at September&#160;30,&#160;2024 and December&#160;31,&#160;2023, respectively. As of September&#160;30,&#160;2024 and December&#160;31,&#160;2023, we have not recorded an allowance for credit losses.&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <lqda:NumberOfCustomers
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_MajorCustomersAxis_lqda_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_VjK3Qv7B0EufQgTVe6t9Mg"
      decimals="INF"
      id="Narr_URHTgK7TiEK8T9lZQI8Y_g"
      unitRef="Unit_Standard_customer_rCtGSEdMk0iBBkxQf_23NA">1</lqda:NumberOfCustomers>
    <lqda:NumberOfCustomers
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_lqda_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_flP9Ohx3sEW9JMma2AxykA"
      decimals="INF"
      id="Narr_ODS74bG4LUyLH71C9KbjHw"
      unitRef="Unit_Standard_customer_rCtGSEdMk0iBBkxQf_23NA">1</lqda:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_MajorCustomersAxis_lqda_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_VjK3Qv7B0EufQgTVe6t9Mg"
      decimals="2"
      id="Narr_2W17woSGgkCa0YQ4wH7Kkw"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.96</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_MajorCustomersAxis_lqda_CustomerOneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CreditConcentrationRiskMember_flP9Ohx3sEW9JMma2AxykA"
      decimals="2"
      id="Narr_b8yUKml0HES0CXt6ft04Xw"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.99</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_FdOnlj_C30umMltJSz2VvQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Prelaunch Inventory&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We capitalize prelaunch inventory prior to receiving regulatory approval if regulatory approval and subsequent commercialization of a product is probable and we also expect future economic benefit from the sales of the product to be realized. Prior to this conclusion, we expense prelaunch inventory as research and development expense in the period incurred. For prelaunch inventory that is capitalized, we consider a number of specific facts and circumstances, including the product&#x2019;s shelf life, the product's current status in the development and regulatory approval process, results from related clinical trials, results from meetings with relevant regulatory agencies prior to the filing of regulatory applications, potential obstacles to the approval process, viability of commercialization and market trends. In late 2023, based on our assessment of the legal and regulatory process related to YUTREPIA, we concluded that we met the criteria to capitalize expenditures for prelaunch inventory. We capitalized $7.4 million of prelaunch inventory as of September&#160;30,&#160;2024 and none as of December&#160;31,&#160;2023. If either regulatory approval or market acceptance post-approval of YUTREPIA do not occur at all or on a timely basis prior to the inventory shelf-life expiration,&#160;we may be required to write-off some or all prelaunch inventory, which could affect our financial condition and financial results.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <lqda:InventoryCapitalizedCost
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-5"
      id="Narr_dIeBQMd8SEKYRRYQNokwag"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">7400000</lqda:InventoryCapitalizedCost>
    <lqda:InventoryCapitalizedCost
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-5"
      id="Narr_uWh-nM-bvE6E9WUwBnCqNA"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</lqda:InventoryCapitalizedCost>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_HVj4Q5EogEyS_iWu1HokSA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Long-Lived Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;"&gt;We review long-lived assets, including definite-life intangible assets, for realizability on an ongoing basis. Changes in depreciation and amortization, generally accelerated depreciation and variable amortization, are determined and recorded when estimates of the remaining useful lives or residual values of long-term assets change. We also review &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 12pt 0pt;"&gt;for impairment when conditions exist that indicate the carrying amount of the assets may not be fully recoverable. In those circumstances, we perform undiscounted operating cash flow analyses to determine if an impairment exists. When testing for asset impairment, we group assets and liabilities at the lowest level for which cash flows are separately identifiable. Any impairment loss is calculated as the excess of the asset&#x2019;s carrying value over its estimated fair value. Fair value is estimated based on the discounted cash flows for the asset group over the remaining useful life or based on the expected cash proceeds for the asset less costs of disposal. Any impairment losses would be recorded in the consolidated statements of operations. To date, no such impairments have occurred.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-5"
      id="Narr_xg4rAWrH_EuGtU1PXBOUtA"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_5FOMDqHlNUy-jNouIKvrEw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Goodwill&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 12pt 0pt;"&gt;We assess goodwill for impairment at least annually as of July 1 or whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. For example, significant and unanticipated changes or our inability to obtain or maintain regulatory approvals for our product candidates, including the NDA for YUTREPIA, could trigger testing of our goodwill for impairment at an interim date. We have one reporting unit. We have the option to first assess qualitative factors to determine whether events or circumstances indicate it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, in which case a quantitative impairment test is not required.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Per ASC 350, &lt;i style="font-style:italic;"&gt;Intangibles Goodwill and Other, &lt;/i&gt;the quantitative goodwill impairment test is performed by comparing the fair value of the reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying amount, goodwill is not impaired. An impairment loss is recognized for any excess of the carrying amount of the reporting unit&#x2019;s goodwill over the fair value up to the amount of goodwill allocated to the reporting unit. Income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit are considered when measuring the goodwill impairment loss, if applicable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September&#160;30,&#160;2024, we concluded there were no events or changes in circumstances which indicated that the carrying amount of goodwill was not recoverable. We completed our annual impairment test as of July 1, 2024 and concluded that no impairments had occurred.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfReportingUnits
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="INF"
      id="Narr_S2gH_qahTUqqmLj3NBP8ZA"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1</us-gaap:NumberOfReportingUnits>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="Duration_7_1_2024_To_7_1_2024_XRrRRtHXS0yYWbSCULb-5g"
      decimals="-5"
      id="Narr_u-GPmecjyEaaSWi1p90-8Q"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:GoodwillImpairmentLoss>
    <lqda:RevenueInterestFinancingPayablePolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_vPmyLVX-PUaNUiOKuqSnEQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Revenue Interest Financing Payable&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We recognized a liability related to amounts received in January 2023, July 2023, and January 2024 pursuant to the RIFA under ASC 470-10, &lt;i style="font-style:italic;"&gt;Debt&lt;/i&gt; and ASC 835-30, &lt;i style="font-style:italic;"&gt;Interest - Imputation of Interest&lt;/i&gt;. The liability will be accreted under the effective interest method based upon the estimated amount of future payments to be made pursuant to the RIFA. If the timing or amounts of any estimated future payments change, we will prospectively adjust the effective interest and the related amortization of the liability and related issuance costs. A significant increase or decrease in these estimates could materially impact the liability balance and related interest expense.&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;Amendments are assessed under ASC 470 to determine appropriate treatment as troubled debt restructurings, extinguishments or modifications.&lt;/p&gt;</lqda:RevenueInterestFinancingPayablePolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_QfkdVlS8UkahqO3PjOpAoQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We recognize revenue in accordance with ASC 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;). The core principle of ASC 606 is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The following five steps are applied to achieve that core principle:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:16.5pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.5pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Step 1: Identify the contract with the customer&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:16.5pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.5pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Step 2: Identify the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:16.5pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.5pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Step 3: Determine the transaction price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:16.5pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.5pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Step 4: Allocate the transaction price to the performance obligations in the contract&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:16.5pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:16.5pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Step 5: Recognize revenue when the company satisfies a performance obligation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In order to identify the performance obligations in a contract with a customer, we assess the promised goods or services in the contract and identify each promised good or service that is distinct.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;If a good or service is not distinct, the good or service is combined with other promised goods or services until a bundle of goods or services is identified that is distinct.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The transaction price is the amount of consideration to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer. The consideration promised in a contract with a customer may include fixed amounts, variable amounts, or both.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Variable consideration is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. We evaluate any non-cash consideration, consideration payable to the customer, potential returns and refunds, and whether consideration contains a significant financing element in determining the transaction price.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Revenue is measured based on consideration specified in a contract with a customer. We recognize revenue when it satisfies a performance obligation by transferring control over a service to a customer. The amount of revenue recognized reflects estimates for refunds and returns, which are presented as a reduction of accounts receivable where the right of setoff exists.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_6WU5M8WeD0yUMfoYvZkdiA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Expense&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred in accordance with ASC 730,&#160;&lt;i style="font-style:italic;"&gt;Research and Development&lt;/i&gt; and include facility-related costs related to research and development activities, direct costs from third parties, such as contract research organizations (&#x201c;CROs&#x201d;), contract manufacturing organizations (CMOs&#x201d;), and consultants, as well as employee-related expenses, including salaries, benefits, and stock-based compensation. Research and development expenses also include costs of acquired product licenses and related technology rights where there is no alternative future use.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <lqda:AccruedResearchAndDevelopmentExpensePolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_7ZhQivB3gkutf7bRasF-KQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Accrued Research and Development Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As part of the process of preparing the condensed consolidated financial statements, we are required to estimate accrued expenses. This process involves reviewing quotations and contracts, identifying services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our condensed consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of these estimates with the service providers and make adjustments if necessary.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The significant estimates in our accrued research and development expenses are related to expenses incurred with respect to CROs, CMOs and other vendors in connection with research and development and manufacturing activities. The financial terms of our agreements with CROs and CMOs are subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the applicable research and development or manufacturing expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from such estimate, we adjust the accrual or prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any particular period. There have been no material changes in estimates for the periods presented.&lt;/p&gt;</lqda:AccruedResearchAndDevelopmentExpensePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_zdocnOuykkiRYhjwMcdJrw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We estimate the grant date fair value of stock-based awards and amortize this fair value to compensation expense over the requisite service period or the vesting period of the respective award. In arriving at stock-based compensation expense, we estimate the number of stock-based awards that will be forfeited due to employee turnover. The forfeiture assumption is based primarily on turn-over historical experience. If the actual forfeiture rate is higher than the estimated forfeiture rate, then an adjustment will be made to increase the estimated forfeiture rate, which will result in a decrease to the expense recognized in our financial statements. If the actual forfeiture rate is lower than the&#160;estimated forfeiture rate, then an adjustment will be made to lower the&#160;estimated forfeiture rate, which will result in an increase to expense recognized in our financial statements. The expense we recognize in future periods will be affected by changes in the&#160;estimated forfeiture rate and may differ from amounts recognized in the current period. See Note 9.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_gdQRyQS9t0m-TYJvphm_Ig">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss Per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period, without consideration of common stock equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. Due to their anti-dilutive effect, the calculation of diluted net loss per share excludes the following common stock equivalent shares:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock Options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,113,427&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,573,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,372,790&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,494,833&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted Stock Units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,131,834&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,704,353&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,062,498&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,689,998&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 450,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 450,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 450,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 450,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,695,261&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,728,033&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,885,288&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,634,831&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Certain common stock warrants are included in the calculation of basic and diluted net loss per share since their exercise price is de minimis.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_7BU58C82hE24vu0aX8dNOQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:22.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock Options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,113,427&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,573,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,372,790&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,494,833&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted Stock Units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,131,834&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,704,353&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,062,498&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,689,998&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 450,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 450,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 450,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 450,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,695,261&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,728,033&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,885,288&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,634,831&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_TzBMkys33EuWe4DPMyM4ng"
      decimals="INF"
      id="Tc_8cFJ-iVoX0esC2-9Tn8ogg_4_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">9113427</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_canxHtd-XkG4uVMvRpE1FQ"
      decimals="INF"
      id="Tc_dkemJZsGpkGUpqERPxtzlA_4_4"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">9573680</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_U5I2QUtyeUKSw5V0JR-EtQ"
      decimals="INF"
      id="Tc_L76sTJpenEm4kzyw0i-Kzw_4_6"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">9372790</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_1muCQV59SEeHsD-Yav1p6Q"
      decimals="INF"
      id="Tc_YnSGC5JY3EKJInCxcBVBFw_4_8"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">9494833</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_bAuPCroLc0CrK6O9kr5tog"
      decimals="INF"
      id="Tc_cD9Ve1TGl02wXY_wV4t-Xw_5_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">3131834</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_aep-yz_sAU6w4KnoDTuRXQ"
      decimals="INF"
      id="Tc_0eg72cDZ5EG0bp8aY0RzpQ_5_4"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">1704353</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_0ZcXs57SsESdiizR7P7_-A"
      decimals="INF"
      id="Tc_0wouIoFEZ0G4YbBnp22QLw_5_6"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">3062498</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_QGpDrn6it0u-SFLEKVzU7A"
      decimals="INF"
      id="Tc_0IV6XVRuHUqicAyDKpdSow_5_8"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">1689998</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_9fQbmG5QVECfc_dtjchxWg"
      decimals="INF"
      id="Tc_uStQDrOrvUW7w5Rxxn_U7g_6_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">450000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_Ccuko3guq0aS4kOvVeM9WQ"
      decimals="INF"
      id="Tc_TAU8f3G-tkeK4C_dARWxXQ_6_4"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">450000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_Qb1al7pN5Eum9jNVekDffw"
      decimals="INF"
      id="Tc_XtMHW35iF02zTX1LRBxNcw_6_6"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">450000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_XlMlf1imU0CKFBvkuE1IEA"
      decimals="INF"
      id="Tc_wLh3UepWlE6jhWMtut4LaA_6_8"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">450000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="INF"
      id="Tc_2FWG8fCjoEm_xeupn9iDUA_7_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">12695261</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA"
      decimals="INF"
      id="Tc_aXiXaW_DHk2oW5bjQIFNGg_7_4"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">11728033</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="INF"
      id="Tc_Zs-1E_28IECXSTf62kzUTA_7_6"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">12885288</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="INF"
      id="Tc_widjw2pz4Uif9yT8pKX5Og_7_8"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">11634831</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_xdt9pqwdBUuth1bFxeRLiQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC 825,&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt; &lt;/span&gt;&lt;i style="font-style:italic;"&gt;Financial Instruments&lt;/i&gt; defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants (an exit price). As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. ASC 825 establishes a three-tiered approach for valuation of financial instruments, which requires that fair value measurements be classified and disclosed in one of three tiers, whether or not recognized on our condensed consolidated balance sheets at fair value. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 1&#160;&#x2014; Quoted prices in active markets for identical assets or liabilities;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 2&#160;&#x2014; Inputs other than quoted prices included in active markets that are observable for the asset or liability, either directly or indirectly; and&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 3&#160;&#x2014; Unobservable inputs for the asset and liability used to measure fair value, to the extent that observable inputs are not available.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The following table presents the placement in the fair value hierarchy of financial assets and liabilities measured at fair value as of September&#160;30,&#160;2024 and December&#160;31,&#160;2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Money market funds (cash equivalents)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 198,565&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 198,565&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds (cash equivalents)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79,912&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Money market funds are included in cash and cash equivalents on our condensed consolidated balance sheet and are classified within Level 1 of the fair value hierarchy since they are valued using quoted market prices.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying amounts reflected in our condensed consolidated balance sheets for cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their short-term nature. The carrying value of the revenue interest financing payable approximate fair value as the respective interest rates are reflective of current market rates on debt with similar terms and conditions. In addition, the revenue interest financing payable is &lt;span style="background:#ffffff;"&gt;updated with the expected amount to be paid back each reporting period based on the contractual terms and current projections.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_qG6-5zLigEul5ujiKjwVRQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Money market funds (cash equivalents)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 198,565&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 198,565&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Prices&#160;in&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Markets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Money market funds (cash equivalents)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79,912&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79,912&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_9_30_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_kMc1M1fUA0aLfEacYxGcNg"
      decimals="-3"
      id="Tc_ApnDAPzuqUmANr9LQImxDA_6_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">198565000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_9_30_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_ANzvLLeodEu35lLZjmLNlw"
      decimals="-3"
      id="Tc_q69b531HskefCLJwv7ya3A_6_12"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">198565000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_RXXfSfHAKUOxB0bjch78SQ"
      decimals="-3"
      id="Tc_YJuIkA_0K0aaIwohMXLE1w_6_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">79912000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember_hRZjTb3f50WuaHZvxqO0dQ"
      decimals="-3"
      id="Tc_XOERFB4cr0KzJBJ28vJJLg_6_12"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">79912000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_WRzgrSwS_UC2H2vRM6Tazw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;"&gt;3. Inventory&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;Inventories are stated at the lower of average cost or net realizable value and consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:13.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,607&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Work in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,835&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,442&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Recognized as:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,404&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Prelaunch Inventory&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;During the nine months ended September&#160;30,&#160;2024, we capitalized costs of $7.4 million associated with the production of YUTREPIA as a result of our determination that regulatory approval and subsequent commercialization is probable, and we also expect future economic benefit from the sales of YUTREPIA to be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Amounts recognized as &lt;i style="font-style:italic;"&gt;Other Assets&lt;/i&gt; are comprised entirely of raw materials and work in process inventories not expected to be sold within one year of the balance sheet date&lt;span style="white-space:pre-wrap;"&gt;.  &lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_0yQtZYzkt0mbE4WTtTNVoA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"&gt;&lt;span style="font-size:13.5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,607&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Work in process&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,835&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,442&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Recognized as:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Other assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,404&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_7AT0cp726UCRZUl40TKHTw_3_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2607000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_NUjb69YFnkqQf6S4X1KWIw_4_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">4835000</us-gaap:InventoryWorkInProcess>
    <lqda:InventoryCurrentAndNonCurrent
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_ypXjr4uD6kOOknVN2GVQEw_5_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">7442000</lqda:InventoryCurrentAndNonCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_HDXRN6-jdUmifnZ2j3X-qA_8_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">38000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="As_Of_9_30_2024_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_xRg1wcXNfk271ht3s4kIeQ"
      decimals="-3"
      id="Tc_TWoY9MWDpUWQxK5E3lE-qA_9_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">7404000</us-gaap:InventoryNoncurrent>
    <lqda:CapitalizedCostsOfInventory
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-5"
      id="Narr_uqBwRbAmFU-Ztj8nAadmbQ"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">7400000</lqda:CapitalizedCostsOfInventory>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_892VfmorlE6htx4L4VMZHQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;4. Property, Plant, and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Property, plant and equipment consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lab and build-to-suit equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,953&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,834&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 241&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 241&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer and other equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 740&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 487&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,450&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,409&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Construction-in-progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,315&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 804&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total property, plant and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,718&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,794&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15,934)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15,314)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property, plant and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,784&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,480&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We recorded depreciation and amortization expense related to property, plant and equipment of $0.3 million and $0.3 million for the three months ended September&#160;30,&#160;2024 and 2023, respectively, and of $0.8 million and $0.9 million for the nine months ended September&#160;30,&#160;2024 and 2023, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_k5MedFYHukyJslH8n7hNQA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Lab and build-to-suit equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,953&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,834&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 241&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 241&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer and other equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 740&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 487&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,450&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,409&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Construction-in-progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,315&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 804&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total property, plant and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 23,718&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,794&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15,934)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15,314)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property, plant and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,784&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,480&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_9_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_lqda_LabAndBuildToSuitEquipmentMember_vbQ7hgEZXU2QQ8szN1HAtw"
      decimals="-3"
      id="Tc_Vj5OGMhW7U22bfwl4p7uHQ_3_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">6953000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_lqda_LabAndBuildToSuitEquipmentMember_3By5Ws9wr0KTAbJFyx2jow"
      decimals="-3"
      id="Tc_3BRyKjLCBkC1rMhcHHTwTQ_3_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">6834000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_9_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_NBou6jkXCUKIl86emqBNpg"
      decimals="-3"
      id="Tc_JPTOnmD14kGIa65gOZoYcQ_4_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">19000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_u0t7q0rYoUCrtJJgFwTvrA"
      decimals="-3"
      id="Tc_I8V614YOq02IechrWt4Cag_4_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">19000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_9_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_HhiaPNdxpU2kL50_8kQ28g"
      decimals="-3"
      id="Tc_HcO1V8QkFk2JekeS3UGfEQ_5_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">241000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_P6CllWvurEyyz948ZgWhnQ"
      decimals="-3"
      id="Tc_HowwOd3a_06a_lTWDc1EtA_5_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">241000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_9_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember__bkosJSnNUKdzQ6jMHMqOA"
      decimals="-3"
      id="Tc_ZGm9Ye62Mk-Zb0RRlN4k6g_6_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">740000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_JDWBnuimj0OiMbqSGdD8Ag"
      decimals="-3"
      id="Tc_aXlCoEnox0WVaul9SBCBLg_6_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">487000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_9_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_VYpHUurxNEuWKkqyAiGjGQ"
      decimals="-3"
      id="Tc_51HlJkSZIUmPPsLNIPe9gg_7_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">11450000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_vuK9MdKws0WBj-FZvfK_jA"
      decimals="-3"
      id="Tc_n2-t3dPthEq7kAvUorE6Mg_7_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">11409000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_9_30_2024_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_iPwI9W-yukKJZYkZvhU5ow"
      decimals="-3"
      id="Tc_KNJu-ZiqE0OdV5XwoN3u-w_8_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">4315000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_W1eYleOODEWnNYcNk76J4A"
      decimals="-3"
      id="Tc_4yKvuIzF3kiVOux6CAxuhg_8_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">804000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_Uq-86EmlcUieJjd8uOiyFw_9_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">23718000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_Q3-ioz8YVEaQjr2Lh67grg_9_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">19794000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_52CbhYEhskueSg-NxSamLg_10_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">15934000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_AXnhqhWL-0K_2Zjx6G_frw_10_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">15314000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_sMj_uNlJ9kG47Tmrbb6CBg_11_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">7784000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_BolTiNiurkS_-qz1W-KW5A_11_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">4480000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="-5"
      id="Narr__vYxDF096Ua5628I2_RdLA"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA"
      decimals="-5"
      id="Narr_NOcVcGq01k-QHOGTrV-zWA"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-5"
      id="Narr_IXQuVGIGhEejSHfAHYtaag"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-5"
      id="Narr_8P8KfVltG06rKdqk9Ru0fg"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">900000</us-gaap:DepreciationAndAmortization>
    <lqda:ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_2gqCcyKgZ0SzZ7pQ3ZejTA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;5. Contract Acquisition Costs and Intangible Asset&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Contract acquisition costs and intangible asset are summarized as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:25.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:25.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross Carrying Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Carrying Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross Carrying Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Carrying Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract acquisition costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,980&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,547)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,433&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,980&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,058)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,922&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,620&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,401)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,620&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,190)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,430&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We are amortizing the value of the contract acquisition costs and intangible asset on a pro-rata basis based on the estimated total revenue or net profits to be recognized over the period from November 18, 2020 through December 2032, the termination date of the Promotion Agreement (see Note 2-Revenue Recognition for our accounting policies). Amortization of contract acquisition costs is recorded as a reduction of revenue, and amortization of the intangible asset is recorded as cost of revenue. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We recorded amortization related to the contract acquisition costs of $0.2 million and $0.1 million for the three months ended September&#160;30,&#160;2024 and 2023, respectively, and of $0.5 million and $0.5 million for the nine months ended September&#160;30,&#160;2024 and 2023, respectively. We recorded amortization related to the intangible asset of $0.1 million and $0.1 million for the three months ended September&#160;30,&#160;2024 and 2023, respectively, and of $0.2 million and $0.2 million for the nine months ended September&#160;30,&#160;2024 and 2023, respectively. Annual amortization over the next five years is expected to immaterially fluctuate from the 2024 amounts, consistent with changes to net profits to be recognized pursuant to the Promotion Agreement over the period.&lt;/p&gt;</lqda:ContractAcquisitionCostsAndIntangibleAssetDisclosureTextBlock>
    <lqda:ScheduleOfContractAcquisitionCostsAndIntangibleAssetsTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_fKMiROLTqEuKk37HiaAiXw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:25.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:25.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross Carrying Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Carrying Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross Carrying Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accumulated Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;width:6.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net Carrying Amount&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract acquisition costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,980&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,547)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,433&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,980&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,058)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,922&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,620&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,401)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,219&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,620&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,190)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,430&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</lqda:ScheduleOfContractAcquisitionCostsAndIntangibleAssetsTableTextBlock>
    <us-gaap:CapitalizedContractCostGross
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_8X83zWpna0Gihkm5C6eVhg_3_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">12980000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostAccumulatedAmortization
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_ub36mTBmlk2-gCqg3OlH_A_3_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">5547000</us-gaap:CapitalizedContractCostAccumulatedAmortization>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_PCbYkCddZkyTze0l1raAxg_3_9"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">7433000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostGross
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_xMoDs-DOnUug7S1eY05TpA_3_12"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">12980000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostAccumulatedAmortization
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_C_0yipGVUkWupzkSHoGPYg_3_15"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">5058000</us-gaap:CapitalizedContractCostAccumulatedAmortization>
    <us-gaap:CapitalizedContractCostNet
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_URlPW1hJk0SGpl_63IhVRw_3_18"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">7922000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_dc0cvBlzZ0WJNDNhaHvw_A_4_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">5620000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_EBi7_58v9U6g20N0HPX4xw_4_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2401000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_k_J4ss33bUS082uUpSXeWw_4_9"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">3219000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_ufpQ_rY5jUGi_pqLXXcTXQ_4_12"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">5620000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_KbEnDdGHhUK8x4Sd0czV8A_4_15"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2190000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_bkZMfshBDUWophdMaoNDKA_4_18"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">3430000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="-5"
      id="Narr_almsw7uGR02UC0CP0TsW8A"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">200000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA"
      decimals="-5"
      id="Narr__auwScfK9kCO5Dclcts9Og"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">100000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-5"
      id="Narr_-etGSQWGqkmCUWV-Ibjhbg"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">500000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-5"
      id="Narr_KhFcm0Bho0iXn1ETXqiivQ"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">500000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="-5"
      id="Narr_Qo-ceyKNmUCcjMljBOJNJg"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA"
      decimals="-5"
      id="Narr_-95rpxy48E-wb3ZGXWAAEA"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-5"
      id="Narr_nvP1DnF4uUidZLr1nbuDkA"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-5"
      id="Narr_IbA9maiIGUS0X3-ePe6PsQ"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">200000</us-gaap:AmortizationOfIntangibleAssets>
    <lqda:IndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_AuReBcxWuEeqPIgQ3Pgg2g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;6. Indemnification Asset with Related Party and Litigation Finance Payable&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;On June 3, 2020, Liquidia PAH entered into a litigation financing arrangement (the &#x201c;Financing Agreement&#x201d;) with Henderson SPV, LLC (&#x201c;Henderson&#x201d;). Liquidia PAH, along with Sandoz (collectively the &#x201c;Plaintiffs&#x201d;), are pursuing litigation against United Therapeutics Corporation (&#x201c;United Therapeutics&#x201d;) (the &#x201c;RareGen Litigation&#x201d;). Under the Financing Agreement, Henderson will fund Liquidia PAH&#x2019;s legal and litigation expenses (referred to as &#x201c;Deployments&#x201d;) in exchange for a share of certain litigation or settlement proceeds. Deployments received from Henderson are recorded as a Litigation finance payable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Litigation proceeds will be split equally between Liquidia PAH and Sandoz. Unless there is an event of default by Henderson, litigation proceeds received by Liquidia PAH must be applied first to repayment of total Deployments received. Litigation proceeds in excess of Deployments received are split between Liquidia PAH and Henderson according to a formula. Unless there is an event of default by PBM (as defined below), all proceeds received by Liquidia PAH are due to PBM as described further below.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 17, 2020, Liquidia PAH entered into a Litigation Funding and Indemnification Agreement (&#x201c;Indemnification Agreement&#x201d;) with PBM RG Holdings, LLC (&#x201c;PBM&#x201d;). PBM is considered to be a related party as it is controlled by a major stockholder (which beneficially owns approximately 7.9% of Liquidia Corporation common stock as of October 30, 2024), who is also a member of our Board of Directors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the Indemnification Agreement, PBM now controls the litigation, with Liquidia PAH&#x2019;s primary responsibility being to cooperate to support the litigation proceedings as needed. The Indemnification Agreement provides that Liquidia PAH and its affiliates will not be entitled to any proceeds resulting from, or bear any financial or other liability for, the RareGen Litigation unless there is an event of default by PBM. Any Liquidia PAH litigation expenses not reimbursed by Henderson under the Financing Agreement will be reimbursed by PBM. Any proceeds received which Henderson is not entitled to under the Financing Agreement will be due to PBM.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Indemnification Asset is increased as we record third party legal and litigation expenses related to the RareGen litigation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September&#160;30,&#160;2024 and December&#160;31,&#160;2023, the Indemnification Asset and Litigation Finance Payable were classified as long-term assets and liabilities, respectively, as it is considered unlikely that the RareGen Litigation would conclude prior to September&#160;30, 2025.&lt;/p&gt;</lqda:IndemnificationAssetWithRelatedPartyAndLitigationFinancePayableDisclosureTextBlock>
    <lqda:RelatedPartyTransactionMajorStockholderOwnershipPercentageInCompany
      contextRef="As_Of_10_30_2024_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lqda_PBMMember_BakiyxxweE66bApftnb0xA"
      decimals="3"
      id="Narr_IyJNFsB-okSFPbpZo0-_3g"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.079</lqda:RelatedPartyTransactionMajorStockholderOwnershipPercentageInCompany>
    <lqda:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_Uqj98I7AN0qqZjFBTNSRJw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;7. Accrued Expenses and Other Current Liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,488&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,544&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,381&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,902&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued inventory costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,916&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,954&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total accrued expenses and other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,039&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,400&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</lqda:AccruedExpensesAndOtherCurrentLiabilitiesTextBlock>
    <lqda:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_Vee674mjZE-6XuXMw9rtmg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,488&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,544&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,381&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,902&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued inventory costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,916&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,954&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total accrued expenses and other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,039&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,400&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</lqda:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_NtDy_Ys9nEG1zEBOBwMXaw_3_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">8488000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_Gg9ljY-850mMKHboigFg7Q_3_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">8544000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <lqda:AccruedResearchAndDevelopmentExpenses
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_Y7lAl9JnqEGpkMXXK2vDAw_4_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2381000</lqda:AccruedResearchAndDevelopmentExpenses>
    <lqda:AccruedResearchAndDevelopmentExpenses
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_en8SUMayc0OHlkI8wxnBxg_4_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2902000</lqda:AccruedResearchAndDevelopmentExpenses>
    <lqda:AccruedInventoryCosts
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_UnygWAXcTUytsDF_9FgRHQ_5_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1916000</lqda:AccruedInventoryCosts>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_ZOiTPzK2b0CmpTMeo2OLaA_6_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">4254000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_eiZpwf2zCUinh-UkcSddMg_6_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1954000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <lqda:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_ZLrjrQ0hVE2THbreoL9yCg_7_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">17039000</lqda:AccruedExpensesAndOtherLiabilitiesCurrent>
    <lqda:AccruedExpensesAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_09L1Tu9xg0qkx6RwxPTkVg_7_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">13400000</lqda:AccruedExpensesAndOtherLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_YZVDt8za40qxelrf47TQ6w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;8. Stockholders&#x2019; Equity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Common Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Issuance of Common Stock on September 11, 2024 from an Underwritten Public Offering and Private Placement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In September 2024, we sold 6,460,674 shares of our common stock in an underwritten registered public offering at an offering price of $8.90 per share (the &#x201c;2024 Offering&#x201d;) for gross proceeds of approximately $57.5 million, before deducting offering costs of approximately $3.8 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;A fund affiliated with Paul B. Manning, a member of our Board of Directors, participated in the 2024 Offering and purchased shares of common stock in an aggregate amount of approximately $3.0 million at the public offering price per share and on the same terms as the other purchasers in the 2024 Offering.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Concurrently with the 2024 Offering referenced above, we entered into a common stock purchase agreement with funds managed by Caligan Partners LP (&#x201c;Caligan&#x201d;), our largest stockholder, for the sale by us in a private placement of an &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;aggregate of 1,123,595 shares of our common stock at a purchase price of $8.90 per share for gross and net proceeds of approximately $10.0 million (the &#x201c;Caligan 2024 Private Placement&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Issuance of Common Stock on January 4, 2024 from a Private Placement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 4, 2024, we entered into a common stock purchase agreement with Legend Aggregator, LP for the sale by us in a private placement (the &#x201c;2024 Private Placement&#x201d;) of an aggregate of 7,182,532 shares of our common stock at a purchase price of $10.442 per share. The 2024 Private Placement closed on January 8, 2024, and we received gross proceeds of approximately $75.0 million, before deducting offering costs of less than $0.1 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Issuance of Common Stock on December 12, 2023 from an Underwritten Public Offering and Private Placement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2023, we sold 3,491,620 shares of our common stock in an underwritten registered public offering at an offering price of $7.16 per share (the &#x201c;2023 Offering&#x201d;) for net proceeds of approximately $25.0 million, before deducting offering costs of approximately $1.9 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Caligan and Paul B. Manning, participated in the 2023 Offering and purchased shares of common stock in an aggregate amount of approximately $10.0&lt;span style="white-space:pre-wrap;"&gt; million at the public offering price per share and on the same terms as the other purchasers in the 2023 Offering.  Caligan purchased &lt;/span&gt;1,117,318 shares of common stock in the 2023 Offering for an aggregate purchase price of $8.0 million and Paul B. Manning purchased 279,330 shares of common stock in the 2023 Offering for an aggregate purchase price of $2.0 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Concurrently with the 2023 Offering referenced above, we entered into a common stock purchase agreement with Roger Jeffs, our Chief Executive Officer, for the sale by us in a private placement of an aggregate of 139,665 shares of our common stock at a purchase price of $7.16 per share for gross proceeds of approximately $1.0 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;During the nine months ended September&#160;30,&#160;2024 and 2023, 9,175 and no warrants to purchase shares of common stock were exercised, respectively. Outstanding warrants consisted of the following as of September&#160;30,&#160;2024:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:30.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;January 6, 2032&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 100,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;February 26, 2031&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 100,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;n/a&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;1&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;February 26, 2031&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 56,397&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;December 31, 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;1&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"&gt;These warrants were issued on February 26, 2021, in connection with our previously outstanding debt with Silicon Valley Bank. These warrants only became exercisable if there was additional funding under the loan agreement, and the exercise price of these warrants was to be set upon such potential additional funding. The additional funding never occurred, and the loan agreement has since been repaid and terminated. While these warrants technically remain outstanding, they are not, and will never be, exercisable.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_lZWG9RJZDEmZsvf2PUlu_g"
      decimals="INF"
      id="Narr_tM2czsjY9EK9DOjaqmKn6A"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">6460674</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_0Q4e0dBgsk2MRpxDh6fJYA"
      decimals="2"
      id="Narr_uPiXdXvtCkOwQdL_SFRWNA"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">8.90</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_lZWG9RJZDEmZsvf2PUlu_g"
      decimals="-5"
      id="Narr_TRJ4Ipix2EqsqFhZKeNJ5Q"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">57500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_lZWG9RJZDEmZsvf2PUlu_g"
      decimals="-5"
      id="Narr_YjpCte6C7E6zurmRxPWY4Q"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">3800000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_TitleOfIndividualAxis_lqda_BoardOfDirectorsMember_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_k0mS-FrErEGcCSQNS7upnA"
      decimals="-5"
      id="Narr_i2svsZs1Mk6WVEU7mvlumg"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">3000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_RIO6XDdLvUCyictd22yGPQ"
      decimals="INF"
      id="Narr_1ieEU6zGLkudC5NNe2jJ_g"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">1123595</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_6YbY13rlnk2AxDHTatb6fA"
      decimals="2"
      id="Narr_g2DFgJb2mUWcTv0rmG_lPw"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">8.90</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_9_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_RIO6XDdLvUCyictd22yGPQ"
      decimals="-5"
      id="Narr_3vDgoiRobkOadxzX4P5odA"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">10000000.0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_4_2024_To_1_4_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_rWhTZuGpl06hF6C5gOgr0g"
      decimals="INF"
      id="Narr_6YCtTf-VZk2Zts0FFcX6Kw"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">7182532</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_1_4_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_VFjgbZY-JEy1XAWMuIb9qw"
      decimals="3"
      id="Narr_ck_SXDt6Fki1zfwAihRcjQ"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">10.442</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_1_8_2024_To_1_8_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_ud0mQkQYWkGjIgetbIuylw"
      decimals="-5"
      id="Narr_yeZsCglw20mdmvM_e3glPg"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">75000000.0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_8_2024_To_1_8_2024_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_u77gK6C1w06rKnCiKbNkfA"
      decimals="-5"
      id="Narr_AKcDZKPkCEG-D_6F44BjYA"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_12_2023_To_12_12_2023_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_-VeA1df9x0OIOsIgO9z0NA"
      decimals="INF"
      id="Narr_5EcK9Op5uUaM3VbXNnyU7w"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">3491620</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_12_2023_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_n5jOtXbc5063nwGCNNyeNg"
      decimals="2"
      id="Narr_byJvaltkvE-FuM_G0__Cjw"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">7.16</us-gaap:SharesIssuedPricePerShare>
    <lqda:ProceedsFromIssuanceOfCommonStockNet
      contextRef="Duration_12_12_2023_To_12_12_2023_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_-VeA1df9x0OIOsIgO9z0NA"
      decimals="-5"
      id="Narr_Ua1bJCfYdEqM8DD8Yc5ciA"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">25000000.0</lqda:ProceedsFromIssuanceOfCommonStockNet>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_12_12_2023_To_12_12_2023_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_-VeA1df9x0OIOsIgO9z0NA"
      decimals="-5"
      id="Narr_rFWcDIT8DkaDP5G7WQFpcA"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_12_12_2023_To_12_12_2023_srt_TitleOfIndividualAxis_lqda_LargestStockholderAndMemberOfBoardOfDirectorsMember_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_gnFwleLvT02Zo7EgTUlKNQ"
      decimals="-5"
      id="Narr_FPQhW80_LkazNn-HWTYB8Q"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">10000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_12_2023_To_12_12_2023_srt_TitleOfIndividualAxis_lqda_CaliganPartnersLPMember_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_yy0o7xFcx0aREDaZ1VnfRw"
      decimals="INF"
      id="Narr_apQT07os8UWocReXRn7ZvQ"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">1117318</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_12_12_2023_To_12_12_2023_srt_TitleOfIndividualAxis_lqda_CaliganPartnersLPMember_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_yy0o7xFcx0aREDaZ1VnfRw"
      decimals="-5"
      id="Narr_1HoLApgzLkGZfkWIIeou8g"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">8000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_12_2023_To_12_12_2023_srt_TitleOfIndividualAxis_lqda_Mr.PaulB.ManningMember_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_ET_kOfe7OUyGZnegoThYVg"
      decimals="INF"
      id="Narr_-64_99jivEGfneanN24vIw"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">279330</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_12_12_2023_To_12_12_2023_srt_TitleOfIndividualAxis_lqda_Mr.PaulB.ManningMember_us-gaap_SubsidiarySaleOfStockAxis_lqda_UnderwrittenPublicOfferingMember_ET_kOfe7OUyGZnegoThYVg"
      decimals="-5"
      id="Narr_l7n5fUKB2kG6bIUOhx1fEg"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_12_2023_To_12_12_2023_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_CQWWEiOLTEaaVRh41M4MgQ"
      decimals="INF"
      id="Narr_wrwqYo7GJk6PpOcY3AW2bQ"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">139665</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_12_2023_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_ZMC_KO-DIESEKNwQeHuFPA"
      decimals="2"
      id="Narr_3fVDUUMiYEygzBRtkeKvEg"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">7.16</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="Duration_12_12_2023_To_12_12_2023_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_CQWWEiOLTEaaVRh41M4MgQ"
      decimals="-5"
      id="Narr_Q-jcSS8X5Ee8FS5i2S8p9Q"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1000000.0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <lqda:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_WarrantsToPurchaseCommonStockMember_nREMiBhLNEmIWUNmI18Y6Q"
      decimals="INF"
      id="Narr_v9RpxNoUMU2n9DT9T2F0sQ"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">9175</lqda:ClassOfWarrantOrRightExercisedDuringPeriod>
    <lqda:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_ClassOfWarrantOrRightAxis_lqda_WarrantsToPurchaseCommonStockMember_W3GhsPkTi0ad1ra4mD2y0Q"
      decimals="INF"
      id="Narr_JBKn90Slt0SYKCT-8jR7Aw"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">0</lqda:ClassOfWarrantOrRightExercisedDuringPeriod>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_Kdy2Z_rO6Ea-c-kIIvc4jg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:30.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 250,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;January 6, 2032&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 100,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;February 26, 2031&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 100,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;n/a&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;1&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;February 26, 2031&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 56,397&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:35.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;December 31, 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_ArSvbWarrantsInitialTrancheMember_ffU72mNG2UiEuncpq3Bk3g"
      decimals="INF"
      id="Tc_J-AH6hskgEK0ciYE7bzoyg_3_0"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">250000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_ArSvbWarrantsInitialTrancheMember_ffU72mNG2UiEuncpq3Bk3g"
      decimals="2"
      id="Tc_pFY2sUz7x0G6qvR8miLjCQ_3_3"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">5.14</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_SvbWarrantInitialTrancheMember_vINmu1l2Ck24QYQ5Ny4zow"
      decimals="INF"
      id="Tc_Rd59S1WHLUOwZ2U_l3Facg_4_0"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">100000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_SvbWarrantInitialTrancheMember_vINmu1l2Ck24QYQ5Ny4zow"
      decimals="2"
      id="Tc_6p_Yt7gM4UWLlO3xIWQGLA_4_3"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">3.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_SvbWarrantTermBAndTermCTranchesMember_wOo46pKdiUGRSW3RPNRPxg"
      decimals="INF"
      id="Tc_TOHrp3N3_U2MSRU3ANLFqQ_5_0"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">100000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_OtherWarrantsMember_n4R8mkRr-0KRugEMPPOtqw"
      decimals="INF"
      id="Tc_1NEh1nUJjkCzQVQn3bRrJQ_6_0"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">56397</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2024_us-gaap_ClassOfWarrantOrRightAxis_lqda_OtherWarrantsMember_n4R8mkRr-0KRugEMPPOtqw"
      decimals="2"
      id="Tc_GXuG8hols06ibDtbrG5mEg_6_3"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">0.02</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_CK75B9u6zEGg0rJGZrLOKw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;9. Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2020 Long-Term Incentive Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;"&gt;Our 2020 Long-Term Incentive Plan (the &#x201c;2020 Plan&#x201d;) provides for the granting of stock appreciation rights, stock awards, stock units, and other stock-based awards and for accelerated vesting under certain change of control transactions. The number of shares of our common stock available for issuance under the 2020 plan will automatically increase on January 1 of each year through 2030, by an amount equal to the smaller of (a) 4% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by the Board of Directors (the &#x201c;Evergreen Provision&#x201d;). On January 1, 2024, the number of shares of common stock &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 12pt 0pt;"&gt;available for issuance under the 2020 Plan automatically increased by 2,745,183 shares pursuant to the Evergreen Provision. As of September&#160;30,&#160;2024, there were 900,518 shares available for future grants under the 2020 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The 2020 Plan replaced all prior equity award plans and such plans have been discontinued. However, the awards outstanding under the prior equity award plans will continue to remain in effect in accordance with their terms. Awards that are forfeited under these prior plans upon cancellation, termination or expiration will not be available for grant under the 2020 Plan. As of September&#160;30,&#160;2024, a total of 473,076 shares of common stock were reserved for issuance related to the remaining outstanding equity awards granted under the prior plans.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2022 Inducement Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 25, 2022, the Board of Directors approved the adoption of our 2022 Inducement Plan (the &#x201c;2022 Inducement Plan&#x201d;). The 2022 Inducement Plan was recommended for approval by the Compensation Committee of the Board (the &#x201c;Compensation Committee&#x201d;), and subsequently approved and adopted by the Board of Directors without stockholder approval pursuant to Rule 5635(c)(4) of the rules and regulations of The Nasdaq Stock Market, LLC (the &#x201c;Nasdaq Listing Rules&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;310,000 shares of our common stock were reserved for issuance pursuant to equity awards that may be granted under the 2022 Inducement Plan, and the 2022 Inducement Plan will be administered by the Compensation Committee. In accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules, equity awards under the 2022 Inducement Plan may only be made to an employee who has not previously been an employee or member of the Board of Directors, or following a bona fide period of non-employment by us, if he or she is granted such equity awards in connection with his or her commencement of employment with us and such grant is an inducement material to his or her entering into employment with us. As of September&#160;30,&#160;2024, a total of 27,608 shares were available for issuance under the 2022 Inducement Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Employee Stock Purchase Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2020, stockholders approved the Liquidia Corporation 2020 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The number of shares of our common stock available for issuance under the ESPP will automatically increase on January 1 of each year through 2030, by the lesser of (a) 1.0% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, (b) 150,000 shares, or (c) an amount determined by the Board of Directors. On January 1, 2024, the number of shares of common stock available for issuance under the ESPP increased by 150,000 shares. As of September&#160;30,&#160;2024, a total of 534,742 shares of common stock are reserved for issuance under the ESPP. The ESPP allows eligible employees to purchase shares of our common stock at a discount through payroll deductions, subject to plan limitations. Unless otherwise determined by the administrator, the common stock will be purchased for the accounts of employees participating in the ESPP at a price per share that is 85% of the lesser of the fair market value of our common stock on the first and last trading day of the offering period. During the nine months ended September&#160;30,&#160;2024 and 2023, 172,395 and 140,922 shares were issued under the ESPP, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation Valuation and Expense&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We account for employee stock-based compensation plans using the fair value method. The fair value method requires us to estimate the grant-date fair value of stock-based awards and amortize this fair value to compensation expense over the requisite service period or vesting term. The fair value of each option grant is estimated using a Black-Scholes option-pricing model.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;For restricted stock units (&#x201c;RSUs&#x201d;), the grant-date fair value is based upon the market price of our common stock on the date of the grant. This fair value is then amortized to compensation expense over the requisite service period or vesting term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Total stock-based compensation expense recognized for employees and non-employees was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;By Expense Category:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cost of revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 45&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 839&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 555&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,676&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,997&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,932&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,935&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,824&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,881&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,487&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,777&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,538&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The following table summarizes the unamortized compensation expense and the remaining&#160;years over which such expense would be expected to be recognized, on a weighted average basis, by type of award:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;September&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recognition&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unamortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expense&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,789&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted and performance stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value of &lt;i&gt;&lt;img alt="Graphic" src="lqda-20240930x10q002.jpg" style="display:inline-block;height:0.65pt;width:0.65pt;"/&gt;&lt;/i&gt;Stock Options Granted and Purchase Rights Issued under the ESPP&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We use the Black-Scholes option-pricing model to determine the fair value of stock options granted and purchase rights issued under the ESPP.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the assumptions used for estimating the fair value of stock options granted under the Black-Scholes option-pricing model:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_fljXNZJ780WhJZl0xfbOZw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_KgzYt7L2DEmD5XrMEpBoAQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;3.98%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;3.46% - 4.62%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;90%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;91% - 95%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;5.8 - 6.1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted average fair value for options granted during the nine months ended September&#160;30,&#160;2024 and 2023 was $9.84 and $5.09 per share, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the assumptions used for estimating the fair value of purchase rights granted to employees under the ESPP under the Black-Scholes option-pricing model:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_od59HwKFmkW8EjvwzxxZHg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden__L855O1ENEa44A4aGasXbw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;4.80% - 5.27%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.20% - 5.47%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;62% - 72%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;60% - 64%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.50&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Option Activity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Options generally vest over a four-year period in multiple tranches.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The following table summarizes stock option activity during the nine months ended September&#160;30,&#160;2024:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding as of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,573,937&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (351,653)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (179,926)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding as of September&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,049,858&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 47,835&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable as of September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,649,860&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,106&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested and expected to vest as of September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,772,869&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,661&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate intrinsic value of stock options in the table above represents the difference between the $10.00 closing price of our common stock as of September&#160;30,&#160;2024 and the exercise price of outstanding, exercisable, and vested and expected to vest in-the-money stock options.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Restricted Stock Units&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Restricted stock units (&#x201c;RSUs&#x201d;) represent the right to receive shares of our common stock at the end of a specified time period and/or upon the achievement of a specific milestone. RSUs can only be settled in shares of our common stock. RSUs generally vest over a four-year period similar to stock options granted to employees.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;The tax withholding method used for most RSUs is the sell-to-cover method, in which shares with a market value equivalent to the tax withholding obligation are sold on behalf of the holder of the RSUs upon vesting and settlement to cover the tax withholding liability and the cash proceeds from such sales are remitted to taxing authorities by us. In circumstances where the sell-to-cover method is not used, the holder of the RSUs is required to remit cash to us to cover the tax withholding liability and the cash is then remitted to taxing authorities by us.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;A summary of unvested RSU awards outstanding as of September&#160;30,&#160;2024 and changes during the nine months ended September&#160;30,&#160;2024 are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant-Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;RSUs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(per&#160;RSU)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,657,978&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.41&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,146,517&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.57&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (615,827)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.48&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (94,047)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.52&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested as of September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,094,621&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10.64&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;RSUs granted during the nine months ended September&#160;30,&#160;2024, included 520,526 performance-based RSUs granted to our executive officers. These performance-based RSUs vest upon the later of (a) time-based vesting conditions and (b) the first commercial sale of YUTREPIA in the United States and are considered probable of vesting. The time-based vesting condition means 25% of the performance-based RSUs vest one year after grant date and quarterly thereafter for three years, subject to the executive&#x2019;s continued service.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <lqda:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentAnnualIncreaseInCapitalShareReservedForFutureIssuance
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_PlanNameAxis_lqda_The2020PlanMember_WZy6bkl5x06pEBTAbp6atA"
      decimals="2"
      id="Narr_8tY_PJ-qhkCzFp6w7djTyA"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.04</lqda:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentAnnualIncreaseInCapitalShareReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_1_1_2024_To_1_1_2024_us-gaap_PlanNameAxis_lqda_The2020PlanMember_CEMyV83-zUCOMl6DTROCNQ"
      decimals="INF"
      id="Narr_WqVV8CF9kUaLjaMCo1mz2g"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">2745183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_9_30_2024_us-gaap_PlanNameAxis_lqda_The2020PlanMember_q3rF1sbUKU-D4Hw_9Wjf4Q"
      decimals="INF"
      id="Narr_pzvXN1AS60-GwRw1q45pxA"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">900518</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_9_30_2024_us-gaap_PlanNameAxis_lqda_The2020PlanMember_q3rF1sbUKU-D4Hw_9Wjf4Q"
      decimals="INF"
      id="Narr_1wU13X2ePkOfNnbacmgB2g"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">473076</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_1_25_2022_us-gaap_PlanNameAxis_lqda_InducementPlan2022Member_QcdutN2Mc0eer7i2vctGcQ"
      decimals="INF"
      id="Narr_dBY1mceNoEOf1SNlOmndcQ"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">310000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_9_30_2024_us-gaap_PlanNameAxis_lqda_InducementPlan2022Member_59X93Oj32UqU-HIAb8N6uw"
      decimals="INF"
      id="Narr_DQs2eLjH-0-0lE0Oc6eUpQ"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">27608</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <lqda:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding
      contextRef="Duration_11_1_2020_To_11_30_2020_lTtrHrdNKk2SU5Ol2ar1-w"
      decimals="3"
      id="Narr_Q-zzYhXES02pgiYO9NWEmA"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.010</lqda:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding>
    <lqda:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuance
      contextRef="Duration_11_1_2020_To_11_30_2020_lTtrHrdNKk2SU5Ol2ar1-w"
      decimals="INF"
      id="Narr_7gcgSpfjVkawqM8TW7_UPA"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">150000</lqda:ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuance>
    <lqda:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAvailableForIssuance
      contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_xFqmiRrTOkqulJr1LBWAnw"
      decimals="INF"
      id="Narr_pTFjHEdH802_c0k6g4eovg"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">150000</lqda:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesAvailableForIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_9_30_2024_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_IvI4h9c3EUuyg5PQrrLhMQ"
      decimals="INF"
      id="Narr_HTX6cRWZakKSoxXMRcdBsQ"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">534742</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_m7APsiBNMkuX9fDgBs78Wg"
      decimals="2"
      id="Narr_iK0BOEb10kSXAM15KPVShg"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_m7APsiBNMkuX9fDgBs78Wg"
      decimals="INF"
      id="Narr_M98HARLOHECjGi3nHT87ZA"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">172395</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_glcrSVianU6a1o46EeXtNg"
      decimals="INF"
      id="Narr_fX6JtAfea0Kv4kXGMXM0Iw"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">140922</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_E_KqVzlC306iBE1s7ntlaw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:19.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;By Expense Category:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cost of revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 45&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 839&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 555&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,676&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,997&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,932&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,935&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,824&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,881&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,487&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,777&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,538&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_9Shl9FOqAEm1xT8OQEZiPA"
      decimals="-3"
      id="Tc_4v1TWC-C0EK98biYS5WFcQ_4_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">45000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_sVbvNMFieEqahGNDqo00CQ"
      decimals="-3"
      id="Tc__lAwcNpcjU6SIj1xA6Sovg_4_9"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">166000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9ztv0G7UzkWrHinKet79MQ"
      decimals="-3"
      id="Tc_F49rLTc-hkW9hOWJNuHzGQ_5_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">839000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_b9IfscRcGUihtJB5srkY2g"
      decimals="-3"
      id="Tc_89SV2kj6mEOImh87HJlAiw_5_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">555000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_MRV76XSit0KBbsAP3TiUpA"
      decimals="-3"
      id="Tc_2yrFcqNqBkeM45Eo2UGpmg_5_9"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2676000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_We2fnt_wf0y9QPYfo6rVXQ"
      decimals="-3"
      id="Tc_hqBohChqe0q71ggc2MwMug_5_12"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1714000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_5JpbAcp9g0S1jyEmoVFeoA"
      decimals="-3"
      id="Tc_kmVF-i1RwECGIZQmhalSbA_6_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">3997000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_wV-uPH-HE0C8hSHXy_alBg"
      decimals="-3"
      id="Tc_GEr0mGSUSEuUbb0xOX9ifw_6_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1932000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_8RApRitnUUKh4kBFAXN1pg"
      decimals="-3"
      id="Tc_dDQ7zc-Lj02wFJ0suOznHA_6_9"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">10935000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ynF1uQCSmUyLHWdxX__Sxg"
      decimals="-3"
      id="Tc_1D0D14I5U02I7p7aXp6HeQ_6_12"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">5824000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="-3"
      id="Tc_RPQyLdTDYEOzbCN2mnqrdw_7_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">4881000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA"
      decimals="-3"
      id="Tc_ZtiAp9jyUESOCLBI4mC1tw_7_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2487000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_e8rfByWwsUSTcKvPcehzFg_7_9"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">13777000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_yvtyTod21UywPMvC23GXeA_7_12"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">7538000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_XqRJIqZH00KjMlhmsvuZdg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;September&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recognition&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unamortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expense&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,789&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.6&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted and performance stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_2wjFZ4y_OU6vooFOFqzXIQ"
      decimals="-3"
      id="Tc_C2L2FK6rD0-WJkmxezCd3g_8_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">9789000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1P_inS6zXkWNbG-ht9J6vg"
      id="Tc_zjUWdM0NJ0uePBYQJ1AgGQ_8_5">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_bNNJw9ET4UKPsBG0tkb61Q"
      decimals="-3"
      id="Tc_rS4uGZDNDE2aNN0e_4DtOA_9_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">26124000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_uwLnN9HvMUyPs1gUVBzqIQ"
      id="Tc_lzjX2DB3BE-KQl2hZ9Lk9A_9_5">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_loqmcF4cM0SKTZJn6ZTBKg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_fljXNZJ780WhJZl0xfbOZw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_KgzYt7L2DEmD5XrMEpBoAQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;3.98%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;3.46% - 4.62%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;90%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;91% - 95%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;5.8 - 6.1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_WDRn4vkaQU-_GJyXGW7r-g"
      decimals="4"
      id="Tc__dofQTGLPUmWCRLReACMrQ_5_2"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.0398</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_CfxUqp13dkiX5pxqnNfcWg"
      decimals="4"
      id="Narr_CJSyBYQGLUm2dhGXyH43kQ"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.0346</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_CfxUqp13dkiX5pxqnNfcWg"
      decimals="4"
      id="Narr_iy3MYW6N-USKBOIiFPNORw"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.0462</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_WDRn4vkaQU-_GJyXGW7r-g"
      decimals="2"
      id="Tc_86EPTWZSlkaFN4rYYgbpMA_6_2"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_CfxUqp13dkiX5pxqnNfcWg"
      decimals="2"
      id="Narr_JibL2aT5GkaHL2ZiHMswUw"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_CfxUqp13dkiX5pxqnNfcWg"
      decimals="2"
      id="Narr_MtQegOs_MkWqMy_xguBbAw"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_WDRn4vkaQU-_GJyXGW7r-g"
      id="Tc_jFc28VpfOkWl_nYSmioQow_7_2">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_c3RkhmYjMUymom-OGSSabQ"
      id="Narr_cci_KIDKC0GIFgsG9jAPsg">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_Y_FZ3m3A40qqKnWMJKMAEw"
      id="Narr_WhCLlDVQ1UKn-UWhXphfhA">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="2"
      id="Narr_SRoC1Px3X02cg-EM7SrKKw"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">9.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="2"
      id="Narr_S6GVimtOYUCfm7W_IYOVJg"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">5.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_m7APsiBNMkuX9fDgBs78Wg"
      id="Tb_M4Kus1T5IUKNbbbnsMkBeQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_od59HwKFmkW8EjvwzxxZHg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden__L855O1ENEa44A4aGasXbw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;4.80% - 5.27%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.20% - 5.47%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;62% - 72%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;60% - 64%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected life (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:16.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.50&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_3f2n43cTpEKLLf2BEff-rw"
      decimals="4"
      id="Narr_fqwbHYzGhE6VF6UZ7oVI-w"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.0480</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_3f2n43cTpEKLLf2BEff-rw"
      decimals="4"
      id="Narr_IgStDFZzPU-Pi1wczztnSw"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.0527</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_58oqF0uKeUmLTXXZbeZuOw"
      decimals="4"
      id="Narr_9geuoq8G7E-Xs0XO4H4HtA"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.0520</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_58oqF0uKeUmLTXXZbeZuOw"
      decimals="4"
      id="Narr_hWjhDJ-MvUWZtTSRtbLb1Q"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.0547</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_3f2n43cTpEKLLf2BEff-rw"
      decimals="2"
      id="Narr_cdiLsOIl2UGKei5xdu8GpQ"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_3f2n43cTpEKLLf2BEff-rw"
      decimals="2"
      id="Narr_1YZ4azIWvUOPsMjwfOe7Ig"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_58oqF0uKeUmLTXXZbeZuOw"
      decimals="2"
      id="Narr_UX9CNDfyJEuzWkVslaPTmw"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_58oqF0uKeUmLTXXZbeZuOw"
      decimals="2"
      id="Narr_jhMeePNv1UKMxTuYf3GLwg"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_3f2n43cTpEKLLf2BEff-rw"
      id="Tc_KnWa5GktpEe0vmPvwpTm9w_7_2">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_lqda_EmployeePurchaseRightsMember_us-gaap_PlanNameAxis_lqda_EmployeeStockPurchasePlan2020Member_58oqF0uKeUmLTXXZbeZuOw"
      id="Tc_pDKwi7HuVEqDBvJuCaHE_g_7_4">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_U5I2QUtyeUKSw5V0JR-EtQ"
      id="Narr_kcIOvfWfwkGGXzIUUnG0og">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_zNyc9zhijkCmT4gYW_sygg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding as of December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,573,937&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.86&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (351,653)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (179,926)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding as of September&#160;30,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,049,858&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.76&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 47,835&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercisable as of September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,649,860&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.48&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 37,106&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested and expected to vest as of September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,772,869&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,661&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="INF"
      id="Tc_rvwEn3N7ykyRbnEiURLB9A_6_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">9573937</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="2"
      id="Tc_8HznTlOAw0qdqGqbuyuMjQ_6_5"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">4.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="INF"
      id="Tc_mXz-szDl10-NzJ-gFNBlYA_7_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="2"
      id="Tc_vmQNiEjq_0KtO6JtgLXSiQ_7_5"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">12.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="INF"
      id="Tc_u7z8hIgVH0u_sxYasf8qlA_8_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">351653</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="2"
      id="Tc_kOLxWb20VEmroq8CrKvSxg_8_5"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">4.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="INF"
      id="Tc_QiI-ImPylUO-febsWZimYA_9_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">179926</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="2"
      id="Tc_9PeqxWUUIUyXMT3bgj-7EA_9_5"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">7.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="INF"
      id="Tc_GSTx1KDlM0CplSffwnfXXA_10_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">9049858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="2"
      id="Tc_9fU-G1ZNTUeFJNHXO2eDww_10_5"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">4.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tc_BydD2C85N0aY4KRKKhRm7Q_10_7">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_Yv7mG3PIMUGmtO6wmNooVA_10_10"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">47835000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="INF"
      id="Tc_qOmfZcUCOkmVVXloi_d_OQ_11_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">6649860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="2"
      id="Tc_7bHAoN8RckqNn-zSuxIJJw_11_5"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">4.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tc_vfxzUV6bWkKtky8fJjOLhg_11_7">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_MpgOWgutoUq8B8gGH3yT7w_11_10"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">37106000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="INF"
      id="Tc_3PqKqUrI-kK74zTVX-pztQ_12_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">8772869</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="2"
      id="Tc_0rvC3a01aUiUCMKIEVn2kQ_12_5"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">4.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tc_hKnNDgHXs0eMfzFFB0TS_Q_12_7">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_JYUQ7PtlYUCI6sOjPc6V4A_12_10"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">46661000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:SharePrice
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MBzkjBjqCku_2H2dhAQG9A"
      decimals="2"
      id="Narr_bxTCZHMCAEWcKyJ6EkWjrA"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">10.00</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_uwLnN9HvMUyPs1gUVBzqIQ"
      id="Narr_pqwR1BCYEkSYZnQAppb8Ew">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_CEtcHBgOLESJuzqVFS9DxQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant-Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;RSUs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(per&#160;RSU)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested as of December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,657,978&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.41&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,146,517&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.57&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (615,827)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.48&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (94,047)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.52&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested as of September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,094,621&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10.64&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_kteGXRriH0alvhRWw4-p7w"
      decimals="INF"
      id="Tc_OpZN4Mh2o02jgbMZTFqA_A_6_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">1657978</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_kteGXRriH0alvhRWw4-p7w"
      decimals="2"
      id="Tc_--2LyKu420y3kpQinGzGOg_6_5"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">6.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_uwLnN9HvMUyPs1gUVBzqIQ"
      decimals="INF"
      id="Tc_eP8bfedF3UedCiB8Tf-eJQ_7_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">2146517</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_uwLnN9HvMUyPs1gUVBzqIQ"
      decimals="2"
      id="Tc_D2gLEfK2qk6SQJVdfj-ZBA_7_5"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">12.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_uwLnN9HvMUyPs1gUVBzqIQ"
      decimals="INF"
      id="Tc_dqUfutJ6W0i4ccpUWND44Q_8_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">615827</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_uwLnN9HvMUyPs1gUVBzqIQ"
      decimals="2"
      id="Tc_v_riC5zMAEO8JHyUCuQIkA_8_5"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">6.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_uwLnN9HvMUyPs1gUVBzqIQ"
      decimals="INF"
      id="Tc_fDmc8PKg5Uqf7ZET4paLxQ_9_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">94047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_uwLnN9HvMUyPs1gUVBzqIQ"
      decimals="2"
      id="Tc_roqY5dCam0iY00uXUqyZMw_9_5"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">7.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_bNNJw9ET4UKPsBG0tkb61Q"
      decimals="INF"
      id="Tc_3fVnukpV2kmCIvajez4M4A_10_2"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">3094621</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_bNNJw9ET4UKPsBG0tkb61Q"
      decimals="2"
      id="Tc_0DJD9wNLgkq_KVALFCpQnw_10_5"
      unitRef="Unit_Divide_USD_shares_vtM-BDZ62keFF9PsKVZgpw">10.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_PerformanceBasedRestrictedStockUnitsMember_Yv0caJPQY0mJtH96769LWA"
      decimals="INF"
      id="Narr_eJ_lEuuq4ECCc-awdbCoLA"
      unitRef="Unit_Standard_shares_Nxh3GwFh9kyjdcisHheRAA">520526</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_PerformanceBasedRestrictedStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_h6JlHh_6Hk2OCYyiU3MA8w"
      decimals="2"
      id="Narr_ikFc1SNRvk-LL6vuxHDLMw"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_PerformanceBasedRestrictedStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_h6JlHh_6Hk2OCYyiU3MA8w"
      id="Narr_xpk6XSs2SEyHKsseV9h8OA">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_lqda_PerformanceBasedRestrictedStockUnitsMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ObYqzytTmk-rYw5p78JFbQ"
      id="Narr_d2HrKZhSqkaUThWakbJisw">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_fAVHubpRHky-NFOQlwKYuw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;10. Revenue From Contracts With Customers&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2018, we entered into a Promotion Agreement with Sandoz under which we have the exclusive rights to conduct commercial activities to encourage the appropriate use of Treprostinil Injection for the treatment of patients with PAH in the United States. We paid Sandoz $20 million at the inception of the Promotion Agreement in consideration for these rights. In exchange for conducting these commercial activities, we are entitled to receive a share of Net Profits (as defined within the Promotion Agreement) based on specified profit levels. The share of Net Profits received is subject to adjustments from Sandoz for certain items, such as distributor chargebacks, rebates, inventory returns, inventory write-offs and other adjustments. We expect to refund certain amounts to Sandoz through a reduction of the cash received from future Net Profits generated under the Promotion Agreement. As of September&#160;30,&#160;2024, a $0.5 million refund liability is offset against accounts receivable from Sandoz related to expected refund amounts. Approximately 98% and 98% of revenue during the three and nine months ended September&#160;30,&#160;2024, respectively, was generated from the Promotion Agreement.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <lqda:PromotionAgreementPayment
      contextRef="Duration_8_1_2018_To_8_31_2018_srt_CounterpartyNameAxis_lqda_SandozMember_bR-PCAVcsEa0W4IuOAk7hQ"
      decimals="-6"
      id="Narr_0WN58_frxkOrWOI5UQw-_w"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">20000000</lqda:PromotionAgreementPayment>
    <us-gaap:ContractWithCustomerRefundLiability
      contextRef="As_Of_9_30_2024_srt_CounterpartyNameAxis_lqda_SandozMember_raO9GBmyIE-5ZvV1IBniiQ"
      decimals="-5"
      id="Narr_0itVf1Ysu02eQ4f09ZN3Xw"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">500000</us-gaap:ContractWithCustomerRefundLiability>
    <lqda:PercentageOfRevenueFromPromotionAgreement
      contextRef="Duration_7_1_2024_To_9_30_2024_srt_CounterpartyNameAxis_lqda_SandozMember_rx6kg0vHT0uP6yMhTHZMqQ"
      decimals="2"
      id="Narr_5WwLI1liQESUbODqRpAh6w"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.98</lqda:PercentageOfRevenueFromPromotionAgreement>
    <lqda:PercentageOfRevenueFromPromotionAgreement
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_CounterpartyNameAxis_lqda_SandozMember_KdRq-SWRhUqv88cPuzMv1w"
      decimals="2"
      id="Narr_K5cusGlI8UWTIiCR3igmCQ"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.98</lqda:PercentageOfRevenueFromPromotionAgreement>
    <lqda:LeaseDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_UuB-YX7siE6jpY8d1N0kAA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;11. Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Operating Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;We are party to a non-cancelable operating lease for our laboratory and office space in Morrisville, North Carolina. The lease expires on October 31, 2026 with an option to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;extend&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; for an additional period of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;five years&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; with appropriate notice. We have not included the optional extension period in the measurement of lease liabilities because it is not reasonably certain that we will exercise the option to extend. The payments under this lease are subject to escalation clauses. Operating lease cost is allocated between research and development and general and administrative expenses based on the usage of the leased facilities. The related right-of-use assets are amortized on a straight-line basis over the lesser of the lease term or the estimated useful life of the asset.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Finance Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;We lease specialized laboratory equipment under finance leases. We do not have access to certain inputs used by our lessors to calculate the rate implicit in our finance leases and, as such, use our estimated incremental borrowing rate at the time of lease inception for the discount rate applied to our finance leases. The incremental borrowing rate used on finance leases was &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;6.5%&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;. Certain finance leases also include options to purchase the leased property. We recognize all such purchase options as part of our right-of-use assets and lease liabilities if we are reasonably certain that such purchase options will be exercised.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Lease Balances, Costs, and Future Minimum Payments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Leases with an initial term of 12 months or less are not recorded on the balance sheet. As of September&#160;30,&#160;2024, we have not entered into any short-term leases. For lease agreements entered into or reassessed after the adoption of ASC 842&lt;/span&gt;&lt;i style="font-style:italic;background:#ffffff;"&gt; Leases&lt;/i&gt;&lt;span style="background:#ffffff;"&gt;, we combine lease and non-lease components, if any. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;Our lease cost is reflected in the accompanying condensed statements of operations and comprehensive loss as follows&lt;/span&gt;:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Fixed lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 175&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 527&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Fixed lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 59&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization of lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 74&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total Lease Cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 221&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 220&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 659&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 673&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted average remaining lease term and discount rates as of September&#160;30,&#160;2024 were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:88.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:88.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average remaining lease term (years):&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:88.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:88.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:88.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average discount rate:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:88.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:88.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The discount rate for leases was estimated based upon market rates of collateralized loan obligations of comparable companies on comparable terms at the time of lease inception.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The future minimum lease payments as of September&#160;30,&#160;2024 were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ending December&#160;31:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024 (three months remaining)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 338&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 367&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,434&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,169&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,169&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,877&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,970&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (278)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (280)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,599&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,690&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</lqda:LeaseDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Narr__Twsqc-XDkm49K0J3hvWIw">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      id="Narr_EUsLfkmiXkCFjt5Tyn-4dA">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeFinanceLeaseDiscountRate
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="3"
      id="Narr_KlRekcbbcU-0oVPeI0I-iQ"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.065</us-gaap:LesseeFinanceLeaseDiscountRate>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Group_yZJL-feD7k6M46MuatvPmw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Fixed lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 175&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 527&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Fixed lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 59&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization of lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 74&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:23.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total Lease Cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 221&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 220&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 659&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 673&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted average remaining lease term and discount rates as of September&#160;30,&#160;2024 were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:88.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:88.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average remaining lease term (years):&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:88.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:88.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:88.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average discount rate:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:88.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:88.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Finance leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9ztv0G7UzkWrHinKet79MQ"
      decimals="-3"
      id="Tc_pQP0avvJjU21jgg-uh3Kxg_4_5"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">177000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_b9IfscRcGUihtJB5srkY2g"
      decimals="-3"
      id="Tc_2o_corZlbkiM8-ILmjpHQQ_4_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">175000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_MRV76XSit0KBbsAP3TiUpA"
      decimals="-3"
      id="Tc_Zcfn56thd0K-a-sFA_YOlw_4_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">527000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_We2fnt_wf0y9QPYfo6rVXQ"
      decimals="-3"
      id="Tc_f92s9QkkrkOLNaJIFgC7rg_4_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">527000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_5JpbAcp9g0S1jyEmoVFeoA"
      decimals="-3"
      id="Tc_iWfAD1Xv0k-tH-Zi6ZCitA_5_5"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">20000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_wV-uPH-HE0C8hSHXy_alBg"
      decimals="-3"
      id="Tc_54vscnmEE0eLDiJFQtIyVg_5_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">20000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_8RApRitnUUKh4kBFAXN1pg"
      decimals="-3"
      id="Tc_yeceGuj0F02zsvb2EDs-Iw_5_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">59000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_ynF1uQCSmUyLHWdxX__Sxg"
      decimals="-3"
      id="Tc_h78yrnAu_kKFhpxT7E8cpw_5_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">59000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_9ztv0G7UzkWrHinKet79MQ"
      decimals="-3"
      id="Tc_Ey3V2cvfJEy0oaxT5qcIoQ_7_5"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">22000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_b9IfscRcGUihtJB5srkY2g"
      decimals="-3"
      id="Tc_d_LXI8Jm3UuIlLfMDfNLHw_7_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">22000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_MRV76XSit0KBbsAP3TiUpA"
      decimals="-3"
      id="Tc_mO93Omoi4EeH88mhefsLAA_7_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">67000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_We2fnt_wf0y9QPYfo6rVXQ"
      decimals="-3"
      id="Tc_swqGn6i4Zkq8-omAAC2Qbw_7_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">74000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_4sm_WwX1i06DJVradQbuAA"
      decimals="-3"
      id="Tc_pvxh0VWlEkGTW6E9JZNqxw_8_5"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_icDoJJYujESK_TgeFGGuBw"
      decimals="-3"
      id="Tc_ZCPqJsqTc02E0pkdp27nSA_8_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">3000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_rJo_5hCZZ0eoAsQBkZvmzQ"
      decimals="-3"
      id="Tc_2IJQHjE7MUGn0JH4Mu8MLA_8_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">6000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_1_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_InterestExpenseMember_seQD86Gg-k-g0j-4Yfw1cw"
      decimals="-3"
      id="Tc_OGjW6gpfKU-P-qakWhYJDg_8_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">13000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="-3"
      id="Tc_WDA_V7oFQUCZCpi9hmAzcw_9_5"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">221000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_7_1_2023_To_9_30_2023_Du-Z5vkmWkyIRBP8dRWpNA"
      decimals="-3"
      id="Tc_sF2PoEtwmEybAR9z7dmd4A_9_8"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">220000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      decimals="-3"
      id="Tc_HHUL9ACHM0ey-CBb2ncsWQ_9_11"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">659000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="Duration_1_1_2023_To_9_30_2023__C2PVKExL0qasGXmbrcAQQ"
      decimals="-3"
      id="Tc_BMrHOinzM0W1amCLoqVBDw_9_14"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">673000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      id="Tc_tIUvhqsEY0-YQdrY_w-M3g_2_2">P2Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      id="Tc_1I7I5pZE502A66OtQMqF1A_3_2">P0Y6M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="3"
      id="Tc_KWdGhheOsUiiI8dabPxUvw_5_2"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.103</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="3"
      id="Tc_fKt1BD7gw0qmIEv7FvSyUw_6_2"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.065</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <lqda:LeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_6_wtufemIUyH_jarQaaSIA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The future minimum lease payments as of September&#160;30,&#160;2024 were as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Operating&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Finance&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Year ending December&#160;31:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Leases&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024 (three months remaining)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 338&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 367&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,370&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 64&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,434&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,169&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,169&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,877&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,970&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (278)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (280)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,599&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,690&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</lqda:LeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_RzvCUWXjd0udel8sPBj0rg_3_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">338000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_9ms5HYfBpESLTNvdfA2E2Q_3_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">29000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <lqda:LeaseLiabilityPaymentsDueRemainderOfFiscalYear
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_uqLAV3BBn0qYFA1lVugCvg_3_9"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">367000</lqda:LeaseLiabilityPaymentsDueRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_8UAOSFJk-U2l1_sXgHCt7g_4_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1370000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_3UHb8kA_yEaANVCAirHQYA_4_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">64000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <lqda:LeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_FB_4pYsnrkyEENxGsevDDA_4_9"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1434000</lqda:LeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_N72tQgOEBUmVKSAWHtSu6g_5_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1169000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_U1TvuzPru0ifJpZGfoy-Vg_5_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <lqda:LeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_RMxvZwTEb0q-1M5uXKnOkA_5_9"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1169000</lqda:LeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_ShI70Piei0aUNgZpdRc8VA_6_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2877000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_hbZB3sI6IUiWfNG9pUr2dw_6_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">93000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <lqda:LeaseLiabilityPaymentsDueTotal
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_40wIU1-cK0i1Tppw79UGbw_6_9"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2970000</lqda:LeaseLiabilityPaymentsDueTotal>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_8YGUmKXbaU-wJmUalB3Oqg_7_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">278000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_KdpazCZXxEGC0xipbQeqdg_7_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <lqda:LeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_-zgMj-DfMUaO4bzs0zlH5g_7_9"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">280000</lqda:LeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_qTyLxedRgkWWVXqoZAvI7Q_8_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2599000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_0O_JWBRjXUGIKN2KCYtSiA_8_6"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">91000</us-gaap:FinanceLeaseLiability>
    <lqda:LeaseLiability
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_s3HBsnkXz0-llm1q913yhw_8_9"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2690000</lqda:LeaseLiability>
    <lqda:RevenueInterestFinancingPayableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_ZPdP6SoXY0WXbAD57O9epw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;12. Revenue Interest Financing Payable&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On January 9, 2023, we entered into the RIFA with HCR and HealthCare Royalty Management, LLC, pursuant to which and subject to the terms and conditions contained therein, HCR agreed to pay us an aggregate investment amount of up to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$100.0&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million (the &#x201c;Investment Amount&#x201d;) in &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;four&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; tranches.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On January 27, 2023, &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$32.5&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million of the Investment Amount was funded from the first tranche, &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$22.2&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million of which was used to satisfy existing obligations due to Silicon Valley Bank. This repayment resulted in a loss on extinguishment during the year ended December&#160;31,&#160;2023 of&#160;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$2.3&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#160;million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 28, 2023 and July 27, 2023, we entered into the Second Amendment to the RIFA and Third Amendment to the RIFA, respectively, pursuant to which HCR funded $10.0 million from the second tranche on July 27, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 3, 2024, we entered into the Fourth Amendment to the RIFA pursuant to which HCR funded an additional $25.0 million from the second tranche on January 5, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 11, 2024 we entered into the Fifth Amendment to the RIFA pursuant to which HCR funded an additional $32.5 million from the second tranche on September 12, 2024 and eliminated the third and fourth tranches.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As consideration for the Investment Amount and pursuant to the RIFA, we have agreed to pay HCR according to a fixed quarterly payment schedule.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;As of  September&#160;30,&#160;2024, we were required to pay &lt;/span&gt;$13.3 million within one year of the balance sheet date, which is classified as current in our condensed consolidated balance sheet.&lt;span style="background:#ffffff;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Aggregate payments to HCR are capped at 175% of funded portion of the Investment Amount (the &#x201c;Hard Cap&#x201d;), plus an amount, if any, that HCR would need to receive to yield an internal rate of return of (i) 18% on the first $67.5 million funded and (ii) 16% on the last $32.5 million funded (the &#x201c;IRR True-Up Payment&#x201d;), unless the RIFA is earlier terminated. If a change of control occurs or upon the occurrence of an event of default, HCR may accelerate payments due under the RIFA up to the Hard Cap, plus the IRR True-Up Payment, plus any other obligations payable under the RIFA.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The RIFA contains customary affirmative and negative covenants and customary events of default and other events that would cause acceleration, including, among other things, the occurrence of certain material adverse events or the material breach of certain representations and warranties and specified covenants, in which event HCR may elect to terminate the RIFA and require us to make payments to HCR equal to the lesser of (a) the Hard Cap, plus any other obligations payable under the RIFA, or (b) the funded portion of the Investment Amount, minus payments received by HCR in respect of the Revenue Interests, plus the IRR True-Up Payment. If the FDA grants final approval to an inhaled treprostinil product therapeutically equivalent to YUTREPIA and HCR has not received 100% of the amount funded by HCR to date, then we will be required to make payments to HCR equal to 100% of the amount funded by HCR to date, minus payments received by HCR in respect of the Revenue Interests.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The RIFA contains certain restrictions on our ability, among other things, to incur additional debt, grant or permit additional liens, make investments and acquisitions, dispose of assets, pay dividends and distributions, subject to certain exceptions.&#160;&lt;span style="background:#ffffff;"&gt;In addition, the RIFA contains a financial covenant that requires us to maintain cash and cash equivalents in an &lt;/span&gt;amount at least equal to $7.5 million during the calendar year beginning on January 1, 2024 and at least equal to $15.0 million for the remainder of the payment term after the calendar year ended December 31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of the filing date of these condensed consolidated financial statements, we are not aware of any breach of covenants, or the occurrence of any material adverse event, nor have we received any notice of event of default from HCR.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Fourth Amendment to the RIFA qualifies as a debt extinguishment and issuance of a new debt instrument in accordance with ASC 405-20, Extinguishments of Liabilities. We recorded a loss on extinguishment during the quarter ended March 31, 2024 of $11.5 million, equal to the fair value of the amended RIFA less the carrying value of the existing RIFA on January 5, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Fifth Amendment to the RIFA qualifies as a debt extinguishment and issuance of a new debt instrument in accordance with ASC 405-20, Extinguishments of Liabilities. We recorded a gain on extinguishment during the quarter ended September 30, 2024 of $7.2 million, equal to the fair value of the amended RIFA less the carrying value of the existing RIFA on September 12, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We recorded the total funds received from HCR under the terms of the RIFA as a liability. The issuance costs, consisting primarily of legal fees, totaled $0.9 million and were recorded as a deduction of the carrying amount of the liability and are being amortized under the effective interest method over the estimated period the liability will be repaid. We estimated the total amount of payments over the life of the RIFA to determine the interest expense to record to accrete the liability to the amount ultimately due. For the three and nine months ended September&#160;30,&#160;2024, we estimated an&#160;effective annual interest rate of approximately&#160;15.2%. Over the course of the RIFA, the effective annual interest rate may be affected by potential changes in forecasted payments. On a quarterly&#160;basis, we will reassess the expected amount and timing of payments, recalculate the amortization and effective interest&#160;rate and adjust the accounting prospectively as needed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the changes in the RIFA payable during the nine months ended September&#160;30,&#160;2024:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,033&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accretion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 107&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization of issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Second tranche funding, net of fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,975&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of January 5, 2024, prior to extinguishment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 71,117&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Loss on extinguishment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,483&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of January 5, 2024, after extinguishment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 82,600&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accretion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,161&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,731)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Second tranche funding, net of fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,485&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of September 12, 2024, prior to extinguishment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 119,515&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;(Gain) on extinguishment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,215)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of September 12, 2024, after extinguishment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 112,300&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accretion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 844&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 113,144&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: current portion of revenue interest financing payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13,252)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term portion of revenue interest financing payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 99,892&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The expected annual payments on the revenue interest financing payable as of September&#160;30,&#160;2024 are as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ending December&#160;31:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024 (three months remaining)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,122&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,017&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,724&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,962&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,962&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,828&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 170,615&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</lqda:RevenueInterestFinancingPayableTextBlock>
    <lqda:RevenueInterestFinancingAgreementMaximumInvestmentAmount
      contextRef="Duration_1_9_2023_To_1_9_2023_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_fo6QHS2lUkOEV604PgAJ-g"
      decimals="-5"
      id="Narr_3nzq_BDSrEKNwAltYTAGLQ"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">100000000.0</lqda:RevenueInterestFinancingAgreementMaximumInvestmentAmount>
    <lqda:RevenueInterestFinancingAgreementNumberOfTranches
      contextRef="Duration_1_9_2023_To_1_9_2023_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_fo6QHS2lUkOEV604PgAJ-g"
      decimals="INF"
      id="Narr_WqQzh72abkuZHKITg5dFlw"
      unitRef="Unit_Standard_tranche_wUAWxTjoVkeKHp1IAnkhew">4</lqda:RevenueInterestFinancingAgreementNumberOfTranches>
    <lqda:RevenueInterestFinancingAgreementInitialInvestmentAmount
      contextRef="Duration_1_27_2023_To_1_27_2023_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_ewbpUOaI7UyQVn102NdAXw"
      decimals="-5"
      id="Narr_9csRUhvIakanf03CS7hpsg"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">32500000</lqda:RevenueInterestFinancingAgreementInitialInvestmentAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_27_2023_To_1_27_2023_us-gaap_DebtInstrumentAxis_lqda_ArSiliconValleyBankTermLoansMember_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_lBeKdvCPDUmyLAg_84HrDg"
      decimals="-5"
      id="Narr_RcpflsnSsU6CcQJ4b79C7A"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">22200000</us-gaap:RepaymentsOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2023_To_12_31_2023_cXF6Jhyv9Ums3sgX3ZsQgg"
      decimals="-5"
      id="Narr_FIwZvSp2UkeIy9OnqcMvuQ"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-2300000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <lqda:RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche
      contextRef="Duration_7_27_2023_To_7_27_2023_us-gaap_TypeOfArrangementAxis_lqda_SecondAndThirdAmendmentsToRevenueInterestFinancingAgreementMember_JoeWZnLjZ0ynl9XNGamlHA"
      decimals="-5"
      id="Narr_iemgDQGrzESO4F9fApT-Pg"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">10000000.0</lqda:RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche>
    <lqda:RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche
      contextRef="Duration_1_5_2024_To_1_5_2024_us-gaap_TypeOfArrangementAxis_lqda_FourthAmendmentToRevenueInterestFinancingAgreementMember_KQa5hA-xwU2M20pCIYuA9w"
      decimals="-5"
      id="Narr_kGudNAnRQE-8OUX_VctlMw"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">25000000.0</lqda:RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche>
    <lqda:RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche
      contextRef="Duration_9_12_2024_To_9_12_2024_us-gaap_TypeOfArrangementAxis_lqda_FifthAmendmentToRevenueInterestFinancingAgreementMember_90dvyAHXdUi7zLcPG7LSyw"
      decimals="-5"
      id="Narr_SbniifkQcEGN6-qG_eRBBQ"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">32500000</lqda:RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche>
    <lqda:RevenueInterestFinancingPayableCurrent
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-5"
      id="Narr_1iLNcp4Qs0C-BGoFOfuK5Q"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">13300000</lqda:RevenueInterestFinancingPayableCurrent>
    <lqda:RevenueInterestFinancingAgreementHardCapPercentage
      contextRef="Duration_1_9_2023_To_1_9_2023_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_fo6QHS2lUkOEV604PgAJ-g"
      decimals="0"
      id="Narr_GVtbqULJIUuaeFN0VSJ4ng"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">175</lqda:RevenueInterestFinancingAgreementHardCapPercentage>
    <lqda:RevenueInterestFinancingAgreementInternalRateOfReturn
      contextRef="Duration_1_9_2023_To_1_9_2023_srt_StatementScenarioAxis_lqda_OnFirstFundedPortionOfInvestmentAmountMember_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_aXDyEn_Gnkq9Wg0YnjtxyQ"
      decimals="2"
      id="Narr_XdFFDY998UWPKo2jXAR28Q"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.18</lqda:RevenueInterestFinancingAgreementInternalRateOfReturn>
    <lqda:RevenueInterestFinancingAgreementAmountFunded
      contextRef="Duration_1_9_2023_To_1_9_2023_srt_StatementScenarioAxis_lqda_OnFirstFundedPortionOfInvestmentAmountMember_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_aXDyEn_Gnkq9Wg0YnjtxyQ"
      decimals="-5"
      id="Narr_6yQg7dffT0-SSUmR4VbAaw"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">67500000</lqda:RevenueInterestFinancingAgreementAmountFunded>
    <lqda:RevenueInterestFinancingAgreementInternalRateOfReturn
      contextRef="Duration_1_9_2023_To_1_9_2023_srt_StatementScenarioAxis_lqda_OnSecondPortionOfFundedInvestmentAmountMember_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_vs2P5tJ_80ax80uJ--MG3g"
      decimals="2"
      id="Narr_1YZ7rcbZZkqwUFmUxYPFrQ"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.16</lqda:RevenueInterestFinancingAgreementInternalRateOfReturn>
    <lqda:RevenueInterestFinancingAgreementAmountFunded
      contextRef="Duration_1_9_2023_To_1_9_2023_srt_StatementScenarioAxis_lqda_OnSecondPortionOfFundedInvestmentAmountMember_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_vs2P5tJ_80ax80uJ--MG3g"
      decimals="-5"
      id="Narr_t_mh048vD0GWmfaPC67jBQ"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">32500000</lqda:RevenueInterestFinancingAgreementAmountFunded>
    <lqda:PercentageOfInvestmentAmountToBeRepaidOnFinalApproval
      contextRef="Duration_1_9_2023_To_1_9_2023_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_fo6QHS2lUkOEV604PgAJ-g"
      decimals="0"
      id="Narr_6SLDBXUSo0uqjYvpTjG2gQ"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">100</lqda:PercentageOfInvestmentAmountToBeRepaidOnFinalApproval>
    <lqda:PercentageOfInvestmentAmountToBePaid
      contextRef="Duration_1_9_2023_To_1_9_2023_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_fo6QHS2lUkOEV604PgAJ-g"
      decimals="0"
      id="Narr_kAvBI3cAikqB1x6WCZanpg"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">100</lqda:PercentageOfInvestmentAmountToBePaid>
    <lqda:MinimumCashAndCashEquivalentsRequiredToBeMaintainedDuringYearTwo
      contextRef="Duration_1_9_2023_To_1_9_2023_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_fo6QHS2lUkOEV604PgAJ-g"
      decimals="-5"
      id="Narr_os8NXhrJY0S3j3Ijn11dxg"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">7500000</lqda:MinimumCashAndCashEquivalentsRequiredToBeMaintainedDuringYearTwo>
    <lqda:MinimumCashAndCashEquivalentsRequiredToBeMaintainedAfterYearTwo
      contextRef="Duration_1_9_2023_To_1_9_2023_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_fo6QHS2lUkOEV604PgAJ-g"
      decimals="-5"
      id="Narr_63nPVeqgyUiX6_14dTp-Jg"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">15000000.0</lqda:MinimumCashAndCashEquivalentsRequiredToBeMaintainedAfterYearTwo>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_1_2024_To_3_31_2024_f-rSQLlZh0qWc3XMDnx8Sw"
      decimals="-5"
      id="Narr_dGAuIfpzE0KZSHaU-9F-mQ"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-11500000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      decimals="-5"
      id="Narr_NNOt3_SnQUmFi03Wk6EgcA"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">7200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <lqda:RevenueInterestFinancingAgreementIssuanceCosts
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_k-djEJags0G4_tYSdX2F1w"
      decimals="-5"
      id="Narr_MpgazgQsr0SV1HlZ0nFWXA"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">900000</lqda:RevenueInterestFinancingAgreementIssuanceCosts>
    <lqda:RevenueInterestFinancingAgreementEffectiveAnnualInterestRate
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_TypeOfArrangementAxis_lqda_RevenueInterestFinancingAgreementMember_k-djEJags0G4_tYSdX2F1w"
      decimals="3"
      id="Narr_wXQh8Xulp0ioO_2_ZafFdg"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.152</lqda:RevenueInterestFinancingAgreementEffectiveAnnualInterestRate>
    <lqda:ScheduleOfActivityOfRevenueInterestFinancingAgreementTableTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_bC-Qfk6s5Ueb0wMLrO3KXA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 46,033&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accretion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 107&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization of issuance costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Second tranche funding, net of fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,975&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of January 5, 2024, prior to extinguishment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 71,117&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Loss on extinguishment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,483&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of January 5, 2024, after extinguishment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 82,600&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accretion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,161&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,731)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Second tranche funding, net of fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,485&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of September 12, 2024, prior to extinguishment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 119,515&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;(Gain) on extinguishment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,215)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of September 12, 2024, after extinguishment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 112,300&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accretion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 844&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance as of September&#160;30,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 113,144&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: current portion of revenue interest financing payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13,252)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Long-term portion of revenue interest financing payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 99,892&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</lqda:ScheduleOfActivityOfRevenueInterestFinancingAgreementTableTextBlock>
    <lqda:RevenueInterestFinancingAgreement
      contextRef="As_Of_12_31_2023_ZLXisrbiMEeenWUC9Flgkw"
      decimals="-3"
      id="Tc_aywVA8ItHUu5EHBlaxniUA_1_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">46033000</lqda:RevenueInterestFinancingAgreement>
    <lqda:RevenueInterestFinancingAgreementAccretion
      contextRef="Duration_1_1_2024_To_1_4_2024_lOhuZ940QEqjnjbxJodNUA"
      decimals="-3"
      id="Tc_Q7vTjLZZ4U68U5Oa5Lpgeg_2_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">107000</lqda:RevenueInterestFinancingAgreementAccretion>
    <lqda:RevenueInterestFinancingAgreementAmortizationOfDebtDiscount
      contextRef="Duration_1_1_2024_To_1_4_2024_lOhuZ940QEqjnjbxJodNUA"
      decimals="-3"
      id="Tc_XGI1j3hpu0eA6pmLQIHIUw_3_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2000</lqda:RevenueInterestFinancingAgreementAmortizationOfDebtDiscount>
    <lqda:RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche
      contextRef="Duration_1_1_2024_To_1_4_2024_lOhuZ940QEqjnjbxJodNUA"
      decimals="-3"
      id="Tc_bH1cI86xS0KwXcfFU8YRCQ_4_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">24975000</lqda:RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche>
    <lqda:RevenueInterestFinancingAgreement
      contextRef="As_Of_1_4_2024_bF-IBdhTwk-KlM3yC7Lrpw"
      decimals="-3"
      id="Tc_htYG3lppPk29xN9jzGavfQ_5_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">71117000</lqda:RevenueInterestFinancingAgreement>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_1_5_2024_To_1_5_2024_viljKiMR20eRuvibROMGtg"
      decimals="-3"
      id="Tc_IJL1H0ghUkaTTlUjPc35wA_6_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">11483000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <lqda:RevenueInterestFinancingAgreement
      contextRef="As_Of_1_5_2024_3NJ3uFG5A06JS2suMz0vng"
      decimals="-3"
      id="Tc_CnRS1BDQ30GOdGal-LUzUQ_7_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">82600000</lqda:RevenueInterestFinancingAgreement>
    <lqda:RevenueInterestFinancingAgreementAccretion
      contextRef="Duration_1_6_2024_To_9_11_2024_EiDEZtBwZ0mjbahWfp4TWA"
      decimals="-3"
      id="Tc_N68OEm84A0mjMHF9rSd8aw_8_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">7161000</lqda:RevenueInterestFinancingAgreementAccretion>
    <lqda:PaymentsOnRevenueInterestFinancingLiability
      contextRef="Duration_1_6_2024_To_9_11_2024_EiDEZtBwZ0mjbahWfp4TWA"
      decimals="-3"
      id="Tc_Cztv6TsFH02qt9LR0Hq9MQ_9_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2731000</lqda:PaymentsOnRevenueInterestFinancingLiability>
    <lqda:RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche
      contextRef="Duration_1_6_2024_To_9_11_2024_EiDEZtBwZ0mjbahWfp4TWA"
      decimals="-3"
      id="Tc_yeYp5ULWGU2p1oAiUNdkIQ_10_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">32485000</lqda:RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche>
    <lqda:RevenueInterestFinancingAgreement
      contextRef="As_Of_9_11_2024_Ev9Bn70vFE2agHiszGrR1Q"
      decimals="-3"
      id="Tc_hGeXhvOHSEKVPmHHQiI2-g_11_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">119515000</lqda:RevenueInterestFinancingAgreement>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="Duration_9_12_2024_To_9_12_2024_aSxtNfNO5k-96RR4O_eJ5w"
      decimals="-3"
      id="Tc_aSyojTFRykitJRQnk2ZL2A_12_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">-7215000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <lqda:RevenueInterestFinancingAgreement
      contextRef="As_Of_9_12_2024_CIE4XyPuXU-VCdM-JmlrRQ"
      decimals="-3"
      id="Tc_KT4CycEer0Ox5KgN7odapw_13_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">112300000</lqda:RevenueInterestFinancingAgreement>
    <lqda:RevenueInterestFinancingAgreementAccretion
      contextRef="Duration_9_13_2024_To_9_30_2024_i691B_ItG0GtXHNs1Fzb9g"
      decimals="-3"
      id="Tc_bXB4sERtrk2S9Jw61Kx98Q_14_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">844000</lqda:RevenueInterestFinancingAgreementAccretion>
    <lqda:RevenueInterestFinancingAgreement
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_xrj0MJm2kk2uqjcF04oJzQ_15_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">113144000</lqda:RevenueInterestFinancingAgreement>
    <lqda:RevenueInterestFinancingPayableCurrent
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_OuYd37zgfkG_7Vm47LAWaQ_16_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">13252000</lqda:RevenueInterestFinancingPayableCurrent>
    <lqda:RevenueInterestFinancingPayableNoncurrent
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_v4jshyj2zU2EnMEACmiBCw_17_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">99892000</lqda:RevenueInterestFinancingPayableNoncurrent>
    <lqda:ScheduleOfExpectedAnnualPaymentsOnRevenueInterestFinancingAgreement
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_wqXJUw7QjkS3Ff5SxTvkuw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The expected annual payments on the revenue interest financing payable as of September&#160;30,&#160;2024 are as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ending December&#160;31:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024 (three months remaining)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,122&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,017&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,724&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,962&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,962&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 31,828&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 170,615&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</lqda:ScheduleOfExpectedAnnualPaymentsOnRevenueInterestFinancingAgreement>
    <lqda:RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_wC8uRElG3k-1yfbv6f78Iw_2_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2122000</lqda:RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear>
    <lqda:RevenueInterestFinancingAgreementExpectedPaymentsYearOne
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_9nqg7IzMG0qZxki-zvxCqg_3_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">18017000</lqda:RevenueInterestFinancingAgreementExpectedPaymentsYearOne>
    <lqda:RevenueInterestFinancingAgreementExpectedPaymentsYearTwo
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_l4LeE9E9vUqkpDoSuw82FA_4_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">52724000</lqda:RevenueInterestFinancingAgreementExpectedPaymentsYearTwo>
    <lqda:RevenueInterestFinancingAgreementExpectedPaymentsYearThree
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc__HV2NlvRMUelmebqISXBew_5_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">32962000</lqda:RevenueInterestFinancingAgreementExpectedPaymentsYearThree>
    <lqda:RevenueInterestFinancingAgreementExpectedPaymentsYearFour
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_9nOYvVI1W0eLD0wM0iJOuA_6_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">32962000</lqda:RevenueInterestFinancingAgreementExpectedPaymentsYearFour>
    <lqda:RevenueInterestFinancingAgreementExpectedPaymentsYearFiveAndThereafter
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_RAC2xh1EZEu9DhPtRY-0Lw_7_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">31828000</lqda:RevenueInterestFinancingAgreementExpectedPaymentsYearFiveAndThereafter>
    <lqda:RevenueInterestFinancingAgreementExpectedPaymentsTotal
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-3"
      id="Tc_Ujhu7Ryp_EqC1TIIsnGkbg_8_3"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">170615000</lqda:RevenueInterestFinancingAgreementExpectedPaymentsTotal>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_cI2Dsun-rEmLml9wDtgsdA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;13. Commitments and Contingencies &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Pharmosa License Agreement and Device License Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2023, we entered into a License Agreement with Pharmosa Biopharm Inc. (&#x201c;Pharmosa&#x201d;) pursuant to which we were granted an exclusive license in North America to develop and commercialize L606, an inhaled, sustained-release formulation of treprostinil currently being evaluated in a clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), and a non-exclusive license for the manufacture, development and use (but not commercialization) of such licensed product in most countries outside North America (the &#x201c;Pharmosa License Agreement&#x201d;). On October 2, 2024, we and Pharmosa entered into a First Amendment to the Pharmosa License Agreement (the &#x201c;First Amendment&#x201d;) which, among other things, expands our licensed territory beyond North America to include key markets in Europe, Japan and elsewhere.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="color:#212529;"&gt;Concurrently with the execution of the First Amendment, we and Pharmosa also entered into a Device License Agreement (the &#x201c;Device License Agreement&#x201d;). Pursuant to the terms of the Device License Agreement, Pharmosa will provide (i) an exclusive license to Liquidia Technologies for the right to develop, manufacture, use and commercialize Pharmosa&#x2019;s next-generation smart-technology nebulizers (the &#x201c;Device&#x201d;) for use with L606 in most countries (subject to certain exceptions) (the &#x201c;Territory&#x201d;) and (ii) a non-exclusive license to Liquidia Technologies for the right to develop, manufacture and use (but not commercialize) the Device outside of the Territory.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the Pharmosa License Agreement, as amended, we will be responsible for development, regulatory and commercial activities of L606 in the Territory. Pharmosa will manufacture clinical and commercial supplies of the liposomal formulation through its global supply chain and support us in establishing a redundant global supply chain. In consideration for these exclusive rights, we paid Pharmosa an upfront license fee of $10 million and paid an additional $3.5 million upfront license fee in October 2024 in &lt;span style="color:#212529;"&gt;connection with the rights granted in the First Amendment and the Device License Agreement. In addition to the upfront fees, we &lt;/span&gt;will pay Pharmosa potential development milestone payments tied to clinical development and approvals in PAH and/or PH-ILD of up to $37.75 million, potential sales milestones of up to $185 million in North America and $150 million outside North American and two tiers of low, double-digit royalties on all net sales of L606. Pharmosa will also receive a $10 million milestone payment for each additional indication approved after PAH and PH-ILD and each additional product approved under the license. We also retain the first right to negotiate for development and commercialization of L606 in Europe and other territories should Pharmosa seek a partner, subject to satisfaction of certain conditions as set forth in the Pharmosa License Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Mainbridge Health Care Device Development and Supply Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2022, we entered into a Device Development and Supply Agreement (the &#x201c;Pump Development Agreement&#x201d;) with Mainbridge Health Partners, LLC (&#x201c;Mainbridge&#x201d;) and Sandoz Inc. (&#x201c;Sandoz&#x201d;). The Pump Development Agreement provides for the cooperation between us, Sandoz and Mainbridge to develop a new pump that is suitable for the subcutaneous administration of Treprostinil Injection. Mainbridge will perform all development, validation and testing activities required for the pump and related consumables in anticipation of submitting a 510(k)&#160;clearance application for the pump to the FDA. In connection with the Pump Development Agreement, we and Sandoz have agreed to pay Mainbridge certain future contingent milestone payments in accordance with the terms and conditions set forth therein.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;UNC License Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;We perform research under a license agreement with The University of North Carolina at Chapel Hill (&#x201c;UNC&#x201d;) as amended to date (the &#x201c;UNC License Agreement&#x201d;). As part of the UNC License Agreement, we hold an exclusive license to certain research and development technologies and processes in various stages of patent pursuit, for use in our research and development and commercial activities, with a term until the expiration date of the last to expire patent subject to the UNC License Agreement, subject to industry standard contractual compliance. Under the UNC License Agreement, we are obligated to pay UNC royalties equal to a low single digit&#160;percentage of all net sales of drug products whose manufacture, use or sale includes any use of the technology or patent rights covered by the UNC License &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Agreement, including YUTREPIA. We may grant sublicenses of UNC licensed intellectual property in return for specified payments based on a&#160;percentage of any fee, royalty or other consideration received.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Chasm Technologies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In March 2012, we entered into an agreement, as amended, with Chasm Technologies, Inc. for manufacturing consulting services related to our manufacturing capabilities during the term of the agreement. We agreed to pay future contingent milestones and royalties on net sales totaling no more than $1.5 million, $0.2 million of which has been accrued as of September&#160;30,&#160;2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Employment Agreements and Executive Severance and Change in Control Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We have agreements with certain employees and an Executive Severance and Change in Control Plan which covers certain other employees which require payments if certain events, such as a change in control or termination without cause, occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Purchase Obligations&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;We enter into contracts in the normal course of business with contract service providers to assist in the performance of research and development and manufacturing activities. Subject to required notice periods and obligations under binding purchase orders, we can elect to discontinue the work under these agreements at any time.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On July 14, 2023, we entered into an Amended and Restated Commercial Manufacturing Services and Supply Agreement with Lonza Tampa LLC (&#x201c;Lonza&#x201d;) (the &#x201c;CSA&#x201d;). Lonza is our sole supplier for encapsulation and packaging services for YUTREPIA. &lt;span style="background:#ffffff;"&gt;Pursuant to the terms of the CSA, we deliver bulk treprostinil powder, manufactured using our proprietary PRINT&lt;/span&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;background:#ffffff;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background:#ffffff;"&gt;&#160;technology, and Lonza encapsulates and packages it. &lt;/span&gt;The CSA was effective upon signing and will be in effect for an initial term of 5 years from receipt of regulatory approval of YUTREPIA by the FDA (&#x201c;Regulatory Approval&#x201d;) absent termination by either party in accordance with the terms of the CSA.&lt;span style="background:#ffffff;"&gt; We may terminate the CSA upon &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;60 days&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;&#x2019; written notice to Lonza in the event that the application for regulatory approval is rejected by the FDA and such FDA decision is not caused by the fault of the Company (the &#x201c;Termination for FDA Rejection&#x201d;). Lonza may terminate the CSA upon &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;120 days&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; written notice if we do not receive regulatory approval by December&#160;31, 2024 (the &#x201c;Termination for FDA Delay&#x201d;). &lt;/span&gt;Upon any Termination for FDA Rejection or Termination for FDA Delay, we would reimburse Lonza for 50% of its documented out-of-pocket expenditures for any capital equipment that is purchased by Lonza after the effective date of the Agreement to perform the services for us, not to exceed $2.5 million in the aggregate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;We are required to provide Lonza with quarterly forecasts of our expected production requirements for the following &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;24-month&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; period, the first &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;twelve months&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; of which is considered a binding, firm order. We are required to purchase certain minimum annual order quantities, which may be adjusted by us after the thirteenth month after receipt of regulatory approval (as defined in the CSA). The CSA provides for tiered pricing depending upon the batch size ordered. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, we are party to a multi-year supply agreement with LGM Pharma, LLC (LGM) to supply active pharmaceutical ingredients for YUTREPIA. Under the supply agreement with LGM, we are required to provide rolling forecasts, a portion of which will be considered a binding, firm order, subject to an annual minimum purchase commitment of $2.7 million for the term of the agreement. The agreement expires five&#160;years from the first marketing authorization approval of YUTREPIA.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of September&#160;30,&#160;2024, we have non-cancelable commitments for product manufacturing and supply costs of approximately $14.7 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Other Contingencies and Commitments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;From time-to-time we are subject to claims and litigation in the normal course of business, none of which do we believe represent a risk of material loss or exposure. See Note&#160;14 for further discussion of pending legal proceedings.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition to the commitments described above, we are party to other commitments, including non-cancelable leases and long-term debt, which are described elsewhere in these notes to the condensed consolidated financial statements.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <lqda:PaymentForUpfrontLicenseFee
      contextRef="Duration_6_1_2023_To_6_30_2023_us-gaap_OtherCommitmentsAxis_lqda_PharmosaLicenseAgreementMember_kTOrGdUxVkmmOH0NFjgVRg"
      decimals="-6"
      id="Narr_7d7Fec2vVESW-K03LHZt8w"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">10000000</lqda:PaymentForUpfrontLicenseFee>
    <lqda:AccruedAdditionalUpfrontLicenseFee
      contextRef="As_Of_6_30_2023_us-gaap_OtherCommitmentsAxis_lqda_PharmosaLicenseAgreementMember_74ZGg3byiEqvxeoe8yh5pw"
      decimals="-5"
      id="Narr_0glbketqXE6yP4YuWlVeHQ"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">3500000</lqda:AccruedAdditionalUpfrontLicenseFee>
    <lqda:MaximumPotentialDevelopmentMilestonePayments
      contextRef="Duration_6_1_2023_To_6_30_2023_us-gaap_OtherCommitmentsAxis_lqda_PharmosaLicenseAgreementMember_kTOrGdUxVkmmOH0NFjgVRg"
      decimals="-4"
      id="Narr_KgbPITkxNkOovuJRfsdLag"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">37750000</lqda:MaximumPotentialDevelopmentMilestonePayments>
    <lqda:MaximumPotentialSalesMilestones
      contextRef="Duration_6_1_2023_To_6_30_2023_srt_StatementGeographicalAxis_srt_NorthAmericaMember_us-gaap_OtherCommitmentsAxis_lqda_PharmosaLicenseAgreementMember_QWvVbOqoFUaZurD06Zgd0w"
      decimals="-6"
      id="Narr_rjXumX2dDUGSUan4YhPhbg"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">185000000</lqda:MaximumPotentialSalesMilestones>
    <lqda:MaximumPotentialSalesMilestones
      contextRef="Duration_6_1_2023_To_6_30_2023_srt_StatementGeographicalAxis_lqda_OtherThenNorthAmericaMember_us-gaap_OtherCommitmentsAxis_lqda_PharmosaLicenseAgreementMember_PWs3djrXF0qDVpc8vjHEMw"
      decimals="-6"
      id="Narr_tR4bd6q28Ua-u8aBq75evg"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">150000000</lqda:MaximumPotentialSalesMilestones>
    <lqda:MilestonePaymentsPayable
      contextRef="As_Of_6_30_2023_us-gaap_OtherCommitmentsAxis_lqda_PharmosaLicenseAgreementMember_74ZGg3byiEqvxeoe8yh5pw"
      decimals="-6"
      id="Narr_o3q69ZRMPUCzp7L392V5UA"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">10000000</lqda:MilestonePaymentsPayable>
    <lqda:MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_OtherCommitmentsAxis_lqda_ChasmTechnologiesAgreementMember_17fard0TZkuq54S0aOBFBQ"
      decimals="-5"
      id="Narr_ZSkuGOijfEyw5TT3APkirQ"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">1500000</lqda:MaximumNetSalesThresholdAsBasisForPaymentOfFutureContingentRoyalties>
    <lqda:NetSalesEarnedRelatingToPaymentOfFutureContingentRoyalties
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_OtherCommitmentsAxis_lqda_ChasmTechnologiesAgreementMember_17fard0TZkuq54S0aOBFBQ"
      decimals="-5"
      id="Narr_k_UUH-_YA0GQY5ZhuGcEtQ"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">200000</lqda:NetSalesEarnedRelatingToPaymentOfFutureContingentRoyalties>
    <lqda:CommercialManufacturingServicesAndSupplyAgreementInitialTerm
      contextRef="Duration_7_14_2023_To_7_14_2023_us-gaap_OtherCommitmentsAxis_lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember_9-1NFSrmLU2h8Mehfb8Z0Q"
      id="Narr_RIhpbNHbKE6xHzvgVFrNDw">P5Y</lqda:CommercialManufacturingServicesAndSupplyAgreementInitialTerm>
    <lqda:CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection
      contextRef="Duration_7_14_2023_To_7_14_2023_us-gaap_OtherCommitmentsAxis_lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember_9-1NFSrmLU2h8Mehfb8Z0Q"
      id="Narr_I4rgWGg7VUeW1KTdaMUCdQ">P60D</lqda:CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaRejection>
    <lqda:CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay
      contextRef="Duration_7_14_2023_To_7_14_2023_us-gaap_OtherCommitmentsAxis_lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember_9-1NFSrmLU2h8Mehfb8Z0Q"
      id="Narr_V5oTno9bE0SJcrqGtDL-_A">P120D</lqda:CommercialManufacturingServicesAndSupplyAgreementTerminationTermForFdaDelay>
    <lqda:PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures
      contextRef="Duration_7_14_2023_To_7_14_2023_us-gaap_OtherCommitmentsAxis_lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember_9-1NFSrmLU2h8Mehfb8Z0Q"
      decimals="2"
      id="Narr_OOJpai2Fm0exbiNTeobcLQ"
      unitRef="Unit_Standard_pure_-akBLxf620GHsAsrBmTmhw">0.50</lqda:PercentageOfReimbursementOfDocumentedOutOfPocketExpenditures>
    <lqda:ReimbursementOfCapitalExpenditureIncurredBySupplier
      contextRef="As_Of_7_14_2023_us-gaap_OtherCommitmentsAxis_lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember_zRac0Pl5b0Geps4g1_aVUg"
      decimals="-5"
      id="Narr_b4wr11ZmmEOj748_uOP14A"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2500000</lqda:ReimbursementOfCapitalExpenditureIncurredBySupplier>
    <lqda:TermOfSubmissionOfQuarterlyForecastOfExpectedProduction
      contextRef="Duration_7_14_2023_To_7_14_2023_us-gaap_OtherCommitmentsAxis_lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember_9-1NFSrmLU2h8Mehfb8Z0Q"
      id="Narr_A_qBWJGebEyhXnUuwiTkyg">P24M</lqda:TermOfSubmissionOfQuarterlyForecastOfExpectedProduction>
    <lqda:InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder
      contextRef="Duration_7_14_2023_To_7_14_2023_us-gaap_OtherCommitmentsAxis_lqda_AmendedAndRestatedCommercialManufacturingServicesAndSupplyAgreementWithLonzaTampaLlcMember_9-1NFSrmLU2h8Mehfb8Z0Q"
      id="Narr_1JMUJg5BPk65DmAyW0Gb-g">P12M</lqda:InitialTermOfSubmissionOfQuarterlyForecastOfExpectedProductionBindingFirmOrder>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="As_Of_9_30_2024_us-gaap_OtherCommitmentsAxis_lqda_AgreementWithLGMPharmaLLCMember_a_fkJlyRgkS7OKPppsJs0Q"
      decimals="-5"
      id="Narr_x7MVsAvPwkuYwgSi5FqMGA"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">2700000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <lqda:AgreementExpirationTerm
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_OtherCommitmentsAxis_lqda_AgreementWithLGMPharmaLLCMember_HIEBrzKy8U2iausIsKFPnA"
      id="Narr_BIWnsWGT2UyBJEqQhzZsrw">P5Y</lqda:AgreementExpirationTerm>
    <lqda:NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts
      contextRef="As_Of_9_30_2024_gAxFSnN7606JMyQ9X7DOpg"
      decimals="-5"
      id="Narr_0Ot18xxtgEO17uIqI8-ipw"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">14700000</lqda:NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_8gI4yQSmU0ubFkumn_Xy2g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;14. Legal Proceedings&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;YUTREPIA-Related Litigation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2020, United Therapeutics filed a complaint for patent infringement against the Company in the U.S. District Court for the District of Delaware (the &#x201c;Original Hatch-Waxman Litigation&#x201d;), asserting infringement by the Company of U.S. Patent Nos. 9,604,901, entitled &#x201c;Process to Prepare Treprostinil, the Active Ingredient in Remodulin&#xae;&#x201d; (the &#x201c;&#x2018;901 Patent&#x201d;), 9,593,066, entitled &#x201c;Process to Prepare Treprostinil, the Active Ingredient in Remodulin&#xae;&#x201d; (the &#x201c;&#x2018;066 Patent&#x201d;), and 10,716,793, entitled &#x201c;Treprostinil Administration by Inhalation&#x201d; (the &#x201c;&#x2018;793 Patent&#x201d;) relating to United Therapeutics&#x2019; Tyvaso&#xae;, a nebulized treprostinil solution for the treatment of PAH. United Therapeutics&#x2019; complaint was in response to the Company&#x2019;s NDA for YUTREPIA, filed with the FDA, requesting approval to market YUTREPIA, a dry powder formulation of treprostinil for the treatment of PAH. The YUTREPIA NDA was filed under the 505(b)(2) regulatory pathway with Tyvaso&#xae; as the reference listed drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In December 2021, United Therapeutics filed a stipulation of partial judgment with respect to the &#x2018;901 Patent under which United Therapeutics agreed to the entry of judgment of the Company&#x2019;s non-infringement of the &#x2019;901 Patent.  In August 2022, Judge Andrews, who was presiding over the Original Hatch-Waxman Litigation, issued an opinion that claims 1, 2, 3, 6 and 9 of the &#x2018;066 Patent were invalid, that the remaining asserted claims of the &#x2018;066 Patent were not infringed by the Company.  In January 2021, the Company filed a petition for &lt;/span&gt;&lt;i style="font-style:italic;"&gt;inter partes&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt; review with the Patent Trial and Appeal Board (the &#x201c;PTAB&#x201d;) relating to the &#x2018;793 Patent, seeking a determination that the claims in the &#x2018;793 Patent are invalid. In July 2022, the PTAB ruled in the Company&#x2019;s favor, concluding that based on the preponderance of the evidence, all the claims of the &#x2019;793 Patent have been shown to be unpatentable. These decisions related to the &#x2018;901 Patent, the &#x2018;066 Patent and the &#x2018;793 Patent have all been affirmed on appeal and are not subject to further appeal.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In connection with an amendment to the Company&#x2019;s NDA filed in July 2023 to add PH-ILD as an indication for YUTREPIA, the Company provided a new notice of the paragraph IV certification to United Therapeutics as the owner of the patents that are the subject of the certification to which the NDA for YUTREPIA refers. As a result, in September 2023, United Therapeutics filed a second complaint for patent infringement against the Company in the U.S. District Court for the District of Delaware (Case No. 1:23-cv-00975-RGA) (the &#x201c;New Hatch-Waxman Litigation&#x201d;), again asserting infringement by the Company of the &#x2018;793 Patent.  In November 2023, the U.S. Patent and Trademark Office (the &#x201c;USPTO&#x201d;) issued U.S. Patent No. 11,826,327, or the &#x2018;327 Patent, entitled &#x201c;Treatment for Interstitial Lung Disease&#x201d;, to United Therapeutics. On November 30, 2023, United Therapeutics filed an amended complaint in the New Hatch-Waxman Litigation asserting infringement of the &#x2018;327 Patent by the practice of YUTREPIA based on the amended NDA.  In January 2024, the Company filed an answer, counterclaims and a partial motion to dismiss the claims related to the &#x2018;793 Patent as a result of the decision by the United States Court of Appeals for the Federal Circuit to affirm the PTAB&#x2019;s finding that the &#x2019;793 patent is unpatentable.  In February 2024, United Therapeutics stipulated to the dismissal of the claims in the New Hatch-Waxman Litigation related to the &#x2018;793 Patent.  In February 2024, United Therapeutics also filed a motion seeking a preliminary injunction to prevent the Company from manufacturing, marketing, storing, importing, distributing, offering for sale, and/or selling YUTREPIA for the treatment of PH-ILD.  Judge Andrews denied the motion for a preliminary injunction in May 2024. Discovery in the case remains ongoing.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;FDA Litigation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In February 2024, United Therapeutics filed a complaint against the FDA in the U.S. District Court for the District of Columbia (the &#x201c;D.C. District Court&#x201d;), challenging the FDA&#x2019;s acceptance of the Company&#x2019;s amended NDA for review (the &#x201c;Original FDA Litigation&#x201d;).  The Company intervened and became a party to the lawsuit in March 2024.  &lt;/span&gt;&lt;span style="letter-spacing:0.2pt;"&gt;In March&#160;2024, United Therapeutics filed a motion for a temporary restraining order and preliminary injunction in the FDA Litigation, seeking to enjoin the FDA from approving the Company&#x2019;s NDA for YUTREPIA with respect to the indication to treat PH-ILD. United Therapeutics&#x2019; motion was denied in March&#160;2024. On August&#160;20, 2024, United Therapeutics voluntarily dismissed its complaint, without prejudice.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;On August 21, 2024, the Company filed a lawsuit in the D.C. District Court to challenge the decision by the FDA to grant three-year regulatory exclusivity to Tyvaso DPI (the &#x201c;New FDA Litigation&#x201d;). The D.C. District Court has granted the parties&#x2019; motion for an expedited summary judgment briefing schedule, with briefing to be completed on or before November 15, 2024 and a summary judgment hearing scheduled for December 5, 2024.  On September 16, 2024, United Therapeutics filed a cross claim in the New FDA Litigation, re-asserting its challenge to FDA&#x2019;s acceptance of the Company&#x2019;s amended NDA for review.  The Company intervened and became a party with respect to the cross claim on November 5, 2024.  United Therapeutics has filed a motion for an expedited summary judgment briefing schedule for its cross claim.  That motion remains pending.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Trade Secret Litigation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In December 2021, United Therapeutics filed a complaint in the Superior Court in Durham County, North Carolina, alleging that the Company and Robert Roscigno (&#x201c;Dr. Roscigno&#x201d;) a former United Therapeutics employee, who later joined the Company as an employee many years after terminating his employment with United Therapeutics, conspired to misappropriate certain trade secrets of United Therapeutics and engaged in unfair or deceptive trade practices. In January 2024, Dr. Roscigno filed a motion for summary judgment with respect to all claims, but the motion was denied in July 2024.  In addition, in July 2024, the Company filed a motion for summary judgment with respect to all claims.  A hearing on the Company&#x2019;s motion for summary judgment has been scheduled for December 19, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In May 2024, United Therapeutics filed a second complaint in the Superior Court in Durham County, North Carolina, against Dr. Roscigno, alleging that he breached prior employment agreements with United Therapeutics by failing to assign to United Therapeutics his interest in patents obtained by the Company that relied upon or benefitted from certain inventions, discoveries, materials, authorship, derivatives and results developed by Dr. Roscigno while he was employed by United Therapeutics. The Company was also named as a defendant in this new lawsuit. As part of the lawsuit, United Therapeutics alleges that Dr. Roscigno misappropriated certain intellectual property of United Therapeutics which led to the development of YUTREPIA. The complaint also seeks declaratory judgement such that all right, title and interest in and to any patentable or unpatentable inventions, discoveries, and ideas made or conceived by Dr. Roscigno while employed by the Company should be assigned and transferred to United Therapeutics because they involved the use of United Therapeutics&#x2019; confidential information. On July 30, 2024, the Company filed a motion to dismiss all claims.  A hearing on the Company&#x2019;s motion to dismiss has been scheduled for December 19, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 0pt;"&gt;&lt;span style="margin-right:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;RareGen Litigation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In April 2019, Sandoz and Liquidia PAH (then known as RareGen) filed a complaint against United Therapeutics and Smiths Medical (now ICU Medical) in the District Court of New Jersey (Case No. No. 3:19 cv 10170), (the &#x201c;RareGen Litigation&#x201d;), alleging that United Therapeutics and Smiths Medical violated the Sherman Antitrust Act of 1890, state law antitrust statutes and unfair competition statutes by engaging in anticompetitive acts regarding the drug treprostinil for the treatment of PAH. In March 2020, Sandoz and Liquidia PAH filed a first amended complaint adding a claim that United Therapeutics breached a settlement agreement that was entered into in 2015, in which United Therapeutics agreed to not interfere with Sandoz&#x2019;s efforts to launch its generic treprostinil, by taking calculated steps to restrict and interfere with the launch of Sandoz&#x2019;s competing generic product. United Therapeutics developed treprostinil under the brand name Remodulin&#xae; and Smiths Medical manufactured a pump and cartridges that are used to inject treprostinil into patients continuously throughout the day. Sandoz and Liquidia PAH allege that United Therapeutics and Smiths Medical entered into anticompetitive agreements (i) whereby Smiths Medical placed restrictions on the cartridges such that they can only be used with United Therapeutics&#x2019; branded Remodulin&#xae; product and (ii) requiring Smiths Medical to enter into agreements with specialty pharmacies to sell the cartridges only for use with Remodulin&#xae;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In November 2020, Sandoz and Liquidia PAH entered into a binding term sheet (the &#x201c;Term Sheet&#x201d;) with Smiths Medical in order to resolve the outstanding RareGen Litigation solely with respect to disputes between Smiths Medical, Liquidia PAH and Sandoz. In April 2021, Liquidia PAH and Sandoz entered into a Long Form Settlement Agreement (the &#x201c;Settlement Agreement&#x201d;) with Smiths Medical to further detail the terms of the settlement among such parties as reflected in the Term Sheet. Pursuant to the Term Sheet and the Settlement Agreement, the former RareGen members and Sandoz received a payment of $4.25 million that was evenly split between the parties. In addition, pursuant to the Term Sheet and Settlement Agreement, Smiths Medical disclosed and made available to Sandoz and Liquidia PAH &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;certain specifications and other information related to the cartridge that Smiths Medical developed and manufactures for use with the CADD-MS 3 infusion pump (the &#x201c;CADD-MS 3 Cartridge&#x201d;). Pursuant to the Settlement Agreement, Smiths Medical also granted Liquidia PAH and Sandoz a non-exclusive, royalty-free license in the United States to Smiths Medical&#x2019;s patents and copyrights associated with the CADD-MS 3 Cartridge and certain other information for use of the CADD-MS 3 pump and the CADD-MS 3 Cartridges. Smiths also agreed in the Settlement Agreement to provide information and assistance in support of Liquidia PAH&#x2019;s efforts to receive FDA clearance for the RG 3ml Medication Cartridge (the &#x201c;RG Cartridge&#x201d;) and to continue to service certain CADD-MS 3 pumps that are available for use with the Treprostinil Injection through January 1, 2025. Liquidia PAH and Sandoz agreed, among other things, to indemnify Smiths from certain liabilities related to the RG Cartridge.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;In September 2021, United Therapeutics filed a motion for summary judgment with respect to all of the claims brought by Sandoz and Liquidia PAH against United Therapeutics. At the same time, Sandoz filed a motion for summary judgment with respect to the breach of contract claim. In March 2022, the Court issued an order granting partial summary judgment to United Therapeutics with respect to the antitrust and unfair competition claims, denying summary judgment to United Therapeutics with respect to the breach of contract claim, and granting partial summary judgment to Sandoz with respect to the breach of contract claim. A trial to determine the amount of damages due from United Therapeutics to Sandoz with respect to the breach of contract claim was held from late April to early May 2024, and closing arguments were held in June 2024.  On November 1, 2024, the Court entered a judgment in the amount of &lt;/span&gt;$70.6&lt;span style="white-space:pre-wrap;"&gt; million.  United Therapeutics has filed a notice of its intent to appeal the decision.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Under the Promotion Agreement, all proceeds from the litigation will be divided evenly between Sandoz and Liquidia PAH. Under the litigation finance agreements that Liquidia PAH has entered into with Henderson and PBM, any net proceeds received by Liquidia PAH with respect to the RareGen Litigation will be divided between Henderson and PBM.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:ProceedsFromLegalSettlements
      contextRef="Duration_4_1_2021_To_4_30_2021_dei_LegalEntityAxis_lqda_LiquidiaPAHAndSandozMember_srt_LitigationCaseAxis_lqda_UTCAndSmithsMedicalLitigationMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_HugoVmm5y0mmurW4-YSz7g"
      decimals="-4"
      id="Narr_Z_xwQ_g4oU-CmYkPKClmhA"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">4250000</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="Duration_11_1_2024_To_11_1_2024_dei_LegalEntityAxis_lqda_LiquidiaPAHAndSandozMember_srt_LitigationCaseAxis_lqda_BreachOfContractClaimMember_dVqpqeHTvEyS2ITxDkE5Vw"
      decimals="-5"
      id="Narr_s1stYe0rj0WdCDs-nj_EiA"
      unitRef="Unit_Standard_USD_EdkvZZneCka-5pLkmXSVyQ">70600000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2024_To_9_30_2024_cncjGGf1Z0qDYAV_DGDLjg"
      id="Tb_cFLX_2-RBEiQ7juBqKwHMQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;15. Subsequent Event&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 2, 2024, we and Pharmosa entered into a First Amendment to the Pharmosa License Agreement (the &#x201c;First Amendment&#x201d;) and concurrently entered into a &lt;span style="color:#212529;"&gt;Device License Agreement with Pharmosa. See Note 13 for additional information.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      id="Narr_WzzRIkTEfUed9YNtjhERlw">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      id="Narr_lFK9bxdFeEatLYFbsE5Iww">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      id="Narr_TDiqbrorgkm8lkOBS9xfWg">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_7_1_2024_To_9_30_2024_99rww03-_0WyyrBQXXkw0Q"
      id="Narr_-wtq7w8rr0iV-LNdvX9Dew">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
